



WORLD HEALTH ORGANIZATION

INTERNATIONAL AGENCY FOR RESEARCH ON CANCER

IARC MONOGRAPHS

ON THE

EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS

Tobacco Smoking

VOLUME 38

IARC, LYON, FRANCE

1986



WORLD HEALTH ORGANIZATION
INTERNATIONAL AGENCY FOR RESEARCH ON CANCER

IARC MONOGRAPHS
ON THE
EVALUATION OF THE
CARCINOGENIC RISK
OF CHEMICALS TO HUMANS

Tobacco Smoking

VOLUME 38

This publication represents the views and expert opinions
of an IARC Working Group on the
Evaluation of the Carcinogenic Risk of Chemicals to Humans
which met in Lyon,

12-20 February, 1985

IARC MONOGRAPHS

In 1969, the International Agency for Research on Cancer (IARC) initiated a programme on the evaluation of the carcinogenic risk of chemicals to humans involving the production of critically evaluated monographs on individual chemicals. In 1980, the programme was expanded to include the evaluation of the carcinogenic risk associated exposures to complex mixtures.

The objective of the programme is to elaborate and publish in the form of monographs critical reviews of data on carcinogenicity for chemicals and complex mixtures to which humans are known to be exposed, and on specific occupational exposures, to evaluate these data in terms of human risk with the help of international working groups of experts in chemical carcinogenesis and related fields, and to indicate where additional research efforts are needed.

This project was supported by PHS Grant No. 1 UO1 CA33193-03 awarded by the US National Cancer Institute, Department of Health and Human Services.

International Agency for Research on Cancer 1986

ISBN 92 832 1238 X (soft-cover edition)

ISBN 92 832 1538 9 (hard-cover edition)

ISSN 0250-9555

Distributed for the International Agency for Research on
Cancer by the Secretariat of the World Health Organization

REPRINTED 1991
PRINTED IN THE UNITED KINGDOM

CONTENTS

NOTE TO THE READER	7
LIST OF PARTICIPANTS	9
PREAMBLE	
Background	15
Objective and Scope	15
Selection of Chemicals and Complex Mixtures for Monographs	16
Working Procedures	16
Data for Evaluations	17
The Working Group	17
General Principles	17
Explanatory Notes on the Monographs Contents	25
TOBACCO SMOKING	
General introduction: Smoking and the public health	37
Worldwide use of smoking tobacco	47
1. Production of and trade in tobacco	47
(a) Historical aspects	47
(b) Tobacco types	49
(c) Production and trade	49
(d) Modification of raw materials	54
2. Manufacture and usage	54
(a) Forms utilized	54
(b) Product design and delivery	57
(c) Tar and nicotine yields	60
3. Smoking and public health considerations	65
(a) Estimates of tobacco consumption in different countries	67
(b) Sales trends	74

(c) Surveys of smoking behaviour	74
(d) Indices of dose in developing countries	75
4. Summary	80
Chemistry and analysis of tobacco smoke	83
1. Physicochemical nature of tobacco smoke	83
2. Total particulate matter	84
3. Chemical composition	86
(a) Carbon oxides	94
(b) Nitrogen oxides	95
(c) Ammonia and volatile amines	95
(d) Hydrogen cyanide	96
(e) Volatile aldehydes and ketones	96
(f) Other volatile compounds	97
(g) Nonvolatile alkanes and alkenes	98
(h) Isoprenoids	98
(i) Phytosterols	99
(j) Polynuclear aromatic compounds	100
(k) Alcohols	103
(l) Nonvolatile aldehydes and ketones	103
(m) Phenolic compounds and quinones	104
(n) Carboxylic acids, esters and lactones	105
(o) Amines and amides	107
(p) Tobacco alkaloids	109
(q) Pyridines, pyrroles and pyrazines	110
(r) <i>N</i> -Nitrosamines	110
(s) Inorganic constituents	114
(t) Radioelements	116
(u) Agricultural chemicals	118
(v) Additives	118
4. Sidestream smoke and air pollution by tobacco smoke	120
(a) Formation of sidestream smoke	120
(b) Analysis of sidestream smoke	121
(c) Air pollution by tobacco smoke	124

5. Summary	126
Biological data relevant to the evaluation of carcinogenic risk to humans	127
1. Carcinogenicity studies in animals	127
(a) Inhalation of tobacco smoke	127
(b) Inhalation of cigarette smoke in conjunction with administration of known carcinogens and other agents	134
(c) Administration of tobacco-smoke condensates	135
2. Other relevant biological data from experimental studies	140
(a) Toxicity of tobacco smoke in animals	140
(b) Metabolic effects of tobacco smoke	149
(c) Mutagenicity and other short-term tests	153
3. Observations in humans	163
(a) Methods of measuring intake of tobacco smoke	163
(b) Measurement of inhalation and factors influencing the extent of inhalation	170
(c) Deposition of smoke on bronchi	179
(d) Tobacco smoke-induced alterations in host defence mechanisms	183
(e) Genetic host factors that influence susceptibility to tobacco smoke	185
(f) Biological measures of exposure and effects of tobacco smoke	189
4. Summary	194
Epidemiological studies of cancer in humans	199
1. Introduction	199
2. Cancer of the lung	203
(a) Factors affecting risk	203
(b) Histological types and association with smoking	221
(c) Proportion of risk currently attributable to smoking	228
(d) Trends in lung cancer incidence in relation to cigarette usage	235
(e) Summary	242
3. Cancer of the urinary tract	244
(a) Geographic and temporal correlation studies	244
(b) Analytical studies	244
(c) Estimates of risk attributable to smoking	270
(d) Summary	270

4. Cancer in other organs	270
(a) Cancers of the upper respiratory and upper digestive tracts	270
(b) Cancer of the stomach	276
(c) Cancer of the liver	276
(d) Cancer of the pancreas	279
(e) Cancer of the cervix	282
(f) Cancer of the endometrium	292
(g) Cancer of the breast	293
(h) Summary	293
5. Interactions with other causative factors	298
(a) Alcohol	299
(b) Asbestos	300
(c) Radiation	302
(d) Summary	302
6. Cancers related to passive exposure to tobacco smoke	303
(a) Cancer of the lung	304
(b) Cancers in organs other than the lung	305
(c) Childhood cancers and parental cigarette smoking	305
(d) Summary	308
Conclusions and evaluations	309
1. Conclusions	309
(a) Usage and trends	309
(b) Carcinogenicity in animals	309
(c) Genetic activity and short-term test results	310
(d) Human exposure	311
(e) Genetic host factors	312
(f) Cancer in humans	312
2. Evaluations	314
References	315
Appendix 1: International tobacco sales, 1966-1984	379
Appendix 2: Chemical compounds identified in tobacco smoke that have been evaluated for carcinogenicity in the IARC Monographs series	387
SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-37	395
CUMULATIVE INDEX TO THE MONOGRAPH SERIES	397

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to the chemical will lead to cancer in humans.

Inclusion of a chemical in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that a chemical has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of a chemical to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, Division of Environmental Carcinogenesis, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the chemical may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.

**IARC WORKING GROUP ON THE EVALUATION
OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS:
TOBACCO SMOKING**

Lyon, 12-20 February 1985

Members

- O. Axelson, Department of Occupational Medicine, University Hospital, 581 85 Linköping, Sweden
- F.G. Bock, The Pap Institute, 1155 NW 14th Street, Box 016188, Miami, FL 33101, USA
- M. Caraballoso, National Cancer Registry, Institute of Oncology and Radiobiology, 29yE Vedado, Havana 4, Cuba
- I. Chouroulinkov, Institute for Scientific Research on Cancer, BP 8, 94802 Villejuif Cedex, France
- D.L. Davis, Director, Tobacco and Health Research Institute, University of Kentucky, Cooper and Alumni Drives, Lexington, KY 40506, USA
- D.M. DeMarini, Genetic Toxicology Division (MD68), US Environmental Protection Agency, Research Triangle Park, NC 27711, USA
- R. Doll, Imperial Cancer Research Fund, Cancer Epidemiology and Clinical Trials Unit, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE, UK (*Chairman*)
- H.J. Evans, MRC Clinical and Population Cytogenetics Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
- Y.-T. Gao, Director, Shanghai Cancer Institute, 270 Dong An Road, Shanghai, China
- N. Gray, Director, Anti-Cancer Council of Victoria, 1 Rathdowne Street, Carlton South, Australia 3053
- R.A. Griesemer, Director, Biology Division, Oak Ridge National Laboratory, PO Box Y, Oak Ridge, TN 37831, USA
- T. Hirayama, Chief, Epidemiology Division, National Cancer Center Research Institute, Tsukiji 5-chome, Chuo-ku, Tokyo, Japan
- D. Hoffmann, Associate Director, Naylor Dana Institute for Disease Prevention, American Health Foundation, Dana Road, Valhalla, NY 10595, USA
- J. Jacob, Biochemical Institute of Environmental Carcinogens, Sieker Landstrasse 19, 2070 Ahrensburg, Federal Republic of Germany

- A.B. Miller, Director, Epidemiology Unit, National Cancer Institute of Canada, Faculty of Medicine, McMurrich Building, University of Toronto, Toronto, Ontario M5S 1A8, Canada
- S. Moolgavkar, The Fred Hutchinson Cancer Research Center, 1124 Columbia Street, Seattle, WA 98104, USA
- N.P. Napalkov, Director, N.N. Petrov Research Institute of Oncology, Leningradskaya Street 68, Pesochny 2, Leningrad 188646, USSR (*Vice-Chairman*)
- R. Peto, Reader in Cancer Studies, Imperial Cancer Research Fund, Cancer Epidemiology and Clinical Trials Unit, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE, UK
- J. Pritchard, Environmental and Medical Sciences Division, Building 551, Atomic Energy Research Establishment, Harwell, Oxon OXH 0RA, UK
- M.A.H. Russell, Reader in Addiction, Institute of Psychiatry, The Maudsley Hospital, London SE5 8AF, UK
- J. Samet, New Mexico Tumor Registry, University of New Mexico, Albuquerque, NM 87131, USA
- M. Sorsa, Institute of Occupational Health, Haartmaninkatu 1, 00290 Helsinki 29, Finland
- L. Teppo, Finnish Cancer Registry, Liisankatu 21B, 00170 Helsinki 17, Finland
- T.C. Tso, US Department of Agriculture, Agricultural Research Service, National Program Staff, Room 25, Building 005, BARC West, Beltsville, MD 20705, USA
- P. Vineis, Unit of Cancer Epidemiology, Istituto di Anatomia Patologica, Via Santena 7, 10126 Turin, Italy
- N.J. Wald, Department of Environmental and Preventive Medicine, The Medical College of St Bartholomew's Hospital, Charterhouse Square, London EC1M 6BO, UK
- M.I. Willems, Institute CIVO-Toxicology and Nutrition, TNO, PO Box 360, 3700 AJ Zeist, The Netherlands
- E.L. Wynder, President, American Health Foundation, 320 East 43rd Street, New York, NY 10017, USA

Representatives of the National Cancer Institute

- J. Cullen, Deputy Director, Division of Cancer Prevention and Control, National Cancer Institute, Building 31, Room 4A-32, Bethesda, MD 20205, USA
- C. Harris, Chief, Laboratory of Human Carcinogenesis, Division of Cancer Etiology, National Cancer Institute, Building 37, Room 2C-07, Bethesda, MD 20205, USA

Observers

World Health Organization

- R. Masironi, Coordinator, Smoking and Health Programme, WHO, 1211 Geneva 27, Switzerland
- K. Stanley, Cancer Unit, WHO, 1211 Geneva 27, Switzerland
- R. Türck, WHO, Regional Office for Europe, 8 Scherfigsvej, DK-2100 Copenhagen Ø, Denmark

US National Academy of Sciences

D. Davis, National Academy of Sciences, 2101 Constitution Avenue NW, Washington DC 20418, USA

Naylor Dana Institute for Disease Prevention, American Health Foundation

N. Haley, Naylor Dana Institute for Disease Prevention, Dana Road, Valhalla, NY 10595, USA

Serbian Academy of Sciences and Arts

D. Kanazir, President, 35 Knez Mihailova, 1100 Belgrade, Yugoslavia

Secretariat

H. Bartsch, Division of Environmental Carcinogenesis

J.R.P. Cabral, Division of Environmental Carcinogenesis

N.E. Day, Division of Epidemiology and Biostatistics

J. Estève, Division of Epidemiology and Biostatistics

M. Friesen, Division of Environmental Carcinogenesis

L. Haroun, Division of Environmental Carcinogenesis (*Secretary*)

E. Heseltine, Research Training and Liaison

M. Hollstein, Division of Environmental Carcinogenesis

D. Mietton, Division of Environmental Carcinogenesis

R. Montesano, Division of Environmental Carcinogenesis

I. O'Neill, Division of Environmental Carcinogenesis

C. Partensky, Division of Environmental Carcinogenesis

I. Peterschmitt, Division of Environmental Carcinogenesis, Geneva, Switzerland

S. Poole, Birmingham, UK

S. Preston-Martin, Division of Epidemiology and Biostatistics

E. Riboli, Division of Epidemiology and Biostatistics

R. Saracci, Division of Epidemiology and Biostatistics

L. Simonato, Division of Epidemiology and Biostatistics

L. Tomatis, Director

A. Tossavainen, Division of Environmental Carcinogenesis

A. Tuyns, Division of Epidemiology and Biostatistics

H. Vainio, Division of Environmental Carcinogenesis (*Head of the Programme*)

J. Wahrendorf, Division of Epidemiology and Biostatistics

A. Walker, Division of Epidemiology and Biostatistics

J. Wilbourn, Division of Environmental Carcinogenesis

H. Yamasaki, Division of Environmental Carcinogenesis

D. Zaridze, Division of Epidemiology and Biostatistics

Secretarial assistance

J. Cazeaux
S. Cotterell
M.-J. Ghes
M. Lézère
S. Reynaud
K. Zouhair

PREAMBLE

IARC MONOGRAPHS PROGRAMME ON THE EVALUATION OF THE CARCINOGENIC RISK OF CHEMICALS TO HUMANS¹

PREAMBLE

1. BACKGROUND

In 1969, the International Agency for Research on Cancer (IARC) initiated a programme to evaluate the carcinogenic risk of chemicals to humans and to produce monographs on individual chemicals. Following the recommendations of an ad-hoc Working Group, which met in Lyon in 1979 to prepare criteria to select chemicals for *IARC Monographs*(1), the *Monographs* programme was expanded to include consideration of exposures to complex mixtures which may occur, for example, in many occupations or as a result of human habits.

The criteria established in 1971 to evaluate carcinogenic risk to humans were adopted by all the working groups whose deliberations resulted in the first 16 volumes of the *IARC Monographs* series. This preamble reflects subsequent re-evaluation of those criteria by working groups which met in 1977(2), 1978(3), 1982(4) and 1983(5).

2. OBJECTIVE AND SCOPE

The objective of the programme is to elaborate and publish in the form of monographs critical reviews of data on carcinogenicity for chemicals, groups of chemicals, industrial processes and other complex mixtures to which humans are known to be exposed, to evaluate the data in terms of human risk with the help of international working groups of experts, and to indicate where additional research efforts are needed. These evaluations are intended to assist national and international authorities in formulating decisions concerning preventive measures. No recommendation is given concerning legislation, since this depends on risk-benefit evaluations, which seem best made by individual governments and/ or other international agencies.

¹This project is supported by PHS Grant No. 1 U01 CA33193-03 awarded by the US National Cancer Institute, Department of Health and Human Services.

The *IARC Monographs* are recognized as an authoritative source of information on the carcinogenicity of environmental and other chemicals. A users' survey, made in 1984, indicated that the monographs are consulted by various agencies in 45 countries. As of March 1986, 38 volumes of the *Monographs* had been published or were in press. Five supplements have been published: two summaries of evaluations of chemicals associated with human cancer, an evaluation of screening assays for carcinogens, and two cross indexes of synonyms and trade names of chemicals evaluated in the series(6).

3. SELECTION OF CHEMICALS AND COMPLEX EXPOSURES FOR MONOGRAPHS

The chemicals (natural and synthetic including those which occur as mixtures and in manufacturing processes) and complex exposures are selected for evaluation on the basis of two main criteria: (a) there is evidence of human exposure, and (b) there is some experimental evidence of carcinogenicity and/or there is some evidence or suspicion of a risk to humans. In certain instances, chemical analogues are also considered. The scientific literature is surveyed for published data relevant to the *Monographs* programme; and the *IARC Survey of Chemicals Being Tested for Carcinogenicity* (7) often indicates those chemicals that may be scheduled for future meetings.

As new data on chemicals for which monographs have already been prepared become available, re-evaluations are made at subsequent meetings, and revised monographs are published.

4. WORKING PROCEDURES

Approximately one year in advance of a meeting of a working group, a list of the substances or complex exposures to be considered is prepared by IARC staff in consultation with other experts. Subsequently, all relevant biological data are collected by IARC; recognized sources of information on chemical carcinogenesis and on-line systems such as CANCERLINE, MEDLINE and TOXLINE are used in conjunction with US Public Health Service Publication No. 149(8). Bibliographical sources for data on mutagenicity and teratogenicity are the Environmental Mutagen Information Center and the Environmental Teratology Information Center, both located at the Oak Ridge National Laboratory, TN, USA.

The major collection of data and the preparation of first drafts for the sections on chemical and physical properties, on production and use, on occurrence, and on analysis are carried out by Tracor Jitco, Inc., and its subcontractor, Technical Resources, Inc., both in Rockville, MD, USA, under a separate contract with the US National Cancer Institute. Most of the data so obtained refer to the USA and Japan; IARC attempts to supplement this information with that from other sources in Europe. Representatives from industrial associations may assist in the preparation of sections describing industrial processes.

Six months before the meeting, articles containing relevant biological data are sent to an expert(s), or are used by IARC staff, to prepare first drafts of the sections on biological effects. The complete drafts are then compiled by IARC staff and sent, prior to the meeting,

to all participants of the Working Group for their comments.

The Working Group meets in Lyon for seven to eight days to discuss and finalize the texts of the monographs and to formulate the evaluations. After the meeting, the master copy of each monograph is verified by consulting the original literature, edited by a professional editor and prepared for reproduction. The aim is to publish monographs within nine months of the Working Group meeting. Each volume of monographs is printed in 4000 copies for distribution to governments, regulatory agencies and interested scientists. The monographs are also available *via* the WHO Distribution and Sales Service.

These procedures are followed for the preparation of most volumes of monographs, which cover chemicals and groups of chemicals; however, they may vary when the subject matter is an industry or life-style factor.

5. DATA FOR EVALUATIONS

With regard to biological data, only reports that have been published or accepted for publication are reviewed by the working groups, although a few exceptions have been made: in certain instances, reports from government agencies that have undergone peer review and are widely available are considered. The monographs do not cite all of the literature on a particular chemical or complex exposure: only those data considered by the Working Group to be relevant to the evaluation of carcinogenic risk to humans are included.

Anyone who is aware of data that have been published or are in press which are relevant to the evaluations of the carcinogenic risk to humans of chemicals or complex exposures for which monographs have appeared is asked to make them available to the Unit of Carcinogen Identification and Evaluation, Division of Environmental Carcinogenesis, International Agency for Research on Cancer, Lyon, France.

6. THE WORKING GROUP

The tasks of the Working Group are five-fold: (a) to ascertain that all data have been collected; (b) to select the data relevant for evaluation; (c) to ensure that the summaries of the data enable the reader to follow the reasoning of the Working Group; (d) to judge the significance of the results of experimental and epidemiological studies; and (e) to make an evaluation of the carcinogenicity of the chemical or complex exposure.

Working Group participants who contributed to the consideration and evaluation of chemicals or complex exposures within a particular volume are listed, with their addresses, at the beginning of each publication. Each member serves as an individual scientist and not as a representative of any organization or government. In addition, observers are often invited from national and international agencies and industrial associations.

7. GENERAL PRINCIPLES APPLIED BY THE WORKING GROUP IN EVALUATING CARCINOGENIC RISK OF CHEMICALS OR COMPLEX MIXTURES

The widely accepted meaning of the term 'chemical carcinogenesis', and that used in these monographs, is the induction by chemicals (or complex mixtures of chemicals) of

neoplasms that are not usually observed, the earlier induction of neoplasms that are commonly observed, and/or the induction of more neoplasms than are usually found—although fundamentally different mechanisms may be involved in these three situations. Etymologically, the term ‘carcinogenesis’ means the induction of cancer, that is, of malignant neoplasms; however, the commonly accepted meaning is the induction of various types of neoplasms or of a combination of malignant and benign tumours. In the monographs, the words ‘tumour’ and ‘neoplasm’ are used interchangeably. (In the scientific literature, the terms ‘tumorigen’, ‘oncogen’ and ‘blastomogen’ have all been used synonymously with ‘carcinogen’, although occasionally ‘tumorigen’ has been used specifically to denote a substance that induces benign tumours.)

(a) Experimental Evidence

(i) Evidence for carcinogenicity in experimental animals

The Working Group considers various aspects of the experimental evidence reported in the literature and formulates an evaluation of that evidence.

Qualitative aspects: Both the interpretation and evaluation of a particular study as well as the overall assessment of the carcinogenic activity of a chemical (or complex mixture) involve several considerations of qualitative importance, including: (a) the experimental parameters under which the chemical was tested, including route of administration and exposure, species, strain, sex, age, etc.; (b) the consistency with which the chemical has been shown to be carcinogenic, e.g., in how many species and at which target organ(s); (c) the spectrum of neoplastic response, from benign neoplasm to multiple malignant tumours; (d) the stage of tumour formation in which a chemical may be involved: some chemicals act as complete carcinogens and have initiating and promoting activity, while others may have promoting activity only; and (e) the possible role of modifying factors.

There are problems not only of differential survival but of differential toxicity, which may be manifested by unequal growth and weight gain in treated and control animals. These complexities are also considered in the interpretation of data.

Many chemicals induce both benign and malignant tumours. Among chemicals that have been studied extensively, there are few instances in which the only neoplasms induced are benign. Benign tumours may represent a stage in the evolution of a malignant neoplasm or they may be ‘end-points’ that do not readily undergo transition to malignancy. If a substance is found to induce only benign tumours in experimental animals, it should nevertheless be suspected of being a carcinogen, and it requires further investigation.

Hormonal carcinogenesis: Hormonal carcinogenesis presents certain distinctive features: the chemicals involved occur both endogenously and exogenously; in many instances, long exposure is required; and tumours occur in the target tissue in association with a stimulation of non-neoplastic growth, although in some cases hormones promote the proliferation of tumour cells in a target organ. For hormones that occur in excessive amounts, for hormone-mimetic agents and for agents that cause hyperactivity or imbalance in the endocrine system, evaluative methods comparable with those used to identify chemical carcinogens may be required; particular emphasis must be laid on quantitative

aspects and duration of exposure. Some chemical carcinogens have significant side effects on the endocrine system, which may also result in hormonal carcinogenesis. Synthetic hormones and anti-hormones can be expected to possess other pharmacological and toxicological actions in addition to those on the endocrine system, and in this respect they must be treated like any other chemical with regard to intrinsic carcinogenic potential.

Complex mixtures: There is an increasing amount of data from long-term carcinogenicity studies on complex mixtures and on crude materials obtained by sampling in occupational environments. The representativity of such samples must be considered carefully.

Quantitative aspects: Dose-response studies are important in the evaluation of carcinogenesis: the confidence with which a carcinogenic effect can be established is strengthened by the observation of an increasing incidence of neoplasms with increasing exposure.

The assessment of carcinogenicity in animals is frequently complicated by recognized differences among the test animals (species, strain, sex, age) and route and schedule of administration; often, the target organs at which a cancer occurs and its histological type may vary with these parameters. Nevertheless, indices of carcinogenic potency in particular experimental systems (for instance, the dose-rate required under continuous exposure to halve the probability of the animals remaining tumourless(9)) have been formulated in the hope that, at least among categories of fairly similar agents, such indices may be of some predictive value in other species, including humans.

Chemical carcinogens share many common biological properties, which include metabolism to reactive (electrophilic(10-11)) intermediates capable of interacting with DNA. However, they may differ widely in the dose required to produce a given level of tumour induction. The reason for this variation in dose-response is not understood, but it may be due to differences in metabolic activation and detoxification processes, in different DNA repair capacities among various organs and species or to the operation of qualitatively distinct mechanisms.

Statistical analysis of animal studies: It is possible that an animal may die prematurely from unrelated causes, so that tumours that would have arisen had the animal lived longer may not be observed; this possibility must be allowed for. Various analytical techniques have been developed which use the assumption of independence of competing risks to allow for the effects of intercurrent mortality on the final numbers of tumour-bearing animals in particular treatment groups.

For externally visible tumours and for neoplasms that cause death, methods such as Kaplan-Meier (i.e., 'life-table', 'product-limit' or 'actuarial') estimates(9), with associated significance tests(12), have been recommended. For internal neoplasms that are discovered 'incidentally'(12) at autopsy but that did not cause the death of the host, different estimates(13) and significance tests(12) may be necessary for the unbiased study of the numbers of tumour-bearing animals.

The design and statistical analysis of long-term carcinogenicity experiments were reviewed in Supplement 2 to the *Monographs* series(14). That review outlined the way in

which the context of observation of a given tumour (fatal or incidental) could be included in an analysis yielding a single combined result. This method requires information on time to death for each animal and is therefore comparable to only a limited extent with analyses which include global proportions of tumour-bearing animals.

Evaluation of carcinogenicity studies in experimental animals: The evidence of carcinogenicity in experimental animals is assessed by the Working Group and judged to fall into one of four groups, defined as follows:

(1) *Sufficient evidence* of carcinogenicity is provided when there is an increased incidence of malignant tumours: (a) in multiple species or strains; or (b) in multiple experiments (preferably with different routes of administration or using different dose levels); or (c) to an unusual degree with regard to incidence, site or type of tumour, or age at onset. Additional evidence may be provided by data on dose-response effects.

(2) *Limited evidence* of carcinogenicity is available when the data suggest a carcinogenic effect but are limited because: (a) the studies involve a single species, strain or experiment; or (b) the experiments are restricted by inadequate dosage levels, inadequate duration of exposure to the agent, inadequate period of follow-up, poor survival, too few animals, or inadequate reporting; or (c) the neoplasms produced often occur spontaneously and, in the past, have been difficult to classify as malignant by histological criteria alone (e.g., lung adenomas and adenocarcinomas and liver tumours in certain strains of mice).

(3) *Inadequate evidence* of carcinogenicity is available when, because of major qualitative or quantitative limitations, the studies cannot be interpreted as showing either the presence or absence of a carcinogenic effect.

(4) *No evidence* of carcinogenicity applies when several adequate studies are available which show that, within the limits of the tests used, the chemical or complex mixture is not carcinogenic.

It should be noted that the categories *sufficient evidence* and *limited evidence* refer only to the strength of the experimental evidence that these chemicals or complex mixtures are carcinogenic and not to the extent of their carcinogenic activity nor to the mechanism involved. The classification of any chemical may change as new information becomes available.

(ii) *Evidence for activity in short-term tests*¹

Many short-term tests bearing on postulated mechanisms of carcinogenesis or on the properties of known carcinogens have been developed in recent years. The induction of cancer is thought to proceed by a series of steps, some of which have been distinguished experimentally (15-19). The first step — initiation — is thought to involve damage to DNA, resulting in heritable alterations in or rearrangements of genetic information. Most short-term tests in common use today are designed to evaluate the genetic activity of a substance.

¹Based on the recommendations of a working group which met in 1983(5).

Data from these assays are useful for identifying potential carcinogenic hazards, in identifying active metabolites of known carcinogens in human or animal body fluids, and in helping to elucidate mechanisms of carcinogenesis. Short-term tests to detect agents with tumour-promoting activity are, at this time, insufficiently developed.

Because of the large number of short-term tests, it is difficult to establish rigid criteria for adequacy that would be applicable to all studies. General considerations relevant to all tests, however, include (a) that the test system be valid with respect to known animal carcinogens and noncarcinogens; (b) that the experimental parameters under which the chemical (or complex mixture) is tested include a sufficiently wide dose range and duration of exposure to the agent and an appropriate metabolic system; (c) that appropriate controls be used; and (d) that the purity of the compound or, in the case of complex mixtures, that the source and representativity of the sample being tested be specified. Confidence in positive results is increased if a dose-response relationship is demonstrated and if this effect has been reported in two or more independent studies.

Most established short-term tests employ as end-points well-defined genetic markers in prokaryotes and lower eukaryotes and in mammalian cell lines. The tests can be grouped according to the end-point detected:

Tests of DNA damage. These include tests for covalent binding to DNA, induction of DNA breakage or repair, induction of prophage in bacteria and differential survival of DNA repair-proficient/-deficient strains of bacteria.

Tests of mutation (measurement of heritable alterations in phenotype and/or genotype). These include tests for detection of the loss or alteration of a gene product, and change of function through forward or reverse mutation, recombination and gene conversion; they may involve the nuclear genome, the mitochondrial genome and resident viral or plasmid genomes.

Tests of chromosomal effects. These include tests for detection of changes in chromosome number (aneuploidy), structural chromosomal aberrations, sister chromatid exchanges, micronuclei and dominant-lethal events. This classification does not imply that some chromosomal effects are not mutational events.

Tests for *cell transformation*, which monitor the production of preneoplastic or neoplastic cells in culture, are also of importance because they attempt to simulate essential steps in cellular carcinogenesis. These assays are not grouped with those listed above since the mechanisms by which chemicals induce cell transformation may not necessarily be the result of genetic change.

The selection of specific tests and end-points for consideration remains flexible and should reflect the most advanced state of knowledge in this field.

The data from short-term tests are summarized by the Working Group and the test results tabulated according to the end-points detected and the biological complexities of the test systems. The format of the table used is shown below. In these tables, a '+' indicates that the compound was judged by the Working Group to be significantly positive in one or more assays for the specific end-point and level of biological complexity; '-' indicates that it was judged to be negative in one or more assays; and '?' indicates that there were contradictory

results from different laboratories or in different biological systems, or that the result was judged to be equivocal. These judgements reflect the assessment by the Working Group of the quality of the data (including such factors as the purity of the test compound, problems of metabolic activation and appropriateness of the test system) and the relative significance of the component tests.

Overall assessment of data from short-term tests

Genetic activity			Cell transformation
DNA damage	Mutation	Chromosomal effects	
Prokaryotes			
Fungi/ Green plants			
Insects			
Mammalian cells (<i>in vitro</i>)			
Mammals (<i>in vivo</i>)			
Humans (<i>in vivo</i>)			

An overall assessment of the evidence for *genetic activity* is then made on the basis of the entries in the table, and the evidence is judged to fall into one of four categories, defined as follows:

- (1) *Sufficient evidence* is provided by at least three positive entries, one of which must involve mammalian cells *in vitro* or *in vivo* and which must include at least two of three end-points — DNA damage, mutation and chromosomal effects.
- (2) *Limited evidence* is provided by at least two positive entries.
- (3) *Inadequate evidence* is available when there is only one positive entry or when there are too few data to permit an evaluation of an absence of genetic activity or when there are unexplained, inconsistent findings in different test systems.

- (4) *No evidence* applies when there are only negative entries; these must include entries for at least two end-points and two levels of biological complexity, one of which must involve mammalian cells *in vitro* or *in vivo*.

It is emphasized that the above definitions are operational, and that the assignment of a chemical or complex mixture into one of these categories is thus arbitrary.

In general, emphasis is placed on positive results; however, in view of the limitations of current knowledge about mechanisms of carcinogenesis, certain cautions should be respected: (i) At present, short-term tests should not be used by themselves to conclude whether or not an agent is carcinogenic nor can they predict reliably the relative potencies of compounds as carcinogens in intact animals. (ii) Since the currently available tests do not detect all classes of agents that are active in the carcinogenic process (e.g., hormones), one must be cautious in utilizing these tests as the sole criterion for setting priorities in carcinogenesis research and in selecting compounds for animal bioassays. (iii) Negative results from short-term tests cannot be considered as evidence to rule out carcinogenicity, nor does lack of demonstrable genetic activity attribute an epigenetic or any other property to a substance (5).

(b) Evaluation of Carcinogenicity in Humans

Evidence of carcinogenicity can be derived from case reports, descriptive epidemiological studies and analytical epidemiological studies.

An analytical study that shows a positive association between an exposure and a cancer may be interpreted as implying causality to a greater or lesser extent, on the basis of the following criteria: (a) There is no identifiable positive bias. (By 'positive bias' is meant the operation of factors in study design or execution that lead erroneously to a more strongly positive association between an exposure and disease than in fact exists. Examples of positive bias include, in case-control studies, better documentation of the exposure for cases than for controls, and, in cohort studies, the use of better means of detecting cancer in exposed individuals than in individuals not exposed.) (b) The possibility of positive confounding has been considered. (By 'positive confounding' is meant a situation in which the relationship between an exposure and a disease is rendered more strongly positive than it truly is as a result of an association between that exposure and another exposure which either causes or prevents the disease. An example of positive confounding is the association between coffee consumption and lung cancer, which results from their joint association with cigarette smoking.) (c) The association is unlikely to be due to chance alone. (d) The association is strong. (e) There is a dose-response relationship.

In some instances, a single epidemiological study may be strongly indicative of a cause-effect relationship; however, the most convincing evidence of causality comes when several independent studies done under different circumstances result in 'positive' findings.

Analytical epidemiological studies that show no association between an exposure and a cancer ('negative' studies) should be interpreted according to criteria analogous to those listed above: (a) there is no identifiable negative bias; (b) the possibility of negative confounding has been considered; and (c) the possible effects of misclassification of

exposure or outcome have been weighed. In addition, it must be recognized that the probability that a given study can detect a certain effect is limited by its size. This can be perceived from the confidence limits around the estimate of association or relative risk. In a study regarded as 'negative', the upper confidence limit may indicate a relative risk substantially greater than unity; in that case, the study excludes only relative risks that are above the upper limit. This usually means that a 'negative' study must be large to be convincing. Confidence in a 'negative' result is increased when several independent studies carried out under different circumstances are in agreement. Finally, a 'negative' study may be considered to be relevant only to dose levels within or below the range of those observed in the study and is pertinent only if sufficient time has elapsed since first human exposure to the agent. Experience with human cancers of known etiology suggests that the period from first exposure to a chemical carcinogen to development of clinically observed cancer is usually measured in decades and may be in excess of 30 years.

The evidence for carcinogenicity from studies in humans is assessed by the Working Group and judged to fall into one of four groups, defined as follows:

- (1) *Sufficient evidence* of carcinogenicity indicates that there is a causal relationship between the exposure and human cancer.
- (2) *Limited evidence* of carcinogenicity indicates that a causal interpretation is credible, but that alternative explanations, such as chance, bias or confounding, could not adequately be excluded.
- (3) *Inadequate evidence* of carcinogenicity, which applies to both positive and negative evidence, indicates that one of two conditions prevailed: (a) there are few pertinent data; or (b) the available studies, while showing evidence of association, do not exclude chance, bias or confounding.
- (4) *No evidence* of carcinogenicity applies when several adequate studies are available which do not show evidence of carcinogenicity.

(c) Relevance of Experimental Data to the Evaluation of Carcinogenic Risk to Humans

Information compiled from the first 38 volumes of the *IARC Monographs* shows that, of the chemicals or groups of chemicals now generally accepted to cause or probably to cause cancer in humans, all of those that have been tested appropriately produce cancer in at least one animal species. For several of the chemicals (e.g., aflatoxins, 4-aminobiphenyl, diethylstilboestrol, melphalan, mustard gas and vinyl chloride), evidence of carcinogenicity in experimental animals preceded evidence obtained from epidemiological studies or case reports.

For many of the chemicals (or complex mixtures) evaluated in the *IARC Monographs* for which there is *sufficient evidence* of carcinogenicity in animals, data relating to carcinogenicity for humans are either insufficient or nonexistent. **In the absence of adequate data on humans, it is reasonable, for practical purposes, to regard chemicals for which there is sufficient evidence of carcinogenicity in animals as if they presented a carcinogenic risk to humans.** The use of the expressions 'for practical purposes' and 'as if they presented a

carcinogenic risk' indicates that, at the present time, a correlation between carcinogenicity in animals and possible human risk cannot be made on a purely scientific basis, but only pragmatically. Such a pragmatic correlation may be useful to regulatory agencies in making decisions related to the primary prevention of cancer.

In the present state of knowledge, it would be difficult to define a predictable relationship between the dose (mg/kg bw per day) of a particular chemical required to produce cancer in test animals and the dose that would produce a similar incidence of cancer in humans. Some data, however, suggest that such a relationship may exist(20,21), at least for certain classes of carcinogenic chemicals, although no acceptable method is currently available for quantifying the possible errors that may be involved in such an extrapolation procedure.

8. EXPLANATORY NOTES ON THE CONTENTS OF MONOGRAPHS ON CHEMICALS AND COMPLEX MIXTURES

These notes apply to the format of most monographs, except for those that address industries or life-style factors. Thus, sections 1 and 2, as described below, are applicable in monographs on chemicals or groups of chemicals; in other monographs, they may be replaced by sections on the history of an industry or habit, a description of a process and other relevant information.

(a) Chemical and Physical Data (Section 1)

The Chemical Abstracts Services Registry Number, the latest Chemical Abstracts Primary Name (Ninth Collective Index)(22) and the IUPAC Systematic Name(23) are recorded in section 1. Other synonyms and trade names are given, but the list is not necessarily comprehensive. Some of the trade names may be those of mixtures in which the compound being evaluated is only one of the ingredients.

The structural and molecular formulae, molecular weight and chemical and physical properties are given. The properties listed refer to the pure substance, unless otherwise specified, and include, in particular, data that might be relevant to identification, environmental fate and human exposure, and biological effects, including carcinogenicity.

A separate description of the composition of technical products includes available information on impurities and formulated products.

(b) Production, Use, Occurrence and Analysis (Section 2)

The purpose of section 2 is to provide indications of the extent of past and present human exposure to the chemical.

Monographs on occupational exposures to complex mixtures or exposures to complex mixtures resulting from human habits include sections on: historical perspectives; description of the industry or habit; manufacturing processes and use patterns; exposures in the workplace; chemistry of the complex mixture.

(i) *Synthesis*

Since cancer is a delayed toxic effect, the dates of first synthesis and of first commercial production of the chemical are provided. This information allows a reasonable estimate to be made of the date before which no human exposure could have occurred. In addition, methods of synthesis used in past and present commercial production are described.

(ii) *Production*

Since Europe, Japan and the USA are reasonably representative industrialized areas of the world, most data on production, foreign trade and uses are obtained from those regions. It should not, however, be inferred that those areas or nations are the sole or even necessarily the major sources or users of any individual chemical.

Production and foreign trade data are obtained from both governmental and trade publications. In some cases, separate production data on organic chemicals manufactured in the USA are not available because their publication could disclose confidential information. In such cases, an indication of the minimum quantity produced can be inferred from the number of companies reporting commercial production. Each company is required to report on individual chemicals if the annual sales value or production volume exceeds a specified minimum level. These levels vary for chemicals classified for different uses, e.g., medicinals and plastics; in fact, the minimal reportable level for annual sales value ranges from \$1000-\$50 000, and the minimal reportable level for annual production volume ranges from 450-22 700 kg for different classes of use. Data on production are also obtained by means of general questionnaires sent to companies thought to produce the compounds being evaluated. Information from the completed questionnaires is compiled by country, and the resulting estimates of production are included in the individual monographs.

(iii) *Use*

Information on uses is usually obtained from published sources but is often complemented by direct contact with manufacturers. Some uses identified may not be current or major applications, and the coverage is not necessarily comprehensive. In the case of drugs, mention of their therapeutic uses does not necessarily represent current practice nor does it imply judgement as to their clinical efficacy.

Statements concerning regulations and standards (e.g., pesticide registrations, maximum levels permitted in foods, occupational standards and allowable limits) in specific countries may not reflect the most recent situation, since such standards are continuously reviewed and modified. The absence of information on regulatory status for a country should not be taken to imply that that country does not have regulations with regard to the chemical.

(iv) *Occurrence*

Information on the occurrence of a chemical in the environment is obtained from published data, including that derived from the monitoring and surveillance of levels of the chemical in occupational environments, air, water, soil, foods and tissues of animals and humans. When no published data are available to the Working Group, unpublished reports,

deemed appropriate, may be considered. When available, data on the generation, persistence and bioaccumulation of a chemical are also included.

(v) *Analysis*

The purpose of the section on analysis is to give the reader an overview, rather than a complete list, of current methods cited in the literature. No critical evaluation or recommendation of any of the methods is meant or implied.

(c) **Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans (Section 3)**

In general, the data recorded in section 3 are summarized as given by the author; however, comments made by the Working Group on certain shortcomings of reporting, of statistical analysis or of experimental design are given in square brackets. The nature and extent of impurities/contaminants in the chemicals being tested are given when available.

(i) *Carcinogenicity studies in animals*

The monographs are not intended to cover all reported studies. A few studies are purposely omitted because they are inadequate (e.g., too short a duration, too few animals, poor survival) or because they are judged irrelevant for the purpose of the evaluation. In certain cases, however, such studies are mentioned briefly, particularly when the information is considered to be a useful supplement to other reports or when they are the only data available. Their inclusion does not, however, imply acceptance of the adequacy of their experimental design or of the analysis and interpretation of their results.

Mention is made of all routes of administration by which the test material has been adequately tested and of all species in which relevant tests have been done(24). In most cases, animal strains are given. Quantitative data are given to indicate the order of magnitude of the effective carcinogenic doses. In general, the doses and schedules are indicated as they appear in the original report; sometimes units have been converted for easier comparison. Experiments in which the compound was administered in conjunction with known carcinogens and experiments on factors that modify the carcinogenic effect are also reported. Experiments on the carcinogenicity of known metabolites and derivatives are also included.

(ii) *Other relevant biological data*

LD₅₀ data are given when available, and other data on toxicity are included when considered relevant.

Data on effects on reproduction, on teratogenicity and embryo- and fetotoxicity and on placental transfer, from studies in experimental animals and from observations in humans, are included when considered relevant.

Information is given on absorption, distribution and excretion. Data on metabolism are usually restricted to studies that show the metabolic fate of the chemical in experimental animals and humans, and comparisons of data from animals and humans are made when possible.

Data from short-term tests are also included. In addition to the tests for genetic activity and cell transformation described previously (see pages 20-21), data from studies of related effects, but for which the relevance to the carcinogenic process is less well established, may also be mentioned.

The criteria used for considering short-term tests and for evaluating their results have been described (see pages 21-23). In general, the authors' results are given as reported. An assessment of the data by the Working Group which differs from that of the authors, and comments concerning aspects of the study that might affect its interpretation are given in square brackets. Reports of studies in which few or no experimental details are given, or in which the data on which a reported positive or negative result is based are not available for examination, are cited, but are identified as 'abstract' or 'details not given' and are not considered in the summary tables or in making the overall assessment of genetic activity.

For several recent reviews on short-term tests, see IARC(24), Montesano *et al.*(25), de Serres and Ashby(26), Sugimura *et al.*(27), Bartsch *et al.*(28) and Hollstein *et al.*(29).

(iii) *Case reports and epidemiological studies of carcinogenicity to humans*

Observations in humans are summarized in this section. These include case reports, descriptive epidemiological studies (which correlate cancer incidence in space or time to an exposure) and analytical epidemiological studies of the case-control or cohort type. In principle, a comprehensive coverage is made of observations in humans; however, reports are excluded when judged to be clearly not pertinent. This applies in particular to case reports, in which either the clinico-pathological description of the tumours or the exposure history, or both, are poorly described; and to published routine statistics, for example, of cancer mortality by occupational category, when the categories are so broadly defined as to contribute virtually no specific information on the possible relation between cancer occurrence and a given exposure. Results of studies are assessed on the basis of the data and analyses that are presented in the published papers. Some additional analyses of the published data may be performed by the Working Group to gain better insight into the relation between cancer occurrence and the exposure under consideration. The Working Group may use these analyses in its assessment of the evidence or may actually include them in the text to summarize a study; in such cases, the results of the supplementary analyses are given in square brackets. Any comments by the Working Group are also reported in square brackets; however, these are kept to a minimum, being restricted to those instances in which it is felt that an important aspect of a study, directly impinging on its interpretation, should be brought to the attention of the reader.

(d) Summary of Data Reported and Evaluation (Section 4)

Section 4 summarizes the relevant data from animals and humans and gives the critical views of the Working Group on those data.

(i) *Exposures*

Human exposure to the chemical or complex mixture is summarized on the basis of data on production, use and occurrence.

(ii) *Experimental data*

Data relevant to the evaluation of the carcinogenicity of the test material in animals are summarized in this section. The animal species mentioned are those in which the carcinogenicity of the substance was clearly demonstrated. Tumour sites are also indicated. If the substance has produced tumours after prenatal exposure or in single-dose experiments, this is indicated. Dose-response data are given when available.

Significant findings on effects on reproduction and prenatal toxicity, and results from short-term tests for genetic activity and cell transformation assays are summarized, and the latter are presented in tables. An overall assessment is made of the degree of evidence for genetic activity in short-term tests.

(iii) *Human data*

Case reports and epidemiological studies that are considered to be pertinent to an assessment of human carcinogenicity are described. Other biological data that are considered to be relevant are also mentioned.

(iv) *Evaluation*

This section comprises evaluations by the Working Group of the degrees of evidence for carcinogenicity of the exposure to experimental animals and to humans. An overall evaluation is then made of the carcinogenic risk of the chemical or complex mixture to humans. This section should be read in conjunction with pages 20 and 24 of this Preamble for definitions of degrees of evidence.

When no data are available from epidemiological studies but there is *sufficient evidence* that the exposure is carcinogenic to animals, a footnote is included, reading: 'In the absence of adequate data on humans, it is reasonable, for practical purposes, to regard chemicals for which there is *sufficient evidence* of carcinogenicity in animals as if they presented a carcinogenic risk to humans' (pp. 24-25).

References

1. IARC (1979) Criteria to select chemicals for *IARC Monographs*. *IARC intern. tech. Rep. No. 79/003*
2. IARC (1977) IARC Monographs Programme on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Preamble. *IARC intern. tech. Rep. No. 77/002*
3. IARC (1978) Chemicals with *sufficient evidence* of carcinogenicity in experimental animals — *IARC Monographs* volumes 1-17. *IARC intern. tech. Rep. No. 78/003*
4. IARC (1982) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Supplement 4, *Chemicals, Industrial Processes and Industries Associated with Cancer in Humans* (IARC Monographs Volumes 1 to 29)
5. IARC (1983) Approaches to classifying chemical carcinogens according to mechanism of action. *IARC intern. tech. Rep. No. 83/001*

6. IARC (1972-1986) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Volumes 1-38, Lyon, France
- Volume 1 (1972) Some Inorganic Substances, Chlorinated Hydrocarbons, Aromatic Amines, *N*-Nitroso Compounds and Natural Products (19 monographs), 184 pages
- Volume 2 (1973) Some Inorganic and Organometallic Compounds (7 monographs), 181 pages
- Volume 3 (1973) Certain Polycyclic Aromatic Hydrocarbons and Heterocyclic Compounds (17 monographs), 271 pages
- Volume 4 (1974) Some Aromatic Amines, Hydrazine and Related Substances, *N*-Nitroso Compounds and Miscellaneous Alkylating Agents (28 monographs), 286 pages
- Volume 5 (1974) Some Organochlorine Pesticides (12 monographs), 241 pages
- Volume 6 (1974) Sex Hormones (15 monographs), 243 pages
- Volume 7 (1974) Some Anti-thyroid and Related Substances, Nitrofurans and Industrial Chemicals (23 monographs), 326 pages
- Volume 8 (1975) Some Aromatic Azo Compounds (32 monographs), 357 pages
- Volume 9 (1975) Some Aziridines, *N*-, *S*- and *O*-Mustards and Selenium (24 monographs), 268 pages
- Volume 10 (1976) Some Naturally Occurring Substances (22 monographs), 353 pages
- Volume 11 (1976) Cadmium, Nickel, Some Epoxides, Miscellaneous Industrial Chemicals and General Considerations on Volatile Anaesthetics (24 monographs), 306 pages
- Volume 12 (1976) Some Carbamates, Thiocarbamates and Carbazides (24 monographs), 282 pages
- Volume 13 (1977) Some Miscellaneous Pharmaceutical Substances (17 monographs), 255 pages
- Volume 14 (1977) Asbestos (1 monograph), 106 pages
- Volume 15 (1977) Some Fumigants, the Herbicides, 2,4-D and 2,4,5-T, Chlorinated Dibenzodioxins and Miscellaneous Industrial Chemicals (18 monographs), 354 pages
- Volume 16 (1978) Some Aromatic Amines and Related Nitro Compounds — Hair Dyes, Colouring Agents, and Miscellaneous Industrial Chemicals (32 monographs), 400 pages
- Volume 17 (1978) Some *N*-Nitroso Compounds (17 monographs), 365 pages
- Volume 18 (1978) Polychlorinated Biphenyls and Polybrominated Biphenyls (2 monographs), 140 pages
- Volume 19 (1979) Some Monomers, Plastics and Synthetic Elastomers, and Acrolein (17 monographs), 513 pages

- Volume 20 (1979) Some Halogenated Hydrocarbons (25 monographs), 609 pages
- Volume 21 (1979) Sex Hormones (II) (22 monographs), 583 pages
- Volume 22 (1980) Some Non-nutritive Sweetening Agents (2 monographs), 208 pages
- Volume 23 (1980) Some Metals and Metallic Compounds (4 monographs), 438 pages
- Volume 24 (1980) Some Pharmaceutical Drugs (16 monographs), 337 pages
- Volume 25 (1981) Wood, Leather and Some Associated Industries (7 monographs), 412 pages
- Volume 26 (1981) Some Antineoplastic and Immunosuppressive Agents (18 monographs), 411 pages
- Volume 27 (1981) Some Aromatic Amines, Anthraquinones and Nitroso Compounds, and Inorganic Fluorides Used in Drinking-Water and Dental Preparations (18 monographs), 344 pages
- Volume 28 (1982) The Rubber Industry (1 monograph), 486 pages
- Volume 29 (1982) Some Industrial Chemicals and Dyestuffs (18 monographs), 416 pages
- Volume 30 (1982) Miscellaneous Pesticides (18 monographs), 424 pages
- Volume 31 (1983) Some Food Additives, Feed Additives and Naturally Occurring Substances (21 monographs), 314 pages
- Volume 32 (1983) Polynuclear Aromatic Compounds, Part 1, Chemical, Environmental and Experimental Data (42 monographs), 477 pages
- Volume 33 (1984) Polynuclear Aromatic Compounds, Part 2, Carbon Blacks, Mineral Oils and Some Nitroarenes (8 monographs), 245 pages
- Volume 34 (1984) Polynuclear Aromatic Compounds, Part 3, Industrial Exposures in Aluminium Production, Coal Gasification, Coke Production, and Iron and Steel Founding (4 monographs), 219 pages
- Volume 35 (1984) Polynuclear Aromatic Compounds, Part 4, Bitumens, Coal-Tars and Derived Products, Shale-Oils and Soots (4 monographs), 271 pages
- Volume 36 (1985) Allyl Compounds, Aldehydes, Epoxides and Peroxides (15 monographs), 369 pages
- Volume 37 (1985) Tobacco Habits other than Smoking; Betel-quid and Areca-nut Chewing; and Some Nitroso Compounds (8 monographs), 291 pages
- Volume 38 (1986) Tobacco Smoking (1 monograph), 421 pages
- Supplement No. 1 (1979) Chemicals and Industrial Processes Associated with Cancer in Humans (IARC Monographs, Volumes 1 to 20), 71 pages
- Supplement No. 2 (1980) Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal, 426 pages
- Supplement No. 3 (1982) Cross Index of Synonyms and Trade Names in Volumes 1 to 26, 199 pages
- Supplement No. 4 (1982) Chemicals, Industrial Processes and Industries Associated with Cancer in Humans (IARC Monographs, Volumes 1 to 29), 292 pages
- Supplement No. 5 (1985) Cross Index of Synonyms and Trade Names in Volumes 1 to 36, 259 pages

7. IARC (1973-1984) *Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity*, Numbers 1-11, Lyon, France
 - Number 1 (1973) 52 pages
 - Number 2 (1973) 77 pages
 - Number 3 (1974) 67 pages
 - Number 4 (1974) 97 pages
 - Number 5 (1975) 88 pages
 - Number 6 (1976) 360 pages
 - Number 7 (1978) 460 pages
 - Number 8 (1979) 604 pages
 - Number 9 (1981) 294 pages
 - Number 10 (1983) 326 pages
 - Number 11 (1984) 370 pages

8. PHS 149 (1951-1983) Public Health Service Publication No. 149, *Survey of Compounds which have been Tested for Carcinogenic Activity*, Washington DC, US Government Printing Office
 - 1951 Hartwell, J.L., 2nd ed., Literature up to 1947 on 1329 compounds, 583 pages
 - 1957 Shubik, P. & Hartwell, J.L., Supplement 1, Literature for the years 1948-1953 on 981 compounds, 388 pages
 - 1969 Shubik, P. & Hartwell, J.L., edited by Peters, J.A., Supplement 2, Literature for the years 1954-1960 on 1048 compounds, 655 pages
 - 1971 National Cancer Institute, Literature for the years 1968-1969 on 882 compounds, 653 pages
 - 1973 National Cancer Institute, Literature for the years 1961-1967 on 1632 compounds, 2343 pages
 - 1974 National Cancer Institute, Literature for the years 1970-1971 on 750 compounds, 1667 pages
 - 1976 National Cancer Institute, Literature for the years 1972-1973 on 966 compounds, 1638 pages
 - 1980 National Cancer Institute, Literature for the year 1978 on 664 compounds, 1331 pages
 - 1983 National Cancer Institute, Literature for years 1974-1975 on 575 compounds, 1043 pages

9. Pike, M.C. & Roe, F.J.C. (1963) An actuarial method of analysis of an experiment in two-stage carcinogenesis. *Br. J. Cancer*, 17, 605-610
10. Miller, E.C. (1978) Some current perspectives on chemical carcinogenesis in humans and experimental animals: Presidential address. *Cancer Res.*, 38, 1479-1496

11. Miller, E.C. & Miller, J.A. (1981) Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. *Cancer*, 47, 2327-2345
12. Peto, R. (1974) Guidelines on the analysis of tumour rates and death rates in experimental animals. *Br. J. Cancer*, 29, 101-105
13. Hoel, D.G. & Walburg, H.E., Jr (1972) Statistical analysis of survival experiments. *J. natl Cancer Inst.*, 49, 361-372
14. Peto, R., Pike, M.C., Day, N.E., Gray, R.G., Lee, P.N., Parish, S., Peto, J., Richards, S. & Wahrendorf, J. (1980) *Guidelines for simple sensitive significance tests for carcinogenic effects in long-term animal experiments*. In: *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Supplement 2, Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal*, Lyon, pp. 311-426
15. Berenblum, I. (1975) *Sequential aspects of chemical carcinogenesis: Skin*. In: Becker, F.F., ed., *Cancer. A Comprehensive Treatise*, Vol. 1, New York, Plenum Press, pp. 323-344
16. Foulds, L. (1969) *Neoplastic Development*, Vol. 2, London, Academic Press
17. Farber, E. & Cameron, R. (1980) The sequential analysis of cancer development. *Adv. Cancer Res.*, 31, 125-126
18. Weinstein, I.B. (1981) The scientific basis for carcinogen detection and primary cancer prevention. *Cancer*, 47, 1133-1141
19. Slaga, T.J., Sivak, A. & Boutwell, R.K., eds (1978) *Mechanisms of Tumor Promotion and Cocarcinogenesis*, Vol. 2, New York, Raven Press
20. Rall, D.P. (1977) *Species differences in carcinogenesis testing*. In: Hiatt, H.H., Watson, J.D. & Winsten, J.A., eds, *Origins of Human Cancer*, Book C, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 1383-1390
21. National Academy of Sciences (NAS) (1975) *Contemporary Pest Control Practices and Prospects: The Report of the Executive Committee*, Washington DC
22. Chemical Abstracts Services (1978) *Chemical Abstracts Ninth Collective Index (9CI), 1972-1976*, Vols 76-85, Columbus, OH
23. International Union of Pure & Applied Chemistry (1965) *Nomenclature of Organic Chemistry*, Section C, London, Butterworths
24. IARC (1980) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Supplement 2, Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal*, Lyon
25. Montesano, R., Bartsch, H. & Tomatis, L., eds (1980) *Molecular and Cellular Aspects of Carcinogen Screening Tests (IARC Scientific Publications No. 27)*, Lyon
26. de Serres, F.J. & Ashby, J., eds (1981) *Evaluation of Short-Term Tests for Carcinogens. Report of the International Collaborative Program*, Amsterdam, Elsevier/North-Holland Biomedical Press

27. Sugimura, T., Sato, S., Nagao, M., Yahagi, T., Matsushima, T., Seino, Y., Takeuchi, M. & Kawachi, T. (1976) *Overlapping of carcinogens and mutagens*. In: Magee, P.N., Takayama, S., Sugimura, T. & Matsushima, T., eds, *Fundamentals in Cancer Prevention*, Tokyo/Baltimore, University of Tokyo/University Park Press, pp. 191-215
28. Bartsch, H., Tomatis, L. & Malaveille, C. (1982) *Qualitative and quantitative comparison between mutagenic and carcinogenic activities of chemicals*. In: Heddle, J.A., ed., *Mutagenicity: New Horizons in Genetic Toxicology*, New York, Academic Press, pp. 35-72
29. Hollstein, M., McCann, J., Angelosanto, F.A. & Nichols, W.W. (1979) Short-term tests for carcinogens and mutagens. *Mutat. Res.*, 65, 133-226

TOBACCO SMOKING

GENERAL INTRODUCTION: SMOKING AND THE PUBLIC HEALTH

Tobacco has been smoked for centuries and possibly used for millenia. At first it was smoked only by the native populations of America; but, subsequently, after tobacco was brought to Europe in the middle of the sixteenth century, smoking became widespread throughout the world. Its use must, therefore, satisfy some common needs. What these are is still imperfectly understood, but they are probably partly psychosocial and partly pharmacological. The former include the use of tobacco as a social activity that helps to break down personal reserve and as a distraction that is provided by filling and lighting a pipe, holding a cigarette and watching the smoke, or chewing. The latter are complex and include, in different circumstances, both cerebral stimulation and sedation, as smokers sometimes find that tobacco helps them to concentrate and at other times that it helps them to relax.

What is incontrovertible is that once smokers have become accustomed to its effects, prolonged abstention is distressing, and the feeling of distress can be relieved by further use. The simplest explanation for this is that it depends on the neuropharmacological action of nicotine, as some relief can sometimes be obtained by administering nicotine in other ways (e.g., in chewing-gum). This, however, may be an over-simplification, and the nonpharmacological effects (taste, smell, and sensory stimulation to respiratory tract) may also be important (Russell, 1979).

Development of knowledge of effects on health

When tobacco was first introduced into Europe, smoking was recommended for medicinal purposes; but its value soon became controversial. It was praised as a prophylactic against many ills and condemned as a noxious vice, one of its notable opponents being James I, King of the United Kingdom, who wrote vehemently against it and published anonymously in 1604 a treatise entitled *A Counterblaste to Tobacco*.

Faith in the positive benefits of smoking began to fade in the second half of the nineteenth century. Its critics, however, cast their net so widely, attributing to tobacco virtually all types of physical degeneration, that the mounting evidence that pipe smoking was responsible for many cancers of the lip and tongue was largely lost sight of amid the welter of other accusations.

With the growth of the cigarette habit, which became as entrenched among doctors as in the general population, the collective sense that tobacco might be a threat to health was dulled. By the time of the Second World War, references to tobacco in medical text-books

were commonly limited to its role in producing tobacco amblyopia (now certainly a rare disease, possibly occurring only in association with malnutrition) and tobacco angina (that is, attacks of angina brought on by smoking, which are also rare).

The idea that smoking might cause cancer was first clearly expressed by Sömmering (1795) in Germany, in a thesis¹ submitted for a prize offered by the Rhineland-Frankfurt Society, when he stated that 'carcinoma of the lip is most frequent when people indulged in tobacco pipes. For the lower lip is particularly attacked by carcinoma because it is compressed between the pipe and the teeth.' Most of the early reports of the association concerned cancer of the lip, but by the end of the nineteenth century many experienced surgeons believed that smoking might also cause cancer of the tongue (Anon., 1890).

The idea that lung cancer might be caused by smoking occurred to many people independently, particularly after it began to appear that the disease was increasing in incidence. Much of the early evidence was occupational in character. Rottman, for example, suggested in 1898 that the chemical or physical effects of tobacco dust might cause the disease among tobacco workers; and, 16 years later, Brinkmann (1914) reported a high proportion of cigar makers and sellers, waiters and innkeepers among 108 subjects with lung cancer observed at the Leipzig Pathological Institute between 1900 and 1912. There was, however, no detailed evidence relating to individuals' smoking habits until just before the Second World War, when Müller, F.H. (1939) reported the histories of 86 men with lung cancer and 86 'healthy men of the same age group'.

Very little attention was paid to any of this evidence or to other case-control studies by Schairer and Schöniger (1943) in Germany and Wassink (1948) in the Netherlands, until 1950 when five case-control studies were reported. These were mostly concerned with cancer of the lung, but they also provided evidence on several other cancers of the upper respiratory and digestive tracts (Doll & Hill, 1950; Levin, M.L. *et al.*, 1950; Mills & Porter, 1950; Schrek *et al.* 1950; Wynder & Graham, 1950).

At this time, there was so little awareness that smoking could cause any other disease that, in at least one of the case-control studies (Doll & Hill, 1952), the control patients whose smoking habits were compared with those of lung cancer patients included men with myocardial infarction and chronic obstructive lung disease. This attitude began to change only with the reports of cohort studies that were able to relate separately the risk of death from each individual cause. The first of these drew attention to myocardial infarction (Doll & Hill, 1954; Hammond & Horn, 1954), but, subsequently, as more data were obtained, many other diseases were also related to smoking.

Effects of smoking

For four diseases — cancer of the lung, myocardial infarction, peripheral vascular disease and chronic obstructive lung disease — the association with smoking has attracted a great deal of attention and has been investigated in many different ways. For many others, the

¹ For the original Latin text, see Clemmesen (1965), who also gave reasons for thinking that the first recognition of this association should not be attributed to Holland, 50 years earlier, as it sometimes has been.

conclusion that smoking is one of the factors that contribute to their production (or to their lethality) is more fairly described as presumptive than as proved. This is unimportant for public health policy, as those for which smoking is sufficiently well established as a cause to justify its avoidance are so common, and the death rate attributed to them so high, that it is immaterial whether another one or two dozen less common diseases are added to them. A proper understanding of the role of tobacco is, however, important medically, as, for some diseases, we need to know whether the cessation of smoking improves the results of treatment and, for all diseases, it helps our attempts to unravel the mechanism by which the disease is produced.

Case-control and cohort studies are, for the most, in complete agreement in differentiating the diseases and causes of death that are associated with smoking from those that are not. In some cohort studies, the numbers of deaths attributed to the less common diseases have been small, and differences between the recorded results have arisen through random variation, while differences in environmental factors that interact or compete with smoking must also have affected the results. It is possible, however, to distinguish with a fair degree of confidence between the diseases or causes of death that are associated with smoking in different ways.

A. Associations reflecting causation

For six diseases, the evidence suggests that practically the whole of the difference in mortality between smokers and life-long nonsmokers is due to tobacco. These are listed in part A of Table 1. Three are among the most common causes of death in men in developed countries, as is shown in the Table by the proportion of deaths from these causes in two regions (England and Wales, and Denmark). Reasonable proportions to attribute to smoking would be about 85% of the deaths due to cancer of the lung, chronic obstructive lung disease and aortic aneurysm, and 25% of the deaths due to ischaemic heart disease; this leads to the conclusion that the proportion of all deaths in such countries from these diseases alone caused prematurely by smoking is of the order of 15%.

B. Associations reflecting confounding

For a few other causes, the differences in mortality between smokers and nonsmokers can be attributed to confounding. These are listed in part B of Table 1. In people who die from these causes, smoking is presumably confounded with use of alcohol, with personality or with psychological stress, or even with all three. For these causes of death, cultural differences that affect the nature and prevalence of the factors that are truly responsible for them may well also affect their confounding with tobacco. Research into these causes of death may, consequently, reveal different associations with smoking in different communities.

C. Positive associations of uncertain character

Twenty other diseases (or groups of diseases) that have been associated with smoking are listed in part C of Table 1. Eight are specific types (or groups) of cancer, and these are considered later in the monograph.

Table 1. Importance of different causes of death related to smoking in different ways in two regions

Category ^a	Cause of death	No. of deaths as % of total deaths	
		England & Wales 1983	Denmark 1982
A	Cancer of lung	6.1	5.2
	Ischaemic heart disease	27.0	29.9
	Respiratory heart disease	<0.1	<0.1
	Aortic aneurysm	1.2	0.5
	Peripheral vascular disease	0.2	0.1
	Chronic obstructive lung disease	4.0	3.1
	Subtotal	38.5	38.8
B	Alcoholism	<0.1	0.1
	Cirrhosis of liver	0.4	1.0
	Poisoning	0.2	0.3
	Suicide	0.7	2.7
	Subtotal	1.3	4.1
C	Cancer of oesophagus	0.7	0.4
	Cancer of lip, tongue, mouth, pharynx, larynx	0.4	0.5
	Cancer of stomach	1.8	1.4
	Cancer of liver	0.2	0.3
	Cancer of bladder	0.8	0.9
	Cancer of kidney	0.4	0.6
	Cancer of pancreas	1.0	1.4
	Cancer of cervix uteri	0.3	0.5
	Cancer of unspecified site	1.4	0.9
	Respiratory tuberculosis	<0.1	<0.1
	Pneumonia	9.6	2.9
	Other respiratory disease	1.3	1.0
	Myocardial degeneration	1.0	0.2
	Hypertension	1.0	0.7
	Arteriosclerosis	1.1	1.7
	Cerebral thrombosis	1.7	1.5
	Other cerebrovascular disease	10.0	8.1
	Gastric ulcer	0.3	0.4
	Duodenal ulcer	0.4	0.2
	Hernia	0.1	0.1
Subtotal	33.5	23.7	
D	Cancer of endometrium	0.2	0.4
	Parkinsonism	0.4	0.3
	Ulcerative colitis	<0.1	<0.1
	Toxaemia of pregnancy	<0.1	<0.1
	Osteoporosis	<0.1	<0.1
	Subtotal	0.6	0.7
E	All others	26.1	32.7

^aA, disease for which excess mortality in smokers is attributable to smoking; B, disease for which excess mortality in smokers is attributable to confounding; C, disease for which excess mortality in smokers may be partly or wholly attributable to smoking; D, disease for which excess mortality in nonsmokers may be preventable by smoking; E, other diseases

Many of the diseases listed have not been examined in detail. A variety of reasons have been suggested for their association with smoking (e.g., Doll & Peto, 1976). For some, the excess mortality in smokers is relatively small (although sometimes absolutely large), and it may, perhaps, be attributed to smoking on the grounds of analogy with a disease that smoking is known to cause. On these grounds, for example, some deaths from cerebral thrombosis may be attributed to smoking, because of the known effect of smoking on the development of atheroma, and some deaths attributed to myocardial degeneration must really be due to an undiagnosed myocardial infarction. For others, the evidence is confused. Gastric ulcer, for example, has become less common as smoking has increased; yet controlled trials have shown that gastric ulcers heal more quickly when smoking is stopped, and it seems very likely that the grossly increased mortality in smokers that has been reported consistently in cohort studies reflects, at least in part, the inhibitory effect of smoking on an ulcer's healing.

Other diseases, such as respiratory tuberculosis and inguinal hernia, can hardly be said to be caused by tobacco in the ordinary sense; but they may be aggravated by the cough that accompanies chronic obstructive lung disease (which certainly is due to smoking), and they may, consequently, be more often fatal in those who smoke than in those who do not. Some of the excess mortality from respiratory tuberculosis in smokers could, however, be due to confounding with use of alcohol.

D. Associations possibly reflecting protection

A few diseases that some component of tobacco smoke may help to prevent or ameliorate are listed in part D of Table 1. Only Parkinsonism has been studied intensively, and the evidence that smoking protects against it — obtained from both case-control and cohort studies — is strong. Further research is needed before any firm conclusions can be drawn about the role of tobacco in the others; but it would not be surprising if smoking reduced the incidence of some hormone-dependent diseases (for example, osteoporosis, with its attendant risk of fractured neck of the femur), as it reduces the level of some oestrogens in the blood (Baron, 1984).

E. Diseases generally unrelated to smoking

There remain many diseases that are essentially unaffected by smoking. Few, however, are common in developed countries and, in England and Wales, they account, in total, for only a little over a quarter of the deaths that occur annually from all causes. In many developing countries, where parasitic and other infectious diseases are common, the proportion is likely to be much higher.

F. Effects on foetuses

In addition to its other effects, smoking by pregnant women has also been found to affect foetuses transplacentally. The principal effect has been a reduction in birth weight with, in consequence, a small increase in perinatal fatality. It has also been reported to be associated with an increased risk of foetal malformation; but the results differ from one study to another, and if any teratogenic effect is produced it is certainly small (for reviews, see Landesman-Dwyer & Emanuel, 1979; Johnston, 1981).

Active agents in tobacco smoke

That smoking should be associated with the causation of (or death from) so many very different diseases was at one time held to be a reason for its being the cause of none — specificity being held to be one of the criteria for accepting a causal relationship. Had this been an important criterion, it would equally have weighed against the possibility that the consumption of milk could have been a cause of tuberculosis, diphtheria and scarlet and enteric fevers. Milk, of course, is not a simple agent, but a medium that is capable of conveying many different infectious agents from one person to another; and tobacco smoke, in which some 3000 chemicals have been identified, is equally complex, if indeed not more so.

This complexity has made it difficult to identify any individual agent within tobacco smoke as the chief cause of any of the diseases that are caused by smoking. Much progress has been made in identifying the fractions of smoke that contain the most active laboratory carcinogens and in demonstrating that different fractions of the particulate phase contain agents that affect different stages in the carcinogenic process (i.e., that exhibit initiating and promoting activity), as discussed later in the monograph. Laboratory models for the production of diseases due to smoking are not, however, satisfactory for diseases other than cancer, so that it has not been possible to show whether the particulate or the vapour phase is more important in the production of vascular and chronic obstructive lung disease. Nor do we know whether the nicotine content, which is generally thought to be the component of smoke that habituated smokers seek to obtain, plays any part in the production of any of the major smoking-induced diseases.

In this state of limited knowledge, it has been a priority for research to monitor the trends in smoking-induced disease in countries that have experienced major changes in the type of cigarette consumed. Major changes in mortality from lung cancer, myocardial infarction and chronic obstructive lung disease have been observed in some countries. The interpretation of these changes has, however, been difficult, as changes in smoking habits have sometimes been accompanied by changes in some other potentially important factors.

Morbidity and mortality attributable to smoking

The proportion of illness attributable to smoking varies from country to country as a result of variation in the amount of illness due to other causes, the prevalence of etiological agents that interact with tobacco smoke in the production of disease, and the smoking habits of the population, both currently and in the past. In countries where infectious diseases are common, particularly tropical countries, where a great deal of illness is due to parasitic infections, the consumption of tobacco tends to have been small in the past, and therefore the proportion of all illness that is now attributable to smoking is also small.

In other countries, smoking may be common and may have been so for many years, yet the effects on the incidence of some diseases may vary greatly, because of variation in the prevalence of other agents with which it interacts. It interacts, for example, with the level of blood cholesterol, approximately multiplying the effect of high levels (Mann *et al.*, 1976); and, in countries where these levels are low, the amount of myocardial infarction it

produces, although still absolutely large, can be relatively small. This is so, for example, in Japan and some other parts of eastern Asia, where low levels of blood cholesterol are prevalent due to a diet that includes relatively little fat, much of which is polyunsaturated. How far smoking interacts with other factors to increase the risk of many other smoking-related diseases is still unclear. It is, for example, uncertain how far the effect of smoke in producing chronic obstructive lung disease is modified by background levels of atmospheric pollution.

The third factor — the variation in smoking habits — is obviously important, as the amount of disease produced by smoking cannot be large when smoking is uncommon. The effect is, however, much more complex than may appear at first sight, as heavy consumption is associated with little disease until smoking has been common for many years. The relationship between the risk of disease and the duration of smoking has been worked out most clearly for cancer of the lung and chronic obstructive lung disease, but a similar relationship may hold for many other smoking-induced diseases as well.

The combination of these factors may make it difficult to estimate the contribution of smoking to morbidity and mortality in different countries. It certainly cannot be estimated solely from knowledge of current smoking habits, and the figures for each country can be determined only after detailed enquiry.

The contribution of smoking to total mortality can be estimated by calculating the total number of deaths that would be observed if the population in question had experienced the same age- and sex-specific total mortality rates as were observed in nonsmokers. Such a calculation is, however, likely to be less reliable than the corresponding calculation of cancer deaths (see p. 228 of the monograph), because confounding between smoking and other etiological factors, such as alcohol consumption and psychological stress, is likely to be more important. In the study by Rogot and Murray (1980) of a quarter of a million US veterans, the nonsmokers' mortality rates were, in general, much lower than those observed for the whole group. Doll and Peto (1981) calculated that 15 286 of 36 143 deaths (more than 40%) occurred prematurely as a result of smoking or of other factors associated with it, most of which were likely to have been due to smoking. Similar calculations led the Royal College of Physicians (1983) to estimate that, in England and Wales, the number of deaths that occur prematurely as a result of smoking each year is at least 100 000 (i.e., approximately 18% of the total). As about one-fifth of all deaths in the UK and the USA are due to cancer, it is clear that smoking-induced cancer deaths, which account for approximately 6 or 7% of all deaths (that is, a third of a fifth) constitute about one-half of the deaths from other diseases that have been caused in other ways by smoking (19% less 6 or 7%).

Trends in prevention

With so many diseases caused or aggravated by smoking, so many premature deaths attributable to it, and the habit so widespread throughout the world and becoming increasingly more common in countries where it has as yet been rare, smoking is probably the largest single preventable cause of ill health in the world today. Prevention is easy enough in concept, and those who have studied the subject have agreed, with only minor differences of emphasis, on the lines of action summarized in Table 2 (WHO, 1979;

Royal College of Physicians, 1983; Loeb *et al.*, 1984), except that some have doubted the value of taking steps to restrict the maximum yield of tar (National Research Council, 1982).

Table 2. Action to reduce smoking-related disease

Professional action

Health workers	set example educate at consultation treat dependence
Teachers	set example educate at school

Public action

Nonsmokers	press for nonsmoking areas
------------	----------------------------

Government action

Finance health education
Increase effectiveness of packet warnings
Ban sales promotion
Increase taxation progressively
Restrict progressively maximum yields of tar and (where appropriate)
Eliminate support for growing tobacco and for manufacture and distribution of tobacco products

The extent to which these recommendations have been put into effect varies from one country to another. Their adoption is, however, spreading steadily. At least 21 governments have already legislated to prevent the advertisement of tobacco products, except at the point of sale.

The impact on the amount smoked has been substantial. In countries such as Norway, where smoking had been becoming more common, the spread of the habit and the increase in the amount smoked has ceased. In others (like Finland, the UK and the USA), where smoking had long been prevalent in men, the proportion of smokers has fallen and so, after a delay of a few years, has the average amount consumed. In some of these countries, too, the prevalence of smoking among women, which had begun to increase many years after it had become common in men, has ceased to rise and begun to fall. Care, however, must be taken in assessing trends in smoking habits to check the extent to which reported habits correspond with sales. There has long been a tendency for reports of consumption to underestimate the amount sold and, with the increasing publicity given to the harmful effects of smoking, this tendency has increased. Trade figures, however, confirm that in many countries there has already been a reduction in the amount consumed which, in England and Wales, has amounted to more than 25% in the last 10 years.

Where changes in smoking habits have occurred there is evidence that they have begun first in the medical profession, extended to men and women in professional and other similar occupations, and subsequently spread to skilled and nonskilled manual workers. This steady progression through society holds out hope that smoking can be progressively diminished and largely eliminated.

These changes in smoking habits have already begun to be reflected by changes in mortality from some of the smoking-associated diseases, but the pattern is confused by cohort effects, changes in the prevalence of other etiological agents, and changes in nosological custom. And it is further confused by the fact that the changes in the type of cigarette, which have affected differently the concentrations of the different constituents of smoke, may have different effects on the different smoking-induced diseases. What helps to reduce the risk of one disease may not, in consequence, also help to reduce the risk of another, and the effect on each disease must be assessed carefully.

WORLDWIDE USE OF SMOKING TOBACCO

1. Production of and trade in tobacco

(a) *Historical aspects*

When Columbus landed in the New World on 11 October 1492, he was offered dried tobacco leaves at the House of the Arawaks. Although the Chinese claimed that they grew and used tobacco long before the discovery of America, no convincing documentation is available (Tso, 1986).

Various names were given to the tobacco plant, including 'Nicotiana', after Jean Nicot, French Ambassador at Lisbon. Nicot was one of the first people to grow tobacco in Portugal and was largely responsible for introducing the plant to the royal court in Paris; the Duc de Guise proposed using his name in 1585. However, the word 'tobacco' had become established in North America and survived all others for common usage. Early writers differ as to the origin of this name; it seems to have been used originally not for tobacco itself but for a type of tube used by natives for inhaling smoke from tobacco, or for a cylinder of tobacco leaf prepared for smoking (Encyclopaedia Britannica, Inc., 1966). 'Nicotiana' was retained as the generic name.

The tobacco plant thus belongs to the genus *Nicotiana*, which is a member of the family Solanaceae. The tobacco grown in France and Spain was *Nicotiana tabacum*, from seed originating in Brazil and Mexico. The species first grown in Portugal and England was *N. rustica*, the seed in Portugal coming from Florida and that used in England from Virginia (Tso, 1986).

There is no clear record of the history of tobacco cultivation in different areas of the world. Several reports, including that of Akehurst (1981), have presented partial information on the distribution of tobacco species in various locations. Table 3 gives a summarized chronicle of early tobacco cultivation and use and is based on those reports (Tso, 1986).

Originally, tobacco was smoked in pipes; gradually cigarettes and cigars became more popular. The primitive form of cigarettes was tobacco stuffed into a hollow reed or cane tube, or crushed tobacco leaves and shreds rolled in a corn husk or other vegetable wrapper. During the eighteenth century, the cigarette became more widely accepted; the first cigarette-machine factories were set up in Havana, Cuba, in 1853, in London in 1856 and in the American colonies in 1860 (Encyclopaedia Britannica, Inc., 1966).

Table 3. Chronicle of early tobacco cultivation and use^a

Date	Event
1492 (11 Oct.)	Columbus sighted the home of the Arawaks and was offered 'dried' tobacco leaves.
1499	Amerigo Vespucci recorded the use of chewing tobacco on an island off Venezuela.
1545	Iroquois Indians near Montreal, Canada, were found to have smoking habits.
1556	Tobacco was first grown or became known in France.
1558	Tobacco was used in Brazil and Portugal.
1559	Tobacco was used in Spain.
1560	<i>Nicotiana rustica</i> was used in Central Africa.
1565	Tobacco was used in England.
1600	Tobacco was introduced to Italy, Germany, Norway, Sweden, Russia, Persia, India, Indochina, Japan, China, and the west coast of Africa.
1612	John Rolfe, at Jamestown, Virginia, was the first man known to grow tobacco commercially for export.
1631	Tobacco production extended to Maryland and then gradually to other areas.
1650s	Portuguese took tobacco to South Africa and other countries. Spaniards distributed tobacco to the Philippines, Guatemala and other Central and South American countries and to the West Indies. Tobacco cultivation was begun in Indonesia. Tobacco cultivation was extended in Europe.
1900s	Tobacco was produced in New Zealand. <i>Nicotiana tabacum</i> species were introduced to Australia (<i>N. suaveolens</i> had been grown prior to this period).

The term 'cigar' is derived from the Spanish word *cigarro*, which was probably an adaptation of *sik'ar*, the Mayan term for smoking. The primitive form of cigar was a long, thick bundle of twisted tobacco leaves wrapped in a dried palm or maize leaf; this was the form that Columbus observed being smoked by American Indians. Cigars were introduced to Spain in 1600 and to Connecticut in 1762. The first cigars were manufactured in Sweden in 1814 (Swedish Tobacco Co., 1982). The first cigar-making factory was established in New Jersey, USA, in 1919 (Encyclopaedia Britannica, Inc., 1966).

(b) *Tobacco types*

A special terminology has developed with regard to the cultivation and handling of tobacco, which may differ to some extent with locality. In general, either individual green leaves or the entire stalk is cut and hung up in a barn to 'cure'. A roughly regulated regime of ventilation, temperature and humidity slowly dries the leaves and favours those catabolic processes considered desirable (Tso, 1972).

The methods of harvesting and curing different types of tobacco differ radically. There are two distinct methods of harvesting tobacco — priming and stalk cutting. For flue-cured tobacco, individual leaves are cut, or 'primed', as they ripen, two or three leaves at a time, starting from the bottom of the plant. For air-cured tobacco, including cigar filler and binder, burley, Maryland, dark air- and fire-cured, sun-cured and Perique tobacco, the entire plant is harvested by cutting the stalk near ground level. Oriental (aromatic or Turkish) tobacco and shade-grown cigar wrapper tobacco are harvested by priming (Tso, 1972).

There are two major methods of curing tobacco. In flue-curing, tobacco is dried entirely by artificial heat and in such a way as to prevent smoke from coming into contact with the leaf. In air-curing, little or no artificial heat is applied. Several other minor methods are also used, including (1) fire-curing, in which tobacco is partially cured by heat from open fires made on the floor of the barn and smoke is allowed to come into contact with the leaf; (2) sun-curing, in which tobacco is placed on scaffolds in the sun; and (3) combined sun-curing and air-curing, as for oriental tobacco (Tso, 1972).

A general list of tobacco types is given in Table 4.

(c) *Production and trade*

Since its discovery, tobacco has played an important role in farm economics and international trade. In the early 1600s, when tobacco began to be cultivated commercially in Virginia, shipping of the tobacco leaf greatly helped the development of England's merchant navy and opened up a valuable export. The Anglo-American tobacco colonies continued to supply the fast-spreading tobacco market throughout the colonial period.

In the late 1920s and early 1930s, large amounts of dark fire-cured and dark air-cured tobaccos were consumed. Immediately before the Second World War, the demand for light flue-cured types increased radically with the new popularity of cigarettes. During recent years, there has been a worldwide trend to increase taxes on tobacco, resulting in higher prices and reductions in production and consumption (see p. 74).

Table 4. Tobacco types and method of curing^a

Types of tobacco (common names)	Method of curing
Flue-cured, yellow, blond, bright, Virginia	Flue-curing
Burley, Maryland	Air-curing
'One sucker', 'Green River', black (slightly fermented)	light air-curing
Cigar binder, cigar filler, cigar wrapper	dark air-curing
	for cigars
Fire-cured, dark-fired, black fat	Fire-curing
Sun-cured	Sun-curing
Aromatic, oriental, Turkish	Combined sun-curing and air-curing
Perique, etc.	Miscellaneous

^aAdapted from Tso (1972)

Total areas of tobacco cultivated, total yield and quantity of production in certain continents and countries in 1981 and 1982 are shown in Table 5. China, the USA, India and Brazil were the leading producers in both years.

Trends in tobacco production and trade have changed extensively over the years. No definite relationship exists between the amount of tobacco a country produces and the extent of its exports or imports: the USA, one of the largest producing countries, also exports and imports the most; China is the largest producer of tobacco in the world but exports little, due to the high domestic demand.

Countries that produce well-defined types of good quality leaf export a large part of the crop. Examples are the exports of flue-cured tobacco from the USA; high-grade cigar tobacco from Cuba; and fine oriental leaf from Greece, Bulgaria and Turkey. Countries that import large quantities of leaf tobacco due to insufficient supply to meet consumption requirements are the Federal Republic of Germany, France, Japan, the Netherlands and the UK.

Table 6 shows international trade in unmanufactured tobacco during 1980 and 1981 (US Department of Agriculture, 1983). Countries with the highest exports were: first, the USA; second, Brazil; third (1980)/fourth (1981), Zimbabwe; fourth (1980)/third (1981), Turkey; and fifth, India. Other countries, such as Greece, Italy, Bulgaria, Thailand and Malawi, also exported considerable amounts of tobacco during those years. Certain countries that exported unmanufactured tobacco also imported considerable amounts. In 1981, the USA was the leading tobacco importer, followed by the Federal Republic of Germany, the UK, the USSR, Japan and China.

Table 5. Areas, yields and quantities of tobacco produced in certain areas of the world, 1981-1982^a

Continent or country	Area (hectares)		Yield (kg/hectare) ^b		Production (tonnes)	
	1981	1982	1981	1982	1981	1982
World total	4 075 138	4 276 392	1.46	1.56	5 947 631	6 660 964
North and Central America (total)	592 761	562 396	2.08	2.06	1 234 209	1 158 506
Canada	47 356	40 875	2.37	1.19	112 360	77 947
Cuba	60 000	60 000	0.83	0.75	50 000	45 000
USA	395 181	365 853	2.37	2.43	936 266	890 240
South America (total)	345 810	356 453	1.29	1.46	446 939	519 641
Brazil	239 000	246 000	1.31	1.51	314 000	372 000
Europe (total)	501 294	510 046	1.48	1.49	740 098	760 086
Bulgaria	113 080	114 881	1.24	1.36	140 500	156 000
France	16 996	14 970	2.52	2.72	42 774	40 770
Germany, Federal Republic of	3 161	3 056	2.48	2.41	7 839	3 350
Greece	91 152	93 320	1.40	1.39	127 401	130 017
Italy	60 688	60 600	2.16	2.20	130 971	133 500
Poland	48 590	48 200	1.97	1.70	95 523	82 000
Spain	21 522	22 764	2.02	1.94	43 534	44 125
USSR (Europe and Asia)	183 000	186 000	1.49	1.56	273 000	290 000
Africa (total)	242 968	254 856	0.96	1.08	234 228	274 624
Malawi	68 880	69 545	0.74	0.85	50 700	58 800
Zimbabwe	39 752	49 018	1.75	1.89	69 408	92 380
Middle East and Asia (total)	2 201 445	2 399 246	1.36	1.52	3 001 888	3 642 525
China	757 000	930 000	1.98	2.15	1 500 000	2 000 000
India	451 500	448 300	1.07	1.17	480 800	525 000
Philippines	94 655	104 485	0.86	0.87	81 366	90 878
Thailand	86 497	91 415	0.87	0.99	75 230	90 020

^aFrom US Department of Agriculture (1983); data for 1982 have not been finalized

^bDried material

Table 6. International trade in unmanufactured tobacco, 1980-1981 (tonnes)^a

Continent or country	1980		1981	
	Exports	Imports	Exports	Imports
World total	1 345 989	1 444 838	1 484 144	1 512 638
North and Central America (total)	352 953	208 548	380 480	242 890
Canada	19 491	7 565	33 041	2 754
Cuba	500	-	15 000	-
Mexico	27 000	-	18 000	-
USA	273 477	195 468	266 104	234 910
South America (total)	193 096	11 950	185 224	11 967
Brazil	143 396	-	148 000	-
Europe (total)	293 044	807 958	319 568	772 675
Bulgaria	60 000	3 500	60 000	3 500
France	4 017	71 037	2 558	64 546
Germany, Federal Republic of	30 698	189 285	29 442	182 366
Greece	70 673	2 772	86 430	3 665
Italy	46 450	29 759	75 810	23 228
Poland	8 894	23 099	4 700	25 544
Spain	7 487	77 088	2 788	71 082
UK	5 030	118 438	5 535	130 977
USSR (Europe and Asia)	2 356	83 394	2 200	86 000
Africa (total)	189 109	71 543	187 208	85 989
Malawi	63 772	-	48 000	-
Zimbabwe	98 977	40	116 552	240
Middle East and Asia (total)	314 898	246 131	410 018	298 626
China	10 000	50 000	10 000	80 000
India	73 193	100	104 862	100
Japan	6	71 418	-	84 301
Philippines	20 369	13 936	29 438	15 389
Thailand	39 057	10 618	41 000	12 000
Turkey	83 727	-	130 969	-
Oceania (total)	533	15 314	446	14 491

^aFrom US Department of Agriculture (1983)

As an indication of the destinations of most exported tobacco, US tobacco exports are shown in Table 7 by country and type for 1981 and 1982 (US Department of Agriculture, 1983). Japan purchases the most US tobacco, followed by the Federal Republic of Germany, the UK, Switzerland, Spain, Italy, the Netherlands and Thailand.

Table 7. US exports of tobacco by country of destination and type, 1981-1982 (tonnes)^a

Tobacco type	Country of destination	1981	1982
All types	Total	265 143	259 487
	Germany, Federal Republic of	37 719	30 913
	Italy	12 015	12 734
	Japan	53 063	50 041
	Netherlands	12 976	11 395
	Spain	15 145	14 437
	Switzerland	18 081	12 129
	Thailand	8 355	12 559
	UK	17 884	13 903
Flue-cured	Total	175 191	158 036
	Germany, Federal Republic of	23 213	16 591
	Japan	33 430	29 951
	Spain	12 740	12 320
	UK	13 742	10 311
Burley	Total	33 636	47 014
	Germany, Federal Republic of	7 985	9 000
	Italy	5 218	5 443
	Japan	6 166	7 860
	Switzerland	3 149	4 626
Dark-fired (Kentucky, Tennessee)	Total	7 385	8 517
Black fat	Total	1 149	1 000
Dark-fired (Virginia) and sun cured	Total	694	1 245
Maryland	Total	3 308	3 027
	Switzerland	1 836	2 238
Cigar wrapper, binder, filler	Total	1 440	622
Miscellaneous	Total	38 133	35 579

^aFrom US Department of Agriculture (1983)

(d) *Modification of raw materials*

A reduction in the yields of toxic agents in smoke may be achieved both by manipulating the tobacco plant and leaf material and by physical and chemical methods during manufacturing processes (Tso, 1980). The latter are described under 'Product design and delivery', pp. 57-60.

The botanical, chemical and physical properties of leaf tobacco are affected by genetic make-up, environmental conditions, culture practices and post-harvest treatment. Variables such as differences in variety, field spacing, fertilization, number of leaves per plant, agricultural chemicals, degree of maturity at harvesting and curing all affect the composition of the final products (Tso, 1972).

The interrelationship between variables of leaf components, smoke constituents and biological activity have been studied in order to establish a theoretical model for modified tobacco. Vast genetic resources and a better understanding of the dynamic balance during plant growth and the metabolic changes that occur during senescence and curing can be used to produce plant materials that approach the theoretical model, by developing new varieties and new culturing and curing practices using selected botanical, chemical and physical markers. The homogenized-leaf-curing procedure to promote biochemical changes and remove undesirable products, when perfected and applied in the future for mass production, may have many advantages, including (1) removal of undesirable components that cannot be eliminated by genetic or cultural manipulation, (2) inhibition of the formation of undesirable smoke precursors and (3) control of physical characteristics through reconstitution (Tso, 1980).

The total nitrogen content of leaf tobacco is known to be associated with many potentially hazardous variables in cigarette smoke (Tso & Chaplin, 1977), and there is a correlation between nitrogen content and the content of dry total particulate matter, benzo[*a*]pyrene, benz[*a*]anthracene, hydrogen cyanide, phenols, carbon monoxide and carbon dioxide. Although some of these smoke constituents do not contain nitrogen, the total amount of nitrogen in plants strongly affects the formation of other organic components and thus the properties of tobacco. Furthermore, since the pyrolysis products of soluble proteins include hydrogen cyanide, nitrogen oxides, quinolines and, possibly, nitrosamines, removal or reduction of soluble protein and other nitrogen fractions by the homogenized-leaf-curing process might be expected to result in a less toxic tobacco (Tso, 1980).

2. Manufacture and usage

(a) *Forms utilized*

Most of the wide variety of smoking products manufactured throughout the world contain varieties of *N. tabacum*, although, in some areas, certain varieties of *N. rustica* are used as cigarette and pipe tobaccos (Garner, 1951; Wynder & Hoffmann, 1967; Tso, 1972; Akehurst, 1981).

(i) *Cigarettes*

Cigarettes are made from fine-cut tobaccos and are wrapped in paper or a maize leaf. Those manufactured in the Federal Republic of Germany, Italy, Japan, Sweden, Switzerland, the USA and many other countries are blended with varying proportions of different grades of flue-cured (also called 'Virginia'), burley, Maryland and oriental tobaccos. In Canada, Finland and the UK, cigarettes made entirely of flue-cured tobaccos are preferred, whereas in France and in some North African and some South American countries, cigarettes filled with dark air-cured tobaccos are more popular. Cigarettes measure between 60 and 120 mm in length and between 20 and 30 mm in circumference, and range in weight from 500 to 1200 mg. Before cutting, cigarette tobacco is usually sprayed with 'casing', a 'sauce' composed primarily of sugars, humectants and/or aromatic substances.

A type of cigarette popular in the USSR is the *papirossi* (Cooper, 1982), which is often characterized by a long, hollow mouthpiece that can be twisted before smoking. Such cigarettes are filled either with pure oriental tobacco or a mixture of tobaccos; they are also hand-rolled from granulated tobacco leaves and from midribs of *N. rustica*.

(ii) *Cigars*

Cigars consist of filler, binder and wrapper, all of which are made of air-cured (see Table 4) and fermented tobaccos (Cornell *et al.*, 1979). Since about the mid 1950s, the binder or wrapper, or both, of many brands of cigars consists of reconstituted cigar tobaccos. The aroma and flavour of cigars are in large measure the result of precisely controlled treatment during fermentation, which is a process that promotes hydrolysis and oxidative deamination under conditions of elevated temperature and humidity (Tso, 1972). Although they are usually hand-made, machines for manufacturing cigars have been available since 1919.

Cigars vary greatly in form, length and diameter; they can weigh more than 10 g. They include a large variety of products, which have as a common property that they are wrapped either in tobacco leaf, reconstituted tobacco or paper that has been treated with tobacco extract. Consumption of cigars has decreased drastically over the last 15 years. Since about 1970, manufacturers in many countries have marketed 'little cigars', which are made primarily of cigar tobaccos rolled in cigarette paper that has been saturated with tobacco sauce. These products weigh less than 1.5 g. Cigars weighing between 1.5 and 3.0 g are often called 'small cigars' or, in Europe, 'cigarillos'. They are characterized by being open ended and often have tapered mouthpieces.

Cheroots are a type of small cigar made of heavy-bodied tobaccos, and are found all over the world. In southern Germany and Switzerland, where they are called *Stumpfen* (Schüler *et al.*, 1980), they are usually square. In parts of Asia, especially in India, cheroots are called *chuttas*. They are hand-made, have no wrapper and a single binder; they consist of cured tobacco folded into a dried tobacco leaf (Sanghvi *et al.*, 1980). The *chutta* is frequently associated with the remarkable habit of 'reverse' smoking, during which the burning end is held inside the mouth; often, a wet cloth is wrapped around the smoking end to act as a filter and to reduce heat (Pindborg *et al.*, 1971).

(iii) Pipes

Probably the earliest fashion for tobacco use, pipe smoking had great ceremonial importance in the cultures where it originated. Pipes more than 1000 years old have been found in the Mississippi Valley, USA, and are represented in stone carvings of the Mayas. They were integral to the religious ceremonies of ancient Mexican priests. As a symbol of peace and tranquillity and as a means of delivering a desired dose of nicotine, opium or marijuana, pipe smoking was spread by sailors from the Americas to Europe and thence to the rest of the world (Encyclopaedia Britannica, Inc., 1966). The carved slate peace pipe of the American Indians differed little in principle from the clay pipe of the Elizabethans or the elegant briar of the English gentleman. In parts of India and Nepal, *chillum* (Voges, 1984) and *sulpa* (Anon., 1983a) clay pipes are used. Pipe smoking has been on the decline since the beginning of the twentieth century.

Many pipe tobaccos are blends of 20-25 different leaf tobaccos; however, some of the most popular ones, especially in the USA, may be made of burley varieties only. Some pipe tobaccos contain midrib tissues. Frequently, 'casings' or 'sauces' are added to pipe tobaccos, which contain liquorice, sweetening agents, sugars and/or flavouring agents. Some pipe tobaccos may contain as much as 30% of additives (Hoffmann *et al.*, 1963). Pipe smoke is slightly cooler than cigarette smoke and slightly alkaline.

A large variety of water pipes (known as hookahs, *gozas*, hubble-bubbles, narghiles and *sheeshas*) is used in the Middle East, in Asia, including China, and in some areas of Africa. In the Middle East, the narghile is popular (Voges, 1984). Cut or shredded tobacco is burned in the head, *boori*, the smoke is drawn through a long tube inside the water pipe (*kootbi*), filtered through water in a container called a *shishi*, and reaches the smoker's mouth via a long flexible tube, the *kaseba* (Hoffmann *et al.*, 1963). An even greater variety of tobaccos, or mixtures of tobaccos with other plant products, is used in such pipes. For example, in Saudi Arabia, *jurak*, a mixture of tobacco, banana pulp and molasses, is smoked in *sheeshas* (Sardar, 1982). In Afghanistan and Pakistan, primarily *N. rustica* is smoked in such pipes (Ahmad, 1983). In China, *N. rustica* is used, commonly in combination with linseed oil and rapeseed oil (Houqing, 1984).

The smoking of water pipes is one of the more ancient forms of tobacco use and is widely practised as a form of social communication among groups, usually of men, who sit around a communal pipe. A relatively deep inspiratory effort is required to overcome the resistance of the long narrow airway. Ibrahim (1982) suggests that the water is a relatively effective filter, which may reduce the tar content of the smoke; interestingly, he also indicates that this form of smoking is an efficient way of spreading tuberculosis.

(iv) Bidis

The *bidi* (*biri*) is representative of a number of eastern smoking products. It contains a relatively small amount of locally grown tobacco (0.2 - 0.3 g), usually sun-dried and -cured, which is flaked and hand-rolled in a rectangular piece of dried *temburni* leaf (*Diospyros melanoxylon*). They are sometimes rolled in other leaves, and the size varies considerably. They may produce a smaller volume of smoke than cigarettes (Sanghvi *et al.*, 1980; Jussawalla, 1982); but the longer variants may allow two or three times as many puffs as an

ordinary cigarette and deliver up to 40 or 50 mg of tar (Hoffmann *et al.*, 1974). Since *bidis* lack added burning agents, they must be puffed continuously to be kept alight and therefore probably deliver a relatively high dose of tar to the smoker.

(v) *Kreteks*

Kreteks are cigarettes that are widely manufactured in Indonesia, both by small industries and in factories. They may be similar in size to western cigarettes, but they include a substantial addition of cloves, which gives both the *kretek* and the smoke a characteristic aroma. Other flavourings may be added (Voges, 1984).

(vi) *Sticks*

Brus is the tobacco grown in Papua New Guinea and cured in the sun. It is usually shredded and rolled in paper to produce a long, large cigarette, generally known as a *stick*. Endemic paper shortages in the villages of Papua New Guinea decades ago led to efficient recycling of newspaper as a wrapping for *brus*. Now that cigarette paper is available, this population still prefers to buy a form that is printed with out-of-date news. *Sticks* are now manufactured from commercial tobacco and have been shown to produce 14-25 mg of tar, 1-2 mg of nicotine and 7-8 mg of carbon monoxide. Hand-made *sticks* containing *bru* deliver 18-80 mg of tar, 2-8 mg of nicotine and a volume of carbon monoxide that was too large to be measured in the test system described (Brott, 1981).

(vii) *Others*

A wide variety of home-made smoking materials is prepared from home-grown tobacco in many traditional societies, e.g., in China, Zambia, Pakistan and Thailand, each with its own characteristics and name. No attempt has been made to itemize all of these here.

(b) *Product design and delivery*

Significant changes have been made in the design of cigarettes over the past few decades. Some of these developments occurred as a result of an increased demand for cigarettes with lower yields of certain smoke components, especially of total particulate matter and nicotine. The major changes in cigarette design include: more specific blend selection, variations in length and circumference, addition of filters, the use of reconstituted tobacco sheet, expanded tobacco, and the development of ventilation techniques (Norman, 1982; Baker, 1984; Grise, 1984; Kassman, 1984). A manufacturer may alter several of these parameters to achieve the desired final product in terms of delivery. The exact specifications, especially blend selection, are of a proprietary nature; however, some general statements can be made with regard to the effect of different parameters of cigarette design on the yield of smoke components.

(i) *Blend*

Tobaccos of different genetic origins and differently cured vary in leaf chemistry. For example, US air-cured burley tobacco, US flue-cured tobacco and oriental types result in smoke which differs in flavour and aroma. A low-tar, research cigarette produced at the

University of Kentucky (1R4F) was designed to represent a typical blend (Davis, D.L. *et al.*, 1984). It consists of approximately 33% flue-cured, 20% burley, 11% oriental and 1% Maryland tobacco, and 27% reconstituted sheet (described below), the remainder being additives (reducing sugars and glycerine). When smoked under standard laboratory conditions, this cigarette has a yield of 9.2 mg tar, 0.80 mg nicotine, 11.6 mg carbon monoxide and 0.34 mg nitrogen oxides. The 'puff count', or the number of puffs required to machine-smoke the cigarette, is lower than that of a high-yield Kentucky reference cigarette.

(ii) *Reconstituted sheet:*

The idea of making reconstituted tobacco resulted from a desire to use all of the tobacco purchased from a grower. It is produced by a paper-making process using either small sections of leaf otherwise lost during threshing or leaf stems. The resulting product generally contains more cellulose, fibre, lignin and ash and fewer alkaloids, nitrogenous compounds and reducing sugars (Norman, 1982). The process was first developed and commercialized in the early 1950s for the manufacture of cigars and, subsequently, cigarettes. Reconstituted tobacco now makes up a significant fraction of US cigarette blends and is also widely used in other countries. By using the reconstitution processes, both physical and chemical characteristics that affect not only combustion but also the levels of the constituents of smoke can be changed, e.g., less particulate, condensate, nicotine and isoprene (Selke, 1980). Reconstitution, like the homogenized-leaf-curing procedure for harvested, mature tobacco may remove specific constituents from cured leaf material.

(iii) *Expanded tobacco*

To obtain cigarettes with lower tar and nicotine yields, less tobacco may be used per cigarette; in order to maintain the volume, a procedure for expanding tobacco was developed, in which the tobacco leaf is expanded or 'puffed' to produce a less dense tobacco with more filling capacity. Cigarettes with a high content of expanded tobacco burn more rapidly than other cigarettes (Grise, 1984) and have lower puff counts. This practice was introduced into American blends in the late 1960s and continues to be an important characteristic of many of the 'very-low-tar' brands.

(iv) *Filters*

The major reduction of 'tar' levels in cigarette smoke has been achieved by the design of filter tips (Browne *et al.*, 1984). The popularity of filter cigarettes increased markedly from the early 1950s after the publication of papers demonstrating a causal relationship between smoking and lung cancer. In many countries, filter cigarettes dominate the market. In 1982, they accounted for 90% or more of the cigarette market in a number of countries (Anon., 1983b). A comparison with the percentages in 1973 is shown in Table 8.

Cellulose acetate filters are the most widely used; however, charcoal filters continue to be placed on some brands. In comparison with non-filter cigarettes, filtered types have significantly less dry particulate matter and nicotine, although carbon monoxide delivery may be higher (Wald *et al.*, 1976). The phenol content has been greatly reduced by the use of plasticized, cellulose acetate filters.

The filter tips of these cigarettes vary in length between 12 and 30 mm and consist of cellulose acetate or cellulose 'tow' or crepe paper. Most filter material contains a small percentage of plasticizers, such as triethylene glycerol diacetate. Filters may be made either

Table 8. Percentage of the total production of cigarettes represented by filter cigarettes in various countries^a

Country or territory	1973	1982 ^b	Country or territory	1973	1982 ^b
Algeria	85	90	Japan	96	98
Argentina	90	100	Kenya	79	80
Australia	93	95	Lebanon	33	83
Austria	85	97	Malaysia	82	90
Barbados	87	90	Mexico	61	83
Belgium and Luxembourg	68	84	Morocco	39	45
Brazil	74	93	Netherlands	50	67
Bulgaria	70	70	New Zealand	91	100
Canada	90	95	Nicaragua	80	100
Chile	84	85	Nigeria	75	93
China (Shanghai) ^c			Norway	62	91
Colombia	14	61	Panama	100	100
Costa-Rica	82	90	Philippines	55	93
Czechoslovakia	48	90	Poland	23	45
Denmark	50	60	Portugal	76	84
Dominican Republic	75	88	Republic of Korea	61	98
Ecuador	10	84	Sierra Leone	47	38
Egypt	92	100	Singapore	69	95
El Salvador	98	99	South Africa	90	90
Finland	90	98	Spain	51	90
France	47	47	Spain (Canary Islands)	60	90
Germany, Federal Republic of	85	89	Sweden	79	92
Greece	79	92	Switzerland	96	97
Guatemala	94	99	Syrian Arab Republic	73	99
Guyana	96	99	Taiwan	94	99
Honduras	93	90	Thailand	19	73
Hong Kong	80	89	Tunisia	59	84
Hungary	50	80	Turkey	18	76
India	15	29	UK	83	94
Indonesia	31	35	USA	85	93
Iran	37	45	USSR ^d	20	30
Ireland	78	88	Venezuela	99	99
Israel	97	99	Yugoslavia	88	97
Italy	74	83	Zaire	20	35

^aFrom US Department of Agriculture (1983)^bEstimates are included in the absence of reasonable data.^c26% in 1984 (Gao, 1986)^dWithout *papirossi*

of a single, basic filter material or are composite filters, which combine cellulose acetate, processed cellulose paper, activated carbon, other absorbents and/or solid plastic devices (Reynolds, 1978).

Cigarettes with charcoal filters are especially popular in Japan (62% of all cigarettes sold in 1981; Shien, 1982). They are usually made of two segments — one of tow, the other of charcoal — or of three segments, with charcoal granules sandwiched between tow. Sometimes the entire length of the tow in a filter tip is dusted with charcoal particles (Reynolds, 1978). [It is not known what contribution charcoal filters have made to changing the tar content of cigarettes in Japan.]

Another type of filter tip is the ventilated filter, which dilutes the smoke by allowing air to enter through perforations in the tip and *via* longitudinal air channels at the periphery of the filter, which also reduce the carbon monoxide concentration in smoke (Hoffmann *et al.*, 1983a; Baker, 1984).


(v) *Ventilation:*

Ventilation may be achieved either by increasing the permeability of the cigarette paper or by providing ventilation holes at the filter. With greater ventilation, a smaller proportion of the puff volume is drawn through the pyrolysis zone; less tobacco is burned, and the level of most mainstream smoke components is thus decreased. (For definitions of mainstream and sidestream smoke, see p. 83) All mainstream smoke products are also diluted by the incoming air. The outward diffusion of light gases, such as carbon monoxide, is increased, thereby increasing their levels in sidestream smoke. As ventilation is increased, a larger proportion of tobacco is consumed between the puffs (smoulder period), and the sidestream:mainstream smoke ratio increases (Baker, 1984). The total ventilation of a ventilated cigarette changes as the cigarette is consumed, affecting the delivery of smoke components per puff of cigarette. The percentage of air dilution in the low-yield Kentucky research cigarette (1R4F) is about 28% (Davis, D.L. *et al.*, 1984).

(c) *Tar and nicotine yields*

The effect of these changes in cigarette design is reflected in a trend of declining sales-weighted average tar and nicotine levels in the smoke of cigarettes in many countries since 1955. In 1978-1979, scientists in the UK collected cigarettes from 1934 to 1979 that were still available in adequate numbers (Wald *et al.*, 1981a). These old cigarettes were rehumidified and smoked under standard laboratory conditions in the UK Laboratory of the Government Chemist. In cigarettes of early years (1934-1940), the tar values were about 33 mg, carbon monoxide 19 mg and nicotine 2.0 mg per cigarette. By 1979, these smoke yields had decreased, reaching sales-weighted average values of 17 mg tar, 17 mg carbon monoxide and 1.4 mg nicotine. Thus, since 1934, nicotine yields have decreased to a lesser extent than those of tar, and carbon monoxide yields have changed even less.

In the USA in 1956, sales-weighted average tar and nicotine values were about 38 mg and 2.7 mg, respectively. By 1982, these levels had been reduced to about 13 mg tar and 1.0 mg nicotine (Tobacco Institute, 1984). Figures 1 and 2 graphically document the decline in tar and nicotine levels, denoting the technical modifications that have been introduced.

Fig. 1. Sales-weighted average tar yields of UK and US cigarettes by year of manufacture^a


^aFrom Wald *et al.* (1981a) and Norman (1982)

The following system of classifying cigarettes on the basis of tar yields, as determined under the most widely used laboratory conditions, was adopted by the Working Group:

<i>Description of yield</i>	<i>Tar yield (mg/cigarette)</i>
Very low	≤4.9
Low	5-9.9
Moderate	10-14.9
High	15-19.9
Very high	20 and over

The laboratory conditions comprise a 35-ml puff volume, a 2-sec puff duration, 1 puff per 60 sec and smoking to a 23-mm butt length for nonfilter cigarettes and to 3 mm in front of the

Fig. 2. Sales-weighted average nicotine yields of UK and US cigarettes by year of manufacture^a



^aFrom Wald *et al.* (1981a) and Norman (1982)

filter overwrap for filter cigarettes. The cigarettes are conditioned in an environmental chamber maintained at 60% relative humidity at 24°C (Jenkins, R.A. *et al.*, 1983). It was recognized, however, that the tar delivery of a cigarette is altered if it is smoked under different conditions, and this must be taken into account when describing human smoking experience. (See also section 3, pp. 163-194 of the chapter on 'Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans.') In addition, although machine-smoking parameters can differ substantially from the puff drawing of smokers, especially in the case of cigarettes that deliver low yields of nicotine, publication of tar level measurements was considered to be useful for public health purposes, since it may, over the years, encourage a general lowering of the particulate matter delivered by cigarettes.

A series of research cigarettes has been developed, which is referred to in other sections of this monograph; the tar, nicotine and carbon monoxide levels in these cigarettes are presented in Table 9.

Table 9. Smoke component levels of US research cigarettes as measured under standard laboratory conditions

Designation	Tar (mg/cig)		Nicotine (mg/cig)		Carbon monoxide (mg/cig)	
	23 mm	30 mm	23 mm	30 mm	23 mm	30 mm
Kentucky series^a						
IR1	34.3	30.1	2.16	1.98	20.8	18.1
2R1	36.8	32.9	2.45	2.19	25.1	22.2
2R1F	-	23.4	-	1.74	-	22.0
2A1 ^b	36.4	31.8	0.48	0.42	25.2	22.8
1A2	34.0	29.5	2.08	1.75	21.4	17.1
1A3	29.0	25.8	1.28	1.14	21.9	18.2
1A4	35.5	29.8	2.61	2.20	19.6	17.4
1R4F ^c	-	9.2	-	0.80	-	11.6
NCI series^d						
SEB-1	18.5	-	1.83	-	16.1	-
SEB-16	12.7	-	0.99	-	14.8	-
SEB-20	22.3	-	1.64	-	22.1	-
1R1	30.0	-	2.80	-	17.6	-

^aFrom Davis, D.L. *et al.* (1984)

^bEquivalent to original 1A1

^c35-mm butt length

^dFrom Gori (1976a); carbon monoxide levels given in ml/cigarette

Governmental agencies in several countries issue periodic reports on the tar, nicotine and carbon monoxide values for commercial cigarettes. In the USA, the US Federal Trade Commission (1985) reports twice yearly the levels of tar (<0.5-28 mg), nicotine (<0.05-2.1 mg) and carbon monoxide (<0.5-23 mg) for more than 200 marketed brands. Similar reports are released twice annually by the Health Departments of the United Kingdom (1984) (tar, <4-25 mg; nicotine, <0.3-2.5 mg; carbon monoxide, <3-19 mg). Reports on the tar and nicotine yields of commercial cigarettes are also published on an irregular basis in Australia, Austria, Canada, the Federal Republic of Germany, Japan, Switzerland and elsewhere.

Tar and nicotine yields of commercial cigarettes vary widely around the world (Table 10). Cigarettes delivering more than 35 mg of tar existed in 1983 in Austria, France, India,

Table 10. Ranges of tar and nicotine yields of commercial cigarettes from selected locations^a

Location (year cigarettes bought)	Tar		Nicotine		No. of samples
	mg/ cig.	median	mg/ cig.	median	
Austria (not given)	6-36	19	0.2-2.7	0.9	27
China (1981)	21-33	26	0.7-1.2	0.9	10
France (1978)	15-44	23	0.6-2.2	1.3	10
Germany, Federal Republic of (1979)	2-25	14	0.2-1.5	0.8	18
Hong Kong (1975, 1976, 1981)	1-32	19	0.1-2.6	1.2	47
India (1980)	21-38	27	1.1-2.0	1.5	16
Indonesia (1980)	18-55	36	0.8-2.8	1.7	20
Israel (1979)	9-26	21	0.6-1.3	0.9	10
Italy (1977, 1979)	14-36	23	0.4-2.2	1.1	23
Japan ^b (1980)		15.9		1.05	
(1981)		15.6		1.02	
Kenya (1978)	16-32	23	1.0-3.4	1.7	15
Philippines (1975, 1977)	22-44	32	0.8-2.3	1.4	64
Scotland (1979)	9-33	18	0.7-2.4	1.4	11
Singapore (1981)	13-24	20	0.8-1.6	1.3	14
South Africa (1978)	12-39	28	0.5-2.4	1.7	68
UK (1978)	17-28	21	0.9-1.8	1.1	6
USA (1981) ^c	1-27	14	0.1-1.8	1.1	32
USSR (1983) ^d	21-31	25	1.3-1.9	1.6	17

^aFrom Jenkins, R.A. *et al.* (1986), unless otherwise specified

^bFrom Shien (1982), mean values

^cFrom Jenkins, R.A. *et al.* (1983)

^dFrom Laboratory of the Government Chemist (1984)

Italy, Indonesia, the Philippines and South Africa. One brand in Indonesia delivered 55 mg of tar (Jenkins, R.A. *et al.*, 1986). The tar content of cigarettes in developing countries is thus frequently very high, as is that of products such as *bidis* and *chuttas*.

By contrast, sales-weighted tar and nicotine yields have fallen in many countries, as shown in Figures 1 and 2 for the UK and the USA. For example, in Egypt, Finland, Saudi Arabia, Oman and Australia, brands delivering more than 20 mg of tar do not exist (as a result of legislation or voluntary agreement). The decline in sales-weighted tar yields is also quite widespread in some developing countries (Lee, P.N., 1984) (Table 11).

During 1979-1980 in Finland, the sales-weighted average tar yield decreased progressively from 21 to 16 mg/cigarette. According to analyses made in 1978, the *papirossi* cigarettes (with a hollow mouthpiece) commonly used in the 1950s delivered 26-27 mg of tar and 1.5-1.7 mg of nicotine (Central Statistical Office of Finland, 1980, 1984). During 1950-1970, filter cigarettes displaced the *papirossi* cigarettes; the latter were used by one-half of Finnish smokers in 1960 and by less than 10% in 1970 (Lee, P.N., 1975; Rimpelä, 1978).

The wide range of cigarettes available also results in varying yields of other smoke components. Jenkins, R.A. *et al.* (1983) report that, under laboratory conditions, carbon monoxide yields of US cigarettes ranged from 1-19 mg/cigarette, oxides of nitrogen from 28-543 μg /cigarette, hydrogen cyanide from 7-362 μg /cigarette and acrolein from 3-141 μg /cigarette. Most of the individual constituents were proportional to the tar deliveries within a factor of two. (This measurement did not apply to volatile nitrosamines.)

3. Smoking and public health considerations

The number of tobacco-associated cancers that occurs throughout the world is related to the long-term dose of carcinogens in tobacco. The target organ that is affected depends largely on the way in which tobacco is used; the forms of its use are as diverse as the cultures and countries in which it is used and the people who use it. It is therefore difficult to compare different populations, as habits vary greatly and may be mixed. Although individual differences within countries abound, however, there is some basic uniformity within national habits, e.g., almost all Japanese smokers use cigarettes.

With regard to dose, using cigarettes as an example, the indices bearing on it are: numbers of cigarettes smoked, amount of carcinogen delivered per cigarette (much of this being included in the tar component), duration of the habit and inhalation practice. The components of dose are different and less measurable for such practices as chewing (IARC, 1985a).

In developed countries now, exposure to tobacco components is almost entirely through smoke. The products used are mainly cigarettes, although pipes and cigars provided more of the exposure earlier in the lives of the population at risk today. Three measures bear on the ways in which some populations are exposed to tobacco smoke: estimates of national tobacco consumption, regularly published sales estimates and surveys of smoking habits (which are rarely available in developing countries).

Table 11. Sales-weighted average tar deliveries in various countries, 1982^a

Tar yield (mg/cigarette)	Developed countries	Developing countries or territories
0-10	None	None
11-16	Australia Belgium Canada Finland Germany, Federal Republic of Netherlands New Zealand Sweden Switzerland UK USA	Chile El Salvador Fiji Guatemala Kenya Mauritius Nicaragua Panama Papua New Guinea Trinidad and Tobago Venezuela
17-22	France Italy	Argentina Bangladesh Barbados Brazil Costa Rica Cyprus Hong Kong India Malawi Malaysia Malta Mexico Nigeria Sierra Leone Singapore South Africa Sri Lanka Suriname Zimbabwe
23-28	Denmark	Indonesia Pakistan Zaire
29+	None	None

^aAs supplied by the tobacco industry; from Lee, P.N. (1984)

These measures, discussed below, may provide useful trend lines, with certain limitations. Firstly, it is a common finding that surveys fail to account for total consumption, partly due to restriction of the age groups covered and partly to a tendency to underestimate amounts smoked in personal histories (Todd, 1978). Secondly, changes in cigarette design and composition [e.g., many cigarettes contain less tobacco and deliver smaller quantities of both tar and nicotine (see above)] have come about due to economic and technical factors affecting production as well as to public health pressures. These variations are of such magnitude that numbers of cigarettes alone may no longer constitute a satisfactory measure of exposure for the purpose of international comparisons although such estimates retain some value in individual countries, particularly where tar contents are known and published.

Measurements of reductions in tar and nicotine yields by analytical techniques involving standardized machine smoking of cigarettes do not accurately reflect the variations in yields experienced by smokers of low-yield products. This applies especially to cigarettes with low nicotine yields, true levels of exposure to which are governed by frequency of puff-drawing, size of puff volume, depth of inhalation of the smoke, and, possibly, lip pressure (see section 3, pp. 163-194, of the chapter on 'Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans'). While it has been observed that smokers compensate for low-nicotine delivery by altering their smoking patterns (Russell, 1980; Kozlowski *et al.*, 1980; Herning *et al.*, 1981; Hoffmann *et al.*, 1983a), there appears to be a limit for such compensation when the nicotine yield is ≤ 0.5 mg/cigarette (Hill, P. & Marquardt, 1980). Table 12 summarizes the methodological approaches towards reducing both total smoke yields and the amounts of individual or grouped smoke constituents.

Reduction of an individual compound or of a group of smoke constituents is considered to be selective when it exceeds the reduction of tar to a significant extent. Various methods for selective reduction of toxic and/or carcinogenic smoke constituents have been devised and tested in order to lower the tumorigenic potential of tobacco smoke to mouse skin and/or to hamsters by inhalation (Wynder & Hoffmann, 1967; Dontenwill, 1974; Weber, K.H., 1976; Wynder & Hoffmann, 1979, 1982; Browne *et al.*, 1984).

(a) Estimates of tobacco consumption in different countries

Such trends generally reveal rising consumption in most countries from the 1920s to the 1960s, interrupted in certain cases by major events, such as war, financial depression and reports by health bodies such as the US Surgeon General and the Royal College of Physicians of London. Table 13 gives the consumption of cigarettes per adult in selected countries during the period 1923-1983. This table does not reflect the reduced tobacco consumption in some countries as a consequence of the Second World War, and it conceals some quite substantial differences in smoking practice among a group of relatively developed countries. In Finland, the UK and the USA, the per-caput consumption increased steadily from 1920 to the 1960s and has been declining in recent years (Fig. 3).

The per-caput consumption of manufactured cigarettes in 110 countries in 1982 is shown in Table 14, and ranges from 17 to over 3700 manufactured cigarettes/year. Table 15 gives the proportions of tobacco used for different forms of tobacco consumption in some countries in 1923, 1953 and 1973 (Lee, P.N., 1975).

Table 12. Reductions in smoke constituents of experimental cigarettes^a

Method ^b	Smoke constituent		
	Tar	Nicotine	Benzo[<i>a</i>]pyrene
<i>Agricultural methods</i>			
Tobacco type (flue-cured burley) ^c	*	*	*
Cultivars	*	*	*
Fertilizing (nitrate)	*	*	*
<i>Tobacco processing</i>			
Cut	0	0	0
Use of stems	*	*	*
Reconstituted tobacco sheets ^d	*	*	*
Reconstituted tobacco sheet-paper process	**	*	*
Expanded tobacco	*	**	*
Expanded stems	*	**	*
<i>Cigarette production</i>			
Paper porosity	*	*	*
Cellulose acetate filters	*	*	*
Charcoal filters ^e	*	*	*
Perforated filters	**	**	**

^aFrom Wynder and Hoffmann (1982)

^bMethods known to be applied to commercial US cigarettes. Reductions: **, > 50%; *, 'significant'; 0, 'insignificant'

^cReplacing flue-cured with burley tobaccos

^dData relate to those not made by the paper process

^eReductions of tar, nicotine, benzo[*a*]pyrene (and other nonvolatiles) and volatile *N*-nitrosamines are, in general, greater with cellulose acetate filters than with charcoal filters.

Machine-made cigarettes dominate the modern market, particularly in Japan. Hand-rolling persists in Norway and to a lesser extent in Australia, Belgium, Denmark, the Netherlands, Sweden, the UK, the USA and other countries. Smokeless tobacco retains a significant market, for example, in Scandinavia and the USA (see IARC, 1985a). Cigars are still smoked in Belgium, Denmark and the USA, but their consumption is negligible in Japan, Australia and Norway. Long-term consumption

Table 13. Annual consumption of cigarettes per adult in selected countries in the period 1923-1983^a

Country	Year						
	1923	1933	1943	1953	1963	1973	1983
Australia	540	430	660	1420	2550	3080	
Austria	600	1000	1540	1320	1840	2550	
Belgium	650	880	290	1190	1760	2730	
Denmark	460	420	360	1230	1580	1850	
Finland	1290	1170	1340	1780	2190	2040	1829 ^b
% <i>papirossi</i>			(70%)	(45%)	(19%)	(3%)	
France	-	570	330	1120	1420	1920	
Japan	750	790	1140	1570	2170	3240	
Mexico	900	1150	1460	1530	1530	1360	
Netherlands	410	670	-	1370	1900	2370	
Norway	-	280	230	520	520	640	
South Africa	370	410	1070	1220	1000	1380	
Sweden	250	390	440	950	1310	1580	
UK	1030	1470	2330	2370	2790	3230	
males 15+ years	1980	2820	3930	3690	3820	3980	
males 16-19 years ^c	1150	1650	2350	1850	2950	3450	
USA	840	1230	2510	3380	3910	3850	3494 ^d

^aFrom Lee, P.N. (1975), unless otherwise specified

^bFrom Central Statistical Office of Finland (1984)

^cThe first UK age-specific survey data are from 1980

^dFrom US Department of Agriculture (1984)

figures are available for only a few developing countries. In 1973, tobacco consumption in India was as follows — cigarettes, 30%; cigars/cheroots, 5%; *bidis*, 34%; hookah, 9%; chewing tobacco, 19%; and snuff, 2%. In Indonesia, cigarettes claimed 28% and *kreteks* 72% of the measured market (Lee, P.N., 1975).

Table 14. Manufactured cigarette consumption in 110 countries or territories in 1982^a

Rank	Country or territory	Per-caput consumption	Rank	Country or territory	Per-caput consumption
1	Cyprus	3 117	29	Israel	1 656
2	Greece	2 927	30	Netherlands	1 652
3	Cuba	2 857	31	Denmark	1 636
4	Canada	2 797	32	France	1 608
5	USA	2 678 (3 746) ^b	33	Romania	1 593
6	Spain	2 658	34	Sweden	1 543
7	Japan	2 636	35	Taiwan	1 531
8	Hungary	2 570	36	Portugal	1 428
9	Poland	2 517	37	Philippines	1 371
10	Bulgaria	2 472	38	Trinidad and Tobago	1 318
11	Australia	2 340	39	Turkey	1 305
12	Yugoslavia	2 323	40	Uruguay	1 241
13	New Zealand	2 305	41	Malaysia	1 222
14	Switzerland	2 171	42	Mauritius	1 215
15	Austria	2 111	43	Finland	1 148
16	Belgium and Luxembourg	2 055	44	Argentina	1 136
17	Singapore	1 961	45	Venezuela	1 089
18	Hong Kong	1 957	46	Brazil	1 051
19	Lebanon	1 926	47	Syrian Arab Republic	1 049
20	Germany, Federal Republic of	1 867	48	Democratic Yemen	1 038
21	Italy	1 854	49	South Africa	1 002
22	UK	1 818	50	Fiji	986
23	Czechoslovakia	1 812	51	Suriname	975
24	German Democratic Republic	1 796	52	China	900
25	Ireland	1 778	53	Colombia	873
26	Republic of Korea	1 747	54	Egypt	872
27	USSR	1 715	55	Costa Rica	868
28	Libyan Arab Jamahiriya	1 688	56	Jordan	867
			57	Algeria	861

Table 14 (cont)

Rank	Country or territory	Per-caput consumption	Rank	Country or territory	Per-caput consumption
58	Belize	850	85	Iran	364
59	Chile	847	86	Sri Lanka	341
60	Nicaragua	846	87	Guatemala	325
61	Albania	786	88	Zimbabwe	319
62	Barbados	785	89	Haiti	316
63	Tunisia	768	90	Kenya	283
64	Democratic People's Republic of Korea	713	91	Zambia	223
65	Guyana	656	92	Mozambique	221
66	Jamaica	650	93	Ghana	218
67	Dominican Republic	614	94	Peru	216
68	Thailand	606	95	Lao People's Democratic Republic	209
69	Panama	595	96	Bolivia	206
70	Indonesia	577	97	Malawi	197
71	Iraq	574	98	Tanzania	181
72	Honduras	563	99	Cameroon	175
73	Norway	556	100	Bangladesh	170
74	Morocco	537	101	Uganda	146
75	Congo	531	102	India	141
76	Paraguay	521	103	Zaire	129
77	El Salvador	508	104	Cape Verde	117
78	Ecuador	508	105	Nigeria	98
79	Senegal	448	106	Nepal	93
80	Viet Nam	424	107	Burma	71
81	Ivory Coast	422	108	Ethiopia	48
82	Sierra Leone	419	109	Sudan	37
83	Pakistan	396	110	Guinea	17
84	Angola	375			

^aFrom Collishaw (1984)^bFrom US Department of Agriculture (1984)

Table 15. Proportions of tobacco used for various forms of tobacco consumption in selected countries in 1923, 1953 and 1973 (millions of kg)^a

Country	Year	Cigarettes	Cigars	Snuff	Handrolled/ pipe/ chewing	Total
Australia	1923	2.1 (26%)	0.3 (3%)	-	5.7 (70%)	8.1
	1953	9.1 (47%)	0.1 (0.5%)	-	10.3 (53%)	19.4
	1973	27.6 (86%)	0.3 (0.8%)	-	4.1 (13%)	32.0
Austria	1923	3.2 (32%)	0.7 (7%)	0.1 (1.4%)	5.9 (59%)	9.9
	1953	7.1 (80%)	0.3 (4%)	-	1.4 (16%)	8.9
	1973	14.5 (95%)	0.4 (2.4%)	-	0.4 (3%)	15.3
Belgium	1923	3.8 (20%)	2.1 (11%)	-	13.0 (69%)	18.9
	1953	8.2 (41%)	1.8 (9%)	-	10.0 (50%)	20.0
	1973	20.2 (71%)	3.6 (13%)	-	4.7 (16%)	28.5
Denmark	1923	1.4 (20%)	1.8 (25%)	0.3 (4%)	3.5 (50%)	6.9
	1953	4.9 (45%)	2.5 (23%)	0.5 (5%)	3.0 (27%)	10.9
	1973	9.2 (65%)	2.7 (19%)	0.2 (2%)	2.0 (14%)	14.1
Japan	1923	27.2 (52%)	0.1 (0.1%)	-	24.7 (47%)	51.9
	1953	89.6 (92%)	-	-	7.4 (8%)	97.0
	1973	267.0 (99%)	-	-	0.5 (0.2%)	267.5


Table 15 (contd)

Country	Year	Cigarettes		Cigars		Snuff		Handrolled/pipe/ chewing		Total
Norway	1923	-		-		-		-		-
	1953	1.5	(31%)	0.05	(1%)	0.5	(11%)	2.9	(58%)	5.0
	1973	2.0	(29%)	0.1	(1%)	0.3	(4%)	4.4	(65%)	6.8
Sweden	1923	0.6	(7%)	0.6	(7%)	5.5	(70%)	1.2	(16%)	7.9
	1953	5.6	(53%)	0.4	(4%)	2.9	(28%)	1.5	(15%)	10.4
	1973	7.1	(60%)	0.5	(4%)	2.7	(23%)	1.5	(12%)	11.8
UK	1923	34.1	(53%)	1.2 ^b	(2%)	-	-	28.6	(45%)	63.9
	1953	90.2	(84%)	0.4	(0.3%)	0.4	(0.3%)	16.3	(15%)	107.3
	1973	103.9	(87%)	3.3	(3%)	0.2	(0.2%)	11.7	(10%)	119.1
USA	1923	64.6	(20%)	63.4	(20%)	17.9	(6%)	169.2	(54%)	315.1
	1953	409.9	(74%)	51.6	(9%)	17.7	(3%)	75.5	(14%)	554.7
	1973	508.5	(79%)	59.7	(9%)	11.6	(2%)	60.8	(10%)	640.6

^aAdapted from Lee, P.N. (1975), by converting from pounds to kg

^bIncluding snuff

Fig. 3. Annual per-caput consumption of cigarettes in Finland^a, the UK^b and the USA^c, 1920-1983



^aFrom Central Statistical Office of Finland (1980, 1984)

^bFrom Lee, P.N. (1975)

^cFrom US Department of Agriculture (1984)

(b) Sales trends

Sales are published as millions of 'pieces', i.e., items of manufactured product. Table 16 shows some selected sales figures from developed and developing countries (see also Appendix 1). While short-term trends may be variable, some long-term trends are apparent. Sales increases are not confined to developing countries. Sales figures are influenced by a number of factors, particularly taxation, socioeconomic circumstances, advertising pressure and the presence or absence of anti-smoking programmes. Regular increases in taxation generally produce quite significant falls in sales (Ontario Council of Health, 1982).

(c) Surveys of smoking behaviour

Only from surveys can it be ascertained who is smoking, what is smoked, how much, for how long and (sometimes) in what way. Regular surveys provide useful public health

information, as they may identify populations at risk and some of the reasons they are at risk. Reliable random-sample surveys are carried out routinely in most developed countries and, if similar definitions are used, allow useful international comparisons. Table 17 shows a selective sample of smoking rates collected from the literature, from governmental and national cancer societies and from the World Health Organization. It provides an overview of habits in adults around the world, even though the classification of 'smokers', 'nonsmokers' and 'ex-smokers' varies somewhat and is generally based on self reporting.

Given the variable quality of the available data, some striking trends stand out. Women in Hunan, Shanghai, Japan, Hong Kong, Singapore, Moscow, Romania, Egypt, Kuwait, Tunisia and urban Nepal smoke little, if at all; whereas about a third smoke almost everywhere else, except Maoris in New Zealand and women in some other areas in the developing world where rates have not been measured. Male smokers generally represent between one-third and one-half of the population; Japan is one of the few higher exceptions in the developed world.

Adolescent smoking rates, although of considerable public health importance as an indication of future trends, are extremely difficult to measure accurately and, consequently, to compare. It is usual for smoking habits to become established during adolescence, and smoking rates of young people in their late teens may approximate those of adults.

The detailed anatomy of national smoking habits can be discerned only by regular measures of smoking rates, although, because of problems of underreporting, it is often advisable to use questionnaire responses merely to distribute total sales among various categories (e.g., of age, sex). The results of a nationwide survey in Australia of the proportions of cigarette smokers by year, sex and education are shown in Table 18.

(d) Indices of dose in developing countries

Although the relationship between tobacco smoke and lung cancer in developed countries may be the most researched subject in medical history, there remains a paucity of precise information concerning daily dosage of tobacco in developing countries. That the daily dose may be high is attested to by the exposure levels measured in case-control studies in Bombay (Notani & Sanghvi, 1974).

There is no way of estimating precisely lifetime exposure to smoking products such as *bidi*, *chutta*, *brus*, *sticks* and hookah or the formidable *khi yo* cigars of Thailand. As shown in Table 17, between 30 and 90% of men in Asia smoke compared with less than one-third of women, who, in some parts of the developing world, smoke hardly at all.

It is already clear that there exists a worldwide trend towards the sale of machine-made cigarettes. On the one hand, manufacture of *bidis*, chews and the various other home-grown, home-made products cannot be quantified readily because it is based on village cultivation or, at best, small industry. These products are generally cheap, vary widely from district to district, and may or may not be subject to taxation. On the other hand, cigarettes are mass produced centrally, or imported, easy to count and almost invariably taxed before sale. For this reason, increases in sales can be measured, and taxation figures can be used to monitor sales trends. What cannot be seen is the effect of the market expansion of manufactured cigarettes on the use of other tobacco products. It is not clear how far the

Table 16. Tobacco sales in millions of 'pieces'^a

Country	1968 ^b	1976	1983 ^b	Peak number	Peak year
Argentina	26 188	37 000	35 000	38 300	1980
Australia	23 600	30 900	33 400	34 400	1983
Austria	11 936	14 400	15 500 (1982)	15 700	1979, 1981
Belgium	16 100	20 200	19 800 (1981)	25 700	1974
Brazil	68 125 ^c	115 000	129 200	142 700	1980
Canada	47 113	60 700	62 800	66 500	1981
Denmark	5 799	7 500	7 300	7 800	1982
Egypt	11 141	22 300	35 000 (1982)	35 000	1982
Finland	6 300	6 400	6 900 (1982)	8 100	1975
France	67 200 (1970)	81 200	86 400 (1982)	87 900	1979
Germany, Federal Republic of	104 600	128 000	113 700	129 800	1981
Greece	15 862	20 000	23 500 (1981)	23 500	1981
Guatemala	2 206	2 600	2 200 (1982)	2 700	1977, 1980
Hungary	21 520	24 600	26 500	26 500	1983
India	60 137	66 000	87 700 (1981)	87 700	1981
Israel	3 340	5 500	6 200 (1982)	6 200	1982
Italy	66 600	89 700	102 000	102 000	1983
Japan	196 000	291 772	311 900	313 800	1979, 1982
Mexico	37 707	45 000	49 100	53 300	1980
Netherlands	18 497	22 500	22 000	26 900	1977
Norway	1 800	1 720	1 800	2 200	1980
Philippines	38 224	49 600	60 100	60 200	1982
Poland	63 300	88 052	83 741	94 245	1980
Portugal	9 277	11 834	13 700	13 700	1983
Singapore	2 560 (1969)	3 200	4 200	4 200	1983
Spain	44 797	63 100	75 400	75 400	1983
Sweden	9 700	12 000	12 100 (1982)	12 100	1982
Turkey	35 650	-	78 000 (1982)	78 000	1982
UK	121 800 ^c	130 600	101 600	137 400	1973
USA	528 700	603 530	596 190	627 150	1981
Venezuela	10 368	18 500	20 800	21 600	1978

^aFrom Maxwell (1976-1984)^bUnless otherwise specified^cConsumption

Table 17. Percentage of adult^a male and female smokers in various countries

Country or territory	Comment	Year of survey	Products used ^b	% of total who smoke		Source
				Male	Female	
Australia ^c	national	1983	ct	37	30	Hill, D. & Gray (1984)
Bangladesh ^d	market-place	1979	ct, B, P	71	20	Anon. (1983a); WHO (1983)
	Dhaka urban	1984	ct, B	70	20	Masironi & Rothwell (1985)
Brazil ^c	São Paulo	1972	ct	54	20	Joly, D.J. (1975)
	workers	1983	ct	52	37	Masironi & Rothwell (1985)
Brunei	Tutong urban	1979	ct	20	7	Masironi & Rothwell (1985)
Canada	national	1983	ct, C, P	41	32	Josse (1985)
China ^c	Hunan	1981	ct	56	1	WHO (1983)
	Shanghai county	1981	ct	44	3	Parker, R.L. <i>et al.</i> (1982)
	Ghanzhou urban	1984	ct	95	-	Masironi & Rothwell (1985)
Egypt ^c	national	1982	ct, P	40	1	Omar <i>et al.</i> (1982)
France	national	1978	ct	47 ^e	20	Ledez (1978)
Germany, Federal Republic of ^c	national	1980	ct, C, P	40	29	Anon. (1980)
Guatemala ^c	urban	1972	ct	36	10	Joly, D.J. (1975)
Hawaii	state-wide	1979	ct			Masironi & Rothwell (1985)
	Caucasians			61	50	
	Hawaiians			57	47	
	Chinese			37	18	
	Filipinos			48	28	
	Japanese			53	26	
Hong Kong ^c	national	1982	ct	37	5	Government Information Services (1982)
	national	1984	ct	33	4	Masironi & Rothwell (1985)

Table 17 (contd)

Country or territory	Comment	Year of survey	Products used ^b	% of total who smoke		Source
				Male	Female	
India ^d	Goa	1976	B, P, C	66	26	WHO (1983)
	Goa urban	1984	ct, B, P	29	3	Masironi & Rothwell (1985)
	Goa rural	1984	ct, B, P	61	7	Masironi & Rothwell (1985)
Indonesia	various sites	1984	ct ^f	61-75	5-10	Masironi & Rothwell (1985)
Ireland ^c	national	1980	ct, C, P	49	36	Health Education Bureau (1980)
Israel ^c	national	1983	ct	44	30	Ben-Sira (1983)
	20-21-yr olds	1984	ct	50	-	Masironi & Rothwell (1985)
	21-yr olds	1984	ct	37	-	Masironi & Rothwell (1985)
Italy ^c	national	1981	ct	54	32	Tamburini <i>et al.</i> (1981)
Ivory Coast	Abidjan	1981	ct	24	0.8	Masironi & Rothwell (1985)
Japan ^c	national	1980	ct	70	14	Tominaga (1982)
Kuwait ^c	national	1980	ct	52	12	WHO (1983)
Malaysia		1983	ct	18	2	Masironi & Rothwell (1985)
Nepal ^c	rural plains	1984	ct, B, P	66 (30-39 yr)	68 (50-59 yr)	Masironi & Rothwell (1985)
	urban	1980	ct, B, P	85	14	WHO (1983)
	hills	1984	ct, B, P	95 (40+ yr)	72 (40+ yr)	Masironi & Rothwell (1985)
	Kathmandu valley	1981	ct, B, P	79	58	Masironi & Rothwell (1985)
New Zealand ^c	national	1981	ct	35	29	Hay (1984)
Norway ^c	national	1982	ct	40	34	Löchsen <i>et al.</i> (1982)
Pakistan ^d	Karachi	1972	ct, B, P, C	49	4	WHO (1983)
	Karachi	1982	ct, B, P, C	44 ^g	6 ^g	Masironi & Rothwell (1985)
Papua New Guinea	highlands	1981	ct + brus	77	80	Masironi & Rothwell (1985)
	southcoast	1981	ct + brus	85	76	Masironi & Rothwell (1985)

Table 17 (contd)

Country or territory	Comment	Year of survey	Products used ^b	% of total who smoke		Source
				Male	Female	
Poland ^c	national	1980	ct, C, P	63	29	Oles (1983)
Romania ^c	urban, rural	1970	ct	52	9	Racoveanu <i>et al.</i> (1975)
Singapore ^c	national	1975	ct, C, P	51	8.3	Lee, H.P. (1980)
Sri Lanka	Kandy urban	1968	ct, B	48	2	Masironi & Rothwell (1985)
Sweden ^c	national	1982	ct	30	30	Anon. (1983b)
Switzerland ^c	Zurich county	1980	ct, C, P	50	26	Schüler <i>et al.</i> (1980)
Thailand	urban, nationwide	1976-81	ct	51	4	Masironi & Rothwell (1985)
	rural	1981	ct + local types	70	40	Masironi & Rothwell (1985)
Tunisia	Tunis urban	1984	ct, P	58	6	Masironi & Rothwell (1985)
UK ^c	national	1982	ct	38	33	Office of Population Censuses and Surveys (1983a)
USA ^c	national	1980	ct	38	30	US Department of Health and Human Services (1983)
USSR ^c	Moscow	1981	ct	44	10	Cooper (1982)
Zambia	Lusaka urban	1984	ct	63	56	Masironi & Rothwell (1985)

^aIn most studies, 15 years and older

^bct, cigarettes; C, cigars, cheroots; P, pipe, hookah; B, *bidi*

^cSample probably representative

^dSample not representative

^ePer inhabitant, not per adult

^fMay also include *kreteks*

^gIncluding chewers

Table 18. Australian smoking rates 1980 and 1983 — % of men and women smokers by level of occupation and education^a

	Men		Women	
	1980	1983	1980	1983
Occupational level^b				
Upper white collar	30	32	31	25
Lower white collar	36	32	29	28
Upper blue collar	45	40	32	30
Lower blue collar	47	43	30	36
Educational level				
9 years school	44	41	31	31
10-11 years school	44	41	32	32
12 years school ^c	31	28	27	27

^aFrom Hill, D. and Gray (1984)

^bUpper white collar, professional, managerial, farmer; lower white collar, clerical, sales; upper blue collar, skilled manual worker; lower blue collar, semi-skilled, unskilled or farm worker, unemployed, pensioner, housewife not stating a previous occupation

^cIncludes tertiary educated

habit of cigarette smoking is becoming a substitute for *bidi* smoking or for chewing, or whether cigarette smoking is becoming an additional habit. Mixed tobacco habits are common. Jussawalla and Deshpande (1971) recorded in a case-control study of 2005 patients with head-and-neck cancers that there were 1205 smokers, including 979 *bidi* smokers, 129 cigarette smokers, 54 *bidi* and cigarette smokers, and 1152 chewers, and that these groups included 595 patients with both chewing and smoking habits.

Use of tobacco is indeed worldwide. Although Sikhs, Seventh Day Adventists, Mormons, large populations of women, and the majority of people in developed countries do not use it, there is no country where tobacco is not available for smoking or chewing. After three decades of battle by public health interests in the developing world, the rate of expansion of the tobacco market has been slowed, and in many places sales and consumption have been decreased.

4. Summary

Tobacco was brought from America to the Old World by Columbus in 1492, and its use spread to many countries during the sixteenth century. Tobacco is now produced and consumed in almost every part of the globe; total world production in 1982 reached 6.7 million tonnes. Many types of tobacco are available, which differ in plant variety and in cultivation and curing methods; each type is generally used for one specific product. Recent trends indicate changes in production and utilization, particularly in consumption in developed countries. Modification of raw products and manufacturing techniques to reduce the yields of toxic agents in smoke is being studied widely and, in some cases, used widely,

Many different smoking products are used by hundreds of millions of persons throughout the world. The majority of these products are cigarettes, cigars and pipe tobaccos. During the present century, there has been a significant increase in the consumption of machine-made cigarettes in many countries.

The yields of mainstream smoke components are greatly affected by cigarette design, including ventilation (filter-tip dilution and paper porosity), tobacco composition (blended, reconstituted-sheet and expanded tobacco) and filtration. The yields of sidestream smoke components can be affected by tobacco composition and, to a lesser extent, by ventilation. The standard laboratory methods of determining particulate yields (tar and nicotine) have limited relation to specific human dosage. Individual smoking patterns are important.

Since 1950, there has been a substantial decline in the sales-weighted tar delivery of cigarettes sold in the UK, the USA and some other countries, although it is unlikely that smokers have reduced their tar intake to a similar extent. However, cigarettes with very high tar yields (35-55 mg) remain on the market in many parts of the world, and consumption and sales are increasing worldwide.

During the twentieth century, both the number of smokers and the number of cigarettes sold increased until the 1960s. By the early 1980s, some countries had recorded falls in total consumption, total sales and smoking rates.

CHEMISTRY AND ANALYSIS OF TOBACCO SMOKE

1. Physicochemical nature of tobacco smoke

The burning of tobacco products leads to the formation of mainstream smoke (MS) and sidestream smoke (SS). MS from cigarettes and cigars is generated during puff-drawing in the burning cone and hot zones; it travels through the tobacco column and exits from the mouthpiece. SS is formed in between puff-drawing and is emitted freely from the smouldering tobacco product into the ambient air.

The data presented throughout this section are derived from machine-smoking under standardized laboratory conditions, unless otherwise noted. It was recognized, however, that machine-smoking parameters can differ substantially from the puff-drawing of smokers, especially in the case of cigarettes that deliver low yields of nicotine in the MS (Herning *et al.*, 1981). The most widely used machine-smoking conditions for cigarettes and for little cigars are as follows: one 35-ml puff, taken over 2 seconds, once a minute, until a butt length of 23 mm or a butt length of filter plus overwrap plus 3 mm is reached (Brunnemann *et al.*, 1976a; Jenkins, R.A. *et al.*, 1983). For the smoking of cigars, the International Committee for Cigar Smoke Study (1974) recommended a 1.5-second puff every 40 seconds, a puff volume of 20 ml, and a butt length of 33 mm. Conditions for pipe smoking have not been standardized, although conditions of a 2-second puff every 12 seconds and a puff volume of 50 ml have been used frequently (Miller, J.E., 1964).

For the generation of SS, a number of devices have been developed (Dube & Green, 1982). Much of the chemical analytical work on SS has been carried out using the Neurath-Ehmke chamber or a modification thereof (Neurath & Ehmke, 1964a; Brunnemann & Hoffmann, 1974a). The smoke yields of toxic agents are influenced by the velocity of the air streaming around the smouldering cone of a cigarette in the SS chamber (Rühl *et al.*, 1980; Klus & Kuhn, 1982). Therefore, the air intake must be adjusted until the MS yield in this setting most closely approximates that obtained under free smoking conditions, i.e., without the restrictive apparatus.

The composition of tobacco smoke depends not only on smoking conditions but also on the physical and chemical properties of the leaf or tobacco blend, the wrapper and the filter. A variety of chemical and physical processes occur in the oxygen-deficient, hydrogen-rich environment of the burning cone at temperatures up to 950°C. The majority of the more than 3800 known smoke components (Dube & Green, 1982) are formed in a pyrolysis-distillation zone just behind the heat generating combustion zone (Baker, 1981).

About 20% of the total effluents of the MS originate from tobacco; the remainder come from the air drawn into the cigarette (Keith & Tesh, 1965). When undiluted cigarette smoke leaves the mouthpiece, it contains up to 1.3×10^{10} heterogeneous particles per cm³, with

round and spherical forms ranging from 0.2-1.0 μm in diameter (Dube & Green, 1982). In the case of conventional filter cigarette smoke, the particle size of the MS ranges from 0.15-1.3 μm , with a mean diameter of 0.48 μm . For high-density filter cigarettes, the values range from 0.15-0.8 μm , with a mean diameter of 0.39 μm (Carter & Hasegawa, 1975). The number of particles generated by cigarettes with perforated filter tips which provide air dilution of the MS before it leaves the mouthpiece is significantly lower than that in the smoke of cigarettes without filter tips (Parker, J.A. & Montgomery, 1979).


The smoke particles that are inhaled are slightly charged, having about 10^{12} electrons per gram of smoke (Holmes *et al.*, 1959). Since the smoke is generated in oxygen-deficient zones, the burning cone and hot zones, the MS has a reducing capacity which increases with the number of puffs drawn but disappears completely within a few minutes after smoke generation (Schmeltz *et al.*, 1977). MS also contains two types of free radical — one in the particulate phase, most probably a quinone-hydroquinone complex, and a much more reactive type in the gas phase, not produced in the flame but generated by the oxidation of nitrogen oxide to nitrogen dioxide. The latter then reacts with organic species in the smoke (Church & Pryor, 1986).

The pH of tobacco smoke is of major significance since it influences the proportion of nicotine and other basic components in the vapour phase and thus the inhalability of the MS (Armitage & Turner, 1970). At about pH 5.4, all nicotine in tobacco smoke is monoprotonated and is thus part of the particulate matter. With increasing pH, MS and SS contain increasing amounts of unprotonated nicotine, shifting the balance of this major toxic and habituating agent into the vapour phase of the smoke. While the pH of MS from blended cigarettes or from cigarettes made from flue-cured tobacco does not exceed 6.2, the MS of most cigars and of cigarettes made of burley or black (dark air-cured) tobacco is alkaline, especially in the last few puffs. The pH of SS ranges from 6.8-8.5 (Brunnemann & Hoffmann, 1974a).

The total MS of a cigarette weighs about 400-500 mg (Keith & Tesh, 1965). More than 92% of the total MS is comprised of 400-500 individual gaseous components (Brunnemann & Hoffmann, 1982), with nitrogen ($\approx 58\%$), oxygen ($\approx 12\%$), carbon dioxide ($\approx 13\%$) and carbon monoxide ($\approx 3.5\%$) as major constituents. The remaining fractions of the total MS effluent consist of other vapour-phase components and compounds constituting the particulate phase (8%; Fig. 4) (Norman, 1977).

2. Total particulate matter

The majority of the mutagenic and carcinogenic agents reside in the particulate phase. (See the chapter on 'Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans', pp. 127-198). Thus, specific methods have been developed for the analysis of the smoke particulates of cigarettes, cigars and pipes. The most widely applied method is the Cambridge filter method, in which the filter is a glass-fibre pad stabilized with an organic binder which retains 99.7% of all particles with diameters of 0.1 μm and above. This manner of trapping particles is an arbitrary method: it does not strictly separate the solid and gaseous components of smoke but partially retains vapours and gases, such as acetaldehyde,

Fig. 4. Approximate chemical composition of mainstream smoke^a

^aFrom Norman (1977); Guerin (1980). Abbreviations: PART, particulate matter; MVP, miscellaneous vapour-phase compounds; HC, hydrocarbons; ALD, aldehydes; KET, ketones; EST, esters; ALC, alcohols; HETO, heterocyclic oxygen compounds; NIT, nitriles; VAR, various unclassified compounds

within the precipitated particles (Dube & Green, 1982). Nevertheless, the Cambridge filter method has been standardized by the US Federal Trade Commission and by the Centre de Coopération pour les Recherches Scientifiques Relatives au Tabac, and is used widely for 'tar' determination (Pillsbury *et al.* 1969; Brunnemann *et al.*, 1976a). In the USA, 'tar' is defined as that portion of cigarette smoke that is retained on a Cambridge filter minus water and minus nicotine (Pillsbury *et al.*, 1969). Depending on the design of a cigarette and the tobacco used, the MS may contain up to 30 mg 'tar' and 3.0 mg nicotine per cigarette or, in the case of highly efficient filter cigarettes, as little as 0.5 mg 'tar' and 0.05 mg nicotine (US Federal Trade Commission, 1985). 'Tar' and nicotine yields of commercial cigarettes in many countries of the world are discussed on pp. 60-65.

3. Chemical composition

Inside a burning tobacco product, a large variety of chemical and physical processes occur in an oxygen-deficient, hydrogen-rich environment with a steep temperature gradient. The existence of these specific conditions greatly determines the formation of the vast majority of smoke components (Baker, 1980). In this overview, emphasis is placed on those smoke components that are biologically active and have been studied in the laboratory for toxicity and/or carcinogenicity. The concentrations of some of these agents in nonfilter cigarette MS are shown in Table 19.

The structures of some of the chemical constituents of tobacco smoke are given in Figure 5.

Table 19. Concentrations of biologically active agents in nonfilter cigarette mainstream smoke







Smoke constituent	Concentration/cigarette
Total particulate matter	15-40 mg
Carbon monoxide	10-23 mg
Nicotine	1.0-2.3 mg
Acetaldehyde	0.5-1.2 mg
Acetic acid	0.1-1.0 mg
Acetone	100-250 μ g
Methanol	90-180 μ g
Nitrogen oxides	100-600 μ g
Formic acid	80-600 μ g
Hydrogen cyanide	400-500 μ g
Hydroquinone	110-300 μ g
Catechol	100-360 μ g
Ammonia	50-130 μ g
Benzene	20-50 μ g
Acrolein	60-100 μ g
Phenol	60-140 μ g
Croton aldehyde	10-20 μ g
Formaldehyde	70-100 μ g
Pyridine	16-40 μ g
3-Methylpyridine	20-36 μ g
2-Cresol	14-30 μ g
3- and 4-Cresol	40-80 μ g
3- and 4-Methylcatechol	31-45 μ g
Carbazole	1 μ g
2-Nitropropane	0.2-2.2 μ g

Table 19 (contd)

Smoke constituent	Concentration/cigarette
<i>N</i> -Nitrosornicotine	200-3000 ng
4-(Methylnitrosamino)-1- β -pyridyl)-1-butanone	80-770 ng
<i>N</i> -Nitrosoanabasine	0-150 ng
<i>N</i> -Nitrosodiethanolamine	0-36 ng
<i>N</i> -Nitrosopyrrolidine	0-110 ng
<i>N</i> -Nitrosodimethylamine	2-20 ng
<i>N</i> -Nitrosomethylethylamine	0-2.7 ng
<i>N</i> -Nitrosodiethylamine	0-2.8 ng
<i>N</i> -Nitrosodi- <i>n</i> -propylamine	0-1 ng
<i>N</i> -Nitrosodi- <i>n</i> -butylamine	0-3 ng
<i>N</i> -Nitrosopiperidine	0-9 ng
Hydrazine	32-43 ng
Urethane	20-38 ng
Vinyl chloride	1.3-16 ng
Benz[<i>a</i>]anthracene	20-70 ng
Benzo[<i>b</i>]fluoranthene	4-22 ng
Benzo[<i>j</i>]fluoranthene	6-21 ng
Benzo[<i>k</i>]fluoranthene	6-12 ng
Benzo[<i>a</i>]pyrene	20-40 ng
Dibenz[<i>a,h</i>]anthracene	4 ng
Dibenzo[<i>a,i</i>]pyrene	1.7-3.2 ng
Indeno[1,2,3- <i>cd</i>]pyrene	4-20 ng
5-Methylchrysene	0.6 ng
Dibenz[<i>a,j</i>]acridine	2.7 ng
Dibenz[<i>a,h</i>]acridine	0.1 ng
7 <i>H</i> -Dibenzo[<i>c,g</i>]carbazole	0.7 ng
2-Naphthylamine	1.7-22 ng
4-Aminobiphenyl	2.4-4.6 ng
<i>ortho</i> -Toluidine	32-160 ng
Maleic anhydride	Present
2,3-Dimethylmaleic anhydride	Present
Succinic anhydride	Present
Coumarin	Present

Fig. 5. Some chemical constituents of tobacco smoke^a

(1) Acyclic isoprenoids



(2) Cyclic isoprenoids







^aFormulae that do not appear here are given in previous *IARC Monographs*

Fig. 5 (contd)


(2) Cyclic isoprenoids (contd)




α - and β -12-Isopropyl-1, 5, 9-trimethyl-4, 8, 13-cyclotetradecatriene-1, 3-diol




α - and β -12-Isopropyl-1, 5, 9-trimethyl-3, 8, 13-cyclotetradecatriene-1, 5-diol




12-Isopropyl-1, 5, 9-trimethyl 5, 8-oxido-3, 9, 13-cyclotetradecatriene-1-ol



α - and β -12-Isopropyl-1, 5-dimethyl-9-methylene-5, 8-oxido-3, 13-cyclotetradecadiene-1-ol







12 α -Hydroxy-8-epimanoyl oxide



Plastoquinone

Fig. 5 (contd)

(2) Cyclic isoprenoids (contd)



(3) Phytosterols







Fig. 5 (contd)


(4) PACs

(a) PAHs^b

Anthracene (6)	Benzo[a]pyrene (3)	Dibenzo[a,e]fluoranthene
Benz[a]anthracene (5)	Benzo[e]pyrene (3)	Fluoranthene (6)
Benzo[b]fluoranthene (1)	Chrysene (9)	Fluorene(5)
Benzo[j]fluoranthene (1)	Coronene (1)	Indeno[1,2,3- <i>cd</i>]fluoranthene
Benzo[k]fluoranthene	Dibenz[a,c]anthracene	Indeno[1,2,3- <i>cd</i>]pyrene (2)
Benzo[ghi]fluoranthene (2)	Dibenz[a,h]anthracene	Naphtho[1,2,3,4- <i>def</i>]chrysene
Benzo[a]fluorene (1)	Dibenz[a,j]anthracene	(Dibenzo[a,e]pyrene) ^c
Benzo[b]fluorene (1)	Dibenzo[b,def]chrysene	Naphtho[2,3- <i>b</i>]pyrene
Benzo[c]fluorene	(Dibenzo[a,h]pyrene) ^c	Perylene (2)
Benzo[<i>rst</i>]pentaphene	Dibenzo[<i>def,mno</i>]chrysene	Phenanthrene (9)
(Dibenzo[a,i]pyrene) ^c	(Anthanthrene) ^c	Pyrene (7)
Benzo[ghi]perylene (2)	Dibenzo[<i>def,p</i>]chrysene	Triphenylene (1)
Benzo[c]phenanthrene	(Dibenzo[a,j]pyrene) ^c	




Benz[f]indene



Naphtho[2,3-*b*]pyrene


(b) Aza-arenes^d

Benzo[a]acridine
Dibenzo[a,h]acridine




Acridine (2)

Benzo[c]acridine
7H-Dibenzo[c,g]carbazole




1-Azafluoranthene


Carbazole (9)
Dibenzo[a,j]acridine




4-Azafluorene



1-Azapyrene



Benzimidazole (1)



Benzo[*f*]quinoline
(5,6-Benzoquinoline)




^bFigures in parentheses indicate the number of alkyl derivatives of the specific polycyclic aromatic hydrocarbons that have been identified in tobacco smoke

^cAlternative names in common usage.


^dFigures in parentheses indicate the number of alkyl homologues of the specific aza-arene which have been identified in tobacco smoke

Fig. 5 (contd)



(b) Aza-arenes (contd)

Benzo[*h*]quinoline
(7,8-Benzoquinoline) β -Carboline
(Norharman)



Indole (19)




Isoquinoline (1)

1-Methyl- β -carboline
(Harman)



Phenanthridine

Pyrrolo(2, 3-*b*)pyridine

Quinoline (8)





Quinoxaline


(c) *O*-Heterocyclic hydrocarbonsDibenzo[*b,d*]furanBenzo[*b*]furan

(5) Phenols and polyphenols

Phenols

Caffeic acid R=H
Ferulic acid R=CH₃


Eugenol




Isoeugenol

Fig. 5 (contd)

(5) Phenols and polyphenols (contd)



(6) Pyridine alkaloids^e



^eFrom Schmeltz and Hoffmann (1977); figures in parentheses indicate levels in the mainstream smoke per cigarette
^fQuantitative data not available

Those components of tobacco smoke that have been evaluated for carcinogenicity in previous *IARC Monographs* are listed in Appendix 2 to this volume, p. 389.

The gas-phase constituents, comprising those compounds of which >50% is found in the vapour phase when the smoke leaves the butt, are discussed first, followed by the particulate phase constituents.

(a) *Carbon oxides*

Model studies have demonstrated that within a burning cigarette about 30% of the carbon monoxide (CO) in MS is formed by thermal decomposition of tobacco, about 36% by combustion of tobacco and at least 23% from carbon dioxide (CO₂) (Baker, 1984). CO₂ derives primarily from atmospheric oxidation of carbon and CO (60%) and from the decarboxylation of carboxylic acids and amino acids (Brunnemann & Hoffmann, 1982). The delivery of carbon oxides in MS is greatly affected by the physical form of the tobacco filter, the porosity of the wrapper and by additions to the paper which influence the burning rate (Durocher, 1984). The greatest selective reduction of CO in the MS of cigarettes has been achieved by dilution of smoke by perforated filter tips and filter tips with longitudinal air channels (Hoffmann *et al.*, 1983a; Baker, 1984). CO is also selectively reduced in the MS of cigarettes with perforated filter tips because of the reduced velocity of the air entering the burning cone (Baker, 1984).

Commercial cigarettes without filter tips in the UK and USA deliver 10-17 mg CO and those with filter tips yield <0.3-23 mg of CO (Health Departments of the United Kingdom, 1984; US Federal Trade Commission, 1985). Conventional filter cigarettes may generate as much CO or even more than plain cigarettes (Wald *et al.*, 1976), while cigarettes with perforated filter tips reduce the CO concentration in MS by smoke dilution (Baker, 1984). In model studies with perforated filter tip cigarettes, 0, 33, 48 and 83% dilution of air resulted in CO values of 18.6, 12.9, 6.6 and 2.4 mg/cigarette, respectively (Browne *et al.*, 1980). In filter-tip cigarettes with longitudinal air channels, CO values may be reduced to 1.25 mg/cigarette (Hoffmann *et al.*, 1983a). It must be reemphasized, however, that these highly significant reductions in CO, achieved with special filter tips in machine-smoking tests, may not occur to the same extent in human smokers, because the smoker adjusts his puff-volume in order to compensate for the lower nicotine delivery or blocks the holes or air channels of filter tips with his fingers or lips (Wald *et al.*, 1976; Kozlowski *et al.*, 1980; Hoffmann *et al.*, 1983a).

Since *bidi* cigarettes burn poorly, they are puffed at least twice a minute. Under these conditions, one type of commercial *bidi* delivered 78 mg CO and 149 mg CO₂; a US nonfilter cigarette, smoked under the same conditions, yielded 25 mg CO and 96 mg CO₂ (Hoffmann *et al.*, 1974). Little cigars (85 mm, ≈1 g) with a relatively nonporous wrapper delivered up to 46 mg CO and 87 mg CO₂. Cigars weighing up to 7 g may deliver up to 209 mg CO and 681 mg CO₂ (Brunnemann & Hoffmann, 1974b). The MS of a pipe containing 1.2 g tobacco contained up to 64 mg CO and 81 mg CO₂ (Miller, J.E., 1964).

(b) *Nitrogen oxides*

Tobacco smoke contains nitric oxide (NO), nitrogen dioxide (NO₂) and nitrous oxide (N₂O). When freshly generated smoke leaves the butt end of a cigarette, it contains virtually only nitric oxide, with trace amounts of nitrous oxide and no nitrogen dioxide. Freshly generated cigarette smoke contains up to 600 µg/cigarette of nitric oxide (Brunnemann & Hoffmann, 1982; US Department of Health and Human Services, 1982; Jenkins, R.A. *et al.*, 1983). Nitrogen dioxide is quickly formed upon ageing of smoke (Vilcins & Lephardt, 1975), and it has been estimated that within 500 seconds half of the nitric oxide in undiluted smoke is oxidized to nitrogen dioxide (Neurath, 1972). It takes even less time for such oxidation to occur in air-diluted smoke (Vilcins & Lephardt, 1975). Tobaccos with a high nitrate content also appear to generate microgram amounts of nitrous oxide in the smoke (Philippe & Hackney, 1959).

The yield of nitrogen oxides in smoke is determined primarily by the nitrate content of the tobacco, which may reach 5% in processed tobacco, midribs being the richest source (Johnson *et al.*, 1973a; Neurath & Ehmke, 1964b). The nitric oxide concentration in MS is correlated linearly with the sum of innate and added nitrate in a cigarette (Brunnemann & Hoffmann, 1982; Norman *et al.*, 1983; Adams *et al.*, 1984); however, up to 100 µg of nitric oxide in the smoke of a nonfilter cigarette derive from oxidation of nitrogenous components in tobacco and, probably, from the oxidation of atmospheric nitrogen (Norman *et al.*, 1983).

Since the filler tobaccos of little cigars and of cigars are rich in nitrate, the MS of these products is relatively high in nitrogen oxides; the MS of little cigars may contain 193-1990 µg/cigar (Adams *et al.*, 1978). The most promising method for the reduction of nitrogen oxides in cigarette smoke appears to be the use of perforated filter tips, in which the smoke is diluted with air and the velocity of the smoke is reduced (Williams, T.B., 1980).

Nitrogen oxides in MS may serve as precursors for *N*-nitrosamines (see pp. 110-114).

(c) *Ammonia and volatile amines*

Ammonia is a major volatile constituent of MS and SS, and concentrations in MS have been reported of 5-220 µg/cigarette, 150-935 µg/little cigar and 150-660 µg/cigar (Brunnemann & Hoffmann, 1975; Park, K.-H. & Shin, 1980). The SS of cigarettes can contain up to 14.3 mg of ammonia per cigarette, that of little cigars up to 28.5 mg and that of cigars up to 106 mg (Johnson *et al.*, 1973a; Brunnemann & Hoffmann, 1974a, 1975). Since the SS of cigarettes and cigars have pH values above 6.0, the ammonia occurs partially in free form in the vapour phase (Brunnemann & Hoffmann, 1974a). Model studies have indicated that the nitrogen oxides resulting from decomposition of tobacco nitrate serve as major precursors for ammonia, and are reduced in the burning cone (Johnson *et al.*, 1973a).

In tobacco smoke, 31 aliphatic amines, 26 pyrroles, pyrrolines and pyrrolidines, about 70 pyridines, 11 piperidines and hydroxyridines and several pyrazines have been identified. In cigarette smoke, the most abundant are (µg/cigarette): methylamine (4.6-5), ethylamine (0.96-1.5), dimethylamine (1-1.2), trimethylamine (0.7), 1-methylpyrrolidine (3),

pyrrolidine (0.16), pyridine (6-218), 2-,3- and 4-methylpyridines (31-82), methylpyrazines (1.1-1.2) and 2,5-dimethylpyrazine (7-15.5) (Vickroy, 1976; Schmeltz & Hoffmann, 1977; Brunnemann *et al.*, 1978; Matsushima *et al.*, 1979).

(d) *Hydrogen cyanide*

Hydrogen cyanide (HCN) is one of the most toxic agents in the vapour phase of tobacco smoke. Model studies indicate that nitrate is an important precursor for HCN in smoke and that tobacco proteins, especially glycine, proline and aminodicarboxylic acids, also give rise to HCN (Johnson & Kang, 1971; Johnson *et al.*, 1973a). Tobacco smoke also contains microgram amounts of cyanogen [(CN)[†]], which hydrolyses during analytical procedures and thus contributes to the total amount of HCN found (Brunnemann *et al.*, 1977a).

The MS of commercial cigarettes contains 160-550 μg /cigarette of HCN; however, the MS emission of HCN in the smoke of cigarettes with filter tips containing charcoal, with perforated filter tips or with filter tips with longitudinal air channels is lower ($<100 \mu\text{g}$) (Johnson *et al.*, 1973b; Brunnemann *et al.*, 1977a; Sloan, 1980; Jenkins, R.A. *et al.*, 1983; Norman *et al.*, 1983). The release of HCN into SS is significantly lower than that into MS (14-134 μg /cigarette) (Johnson *et al.*, 1973b; Brunnemann *et al.*, 1977a).

After inhalation of tobacco smoke, HCN is metabolized rapidly in the liver to thiocyanate. The concentration of thiocyanate in the saliva, blood and urine of smokers is often used as an indicator for the uptake or depth of inhalation of tobacco smoke (Benowitz, 1983). (See section 3 of the chapter on 'Biological Data Relevant to the Evaluation of Carcinogenic Risk to Humans', p. 167.)

Thiocyanate catalyses the formation of *N*-nitrosamines (Boyland *et al.*, 1971) (see pp. 110-114).

(e) *Volatile aldehydes and ketones*

A certain percentage of the aldehydes and ketones in the vapour phase of smoke is transferred directly from tobacco, where these compounds are formed by nonenzymatic browning reactions. However, most are formed during smoking from such precursors as polysaccharides, pectins, proteins and, possibly, triglycerides in tobacco (Brunnemann & Hoffmann, 1982). At least 20 aldehydes and six ketones have so far been identified in the vapour phase, the most abundant being formaldehyde (IARC, 1982a) (3-40 μg /cigarette), acetaldehyde (IARC, 1985b) (519-1144 μg), propionaldehyde (25-116 μg), acrolein (IARC, 1985c) (11-228 μg), crotonaldehyde (14-16 μg), furfural (45-110 μg) and acetone (110-560 μg) (Wynder & Hoffmann, 1967; Elmenhorst & Schultz, 1968; Sakuma *et al.*, 1978; Richter & Erfurth, 1979). Several of these volatile carbonyl compounds, especially formaldehyde, acrolein and crotonaldehyde, are ciliotoxic; like hydrogen cyanide and ammonia, they inhibit lung clearance after smoke inhalation (Battista, 1976). Formaldehyde induces nasal carcinoma in rats (IARC, 1982a).

The smoke of little cigars (0.9-1.5 g) was reported to contain 630-1150 μg of acetaldehyde and 20-100 μg of acrolein, whereas the smoke of large cigars (6.4-6.8 g) contained 3200-5920 μg of acetaldehyde and 180-250 μg of acrolein (Hoffmann & Wynder, 1972a;

Schmeltz *et al.*, 1976a). Filter tips containing charcoal, perforated filter tips and highly porous paper wrappers reduce the content of volatile aldehydes and ketones in smoke significantly (Wynder & Hoffmann, 1967; Maeda *et al.*, 1978; Parker, J.A. & Montgomery, 1979).

(f) *Other volatile compounds*

In addition to volatile *N*-nitrosamines, which are discussed below (pp. 110-114), the vapour phase of tobacco smoke contains traces of other volatile compounds found to be carcinogenic in humans or in experimental animals. These are benzene, hydrazine, urethane, 2-nitropropane and vinyl chloride.

Benzene, a human carcinogen (IARC, 1982b), has been reported in the MS of cigarettes (12-48 μg /cigarette) and in the SS of a 100-mm US filter cigarette (453 μg /cigarette) (Wynder & Hoffmann, 1967; Elmenhorst & Schultz, 1968; Jermini *et al.*, 1976). It can be assumed that benzene is formed during the burning of tobacco either from precursors with an aromatic or cyclohexane ring or by pyrosynthesis from primary radicals such as $\text{C}_6\text{H}_5\cdot$ (Badger, 1962). The most abundant volatile aromatic hydrocarbon in tobacco smoke is toluene, which has been reported to occur at levels of up to 164 μg /cigarette in MS and 904 μg in the SS of a 100-mm US nonfilter cigarette (Wynder & Hoffmann, 1967; Elmenhorst & Schultz, 1968; Jermini *et al.*, 1976).

Hydrazine, a carcinogen in mice and rats (IARC, 1974a), occurs in cigarette MS (24-43 ng/cigarette) and cigarette SS (94 ng/cigarette). Some of the hydrazine in processed tobacco derives from its presence as an impurity in the plant sucker growth inhibitor maleic hydrazide. Hydrazine may also be formed in tobacco by reduction of nitrate. Hydrazine in smoke originates partly by transfer from tobacco and partly by reduction of maleic hydrazide, protein and nitrate in the burning cone (Liu *et al.*, 1974).

Urethane (ethyl carbamate), a carcinogen in mice, rats and hamsters (IARC, 1974b), has been identified in cigarette smoke (20-38 ng/cigarette). It has been postulated that, during smoking, residues of maleic hydrazide sprayed on tobacco give rise to isocyanic acid and that the latter reacts in the gas phase with alcohols to form urethanes. However, urethane was found in comparable concentrations in the smoke of cigarettes whether the tobacco contained maleic hydrazide or not (Schmeltz *et al.*, 1978).

2-Nitropropane, a carcinogen in rats (IARC, 1982c), has also been identified in cigarette MS (0.22-2.2 μg /cigarette). Other nitroalkanes — nitromethane (0.19-1.05 μg), nitroethane (0.27-2.2 μg), 1-nitropropane (0.18-1.4 μg), 1-nitro-*n*-butane (0.19-1.4 μg) and 1-nitron-pentane (<0.05-0.39 μg) — have also been found. The smoke yields of the nitroalkanes, including 2-nitropropane, are influenced by the nitrate concentration of tobacco (Hoffmann & Rathkamp, 1968). A study by El-Bayoumy *et al.* (1985) with ^{14}C -labelled tracers and internal standards did not reveal the presence of nitroaromatic hydrocarbons such as 1-nitronaphthalene, 1-nitropyrene or 6-nitrochrysene in the MS of experimental and commercial US and French cigarettes.

Vinyl chloride, a human carcinogen (IARC, 1982b), has been identified in the smoke of cigarettes (1.3-16 ng/cigarette) and of little cigars (14-27 ng/cigar), the level in MS being directly correlated with the chloride content of the tobacco. Filter tips with charcoal reduce the vinyl chloride content of cigarette smoke selectively (Hoffmann *et al.*, 1976).

Acrylonitrile and methyl acrylate have been identified in cigarette smoke, at concentrations of 10 and 3 $\mu\text{g}/\text{cigarette}$, respectively (Grob, 1962). Acrylonitrile is carcinogenic to rats and is probably carcinogenic to humans (IARC, 1982b).

Tobacco smoke also contains 150-840 $\mu\text{g}/\text{cigarette}$ of methyl chloride (Wynder & Hoffmann, 1967), and MS has been shown to contain 1.5-5 $\mu\text{g}/\text{cigarette}$ of methyl isocyanate, a highly toxic agent (Philippe & Honeycutt, 1965).

(g) *Nonvolatile alkanes and alkenes*

Tobacco leaves are coated with waxes, of which alkanes, alkenes, alcohols, carboxylic acids, esters, aldehydes, ketones and alkaloids are the major constituents. Alkanes with chain lengths of C_{25} - C_{36} are comprised of a homologous series of normal (*n*), *iso* (*i*, 2-methyl-) and *ante-iso* (*a*, 3-methyl-) saturated hydrocarbons (Wynder & Hoffmann, 1967). They are transferred into MS and SS either structurally intact or fragmented into alkanes and alkenes of chain lengths shorter than C_{25} . So far, more than 75 aliphatic hydrocarbons have been identified in tobacco smoke (Newell *et al.*, 1978). The transfer rate of C_{25} - C_{33} hydrocarbons from cigarette tobacco (C_{25} - C_{34} : 1540 $\mu\text{g}/\text{g}$) into the MS (228 $\mu\text{g}/\text{g}$ cigarette) of a commercial nonfilter cigarette averaged 25.2% (Severson *et al.*, 1978). The crystalline fraction representing alkanes isolated from smoke condensate in another investigation amounted to ≈ 750 $\mu\text{g}/\text{cigarette}$, and they ranged in chain length from C_{12} to C_{33} (Spears *et al.*, 1963). The major individual hydrocarbons are *n*- $\text{C}_{31}\text{H}_{64}$ (182 $\mu\text{g}/\text{cigarette}$), *n*- $\text{C}_{32}\text{H}_{66}$ (108 μg) and *n*- $\text{C}_{33}\text{H}_{68}$ (69 μg) (Wynder & Hoffmann, 1967). In addition, cigarette smoke contains all homologous *n*-alkanes from octane (C_8H_{18}) to *n*-hexatriacontane ($\text{C}_{36}\text{H}_{74}$) and a number of *i*- and *a*-saturated hydrocarbons from *i*- C_8H_{18} to *i*- and *a*- $\text{C}_{35}\text{H}_{72}$ (Spears *et al.*, 1963; Wynder & Hoffmann, 1967; Newell *et al.*, 1978; Severson *et al.*, 1978).

The cyclic, nonaromatic hydrocarbons that have been identified in tobacco smoke, primarily in the vapour phase, include cyclopentane, cyclohexane and bicyclohexyl. More than 100 acyclic and cyclic nonaromatic alkanes and alkenes have been identified in the vapour and particulate phases of tobacco smoke (Wynder & Hoffmann, 1967; Newell *et al.*, 1978). Whereas most of these are isoprenoids or are formed from them by pyrolysis, some are formed during smoking from tobacco-leaf-specific long-chain alkenes (3 $\mu\text{g}/\text{cigarette}$; $\approx 0.01\%$ of the condensate) (Entwistle & Johnstone, 1965).

(h) *Isoprenoids* (see Fig. 5)

The typical aroma of tobacco leaves is generated during post-harvest treatment and is due chiefly to isoprenoids. These compounds are also a major factor in tobacco smoke 'bouquet' and are either transferred into smoke or serve as precursors for flavour compounds in the smoke. Hundreds of isoprenoids, including tobacco-specific compounds, have been identified in tobacco and tobacco smoke (Rowland & Roberts, 1963; Enzell *et al.*, 1977; Newell *et al.*, 1978; Enzell & Wahlberg, 1980; Wahlberg & Enzell, 1984). The most prevalent acyclic isoprenoids are solanesol, solanesenes, solanone, phytone, neophytadiene and norphytene, and the predominant cyclic isoprenoids are cyclotetradecanols, levantenolides, cembranoids and carotenes (Wynder & Hoffmann, 1967). Isoprenoids are present in several neutral subfractions that have been reported to have carcinogenic and tumour-promoting activity on mouse skin (Wynder & Hoffmann, 1967; Hoffmann & Wynder, 1971).

One of the pyrolytic decomposition products of most isoprenoids is the volatile isoprene itself (2-methyl-1,3-butadiene) (Burton & Childs, 1975), which has been detected at levels of 460-630 $\mu\text{g}/\text{cigarette}$ (Elmenhorst & Schultz, 1968; National Cancer Institute, 1980). Cigarettes made exclusively of tobacco stems did not deliver measurable amounts of isoprene into MS, and cigarettes with filter tips containing charcoal and with perforated filter tips effect a selective reduction of isoprene in smoke (National Cancer Institute, 1980; Baker, 1984). The smoke of little cigars weighing 0.9-1.1 g and that of large cigars (6.4-6.8 g) was reported to contain 270-570 μg and 2400-4000 μg of isoprene, respectively (Schmeltz *et al.*, 1976a).

Solanesol, phytol and neophytadiene were transferred unchanged from tobacco into MS of nonfilter cigarettes at levels of 9.4%, 15.2% and 18.1%, respectively (Severson *et al.*, 1978). The MS of cigarettes made entirely of flue-cured, burley and oriental tobaccos, respectively, contained 255-308 μg , 218-257 μg and 142-160 μg of neophytadiene per cigarette (Matsushima *et al.*, 1979). Isoprenoids with large particle size are apparently evenly distributed in smoke particles of different sizes, and their levels cannot, therefore, be reduced selectively by filter tips (Morie & Baggett, 1977). Several other isoprenoids of low volatility have been identified in cigarette smoke, including squalene, α - and β -levantenolides and solanesyl esters, but quantitative data have not been given (Wynder & Hoffmann, 1967; Stedman, 1968; Green, C.R., 1977).

Pyrolysis of fractions of tobacco extract highly enriched with solanesol and its esters gave rise to the highest amounts of polynuclear aromatic hydrocarbons determined in any of the tobacco extract fractions or subfractions studied (Schlotzhauer *et al.*, 1976).

(i) *Phytosterols* (see Fig. 5)

Like all higher plants, tobacco contains several phytosterols, the most abundant being C_{28} and C_{29} sterols with a 3-hydroxyl group and $\Delta^{5,6}$ -unsaturation. Stigmasterol, sitosterol, campesterol, cholesterol and ergosterol are the most representative compounds of this group. They are present in unbound form and as fatty acid esters (Wynder & Hoffmann, 1967; Stedman, 1968; Enzell *et al.*, 1977).

A proportion of tobacco phytosterols remains unchanged during transfer into the MS and SS (Schmeltz *et al.*, 1975). The transfer rates of phytosterols from tobacco into the MS of a nonfilter cigarette were as follows: cholesterol, 12.5%; campesterol plus stigmasterol, 18.7%; and sitosterol, 16.1%. Transfer of these compounds into the MS of filter cigarettes was 7.1-12.7%, 7.6-13.7% and 6.7-13.4%, respectively (Severson *et al.*, 1978). Concentrations ($\mu\text{g}/\text{cigarette}$ or cigar) of cholesterol, campesterol, stigmasterol and sitosterol, respectively, in MS of cigarettes were 22, 43, 78 and 59; in SS of cigarettes, 19, 26, 54 and 28; in MS of cigars, 37, 56, 116 and 63; in SS of cigars, 22, 44, 94 and 50 (Schmeltz *et al.*, 1975). Other phytosterols that have been identified in tobacco smoke are β -amyirin and cycloartenol (Stedman, 1968; Severson *et al.*, 1978). The phytosterols in tobacco are specific precursors of polycyclic aromatic hydrocarbons in smoke (Hoffmann *et al.*, 1973).

Neutral subfractions of cigarette smoke condensate in which the phytosterols were concentrated were biologically inactive when applied as a 10% solution in acetone to the skin of mice for up to 24 months (Wynder & Wright, 1957).

(j) *Polynuclear aromatic compounds (PAC)*

The burning cone of a tobacco product (850-950°C) represents a reducing atmosphere (N₂ 53%; CO₂ 18%; CO 12%; H₂ 8%; O₂ 1.4%) (Newsome & Keith, 1965) in which primary CH-radicals are formed by pyrolysis of organic matter. These unstable CH-radicals serve as precursors of the pyrosynthesis of the thermodynamically preferred PAC, and especially polynuclear aromatic hydrocarbons (PAH) (Badger, 1962). Not only are there favourable conditions for the formation of PAC in the burning cone, but certain cyclic isoprenoids and phytosterols also serve as specific precursors of PAH, while nicotine, other alkaloids and certain amino acids are precursors of the pyrosynthesis of aza-arenes (Van Duuren *et al.*, 1960; Poindexter & Carpenter, 1962; Schlotzhauer & Schmeltz, 1967; Wynder & Hoffmann, 1967; Schlotzhauer *et al.*, 1976).

(i) *Polynuclear aromatic hydrocarbons (PAH)* (see Fig. 5)

Several analytical studies have shown the presence in tobacco smoke of at least 22 naphthalenes (constituting 5-7 µg/cigarette), seven indenenes, azulene, two acenaphthalenes, two benz[*e*]indenenes, two benz[*f*]indenenes and at least 35 parent hydrocarbons and a larger number of methylated hydrocarbons with three or more rings (Wynder & Hoffmann, 1967; Stedman, 1968; Lee, M.L. *et al.*, 1976; Schmeltz *et al.*, 1976b; Grimmer *et al.*, 1977a,b; Severson *et al.*, 1977; Snook *et al.*, 1977; Arrendale *et al.*, 1980; IARC, 1983a). Quantitative data on the occurrence of PAH in cigarette MS, cigarette SS, cigar smoke and pipe smoke are summarized in Table 20 (IARC, 1983a).

The concentration of PAHs in smoke condensate depends on the tobacco brand; e.g., benzo[*a*]pyrene was found at levels of 5.3, 4.4, 2.4 and 1.4 µg/100 cigarettes in Virginia, oriental, burley and Maryland tobaccos, respectively, and at levels of 2.8-3.7, 2.3-3 and 1.6-2.2 µg/100 cigarettes in the MS of Virginia cigarettes, oriental tobacco and burley tobacco, respectively (Wynder & Hoffmann, 1967).

When puffed twice a minute, a *bidi* cigarette yielded 117 ng of benz[*a*]anthracene and 78 ng of benzo[*a*]pyrene in the MS, in comparison with 81.3 ng of benz[*a*]anthracene and 46.7 ng of benzo[*a*]pyrene in the MS of a US blended cigarette without a filter tip, smoked under the same conditions (Hoffmann *et al.*, 1974).

Of the PAH listed in Figure 5 and their methyl derivatives, 40 have been evaluated for evidence of carcinogenic activity to experimental animals by the IARC (1983a). (See also Appendix 2, pp. 387-394.)

(ii) *Aza-arenes*

The aza-arenes identified in tobacco smoke are also shown in Figure 5 (Van Duuren *et al.*, 1960; Schmeltz & Hoffmann, 1977; Dong *et al.*, 1978; Snook *et al.*, 1981). The major indoles in smoke are indole (13.9 µg/cigarette) and skatole (14 µg). In addition, the MS of a nonfilter cigarette contained 1.67 µg of quinoline, 0.12 µg of isoquinoline, 11 µg of carbazole and 0.1-100 ng of other *N*-heterocyclic hydrocarbons (Schmeltz & Hoffmann, 1977; Dong *et al.*, 1978). During smoking, tryptophan gives rise to β-carboline (norharman; 9.5-14.1 µg/cigarette) and 1-methyl-β-carboline (harman, 2.6-5.8 µg/cigarette; Poindexter & Carpenter, 1962; Snook & Chortyk, 1984). Van Duuren *et al.* (1960) isolated from the

Table 20. Concentrations of some polynuclear aromatic hydrocarbons and heterocyclic compounds in tobacco smoke (with references^a)

Polynuclear aromatic compound	Cigarette main-stream smoke ($\mu\text{g}/100$ cigarettes)	Cigarette side-stream smoke ($\mu\text{g}/100$ cigarettes)	Cigarette smoke-polluted environments (ng/m^3)	Cigar smoke ($\mu\text{g}/100$ g)	Pipe smoke ($\mu\text{g}/100$ g)
<i>Polynuclear aromatic hydrocarbons</i>					
Anthanthrene	0.2-2.2 (7,23)	3.9 (7)	0.5 (8, 19)		
Anthracene	2.3-23.5 (20,22,23)			11.9 (3)	110.0 (3)
Benzo[<i>a</i>]anthracene	0.4-7.6 (1,20,22,23,28)			2.5-3.9 (13)	
Benzo[<i>b</i>]fluoranthene	0.4-2.2 (11,20,23)				
Benzo[<i>j</i>]fluoranthene	0.6-2.1 (11,22)				
Benzo[<i>k</i>]fluoranthene	0.6-1.2 (21,23)				
Benzo[<i>ghi</i>]fluoranthene	0.1-0.4 (34,36)				
Benzo[<i>a</i>]fluorene	4.1-18.4 (1,7,22)	75 (7)	39 (8)		
Benzo[<i>b</i>]fluorene	2 (11)				
Benzo[<i>ghi</i>]perylene	0.3-3.9 (7,11,22)	9.8 (7)	5.9-17 (8,19)		
Benzo[<i>c</i>]phenanthrene	present (30)				
Benzo[<i>a</i>]pyrene	0.5-7.8 (11,14,;17,20,23,24,28,32,33)	2.5-19.9 (7,27)	2.8-760 (5,6,26)	1.8-5.1 (3,13,14)	8.5 (3)
Benzo[<i>e</i>]pyrene	0.2-2.5 (7,20,22,23)	13.5 (7)	3-18 (8,19)		
Chrysene	0.6-9.6(1,4,10,11,20,22,23)				
Coronene	0.1 (30)		0.5-2.8 (19)		
Dibenz[<i>a,c</i>]anthracene	present (30)				
Dibenz[<i>a,h</i>]anthracene	0.4 (11)				
Dibenz[<i>a,j</i>]anthracene	1.1 (7)	4.1 (7)	6 (8)		
Dibenzo[<i>a,e</i>]pyrene	present (30)				
Dibenzo[<i>a,h</i>]pyrene	present (30)				
Dibenzo[<i>a,i</i>]pyrene	0.17-0.32 (25)				
Dibenzo[<i>a,l</i>]pyrene	present (33)				
Fluoranthene	1-27.2(7,16,20,22,29,33)	126 (7)	99 (8)	20.1 (3)	

Table 20 (contd)

Polynuclear aromatic compound	Cigarette main-stream smoke ($\mu\text{g}/100$ cigarettes)	Cigarette side-stream smoke ($\mu\text{g}/100$ cigarettes)	Cigarette smoke polluted environments (ng/m^3)	Cigar smoke ($\mu\text{g}/100$ g)	Pipe smoke ($\mu\text{g}/100$ g)
Fluorene	present (9,31)				
Indeno[1,2,3- <i>cd</i>]pyrene	0.4-2.0 (1,38)				
1-Methylchrysene	0.3 (10)				
2-Methylchrysene	0.12 (10)				
3-Methylchrysene	0.61 (10)				
4-Methylchrysene	present (31)				
5-Methylchrysene	0.06 (10)				
6-Methylchrysene	0.7 (10)				
2-Methylfluoranthene	present (22)				
3-Methylfluoranthene	present (22)				
Perylene	0.3-0.5 (23,30)	3.9 (7)	0.1-11(8,19)		
Phenanthrene	8.5-62.4 (20,22,23)			115 (3)	
Pyrene	5-27 (2,4,7,20,22,23,25,29,33)	39-101 (7,21)	2-66 (8,19)	17.6 (3)	75.5 (3)
Triphenylene	present (30)				
<i>Heterocyclic compounds</i>					
Carbazole	100 (15)				
Dibenz[<i>a,h</i>]acridine	0.01 (35)				
Dibenz[<i>a,j</i>]acridine	0.27 (35)				
7 <i>H</i> -Dibenzo[<i>c,g</i>]carbazole	0.07 (35)				
Benzo[<i>c</i>]fluorene	present (12,30)				
Dimethylphenanthrene ^b	present (30)				
1-Methylphenanthrene	3.2 (22)				

^aReferences: (1) Ayres & Thornton (1965); (2) Bonnet & Neukomm (1956); (3) Campbell & Lindsey (1957); (4) Ellington *et al.* (1978); (5) Elliot & Rowe (1975); (6) Galušíkinová (1964); (7) Grimmer *et al.* (1977a); (8) Grimmer *et al.* (1977b); (9) Grob & Voellmin (1970); (10) Hecht *et al.* (1974); (11) Hoffmann & Wynder (1960); (12) Hoffmann & Wynder (1971); (13) Hoffmann & Wynder (1972a); (14) Hoffmann *et al.* (1963); (15) Hoffmann *et al.* (1968); (16) Hoffmann *et al.* (1972); (17) Hoffmann *et al.* (1974); (18) Hoffmann *et al.* (1975); (19) Just *et al.* (1972); (20) Kiryu & Kuratsune (1966); (21) Kotin & Falk (1960); (22) Lee, M.L. *et al.* (1976); (23) Masuda & Kuratsune (1972); (24) Müller, K.H. *et al.* (1964); (25) Müller, R. *et al.* (1967); (26) Perry (1973); (27) Pyriki (1963); (28) Rathkamp *et al.* (1973); (29) Severson *et al.* (1979); (30) Snook *et al.* (1977); (31) Snook *et al.* (1978); (32) US Department of Health & Human Services (1982); (33) Van Duuren (1958a); (34) Van Duuren (1958b); (35) Van Duuren *et al.* (1960); (36) Wynder & Hoffmann (1959); (37) Wynder & Hoffmann (1961a); (38) Wynder & Hoffmann (1963)

^bUnspecified isomer

smoke condensate of nonfilter cigarettes 0.1 ng/cigarette of dibenz[*a,h*]acridine, 2.7 ng of dibenz[*a,j*]acridine and 0.7 ng of 7*H*-dibenzo[*c,g*]carbazole; nicotine is a specific precursor for the two acridines. Matsumoto *et al.* (1981) reported 80 ng of 2-amino- α -carboline and 6-8 ng of 2-amino-3-methyl- α -carboline in the smoke condensate of blended cigarettes. Both of these 2-amino carbolines have been reported to be potent mutagens toward *Salmonella typhimurium* (Yoshida *et al.*, 1978). Evaluations of the carcinogenicity of several aza-arenes are given by the IARC (1983a). (See also Appendix 2, pp. 387.)

(iii) *O*-Heterocyclic hydrocarbons

So far, only a few *O*-heterocyclic hydrocarbons have been reported in tobacco smoke: benzo[*b*]furan, three methylbenzo[*b*]furans and three dimethylbenzo[*b*]furans (Neurath *et al.*, 1968), dibenzo[*b,d*]furan (106 ng/cigarette) and the four isomeric methyl dibenzo[*b,d*]furans (192 ng/cigarette; Hoffmann & Mazzola, 1970) and 1,8,9-perinaphthoxanthene (Van Duuren, 1958a).

(k) Alcohols

In addition to the short-chain alcohols such as allyl alcohol, methanol (90-180 μ g/cigarette), ethanol (2 μ g), propanol-1 (4 μ g), propanol-2, butanol-1 (5 μ g), butanol-2 (<4 μ g) and 2-methylpropanol-1 (<6 μ g), tobacco smoke contains all primary alcohols from *n*-C₁₇H₃₅OH to *n*-C₂₄H₄₉OH, and *n*-C₂₈H₅₇OH (Elmenhorst & Schultz, 1968; Schumacher *et al.*, 1977; Severson *et al.*, 1978). The long-chain alcohols in smoke originate from tobacco. The following amounts were isolated from 1 g of cigarette smoke condensate: 1.7-3.7 μ g of eicosanol-1, 5.6-12.4 μ g of docosanol-1, 0.6-1.0 μ g of tetracosanol and 1.6-2.8 μ g of octacosanol (Severson *et al.*, 1978). Tobacco smoke also contains benzyl alcohol and 2-phenylethyl alcohol (Schumacher *et al.*, 1977).

The origin of such diols and triols as ethylene glycol, diethylene glycol, and 2,3-butanediol, 1,2-propanediol, 1,3-propanediol, 1,2,3-butanetriol and glycerol in smoke has not been investigated. Some or at least portions may be transferred into smoke from the casing materials added to tobacco.

(l) Nonvolatile aldehydes and ketones

In addition to the volatile aldehydes and ketones (see pp. 96-97), several carbonyl compounds have been identified in the particulate phase of tobacco smoke. These include benzaldehyde, 4-anisaldehyde, glycolaldehyde and monosaccharides such as arabinose, glucose and xylose. Among the group of ketones are a number of alkyl methyl ketones such as 2-pentanone, 2-hexanone, 4-heptanone and 2-decanone. Representatives of the group of cyclic ketones are cyclopentanone, cyclohexenone, 1-indanone, tetralone, fluorenone and all four isomeric methylfluorenones (Wynder & Hoffmann, 1967; Stedman, 1968; Bell *et al.*, 1969; Schumacher *et al.*, 1977; Newell *et al.*, 1978). Detailed studies have not been carried out on the mechanism of formation of these compounds or on their significance to tobacco carcinogenesis.

(m) *Phenolic compounds and quinones*

Smoke contains more than 200 semivolatile phenols (Ishiguro *et al.*, 1976; Schumacher *et al.*, 1977; Newell *et al.*, 1978; Snook *et al.*, 1980; Arrendale *et al.*, 1984); the major phenols in the smoke of cigarettes and cigars are listed in Table 21. In addition to these simple volatile phenols, smoke contains various polyphenols, which are transferred directly from tobacco (see Fig. 5). The total concentration of phenols in the smoke of a blended nonfilter cigarette amounted to about 600 μg (Guerin, 1980).

Analyses of the smoke of cigarettes (85 mm, nonfilter) made exclusively from one type of tobacco show that oriental and flue-cured tobaccos yield more phenols (e.g., phenol: 120 μg and 95 μg /cigarette, respectively) than burley and Maryland tobaccos (60 and 43 μg phenol/cigarette, respectively) (Wynder & Hoffmann, 1963). A major reason for the low yields in the smoke of burley and Maryland tobaccos is their higher nitrate content (Neurath & Ehmke, 1964b), which inhibits formation of phenolic compounds during smoking (Adams *et al.*, 1984). Smoke deriving exclusively from cigarettes made of the leaves lower on the stalk contains less volatile phenols (42-71 μg phenol/cigarette) than smoke from cigarettes made of the upper leaves (173-321 μg phenol/cigarette) (Rathkamp *et al.*, 1973). Primary precursors of volatile phenols and catechols are polysaccharides and polyphenols (Bell *et al.*, 1966; Schlotzhauer *et al.*, 1982; Carmella *et al.*, 1984). In contrast to catechols, up to 90% of the volatile phenols is selectively removed from smoke by cellulose acetate filter tow and by other hydrophilic filter materials (Wynder & Hoffmann, 1967).

In addition to long-chain fatty acids, the weakly acidic fraction of tobacco smoke contains volatile phenols and dihydroxybenzenes (Ishiguro *et al.*, 1976) and also alkyl-1,2-cyclopentadiones. The latter are present in the acidic smoke in their mono-enolic form as alkyl-2-hydroxy-2-cyclopenten-1-ones at levels of 1-100 μg /cigarette (Hecht *et al.*, 1981a).

The approximately 20 phenol carboxylic acids in tobacco smoke include sinapic acid (3,5-dimethoxy-4-hydroxycinnamic acid), ferulic acid (4-hydroxy-3-methoxycinnamic acid) and syringic acid (4-hydroxy-3,5-dimethoxybenzoic acid) (Stedman, 1968). The phenolic acids in smoke are probably formed from the polyphenols in tobacco during smoking.

Traces of quinones deriving from 1,2- and 1,4-dihydroxybenzenes (catechols and hydroquinones), such as 1,4-benzoquinone and a number of methylated 1,4-benzoquinones, have been found in cigarette smoke. However, 1,2-benzoquinone was absent, since the redox potential of the smoke precludes oxidation of the catechols (Schmeltz *et al.*, 1977; Arrendale *et al.*, 1984). The naphthoquinones and anthraquinones in tobacco smoke are quite stable; the major representatives of this group are 2,3,6-trimethyl-1,4-naphthoquinone (220 ng/cigarette), 2,3-dimethyl-1,4-naphthoquinone (34 ng), 2-methyl-9,10-anthraquinone (190 ng) and 9,10-anthraquinone (88 ng) (Schmeltz *et al.*, 1977).

The weakly acidic (phenolic) fraction of cigarette smoke condensate has been reported to have tumour-promoting and cocarcinogenic activity on mouse skin (Wynder & Hoffmann, 1967; Bock *et al.*, 1971); a major group of tumour-promoting agents in smoke comprises phenols (Boutwell & Bosch, 1959), and the predominant group of cocarcinogens is the catechols (Van Duuren & Goldschmidt, 1976; Hecht *et al.*, 1981b). (See also Appendix 2, pp. 387-394, for evaluations of the evidence for carcinogenicity of catechol, resorcinol and hydroquinone.)

Table 21. Concentrations of some phenols in tobacco smoke (with references^a)

Phenolic compound	Cigarette mainstream smoke - nonfilter ($\mu\text{g}/\text{cigarette}$)	Cigarette sidestream smoke ($\mu\text{g}/\text{cigarette}$)	Cigar smoke ($\mu\text{g}/\text{cigar}$)
<i>Phenols</i>			
Phenol	9-161 (5,6,9,11)	603 (phenols) (7)	35-110 (5,8)
<i>o</i> -Cresol	7-26 (5,6,11)		4-20 (5,8)
<i>m</i> - and <i>p</i> -Cresol	22-82 (5,6,11)		17-90 (5,8)
Xylenols	5-9 (5,11)		1-17 (5,8)
2-, 3- and 4-Vinylphenols	Present (6)		
Ethylphenols	9-28 (5,11)		7-27 (5,8)
2-Methoxyphenol (Guaiacol)	13 (6)		
4-Vinylguaiacol	11 (6)		
1-Naphthol	0.27 (2)		
2-Naphthol	0.54 (2)		
2-Methoxy-4-(2-propenyl)phenol (Eugenol)	2-4 (3,11)		
2-Methoxy-4-propenylphenol (Isoeugenol)	3-15 (3,11)		
Coniferyl alcohol (3'-Hydroxyisoeugenol)	1 (6)		
<i>Di- and trihydroxybenzenes</i>			
Catechol	21-502 (1,4,6,10,11)	88-212 (1)	140-362 (1)
3- and 4-Methylcatechol	32-46 (1,6)		
4-Ethylcatechol	10-46 (1,6)		
4-Vinylcatechol	84 (6)		
Resorcinol	8-80 (2,11)		
Hydroquinone	88-155 (6,11)		
1,3-Dimethoxypropylgallol	Present (11)		

^aReferences: (1) Brunneemann *et al.* (1976b); (2) Commins & Lindsey (1956); (3) Grob & Voellmin (1970); (4) Guerin & Olerich (1976); (5) Hoffmann & Wynder (1972a); (6) Ishiguro *et al.* (1976); (7) Neurath & Ehmke (1964a); (8) Osman *et al.* (1963); (9) Spears (1963); (10) Waltz *et al.* (1965); Wynder & Hoffmann (1967)

(n) Carboxylic acids, esters and lactones

(i) Carboxylic acids

Tobacco smoke contains volatile carboxylic acids (C_1 to C_5), long-chain fatty acids (C_6 - C_{22}), hydroxy carboxylic acids, dicarboxylic acids and benzoic acids. The major volatile acids are ($\mu\text{g}/\text{cigarette}$): formic acid (50-600), acetic acid (35-1700), propionic acid (30-300) and *n*-butyric acid (10-44) (Elmenhorst & Schultz, 1968; Elmenhorst, 1972; Morie, 1972; Matsushima *et al.*, 1979). These acids are to some extent formed during pyrolysis and are also transferred from tobacco into smoke (Wynder & Hoffmann, 1967; Bourlas *et al.*, 1980). The characteristic flavour of the smoke of oriental tobaccos appears to be associated with high concentrations of 3-methylvaleric acid (3-300 times higher in the smoke of oriental tobaccos than in that of other varieties) (Stedman *et al.*, 1963; Elmenhorst, 1972).

The weakly acidic (phenolic) fraction of the smoke particulate matter that has been reported to have tumour-promoting and cocarcinogenic activity on mouse skin (Wynder & Hoffmann, 1967; Bock *et al.*, 1971; Hecht *et al.*, 1981b) contains most of the long-chain saturated and unsaturated fatty acids from C₁₀ to C₂₃, comprising at least 40 compounds (Stedman, 1968; Ishiguro *et al.*, 1976; Newell *et al.*, 1978). These acids originate in tobacco and transfer into smoke (Wynder & Hoffmann, 1967; Severson *et al.*, 1978). The concentrations of the major fatty acids in the smoke of cigarettes and their transfer rates are given in Table 22 (Hoffmann & Woziwodzki, 1968), which shows that the smoke of oriental cigarette tobacco contains the highest concentration of long-chain fatty acids (957 µg/g tobacco burned), followed, in order of decreasing concentration, by the smoke from cigarettes made entirely from flue-cured, Maryland and burley tobaccos (733, 300 and 211 µg/g tobacco burned, respectively).

In addition to the volatile and long-chain fatty acids, tobacco smoke contains a great variety of other types of carboxylic acids, including benzoic acid (26-310 µg/cigarette), phenyl acetic acid (18-70 µg/cigarette), other phenylalkyl acids, furancarboxylic acids, phenolic acids and methyl derivatives of long-chain acids (Stedman, 1968; Elmenhorst, 1972; Ishiguro *et al.*, 1976; Newell *et al.*, 1978). The strongly acidic fraction of the 'tar' contains dicarboxylic acids and tricarboxylic acids, all of which originate from tobacco. The most abundant of these are lactic acid (63-174 µg/cigarette), succinic acid (112-163 µg/cigarette) and maleic acid (amount not given) (Sakuma *et al.*, 1983). Per gram of tobacco burned, the MS of an 8-g cigar contained 14.3 µg of succinic acid, 10.7 µg of 2-furancarboxylic (2-furoic) acid, 9.6 µg of lactic acid, 8.3 µg of oxalic acid, 4.8 µg of benzoic acid and 3.7 µg of malic acid (Schmeltz & Schlotzhauer, 1962).

Table 22. Concentrations of free fatty acids in cigarette smoke^a

Acid	Tobacco burned (µg/g)				
	Oriental	Flue-cured	Maryland	Burley	Blend ^b
Palmitic	284	197	107	55	152
Stearic	90	74	43	33	75
Oleic	108	39	32	21	58
Linoleic	146	113	52	50	96
Linolenic	329	310	66	52	240
Total (mg)	0.96	0.73	0.30	0.21	0.62
Wet TPM ^c (mg)	37.2	37.6	26.4	20.1	32.3
% Fatty acids in wet TPM	2.6	1.95	1.14	1.05	1.9

^aFrom Hoffmann and Woziwodzki (1968). Cigarettes were 85 mm long without filter tips.

^bUS commercial cigarette

^cTPM, total particulate matter

At least eight acid anhydrides have been found in cigarette smoke, including maleic anhydride and succinic anhydride and their alkylated derivatives (Schumacher *et al.*, 1977; Newell *et al.*, 1978). These smoke constituents are of particular concern because of their alkylating potential. Maleic anhydride, 2,3-dimethyl maleic anhydride and succinic anhydride have produced local tumours in one experiment in rats (Dickens & Jones, 1963, 1965; IARC, 1977). (See also Appendix 2, pp. 387-394)

(ii) *Esters*

About 400 esters have been identified in tobacco smoke (Green, C.R., 1977), the most abundant being fatty acid esters of phytosterols, solanesol and glycerol. The phytosterols cholesterol, campesterol, stigmasterol and sitosterol are esterified primarily with C₁₆ and C₁₈ saturated and unsaturated fatty acids. A total of 73.3 µg/cigarette of bound phytosterols (esters, calculated as the sterol moiety) was found in MS and 22.2 µg/cigarette in SS; the MS of one little cigar (1.05 g) contained 45.6 µg of phytosterol esters (Schmeltz *et al.*, 1975). Analysis of the smoke of a blended filter cigarette showed isolated amounts of esters of solanesol with long-chain fatty acids (Rodgman *et al.*, 1959). Esters of the saturated fatty alcohols C₁₂-C₂₇ with C₁₄-C₂₈ saturated and unsaturated acids have also been reported in smoke (Rodgman *et al.*, 1962).

(iii) *Lactones*

About 80 lactones have been identified in tobacco smoke. These compounds, especially the γ -butyrolactones, and others, have alkylating potential and some have been reported to be carcinogenic in laboratory animals (Lawley, 1984). (See also Appendix 2, pp. 387-394.) Quantitatively, about half of the lactones in the smoke consist of γ -butyrolactone (IARC, 1976a) (about 10 µg/cigarette) and its derivatives; δ -valerolactone and some alkylated and unsaturated δ -valerolactones, as well as coumarin (Wynder & Hoffmann, 1967), 6-methylcoumarin and 3,4-dihydrocoumarin have also been isolated (Schumacher *et al.*, 1977). The occurrence of coumarin derivatives in smoke could be due to pyrolysis of polyphenols with a coumarin structure (see Fig. 5) or of plant extracts added to tobacco to enhance flavour (Wynder & Hoffmann, 1967). Coumarin itself is carcinogenic to rats after oral administration (IARC, 1976b).

(o) *Amines and amides*

Volatile and nonvolatile amines are not discussed separately, since the amines in the smoke of flue-cured tobaccos and blended cigarette tobaccos are present in the particulate matter in protonated form whereas the volatile amines in the smoke of burley tobacco, cigars and pipes and in SS are at least partially present in the vapour phase as free amines (Brunnemann & Hoffmann, 1974a; Schmeltz & Hoffmann, 1977). When evaluating quantitative data on volatile amines, consideration must be given to the fact that partial hydrolysis of amides during the trapping of smoke in diluted acid may artificially elevate levels of amines.

(i) *Amines*

About 200 amines have been identified in tobacco smoke (Schmeltz & Hoffmann, 1977; Dube & Green, 1982). The major primary, secondary and tertiary acyclic and cyclic nonaromatic amines in the MS of nonfilter cigarettes are (µg/cigarette): methylamine

(4.6-28.7), ethylamine [+ trimethylamine] (0.96-25.5), *n*-butylamine (0.09-1.5), dimethylamine (1-10.0), diethylamine (0.1), pyrrolidine (0.16-18.3), trimethylamine (0.7) and *N*-methylpyrrolidine (3). The presence of another 30 aliphatic amines has been ascertained. In general, the largest amounts of these amines are found in the smoke of burley tobacco (Vickroy, 1976; Schmeltz & Hoffmann, 1977; Sakuma *et al.*, 1984a). The presence of pyrrolidines and piperidines and of some other amines and of pyridines and quinolines in smoke is due, at least in part, to pyrolytic formation from nicotine and other pyridine alkaloids. However, studies with ¹⁴C-labelled nicotine have shown that its pyrolysis products correlate neither qualitatively nor quantitatively with the thermal decomposition products in burning cigarettes (Schmeltz *et al.*, 1979).

Table 23. Concentrations of aromatic amines in cigarette smoke (ng/cigarette)^a

Aromatic amine	Mainstream smoke		Sidestream smoke
	US 85-mm nonfilter	French 70-mm nonfilter	French 70-mm nonfilter
Aniline	102	364	10 800
<i>ortho</i> -Toluidine	32.2	162	3 030
<i>meta</i> -Toluidine	15.3	30.4	2 080
<i>para</i> -Toluidine	13.5	33.8	1 730
2-Ethylaniline + 2,6-dimethyl-aniline	14.9	54.2	1 240
2,5-Dimethylaniline	19.1	87.2	2 370
3-Ethylaniline + 2,4-dimethyl-aniline	14.0	56.7	1 200
4-Ethylaniline + 2,3-dimethyl-aniline	7.8	27.3	494
1-Naphthylamine	4.3	2.5	103
2-Naphthylamine	1.0	1.7	67
2-Aminobiphenyl	1.8	3.0	110
3-Aminobiphenyl	2.7	5.0	132
4-Aminobiphenyl	2.4	4.6	143
2-Methyl-1-naphthylamine	5.8	3.6	117

^aFrom Patrianakos and Hoffmann (1979)

Aniline and about 30 of its derivatives have been identified in tobacco smoke (Schmeltz & Hoffmann, 1977). Concentrations in MS and SS of certain cigarettes without filter tips are given in Table 23, which shows that the emission of aromatic amines into SS exceeds that into MS by about 30 times (Patrianakos & Hoffmann, 1979). In another study, 27.3 ng of 1-naphthylamine and 21.8 ng of 2-naphthylamine were reported in the MS of an 85-mm blended nonfilter US cigarette (Masuda & Hoffmann, 1969). The evidence for carcinogenicity of 2-naphthylamine, 4-aminobiphenyl, *ortho*-toluidine, aniline, 1-naphthylamine, *N*-phenyl-2-naphthylamine and *ortho*-anisidine has been evaluated by the IARC (see Appendix 2, pp. 387-394).

(ii) *Amides*

Tobacco smoke contains a large spectrum of amides, imides and lactames (Schmeltz & Hoffmann, 1977; Schumacher *et al.*, 1977; Heckman & Best, 1981), including about 30 aliphatic amides. Johnson *et al.* (1973c) reported the concentrations of some major representatives of this class in the MS and SS of cigarettes made exclusively of burley, flue-cured and oriental tobacco and of the Kentucky reference cigarette, respectively, as follows ($\mu\text{g}/\text{cigarette}$): formamide (MS, 12, 4, 4, 27; SS, 5, 17, 10, 21), acetamide (MS, 56, 38, 46, 51; SS, 32, 53, 47, 70) and propionamide (MS, 6, traces, 7, 25; SS, 5, 10, 10, 11).

Of specific interest are the approximately 24 secondary amides in smoke, which may give rise to carcinogenic *N*-nitrosamides during smoking or *in vivo* upon uptake of the smoke. These secondary amides include *N*-methylformamide, *N*-methylacetamide, *N*-methylpropionamide, *N*-methylnicotinamide and the cyclic amides, *N*-methyl-2-pyrrolidinone and *N*-methyl-2-piperidone, as well as urethanes (Schumacher *et al.*, 1977), discussed above.

(p) *Tobacco alkaloids*

A major reason that people use tobacco is the presence of alkaloids, especially nicotine. The nicotine content of the MS of a UK commercial cigarette in 1983 ranged from <0.3 -2.5 mg/cigarette (Health Departments of the United Kingdom, 1984); that of a US cigarette in 1984 was 0.1-2.1 mg/cigarette (US Federal Trade Commission, 1985). Nicotine is determined under standardized machine-smoking conditions, and these measurements do not necessarily represent the true amount of nicotine in MS that is available to the smoker, especially in the case of low-nicotine cigarettes (Herning *et al.*, 1981). The nicotine delivery in the MS of little cigars may vary between 0.7 and 2.9 mg, and large cigars may deliver up to 3.2 mg (Schmeltz *et al.*, 1976a). As stated earlier, the pH of smoke of blended cigarettes and cigarettes made entirely from flue-cured or oriental tobacco is below 6.2; therefore, since nicotine is a constituent of the particulate phase, in the smoke of such cigarettes it is present mostly in monoprotonated or, to a small extent, in diprotonated form. However, smoke from burley tobaccos and from cigars with smoke of pH 6-7 or higher, especially in the last puffs, contains free nicotine in the vapour phase. The pH of SS varies between 6.5 and 8.0; thus, free nicotine is emitted as an air pollutant as part of the vapour phase (Brunnemann & Hoffmann, 1974a). The SS:MS ratio of nicotine varies between 2.6 and 3.3 in the case of nonfilter cigarettes; but, since the nicotine delivery in SS is independent of the filter tip (which reduces 'tar', including nicotine, only in MS), the SS:MS ratio for filter cigarettes may reach 12 (Johnson *et al.*, 1973b; Browne *et al.*, 1980; Laboratory of the Government Chemist, 1982).

The 10 major pyridine alkaloids in the smoke of cigarettes are shown in Figure 5. Nicotine accounts for ~ 85 -90% of the total alkaloids in the smoke. In addition to the compounds shown in Figure 5, minor alkaloids have been identified in tobacco smoke, including *N*-methylanabasine and 2,2'-bipyridyl (Schmeltz & Hoffmann, 1977). Tobacco smoke also contains 12 *N*-acyl derivatives of the pyridine alkaloids, including formyl-nornicotine and *n*-octanoylnornicotine (Snook *et al.*, 1984).

(q) Pyridines, pyrroles and pyrazines

Alkaloids, amino acids, protein and saccharides give rise to pyridines, pyrroles and pyrazines in MS and SS (Brunnemann & Hoffmann, 1982). These semivolatile five- and six-ring *N*-heterocyclic hydrocarbons contribute significantly to the flavour of tobacco smoke, and especially that of the alkaline smoke of cigars and pipes. So far, about 100 pyridines, 15 pyrroles and 35 pyrazines have been identified in tobacco smoke (Schmeltz & Hoffmann, 1977; Heckman & Best, 1981).

The major pyridines and pyrazines in MS and SS of certain cigarettes are shown in Table 24. The SS:MS ratio of the combined total of 21 pyridines and pyrazines is 14 for cigarettes and 30 for cigars. Cellulose acetate filter tips and especially charcoal-containing filter tips reduce the level of pyridines in cigarette smoke selectively (Brunnemann *et al.*, 1978).

Table 24. Concentrations of major pyridines and pyrazines in mainstream cigarette smoke ($\mu\text{g}/\text{cigarette}$)

Compound	US nonfilter ^a 85 mm	US filter ^a 85 mm	US filter ^a 85 mm	Japanese presu- mably nonfilter ^b 70 mm
Pyridine	32.4	21.4	28.7	21.7
2-Picoline	12.3	12.1	11.5	11.0
3-Picoline	24.1	9.8	15.7	36.1
4-Picoline				6.7
2,6-Lutidine	1.4	1.0	1.1	12.8
2,5-Lutidine	3.9	2.7	3.0	2.7 ^c
2,4-Lutidine	1.7	1.1	1.1	5.8
3-Vinylpyridine ^d	23.3	7.0	14.9	14.0
2-Methylpyrazine	2.2	1.6	0.9	4.9
2,3-Dimethylpyrazine	0.4	0.4	0.2	-

^aFrom Brunnemann *et al.* (1978)

^bFrom Sakuma *et al.* (1984a,b)

^c2,3-Lutidine

^d+ 3,4-lutidine in US cigarettes

(r) N-Nitrosamines

During the processing of tobacco and especially during tobacco smoking, three types of *N*-nitrosamines are formed: volatile *N*-nitrosamines (VNA), nonvolatile nitrosamines and tobacco-specific *N*-nitrosamines. The VNA in tobacco smoke are formed primarily from amines and nitrogen oxides during the burning of tobacco, and only a small fraction (0-180 $\mu\text{g}/\text{kg}$) originates from the VNA already present in cured tobacco. The concentrations of the seven VNA so far reported in the MS of cigarettes made entirely from burley, flue-cured or French black (dark air-cured) tobaccos and in the MS of commercial nonfilter and filter cigarettes are given in Table 25 (Hoffmann *et al.*, 1984a). Each of these has been evaluated by the IARC (1978, 1985a) for carcinogenicity and found to be carcinogenic in experimental

Table 25. Concentrations of *N*-nitrosamines in cigarette smoke (ng/cigarette)^a

Nitrosamine	Burley tobacco	Flue-cured tobacco	French black tobacco	Commercial cigarettes	
				Nonfilter	Filter
<i>N</i> -Nitrosodimethylamine	11-180	0.5-13.2	29-143	2-20	0.1 - 17
<i>N</i> -Nitrosomethylethylamine	9.1-13	> 0.1	2.7-12	ND-2.7	ND-2.5
<i>N</i> -Nitrosodiethylamine	4-25	ND-1.8	0.6-6	ND-2.8	ND-7.6
<i>N</i> -Nitrosodi- <i>n</i> -propylamine	ND	ND	ND	ND-1.0 ^b	ND
<i>N</i> -Nitrosodi- <i>n</i> -butylamine	ND	ND	ND	ND-3 ^b	ND
<i>N</i> -Nitrosopyrrolidine	52-76	6.2	25-110	ND-110	1.5 - 30
<i>N</i> -Nitrosopiperidine	9	ND	ND	ND-9 ^b	ND
<i>N</i> -Nitrosodiethanolamine	2-90	ND	ND	36	24
<i>N</i> '-Nitrososornicotine	3700	620	590	120-950	310
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone	320	420	220	80-770	150
<i>N</i> '-Nitrosoanatabine	4600	410	200	140-990	370
<i>N</i> '-Nitrosoanabasine			ND-150		

^aFrom Hoffmann *et al.* (1984a); ND, not detected

^bReported only in isolated instances

animals. The most abundant VNA are *N*-nitrosodimethylamine (NDMA) and *N*-nitrosopyrrolidine (NPYR). The protein fraction of the tobacco is a major precursor of VNA in the smoke (Brunnemann & Hoffmann, 1982): proline can serve as a precursor for *N*-nitrosoproline, which can serve as an indicator for the formation of *N*-nitrosamines, such as NPYR, in smoke (Brunnemann *et al.*, 1983), NPYR being formed by decarboxylation and *N*-nitrosation (Ishiguro *et al.*, 1984).

The tobacco of cigarettes, cigars and pipes contains the nonvolatile nitrosamino acids 3-(*N*-nitroso-*N*-methylamino)propionic acid (0.15-7.01 $\mu\text{g/g}$), 4-(*N*-nitroso-*N*-methylamino)butyric acid (0.03-0.34 $\mu\text{g/g}$) and *N*-nitroso-DL-pipecolic acid (0.04-0.34 $\mu\text{g/g}$) (Ohshima *et al.*, 1985); it is probable that these agents decarboxylate during smoking and give rise to the carcinogenic nitrosamines *N*-nitrosomethylethylamine, *N*-nitrosomethylpropylamine and *N*-nitrosopiperidine (IARC, 1978).

The highest levels of *N*-nitrosamines in smoke have been found in the nitrate-rich burley and French black (dark air-cured) tobaccos (Table 25). The importance of the nitrate content of tobacco as a determinant of VNA yields in smoke was also shown in a model study (Adams *et al.*, 1984). Since ribs and stems are the major nitrate reservoirs of the tobacco plant (Tso, 1972), their incorporation into tobacco blends increases VNA yields in smoke. VNA are amenable to selective removal from smoke by most cigarette filter tips (Hoffmann *et al.*, 1980).

In an analysis of VNA in a little cigar with a filter tip, 43 ng of NDMA and 19 ng of NPYR were found in MS; 70 ng of NDMA and 10 ng of NPYR were found in smoke from a 7.5-g cigar (Brunnemann & Hoffmann, 1978). Because different burning conditions are encountered during puffing and during smouldering, the material balance of certain volatile smoke constituents favours SS to a significant extent. SS:MS ratios particularly affected by this phenomenon are those for nitrogen oxides (4.3-9.9; Norman *et al.*, 1983), ammonia (37-64; see pp. 95-96), volatile amines (dimethylamine, 3.7-5.1; Sakuma *et al.*, 1984a) and VNA (see Table 26). Ishiguro *et al.* (1984) investigated the mechanisms of VNA formation in SS of cellulose-filter cigarettes experimentally by varying the amounts of *N*-containing compounds, including proteins and nitrates. The absence of nitrates reduced the yields of NDMA and NPYR by up to 70%. The presence of VNA from SS as air pollutants in smoke-filled rooms is discussed below (pp.123-124).

The only non-tobacco-specific nonvolatile *N*-nitrosamine that has been identified in tobacco and smoke is *N*-nitrosodiethanolamine (IARC, 1978). Its presence in tobacco products has been related to the use of the sucker growth inhibitor, maleic hydrazide when formulated with the diethanolamine salt ('MH-30' or 'MH-40'; Tso, 1972); in the USA, that formulation has been replaced by the potassium salt. Tobacco grown in a pesticide-free environment and smoke generated from such tobaccos are devoid of *N*-nitrosodiethanolamine (Brunnemann & Hoffmann, 1981). Although tobacco contains *N*-nitrosoproline (IARC, 1978), this nonvolatile nitrosamine is not present in tobacco smoke (<1 ng/cigarette; Brunnemann *et al.*, 1983).

Tobacco-specific nitrosamines (TSNA) are formed during the curing and smoking of tobacco, by *N*-nitrosation of nicotine and the minor pyridine alkaloids (Fig. 6). The predominant members of this class of compound are *N'*-nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), *N'*-nitrosoanatabine (NAT) and *N'*-nitrosoanabasine (NAB). The evidence for the carcinogenicity of these compounds has been evaluated by the IARC (1985a): NNN and NNK are carcinogenic in experimental animals; there is limited evidence for the carcinogenicity of NAB; and the available data for NAT were inadequate to evaluate its carcinogenicity to experimental animals. (See also Appendix 2, pp. 387-394.) TSNA are by far the most abundant suspected carcinogens in tobacco smoke of all the compounds so far determined.


During smoking, 54-59% of the NNN appearing in the MS of a cigarette has been pyrosynthesized, and the remainder is transferred directly from the tobacco into the smoke; 63-74% of NNK in smoke has been pyrosynthesized (Hoffmann *et al.* 1980; Adams *et al.*, 1983). As for VNA, the yield of TSNA is significantly increased by the increased nitrate content of tobacco (Adams *et al.*, 1984). The MS of a little cigar and of a 5.7-g cigar was found to contain 5.5 and 3.2 μg of NNN, 4.2 and 1.9 μg of NNK and 1.7 and 1.9 μg of NAT, respectively, per cigar (Hoffmann *et al.*, 1980). The release of TSNA into SS of certain tobacco products is quantified in Table 26.

Table 26. Concentrations of *N*-nitrosamines in sidestream smoke of commercial cigarettes and cigars (ng/tobacco product)^a

Tobacco product ^b	Volatile <i>N</i> -nitrosamines ^c			Tobacco-specific nitrosamines ^c		
	NDMA	NEMA	NPYR	NNN	NNK	NAT
US nonfilter cigarette (1) ^d	680 (52)	9.4 (5)	300 (27)	1700 (7)	410 (4)	270 (0.8)
US filter cigarette (1)	736 (139)	10 (8)	387 (76)	150 (0.5)	190 (1.3)	150 (0.4)
French nonfilter cigarette (1)	823 (19)	30 (25)	204 (9)			
French filter cigarette (1)	1040 (160)	10 (20)	213 (25)			
Swiss nonfilter cigarette (1)	359 (13)	15 (12)	90 (7)			
Swiss filter cigarette (11)	143-415 (12-830)	0-27 (5)	28-143 (3-53)			
German nonfilter cigarette (4)	156-401 (20-100)	3.1-19 (8)	84-107 (4-36)			
German filter cigarette (6)	175-398 (50-438)	6-24	7.2-150 (7-39)			
German nonfilter cigarette (2)	213-514 (32-37)	15.4-31	281-510 (17-24)			
German filter cigarette (4)	330-558 (106-310)	13.2-35	296-700 (35-123)			
Little cigar with filter (10)	1700 (41)	75 (10)	612 (32)	880 (0.2)	810 (0.2)	570 (0.3)
Cigar (1)				16 600 (5)	15 700 (8)	

^aFrom Hoffmann *et al.* (1980, 1984a)^bIn parentheses, number of cigarettes tested^cNDMA, *N*-nitrosodimethylamine; NEMA, *N*-nitrosoethylmethylamine; NPYR, *N*-nitrosopyrrolidine; NNN, *N'*-nitrosoanornicotine; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NAT, *N'*-nitrosoanatabine. In parentheses, ratio of content in sidestream smoke to that in mainstream smoke^d*N*-Nitrosodiethanolamine: 43 ng in sidestream smoke; 36 ng in mainstream smoke

Fig. 6. Formation of tobacco-specific *N*-nitrosamines^a.



^aNNN, *N*'-nitrosornnicotine; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NAT, *N*'-nitrosoanatabine; NAB, *N*'-nitrosoanabasine

The presence of nitrogen oxides in the MS of cigarettes suggests that they may contribute to the formation of carcinogenic *N*-nitrosamines not only in the smoke but also, upon smoke inhalation, endogenously (Hoffmann & Brunnemann, 1983; Ladd *et al.*, 1984). Several of the amines present may also serve as precursors of volatile *N*-nitrosamines in cigarette smoke.

[Inhalation of nitrogen dioxide from smoke-polluted environments (see p. 120-126) may also contribute to the endogenous formation of carcinogenic *N*-nitrosamines in both non-smokers and smokers.]

(s) *Inorganic constituents*

Like other plant tissues, tobacco contains minerals and other inorganic constituents deriving from soil, fertilizers, mulch, agricultural sprays and polluted rainfall. Upon combustion, most metals remain in the ashes; however, they may be vaporized or carried in microfragments of ash and thus appear in MS. Figure 7 indicates those metals in the periodic system of elements that have been identified in tobacco smoke; Table 27 presents the available quantitative data.

The evidence for the carcinogenicity of certain metals has been evaluated by the IARC (see Appendix 2, pp. 387-394). Arsenic and arsenic compounds and chromium and certain chromium compounds are causally associated with cancer in humans; nickel and cadmium

Fig. 7. Metals occurring in tobacco smoke (shaded elements)^a

Period	Group Ia	Group IIa	Group IIIa	Group IVa	Group Va	Group VIa	Group VIIa	Group VIII						Group Ib	Group IIb	Group IIIb	Group IVb	Group Vb	Group VIb	Group VIIb	Group O
1 1s	1 H																			1 H	2 He
2 2s2p	3 Li	4 Be														5 B	6 C	7 N	8 O	9 F	10 Ne
3 3s3p	11 Na	12 Mg														13 Al	14 Si	15 P	16 S	17 Cl	18 Ar
4 4s3d 4p	19 K	20 Ca	21 Sc	22 Ti	23 V	24 Cr	25 Mn	26 Fe	27 Co	28 Ni	29 Cu	30 Zn	31 Ga	32 Ge	33 As	34 Se	35 Br	36 Kr			
5 5s4d 5p	37 Rb	38 Sr	39 Y	40 Zr	41 Nb	42 Mo	43 Tc	44 Ru	45 Rh	46 Pd	47 Ag	48 Cd	49 In	50 Sn	51 Sb	52 Te	53 I	54 Xe			
6 6s (4f) 5d 6p	55 Cs	56 Ba	57* La	72 Hf	73 Ta	74 W	75 Re	76 Os	77 Ir	78 Pt	79 Au	80 Hg	81 Tl	82 Pb	83 Bi	84 Po	85 At	86 Rn			
7 7s (5f) 6d	87 Fr	88 Ra	89** Ac																		

*Lanthanide series 4f	58 Ce	59 Pr	60 Nd	61 Pm	62 Sm	63 Eu	64 Gd	65 Tb	66 Dy	67 Ho	68 Er	69 Tm	70 Yb	71 Lu
**Actinide series 5f	90 Th	91 Pa	92 U	93 Np	94 Pu	95 Am	96 Cm	97 Bk	98 Cf	99 Es	100 Fm	101 Md	102 No(?)	103 Lw

^aFrom Norman (1977)

and their compounds are probably carcinogenic to humans. For lead, there were inadequate data to evaluate carcinogenicity to humans, although certain salts are carcinogenic to experimental animals (IARC, 1982b). Cobalt compounds have been reported to be carcinogenic to laboratory animals (Furst & Haro, 1969).

Arsenical pesticides were used in the cultivation of tobacco in the USA from 1917-1951, during which time the arsenic content of US cigarettes rose from 10 to 50 $\mu\text{g/g}$ (Guthrie & Bowery, 1967). In 1952, arsenicals were removed from the list of recommended insecticides for tobacco, and the arsenic content of US tobaccos was decreased to 0.5-1 $\mu\text{g/g}$ by 1968. Machine-smoking studies show that 4-12% of the total arsenic on tobacco leaves appears in the MS of cigarettes (Guthrie, 1968).

Lewis, G.P. *et al.* (1972) analysed kidney, liver and lung specimens and found a statistically significant relationship between the body burden of cadmium in smokers and the number of past years of smoking history, so that a heavy smoker accumulated more than twice the body burden of cadmium as a nonsmoker. The cadmium content of cigarette smoke is believed to be due to the presence of that metal in phosphate fertilizers (Friberg *et al.*, 1974).

Table 27. Concentrations of metals in cigarette smoke with references^{a)}

Metal	$\mu\text{g/Cigarette}$	
Na	1.3	(3)
K	70	(3)
Cs	0.0002	(3)
Mg	0.070	(3)
Sc	0.0014	(3)
La	0.0018	(3)
Cr	0.004-0.069	(1,3)
Mn	0.003	(3)
Fe	0.042	(3)
Co	0.0002	(3)
Ni	0.0-0.51	(1,2,3,4,5)
Cu	0.19	(3)
Ag	0.0012	(3)
Au	0.00002	(3)
Zn	0.12-1.21	(1,3,4)
Cd	0.007-0.35	(1,3,4,5)
Hg	0.004	(3)
Al	0.22	(3)
Pb	0.017-0.98	(1,3,4)
As	0.012-0.022	(1,3)
Sb	0.052	(3)
Bi	0.004	(3)
Se	0.001-0.063	(1,3)
Te	0.006	(3)

^{a)}References: (1) Jenkins, R.A. (1985); (2) National Research Council (1975); (3) Norman (1977); Perinelli & Carugno (1978); (5) Bache *et al.* (1986)

(i) Radioelements

Tobacco and tobacco smoke contain radioactive elements, including radium-226, radium-228 and thorium-228; however, 99% of the α -activity derives from polonium-210 (Cohen, B.S. *et al.*, 1979). ^{210}Pb and ^{210}Po in tobacco originate from phosphate fertilizers (Tso *et al.*, 1966) and/or from airborne ^{210}Pb -containing aerosol particles that are trapped by the trichomes of tobacco leaves (Martell, 1974).

Pujić and Knežević (1963) observed 3 pCi [0.1 Bq] of ^{210}Po per 100 g of cigarette tobacco, of which about 35% was recovered in the MS upon constant puffing. Radford and Hunt (1964) reported 0.39-0.48 pCi [0.014-0.015 Bq]/cigarette of ^{210}Po in the tobacco from four brands of US cigarettes; up to 25% of this amount was recovered in the particulate matter of

MS. Many studies subsequently confirmed the presence in tobacco products of ²¹⁰Pb (the long-lived α-emitting precursor that supports ²¹⁰Po) (Wynder & Hoffmann, 1967; Harley *et al.*, 1980; Martell, 1982). Harley *et al.* (1980) examined tobacco samples from 24 countries and found 0.14-1.0 pCi [0.005-0.04 Bq] ²¹⁰Po/g cigarette tobacco; Bodgen *et al.* (1981) reported mean values of 0.28 ± 0.06 pCi [0.01 ± 0.002 Bq]/cigarette in 13 US and UK cigarettes and 0.26 ± 0.13 pCi [0.01 ± 0.005 Bq]/cigarette in 11 Mexican-Colombian cigarettes.

The fate of ²¹⁰Po during smoking of a nonfilter cigarette and of three types of filter cigarette is shown in Table 28 (Ferri & Baratta, 1966).

Table 28. Polonium-210 distribution (pCi[Bq]/g tobacco)^a

Sample	Polonium-210 concentration (pCi[Bq]/g tobacco)							
	Nonfilter		Filter					
			Cellulose		Cellulose, charcoal-treated		Cellulose, pipe tobacco ^b	
Total cigarette	0.411	[0.015]	0.403	[0.015]	0.410	[0.015]	0.357	[0.013]
Inhaled smoke	0.091	[0.003]	0.061	[0.002]	0.045	[0.002]	0.109	[0.004]
	(22.2%)		(15.1%)		(11.0%)		(30.7%)	
Sidestream smoke	0.100	[0.004]	0.133	[0.005]	0.168	[0.006]	0.116	[0.004]
	(24.5%)		(32.9%)		(40.8%)		(32.4%)	
Butt and ash	0.191	[0.007]	0.157	[0.006]	0.206	[0.008] ^c	0.115	[0.004]
	(46.7%)		(38.8%)		(50.3%)		(32.2%)	
Filter	-		0.055	[0.002]	-		0.031	[0.001]
			(13.7%)				(8.8%)	
Material balance (%) ^d	93.4±5.4		100.5±5.2		102.1±6.3		104.1±5.2	

^aFrom Ferri and Barrata (1966); numbers in parentheses are percentages of polonium-210 relative to that of origin: product.

^bPipe tobacco was used to make cigarettes with a cellulose filter.

^cIncludes filter

^dTotal error term is one standard deviation.

Bergman *et al.* (1984) have shown in model studies that indoor air with moderate concentrations of radon daughters can more than double its content of short-lived radon daughters when polluted by tobacco smoke, as the smoke particles may pick up the radon daughters and hinder them from plating out on walls and other surfaces.

Tobacco also contains the β-emitter potassium-40 (natural abundance, 0.012% of potassium) (Windholz, 1983). The transfer rate into cigarette MS varied from 0.41 to 0.75%, amounting to 0.094-0.159 pCi [0.003-0.006 Bq]/cigarette (Runeckles, 1961). Although in one study strontium-90 was reported in cigar tobaccos, it has not been determined in tobacco smoke (Tso, 1966; Wynder & Hoffmann, 1967).

(u) *Agricultural chemicals*

Many chemicals are currently in use or have been used in the cultivation of tobacco (Wynder & Hoffmann, 1967). The use of arsenical compounds is discussed above (p. 115). The major agricultural chemicals that have been reported in tobacco smoke and their known degradation products are shown in Table 29. In addition to the pyrolysis products shown in the table, *para,para'*-DDT also gives rise to bis(*para*-chlorophenyl)methane and *para,para'*-dichlorobenzophenone; however, quantitative data are not available (Chopra & Domanski, 1972). The elimination of chlorinated hydrocarbon insecticides (TDE, DDT, endrin, aldrin, dieldrin and others) from tobacco culture in the USA in the late 1960s resulted in a drastic reduction in total DDT residues in leaf tobacco: according to available data, the residue level of total DDT in US flue-cured tobacco in 1968 was 52 $\mu\text{g/g}$, dropped to 6 $\mu\text{g/g}$ in 1970 and reached 0.23 $\mu\text{g/g}$ in 1974 (Sheets & Leidy, 1979). Thiodan (endosulphan) gives rise to chlorobenzene and higher chlorinated benzenes upon pyrolysis (Chopra *et al.*, 1978). Methyl bromide has occasionally been used for field fumigation in tobacco seed beds. No other bromine compound is used in tobacco production or storage (Tso, 1972). Methyl bromide has been detected in the MS of a reference 85-mm nonfilter cigarette ($\sim 0.45 \mu\text{g/cigarette}$) and in its SS ($\sim 0.80 \mu\text{g/cigarette}$). Methyl bromide appears to be formed during smoking, primarily from the reaction of ionic bromide with methyl radicals (Jenkins, R.W. *et al.*, 1982).

The evidence for carcinogenicity of a number of the chemicals listed in Table 29 has been evaluated by the IARC (see Appendix 2, pp. 387-394). Carbaryl (IARC, 1976c) is easily *N*-nitrosated *in vitro* to *N*-nitrosocarbaryl and, on ingestion, could be expected to lead to the formation of *N*-nitrosocarbamate in the stomach. *N*-Nitrosocarbaryl is carcinogenic in rats (IARC, 1983b).

(v) *Additives*

Various additives are used in processing tobacco, and especially that for low-yield cigarettes. Certain countries, however, such as Canada and the UK, are bound by law to utilize only 'genuine tobacco'.

(i) *Humectants*

The principal humectants used are propylene glycol and glycerol and, to a lesser extent, diethylene glycol, triethylene glycol and sorbitol. The concentrations of these humectants in cigarette tobacco may reach several percent (Wynder & Hoffmann, 1967); their transfer rate into MS varies from 3-6% in cigarettes and from 35-43% in pipes (Miller, J.E., 1964; Doihara *et al.*, 1965; Laurene *et al.*, 1965). About 5.2% of glycerol is transferred into MS, independent of its concentration in the tobacco; the transfer rate of propylene glycol is below 5%, and there are indications that more propylene glycol is vaporized from tobacco into SS (Laurene *et al.*, 1965). Unadulterated tobacco already contains some glycerol; its addition as a humectant increases the potential additional formation of acrolein (Wynder & Hoffmann, 1967; see IARC, 1985a), a strong ciliotoxic agent (Battista, 1976). (See also Appendix 2, pp. 387-394).

Table 29. Concentrations of agricultural chemicals in tobacco smoke

Chemical	Concentration ($\mu\text{g}/\text{cigarette}$) ^a	Thermal decomposition products ($\mu\text{g}/\text{cigarette}$)	Reference
Captan (IARC, 1983a)	<0.4-33.7 (2.7%)		Yamasaki, Y. & Tomaru (1976)
Carbaryl (IARC, 1976c)	Traces (1%)		Stedman (1968)
<i>para, para'</i> -DDT (IARC, 1974c)	0.71-1.2 (9-12.4%)	DDE (0.2; 29%) <i>trans</i> -4,4'-Dichlorostilbene (0.3-1.73)	Hoffmann <i>et al.</i> (1969); Thorstenson & Dorough (1976)
<i>para, para'</i> -DDD (IARC, 1974c)	1.7-2.5 (10-18%)	1-Chloro-2,2-bis(<i>para</i> - chlorophenyl)ethylene (0.81)	Hoffmann <i>et al.</i> (1969); Thorstenson & Dorough (1976)
<i>ortho, para'</i> -DDT (IARC, 1974c)	0.2-0.72 (0.1%)		Hoffmann <i>et al.</i> (1969); Thorstenson & Dorough (1976)
<i>ortho, para'</i> -DDD (IARC, 1974c)	0.40-1.0 (0.2-11.6%)		Hoffmann <i>et al.</i> (1969)
Endrin (IARC, 1974c)	(18-30%)		Stedman (1968)
Malathion (IARC, 1983b)	(~9%)		Hengy & Thirion (1970)
Maleic hydrazide (IARC, 1974b)	<0.1-2.1 (1.25-10.3%) SS (0-1.4; 0-3.3%)		Chopra <i>et al.</i> (1982); Liu & Hoffmann (1973)
Thiodan (endosulphan)	Present		Chopra <i>et al.</i> (1978)

^aNumbers in parentheses, transfer from tobacco into smoke

(ii) Tobacco casings

Before being cut, cigarette tobacco is usually sprayed with casing, except when it is prohibited by law. Casing sauce contains primarily sugars, humectants and/or aromatic substances. In some products, such as pipe tobaccos, casing may constitute up to 30% of the weight (Wynder & Hoffmann, 1967). Extracts of the leaves of deer tongue (*Trilisa odoratissima*), which are a source of coumarin (IARC, 1976b), and the root of *Glycyrrhiza glabra* L., from which liquorice is derived, have been used widely. Extracts of the latter are rich in glycyrrhizin (up to 25%), the glucoside of glycyrrhizic acid, sugars and starches, cellulose and terpenoid components (Wynder & Hoffmann, 1967; Bell, 1980; Windholz, 1983; Voges, 1984). Glycyrrhizic acid and its potassium salt may be expected to give rise to polynuclear aromatic hydrocarbons during smoking.

(iii) *Flavour-enhancing agents*

In order to enhance the flavour potential of smoking tobaccos, several varieties or types may be blended, or extracts of 'flavourful' tobaccos or other plants may be added. Either innate tobacco flavouring agents or synthetic agents may be utilized. Flavour enhancement has become especially important for products designed to give low smoke yields, such as 'low-tar' cigarettes with highly efficient filter tips. Some traditional types of cigarettes also contain flavourings, e.g., *kretek* cigarettes from Indonesia contain clove oil. Eugenol levels in the smoke of nonfilter and filter *kreteks* were found to be 19 and 15 mg/cigarette, respectively (Laboratory of the Government Chemist, 1982).

In some countries, there are strict regulations governing the use of additives to tobacco. Such regulations have been in force in the Federal Republic of Germany since 1977 (Federal Republic of Germany, 1977) and in the UK since 1979 (Department of Health and Social Security, 1979). Little is known about the effect of additives in tobacco on the biological activity of the resulting smoke (LaVoie *et al.*, 1980). Table 19 (pp. 86-87) lists the biologically active agents in the MS of cigarettes without filter tips.

4. Sidestream smoke and air pollution by tobacco smoke

(a) *Formation of sidestream smoke*

SS is a composite of effluents generated in different ways during the burning of a tobacco product. In between puff-drawing, SS is freely emitted into the air from the smouldering tobacco product; during puffing some smoke escapes from the burning cone into the surrounding air; and, to some extent, vapour phase components diffuse through the cigarette paper. An important cause of the differences in the specific toxic agents generated in MS and SS is that the peak temperature in the burning cone of a cigarette during puffing reaches 800-900°C (Wynder & Hoffmann, 1967), but that between puffs reaches only about 600°C (Hoffmann *et al.*, 1983b).

Mathematical models devised by Baker (1982) have shown that most of the vapour leaving the pyrolysis/distillation region behind the cone diffuses out of the cigarette, where it condenses to form SS particles. The vapour phase leaving the region of its formation is subjected to greater dilution and faster temperature decline than that part of the vapour phase that is drawn through the tobacco column to form the MS. Thus, the conditions prevailing during SS generation favour formation of aerosol particles of smaller size (0.01-0.1 μm) than those occurring in the MS (0.1-1.0 μm ; Baker, 1982). This is also an important fact to be considered with regard to the toxic effects of inhaled SS (Table 30).

The existence of free, unprotonated nicotine in the gas phase of MS and SS is greatly influenced by the pH of these aerosols. Above pH 6, increasing amounts of unprotonated, vaporized nicotine are present in the smoke, reaching $\approx 50\%$ at pH 8. Unprotonated nicotine is more rapidly absorbed than protonated nicotine during smoke inhalation and has, therefore, higher acute toxicity (Armitage & Turner, 1970). Although the pH of the MS of US blended cigarettes does not exceed 6.2, the pH of SS of the same cigarettes varies between 6.7-7.5 (Brunnemann & Hoffmann, 1974a).

Table 30. Physiochemical comparisons of mainstream and sidestream smoke of cigarettes^a

Parameter	Mainstream smoke	Sidestream smoke
Peak temperature during formation (°C)	≈900	≈600
pH (total aerosol) ^b	5.8-6.1	6.9-8
Particle size (μm) median diameter	0.1-1.0	0.01-0.1
Smoke dilution (vol %) ^c		
Carbon monoxide	3-5	≈ 1
Carbon dioxide	8-11	≈ 2
Oxygen	12-16	16-20
Hydrogen	3-15	≈ 0.5

^aFrom Hoffmann *et al.* (1984a)

^b85-mm nonfilter cigarette (Hoffmann *et al.* (1984b)

^c10 mm from burning cone

Major differences in the composition of MS and SS are also due to the fact that during puff drawing only a small inner segment of the burning cone is free of oxygen, whereas, during smouldering, when SS is formed, most of the burning cone is oxygen-deficient (Hoffmann *et al.*, 1984a) or even devoid of oxygen.

(b) Analysis of sidestream smoke

Special chambers have been developed to generate SS for chemical analysis. In order to ensure that cigarettes burn evenly during puff intervals, a stream of air at a velocity of 25 ml/sec is drawn through the chamber *via* a distributor (Brunnemann & Hoffmann, 1974a).

About 300-400 of the more than 3800 individual compounds identified in tobacco smoke have so far been determined quantitatively in MS and SS. The concentrations of selected agents in the MS of nonfilter cigarettes and the ratio of their relative distribution in SS:MS are given in Table 31. Values >1.0 indicate that more of a given compound is released into SS than into MS, although it must be kept in mind that exposure to SS occurs under considerable air dilution, while the MS of cigarettes is inhaled without major dilution.

Table 31. Concentrations of selected compounds in nonfilter cigarette mainstream smoke (MS) and the ratio of their relative distribution in sidestream smoke (SS): MS^a

Compound	MS	SS:MS
<i>Vapour phase</i>		
Carbon monoxide	10-23 mg	2.5-4.7
Carbon dioxide	20-60 mg	8-11
Carbonyl sulphide	18-42 µg	0.03-0.13
Benzene	12-48 µg	10
Toluene	160 µg	6-8
Formaldehyde	70-100 µg	0.1-50
Acrolein	60-100 µg	8-15
Acetone	100-250 µg	2-5
Pyridine	16-40 µg	7-20
3-Vinylpyridine	15-30 µg	20-40
Hydrogen cyanide	400-500 µg	0.1-0.25
Hydrazine	32 ng	3.0
Ammonia	50-150 µg	40-170
Methylamine	17.5-28.7 µg	4.2-6.4
Dimethylamine	7.8-10 µg	3.7-5.1
Nitrogen oxides	100-600 µg	4-10
<i>N</i> -Nitrosodimethylamine	10-40 ng	20-100
<i>N</i> -Nitrosopyrrolidine	6-30 ng	6-30
Formic acid	210-478 µg	1.4-1.6
Acetic acid	330-810 µg	1.9-3.9
<i>Particulate phase</i>		
Particulate matter	15-40 mg	1.3-1.9
Nicotine	1.7-3.3 mg	1.8-3.3
Anatabine	2.4-20.1 µg	0.1-0.5
Phenol	60-140 µg	1.6-3.0
Catechol	100-360 µg	0.6-0.9
Hydroquinone	110-300 µg	0.7-0.9
Aniline	360 ng	30
<i>ortho</i> -Toluidine	160 ng	19
2-Naphthylamine	1.7 ng	30
4-Aminobiphenyl	4.6 ng	31
Benz[<i>a</i>]anthracene	20-70 ng	2.2-4
Benzo[<i>a</i>]pyrene	20-40 ng	2.5-3.5
Cholesterol	14.2 µg	0.9
γ-Butyrolactone	10-22 µg	3.6-5.0
Quinoline	0.5-2 µg	8-11
Harman	1.7-3.1 µg	0.7-1.9
<i>N</i> '-Nitrosornicotine	200-3000 ng	0.5-3
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone	100-1000 ng	1-4
<i>N</i> -Nitrosodiethanolamine	20-70 ng	1.2
Cadmium	100 ng	3.6-7.2
Nickel	20-80 ng	0.2-30
Zinc	60 ng	0.2-6.7

Table 31 (contd)

Compound	MS	SS:MS
Polonium-210	0.03-0.5 pCi ^c	1.06-3.7 ^b
Benzoic acid	14-28 µg	0.67-0.95
Lactic acid	63-174 µg	0.5-0.7
Glycolic acid	37-126 µg	0.6-0.95
Succinic acid	112-163 µg	0.43-0.62

^aFrom Liu *et al.* (1974); Schmeltz *et al.* (1975); Klus and Kuhn (1982); Hoffmann *et al.* (1983b); Sakuma *et al.* (1983, 1984a,b)

^bCalculated by the Working Group

^c0.001-0.019 Bq

The first part of Table 31 comprises a comparison of certain volatile compounds in MS and SS. On the basis of amount of tobacco burned during puff-drawing and during smouldering of a nonfilter cigarette, one would expect the SS:MS ratio to be 1.3-1.7. This calculation is based on the assumption that the combustion processes during the two phases of smoke generation are comparable. The high yields of carbon monoxide and carbon dioxide in SS, however, show that more carbon monoxide is generated in the oxygen-deficient cone during smouldering than during puff-drawing. After passing very briefly through the hot cone, most of the carbon monoxide gas is oxidized to carbon dioxide, probably because of the high temperature gradient and sudden exposure to air.

The higher yields of volatile pyridines in SS as compared to MS are thought to be due to their preferential formation from alkaloids during smouldering. Hydrogen cyanide is formed primarily from protein at temperatures above 700°C; thus, smouldering of tobacco at about 600°C does not favour the pyrosynthesis of hydrogen cyanide to the same extent as generation of MS (Johnson & Kang, 1971). Perhaps the most important data in this part of the table are the much higher levels of ammonia, nitrogen oxides and the volatile *N*-nitrosamines in SS compared to those in MS. Studies with ¹⁵N-nitrate by Johnson *et al.* (1973a) showed that nitrate in tobacco is reduced to ammonia during burning and is released to a greater extent into SS than into MS during puff-drawing. Thus, the higher levels of ammonia generated in SS are a determinant of its elevated pH, which can be greater than 7, while the pH of MS is about 6.

The much greater release of the highly carcinogenic volatile *N*-nitrosamines into SS (6-100 times more than into MS) has been established (Brunnemann *et al.*, 1977b, 1980). Further, SS releases four to ten times more nitrogen oxides into the environment than are taken up from MS by smokers. Smokers inhale more than 95% of nitrogen oxides in the form of nitric oxide, and only a small portion is oxidized to the powerful nitrosating agent nitrogen dioxide. Nitric oxide is partially retained in the respiratory system bound to haemoglobin. However, nitrogen oxide gases released into the environment as part of the SS oxidize to nitrogen dioxide in a few minutes (Vilcins & Lephardt, 1975), and SS-polluted environments contain this hydrophilic, nitrosating agent. Nitrogen oxide concentrations of up to 0.5 mg/m³ have been measured in smoke-filled rooms (Hoffmann *et al.*, 1984a).

The second part of Table 31 gives data on particulate matter and some of its constituents in MS and SS. It should be noted that the levels of tobacco-specific *N*-nitrosamines in SS are up to four times higher than those in MS (Hoffmann *et al.*, 1984a). It is perhaps more important to examine the significance of the abundant release of amines in SS (up to 30 times higher than in MS), indicated by the measurements of aniline, *ortho*-toluidine, 2-naphthylamine and 4-aminobiphenyl, since certain amines are readily nitrosated to *N*-nitrosamines (although analytical data on secondary reactions of amines in polluted environments are not available).

It must be emphasized that this discussion of SS components and their contribution to indoor air pollution is based on data for nonfilter cigarettes. However, while MS emissions are significantly affected by filtration, SS emissions are not. A report by the Laboratory of the Government Chemist (1982) has shown that 'tar' and nicotine levels in SS are comparable regardless of whether they come from medium-, low- or ultra-low-'tar' cigarettes. Cigarettes with highly ventilated filter tips release the same quantity of carbon monoxide into the environment as do filter cigarettes without ventilation or with a moderate degree of ventilation (Baker, 1984).

(c) *Air pollution by tobacco smoke*

Nonsmokers are exposed involuntarily during passive smoking to a composite of effluents generated in different ways during the burning of tobacco products. These effluents comprise both SS and MS that has not been retained by active smokers. Active smokers are generally exposed to the highest concentrations of SS.

Whereas much is known about the physicochemical nature of cigarette SS (Tables 30 and 31), the major indoor smoke pollutant, little is known about the composition of exhaled smoke. Dalhamn *et al.* (1968a,b) have shown that about 60% of hydrophilic smoke components are absorbed in the oral cavity, and retention of both hydrophilic and hydrophobic smoke constituents, except for carbon monoxide, is high (>86%; Table 32).

Table 32. Pulmonary retention and mouth absorption of cigarette smoke components^a

Compound	Water-soluble	Boiling-point (°C)	% Retention ± SD	% Absorption by mouth
Acetaldehyde	Yes	21	99 ± 1.2	60
Isoprene	No	34	99 ± 0.6	20
Acetone	Yes	56	86 ± 5.5	56
Acetonitrile	Yes	85	91 ± 4.1	74
Toluene	No	111	93 ± 4.3	29
Particulate matter	-	-	96 ± 3.1	16
Carbon monoxide (5 subjects)	No	-	54 ± 12.7	3 ± 0.7

^aFrom Dalhamn *et al.* (1968b)

The most widely monitored pollutant originating from burning tobacco is carbon monoxide. In controlled studies of enclosed spaces in which machine-smoking was carried out in the presence of people, carbon monoxide levels ranged from 24-110 ppm (26-120 mg/m³) without ventilation and were reduced to 6-25 ppm (6.6-27.5 mg/m³) with 6-8.8 air exchanges per hour (Hoffmann *et al.*, 1983b). Weber, A. (1984) reported that 353 measurements in 44 workrooms had shown a mean of 1.1 ppm (1.2 mg/m³) carbon monoxide and a maximum level of 6.5 ppm (7.2 mg/m³); 30-70% of the carbon monoxide pollution derived from tobacco smoke in these environments. Generally, tobacco smoke pollution contributed less than 35 ppm (38.5 mg/m³) carbon monoxide (National Research Council, 1981). Table 33 lists concentrations of tobacco smoke pollutants measured in various indoor spaces. Most notably, levels of *N*-nitrosamines and polynuclear aromatic hydrocarbons exceeded maximum levels reported for urban air pollutants by one to three orders of magnitude (Brunnemann & Hoffmann, 1978; IARC, 1983a). In model studies of tobacco-smoke polluted indoor air, Jermini *et al.* (1976) also detected toxic agents, such as volatile aldehydes, ketones and aromatic hydrocarbons.

Table 33. Concentrations of tobacco smoke pollutants in various indoor spaces (with references^a)

Pollutant	Location	Concentration (/m ³)
Nitrogen oxide (12,13)	Workrooms	39-345 µg
Nitrogen dioxide (12)	Workrooms	50 µg
Acrolein (11)	Public places	25 µg
<i>N</i> -Nitrosodimethylamine (1,10)	} Restaurants, public places or simulating	0.01-0.24 µg
<i>N</i> -Nitrosodiethylamine (10)		<0.01-0.2 µg
Anthanthrene (5,7)		0.5-3 ng
Benzo[<i>a</i>]fluorene (5)		6-44 ng
Benzo[<i>ghi</i>]perylene (5,7)		5-25 ng
Benzo[<i>a</i>]pyrene (4,5,7,9)		0.25-760 ng
Benzo[<i>e</i>]pyrene (5,7)		<2-23 ng
Coronene (7)		0.2-5 ng
Fluoranthene (5)		50-116 ng
Perylene (5,7)		0.2-18 ng
Pyrene (5,7)	1-84 ng	
Nicotine (2)	Experiments simulating:	
(6)	Submarines	15-35 µg
(6)	Public places	1-6 µg
(12,13)	Restaurants	3-10 µg
	Workrooms	1-13.8 µg
Particulate matter (8)	Aeroplanes	<120 µg
(3)	Taverns	233-986 µg
(12,13)	Workrooms	130-960 µg

^aReferences: (1) Brunnemann & Hoffmann (1978); (2) Cano *et al.* (1970); (3) Cuddeback *et al.* (1976); Galušíkinová (1964); (5) Grimmer *et al.* (1977b); (6) Hinds, W.C. & First (1975); (7) Just *et al.* (1972); (8) National Institute for Occupational Safety & Health (1971); (9) Perry (1973); (10) Stehlik *et al.* (1982); (11) Weber-Tschopp *et al.* (1976); (12) Weber, A. & Fischer (1980); (13) Weber, A. (1984)

Measurements of nicotine and its major metabolite, cotinine, in the urine of nonsmokers have clearly shown that passive smoking does indeed lead to measurable uptake of the combustion products of tobacco (Greenberg, R.A. *et al.*, 1984; Matsukura *et al.*, 1984; Wald *et al.*, 1984a). Studies in the USA have shown higher levels of respirable particulate matter in residences with smokers in comparison with those of nonsmokers (National Research Council, 1981).

5. Summary

Tobacco smoke contains more than 3800 constituents. This section summarizes present knowledge as to the physicochemical nature of tobacco mainstream and sidestream smoke and the presence of specific agents in these aerosols. Emphasis has been placed on the formation and identification of biologically active agents in tobacco smoke that have been the subject of extensive laboratory studies; their amounts in the mainstream smoke of nonfilter cigarettes are summarized. These agents include carbon monoxide, benzene, hydrogen cyanide, volatile and nicotine-derived *N*-nitrosamines, nicotine, phenols, aromatic amines, polynuclear aromatic compounds, polonium-210 and trace metals. Recently, studies have reported potential endogenous formation of *N*-nitrosamines after smoke inhalation and the formation of heterocyclic amines during pyrolysis. The development of standard conditions for analysis of sidestream smoke was considered to be important.

BIOLOGICAL DATA RELEVANT TO THE EVALUATION OF CARCINOGENIC RISK TO HUMANS

1. Carcinogenicity studies in animals

(a) *Inhalation of tobacco smoke*

Although the evidence for carcinogenicity of tobacco smoke emerged first in humans, there was need for an inhalation model in experimental animals in which the carcinogenicity of different types of tobacco and tobacco products could be studied. The availability of animal models also permits the comparison of different products and the investigation of various modifying factors in the development of respiratory cancer.

Early inhalation studies in rodents were reviewed by Wynder and Hoffmann (1967). From about 1960, the animal species selected most often for model studies was the Syrian golden hamster, which has a low background incidence rate of spontaneous pulmonary tumours and few interfering respiratory infections. The discovery that inhalation of tobacco smoke caused carcinomas in the larynx of hamsters established a model system in which the carcinogenicity of tobacco smoke for hamsters has been confirmed repeatedly (*vide infra*). Few bioassays have been conducted, however, in longer-lived mice, rats and dogs, because of low priority and high cost; therefore, the spectrum of possible tumour responses in animals to inhalation of tobacco smoke is little known.

In order to study the response of animals to smoke inhalation, it was necessary to develop methods and equipment to deliver smoke in a standardized, effective way. A number of exposure devices have been employed, some involving whole-body exposure and some 'nose-only' exposure. Usually, in order to simulate human smoking patterns, a 2-second puff from a burning cigarette is diluted with air and forced into a chamber for a short period, followed by an air purge. However, animals, which are being forced involuntarily to inhale the smoke, undergo avoidance reactions and change their breathing patterns to shallow, hesitant inspirations with reduced minute volumes. This affects the doses delivered to the different parts of the respiratory system. Because rodents are obligatory nose-breathers and because rodents and dogs have more convoluted and intricate nasal turbinate patterns than humans, the dynamics of particle deposition in the upper respiratory tract might be expected to be different (see Wynder & Hoffmann, 1967; Nagano *et al.*, 1982; Proctor & Chang, 1983; Reznik, 1983).

Under experimental conditions, the smoke in the chamber can be assayed for total particulate and carbon monoxide, and animals can be examined at intervals to determine the levels of carboxyhaemoglobin, nicotine or cotinine in blood, and for particulate deposition and retention in tissues, which give some indication of the doses administered. In typical experiments, rodents were exposed to the smoke of seven to ten cigarettes per day on five to seven days per week (Dalbey *et al.*, 1980; Wehner, A.P. *et al.*, 1981) and developed carboxyhaemoglobin levels of 20-40% (Bernfeld *et al.*, 1974).

Inhalation of tobacco smoke is irritating and toxic to animals (see pp. 140-149). They can adapt to many short exposures over a period of time, but require varying periods of recovery between exposures, depending somewhat on the species. Both smoke-exposed and sham-exposed animals have reduced body weights, and may live longer (see also pp. 140-149).

Mouse: Groups of 100 male and 100 female young adult C57Bl mice were exposed (nose only) for 12 min/day to a mixture of fresh cigarette smoke/air (1/39, v/v) every other day for life. [The cigarettes were made from a composite blend of flue-cured tobaccos typical of the major nonfilter cigarette brands smoked in the UK (Harris, R.J.C. *et al.*, 1974).] The concentration of nicotine in the mixture was about 0.1 mg/ml and that of carbon monoxide, 0.064 vol %. The nicotine content in the lungs of mice that died during exposure amounted to 14-17 µg. Groups of 100 males and 100 females were used as controls. No lung tumour, either adenoma or carcinoma, was found in control mice. Lung tumours (alveogenic adenocarcinomas) were found in 4/100 male and in 4/100 female exposed mice [$p = 0.06$]. Some of the adenocarcinomas were transplantable. Mice exposed to smoke often showed emphysema and marked peribronchial and perivascular infiltration with lymphocytes, independent of the presence of tumours (Harris, R.J.C. & Negroni, 1967).

A total of 126 C57Bl and 126 BLH mice [sex and initial group sizes unspecified] were exposed to the gas phase of 12 cigarettes [unspecified] puffed for 2 sec/min. The gas phase was generated by passing the smoke through a Cambridge filter which retained the particulate matter. The mice were exposed in a 200-l chamber for 90 min daily (approximately the maximal tolerated dose) until spontaneous death (for approximately 27 months). Survival rates for more than 12 months of treatment were not affected by treatment in either strain of mice [numbers not provided]. The percentages of mice with lung adenomas were 5.5 and 32% in exposed C57Bl and BLH mice and 3.4 and 22% in 90 C57Bl and 60 BLH controls, respectively. The percentages of BLH mice with lung adenomas that survived at least 10 months were 37% of the treated group and 31% of the controls. The difference in adenoma incidence between control and treated groups was stated to be not statistically significant (Otto & Elmenhorst, 1967). [The Working Group noted the incomplete reporting of the experiment.]

A group of 50 male C57Bl6/Mil mice, six weeks of age, were exposed to cigarette smoke from 85-mm nonfilter cigarettes [unspecified] in a vacuum chamber for 15 min, five times per week for 63 weeks. The nicotine content in the lungs of mice that were killed ranged from 14-27 µg. When the nasal cavity and respiratory tree were examined microscopically, the incidences of hyperplasia and metaplasia were increased in exposed mice. These conditions were considered to be secondary to inflammation. No tumour was found (Wynder *et al.*, 1968). [The Working Group noted the relatively short duration of the study.]

Groups of 100 male and 100 female C57Bl mice, aged 14-18 weeks, were exposed (nose only) to a mixture of fresh cigarette smoke/air (1/39, v/v) for a 12-min period, generally on alternate days, for life. Groups were exposed to the whole smoke of two different types of cigarette: one made from flue-cured and the other from air-cured tobacco. The latter more closely resembled flue-cured cigarettes than typical air-cured cigarettes which contain, for example, burley tobacco. A further group was exposed to the gas phase only of smoke from the flue-cured cigarette, which was generated by passing the whole smoke through a Cambridge filter to remove the particulate matter. A group of 200 males and 200 females served as controls. The experiments with whole smoke were performed again under similar conditions with another group of 100 males and 100 females. Mean survival time in eight of ten groups of mice exposed to whole smoke was 4-14 weeks longer than that in controls (see also p. 140). The incidences of lung tumours in controls were 3/160 in males and 1/159 in females; those in mice exposed to whole smoke of cigarettes made from flue-cured tobacco were 9/162 in males and 7/164 in females [$p=0.07$ and 0.04 , respectively]; incidences in mice exposed to the gas phase of cigarettes made from flue-cured tobacco were 3/81 in males [$p>0.05$] and 2/88 in females [$p>0.05$]; and those in mice exposed to the whole smoke of cigarettes made from air-cured tobacco were 7/189 in males [$p>0.05$] and 0/173 in females. The majority of the lung tumours were adenomas (Harris, R.J.C. *et al.*, 1974).

Groups of Snell's mice, three to four months of age at the start of treatment, were exposed to two puffs (15-ml puff volume, 2-sec duration, 58-sec interval between puffs) of either whole fresh cigarette smoke [unspecified] (160 males and 118 females) or to the gas phase (100 males and 89 females); 117 males and 83 females served as controls. Animals were exposed in individual containers once a day (except for holidays and weekends) for life. When body weight loss was 4 g or more, animals were withdrawn from exposure for periods varying from two days to two months. Two popular brands of nonfilter cigarettes were used; each cigarette was smoked to a butt length of 23 mm. The gas phase was produced by passing the smoke through a Cambridge filter. Effectiveness of exposure was assessed by determining the carbon monoxide level in blood and the nicotine content of the lungs (about 5 μg). Survival after 12 months of age was distinctly affected by treatment, being about 92% (184/200), 60% (172/278) and 40% (88/189) in the control, whole-smoke and gas-phase groups, respectively. After 12 months of age, there was an earlier occurrence of pulmonary tumours in exposed mice than in controls. At the end of the experimental period (26 months), the proportions of mice surviving 12 months or more that had pulmonary adenomas were 8/106 and 1/78 in male and female controls, 7/107 and 2/65 ($p=0.475$) in male and female whole-smoke-exposed animals and 1/44 and 3/44 ($p=0.15$) in male and female gas-phase-exposed animals, respectively. The proportions of mice with pulmonary adenocarcinomas were 5/106 and 3/78 in male and female controls, 11/107 ($p=0.15$) and 5/65 ($p=0.35$) in whole-smoke-exposed animals and 10/44 ($p=0.005$) and 5/44 ($p=0.15$) in male and female gas-phase-exposed animals (Leuchtenberger & Leuchtenberger, 1970).

A group of 117 female BALB/c mice, nine weeks old, were exposed to smoke from 'high-tar' (16 mg tar, 1.1 mg nicotine) cigarettes diluted with air (7:1, air:smoke) for 7-8 min per day on five days per week for 95 weeks; exposure was interrupted for three weeks between the 48th and 49th week of treatment. An untreated group of 130 females served as

controls. Approximately 16 control and 16 exposed mice were killed after 56, 64, 72 and 80 weeks of treatment. Twenty control and ten exposed mice survived until termination of the experiment after 95 weeks. The 'relative incidence' of neoplasms, reported as bronchial adenomas, was calculated by the authors to be higher in the exposed groups of mice than in the control groups after 83 weeks, but similar in the two groups after 95 weeks of exposure. The authors also reported an increase in the 'relative incidence' of lymphomas after both 83 and 95 weeks of exposure (Keast *et al.*, 1981). [The Working Group noted that insufficient numerical data were provided in relation to the number of animals at risk.]

Rat: A group of 408 female Wistar rats, 10 weeks of age, were exposed (nose only) to a 1:5 smoke:air mixture generated from T29 cigarettes (specially manufactured from a composite blend of flue-cured tobaccos, representing the major nonfilter cigarette brands smoked in the UK during 1967-1968), for 15 sec/min during 11 min, twice a day on five days per week for life. After one year, the rats received 5% carbon dioxide in air instead of air for 5 min before the start of each smoke exposure session and for the 45-sec/min interval during which smoke was not generated. Measurement of an arsenious sulphate tracer showed that 8.5 and 17.5% of the delivered tar was recovered in the lungs of rats with the air and with the air/carbon dioxide regimes, respectively. Two control groups of 104 animals were available, one sham-exposed and one untreated. The smoke-exposed and sham-exposed animals had lower body weights than untreated controls. About 25% of the treated rats were still alive at 100 weeks compared with 73% of 102 untreated controls and 66% of 102 sham-exposed controls. All treated animals had died by 140 weeks compared with 160 weeks in controls. Three smoke-exposed rats had pulmonary squamous neoplasms of uncertain malignancy, and one had an invasive squamous-cell carcinoma of the lung. No lung tumour was observed in the sham-treated or untreated controls. The incidence of benign mammary tumours was lower in smoke-exposed rats than in sham-exposed or untreated controls (Davis, B.R. *et al.*, 1975a).

A group of 18 female Wistar rats, 13-14 weeks of age, were exposed (nose only) to the gas phase of smoke (produced by passing the smoke through a Cambridge filter) from a standard British reference cigarette diluted 1:5 with air. Exposure was for 15 sec followed by air for 45 sec during 11 min, twice daily on five days per week for life. A control group of 16 animals was available. Average length of survival was 100 weeks for treated animals and 114 weeks for controls. No lung tumour was reported in exposed or control rats (Davis, B.R. *et al.*, 1975b). [The Working Group noted the small number of animals used.]

A group of 80 female Fischer 344 rats, 12-14 weeks of age, were exposed (nose only) to a 1:10 smoke:air mixture for 28-30 sec/min followed by air for 30 sec during standard smoking of a US reference nonfilter cigarette (average, 8.4 exposures/cigarette). Mean smoke particulate and nicotine levels observed during chamber monitoring were 18.4 mg and 0.89 mg per cigarette, respectively. The animals were exposed to 1 cigarette/h, 7 cigarettes/day, on five days per week for 128 weeks, followed by observation for a further six months. The mean pulmonary particulate deposition during exposure was 0.25 mg/cigarette (total, 1.75 mg/rat per day). A group of 63 rats served as untreated controls, and 30 rats were sham-exposed. The length of survival of smoke-treated, sham-treated and untreated controls was not significantly different, but smoke- and sham-treated animals had

lower mean body weights. Since the tumour incidences in untreated and sham-treated controls were similar, the two groups were combined (93 animals). One alveogenic carcinoma and two pulmonary adenomatoid lesions were observed in three control rats. Ten respiratory tumours were observed in seven smoke-exposed rats: one nasal adenocarcinoma, one nasal squamous-cell carcinoma, five pulmonary adenomas, two alveogenic carcinomas and one squamous-cell carcinoma ($p < 0.05$). Of the smoke-exposed animals, 21 developed subcutaneous sarcomas at sites of ulcerations on the forelimbs ($p < 0.05$); four rats developed benign tumours of the oral tissues ($p < 0.1$); and four developed one adenoma and three carcinomas of the adrenal gland ($p < 0.1$). No such tumour occurred in controls. The incidences of tumours of the hypophysis, uterus and ovary, haematolymphatic system and mammary gland were lower in smoke-exposed rats than in controls (Dalbey *et al.*, 1980).

Three groups of 80 female Fischer 344 rats were exposed to a 1:10 smoke:air mixture generated from three US research cigarettes (25.4 mg tar, 0.16 mg nicotine; 13.3 mg tar, 1.06 mg nicotine; or 25.7 mg tar, 1.91 mg nicotine; see also Griest *et al.*, 1980). Each rat was exposed for 28 sec/min followed by air for 30 sec during standard smoking of the cigarettes, to provide 10-11 exposures/cigarette. The animals were exposed to 8 cigarettes/day during a 16-h period, on seven days per week for 96 weeks, at which time all survivors (50-70% of animals) were killed. Groups of 80 animals served as untreated and sham-treated controls. The occurrence of squamous metaplasia of the laryngeal and tracheal epithelium was significantly increased in smoke-exposed rats. One squamous-cell carcinoma of the lung was observed in a rat exposed to low-tar-medium-nicotine smoke; the incidences of other tumours were similar in treated and control animals (Wehner, A.P. *et al.*, 1981). [The Working Group noted that, in contrast to the study described previously, all surviving animals were killed at 104 weeks and that the method for sampling for histopathology was not fully reported.]

Hamster: In a study involving 4440 animals, including 600 controls, groups of 80 male and 80 female Syrian golden hamsters, eight weeks old, were exposed to a 1:15 smoke:air mixture generated during a 7-10-min period from 30 German reference cigarettes, or a modification thereof, once, twice or three times a day on five days per week for lifespan or up to 52 weeks (830 animals). One group of 80 males and 80 females was exposed to the smoke of black (dark air-cured)-tobacco cigarettes twice a day. One group of animals received the vapour phase of the reference cigarette, generated from 30 cigarettes during a 10-min period three times a day. The average length of survival was 52-65 weeks for treated males and 41-49 weeks for treated females; a shorter survival time and loss of body weight were noted in animals exposed to smoke as compared with untreated controls (see also pp. 140-141). In all treated groups, 'the most remarkable and severe alterations' were observed in the larynx, and their severity depended on duration of treatment and dosage. The incidence of laryngeal leukoplakias ranged from an average of 11.3% in animals exposed for 10 min to 30.6% in those exposed for 30 min to the reference cigarette; the incidence in animals exposed to smoke from black-tobacco cigarettes was 10%; and in controls slight leukoplakia was observed in 1-5% of animals. The incidences of laryngeal carcinomas were 0.62-10.6% in

animals exposed to smoke from the reference cigarette and 1.25% in animals exposed to smoke from black-tobacco cigarettes. No such tumour was observed in controls nor in animals exposed to the vapour phase (Dontenwill *et al.*, 1973).

Similar results were obtained in a study involving 2160 hamsters exposed to the smoke from German reference cigarettes or a modification thereof (Dontenwill *et al.*, 1977a).

In a study in which a modification of the method of Dontenwill (above) was used on inbred hamsters, groups of 102 male BIO® 87.20 and BIO® 15.16 hamsters (13 weeks of age) were exposed to smoke (1:5 in air) from Ky 1R1 (US) reference cigarettes twice a day on five days per week for up to 100 weeks. Groups of 60 animals served as sham-exposed or cage-held controls for each strain. Smoke exposure for up to 100 weeks had no effect on length of survival; however, a reduction in body weight was noted. Over 90% of the smoke-exposed animals of both strains showed hyperplastic or neoplastic changes in the larynx; and benign squamous-cell papillomas of the larynx were observed in both strains. Laryngeal cancer was nearly five times more frequent in strain BIO® 15.16, however, and two animals of this strain developed nasopharyngeal tumours. The incidences of tumours at locations other than the respiratory tract were similar in the two strains (Bernfeld *et al.*, 1974).

Groups of 35-64 male BIO® 15.16 inbred Syrian golden hamsters, 60-70 days old, were exposed to concentrations of 11 or 22% smoke from commercial UK filter cigarettes or filter cigarettes composed of tobacco and Cytrel®, or cigarettes made of 100% Cytrel® twice a day (12-min sessions of 27 smoke exposures/min) on seven days per week for up to 74-80 weeks. Groups of 40 sham-exposed animals and 51 untreated animals served as controls. Survival rates were reduced markedly in all groups after 59 weeks of age; a reduction in body weight was noted in treated animals as compared with controls. Laryngeal carcinomas occurred in 47.4% of the animals exposed to smoke from the UK filter cigarettes, the first tumours occurring after 59 weeks in hamsters treated with the highest dose of smoke. The incidence of this type of tumour was dose-related and decreased as the proportion of Cytrel® in the blends increased. No such tumour was observed in controls. Laryngeal papillomas, laryngeal epithelial hyperplasia and a few tracheal papillomas were also observed in treated animals. Histopathological findings at other sites did not appear to be related to smoke inhalation (Bernfeld *et al.*, 1979).

A group of 51 male Syrian golden hamsters, two months of age, were exposed three times a day for 10 min to smoke from Ky 1R1 (US) reference cigarettes on five days per week for life. Another group of 51 male hamsters served as sham-exposed controls. The smoke-exposed animals survived longer (mean, 19.6 months) than the sham-exposed animals (mean, 15.3 months) (see also p. 140). The smoke-exposed animals had significantly higher incidences of epithelial lesions of the larynx than sham-exposed controls (22% versus 0%, $p < 0.01$) and a significantly higher total number of tumours than sham-exposed controls (28% versus 6%; $p < 0.05$). The laryngeal changes in the smoke-exposed group ranged from inflammatory conditions, with growth abnormalities of the epithelium, to squamous-cell papilloma formation (Wehner, A.P. *et al.*, 1974, 1975a,b, 1976). [The Working Group noted the inadequate reporting of the histopathological results.]

Rabbit: Thirty rabbits were exposed daily in individual compartments to the smoke from 20 cigarettes (2 puffs/min, 2 cigarettes at each treatment period) for up to 66 months. No tumour that could be related to the exposure was observed in 30 exposed rabbits or in 31 controls that survived for 24 months or more (Holland *et al.*, 1958, 1963). [Details of the types of cigarettes, method of smoke generation and doses delivered are not provided.]

Dog: Groups of male beagle dogs, 1.7-3.3 years old, trained to inhale cigarette smoke through tracheostomata, were exposed to (1) smoke from seven nonfilter cigarettes containing 34.8 mg tar and 1.85 mg nicotine per day (62 dogs); (2) smoke from cigarettes containing the same tobacco but with filters, containing 17.8 mg tar and 1.17 mg nicotine (12 dogs); or (3) smoke from 3.5 nonfilter cigarettes/day (12 dogs). Eight non-exposed tracheotomized dogs served as controls. The body weights of dogs in the various groups did not differ significantly. Between day 57, when the training period ended, and day 876, when killing of the surviving dogs began, 28 dogs died: 24 in the first group, 2 in the second, 2 in the third and no control. Examination of the lungs and bronchial tree at autopsy and microscopically was extensive. Tumours of the lung, described as 'bronchioloalveolar, invasive and noninvasive', were found in 23/62 in group 1; two of the tumour-bearing dogs in this group also had small bronchial carcinomas. Noninvasive bronchioloalveolar tumours were also found in 4/12 dogs in group 2, 7/12 dogs in group 3 and 2/8 control dogs. The bronchioloalveolar tumours tended to be multiple, with as many as 20/lung lobe, and were found in 41 of the 203 lung lobes from the 29 dogs with such tumours. No distant metastasis was found (Auerbach *et al.*, 1970; Hammond *et al.*, 1970). [The Working Group noted that no data were given on specific smoking parameters or measures of exposure. They also noted the small number of control dogs used and the unusually high incidence of lung tumours in these animals, since these are tumours that rarely occur spontaneously in dogs. The focal inflammatory lesions usually found in the lungs of animals exposed to smoke were not mentioned in the report. Examination of the upper respiratory tract and other organ systems is not reported. The authors' interpretation of the photomicrographs as representing neoplasia was considered to be not entirely convincing.]

As part of a study on the combined effects of radon daughters or uranium ore dust and cigarette smoke on the induction of respiratory tumours (see below), 19 beagle dogs of both sexes, 24-30 months of age, were exposed to cigarette smoke only. The dogs were exposed to the smoke of 10 Ky 1R1 (US) cigarettes/day (three in the morning, four at midday and three in the afternoon) on seven days per week for 48-60 months; individual masks permitted smoke to be inhaled at every tenth breath. Eight further dogs served as sham-exposed controls. Carboxyhaemoglobin levels in smoke-exposed dogs increased with the duration of the experiment, from 2% at 19 months to 4.7% after 50 months; the corresponding mean values for sham-exposed dogs were 1.4% and 1.8%. Smoke-exposed animals killed after 49 (6 dogs), 60 (6 dogs), 64 (6 dogs) and 65 (3 dogs) months were available for analysis. No significant respiratory lesion and no lung tumour was found in either group (Cross *et al.*, 1982). [The Working Group noted the small sizes of the groups and the limited evidence of smoke delivery.]

(b) *Inhalation of cigarette smoke in conjunction with administration of known carcinogens and other agents*

Benzo[*a*]pyrene: A group of 84 Wistar rats received a single intratracheal instillation of 2 mg benzo[*a*]pyrene (with infusine and carbon black) followed by exposure to cigarette smoke (T29, UK reference, diluted 1:5 with air) twice daily, five times per week for life. Three developed squamous-cell carcinomas of the lung. One squamous-cell carcinoma of the lung was observed in 84 rats treated with the benzo[*a*]pyrene mixture alone, and four squamous-cell neoplasms (of which only one was clearly malignant) occurred among 408 rats exposed to cigarette smoke only. The mean survival times were 65 weeks for animals exposed to smoke plus benzo[*a*]pyrene mixture, 63 weeks for animals exposed to smoke alone and 108 weeks for rats treated with the benzo[*a*]pyrene mixture alone. No lung tumour was observed in untreated or sham-exposed controls (Davis, B.R. *et al.*, 1975a).

A group of 40 hamsters received a single intratracheal administration of 5 mg benzo[*a*]pyrene mixed with ferric oxide, followed by exposure to cigarette smoke twice for 10 min daily, five times per week for 48 weeks. Two papillomas of the larynx and three pseudoepitheliomatous hyperplasias of the larynx were observed. No such lesion was observed in control groups of 20 hamsters that received benzo[*a*]pyrene plus ferric oxide or smoke alone, and no lung tumour was observed (Hoffmann *et al.*, 1979).

Dimethylbenz[*a*]anthracene (DMBA): Groups of 80 male and 80 female Syrian golden hamsters received 500 µg DMBA intratracheally, followed by a 10-min exposure to cigarette smoke twice daily, five times per week for life. A total of 32 squamous-cell carcinomas of the larynx were observed, in comparison with 17 in hamsters exposed to cigarette smoke only and none in controls treated with DMBA alone. A significant increase in the incidence of laryngeal leukoplakia was also observed. No increase was found in the incidences of tumours at other sites as compared with animals treated with DMBA alone. Mean survival rates were comparable in all groups (Dontenwill *et al.*, 1973). Similar results were observed in other experiments in which Syrian golden hamsters were exposed to DMBA and cigarette smoke (Kobayashi, N. *et al.*, 1974; Hoffmann *et al.*, 1979).

Blue Cape asbestos: Groups of 80 male and 80 female Syrian golden hamsters were exposed to a single intratracheal instillation of asbestos, followed by exposure to cigarette smoke twice daily, five times per week for life. No significant difference in the occurrence of laryngeal lesions or tumours was observed when compared to another group exposed to cigarette smoke alone. No laryngeal tumour occurred in a control group exposed to a single dose of asbestos alone (Dontenwill *et al.*, 1973).

4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): Groups of 10 male and 9-10 female Syrian golden hamsters received a single subcutaneous injection of NNK at doses ranging from 1-10 mg, followed by exposure to cigarette smoke twice daily for 69 weeks. Tumours of the respiratory tract were observed in NNK-treated hamsters; their incidence was not affected by exposure to cigarette smoke (Hecht *et al.*, 1983).

Radon daughters: Groups of 28-50 Sprague-Dawley rats were exposed to radon daughters at cumulative doses of 4000, 500 or 100 work-level-months (WLM)¹, with or without concurrent exposure to cigarette smoke, by inhalation on four days per week for one year. Of the 47 rats exposed to 4000 WLM radon daughters without smoke, 17 developed carcinomas of the lung, compared to 34 carcinomas in 48 rats also exposed to cigarette smoke. In the groups of rats exposed to 500 WLM radon daughters, 8 carcinomas of the lung were seen among the 30 rats also exposed to cigarette smoke, as compared to 2/25 rats exposed to radon daughters alone. No lung tumour was observed in rats exposed to 100 WLM radon daughters with or without exposure to cigarette smoke; one carcinoma occurred among 27 rats exposed to cigarette smoke alone (Chameaud *et al.*, 1982).

Nineteen beagle dogs of both sexes, 24-30 months old, were exposed by inhalation to a combination of radon (105 nCi/l [3900 Bq/l]), radon daughters (605 WL) and uranium-ore dust (12.9 mg/m³) daily, on five days per week, for 54 months. A second group of 19 beagle dogs was exposed to the smoke from 10 cigarettes/day on seven days per week at intervals between similar exposures to radon dust. Lifespan was shortened in both groups in comparison to controls. Eight dogs exposed to radon dust alone had nine respiratory tumours (two nasal carcinomas, six pulmonary carcinomas, one pulmonary fibrosarcoma); and 2/19 dogs in the group that received radon dust plus cigarette smoke had respiratory tumours (one nasal carcinoma, one pulmonary carcinoma) (Cross *et al.*, 1982). [The Working Group noted the small sizes of the groups and the incomplete reporting.]

Influenza virus: The possible interaction between various types of influenza viruses and inhalation of cigarette smoke in the induction of lung tumours in mice has been examined in a series of studies (Harris, R.J.C. & Negroni, 1967; Harris, R.J.C. *et al.*, 1974; Wynder *et al.*, 1968). No additive or synergistic effect was observed.

(c) *Administration of tobacco-smoke condensates*²

Attempts to induce tumours with tobacco products were reported as early as 1911 (for a summary of early studies, see Wynder & Hoffmann, 1967). Wynder *et al.* (1953) painted CAF₁ mice with cigarette-smoke condensate (CSC) suspended in acetone; after 24 months, 48/81 mice developed papillomas and 36/81 developed carcinomas at the sites of application.

¹WL is defined as any combination of the short-lived radon daughters in 1 litre of air that will result in an ultimate emission of 1.3×10^5 MeV of potential alpha energy in their decay through RaC' (²¹⁴Po). WLM is equivalent to 170 h of exposure to 1 WL.

²The terms 'smoke condensate' and 'tar' are often used interchangeably. Cigarette-smoke condensates (CSC) are produced by passing smoke through cold traps and recovering the material retained within them. This material is often washed from the traps with a volatile solvent, which is later removed, and unknown amounts of the volatile and semivolatile constituents are lost. Total particulate matter (TPM) is that material which is retained in a high-efficiency particulate filter. If this material is washed from the filter and concentrated as above, semivolatiles are lost. In the USA, the term 'tar' as used in official reports of tar yield is equivalent to TPM less nicotine and water.

During the next decade, methods to generate CSC and to treat animals were refined and standardized within and among laboratories. At the present time, cigarettes are machine smoked, generally using a 35-ml puff drawn for 2 sec each minute. The condensate is collected in glass vessels at low temperatures and removed using a volatile solvent, such as acetone, under reduced pressure. Animals have also been treated with a diluted suspension of CSC in a suitable solvent. Some of the variables that have not been standardized among different laboratories include choice of animal (or strain), dose and frequency of treatment, choice of solvent, conditions of storage of CSC, the puff profile of the smoking machine, and the number of cigarettes that are puffed simultaneously.

Nevertheless, when mouse skin has been used as the test tissue in experiments carried out over the last 20 years, the results from various laboratories are similar with respect to the overall degree of carcinogenic activity of CSC and to the major differences in activity among CSC from cigarettes of different design (Wynder *et al.*, 1957a; Davies, R.F. & Day, 1969; Dontenwill *et al.* 1972; Bernfeld & Homburger, 1976; Dontenwill *et al.*, 1977a; Lee, P.N. *et al.*, 1977; Gori 1976a,b, 1977, 1980). Subtle differences in smoking technique, CSC storage and animal exposure procedures do not appear to affect the results critically.

Animal studies conducted prior to 1964 provided an important measure of support for the epidemiological demonstration that cigarette smoke is an important human carcinogen. Since that time, the mouse-skin studies have served primarily to determine whether differences in cigarette design affect the carcinogenic effects of CSC and whether these effects can be correlated with the chemical composition of the condensates. In addition, mouse-skin studies may help to elucidate the mechanisms through which CSC induce tumours in animal tissues. For example, it has been shown that CSC contains tumour initiators (Hoffmann & Wynder, 1971) and that CSC and some of its fractions and components can exhibit tumour-promoting activity (see, for example: Wynder & Hoffmann, 1961b; Bock *et al.*, 1969; Hoffmann & Wynder, 1971; Lazar *et al.*, 1974; Van Duuren & Goldschmidt, 1976). The relative activities of different CSCs in short-term promoting assays based either on the disappearance of the sebaceous glands or on thickening of the cutaneous epithelium may be similar to their relative activities in long-term assays for promotion on mouse skin, based on the appearance of skin tumours (Lazar *et al.*, 1974), although the data available are insufficient to establish this point clearly.

(i) *Skin application*

Mouse: CSC produces both benign and malignant tumours on mouse skin. The carcinogenic potency of the CSC is a function of tobacco variety, use of replacement materials (sheet or semi-synthetics) and presence of additives (see, for example, Wynder *et al.*, 1957a; Davies, R.F. & Day, 1969; Dontenwill *et al.*, 1972; Gori, 1976a,b; Dontenwill *et al.*, 1977b; Gori, 1977, 1980). The tumours induced are usually of epidermal origin. Ohmori *et al.* (1981) reported a low, but significant incidence of mastocytomas in a series of mouse-skin experiments with CSC.

An example of mouse skin studies is given in a series of four publications (Gori, 1976a,b, 1977, 1980) that report the results of skin-painting experiments in which more than 100 CSC were tested in female ICR Swiss mice. These data permit an evaluation of the overall carcinogenicity of CSC and of intralaboratory variation in bioassay results over time, since,

in these studies, Ky 1R1 and SEB cigarettes stored at -20°C were tested in four series of studies begun in 1970, 1972, 1974 and 1975 (Table 34), and the results are representative of the tumour response found in such studies. The purpose of the studies was to investigate possible relationships between biological activity and cigarette design as well as chemical characteristics of cigarette smoke. CSC derived from reference cigarettes and specially modified cigarettes was applied generally at two dose levels, usually 25 mg and 50 mg, per 0.1-ml application in six weekly applications for 78 weeks. Acetone was used as the solvent. In some instances, 3, 6 and 12.5 mg were also given, and, for a single type of CSC, doses of 10 mg and 20 mg were given twice daily or five times a week for 78 weeks. Concurrent solvent-treated and untreated controls were available. Test groups size usually comprised 100 animals, but up to 800 controls were used; 6400-9200 mice were used for each of the four sets of experiments. A skin tumour was observed in 3/800 acetone-treated controls; otherwise, no tumour and no carcinoma was found in control animals. Skin tumours, frequently malignant, were found in every CSC-treated group.

Table 34. Percentages of animals with skin tumours^a after treatment with smoke condensates from reference cigarettes^b

Series	Date of start of study	Reference cigarette				
		1R1	SEBI	SEBII	SEBIII	SEBIV
I	1970	41	44	-	-	
II	1972	49	58	48	-	
III	1974	49	51	-	46	
IV	1975	48	-	-	44	41

^aNot corrected for interim deaths; tumours classified as 'papillomas' and 'carcinomas' in series I and II, as 'papillomas' and 'other malignancies' in III, and as 'tumours' in IV.

^bFrom Gori (1976a,b, 1977, 1980)

^cAge of animals at start: 'approximately' six weeks in series I and II; 'at least' six weeks in III and IV.

[These extensive studies reported differences in the activity of CSCs from cigarettes of different design. The Working Group noted that, although the trends of the differences were often consistent, different statistical procedures were used to analyse the data, and insufficient data are provided to permit a uniform analysis for quantitative comparison of these data.]

Cigar and pipe smoke condensates have also been tested on mouse skin. In one such study, a 1:1 (w/v) acetone solution of nicotine-free cigar or pipe tar was painted three times a week on the skin of female Swiss mice. A 1:1 acetone solution of whole CSC was also employed. At the end of 19 months, skin papillomas were produced in 65% and carcinomas in 41% of 46 mice treated with the nicotine-free cigar tar, in 69% and 33% of 45 mice treated with the nicotine-free pipe tar and in 47% and 33% of 86 mice treated

with CSC. No tumour was produced in 23 acetone-treated controls. At nine months, when the first tumours appeared, 78% of the controls and 70-91% of the tar-treated animals were still alive (Croninger *et al.*, 1958). [The Working Group recognized that the nicotine-free cigar and pipe tars were prepared in a manner that would cause unknown changes in composition.]

Rat: McGregor (1976) and McGregor and Myers (1982) reported that CSC appeared to act as a cocarcinogen with β -irradiation on rat skin. CSC alone was reported to induce one benign tumour in 72 normal rats and six benign skin tumours in 78 rats in which the skin keratin layer had been removed prior to skin painting. [The Working Group noted that the data, as presented, are not adequate to permit evaluation of these reports.]

Hamster: Bernfeld and Homberger (1983) reported that hamster skin is not responsive to CSC applied alone. [The Working Group noted that only 16 of the 50 animals treated with CSC alone were observed for up to 46-47 weeks.]

Rabbit: CSC was applied to the inner surface of the ears of 38 rabbits five times a week as a 50% w/v suspension in acetone using a brush. On alternate weeks, the accumulated surface tar was removed using an acetone-soaked cotton ball or forceps. After four to six years of treatment, all of the rabbits had developed large papillomas, and four had skin cancer. Of seven control animals treated with acetone, none developed cancer, but five had small papillomas on the ears (Graham, E.A. *et al.*, 1957).

(ii) 'Initiation-promotion' studies

Mouse: A number of investigators have found that CSC and its fractions can act as cocarcinogens when applied with other agents. In one assay for tumour-initiating activity, 50 μ l of an acetone solution containing 2.5 mg of a CSC fraction (0.6% of the whole tar) was applied to the dorsal skin of mice during the second telogen phase of hair growth. This procedure was repeated on alternate days for a total of ten doses. Ten days after the last initiating dose, the mice were painted three times a week with 2.5% croton oil in acetone. After 12 months, 67% of 30 mice had developed papillomas and 13% had carcinomas; after 15 months, 73% had papillomas and 13% carcinomas. Sixty-five mice treated with croton oil only developed no tumour, either malignant or benign. The first tumour appeared within four months (Hoffmann & Wynder, 1971).

Groups of 30 female Swiss mice were painted twice weekly with a 50% acetone solution of CSC for 12 months. Of animals treated first with 75 μ g DMBA, 13/30 developed papillomas and 8 had carcinomas in 15 months; without DMBA treatment, only 4/40 had papillomas and 1 a carcinoma. Of 50 mice painted three times weekly with a 50% acetone solution of CSC, 22 (44%) developed skin papillomas and 11 had carcinomas. Of 30 animals treated first with a single dose of DMBA, 19 (63%) developed skin papillomas and 11 had carcinomas. Of mice treated with DMBA alone, 3/30 had skin papillomas and 2 had carcinomas. When a 10% solution of the phenolic fraction in acetone was applied three times weekly, 30% of the animals developed papillomas, but no carcinomas, when DMBA was applied first; no tumour was seen in mice without DMBA initiation (Wynder & Hoffmann, 1961b). [The Working Group noted that the data do not establish that this effect was due to promotion or whether it represented an additive effect of two weak tumorigenic stimuli.]

(iii) *Topical application to oral mucosa*

Mouse: The lips and oral areas of groups of 100 ICR/Ha Swiss mice were painted five times a week for 15 months with approximately 26 mg CSC in an acetone suspension. Control groups of 100 mice were either untreated or treated with acetone alone. The study was terminated after 18-19 months, at which time 81-90% of the animals were still alive. Of the surviving mice in the experimental group, 64% developed lung tumours, in contrast to 22% in the control groups. In addition, 21% of the experimental animals developed tumours of other organs, primarily lymphomas, in contrast to 3-8% in the two control groups (DiPaolo & Levin, 1965).

(iv) *Intrapulmonary administration*

Rat: Stanton *et al.* (1972), following up earlier studies of Blacklock (1961), injected 0.05 ml of 1:1 beeswax:tricaprylin containing 24 mg CSC into the lungs of female Osborne-Mendel pathogen-free rats after thoracotomy. The pellets thus formed were large enough to entrap bronchioles. Residues of the pellets could be recognized for more than two years after treatment. Fourteen of 40 rats that died between 43 and 120 weeks developed epidermoid carcinomas. The nonpolar constituents of CSC appeared to be an important but not the sole contributor to this activity. Thus, when the beeswax contained 12 mg of the heptane-soluble fraction of CSC, epidermoid carcinomas developed in 5/18 rats. No tumour was seen in 76 rats injected with beeswax:tricaprylin alone.

These observations were confirmed by Dagle *et al.* (1978) using CSC from two different types of cigarettes. They observed a dose-dependent incidence of lung carcinomas when either condensate was injected in beeswax:tricaprylin. No carcinoma was induced by beeswax:tricaprylin alone. With the highest dose of CSC (67 mg), carcinoma prevalence reached 42% in 120 weeks. No difference was observed in tumour response to the two CSCs.

CSC without vehicle was injected every two weeks into rat lungs by intratracheal instillation. There was a dose-dependent increase in the mean grade of squamous lesions in the groups treated with CSC and with several fractions of CSC. With CSC and most fractions, tumours were not observed, but with the fraction containing most of the polynuclear aromatic hydrocarbons, 5/54 rats developed neoplastic lung lesions (Davis, B.R. *et al.*, 1975c). The Working Group noted that the relatively infrequent dosage employed by Davis *et al.* may have been less adequate as a stimulus than prolonged release of the material from a lipid vehicle that persists at the injection site. There may also have been injury from injection of material into the lung, from the heat of the melted wax or from chemical constituents in the wax.]

Hamster: CSC and the 'nitromethane-soluble' fraction of CSC were found to be weak carcinogens when injected in beeswax directly into hamster lung (Ketkar *et al.*, 1979). The method used was similar to that of Stanton *et al.* (1972) in rats; 0.03 ml of a 1:1 beeswax:tricaprylin mixture was used as the solvent. A group of 31 hamsters injected with 50 mg CSC developed one bronchogenic adenoma; two animals exhibited metaplasia. When 25 mg of the nitromethane fraction of CSC were given to another group of 31 animals, three had bronchogenic adenomas and nine had metaplasia.

2. Other relevant biological data from experimental studies

(a) Toxicity of tobacco smoke in animals

Tobacco smoke contains hundreds of chemicals that are potentially toxic to animals (see the section 'Chemistry and Analysis of Tobacco Smoke', pp. 83-126). Only the toxicity of whole tobacco smoke is discussed below; studies on the carcinogenicity of tobacco smoke and tobacco smoke condensate are discussed in the previous section (pp. 127-139), and mutagenicity and short-term tests are discussed on pp. 153-163.

(i) Survival

Measurement of the toxicity of tobacco smoke by the length of survival of exposed animals is complicated by differences in such factors as the use of naive *versus* preadapted animals, continuous *versus* intermittent exposure, concentration of smoke, duration of exposure, type of cigarette, and species and strain of animals. Some of these factors are discussed on pp. 127-128 above.

The mean survival times of mice exposed to smoke from 11 different cigarettes (using an intermittent regimen) ranged from 10 min (i.e., ~ 3 cigarettes) to >175 min (i.e., 54-66 cigarettes). There was a weak correlation between tar and/or nicotine content and length of survival, but the difference in toxicity of certain cigarette types was greater than would be expected from differences in their tar or nicotine content. The nature of the material that caused this differential toxicity is not known but presumably occurred in the particulate phase, since Cambridge-filtered smoke (i.e., gas phase) was approximately 10-20 times less toxic than whole smoke (Bernfeld, 1975). Using an intermittent exposure regimen, Schell and Griffith (1972) showed that survival is (1) closely associated with the nicotine content of cigarettes and (2) dependent on the strain of mice employed: a more than three-fold variation in sensitivity was observed among strains. The occurrence of lung haemorrhage in hamsters paralleled the nicotine but not the carbon monoxide content of the experimental cigarettes to which they were exposed intermittently (Reznik-Schuller, 1980); however, with a continuous exposure regimen, the toxicity of cigarette smoke to mice was correlated with both nicotine and carbon monoxide levels (Reckzeh *et al.*, 1969).

Studies of survival with longer periods of daily exposure (i.e., 14-90 days) are usually not informative, because, if animals survive an acute exposure regimen, they usually survive such subchronic exposures. For these studies, other measures of toxicity must be used to determine the effects of tobacco. It is of interest to note, however, that smoke-exposed and sham-exposed animals can outlive unexposed animals (Wehner, A.P. *et al.*, 1976).

(ii) *Rate of weight gain* (see also section 1, pp. 129-133)

The rate of weight gain of hamsters (Wehner, A.P. *et al.*, 1976) and rats (Kendrick *et al.*, 1976; Smith *et al.*, 1978) exposed daily to tobacco smoke is generally slower than that of sham-exposed controls; and sham-exposed controls usually have a slower rate of weight gain than untreated controls (Kendrick *et al.*, 1976; Smith *et al.*, 1978). Both food consumption and rate of weight gain are increased when daily exposure to smoke is stopped (Smith *et al.*, 1978).

(iii) *Cellular and chemical responses*

Carboxyhaemoglobin (COHb) levels of 17 and 29% were observed in rats exposed to the smoke of one and five-to-ten cigarettes, respectively (Kendrick *et al.* 1976). The effects in rats and mice of a six-week exposure to smoke are described in preliminary reports by Henry *et al.* (1984) and Curren *et al.* (1984). The results can be summarized as follows: (1) the numbers of serum neutrophils and segmental alveolar macrophages in the lung were increased; (2) the mitotic index of the pulmonary epithelium was not altered; and (3) pulmonary lavage fluids from exposed rats, as compared to sham-exposed animals, showed an increased level of γ -glutamyl transpeptidase, but not of alkaline phosphatase or total protein. Serum oxalacetic transaminase and serum lactate dehydrogenase activities were unchanged as a result of chronic exposure.

A major clinical change that has been associated with exposure to smoke is alteration in pulmonary function. Daily exposure to cigarette smoke has resulted in: (1) increases in lung compliance in rats (Coggins, 1980) and decreases in lung compliance and increased pulmonary resistance in mice (Aviado & Watanabe, 1974); (2) alterations in tidal volume and in respiratory rates in mice and in minute volume in mice, rats and hamsters (Aviado & Watanabe, 1974; Kendrick *et al.*, 1976; Klimisch & Dontenwill, 1977; Coggins *et al.*, 1982); (3) impairment of tracheal mucociliary transport in dogs (Park, S.S. *et al.*, 1977); and (4) increased permeability of airways in guinea-pigs (Boucher *et al.*, 1980; Hulbert *et al.*, 1981).

(iv) *Histopathological manifestations following subchronic exposure to tobacco smoke*

Histopathological and related changes in respiratory tissue of model animal systems following subchronic exposure to cigarette smoke are summarized in Table 35. The studies involved daily exposure of rats, mice, hamsters and dogs to cigarette smoke for six- to ten-week periods. In general, hamsters and rats were more responsive to the effects of smoke and showed high incidences of epithelial hyperplasia of the larynx, trachea, bronchioli and alveoli (Kendrick *et al.*, 1976; Smith *et al.*, 1978; Walker *et al.*, 1978a,b; Coggins *et al.*, 1980). The pulmonary tissue of dogs showed evidence of fibrosis and emphysema (Frasca *et al.*, 1983). All animals showed increased accumulation of pulmonary alveolar macrophages. Most of these effects were attributed to constituents in the particulate phase of smoke (Coggins *et al.*, 1980) and were correlated in a dose-related fashion to the total particulate matter of the cigarette smoke (Walker *et al.*, 1978a); some of the effects were reversible when the animals were no longer exposed to smoke (Smith *et al.*, 1978).

Table 35. Histopathological manifestations in model animal systems during subchronic exposure to cigarette smoke

Study reference	Experimental conditions ^a	Histopathology ^b
Smith <i>et al.</i> (1978)	Rats; reference filter cigarettes (19.6 mg TPM/cigarette); 8% smoke; 10-min exposure twice/day on week-days and once per day on weekends for 42 or 84 days; groups of animals removed after 42 days to evaluate reversion	Goblet-cell hyperplasia of tracheal and bronchial epithelia Increased PAM and alveolar metaplasia Increased squamous metaplasia and hyperplasia of larynx Larynx, trachea and bronchus all reverted to normal Alveolar metaplasia not reverted
Kendrick <i>et al.</i> (1976)	Rats; NCI references nonfilter cigarettes (codes 9 and 16); 10% smoke from 7 or 10 cigarettes/day for 12-18 months	Chronic alveolitis Increased PAM, mast cells and PMN Increased bronchial and alveolar hyperplasia Bronchiolitis of terminal bronchioles
Walker <i>et al.</i> (1978a,b)	Rats; 4 types of reference cigarette; 8%, 12.5% and 20% smoke twice/day, 7 days/week, for 47 days	Increased PAM correlated with TPM content of cigarettes Increased incidence of alveolar metaplasia in rats exposed to high levels of TPM Increased squamous metaplasia and keratinizing hyperplasia in the larynx, and goblet-cell hyperplasia in the nasal cavity, trachea and bronchus, all in parallel with TPM content of cigarettes, except for hyperplasia in trachea
Jones, R. <i>et al.</i> (1973, 1978)	Rats; reference cigarette (13.7 mg TPM and 2.0 mg nicotine); 1% smoke for 6 or 4 min for 4 h/day for 1 day and up to 6 weeks (25 cigarettes/day, 4-6 days/week for up to 6 weeks)	Apparent number of goblet cells in extra-pulmonary airways decreased after 1 day; but increased in extra- and intrapulmonary regions by 3 days and up to 6 weeks of smoke exposure Increased incidence of goblet cells containing acid glycoprotein Addition of anti-inflammatory agent, phenylmethyloxadiazole, protects against increased number of goblet cells
Frasca <i>et al.</i> (1983)	Dogs; NCI reference cigarette (code 26); undiluted smoke from 2-7 cigarettes/day <i>via</i> tracheostomy for 2-4 months	Increases in PAM Increases in pulmonary fibrosis and emphysema No bronchitis or bronchiolitis

Table 35 (contd)

Study reference	Experimental conditions ^a	Histopathology ^b
Bernfeld <i>et al.</i> (1983)	Hamsters; reference filter cigarette plus cigarettes containing cellulose-derived tobacco supplement; 22% smoke from 1 cigarette, twice/day, 7 days/week for up to 20 weeks	Increased incidence of laryngeal hyperplasia and papillomas Increase in PAM Increased hyperplasia of terminal bronchiolar epithelium Effects most severe in animals exposed to all-tobacco cigarettes.
Coggins <i>et al.</i> (1980)	Rats; commercial filter cigarettes; 3.5% smoke, 20 min smoke/day, twice/day, 5 days/week for 12 weeks	Epithelial hyperplasia, squamous metaplasia and epithelial thickening in nasal passages and larynx Tracheal changes similar, but more diffuse than in larynx Bronchial thickening from hypertrophy of ciliated cells and squamous metaplasia; bronchiolar hypertrophy and alveolar metaplasia; increased numbers of goblet cells Electron microscopy showed loss of cilia and extensive squamous-cell production Gas phase of smoke failed to induce these changes
Lam, R. (1980)	Rats; 4 types of commercial filter cigarettes; 1-8% smoke from 6 cigarettes over 1-h period	Partial or complete loss of epithelium on ventral wall of larynx Regeneration and hyperplasia Regenerative phase delayed with higher concentrations of smoke Gas phase failed to induce effects
Lewis, D.J. (1981)	Rats and hamsters; commercial cigarette (12 mg tar); 6% smoke for 4 x 10 min/day on 7 days/week or 2 x 10 min/day for rats and 7% smoke at 2 x 30 min/day, 7 days/week for hamsters. Rats exposed for 6 or 12 weeks and hamsters for 10 weeks	Laryngeal hyperplasia at specific locations Hyperplasia and metaplasia of squamous epithelium of larynx Keratinization of squamous epithelium Effects smoke-dose-related Distribution of lesions influenced by anatomy, histology, airflow and smoke characteristics
Henry <i>et al.</i> (1984)	Mice and rats; commercial cigarette; 10% smoke (5 mg total particulate matter/litre) from 9 cigarettes/day, 5 days/week for 6 weeks	Increase in PAM in mice In rats, increase in PAM, increase in squamous metaplasia of nasal passages and hypertrophy of larynx, trachea and bronchial epithelium Increase in squamous metaplasia and hyperplasia of trachea and larynx in rats

^aTPM, total particulate matter^bPAM, pulmonary alveolar macropages; PMN, polymorphonuclear neutrophils

(v) *Reproductive toxicity following exposure to smoke*

The effect of tobacco smoke exposure on the reproductive system of model animal systems and of humans has been reviewed (Mattison, 1982) and is not discussed in detail here. In summary, cigarette smoke may play a role in: (1) decreasing sperm number and increasing the frequency of sperm-shape abnormalities; (2) altering hypothalamic-pituitary relationships resulting in changes in levels of hormones associated with reproduction; (3) altering the motility of the female reproductive tract; (4) impairing implantation of embryos; and (5) reducing the number of primary oocytes.

Two recent studies came to slightly different conclusions regarding the effects of exposure to smoke on fetal growth. Bertolini *et al.* (1982) reported that exposure of pregnant rats to smoke during gestation resulted in slower maternal weight gain, but that there were no effects on delivery rate, litter size, weight of offspring, percent weight of brain, number of dead fetuses, offspring mortality during lactation, or sex ratio of offspring. Bassi *et al.* (1984) observed, however, that when pregnant rats were exposed to smoke during gestation fetal weight was significantly reduced in comparison to pair-fed controls. No effect was observed on fetal brain weight or nucleic acid content, but fetal lung and liver weights (and nucleic acid content) were decreased by exposure to smoke. No effect on placental growth was observed. [The Working Group concluded that maternal exposure to smoke is capable of altering fetal growth, but the magnitude of the response and the subsequent effects on normal tissue function remain to be determined.]

(vi) *Immunotoxicity*

Exposure to cigarette smoke causes both short- and long-term effects on the immune system of animals. The effects may be either localized to pulmonary tissues or may be systemic.

The cellular components of the pulmonary defense system consist of several cell types that are present on and in the airway epithelium. Cells on the surface are studied by means of bronchial lavage and comprise pulmonary alveolar macrophages, lymphocytes and various polymorphonuclear cells. These cells play a vital role in the defence of the lung against inhaled particles by taking up particulates, functioning in the development of an immune response, and secreting tissue-destroying enzymes. The latter function is discussed in more detail below (see pp. 149-152). Exposure to cigarette smoke causes a prompt decrease in the numbers of pulmonary alveolar macrophages and polymorphonuclear neutrophils (Rylander, 1973), but it is transient, and usually an increase is seen in the numbers of these cell types following more than two to three weeks of daily exposure to smoke (see Tables 35 and 36). The new alveolar macrophages usually have an increased capacity for phagocytosis (Fogelmark *et al.*, 1980), a decreased capacity for phagolysosome fusion (Harris, J.O. & Gonzalez-Rothi, 1984) and quite different morphometry (Lewis, D.J. *et al.*, 1979) compared to cells from control animals. In-vitro exposure of alveolar and peritoneal macrophages to tobacco smoke also resulted in impaired phagocytic function, metabolism and viability (Green, G.M. & Carolin, 1967; Holt *et al.*, 1978).

Table 36. Metabolic responses of rodent pulmonary tissue following exposure to cigarette smoke

Metabolic response	Experimental conditions ^a	Result	Reference
Protein synthesis	Rats; 1R1 or 1A1 cigarettes, 1 or 3 cigarettes twice daily for 30 days	Decreased by 30% by exposure to 1R1; slightly decreased by exposure to 1A1	Hamosh <i>et al.</i> (1979)
Glycoprotein synthesis	Rats; 1R1 or 1A1 cigarettes, 1 or 3 cigarettes twice daily for 30 days	Increased 2 fold by exposure to both 1R1 and 1A1	Hamosh <i>et al.</i> (1979)
Lipid metabolism	Rats; 1R1 or 1A1 cigarettes, 1 or 3 cigarettes twice daily for 30 days	Palmitic acid uptake and esterification unchanged	Hamosh <i>et al.</i> (1979)
DNA synthesis	Hamsters; 4 commercial cigarettes every 6 h for 48 h	Percent cells in S-phase increased in bronchi, bronchioles and alveoli within 72 h after exposure	Boren (1970)
	Mice; 2A1 cigarettes, 10% smoke, 50 min/day for up to 17 weeks	Replication DNA synthesis increased by more than 2 fold	Rasmussen <i>et al.</i> (1981)
	Mice; 3A1 or 2R1 cigarettes, 10% smoke for 126 min (15 sec of smoke, followed by 45 sec of air per min), 5 days/week for 3-13 weeks	Percent cells in S-phase increased by 3 to 10 fold	Henry <i>et al.</i> (1983)
Cyclic nucleotide activity	Rats; minced tissues exposed to gas phase of commercial cigarettes <i>in vitro</i>	Guanylate cyclase activity increased by 2 to 36 fold in various tissues	Arnold <i>et al.</i> (1977)
Glucose metabolism	Rats; 1R1 or 1A1 cigarettes, 1 or 3 cigarettes twice daily for 30 days	CO ₂ production increased by 20-25% by exposure to 1A1; lactate production unchanged; glucose incorporation into lipid increased by 30% by 1A1; greater response to 1A1 than to 1R1	Hamosh <i>et al.</i> (1979)
In alveolar macrophages	Rats; 2R1 cigarettes, 10% smoke from 10 cigarettes, 3 times per day for 30 days	CO ₂ production from glucose carbon-6 slightly increased; CO ₂ production from glucose carbon-1 slightly decreased; lactate production increased by 65%	Drath <i>et al.</i> (1978)

Table 36 (contd)

Metabolic response	Experimental conditions ^a	Result	Reference
In alveolar macrophages	Hamsters; 2R1 cigarettes, 4 exposures of 15 min to cigarette smoke/day, 5 days/ week for 2 or 6 weeks	CO ₂ production increased by 4-5 fold; O ₂ consumption increased by 1.5 fold	Hoidal & Niewoehner (1982)
Arachidonic acid (AA) metabolism	Perfused rat and hamster lung; ventilated with six commercial cigarettes	Decreased AA incorporation in lung phospholipid only with high-tar non-filter cigarettes; decreased prostaglandin E ₂ formation and metabolism; high-tar cigarette more active	Matintalo & Uotila (1983); Matintalo <i>et al.</i> (1983)
	Rats; 2R1 cigarette; 10-min exposure/day for 4-8 weeks	Increased 12-lipoxygenase activity but no effect on cyclooxygenase levels in platelets; suggested increases in 12-(S)-hydroxy-5,8,10,14- eicosatetraenoic acid	Chang <i>et al.</i> (1983)
	Rats exposed to whole smoke from 2R1 cigarettes 10 min/day, 5 times/week for 10 weeks	Metabolism of AA to prostaglandin I ₂ by pulmonary microsomes decreased by 50-70%; metabolism of AA to thromboxane by pulmonary microsomes increased by 150-200%	Lubawy <i>et al.</i> (1983)
α -1-Antiprotease (α ₁ -PI) levels	Aqueous smoke solution from 2 commercial cigarettes	Human α ₁ -PI inactivated by cigarette smoke <i>in vitro</i>	Carp & Janoff (1978)
	Rats; 2A1 cigarettes; 10% smoke; single exposure	α ₁ -PI inactivated in lungs	Janoff <i>et al.</i> (1979)
	Aqueous solution of cigarette smoke or dimethylsulphoxide extract of CSC	α ₁ -PI not inactivated by smoke <i>in vitro</i> ; slowly inactivated by CSC extract	Wyss <i>et al.</i> (1984)
	Fluid from bronchoalveolar lavage from smokers	No decrease in α ₁ -PI activity	Stone <i>et al.</i> (1983)

Table 36 (contd)

Response	Experimental conditions ^a	Result	Reference
Oxidant/antioxidant levels	Rats; commercial cigarettes; 3 cigarettes/day for 35 days	Glucose-6-phosphate dehydrogenase level increased by 27%	Peirce <i>et al.</i> (1976)
In lungs	Rats; 1R1 cigarettes; 13 cigarettes/day for 21 days	Glutathione peroxidase level increased by 34%; glutathione reductase level increased by 24%; glucose-6-phosphate dehydrogenase level increased by 38%	York <i>et al.</i> (1976)
In lungs	Rats; 1A1 cigarettes, 50 puffs (10% smoke)/day for 7 days	Glutathione, glutathione peroxidase and glucose-6-phosphate dehydrogenase levels increased	Chow <i>et al.</i> (1984)
In alveolar macrophages	Hamsters; 2R1 cigarettes, 4 exposures of 15 min to cigarette smoke/day, 5 days/week for 2 or 6 weeks	Superoxide anion levels increases by 1.5-3 fold	Hoidal & Niewoehner (1982)
In alveolar macrophages	Rats; 2R1 cigarettes, 10% smoke, 3 times/day for 30 days	Superoxide anion levels unaffected; hydrogen peroxide levels increased by 2 fold	Drath <i>et al.</i> (1978)
Pulmonary alveolar macrophage (PAM) activity			
Number of PAM	Mice; 2A1 cigarettes, 10% smoke, 8 cigarettes/day for 4 weeks	Increased by 2 fold	White <i>et al.</i> (1979)
	Hamsters; 2R1 cigarettes, 4 exposures of 15 min to cigarette smoke/day, 5 days/week for 2 or 6 weeks	Increased by 2 fold	Hoidal & Niewoehner (1982)
	Mice; 2A1 cigarettes, 20% smoke, 3 cigarettes twice daily, 5 days/week for up to 24 weeks	Increased by 8 fold	Matulionis & Traurig (1977)
	Rats; 2R1 cigarettes, 10% smoke, 10 cigarettes 3 times/day for 30 days	Not affected	Drath <i>et al.</i> (1978)

Table 36 (contd)

Response	Experimental conditions ^a	Result	Reference
Function of PAM	Mice; 2A1 cigarettes, 10% smoke, 8 cigarettes/day for 4 weeks	Elastase secretion increased by 2 fold	White <i>et al.</i> (1979)
	Mice; 2A1 cigarettes, 20% smoke, 3 cigarettes twice daily, 5 days/week for up to 36 weeks	Lysosomal enzymes (e.g., β -glucuronidase and glucosaminidase) increased by more than 3 fold	Matulionis & Traurig (1977)
	Rats and hamsters; 2R1 cigarettes, 0.4% smoke, 7 hr/day for 45 days	Rate of phagocytosis increased	Fogelmark <i>et al.</i> (1980)
	Rats; commercial cigarettes (20.6 mg tar, 1.42 mg nicotine); 10% smoke; 3 cigarettes/day for 8 weeks	Decreased phagolysosome fusion; no effect on phagocytosis	Harris, J.O. & Gonzales-Rothi (1984)
DNA repair	Mice; 2A1 cigarettes, 10% smoke, 50 min/day for up to 17 weeks	4-Nitroquinoline-1-oxide and methylmethane-sulphonate-induced unscheduled DNA synthesis depressed by 40-50% by 11 weeks of daily exposure	Rasmussen <i>et al.</i> (1981)
Microsomal mono-oxygenases		Variety of cytochrome P-450-dependent enzymes increased (see Table 37 for details)	

^aCharacteristics of the reference cigarettes tested, including 'tar' levels, are given in the section on 'Worldwide Use of Smoking Tobacco', p. 63.

Exposure to smoke can also alter the systemic immune response of test animals. Studies involving chronic exposure of mice to cigarette smoke have shown that: (1) T-cell function is inhibited progressively with time both in terms of humoral and cell-mediated responses (Thomas, W.R. *et al.*, 1974, 1975; Holt *et al.*, 1976; Holt & Keast, 1977; Keast & Ayre, 1980); (2) B-cell function is less affected (Thomas, W.R. *et al.*, 1975); (3) the effects on B and T cells are mediated by both smoke particulates and gaseous (i.e., nitrogen oxide) compounds (Esber *et al.*, 1973; Holt *et al.*, 1979); and (4) the phagocytic and killing capacity of peritoneal polymorphonuclear neutrophils is inhibited (Keast & Taylor, 1983). Exposure of lymphocytes *in vitro* to tobacco smoke and to nicotine decreases lymphocyte responsiveness to mitogen stimulation (Roszman *et al.*, 1975; Jacob *et al.*, 1980).

Smoke contains chemicals that inhibit blood coagulation; one prolongs the clotting time of plasma by delaying fibrin aggregation, and another inactivates factor XIIIa (Galanakis *et al.*, 1982).

Exposure to tobacco smoke causes similar changes in humans; these are discussed in section 3, p. 163.

(b) *Metabolic effects of tobacco smoke*

Exposure of animals to whole smoke from cigarettes or to the gas-phase constituents results in the alteration of a number of enzyme systems in pulmonary and other tissues. A summary of these metabolic responses is given in Table 36.

Levels of protein, glycoprotein and DNA synthesis are usually modified in pulmonary tissue following exposure to cigarette smoke: total protein synthesis may be decreased by 30%, while glycoprotein synthesis may be increased two fold. The latter change presumably reflects increases in mucus production (Hamosh *et al.*, 1979). DNA synthesis rates may be increased up to 10 fold following exposure to smoke (Boren, 1970; Rasmussen *et al.*, 1981; Henry *et al.*, 1983). This observation probably reflects in-situ stimulation of cells at all levels of the lung, i.e., bronchi, bronchioles and alveoli (Boren, 1970). Such general stimulation is also usually associated with increases in mitotic activity, as shown by the DNA labelling index (Henry *et al.*, 1983).

Some of the earliest effects of tobacco smoke are changes in levels of cyclic nucleotides. Pulmonary tissues contain high levels of cyclic guanosine monophosphate (cGMP), and levels of both cGMP and the enzyme that forms this intermediate, guanylate cyclase, are increased by gas-phase constituents of smoke (Maron *et al.*, 1984; Arnold *et al.*, 1977). cGMP levels can be increased up to seven fold within 2 sec of exposure to a single bolus of smoke; the levels return to control values within 2 min, and the process can be repeated (Maron *et al.*, 1984).

Lung tissues usually show higher rates of glucose metabolism following exposure to smoke. The level of carbon dioxide production is increased by ~ 25% in lung tissues of rats (Hamosh *et al.*, 1979) and by four to five fold in alveolar macrophages of hamsters (Hoidal & Niewoehner, 1982).

The lung plays two major roles in the metabolism of prostaglandins, and exposure to cigarette smoke can alter both functions. (1) Lung tissue has a high capacity for inactivating circulating prostaglandins, since it is particularly rich in two enzymes, 15-hydroxyprostaglandin dehydrogenase and 13,14-reductase, which degrade prostaglandins. (2) Lung tissue has a high capacity for converting arachidonic acid into a variety of prostaglandins and related substances (see Eling & Ally, 1984). Exposure to cigarette smoke results in a decreased rate of prostaglandin E₂ metabolism, which seems to be related to the 'tar' content of the cigarette, in that cigarettes with a very high 'tar' content cause greater inhibition (Matintalo & Uotila, 1983; Matintalo *et al.*, 1983). Chronic exposure to cigarette smoke also adversely alters arachidonic acid metabolism. Lung tissues from rats exposed to cigarette smoke once a day for 10 weeks synthesized more thromboxane and less prostaglandin GI₂ (i.e., prostacyclin) than sham-exposed animals (Lubawy *et al.*, 1983). Exposure to smoke

also results in higher activity of lipooxygenase in platelets but has a limited effect on cyclooxygenase activity (Chang *et al.*, 1983).

Smoke can be a major indirect or direct source of chemical oxidants and free radicals, and also causes a rapid influx of pulmonary alveolar macrophages and polymorphonuclear neutrophils into the lung. These actively phagocytic cells release a variety of oxidative intermediates when exposed to particulates such as those in cigarette smoke. The intermediates found in cigarette smoke and/or released by activated macrophages include superoxide anion, hydrogen peroxide and hydroxyl radical (Drath *et al.*, 1978; Baehner *et al.*, 1982; Hoidal & Niewoehner, 1982). As a result of their presence, a variety of cell components and extracellular materials undergo oxidative reactions. Pulmonary tissues respond to this insult by altering levels of glutathione, glutathione peroxidase, glutathione reductase and glucose-6-phosphate dehydrogenase (Peirce *et al.*, 1976; York *et al.*, 1976; Chow *et al.*, 1984). One extracellular product that may be inactivated by these oxidative intermediates is the α_1 -antiprotease inhibitor. This intercellular protein is the major antiprotease in the lungs and forms a covalent one-to-one complex with, and inactivates, a number of serine proteases, including elastase from polymorphonuclear neutrophils and pulmonary alveolar macrophages. Oxidation of α_1 -antiprotease destroys its inhibitor function, and higher levels of elastase are observed. The higher level of elastase found in alveolar macrophages from lungs of smoke-exposed animals may cause enzymatic destruction of elastic fibres in the walls of the air spaces in the lungs (White *et al.*, 1979). Although certain laboratories have reported that smoke is capable of inactivating α_1 -antiprotease inhibitor (Carp & Janoff, 1978; Janoff *et al.*, 1979), another laboratory has failed to observe a decrease in α_1 -antiprotease in fluid obtained by broncholavage from smokers (Stone *et al.*, 1983).

The increased numbers and activity of pulmonary alveolar macrophages and polymorphonuclear neutrophils also cause an increase in lysosomal enzyme activity (Matulionis & Traurig, 1977). The increased levels of lysosomal acid hydrolases and decreased mucociliary mechanisms that occur after exposure to smoke render lung tissue that has been exposed to cigarette smoke at greater risk of tissue injury (Park, S.S. *et al.*, 1977).

One of the best studied metabolic alterations caused by exposure to tobacco smoke is the induction of the cytochrome P-450-dependent microsomal monooxygenases (MMO). These multicomponent enzymes metabolize a highly diverse group of lipid-soluble chemicals to more water-soluble forms (see Nebert *et al.*, 1978; Kouri *et al.*, 1980; Boobis & Davies, 1984). Studies in model animal systems have shown that MMO levels can be induced by a variety of chemicals, environmental pollutants and other foreign chemicals, that this induction is under genetic control, and that the genetic regulation can influence susceptibility to chemically-induced cancers (see review by Pelkonen & Nebert, 1982). MMO responses to smoke in six species of rodents are summarized in Table 37. The two most responsive organs are the lung and kidney, but induction of MMO by smoke has also been observed in small intestine (Uotila & Marniemi, 1976; Cohen, G.M. *et al.*, 1977; Uotila, 1977) and trachea (Simberg & Uotila, 1978). Lung tissue is also capable of metabolizing steroid hormones, e.g., testosterone: exposure to smoke inhibits rather than induces testosterone metabolism in lung tissue (Hartiala *et al.*, 1978).

Table 37. Effects of exposure to cigarette smoke on microsomal monooxygenase (MMO) activity in tissues of various rodent species

Species	Levels of MMO in tissues ^a	
	Lung	Kidney
Rat	Increased (Welch <i>et al.</i> , 1971; Van Cantfort & Gielen, 1975; Akin & Benner, 1976; Uotila & Marniemi, 1976; Van Cantfort & Gielen, 1977; Uotila, 1977; Bilimoria & Ecobichon, 1980)	Increased (Van Cantfort & Gielen, 1975; Uotila & Marniemi, 1976; Uotila, 1977; Van Cantfort & Gielen, 1977; Bilimoria & Ecobichon, 1980)
Mouse	Increased (Abramson & Hutton, 1975; Van Cantfort & Gielen, 1975; Akin & Benner, 1976; Kouri <i>et al.</i> (1979a)	No significant increase (Abramson & Hutton, 1975)
Hamster	Increased (Akin & Benner, 1976; Bilimoria & Ecobichon, 1980)	Increased (females only) (Bilimoria & Ecobichon, 1980)
Guinea-pig	Decreased (Bilimoria <i>et al.</i> , 1977); no effect (Bilimoria & Ecobichon, 1980)	Increased (Bilimoria & Ecobichon, 1980)
Gerbil	Increased (Bilimoria & Ecobichon, 1980)	No effect (Bilimoria & Ecobichon, 1980)
Rabbit	Decreased within 20 min (Lubawy & Isaac, 1980)	Not done

^aConsidered to be increased if more than two-fold increase observed within 24 h after exposure to smoke

Smoke-induced MMO have characteristics that distinguish them from those induced by 3-methylcholanthrene (MC) (Table 38). Smoke-induced levels increase more rapidly, are lower and have a longer half-life than MC-induced enzyme levels (Van Cantfort & Gielen, 1975, 1977; Kouri *et al.*, 1979a, 1980). Both enzyme systems require RNA and protein synthesis for induction (Van Cantfort & Gielen, 1977; Kouri *et al.*, 1979a). The inducing components occur in the particulate phase of smoke, since Cambridge-filtered (*i.e.*, gas phase) smoke failed to induce pulmonary MMO (Akin & Benner, 1976). Certain strains of mice are more responsive to smoke (as they are to MC), but no clear-cut genetic regulation has been observed for smoke-induced MMO (Abramson & Hutton, 1975) as has been for MC-induced MMO (Nebert *et al.*, 1978; Kouri *et al.*, 1979a).

Exposure to cigarette smoke may also alter the levels of other enzymes, *e.g.*, epoxide hydrolases and UDP-glucuronosyltransferase, which are associated with MMO. Pulmonary epoxide hydrolase levels have been shown to be decreased after exposure to smoke (Uotila & Marniemi, 1976; Uotila, 1977; Uotila *et al.*, 1977a), whereas levels in the small

Table 38. Comparison of characteristics of microsomal monooxygenase (MMO) induction in lung of rodents after exposure to smoke and to 3-methylcholanthrene (MC)^a

Characteristic	Treatment	
	Smoke	MC
Time to peak response	4-6 h	24-48 h
Level of responsiveness	2 to 5 fold	10 fold
Half-life of induced enzymes	24 h	4-5 h
Dependent on RNA and protein synthesis	yes	yes
Dose-related responsiveness	inadequate data	yes
Genetic regulation	inadequate data	yes
Induced MMO metabolizes new substrates at higher rates	yes	yes
Induced MMO metabolizes chemicals to forms that bind to DNA	yes	yes

^aFrom Abramson & Hutton (1975), Van Cantfort & Gielen (1975), Akin & Benner (1976), Van Cantfort & Gielen (1977), Cohen, G.M. *et al.* (1977) and Kouri *et al.* (1979b, 1980)

intestine are increased and those in kidney unchanged (Uotila & Marniemi, 1976; Uotila, 1977). The activity of UDP-glucuronosyltransferase in lung tissue (Uotila, 1977; Uotila & Marniemi, 1976) and in isolated perfused lungs (Uotila *et al.*, 1977b) has been shown to be practically unaffected by smoke levels, but levels in small intestine (Uotila, 1977) and trachea (Simberg & Uotila, 1978) are increased by exposure to smoke. In isolated rat lung, however, glucuronide conjugation is significantly increased by smoke (Uotila *et al.*, 1977b).

As a result of such altered levels of MMO and its associated enzymes, metabolism of chemicals such as benzo[*a*]pyrene by pulmonary tissues from smoke-exposed animals is altered (Cohen, G.M. *et al.*, 1977; Uotila *et al.*, 1977a; Lubawy & Isaac 1980). These benzo[*a*]pyrene intermediates are shown to bind covalently to cellular macromolecules, especially DNA, at much higher levels (Cohen, G.M. *et al.*, 1977). The higher MMO levels in lungs and/or other tissues of smoke-exposed rats also seem to account for the more rapid clearance times of drugs, such as phenacetin (Kuntzman *et al.*, 1977) and antipyrine (Nakagawa *et al.*, 1983).

Many of the alterations in metabolism caused by tobacco smoke described above have also been observed in humans exposed to tobacco smoke. (See section 3 of this chapter, pp. 186-189).

(c) *Mutagenicity and other short-term tests*

The results obtained from a variety of short-term tests on tobacco smoke and tobacco smoke condensate have been reviewed by DeMarini (1983) and by Obe (1984). Only a few of the studies deal with tobacco smoke; most are concerned with cigarette smoke condensate. The studies reviewed here are summarized briefly in Tables 39 and 40.

(i) *Tobacco smoke*

Tests with Salmonella typhimurium (Table 39)

Basrur *et al.* (1978) demonstrated that the smoke from four types of tobacco were mutagenic to *S. typhimurium* TA1538; the number of revertants per cigarette was at least two-fold greater with the smoke than with cigarette smoke condensate (CSC). Ong *et al.* (1984) showed that sidestream smoke (SS) was also mutagenic in a system in which bacterial plates were exposed directly.

Extracts of SS collected on filters were shown to account for most of the mutagenicity of the indoor air of an office building; the basic fraction of the air extract contained most of the mutagenic activity (Löfroth *et al.*, 1983). The air in which 157 cigarettes had been smoked within 6 h in a 110-m³ room with poor ventilation was ten times more mutagenic than air from a control room (Bos *et al.*, 1983). [The Working Group noted that this study was designed so that cigarette smoke would have accounted for most of the mutagenic activity in the air; however, this does not imply that cigarette smoke would account for most of the mutagenicity of other indoor air samples.]

Extracts of particles collected in a room where moderate smoking occurred were more mutagenic than particles collected in a room with an open fireplace or than samples of urban air (Alfheim & Ramdahl, 1984).

Concentrated urine from 17 cigarette-smoking baboons had higher average mutagenic activity in *S. typhimurium* than that from 12 nonsmoking baboons. When the urine concentrates were further fractionated, some fractions were more active in strain TA100 and others more active in strain TA1538 (Marshall, M.V. *et al.*, 1983).

Exposure of rats to either SS or mainstream smoke (MS) of two to four filter cigarettes (13 mg tar; 0.9 mg nicotine per cigarette) smoked by an automatic smoking machine resulted in the excretion of frameshift mutagens in the urine, as detected by *S. typhimurium* TA1538 (Mohtashamipur *et al.*, 1984).

Tests in eukaryotic systems (Table 40)

A solution of the gas phase of cigarette smoke dissolved in phosphate buffer induced reciprocal mitotic recombination in *Saccharomyces cerevisiae* D3 and petite mutants in an

Table 39. Summary of studies on the mutagenicity of tobacco smoke and tobacco smoke condensates (CSC) in *Salmonella typhimurium*^a

Tobacco	Metabolic system	Strain	Comments	Reference
Smoke and CSC from University of Kentucky K1R1-40 cigarette; standard experimental blend, no filter SEB 11-42; freeze-dried standard experimental blend FD-50; and straight burley, low-nicotine BLN-52	Rat liver (not stated if induced)	TA1538	Cigarette smoke more mutagenic than CSC	Basrur <i>et al.</i> (1978)
SS from 4 US brands	Aroclor-induced rat liver	TA98	After 4 h, increase in mutation frequency >10-fold average control value	Ong <i>et al.</i> (1984)
Extracts of particulate matter from SS of common US brands	Aroclor-induced rat liver	TA98	Most mutagenic activity found in basic fraction	Löfroth <i>et al.</i> (1983)
Smoke from cigarettes (brand not stated); extracts of particulates collected by filtration	Aroclor-induced rat liver	TA1538	Air in which 157 cigarettes were smoked in 6 h in a 110-m ³ room with poor ventilation 10 times more mutagenic than control air	Bos <i>et al.</i> (1983)
SS from cigarettes (brand not stated); extracts of particulates collected by filtration	Aroclor-induced rat liver	TA98	Cigarette smoke produced more mutagens in air than wood-burning in an open fireplace.	Alfheim & Ramdahl (1984)
Tobacco smoke ^b		TA1538 TA100	Urine of smoking baboons mutagenic	Marshall, M.V. <i>et al.</i> (1983)
MS and SS from cigarettes ^c		TA1538	Urine of exposed rats mutagenic	Mohtashampur <i>et al.</i> (1984)
CSC from control and high-charcoal filter commercial cigarettes	Aroclor-induced rat liver and lung	TA1538	High-charcoal filters still allow mutagens to pass into smoke. Aroclor-induced rat liver and lung effective	Kier <i>et al.</i> (1974)
CSC from commercial and nitrate-treated, unfiltered cigarettes	Aroclor-induced rat liver and lung	TA1538 TA1535	CSC from nitrate-treated cigarettes contains directly acting mutagens detected in TA1535 and TA1538; all other CSCs required S9. Aroclor-induced rat liver and lung effective.	Kier <i>et al.</i> (1974)

Table 39 (contd)

Tobacco	Metabolic system	Strain	Comments	Reference
CSC, 12 Swain fractions and all fractions recombined from University of Kentucky 1A1 low-nicotine cigarettes	Aroclor-induced rat liver and lung	TA1538	Basic and some acidic fractions most mutagenic; neutral weakly mutagenic	Kier <i>et al.</i> (1974)
CSC and 19 fractions from University of Kentucky 1R1 cigarettes	Uninduced, PB- or MC-induced rat liver and lung; human liver	TA1538	MC a better inducer than PB for rat liver S9; uninduced, PB- or MC-induced rat lung and human liver not effective. Whole CSC and the water-insoluble fraction of CSC were mutagenic with uninduced rat liver S9	Hutton & Hackney (1975)
Whole CSC and 12 Swain fractions from University of Kentucky 1R1 cigarettes	MC-induced rat liver	TA1538	Basic and acidic fractions more mutagenic than neutral fractions	Hutton & Hackney (1975)
CSC from 8 American, 5 European and 5 Japanese cigarettes; 5 brands of cigars; and 3 pipe tobaccos	PCB-induced rat liver	TA98 TA100	TA98 more sensitive than TA100. Mutagenicity per mg of CSC nearly the same for low-tar and high-tar cigarettes and for CSC collected from either the first, middle or last third of cigarettes. Most filters reduced the amount of CSC by about 12%; however, the specific mutagenic activity of CSCs is similar for CSCs from filter and nonfilter cigarettes. Specific mutagenic activity of the smoke condensates was: cigar > cigarettes > pipe.	Sato <i>et al.</i> (1977)
CSC from 12 flue-cured tobaccos, 2 burley tobaccos, 6 Japanese domestic tobaccos, and 3 varieties of Japanese domestic tobaccos	PCB-induced rat liver	TA98	Total nitrogen, protein nitrogen, and soluble nitrogen positively related to increases in mutagenicity, but nicotine and nitrate were not. CSC from old leaves (low on the stalk) less mutagenic than CSC from young leaves (high on the stalk). CSC from tobacco with high sugar content less mutagenic than CSC from tobacco with low sugar content	Mizusaki <i>et al.</i> (1977a)
CSC from burley tobacco with 4 amounts of nitrogen fertilizer; flue-cured tobacco; 7 American, 4 Japanese, 3 UK and 1 German brand of cigarettes	MC-induced rat liver	TA1538	CSC from burley tobacco more mutagenic than CSC from flue-cured tobacco. CSCs from high-nitrate-containing cigarettes more mutagenic than CSCs from low-nitrate cigarettes. CSC prepared from cigarettes with high draw resistance more mutagenic than CSC from cigarettes with low draw resistance	Mizusaki <i>et al.</i> (1977b)

Table 39 (contd)

Tobacco	Metabolic system	Strain	Comments	Reference
Swain fraction 5 of CSC	Aroclor-, PB- or MC-induced, or uninduced maternal or fetal rat liver	TA98 TA100	Swain 5 (basic) fraction mutagenic in TA98 with PB-, MC- or Aroclor-induced S9. Fetal liver ineffective	Sehgal & Hutton (1977a,b)
CSC from burley and flue-cured tobacco	PCB-induced rat liver	TA98 TA100	Nitrite-treated CSC less mutagenic than untreated CSC in TA98, but nitrite treatment increased mutagenic potency of CSC in TA100	Yoshida & Matsumoto (1978)
CSC from 3 commercial brands of Japanese cigarettes	PCB-induced rat liver	TA98 TA100	Addition of sugar to tobacco reduced mutagenicity of resulting CSC, fructose and sorbitol being most effective	Sato <i>et al.</i> (1979)
CSC and 12 Swain fractions of 1A1 cigarettes	Aroclor-induced rat liver and lung	TA1538	Basic fractions most mutagenic	Kouri <i>et al.</i> (1979a)
CSC and 12 Swain fractions of 1A1 and 2A1 cigarettes	Aroclor-induced rat liver and TCDD-induced mouse liver and lung	TA98	TCDD-induced lung S9 from mice not effective; basic fraction most mutagenic	Kouri <i>et al.</i> (1979a)
CSC from 3 European brands	Aroclor-, PCB- and MC-induced or uninduced rat liver	TA98 TA100	Uninduced liver ineffective; TA98 more sensitive than TA100	De Raat (1979)
CSC from 2 types of flue-cured, burley, Japanese domestic and blended cigarette tobaccos	PCB-induced rat liver	TA98	CSCs from burley tobaccos more mutagenic than CSCs from flue-cured or blended tobaccos. CSCs from Japanese domestic tobaccos most mutagenic	Yoshida & Matsumoto (1980)
CSC and 10 fractions from University of Kentucky 1R1 cigarettes	Aroclor-induced rat liver	TA1538	Rankings of mutagenic potencies based on plate-incorporation vs. preincubation; protocols not significantly different: basic > acidic and neutrals	DeMarini (1981a)

Table 39 (contd)

Tobacco	Metabolic system	Strain	Comments	Reference
CSC from commercial defiltered low-tar cigarettes	Aroclor-induced rat liver S9 and S12 from human lung (parenchyma or bronchi)	TA98	Mutagenic with rat S9; borderline mutagenicity with human lung parenchyma S12	De Flora <i>et al.</i> (1984)
Smoke condensates from Transkei tobacco, pipe tobacco and commercial cigarette tobacco	Aroclor-induced rat liver	TA98 TA100 TA1538 TA1537	Mutagenic activities were: Transkei > pipe > cigarette. Potencies associated positively with nitrogen content of tobaccos	Wehner, F.C., <i>et al.</i> (1980)
Transkei pipe tobacco residues	Rat liver induced by combined treatment with PB and MC	TA98 TA100	Pipe tobacco residues mutagenic in TA98 and TA100	Hewer <i>et al.</i> (1978)

^aAbbreviations. PB, phenobarbital; MC, 3-methylcholanthrene; PCB, polychlorinated biphenyl; TCDD, 2,3,7,8-tetrachloro-dibenzo-*para*-dioxin

^bUrine from tobacco smoke-exposed baboons

^cUrine from rats exposed to mainstream and sidestream smoke

isolate of strain D3 (Izard *et al.*, 1976, 1980). Fresh cigarette smoke induced mitotic gene conversion, reverse mutation and reciprocal mitotic recombination in strain D7 of *S. cerevisiae*; the nicotine content of the cigarette did not affect the activity of the smoke (Gairola, 1982). In the root-tip cells of garlic the gas phase of cigarette smoke induced chromosomal aberrations (Pandey *et al.*, 1978).

Induction of sex-linked recessive lethal mutations was observed in *Drosophila melanogaster* larvae exposed to two to three puffs of cigarette smoke per day for seven days. However, treatment of adult males with cigarette smoke resulted in no significant increase in the number of sex-linked recessive lethal mutations over that in controls (Pescitelli, 1979). Kale and Baum (1982) confirmed these results and demonstrated that sex-linked recessive lethal mutations occur at a specific stage of germ cells, i.e., in spermatocytes.

A solution of the gas phase of cigarette smoke was shown to induce dose-dependent increases in the incidence of sister chromatid exchanges (SCEs) in cultured human lymphocytes obtained from smoking and nonsmoking subjects. The increases in SCE frequency were dose-dependent (Valadaud-Barrieu & Izard, 1979; Izard *et al.*, 1980).

Table 40. Summary of studies on the mutagenicity and other related effects of tobacco smoke condensate (CSC) and tobacco smoke in eukaryotes^a

Endpoint	Type of condensate or smoke	Test organism	Result	Reference
FUNGI				
Reciprocal mitotic recombination	Gas phase	<i>Saccharomyces cerevisiae</i> D3	+	Izard <i>et al.</i> (1976, 1980)
	Fresh smoke	<i>Saccharomyces cerevisiae</i> D7	+	Gairola (1982)
Gene conversion	CSC	<i>Saccharomyces cerevisiae</i> D7	+	Hannan <i>et al.</i> (1980)
	Fresh smoke	<i>Saccharomyces cerevisiae</i> D7	+	Gairola (1982)
Petite mutations	Gas phase	<i>Saccharomyces cerevisiae</i> D3	+	Izard <i>et al.</i> (1976)
Mutation	CSC	<i>Saccharomyces cerevisiae</i> XV 185-14C	-	Hannan <i>et al.</i> (1980)
	Fresh smoke	<i>Saccharomyces cerevisiae</i> D7	+	Gairola (1982)
	CSC	<i>Neurospora crassa</i>	+	DeMarini (1981a,b)
PLANTS				
Chromosomal aberrations	Aqueous emulsion of CSC after ether extraction	<i>Allium cepa</i>	+	Venema (1959)
	Gas phase	<i>Allium sativum</i>	+	Pandey <i>et al.</i> (1978)
	Water-soluble fraction of CSC from filter and defiltered cigarettes	<i>Allium cepa</i>	+	Sabharwal <i>et al.</i> (1975)
INSECTS				
Sex-linked recessive lethal mutations	CSC and fresh smoke	<i>Drosophila melanogaster</i>	+	Pescitelli (1979)
	Fresh smoke	<i>Drosophila melanogaster</i>	+	Kale & Baum (1982)

Table 40 (contd)

Endpoint	Type of condensate or smoke	Test organism	Result	Reference
MAMMALIAN CELLS <i>IN VITRO</i>				
Mutation	CSC	L5178Y mouse lymphoma cells	+	Clive <i>et al.</i> (1979)
	CSC	L5178Y mouse lymphoma cells	+	Mitchell, A.D. <i>et al.</i> (1981)
Inhibition of metabolic cooperation	CSC	Chinese hamster V79 cells	+	Hartman & Rosen (1983)
SCEs	CSC	Chinese hamster ovary cells	+	De Raat (1979)
	CSC	Human lymphocytes	+	Hopkin & Evans (1979, 1980)
	CSC	Human lymphocytes	+	Madle <i>et al.</i> (1981)
	Gas phase	Human lymphocytes	+	Valadaud-Barrieu & Izard (1979)
	Gas phase	Human lymphocytes	+	Izard <i>et al.</i> (1980)
	CSC	Chinese hamster ovary cells and human lymphocytes	+	Hopkin & Perry (1980)
	CSC	Human lymphocytes	+	Sorsa <i>et al.</i> (1982)
	CSC	Human lymphocytes	+	Vijayalaxmi & Evans (1982)
	CSC	Chinese hamster ovary cells	+	Salomaa <i>et al.</i> (1985)
Cell transformation	CSC	Mouse L-cells and hamster lung fibroblasts	+	Inui & Takayama (1971a,b)
	CSC fractions	Syrian hamster embryo cells	+	Freeman <i>et al.</i> (1971)
	CSC (Basic, weak acidic and two neutral fractions)	Retrovirus-infected mouse and rat embryo cells; uninfected hamster embryo cells	+	Rhim & Huebner (1973)

Table 40 (contd)

Endpoint	Type of condensate or smoke	Test organism	Result	Reference
Cell transformation (contd)	Whole CSC and basic and weak acidic fractions from 1A1 cigarette	C3H 10T ½ cells	+	Benedict <i>et al.</i> (1975)
	CSC extracts	Syrian hamster embryo cells	+	Takayama <i>et al.</i> (1978)
	CSC ± benzo[<i>a</i>]pyrene	Syrian hamster embryo cells	+	Rivedal & Sanner (1980); Rivedal <i>et al.</i> (1980)
	Neutral fractions of CSC and hydrocarbon-enriched fraction of CSC	Human foetal lung	+	Lasnitzki (1958, 1968)
	Ethanol and ethyl acetate extracts of betel and tobacco	Syrian hamster embryo cells	+	Umezawa <i>et al.</i> (1978)
MAMMALS <i>IN VIVO</i>				
Cell transformation	CSC	Syrian hamster embryo cells (transplacental exposure followed by in-vitro culture)	+	Sabharwal <i>et al.</i> (1977)
SCEs (bone marrow)	CSC	Chinese hamster	-	Madle <i>et al.</i> (1981)
SCEs and chromosomal aberrations	Fresh smoke	Chinese hamster	-	Korte <i>et al.</i> (1981)
SCEs (lymphocytes)	Fresh smoke	Wistar rats	-	Basler (1982)
SCEs (bone marrow)	Fresh smoke	BC3F1/Cum mice	+	Benedict <i>et al.</i> (1984)
SCEs (bone marrow)	Fresh smoke	B6C3F1 mice	+	Putman <i>et al.</i> (1985)
Chromosomal aberrations	Fresh smoke	Chinese hamster	-	Korte <i>et al.</i> (1981)

^aAbbreviation: SCE, sister chromatid exchange

No increase in the number of SCEs in bone marrow or of chromosomal aberrations was found in Chinese hamsters exposed to smoke from nonfilter commercial cigarettes for 1h/day for 9-12 weeks; addition of 20% ethanol to their drinking-water also had no effect on the frequency of SCEs or of chromosomal aberrations (Korte *et al.*, 1981). Exposure of female Wistar II rats to the smoke of 30 cigarettes/day for 28 days did not increase the frequency of SCEs in their cultured lymphocytes (Basler, 1982). [The Working Group considered that these negative results may have been due to inadequate exposure.] Recently, Benedict *et al.* (1984) demonstrated that exposure of female BC3F1/Cum mice to cigarette smoke daily for 1-46 weeks caused a two-fold increase in the frequency of SCEs in the bone marrow that persisted for at least one week after cessation of exposure. Putman *et al.* (1985) demonstrated dose-dependent increases in the frequency of SCEs in bone-marrow cells of B6C3F1 mice exposed to cigarette smoke on five days/week for two weeks. Rasmussen *et al.* (1981) reported that cigarette smoke inhibited DNA repair capacity in mice exposed to a test mutagen (methylmethanesulphonate), as evaluated by unscheduled DNA synthesis.

(ii) *Cigarette and other tobacco smoke condensates*

Tests with Salmonella typhimurium (Table 39)

CSC and its fractions have been tested extensively in *S. typhimurium* and shown to be mutagenic. Table 39 summarizes these studies, indicating the type of tobacco tested, the tissues and inducers used for metabolic activation, and the bacterial strains employed.

CSC was mutagenic primarily in strains TA1538 and TA98, which detect frameshift-type mutagens. Most of the activity was in the basic fractions; a small amount was found in the acidic fractions, and little was found in the neutral fractions (Kier *et al.*, 1974; Hutton & Hackney, 1975; Kouri *et al.*, 1979a; DeMarini, 1981a). The basic fractions may be the most mutagenic because the tester strain used, TA1538, is more sensitive to aromatic amines (present in the basic fractions) than to polynuclear aromatic hydrocarbons (present in the neutral fractions) (Kier *et al.*, 1974). Although most of the mutagenicity detected in *S. typhimurium* resides in the basic fractions, most of the carcinogenic activity detected in mouse skin assays has been found in the neutral fractions (Wynder & Hoffmann, 1967, 1968). Nitrate-treated cigarettes were mutagenic in strain TA1535, which detects mutagens that cause base-pair substitutions (Kier *et al.*, 1974).

Except for CSCs from nitrate-treated cigarettes, all tobacco smoke condensates required metabolic activation to be mutagenic in *S. typhimurium*. The mutation yields differed depending on the metabolic system used. Matsumoto *et al.* (1977) and Sugimura *et al.* (1977) demonstrated that the products of pyrolysis of amino acids and protein are mutagenic in the presence of a metabolic system. On the basis of this finding and of the relationship between nitrogen content of tobacco and mutagenicity of CSC, Mizusaki *et al.* (1977a) suggested that protein and amino acid pyrolysates are major contributors to the mutagenicity of CSC that is detected in *S. typhimurium*.

The mutagenic potency of CSC on a weight-to-weight basis was similar for low-tar and high-tar cigarettes (Sato *et al.*, 1977), and the presence of charcoal or other types of filters

had little effect on mutagenic activity (Kier *et al.*, 1974; Sato *et al.*, 1977). The mutagenic potency of CSCs collected from the first, middle and last third of cigarettes was similar; and the relative mutagenic potencies of tobacco smoke condensates were: cigars > cigarettes > pipe (Sato *et al.*, 1977). Neither the benzo[*a*]pyrene content nor the amount of *N*-nitroso compounds present accounts for much of the mutagenic activity of CSC (Kier *et al.*, 1974; Hutton & Hackney, 1975; Sato *et al.*, 1977).

Various characteristics of tobacco leaves may influence the mutagenic potency of CSC (Mizusaki *et al.*, 1977a). Total nitrogen, protein nitrogen and soluble nitrogen were positively associated with mutagenic potency; nicotine was not; CSC from old leaves (low on the stalk) was less mutagenic than that from young leaves (high on the stalk); CSC from tobacco with a high sugar content was less mutagenic than CSC from tobacco with a low sugar content. Sato *et al.* (1979) found that addition of sugars, such as fructose and sorbitol, to tobacco reduced the mutagenicity of the resulting CSC. Nitrate content increased the mutagenicity of CSC, and CSC from cigarettes with high draw resistance was more mutagenic than CSC from cigarettes with low draw resistance (Mizusaki *et al.*, 1977b).

CSC from Japanese domestic and burley tobaccos was more mutagenic (Mizusaki *et al.*, 1977b; Yoshida & Matsumoto, 1980) than CSC from flue-cured or blended tobaccos. [However, CSC from flue-cured tobacco was more carcinogenic to mouse skin than that from cigarettes composed of other types of tobacco (Wynder & Hoffmann, 1963, 1967, 1969; Hoffman & Wynder, 1972b). Burley tobacco cigarettes produce smaller amounts of polynuclear aromatic hydrocarbons than other cigarettes, resulting in lower carcinogenicity (Wynder & Hoffmann, 1969; Hoffmann & Wynder, 1972b). Possible reasons for this discrepancy between carcinogenicity and mutagenicity are discussed above.]

Tests in eukaryotic systems (Table 40)

Studies on the genetic effects of cigarette smoke and CSC in eukaryotic short-term tests are summarized in Table 40. CSC induced gene conversion in yeast (Hannan *et al.*, 1980) and mutation in *Neurospora crassa* (DeMarini, 1981a,b). CSC induced chromosomal aberrations in the root-tip cells of onion (Venema, 1959; Sabharwal *et al.*, 1975). It induced sex-linked recessive lethal mutations in *Drosophila melanogaster* exposed as larvae (Pescitelli, 1979).

The neutral fraction of CSC was reported to inhibit DNA repair in normal human lymphocytes (Gaudin *et al.*, 1972). CSC was mutagenic to mammalian lymphoma cells *in vitro* (Clive *et al.*, 1979; Mitchell, A.D. *et al.*, 1981) and induced SCEs in Chinese hamster ovary cells (De Raat, 1979; Hopkin & Perry, 1980; Salomaa *et al.*, 1985) and in human lymphocytes (Hopkin & Evans, 1979, 1980; Madle *et al.*, 1981; Sorsa *et al.*, 1982). No difference was observed in the response of lymphocytes obtained from cigarettes smokers and from nonsmokers to the induction of SCEs by CSC (or by other mutagens) (Vijayalaxmi & Evans, 1982).

Whole CSC, organic solvent-soluble, acidic and water/methanol-soluble fractions and organic solvent eluates were reported to inhibit intercellular communication (measured by metabolic cooperation) between cultured HGPRT⁺ and HGRPT⁻ V79 Chinese hamster cells (Hartman & Rosen, 1983).

CSC induced in-vitro transformation in a variety of mammalian cell systems (Lasnitzki, 1958, 1968; Freeman *et al.*, 1971; Inui & Takayama, 1971a,b; Rhim & Huebner, 1973; Benedict *et al.*, 1975; Takayama *et al.*, 1978; Umezawa *et al.*, 1978; Rivedal & Sanner, 1980; Rivedal *et al.*, 1980). Transforming activity has been found in basic, acidic and neutral fractions, and, similar to the results obtain in *S. typhimurium*, the basic and some of the acidic fractions were the most active (Benedict *et al.*, 1975).

CSC did not induce SCEs in bone marrow of Chinese hamsters *in vivo* (Madle *et al.*, 1981), but Sabharwal *et al.* (1977) demonstrated that transplacental exposure to CSC could transform Syrian hamster fetal cells.

3. Observations in humans

(a) *Methods of measuring intake of tobacco smoke*

Various methods have been used to measure the extent to which tobacco smoke is inhaled and taken into the human body. Most are designed to measure all phases of inhaling, while others make it possible to study specific phases only. The measurement of inhalation and factors influencing the extent of inhaling are discussed on pp. 170-179. This section discusses the methods employed in measuring intake of tobacco smoke.

(i) *Biochemical markers and biological measures of intake*

Three constituents of tobacco smoke are used routinely to measure exposure: carbon monoxide (CO), nicotine and hydrogen cyanide (HCN).

(1) *Carbon monoxide in blood.* CO can be measured in blood as carboxyhaemoglobin (COHb) or, rapidly and non-invasively, in end-expired air; the two measures have been found to be highly correlated (Jarvis *et al.*, 1980).

Analyses of COHb used to evaluate exposure to cigarette smoke are influenced by other environmental or occupational exposures to CO and to other compounds, such as methylene chloride (dichloromethane) (DiVicenzo & Kaplan, 1981). COHb can be used only as an indicator of recent exposure, since its half-life is relatively short — calculated to be 130 min for men during periods of activity and 220 min for seated men (Joumard *et al.*, 1981).

COHb levels in smokers are generally between 3 and 8% (see Table 41) but may occasionally reach 13% (Russell *et al.*, 1973a). According to Saloojee *et al.* (1982), a convenient cut-off point to discriminate between smokers and nonsmokers is a COHb value of 1.6%. Pojer *et al.* (1984) found that 97.8% of nonsmokers had COHb values below 2%.

A rough dose-response relationship between the amount smoked and COHb values can be obtained in cigarette smokers. Daily consumption of cigarettes accounts for about 21% of the variation in COHb; a further 23% of the variation is estimated to be caused by the pattern of inhalation and puffing; the remaining variation may be due to differences in the CO yields of cigarettes and in individual metabolic and environmental factors. Among heavy smokers (> 25 cigarettes/day), the correlation between cigarette consumption and COHb values is relatively poor; generally, the values 'plateau' at about 7-8% (Vesey *et al.*, 1982). COHb levels have been used to study 'compensatory' smoking (see pp. 171-179, Tables 41 and 48). For example, although the CO yield from cigarettes with ventilated filters was 35% less than that from cigarettes with unventilated filters, COHb values (standardized for recent cigarette consumption) were only 9.3% lower in smokers of the ventilated filter cigarettes (Wald *et al.*, 1980). In another study, smokers of low- and medium-'tar' cigarettes were found to have similar COHb values (Sorsa *et al.*, 1984).

Since pipe and cigar smokers generally inhale to a lesser extent than cigarette smokers, their COHb values are considerably lower (Castleden & Cole, 1973; Janzon *et al.*, 1981).

Nonsmokers usually have COHb values below 2% (Vesey *et al.*, 1982), and COHb is not a sufficiently sensitive measure to detect the low intake from average daily exposure to environmental smoke (Jarvis *et al.*, 1984; see Table 41). However, in nonsmokers with short-term exposure (1-2 h) to fairly extreme conditions in poorly ventilated smoke-filled rooms (ambient CO, 20-38 ppm [23-44 mg/m³]), COHb levels were increased by an amount equivalent to the average increase in smokers after one cigarette (Russell *et al.*, 1973b; Hugod *et al.*, 1978).

(2) *Carbon monoxide in end-expired air.* The concentration of CO in end-expired air is a useful measure of COHb, since the correlation between the two is close (Cohen, S.I. *et al.*, 1971; Jarvis *et al.*, 1980; Ho-Yen *et al.*, 1982; Kanzler *et al.*, 1983; Robinson *et al.*, 1983; Sutton *et al.*, 1983; Pojer *et al.*, 1984). CO taken up *via* the lungs is reversibly bound with various proteins (myoglobin, cytochromes, catalase) and with haemoglobin to form COHb. Both COHb and CO in expired air have a short half-life, but the sampling of expired air for CO is simpler than that of blood for COHb. A cross-sectional study of over 2000 persons showed that CO in expired air is a reliable indicator of recent cigarette smoking. Most regular smokers showed CO levels exceeding 9 ppm (10.4 mg/m³) (range, 5.5-82 ppm [6.3-94 mg/m³]; mean, 27.3 ppm [32 mg/m³]), while nonsmokers had values in the range of 2-19 ppm [2.3-22 mg/m³] (mean, 4.6 ppm [5.3 mg/m³]) (Fortmann *et al.*, 1984). Short-term exposure of nonsmokers in a smoke-filled public house (ambient CO, 13 ppm [15 mg/m³]) resulted in an increase in expired CO (to 5.9 ppm [6.8 mg/m³]), similar to increases in smokers after smoking one cigarette (Jarvis *et al.*, 1983).

(3) *Nicotine in biological samples.* Measurement of nicotine in biological samples has the advantage of being specific to tobacco and tobacco smoke. However, the short initial half-life of 9 min and relatively short terminal half-life of 2 h (Benowitz *et al.*, 1982; Feyerabend *et al.*, 1985) make plasma and salivary nicotine levels unreliable measures of fluctuating intake over several hours. These are therefore unsuitable for estimating intake from everyday exposure to sidestream smoke of nonsmokers in the general population.

Table 41. Comparison of biochemical exposure parameters in nonsmokers, self-reported passive smokers and active smokers^a

Biochemical parameter	Nonsmokers (n = 46)		Passive smokers (n = 54)		Active smokers (n = 94)
	Mean value	% of active smokers' value	Mean value	% of active smokers' value	Mean value
CO in expired air (ppm [mg/m ³])	5.7[6.5]	27	5.5[6.3]	26	20.8[24]
COHb (%)	0.9	23	0.8	21	3.9
Nicotine (ng/ml)					
in plasma	1.0	7	0.8	5.4	14.8
in saliva	3.8	0.6	5.6	0.8	672.5
in urine	3.9	0.2	12.1**	0.7	1749.9
Cotinine (ng/ml)					
in plasma	0.8	0.3	2.0**	0.7	275.2
in saliva	0.7	0.2	2.5***	0.8	309.9
in urine	1.6	0.1	7.7***	0.6	1391.0
Thiocyanate (μ mol/l)					
in plasma	48	39	53	43	123
in saliva	1270	52	1327	54	2450
in urine	73	47	77	50	155

^aCalculated from data reported by Jarvis *et al.* (1984)

** $p < 0.01$; *** $p < 0.001$ between passive smokers and nonsmokers

Nicotine concentrations in plasma of smokers vary considerably, the number of cigarettes smoked recently being the most important variable. The yield of nicotine or of tar of the cigarette, or the average daily number of cigarettes smoked were all poor predictors of blood nicotine concentration. Smokers of cigarettes with ventilated filters (nicotine, 0.6-0.9 mg; tar, 8-12 mg) showed only a small reduction of blood nicotine levels as compared to smokers of nonfilter cigarettes (nicotine, >1.6 mg; tar, >23 mg) (Russell *et al.*, 1980).

Several studies have shown measurable amounts of nicotine in saliva, urine and blood of nonsmokers under controlled conditions (Russell & Feyerabend, 1975; Hoffmann *et al.*, 1984b,c). Passively exposed nonsmokers who reported recent exposure to cigarette smoke showed the highest values (Feyerabend *et al.*, 1982).

The positive correlation between salivary and urinary concentrations of nicotine was significant among both smokers and passively exposed nonsmokers. As with plasma nicotine, the only parameter that was significantly associated with nicotine concentrations in saliva or urine was the number of cigarettes smoked recently. Neither the nicotine yield of cigarettes nor the self-reported degree of inhalation had a demonstrable effect on urinary or salivary nicotine concentrations (Feyerabend *et al.*, 1982). [The Working Group noted that this study was not large enough to have detected a weak association.]

Urinary nicotine concentrations differed approximately three fold in self-reported 'exposed' versus 'nonexposed' nonsmokers (Jarvis *et al.*, 1984) (Table 41), suggesting that they provide a reasonable estimate of everyday exposure to passive tobacco smoke. Since urinary nicotine concentration is affected by urinary pH (Russell & Feyerabend, 1975) and urine flow, these factors must also be taken into account.

Estimates have been made of the amount of nicotine absorbed under various conditions of passive smoking (Foliart *et al.*, 1983; Russell *et al.*, 1985). Exposure that gives rise to a CO intake equivalent to the active smoking of one cigarette results in the absorption of an amount of nicotine equivalent to about one-third of a cigarette dose.

Nicotine has also been measured in other biological matrices, e.g., hair and cervical mucosa (Haley & Hoffmann, 1985; Sasson *et al.*, 1985a).

(4) *Cotinine in plasma, urine and saliva.* Cotinine is a major metabolite of nicotine and the best all-purpose marker of smoke intake in both smokers and nonsmokers (Haley *et al.*, 1983; Robinson *et al.*, 1983; Pojer *et al.*, 1984). It is specific and can be measured reliably at very low concentrations (Langone *et al.*, 1973; Hengen & Hengen, 1978). Urinary concentrations are little affected by pH. Although they differ, the concentrations in urine, saliva and plasma are highly correlated in active and passive smokers (Jarvis *et al.*, 1984). The main advantage of using cotinine is its relatively long half-life in plasma (20-30 h), which makes it a good measure of average daily exposure (Benowitz *et al.*, 1983; Matsukura *et al.*, 1984).

Urinary cotinine levels reported among smokers generally range from 0.5 to 2.0 $\mu\text{g/ml}$; the median value in smokers was about 300 times greater than that in nonsmokers (see Table 41; Jarvis *et al.*, 1984; Wald *et al.*, 1984a).

In a chamber model study of passive smoking, nicotine in saliva provided the best immediate indicator of smoke uptake, whereas cotinine in urine appeared to be the most reliable marker of chronic exposure (Hoffmann *et al.*, 1984b). Nonsmokers exposed under controlled ventilation conditions to smoke from two, three or four cigarettes exhibited a significant dose-response relationship with regard to nicotine uptake (in saliva) and cotinine excretion (in urine) (Hoffmann *et al.*, 1984c).

In both active and passive smokers, a relationship was reported between the number of cigarettes smoked (or to which passive exposure occurred) and the cotinine concentration in an early-morning specimen of urine (Matsukura *et al.*, 1984). [In this study, passive smokers had levels of urinary cotinine (per mg creatinine) approaching 10% of the values found in active smokers. This difference is about ten times greater than that between smokers and nonsmokers found in other studies (Jarvis *et al.*, 1984; Wald *et al.*, 1984b).] Infants living in households with active smokers have been shown to have high levels of urinary cotinine (median level, 351 ng cotinine/mg creatinine) as compared to unexposed infants (4 ng/mg). The amount of urinary cotinine excreted was related to the number of cigarettes smoked per day by the mother or primary caretaker (Greenberg, R.A. *et al.*, 1984).

(5) *Thiocyanate in plasma, urine and saliva.* Thiocyanate is the major metabolite of free hydrogen cyanide in the gas phase of smoke. Although the half-life of thiocyanate in plasma is about two weeks (Borgers & Junge, 1979) and it can, therefore, be used as a long-term indicator of smoke exposure, it is in general a poor marker of smoke exposure, since the levels are influenced by dietary factors, particularly leafy vegetables and nuts (Pettigrew & Fell, 1972; Borgers & Junge, 1979).

Among heavy smokers, of more than 20 cigarettes/day, plasma thiocyanate concentrations range from about 100-250 $\mu\text{mol/l}$ (Borgers & Junge, 1979; Fortmann *et al.*, 1984). A dose-response relationship is generally seen with regard to the number of cigarettes consumed daily (Rickert & Robinson, 1981), although the concentration of thiocyanate reached a plateau among heavy smokers of 1.5-2.5 packs daily. The yield of hydrogen cyanide in a cigarette had no significant effect on levels of plasma thiocyanate (Rickert & Robinson, 1981; Vesey *et al.*, 1982).

There is a good correlation between thiocyanate concentrations measured in blood, urine and saliva from the same individual (see Table 41). The concentration of plasma thiocyanate that differentiates smokers and nonsmokers was judged to be 85 $\mu\text{mol/l}$ (Butts *et al.*, 1974) or 73 $\mu\text{mol/l}$ (Vesey *et al.*, 1982).

Thiocyanate levels in groups of nonsmokers and smokers show considerable day-to-day variation, which is not attributable to smoking (Haley *et al.*, 1983). Passive smoking had virtually no effect on thiocyanate levels (see Table 41).

(6) *N-Nitrosoproline in urine.* The endogenous formation of *N*-nitrosamines in humans following ingestion of a source of nitrate and of proline has been demonstrated (Ohshima & Bartsch, 1981). Tobacco smoke contains up to 600 μg of nitrogen oxides per cigarette and several mg of nitrosatable amines (Schmeltz & Hoffmann, 1977). Salivary thiocyanate, which is increased by smoking, is known to be an effective nitrosation catalyst (Boyland *et al.*, 1971), and inhalation of tobacco smoke may thus increase endogenous

formation of *N*-nitrosamines in smokers.

In a short study by Hoffmann and Brunnemann (1983), smoking and nonsmoking men were placed on a controlled diet. The 24-h urinary excretion of *N*-nitrosoproline (NPRO) was significantly higher in smokers than in nonsmokers; addition of proline to the diet increased NPRO excretion significantly in smokers but not in nonsmokers. Endogenous NPRO formation in smokers could be inhibited by daily addition of 1 g ascorbic acid to their diet. Ladd *et al.* (1984) confirmed that excess NPRO is found in the urine of cigarette smokers following ingestion of nitrate and proline; and Bartsch *et al.* (1984) reported that smokers excreted higher levels of total *N*-nitrosamino acids following ingestion of nitrate and proline.

(7) *Thioethers in urine.* Cigarette smokers excrete significantly higher levels of thioethers derived from electrophilic components of tobacco smoke (van Doorn *et al.*, 1981) than nonsmokers (van Doorn *et al.*, 1979; Heinonen *et al.*, 1983). Interindividual variation was high, and no clear dose-response relationship between the number of cigarettes smoked and the amount of thioethers excreted was observed. Levels were similar in urine of smokers of low-tar (5.4 mg/cigarette) and high-tar (16.3 mg/cigarette) cigarettes (Heinonen *et al.*, 1983).

The lack of specificity of the method and its susceptibility to interacting dietary factors (Aringer *et al.*, 1983) and to individual metabolic differences reduce its value as a measure of smoke exposure.

(8) *Urinary mutagenicity.* Mutagenic activity is usually detectable only after urine has been concentrated and treated with deconjugating enzymes, such as β -glucuronidase and arylsulphatase or a rat hepatic microsomal fraction (S9). The most frequently used biological indicators of mutagenicity have been the bacterial strains routinely applied in mutagenicity testing; the best indicator strains for urinary mutagenicity related to smoking are the frame-shift mutation strains (TA98 and TA1538) of *S. typhimurium*. The test system is sensitive to a marker amino acid (histidine) in concentrated urine samples. With proper concentration methods, the levels of histidine do not, however, reach the critical levels to induce false increases in numbers of revertants (Mohtashamipur *et al.*, 1985).

Yamasaki, E. and Ames (1977), employing XAD-2 resin to concentrate the urine and the *Salmonella*/microsome system as indicator, showed that cigarette smokers have mutagenic urine. The mutagenicity of the urine of smokers has since been confirmed by several research groups (see Table 42). A trend to a dose-response relationship exists between the level of exposure to smoke and the extent of mutagenic activity in urine (van Doorn *et al.*, 1979; Jaffe *et al.*, 1983; Kriebel *et al.*, 1983; Mohtashamipur *et al.*, 1985). Concentrates of urine from cigarette smokers are usually mutagenic only after metabolic activation, suggesting that enzymatic splitting of conjugates may be necessary before activity can be detected.

Guerrero *et al.* (1979) used mammalian cells as indicators to study genetic activity in urine of smokers and nonsmokers. Urine of smokers significantly increased the frequency of sister chromatid exchanges in these cells.

Putzrath *et al.* (1981) analysed concentrates of smokers' urine and concluded that the mutagens are a complex mixture of relatively nonpolar compounds. However, although

Table 42. Studies yielding positive results for mutagenicity of urine of smokers to *Salmonella typhimurium*

Type of test	Method of concentration	Indicator strain ^a	Reference
Plate incorporation assay	XAD-2	TA 1538	Yamasaki, E. & Ames (1977)
Plate incorporation assay	XAD-2	TA 1538	van Doorn <i>et al.</i> (1979)
Plate incorporation assay	XAD-2	TA 98	Møller & Dybing (1980)
Plate incorporation assay	XAD-2	TA 98	Aeschbacher & Chappuis (1981)
Plate incorporation assay	XAD-2	TA98	Hannan <i>et al.</i> (1981)
Plate incorporation assay	XAD-2	TA 1538	Dolara <i>et al.</i> (1981)
Fluctuation test	XAD-2	TA 98	Falck (1982)
Plate incorporation assay	XAD-2	TA 98	Recio <i>et al.</i> (1982)
Plate incorporation assay	XAD-2	TA 1538	Bos <i>et al.</i> (1983)
Plate incorporation assay	XAD-2	TA 98	Jaffe <i>et al.</i> (1983)
Plate incorporation assay	'Blue cotton'	TA 98	Kobayashi, H. & Hayatsu (1984)
Plate incorporation assay	XAD-2	TA 1538	Kriebel <i>et al.</i> (1983)
Plate incorporation assay	XAD-2	TA 1538	Menon & Bhide (1984)
Liquid incubation (microsuspension) system	XAD-2	TA 98	Kado <i>et al.</i> (1985)
Plate incorporation assay	XAD-2; chloroform or 'blue cotton' extraction	TA 98	Mohtashampur <i>et al.</i> (1985)
Plate incorporation assay	XAD-2	TA 1538	Sasson <i>et al.</i> (1985b)

^aAll with S9 metabolic system

cigarette smoke has been fractionated chemically and the mutagenicity and/or carcinogenicity of many of its components ascertained, the actual urinary metabolites of cigarette smoke have not been identified. In one smoker whose urine had exceptionally high mutagenicity, the major mutagenic compound was identified as 2-naphthylamine (and its metabolite 2-amino-7-naphthol), which was excreted as an unconjugated metabolite of a cigarette smoke component (Connor *et al.*, 1983).

Kado *et al.* (1985) and Kobayashi, H. and Hayatsu (1984) have studied the kinetics of the excretion of mutagens in the urine of cigarette smokers. The peak mutagenic activity of urine collected from a smoker appeared four to five hours after the start of smoking, and the activity decreased to pre-smoking levels by approximately 12 h. The peak mutagenic activity of the urine of a one-pack-a-day smoker collected over a 24-h period of smoking (19 cigarettes smoked) appeared approximately 5 h after the first morning cigarette. In occasional smokers, after smoking a single cigarette, the mutagens as detected by the *Salmonella* assay appear to be absorbed rapidly (3-5 h) and eliminated from the body following first-order kinetics.

Smokers of *bidis* showed higher urinary mutagenicity than cigarette smokers or chewers of tobacco (Menon & Bhide, 1984).

Under experimental conditions simulating natural passive smoking, inhaled smoke compounds led to mutagenic urine (Bos *et al.*, 1983; Sorsa *et al.*, 1985). Although the numbers of people exposed were small (eight and five, respectively), the data suggest that not only active smoking but also passive smoking must be considered when monitoring the urines of a group of people for any potential exposures. Also, dietary factors have been shown to influence urinary mutagenicity results and should be considered in any evaluation (Sasson *et al.*, 1985b).

(ii) *Indirect measures of intake*

(1) *Amount of nicotine in cigarette butts* (see p. 175, and see also Ashton *et al.*, 1970; Rawbone, 1984)

(2) *Puffing pattern*, measured by recording the number of puffs, puff volume, etc., using a cigarette holder linked to pressure transducers (Frith, 1971; Sutton *et al.*, 1983; Herning *et al.*, 1983a,b). The pattern can be recorded and simulated by a smoking machine ('slave' or 'duplicated' smoking), so that the 'tar', nicotine and carbon monoxide yields produced by the individual's smoking pattern can be determined (Creighton *et al.*, 1978).

(3) *Chest-wall plethysmography* to determine the respiratory phase of inhaling (Tobin & Sackner, 1982; Tobin *et al.*, 1982)

(4) *Other methods*, such as counting puffs by observation and measuring butt lengths (Ashton *et al.*, 1970; Turner *et al.*, 1974; Ashton *et al.*, 1979; Robinson *et al.*, 1982)

(b) *Measurement of inhalation and factors influencing the extent of inhalation*

There is no generally agreed definition of tobacco smoke inhalation. Some authors restrict use of this term to the extent to which smoke is transferred from the mouth into the

lungs; others regard that as the first (inspiratory) phase of inhalation, and use the term more broadly to cover the total amount of smoke transferred into the lungs. In the latter sense, the inhalation of tobacco smoke can be increased, for example, by taking more puffs from a cigarette, by taking longer puffs and by inspiring these puffs more deeply into the lungs. In this section, 'inhalation' is used in this broad sense. The use of the term 'inhaling' or the phrase 'extent of inhalation' has two advantages: it allows markers of smoke absorption to reflect 'inhalation' without having to determine that this is due to changes in the inspiratory phase only; and it separates the total process of inhaling smoke from a cigarette from the intake of any particular component of the smoke, which depends on the concentration of that component in the smoke as well as the extent of inhalation.

(i) *Factors influencing the extent of inhalation*

(1) *The pH of the smoke* (see also section 1 of the chapter on 'Chemistry and Analysis of Tobacco Smoke'). The pH of tobacco smoke is an important factor in determining the sites of absorption of nicotine. At alkaline pH, nicotine is more readily absorbed across the mucous membrane than at acid pH (Armitage & Turner, 1970). Smoke from pipes and, to a lesser extent, from cigars and cigarettes containing dark (air-cured) tobacco, tends to be more alkaline than that from cigarettes made of blond (flue-cured) tobacco (Elson *et al.*, 1972; Brunnemann & Hoffmann, 1974a), and nicotine can therefore be absorbed more readily through the buccal mucosa (Armitage & Turner, 1970; Elson *et al.*, 1972).

(2) *Product smoked*. Tobacco smoke products contain about 4% or more CO, although cigarettes with ventilated filters can produce smoke with lower concentrations (see section 2 of the chapter on 'Worldwide Use of Smoking Tobacco'). Cigarette smokers consistently have higher average COHb levels than smokers of cigars or pipes, indicating that cigarette smoke is in general inhaled more often than pipe or cigar smoke (Janzon *et al.*, 1981; Wald *et al.*, 1981a,b). Pipe and cigar smokers who have not been regular cigarette smokers ('primary' pipe or cigar smokers) tend to have lower COHb levels than those who switched to them after having smoked cigarettes ('secondary' smokers) (Wald *et al.*, 1981b, 1982). The increased inhalation among secondary smokers may still be less than the extent of inhalation among continuing cigarette smokers, since their COHb levels are, on average, lower (Wald *et al.*, 1981b).

(3) *Type and yield of cigarette*. A large number of studies have investigated the extent of inhalation according to the type of cigarette, i.e., nonfilter or filter and, if filter, whether ventilated or unventilated, and the tar, nicotine and CO yields of the cigarette. The results of these studies are shown in Tables 43-48 (see also section (a), above, pp. 163-170).

(4) *Other factors*. Other factors, such as the flavour of the tobacco and the draw resistance of the cigarette, are likely to influence the extent of inhaling. No published report was available to the Working Group.

(ii) *Studies of the extent of inhalation of cigarettes*

The studies can be broadly divided into two groups: (1) *experimental* studies (Tables 43-47), in which panels of smokers were asked to smoke one type of cigarette and then another (cross-over design) and the extent of inhalation was compared using one or more of the methods described above; these studies have been relatively short-term and small-scale;

and (2) *observational* (Table 48) studies, in which objective measures of inhalation are made in smokers of different types of cigarettes or cigarettes with different yields; these studies rely on voluntary changes and can be performed on much larger numbers of subjects. However, thus far, the latter have always been cross-sectional, and therefore it cannot be stated with certainty whether the differences observed were due to changes that followed the switch from one type of cigarette to another or whether smokers who inhaled in a particular way were more likely to have switched than others.

There is no satisfactory term to describe the difference in the extent of inhalation observed in people who smoke cigarettes of different types or yields. The term 'compensatory smoking' has been used, but this implies that smokers are striving to reach a previously obtained level of smoke intake, and this need not necessarily be the case. It also does not lend itself to simple quantification and is therefore best used only as a general descriptive term.

To overcome the problem of quantifying differences in the extent of inhalation, two measures have been used in varying forms. In order to review and compare the existing studies of inhalation in a consistent way, these are defined as follows:

(1) *Relative extent of inhaling*. This is generally expressed as O/E , where O represents the observed ratio of the tobacco smoke marker (for example, COHb or serum cotinine) when smoking a new cigarette compared with smoking a usual or standard brand, and E is the expected intake based on the ratio of the relevant standard machine-smoked yields (e.g., CO or nicotine) of the two cigarettes.

(2) *Percentage difference in intake*. This is the change in the measured level of the marker divided by the level associated with smoking the usual brand, expressed as a percentage.

The extent of inhalation is greater in smokers switching to cigarettes with yields lower than those of their usual brand. Similarly, those switching to higher yield cigarettes reduce the extent of inhalation. Tables 43-47 show the relative extent of inhalation of different cigarettes as measured by various biochemical markers of smoke intake: COHb/breath CO, plasma nicotine, 24-hour urinary nicotine, 'mouth level' nicotine and plasma/urinary cotinine.

Smokers who switch to cigarettes with lower 'tar' yields tend to reduce their intake of the measured smoke component, but much less than would be expected from the reduction in yield (Tables 43-48). Similarly, smokers who switch to higher yield cigarettes take in more of the measured smoke component, but less than that expected. Thus, although 'compensation' takes place, it is incomplete. The exception to this rule is in the level of CO taken in, shown in the results of observational studies (Table 48): smokers of unventilated filter cigarettes take in greater quantities of CO than smokers of nonfilter cigarettes, because filter cigarettes tend to have higher CO yields than nonfilter cigarettes and also because smoke from filter cigarettes tends to be inhaled to a greater extent than smoke from nonfilter cigarettes (Tables 43-48).

Table 43. Experimental smoking adjustment studies using carboxyhaemoglobin (COHb) or expired carbon monoxide (CO) as marker^a

Marker ^b	Reference	n ^c	Duration	Cigarette comparison ^d (new vs standard)	Tar yield (mg)	Yield			Level of marker taken in			Relative extent of inhaling (O/E) ^e	Percentage change in intake
						New cigarette (mg CO)	Standard cigarette (mg CO)	Relative yield (new/standard) (E) ^e	From new cigarette (COHb/CO)	From standard cigarette (COHb/CO)	Relative intake (new/standard) (O) ^e		
COHb (%)	Turner <i>et al.</i> (1974)	10	1 week	L vs S VL vs S	S = 19.0 L = 12.0 VL = 4.0	L = 17.0 VL = 8.0	S = 22.7	L/S = 0.75 VL/S = 0.35	L = 5.55 VL = 3.10	S = 5.64	L/S = 0.98 VL/S = 0.55	L = 1.31 VL = 1.57	L = ~ 1.6 VL = ~ 45.0
COHb (%)	Ashton <i>et al.</i> (1979)	12	2-6 weeks	H vs S L vs S	H = 26.5 S = 18.0 L = 6.5	H = 24.0 L = 9.9	S = 17.5	H/S = 1.37 L/S = 0.57	H = 7.70 L = 7.12	S = 7.31	H/S = 1.05 L/S = 0.97	H = 0.77 L = 1.70	H = + 5.3 L = - 2.6
COHb (%)	Hill, P. & Marquardt (1980)	3	2 weeks	L vs H	H = 19.3 L = 5.0	L = 5.3	H = 17.7	L/H = 0.3	L = 4.73	H = 4.36	L/H = 1.08	L = 3.60	L = + 8.5
COHb (%)	Russell <i>et al.</i> (1982)	12	1 day 10 weeks	H vs S L vs S	H = 19.0 S = 17.4 L = 10.9	H = 20.0 L = 12.9	S = 17.0	H/S = 1.18 L/S = 0.76	H = 7.3 L = 7.1	S = 6.7	H/S = 1.09 L/S = 1.06	H = 0.92 L = 1.39	H = + 9.0 L = + 6.0
COHb (%)	Benowitz & Jacob (1984)	11	4 days	H vs S L vs S	H = 16 S = 16.3 L = 4.9	H = 16.0 L = 4.3	S = 15.1	H/S = 1.06 L/S = 0.28	H = 7.85 L = 6.90	S = 7.21	H/S = 1.09 L/S = 0.96	H = 1.03 L = 3.42	H = + 8.9 L = - 4.3
Expired CO (ppm)	Stepney (1981)	19	3 weeks	L vs S 'L' vs S	S = 19 L = 11 'L' = 10	L = 13 'L' = 6	S = 18	L/S = 0.72 'L'/S = 0.33	L = 20.9 'L' = 16.8	S = 33.8	L/S = 0.62 'L'/S = 0.50	L = 0.86 'L' = 1.52	L = - 38.2 'L' = - 50.3
Expired CO (ppm)	Fagerström (1982)	12	3x4 weeks	L vs S VL vs S	S = 14 'L' = 5.8 L = 4.8	'L' = 4.1 L = 4.0	S = 12	'L'/S = 0.34 L/S = 0.33	'L' = 0.3 L = 11.2	S = 16.1	'L'/S = 0.64 L/S = 0.70	'L' = 1.88 L = 2.11	'L' = - 36.0 L = - 30.4

^aSubjects smoked either their usual or a standard brand cigarette and were then switched to a cigarette of different type or yield. Studies involving measurements after a single cigarette are not included.

^bCOHb levels corrected for background by subtraction of 0.7% (nonsmoker level); expired CO levels corrected for background by subtraction of 5.9 ppm (nonsmoker level)

^cn, number of subjects under study

^dH, high 'tar'; S, usual or standard brand cigarette; L, low 'tar'; VL, ventilated low 'tar'; 'L', low 'tar', low CO, but medium nicotine cigarettes; tar yields specified in next column

^eE, expected intake based on the ratio of the relevant standard machine smoked yields of the two cigarettes; O, observed ratio of marker when smoking a new cigarette

Table 44. Experimental smoking adjustment studies using plasma nicotine as marker^a

Plasma nicotine	Reference	n ^b	Duration	Cigarette comparison ^c (new vs standard)	Tar yield (mg)	Yield			Level of marker taken in			Relative extent of inhaling (O/E) ^d	Percentage change in intake
						New cigarette (mg nicotine)	Standard cigarette (mg nicotine)	Relative yield (new/standard) (E) ^d	From new cigarette (nicotine)	From standard cigarette (nicotine)	Relative intake (new/standard) (O) ^d		
nmol/l	Russell <i>et al.</i> (1975)	10	5 h	H vs S VL vs S	H = 38 S = 20.4 VL = 4	H = 3.2 VL = 0.14	S = 1.34	H/S = 2.39 VL/S = 0.10	H = 180.0 VL = 52.4	S = 185.6	H/S = 0.97 VL/S = 0.28	H = 0.41 VL = 2.80	H = - 3.0 VL = - 71.8
nmol/l	Ashton <i>et al.</i> (1979)	12	2-6 weeks	H vs S L vs S	H = 26.5 S = 18.0 L = 6.5	H = 1.84 L = 0.6	S = 1.4	H/S = 1.31 L/S = 0.43	H = 139.9 L = 106.5	S = 127.0	H/S = 1.10 L/S = 0.84	H = 0.84 L = 1.95	H = + 10.2 L = - 16.1
ng/ml	Hill, P. & Marquardt (1980)	4	9 days	H vs S L vs S	H = NA S = NA L = NA	H = 0.81 L = 0.6	S = 0.75	H/S = 1.08 L/S = 0.80	H = 14.3 L = 13	S = 13	H/S = 1.10 L/S = 1.0	H = 1.02 L = 1.25	H = + 10 L = 0
ng/ml	Fagerström (1982)	12	3 × 4 weeks	L vs 'L'	'L' = 5.8 L = 4.8	L = 0.53	'L' = 1.1	L/'L' = 0.48	L = 17.4	'L' = 16.5	L/'L' = 1.05	L = 2.19	L = + 5.5
ng/ml	Russell <i>et al.</i> (1982)	12	9 times over 12 weeks	H vs S L vs S	H = 19.0 S = 17.4 L = 10.9	H = 1.30 L = 0.70	S = 1.33	H/S = 0.98 L/S = 0.53	H = 35.2 L = 22.8	S = 32.4	H/S = 1.09 L/S = 0.70	H = 1.11 L = 1.32	H = + 8.6 L = - 29.6
ng/ml	Benowitz & Jacob (1984)	11	4 days	H vs S L vs S	H = 16 S = 16.3 L = 5	H = 1.2 L = 0.4	S = 1.0	H/S = 1.2 L/S = 0.4	H = 14.6 L = 14.1	S = 20.3	H/S = 0.72 L/S = 0.69	H = 0.60 L = 1.74	H = + 28.1 L = + 30.5

^aSubjects smoked either their usual or a standard brand cigarette and were then switched to a cigarette of different type or yield. Studies involving measurements after a single cigarette are not included.

^bn, number of subjects under study

^cH, high 'tar'; L, low 'tar'; VL, ventilated low 'tar'; 'L', low 'tar'; low CO, but medium nicotine cigarettes; 'tar' yields specified in next column

^dNA, not available; E, expected intake based on the ratio of the relevant standard machine-smoked yields of the two cigarettes; O, observed ratio of marker when smoking a new cigarette.

Table 45. Experimental smoking adjustment studies using 24-h urinary nicotine excretion (mg) as marker^a

Reference	n ^b	Duration	Cigarette comparison ^c (new vs standard)	Tar yield (mg)	Yield			Level of marker taken in			Relative extent of inhaling (O/E) ^d	Percentage change in intake
					New cigarette (mg nicotine)	Standard cigarette (mg nicotine)	Relative yield (new/standard) (E) ^d	From new cigarette (nicotine)	From standard cigarette (nicotine)	Relative intake (new/standard) (O) ^d		
Ashton <i>et al.</i> (1979)	12	2-6 weeks	H vs S L vs S	H = 26.5 S = 18.0 L = 6.5	H = 1.84 L = 0.6	S = 1.4	H/S = 1.31 L/S = 0.43	H = 2.83 L = 2.05	S = 2.17	H/S = 1.30 L/S = 0.94	H = 0.99 L = 2.19	H = + 30.4 L = - 5.5
Hill, P. & Marquardt (1980)	4	9 days	H vs S L vs S	H = NA S = NA L = NA	H = 0.81 L = 0.6	S = 0.75	H/S = 1.08 L/S = 0.80	H = 1.70 L = 1.78	S = 1.63	H/S = 1.04 L/S = 1.09	H = 0.96 L = 1.36	H = + 4.3 L = + 9.2
Stepney (1981)	19	3 weeks	L vs S 'L' vs S	S = 19 L = 11 'L' = 10	L = 0.7 'L' = 1.1	S = 1.55	L/S = 0.45 'L'/S = 0.71	L = 0.70 'L' = 1.06	S = 1.04	L/S = 0.67 'L'/S = 1.02	L = 1.49 'L' = 1.44	L = - 32.7 'L' = + 2.0

^aSubjects smoked either their usual or a standard brand cigarette and were then switched to a cigarette of different type or yield. Studies involving measurements after a single cigarette are not included.

^bn, number of subjects under study

^cH, high 'tar'; S, usual or standard brand cigarette; L, low 'tar'; 'L', low 'tar', low CO, but medium nicotine cigarettes; 'tar' yields specified in next column

^dExpected intake based on the ratio of the relevant standard machine-smoked yields of the two cigarettes; O, observed ratio of marker when smoking a new cigarette. NA, not available

Table 46. Experimental smoking adjustment studies using mouth nicotine level (by butt analysis) as marker^a

Marker	Reference	n ^b	Duration	Cigarette comparison ^c (new vs standard)	Tar yield (mg)	Yield			Level of marker taken in			Relative extent of inhaling (O/E) ^d	Percentage change in intake
						New cigarette (mg nicotine)	Standard cigarette (mg nicotine)	Relative yield (new/standard) (E) ^d	From new cigarette (nicotine)	From standard cigarette (nicotine)	Relative intake (new/standard) (O) ^d		
Mouth nicotine (average daily exposure, mg)	Forbes <i>et al.</i> (1976)	27	1-2 weeks	L vs S	NA	L = 0.85	S = 1.24	L/S = 0.69	L = 15.32	S = 19.09	L/S = 0.80	L = 1.16	L = -19.7
mg/cig	Freedman & Fletcher (1976)	35	10 months	NSM vs S	S = 19.8 NSM = 16.6	NSM = 1.01	S = 1.39	NSM/S = 0.73	NSM = 1.05	S = 1.26	NSM/S = 0.83	NSM = 1.14	NSM = -16.7
Total intake (mg)	Ashton <i>et al.</i> (1979)	12	2-6 weeks	H vs S L vs S	H = 26.5 S = 18.0 L = 6.5	H = 1.8 L = 0.6	S = 1.4	H/S = 1.31 L/S = 0.43	H = 31.7 L = 21.4	S = 20.3	H/S = 1.56 L/S = 1.05	H = 1.19 L = 2.44	H = 56.2 L = +5.4
mg/cig	Russell <i>et al.</i> (1982)	12	1 day 10 weeks	H vs S L vs S	H = 19.0 S = 17.4 L = 10.9	H = 1.3 L = 0.7	S = 1.33	H/S = 0.98 L/S = 0.53	H = 0.9 L = 0.6	S = 1.14	H/S = 0.79 L/S = 0.53	H = 0.81 L = 1.00	H = -21.1 L = -47.4
mg/cig	Stepney (1981)	19	3 weeks	L vs S 'L' vs S	S = 19 L = 11 'L' = 10	L = 0.7 'L' = 1.1	S = 1.55	L/S = 0.45 'L' = 0.71	L = 0.81 'L' = 1.19	S = 1.30	L/S = 0.62 'L'/S = 0.92	L = 1.38 'L' = 1.30	L = -37.7 'L' = -8.5

^aSubjects smoked either their usual or a standard brand cigarette and were then switched to a cigarette of different type or yield. Studies involving measurements after a single cigarette are included.

^bn, number of subjects under study

^cH, high 'tar'; L, low 'tar'; 'L', low 'tar', low CO, but medium nicotine cigarette; NSM, an artificial non-tobacco substitute made from cellulose; 'tar' yields specified in next column

^dE, expected intake based on the ratio of the relevant standard machine-smoked yields of the two cigarettes; O, observed ratio of marker when smoking a new cigarette
NA, not available

Table 47. Experimental smoking adjustment studies using 24-h urinary cotinine excretion or plasma cotinine level as marker^a

Marker	Reference	n ^b	Duration	Cigarette comparison ^c (new vs standard)	Tar yield (mg)	Yield			Level of marker taken in			Relative extent of inhaling (O/E) ^d	Percentage change in intake
						New cigarette (mg nicotine)	Standard cigarette (mg nicotine)	Relative yield (new/standard) (E) ^d	From new cigarette (cotinine)	From standard cigarette (cotinine)	Relative intake (new/standard) (O) ^d		
24-h urinary cotinine (mg)	Ashton <i>et al.</i> (1979)	12	2-6 weeks	H vs S L vs S	H = 26.5 S = 18.0 L = 6.5	H = 1.84 L = 0.6	S = 1.4	H/S = 1.31 L/S = 0.43	H = 0.77 L = 0.59	S = 0.58	H/S = 1.33 L/S = 1.02	H = 1.02 L = 2.37	H = + 32.8 L = + 1.7
24-h urinary cotinine (mg)	Hill, P. & Marquardt (1980)	4	9 days	H vs S L vs S	H = NA S = NA L = NA	H = 0.81 L = 0.6	S = 0.75	H/S = 1.08 L/S = 0.80	H = 3.00 L = 3.18	S = 3.50	H/S = 0.86 L/S = 0.91	H = 0.80 L = 1.14	H = - 14.3 L = - 9.1
24-h urinary cotinine (mg)	Stepney (1981)	19	3 weeks	L vs S 'L' vs S	S = 19 L = 11 'L' ^b = 10	L = 0.7 'L' = 1.1	S = 1.55	L/S = 0.45 'L'/S = 0.71	L = 0.74 'L' = 1.06	S = 0.98	L/S = 0.76 'L'/S = 1.08	L = 1.69 'L' = 1.52	L = - 24.5 'L' = + 8.2
Plasma cotinine (ng/ml)	Russell <i>et al.</i> (1982)	12	10 weeks	L vs S	S = 17.4 L = 10.9	L = 0.7	S = 1.33	L/S = 0.53	L = 246	S = 350	L/S = 0.70	L = 1.32	L = - 29.7
Plasma cotinine (ng/ml)	Fagerström (1982)	12	3-4 weeks	L vs 'L'	'L' = 5.8 L = 4.8	L = 0.53	'L' = 1.1	L/'L' = 0.48	L = 270	'L' = 319	L/'L' = 0.85	L = 1.77	L = - 15.4
Plasma cotinine (ng/ml)	Hill, P. & Marquardt (1980)	3	2 weeks	H vs S L vs S	H = 19.3 S = NA L = 5.0	H = 1.25 L = 0.4	S = 0.88	H/S = 1.42 L/S = 0.45	H = 257 L = 213	S = 222	H/S = 1.16 L/S = 0.96	H = 0.82 L = 2.13	H = + 15.8 L = - 4.1
Plasma cotinine (ng/ml)	Hill, P. & Marquardt (1980)	4	9 days	H vs S L vs S	H = NA S = NA L = NA	H = 0.81 L = 0.6	S = 0.75	H/S = 1.08 L/S = 0.80	H = 239 L = 219	S = 224	H/S = 1.07 L/S = 0.98	H = 0.99 L = 1.23	H = + 6.7 L = - 2.2

^aSubjects smoked either their usual or a standard brand cigarette and were then switched to a cigarette of different type or yield. Studies involving measurements after a single cigarette are not included.

^bn, number of subjects under study

^cH, high 'tar', M, medium 'tar'; L, low 'tar'; 'L', low 'tar', low CO, but medium nicotine cigarettes; 'tar' yields specified in next column

^dE, expected intake based on the ratio of the relevant standard machine-smoked yields of the two cigarettes; O, observed ratio of marker when smoking a new cigarette;

Table 48. Observational studies of smoking adjustment^a

Marker ^b	Reference	Cigarette (n) ^c	Cigarette comparison (new vs standard)	Tar yield (mg)	Yield			Level of marker taken in			Relative extent of inhaling (O/E) ^d	Percentage difference in intake
					New cigarette (mg nicotine or CO)	Standard cigarette (mg nicotine or CO)	Relative yield (new/standard) (E) ^d	From new cigarette	From standard cigarette	Relative intake (new/standard) (O) ^d		
COHb ^a (%)	Wald <i>et al.</i> (1977)	NF (41) F (248) VF (54)	F vs NF VF vs NF	NA	F = 19.0 VF = 12.0	NF = 15.2	F/NF = 1.25 VF/NF = 0.79	F = 4.66 VF = 3.72	NF = 3.43	F/NF = 1.36 VF/NF = 1.08	F = 1.09 VF = 1.37	F = + 35.9 VF = + 8.5
Plasma nicotine (nmol/l)	Russell <i>et al.</i> (1980)	NF (15) M (55) L (23)	M vs NF L vs NF	NF = 25.9 M = 17-20 L = 8-12	M = 1.3 L = 0.8	NF = 1.9	M/NF = 0.68 L/NF = 0.42	M = 216 L = 188	NF = 231	M/NF = 0.94 L/NF = 0.81	M = 1.38 L = 1.93	M = - 6.5 L = - 18.6
COHb ^e (%)	Wald <i>et al.</i> (1980)	NF (110) VF (331) F (875)	F vs NF VF vs NF	NF = 26.0 F = 18.1 VF = 9.5	F = 18.9 VF = 12.2	NF = 15.6	F/NF = 1.21 VF/NF = 0.78	F = 4.7 VF = 4.2	NF = 3.3	F/NF = 1.42 VF/NF = 1.27	F = 1.17 VF = 1.63	F = + 42.4 VF = + 27.3
Expired CO ^f (ppm)	Stepney (1982)	M (40) L (38)	L vs M	M = 18.4 L = 9.4	L = 11.7	M = 18.2	L/M = 0.64	L = 24.3	M = 29.1	L/M = 0.84	L = 1.31	L = - 16.5
Plasma nicotine (ng/ml)	Ebert <i>et al.</i> (1983)	H (29) M (23) L (24)	M vs H L vs H	H = 16.0 M = 9.1 L = 1.8	M = 0.76 L = 0.3	H = 1.2	M/H = 0.63 L/H = 0.25	M = 28 L = 24	H = 33	M/H = 0.85 L/H = 0.73	M = 1.35 L = 2.92	M = - 15.2 L = - 27.3
Expired CO ^g (ppm)	Ebert <i>et al.</i> (1983)	H (29) M (23) L (24)	M vs H L vs H	H = 16.0 M = 9.1 L = 1.8	M = 12.4 L = 2.5	H = 17.0	M/H = 0.73 L/H = 0.15	M = 34.1 L = 34.1	H = 38.1	M/H = 0.90 L/H = 0.90	M = 1.23 H = 6.00	M = - 10.5 H = - 10.5
COHb ^f (%)	Wald <i>et al.</i> (1984b)	H1 (360) H2 (638) M (431) L2 (553) L1 (473)	H2 vs H1 M vs H1 L2 vs H1 L1 vs H1	H1 = 29 H2 = 19 M = 18 L2 = 15 L1 = 9	H2 = 19 M = 17 L2 = 15 L1 = 12	H1 = 22	H2/H1 = 0.86 M/H1 = 0.77 L2/H1 = 0.68 L1/H1 = 0.55	H2 = 3.42 M = 3.40 L2 = 3.15 L1 = 3.60	H1 = 3.52	H2/H1 = 0.97 M/H1 = 0.97 L2/H1 = 0.89 L1/H1 = 1.02	H2 = 1.13 M = 1.26 L2 = 1.30 L1 = 1.85	H2 = - 2.8 M = - 3.4 L2 = - 10.5 L1 = + 2.3

^aSubjects smoked either their usual or a standard brand cigarette and were then switched to a cigarette of different type or yield. Studies involving measurements after a single cigarette are not included.

^bCOHb, carboxyhaemoglobin; CO, carbon monoxide

^cNF, nonfilter; F, filter; VF, ventilated filter; M, medium 'tar'; L, low 'tar'; H, high 'tar', ('tar' yields specified in column 5); n, number of subjects under study

^dE, expected intake based on the ratio of the relevant standard machine-smoked yields of the two cigarettes; O, observed ratio of marker when smoking a new cigarette

^eLevels corrected by the Working Group for background by subtraction of 0.7% (nonsmoker level)

^fLevels corrected by the author for background and carry-over from previous day

^gLevels corrected by the Working Group for background by subtraction of 5.9 ppm (nonsmoker level)

NA, not available

Self-described assessments of inhaling. A number of epidemiological studies with disease as the end-point have been conducted in which smokers were asked whether they inhaled tobacco smoke, either allowing the answer 'yes' or 'no' (Schwartz *et al.*, 1961; Doll & Hill, 1964a) or providing the opportunity for a graded response such 'nil', 'slight', 'moderate', 'deep', thus focusing mainly on the inspiratory phase of inhaling (Hammond, 1966).

Some studies have shown that the risk of lung cancer is positively associated with self-described inhaling among light smokers, as would be expected, but, more surprisingly, the risk is *negatively* associated with self-described inhaling in heavy smokers (Schwartz *et al.*, 1961; Doll & Peto, 1976; Higenbottam *et al.*, 1982). Studies based on COHb levels have shown that heavy smokers who say they inhale in fact inhale to a greater extent than light smokers who say they inhale, so that if a smoker inhales sufficiently deeply to deposit more smoke particles in the peripheral parts of the lung than in the main bronchi, he may protect himself to some extent from the risk of lung cancer (Wald *et al.*, 1978, 1983).

(c) *Deposition of smoke on bronchi*

(i) *Mainstream smoke*

Estimates of the uptake of chemical constituents of smoke and their derivatives are discussed in the previous section. Without mouth-level estimates of yield and knowledge of the mechanisms of uptake, these methods cannot provide estimates of the proportion of the yield that is deposited. Further, information cannot be obtained on the location of the deposit in the respiratory tract, which is of particular relevance to lung cancer.

The particulate material retained by smokers has most often been measured by collecting the exhaled fraction and subtracting the value from an estimate of the yield, which, as discussed above, can be subject to large errors. Another source of error in this technique is that the pattern of smoking may be modified by experimental conditions (Comer & Creighton, 1978; Tobin & Sackner, 1982). In such studies, it is important to assay the total exhaled particulate, since the retention of individual chemical constituents in smoke depends on their volatility and solubility (Dalhamn *et al.*, 1968a) and is thus not representative of particulate in general. Estimates of the fraction retained based on exhaled nicotine (e.g., Greenberg, L.A. *et al.*, 1952; Armitage *et al.*, 1975) have been consistently higher than those based on the total exhaled particulate.

Estimates of tar deposits in most of the studies of cigarette smokers cited in Table 49 relied on crude replication of smoking patterns. Only the study of Hinds, W. *et al.* (1983) attempted to reproduce accurately the pattern of puff volumes, although the flow profile, shown to affect yield in the study of Creighton and Lewis (1978), was not controlled, and only average flow was measured. Hinds, W. *et al.* (1983) offered no explanation as to why their estimates of the fraction retained were so much lower than those of other workers. No data are available concerning deposition of tar from cigar and pipe smoke.

The amounts of tar retained in different regions of the respiratory tract depend on the efficiency of deposition, which is primarily a function of particle size. For inert and nonhygroscopic particles, the relationship between deposition efficiency and particle size is well documented (e.g., review by Lippmann *et al.*, 1980). For the range of particle sizes

Table 49. Estimates of proportion of inhaled tar that deposits in the respiratory tract using exhaled particle collection methods

Retained/ Inhaled (%)		Exhaled particle capture technique	Reference
Range	Average		
73-98	88	Electrostatic precipitation	Baumberger (1923)
80-95		Electrostatic precipitation	Wynder & Hoffman (1960)
22-89	74	Vacuum-assisted filter	Polydorová (1961)
70-90 (5-sec inhalation)	82	Balloon	Mitchell, R.I. (1962)
94-99 (30-sec inhalation)	97		
	96	Cold trap	Dalhamn <i>et al.</i> (1968b)
79-97	87	Filter ^a	Hagopian & Rosenkrantz (1969)
2-75	47	Vacuum-assisted filter	Hinds, W. <i>et al.</i> (1983)

^aAnalysed for blue tetrazolium reducing substances

reported in cigarette smoke (0.1-1.0 μm) (see pp. 83-84 and Table 30), only some 10-20% would be expected to be deposited, rather than the observed 80-90%; however, the rapidly changing characteristics of cigarette smoke affect particle size because: (1) volatile components evaporate when smoke is diluted, (2) coagulation occurs since the initial concentration is in excess of 10^9 particles/cm³ (Hinds, W.C., 1978) and (3) many of the compounds identified in cigarette smoke are water soluble (see chapter on 'Chemistry and Analysis of Tobacco Smoke'), so that hygroscopic growth is likely to occur in the high humidity of the respiratory tract. This last point has been debated by Kousaka *et al.* (1982), who found significant growth of dilute smoke only under supersaturated conditions. However, with such dilution, many volatile components are lost, some of which may be responsible for the hygroscopicity of the particles. Further alterations to deposition efficiency could arise from the potentially bronchoconstrictive nature of cigarette smoke (Bohning *et al.*, 1975; Kim *et al.*, 1982). The pattern of deposition is also altered in individuals with diseases of the airways (Lippman *et al.*, 1980).

None of the studies listed in Table 49 gives information on the distribution of deposited tar within the respiratory tract. Radioactive tracer techniques permit measurements that provide such information, and carbon-14-labelled compounds, especially [16,17-¹⁴C]-dotriacontane, have been used in many studies with animals (e.g., Reznik & Borgmeyer, 1980). Such isotopes are unsuitable for use in humans.

Black and Pritchard (1984) and Pritchard and Black (1984) reported preliminary results from an investigation using a radioisotope appropriate for human studies (¹²⁵I; half-life, 13 h). In this study, asymptomatic male smokers inhaled smoke from high-'tar' cigarettes (16-17 mg) labelled with radioactive 1-iodohexadecane under conditions as natural as possible. Subsequently, they switched to a low-'tar' brand (8-9 mg) and smoked a radiolabelled cigarette 4, 12 and 24 weeks after the switch. Deposition of 'tar' particles and their subsequent clearance were measured using collimated detectors in a whole-body monitor. For comparison, the deposition and clearance of 2.5- μm polystyrene microspheres

were studied in the same subjects. Clearance from the lung is normally described by a two-phase exponential, representing clearance from the pulmonary and ciliated regions of the lung; by following lung clearance for 48 h, the deposition in these two regions can be estimated. The data on polystyrene deposition were in good agreement with previous work using these techniques (Pritchard *et al.*, 1980), indicating that the subjects were normal. On the basis of the reported particle size of cigarette smoke, it was expected that 90% of the deposition in the lung would occur in the pulmonary region; however, less than 40% occurred in this region, providing further evidence that cigarette smoke behaves like a much larger particle in the respiratory tract.

The distribution of 'tar' in various regions of the respiratory tract is shown in Table 50 (Pritchard & Black, 1984). Deposition in the tracheobronchial region decreases significantly when smokers switch to a lower-'tar' cigarette, with some evidence for a continuing decline over the period of the study. The amount deposited in the airways external to the lungs was independent of the type of cigarette. The distribution of 'tar' deposits through the respiratory tract is highly dependent on the manner of smoke inhalation, since this affects the particle size of the 'tar' depositing at different levels of the respiratory tract. Mitchell, R.I. (1962) investigated the effect of inhalation pattern on tar deposition (see Table 49), and Hering *et al.* (1983b) correlated inhalation parameters with nicotine retention. Black and Pritchard (1984), modelling their own data, suggested that expiratory parameters play a more important role in deposition than do inspiratory parameters. They postulated that particles enter the respiratory tract, grow rapidly in the high humidity and deposit during exhalation. [The Working Group considered that this is an area requiring further investigation, since the relationship between deposition and pattern of smoke inhalation is not well understood.]

The decrease in total deposition with decrease in 'tar' levels, shown in Table 50, is in good agreement with the relative yields of these brands of high- and low-'tar' cigarettes estimated by butt analysis (Rawbone, 1984). This suggests that the deposit is a similar fraction of the 'tar' yield from both products. It can also be seen from Table 50 that the deposits from the two products are distributed between the different regions of the respiratory tract in a similar fashion, suggesting similar inhalation patterns. Thus, the relative amounts of 'tar' deposited when an individual smokes different products are directly related to the yields obtained from the product by that individual.

The finding that the yield, and hence deposit, from low-'tar' cigarettes is less than that from higher 'tar' grades would appear to differ from the conclusion, based on data obtained with biochemical markers of uptake, that the same level of marker is found after compensation for a lower yield after changing the 'tar' grade of cigarette smoked (see pp. 171-179). This might be explained by the fact that the observations of yield and deposit are made on a per-cigarette basis and that compensation takes the form of smoking more of the product with the lower yield. However, as has already been stated, individual constituents may not represent 'tar' as a whole, so that maintaining the level of a particular marker, such as nicotine, does not necessarily imply a similar 'tar' deposit.

On the basis of studies in hollow casts of the human lung, deposition within the bronchi can be expected to be highly uneven. Schlesinger and Lippmann (1978) demonstrated that

Table 50. Regional deposition of tar relative to total deposition from a high-'tar' cigarette and after changing to a low-'tar' cigarette (mean \pm SE)^a

Region	Deposition (%)			
	High-tar	Low-tar (week 4)	Low-tar (week 12)	Low-tar (week 24)
Total	100.0 \pm 6.8	74.7 \pm 5.5	74.7 \pm 5.5	67.1 \pm 5.1
Extrathoracic	13.9 \pm 3.4	14.3 \pm 3.4	8.0 \pm 2.1	15.6 \pm 3.4
Thoracic	86.1 \pm 6.8	60.3 \pm 5.5	66.7 \pm 6.3	51.5 \pm 4.2
Tracheobronchial	51.1 \pm 3.4	38.4 \pm 3.4	42.2 \pm 3.8	33.8 \pm 3.0
Pulmonary	35.0 \pm 4.2	21.5 \pm 2.1	24.5 \pm 2.5	18.1 \pm 2.1

^aFrom Pritchard and Black (1984)

the surface density of inert particles at bifurcations was greater than that on the remainder of the downstream surface. There was a close correspondence between the relative efficiency of deposition in the cast and the frequency of reported cancers at these sites, suggesting that the initial deposition pattern may play a significant role in cancer pathogenesis. [The Working Group considered that the applicability of such conclusions to cigarette smoke is debatable, in view of the many complicating factors already discussed; however, it is certain that the majority of 'tar' particles deposit in the region of the lung in which cancers associated with smoking are observed.]

(ii) *Sidestream and exhaled smoke*

In view of the unexpected behaviour of fresh cigarette smoke in the human respiratory tract, there is clearly a need to determine the deposition of smoke during passive smoking, although evidence obtained to date would suggest that the aged smoke encountered in the environment is a much more stable aerosol than fresh smoke, whether originating in mainstream or sidestream smoke (Keith & Derrick, 1960). Hiller *et al.* (1982) estimated the fractional deposition of particles to be 11% by collecting exhaled air in a bag. As discussed in the introduction to this section, this value demonstrates that individual biochemical markers give estimates of deposition that differ from the total particulate (see, for example, estimates of nicotine uptake, pp. 164-166). However, this value is similar to that expected for inert particles of 0.2 μm in diameter, the reported size of those in sidestream smoke (Okada & Matsunuma, 1974). Hence, it is likely that in passive exposure to smoke the majority of particles are deposited in the lung periphery and few in the upper respiratory tract (Lippmann *et al.*, 1980). [If the sidestream and exhaled smoke particles do behave in an inert fashion, then a higher proportion of lung cancers might be expected to be found in the

peripheral regions of the lungs of passively exposed persons than in those of smokers, reflecting the assumption that site of deposition is related to site of tumour. In estimating the relative carcinogenic hazard of passive exposure, based upon measurements of ambient 'tar' concentrations, it should be noted that, as an inert particle, much less 'tar' deposits in the tracheobronchial region of the lung than from the same concentration of mainstream smoke, but that the exposure to such a concentration lasts for a different period.]

(iii) *Exposure to radon daughters*

Radford and Hunt (1964) suggested that α -radiation from ^{210}Po in cigarette smoke may contribute to the increased risk of lung cancer in smokers who inhale. Various aspects of this theory have been studied, and some studies have shown that bronchial tissues of smokers, especially at the bifurcation of the bronchus, have significantly higher concentrations of ^{210}Po deposits than those of nonsmokers (see Cohen, J.I., 1982; Cohen, B.S. & Harley, 1982; Di Franza & Winters, 1982; Hill, C.R., 1982; Martell, 1982; Ravenholt, 1982; Wagner, 1982). Using a new, highly sensitive and accurate detection technique, the nuclear tract-etch film method, Cohen, B.S. *et al.* (1980) examined fresh autopsy specimens of bronchial mucosa from three smokers, two ex-smokers, one nonsmoker and one person with a questionable smoking history and found slightly elevated α -activity in the bronchial trees of the smokers as compared to the others. The authors cautioned that their study had dealt with only a limited number of tissues and was therefore inconclusive and that the effect of α -radiation in tobacco carcinogenesis deserves further study. The site of increased radioactivity is consistent with observations on the distribution of 'tar', described above, pp. 180-182.

(d) *Tobacco smoke-induced alterations in host defence mechanisms*

The mucociliary transport system of the airways removes particulate matter by physical transport and absorbs gas-phase constituents. Tobacco smoke has been shown to alter both cilia and mucus (reviewed by Wanner, 1977). Abnormalities of mucociliary transport have not been linked definitively to increased cancer risk, either of the lung or of other sites; however, the hypothesis has been advanced that impaired clearance increases exposure to carcinogens and, thus, the occurrence of malignancy (Hilding, 1957). With regard to cilia, both structural and functional changes result from tobacco smoking. The airways of smokers show denudation of the ciliated epithelium, squamous metaplasia and increased numbers of goblet cells (reviewed by Wanner, 1977; US Department of Health and Human Services, 1979). Auerbach *et al.* (1979) reported that histological changes in the bronchial epithelium (such as loss of cilia and basal-cell hyperplasia) were more frequent in cigarette smokers who died in the period 1955-1960 than in cigarettes smokers who died in the period 1970-1977. The authors attributed this finding to the availability in the USA from the 1950s of cigarettes with lower 'tar' and nicotine yields. In smokers with chronic bronchitis, mucus production is increased, and the properties of the mucus may be altered (reviewed by Wanner, 1977).

Direct measurements of mucociliary transport in humans and in animals confirm that long-term smoking impairs particle clearance, although the evidence for short exposures is

conflicting (Wanner, 1977; US Department of Health and Human Services, 1979). In humans, mucociliary transport has been evaluated by quantifying the clearance of radioactive aerosols or the movement of markers. These techniques have generally, though not uniformly, shown slower mucociliary transport in smokers. For example, Goodman *et al.* (1978) measured tracheal mucus velocity with radio-opaque discs as markers. Young smokers and ex-smokers tended to have decreased tracheal mucus velocity; smokers and patients with simple or obstructive chronic lung disease had a more marked decrease. Observation of an increased rate of tracheobronchial clearance following cessation of smoking further supports the hypotheses that mucociliary transport is impaired by active smoking (Camner *et al.*, 1973). In studies of the acute effects of smoking, increased, unchanged and decreased rates of mucociliary transport have all been demonstrated in active smokers (reviewed by Wanner, 1977).

The airways of the lungs are lined with an epithelial-cell layer, which affords protection against inhaled substances. Recent investigations involving humans and animal models demonstrate that cigarette smoke reduces the integrity of this barrier and increases its permeability to large tracer molecules. Increased airway permeability after exposure to cigarette smoke has been demonstrated in animals (see above, p. 141) and in humans (Jones, J.G. *et al.*, 1980, 1983). [The Working Group noted that increased airway permeability may facilitate exposure of basal-cell layers to carcinogens and increase their systemic absorption.]

Cigarette smoking also alters the cell populations of the lungs and causes functional changes in alveolar macrophages, one of the cell types that remove particulate matter from the alveoli. When the cells of the lungs are sampled by bronchoalveolar lavage, cigarette smokers are found to have increased numbers of inflammatory cells (Hunninghake *et al.*, 1979).

Structural and functional changes have been observed in alveolar macrophages of cigarette smokers (Hocking & Golde, 1979; US Department of Health and Human Services, 1979). Smokers have larger macrophages with altered surface structure; their cytoplasm contains inclusions, which have been identified as aluminium silicate crystals (Brody & Craighead, 1975). Tobacco smoking also alters the enzyme content and cellular metabolism of alveolar macrophages (Hocking & Golde, 1979). Altered macrophage function may explain the observation of Cohen, D. *et al.* (1979) that smokers have much slower long-term dust clearance from their lungs. These investigators assessed the clearance of iron oxide from the lungs of 12 subjects over a one-year period and found five times more dust retention in smokers than in nonsmokers. [The Working Group noted that retention of dusts in the lungs of smokers might increase the risks of exposure to other environmental carcinogens.]

Tobacco smoke affects immune mechanisms, both within the lungs and systemically. These effects on immune function would be relevant to pathogenesis if immune surveillance or other host-immune responses are impaired. Interpretation of the changes in immune function associated with cigarette smoking, however, must be constrained by limitations of current knowledge concerning the immune system and carcinogenesis (Ada, 1982).

Cigarette smoking is associated with abnormalities of the immune system within the lungs (reviewed by Hunninghake *et al.*, 1979). On bronchoalveolar lavage, the lungs of smokers yield increased numbers of lymphocytes, although the distribution of subpopulations of B and T cells is comparable in smokers and nonsmokers. In this study of 10 young asymptomatic smokers, diminished mitogen responsiveness of lung lymphocytes was demonstrated (Daniele *et al.*, 1977). Other studies of bronchoalveolar-lavage fluid from smokers indicated either normal or raised immunoglobulin content (reviewed by Hunninghake *et al.*, 1979).

More extensive data are available concerning systemic immune function and tobacco smoke. Serum immunoglobulin levels differ between smokers and nonsmokers: IgE and IgD tend to be elevated in smokers whereas IgG levels are reduced (Gerrard *et al.*, 1980; Warren *et al.*, 1982; Bahna *et al.*, 1983). In experimental models, exposure to tobacco smoke alters humoral antibody responses to administered antigens (Holt & Keast, 1977). Some, but not all studies suggest impaired humoral immune responsiveness in cigarette smokers (Holt & Keast, 1977; Knowles *et al.*, 1981).

Impaired cellular immunity has been observed in cigarette smokers. Exposure of lymphocytes *in vitro* to cigarette smoke and to nicotine decreases lymphocyte responsiveness to mitogen stimulation (Neher, 1974). Corresponding abnormalities in cellular immunity have been demonstrated in some studies. One study of smokers aged 20-78 years showed increased numbers of T lymphocytes in peripheral blood (Silverman *et al.*, 1975). A smaller study limited to young smokers showed no difference between smokers and nonsmokers (Daniele *et al.*, 1977). The findings of the same two investigations concerning T-cell responsiveness on stimulation were also conflicting, with elevated responses in cells from smokers in the larger (Silverman *et al.*, 1975) but not in the smaller study (Daniele *et al.*, 1977). Another study of lymphocyte transformation found reduced responsiveness only in male smokers (Petersen *et al.*, 1983). Several recent investigations have characterized T-lymphocyte subsets in smokers and nonsmokers. In heavy smokers, Miller, L.G. *et al.* (1982) found a diminished ratio of helper to suppressor cells, which returned to normal six weeks following cessation of smoking. Ginns *et al.* (1982) also found this lowered ratio and reported alterations of T-lymphocyte subsets in persons with lung cancer. Natural killer-cell activity, which may be important for immune surveillance, is also reported to be reduced in smokers (Ferson *et al.*, 1979).

The effects of tobacco smoke on α_1 I-antiprotease inhibitor are discussed on p. 150.

(e) *Genetic host factors that influence susceptibility to tobacco smoke*

The human population is genetically diverse, both in terms of individual differences in DNA sequence and in the types of proteins that are expressed (Neel, 1984). Related individuals nevertheless share some common genetic attributes, and certain familial features may reflect genetic relatedness, albeit influenced by a common environment. In this context, it is relevant to note that there have been a number of reports of familial clustering of a variety of cancers, including cancers of the lung, although the interpretation of such clustering is not always clear (Tokuhata & Lilienfeld, 1963a,b; Lynch *et al.*, 1980; Goffman *et al.*, 1982).

Cigarette smoke is known to influence various steps of the carcinogenic process, e.g., uptake and distribution, metabolism and DNA binding and repair. Certain of these steps come under some form of genetic control, and different expressions of these controls may influence the sensitivity of the organism to smoke-associated effects.

(i) *Clearance, uptake and distribution of smoke components*

Once deposited, smoke particulates are engulfed by pulmonary macrophages, and both free and ingested particulates in macrophages may be swept up the mucociliary transport system. The two major components of this essential host defence system are the mucus blanket and ciliary action to move the blanket. Some of the properties and constituents of mucus have been characterized (Chantler *et al.*, 1982). Increased viscosity can lead to mucus stasis and luminal plugs. α_1 -Antitrypsin and other antiproteases have been shown to be important constituents of mucus; the amount of this glycoprotein is under both genetic and environmental control (Lieberman, 1974; Gadek *et al.*, 1979).

Ciliary function is influenced by genetic and environmental factors (see preceding section). In the general population, large interindividual differences in lung clearance rates of particulates have been observed (Albert *et al.*, 1969; Camner *et al.*, 1972; Wilkey *et al.*, 1980). Studies of monozygotic and dizygotic twins indicate that genetic factors have a major influence on this important host defence (Camner *et al.*, 1972). In a study of ten monozygotic twin pairs, discordant for smoking, smokers in five pairs had an average clearance rate significantly lower than that of nonsmokers (Camner & Philipson, 1972). In another study of monozygotic twins, nonsmokers had greater rates of upper bronchial clearance than their smoking twins, but clearance characteristics were otherwise similar (Bohning *et al.*, 1975).

Uptake and distribution of smoke components are usually dependent on nongenetic factors, such as aerosol concentration, pulmonary function and chemical properties of the particular constituent. However, certain classes of chemicals present in tobacco smoke are inducers and substrates for a variety of enzyme systems, and genetically determined variations in tissue levels of cytosol and nuclear receptors could be important. For example, in cultured human cells the induction of microsomal monooxygenases (MMOs) by 2,3,7,8-tetrachlorodibenzo-*para*-dioxin (TCDD) and benz[*a*]anthracene depends mainly on the presence or the affinity of particular cytosol-receptor proteins for the inducing compound (Jaiswal *et al.*, 1985). Observations in cultured human cells provide less clear-cut results. For human squamous-cell carcinoma cells, there is a good correlation between the amount of receptor protein and the level of TCDD-induced MMO (Hudson *et al.*, 1983); however, no such correlation was seen with breast carcinoma cells (Jaiswal *et al.*, 1985).

Since the presence or affinity of these receptors in mice is under genetic control (Poland *et al.*, 1976; Okey *et al.*, 1979), uptake and distribution in humans may also be genetically determined.

(ii) *Metabolism*

A number of components of smoke are metabolically activated by various enzyme systems, primarily MMOs (see pp. 150-152). These systems are described here in detail because they come under some form of genetic regulation in humans. The genetic control is likely to

be quite complex since MMOs are a multigene family and substrate-inducible, and the primary oxidation component (i.e., cytochrome P-450) has multiple forms (see Pelkonen & Nebert, 1982; Boobis & Davies, 1984).

(1) *In-vitro studies.* In-vitro studies have shown that humans vary in their capacity to metabolize a variety of exogenous chemicals, including those found in cigarette smoke. Following incubation of *N*'-nitrosonornicotine with human tissue explants (autopsy specimens from trachea, bronchus, lung, oesophagus, pancreatic duct, bladder and buccal mucosa), a ten-fold interindividual variation in α -carbon hydroxylation was reported (Castonguay *et al.*, 1983). Interindividual variations in carcinogen metabolism (i.e., MMO levels) and in DNA binding have been reported for liver (Pelkonen *et al.*, 1974; Sabadie *et al.*, 1980), lung (Harris, C.C. *et al.*, 1976; Cohen, G.M. *et al.*, 1979; Sabadie *et al.*, 1981), colon (Autrup *et al.*, 1978), oesophagus (Harris, C.C. *et al.*, 1979), placenta (Nebert *et al.*, 1969; Gurtoo *et al.*, 1983), fibroblasts and epithelial cells (Yamasaki, H. *et al.*, 1977), monocytes (Okuda *et al.*, 1977) and lymphocytes (Kellerman *et al.*, 1973; Atlas *et al.*, 1976; Paigen *et al.*, 1978; Kouri *et al.*, 1979b; Børresen *et al.*, 1981; Kouri *et al.*, 1981). Twin and family studies have shown that genetic factors are primarily responsible for maintaining these variations (Atlas *et al.*, 1976; Okuda *et al.*, 1977; Paigen *et al.*, 1978; Børresen *et al.*, 1981; Kouri *et al.*, 1983, 1984).

The somewhat contradictory data regarding the relationship between these genetically determined enzyme levels and the occurrence of cigarette smoke-associated cancer have been reviewed (Kouri *et al.*, 1983, 1984). The most recent studies (Kouri *et al.*, 1982, 1984) suggest that: (1) MMO levels among humans are probably regulated by more than one genetic locus; (2) environmental as well as genetic factors maintain the large interindividual differences in MMO levels that are observed; and (3) high induced levels of aryl hydrocarbon hydroxylase (one of the MMOs) are frequently found in patients with cigarette smoke-associated lung cancer, but not in patients with solid tumours or in children with leukaemia. The association between lung cancer and higher induced levels of aryl hydrocarbon hydroxylase in humans is similar to that observed in murine model systems (Pelkonen & Nebert, 1982; Kouri *et al.*, 1983, 1984). [However, although in mice the genetically regulated variations in MMO largely determine the susceptibility to cancers induced by many chemicals, there are not enough data to draw this conclusion with regard to humans.] Various environmental and physiological factors can influence MMO levels in mitogen-activated human lymphocytes, including season of the year (Paigen *et al.*, 1981; Suolinna *et al.*, 1982), age (Suolinna *et al.*, 1982), smoking habits (Jett *et al.*, 1978), relative T-cell levels (Jett *et al.*, 1978) and the menstrual cycle (Kouri *et al.*, 1983). Thus, the higher aryl hydrocarbon hydroxylase levels observed in lymphocytes from lung cancer patients may either be the cause or the consequence of the lung cancer.

[The Working Group considered that confirmation and extension of these results await the development of improved methods for phenotyping humans, including assay of MMO receptors, measurement of the mRNAs for specific cytochrome P-450s, analysis of the chromosomal gene(s) that code for MMOs, and determination of types of P-450, using monoclonal antibodies. The complete DNA and amino acid sequence of the 2,3,7,8-tetrachloro-*para*-dibenzodioxin-induced form of cytochrome P-450 has been reported recently (Jaiswal *et al.*, 1985).]

(2) *In-vivo studies.* Genetic factors have been shown to be the primary control mechanism for the large interindividual variations observed in the oxidative metabolism of various xenobiotics, e.g., antipyrine, amobarbitol, dicumarol, ethanol, halothane, nortriptyline, phenylbutazone, phenytoin, phenacetin, salicylate, debrisoquines, sparteine, tolbutamide, carbocysteine and mephenytoin (see Eichelbaum, 1984; Omenn & Gelboin, 1984). Measurements of polymorphisms of drug metabolism may be particularly useful in epidemiological studies of cancer: for example, it has been shown that 5-9% of the European population is deficient in a specific cytochrome P-450 that metabolizes debrisoquine, an antihypertensive drug; in this group, the metabolism of at least 15 other drugs is also altered (Eichelbaum, 1982; Park, B.K., 1982; Eichelbaum, 1984), although metabolism of antipyrine, acetanilide and several other drugs was not affected (Wakile *et al.*, 1979; Park, B.K., 1982; Eichelbaum, 1982; Eichelbaum *et al.*, 1983). Measurement of drug polymorphism may also be important in studying the metabolism of tobacco smoke constituents.

Polymorphism of debrisoquine metabolism was compared in 245 smoking lung cancer patients and 234 sex- and age-matched smoking controls. It was found that a preponderance of those with lung cancer were extensive metabolizers (78.8%) (who may be homozygous dominant), and few were recessive, poor metabolizers (1.6%) when compared with the smoking controls (27.8%; 9.0%) (Ayesh *et al.*, 1984).

In a separate study, Idle *et al.* (1981) also reported a larger number of extensive metabolizers than expected among a group of 59 Nigerians with cancers of the gastrointestinal tract, liver and other sites. No such excess was found in patients with bladder cancer associated with exposure to dye manufacture (Cartwright *et al.*, 1984).

The enzymes epoxide hydrolase, glutathione *S*-transferase and glutathione hydrolase have been detected in human tissues (see Oesch *et al.*, 1980; Glatt & Oesch, 1984; Spielberg, 1984), but no genetically-determined regulation has been reported. Genetic deficiencies in glutathione synthesis have been observed (Spielberg *et al.*, 1977), which result in increased susceptibility of lymphocytes *in vitro* to toxicity from drugs the metabolites of which are detoxified by glutathione conjugation (Spielberg, 1984); however, no effect of smoking has been reported in people who are deficient for this enzyme.

One enzyme system that has been studied in detail is that of *N*-acetyl transferase. This cytosolic enzyme is involved in the metabolism of a variety of carcinogenic aromatic amines (Lower & Bryan, 1973; Miller, J.A. & Miller, 1977; Lower *et al.*, 1979), is polymorphic in humans, with populations of 'slow' and 'rapid' phenotypes (Evans, D.A.P. & White, 1964; Carr *et al.*, 1978), and is noninducible (Cartwright *et al.*, 1984). Studies in animals suggest that hepatic *N*-acetyl transferase can act in a rate-limiting detoxifying step for aryl amines that cause bladder cancer (Lower *et al.*, 1979; Glowinski & Weber, 1982). Studies in humans show that the percentage of individuals who are slow acetylators types ranges from 50-70% in European and North American whites, while in Japanese populations this recessive trait occurs in only about 10% of individuals (Harris, H.W. *et al.*, 1958; Lower *et al.*, 1979). The phenotype of slow acetylation has been shown to be useful in determining the relative risk of some drug-related toxic and therapeutic responses (Drayer & Reidenberg, 1977). Recent studies have suggested a relationship between slow acetylation phenotype and urinary

bladder cancer (Lower *et al.*, 1979; Cartwright *et al.*, 1982; Lower, 1982, 1983). This association is based on assumptions that a significant proportion of bladder cancers results from occupational exposure to arylamines (i.e., dye workers) or from life-style (i.e., cigarette smoking), and that the carcinogenic metabolites of arylamines are probably nonacetylated derivatives. Among bladder cancer patients in Copenhagen, Denmark, there was a 13% excess ($p=0.065$) of individuals of the slow acetylation phenotype; while bladder cancer patients from rural areas (presumably exposed to lower levels of arylamines) showed no difference in acetylator distribution (Lower *et al.*, 1979; Lower, 1982). Cartwright *et al.* (1982) reported an insignificant excess (10%) of individuals of the slow acetylation phenotype among bladder cancer patients from Huddersfield, UK. Two observations were of interest: (1) this population contained a subset of 23 individuals with documented occupational exposure to benzidine, among whom there was an excess of nearly 40% ($p=0.0005$) of slow acetylators; (2) among bladder cancer patients in general, there was an excess of slow phenotypes in those with T3- or T4-stage disease or carcinoma *in situ*. The authors concluded that either arylamines produce tumours with invasive potential more frequently if linked with slow acetylation, or slow acetylators are more susceptible to tumour production when exposed to arylamines. This study also reported no relationship between the occurrence of bladder cancer among individuals with a history of smoking and the slow acetylation phenotype. The authors concluded that either arylamines are not the component of tobacco smoke involved in human bladder cancer, or that there is a dose-related response such that the effects of *N*-acetyl transferase detoxification are not detectable with low-dose, chronic exposure.

(f) *Biological measures of exposure and effects of tobacco smoke*

(i) *Chromosomal aberrations in peripheral blood lymphocytes*

Of the analyses carried out on the prevalence of chromosomal aberrations in peripheral blood lymphocytes of cigarette smokers and nonsmokers, all but two have reported significantly increased levels in smokers. [In the two exceptions (Nordenson *et al.*, 1978; Hedner *et al.*, 1983), an inappropriate culture time of 72 h was used, which would tend to minimize any possible differences due to cellular proliferation *in vitro*.]

Obe and Herha (1978) reported a six-fold increase in the frequency of exchange-type chromosomal aberrations in the lymphocytes of 20 heavy smokers (40-60 cigarettes/day for periods of 9-58 years), as compared to 71 nonsmokers. Vijayalaxmi and Evans (1982) carried out an extensive analysis of 10 000 metaphase cells from 55 mostly 'light' (~10 cigarettes/day) cigarette smokers and 43 nonsmokers and observed a highly significant, four-fold increase in the incidence of exchange aberrations in the smokers. Similar increases have been recorded by Fredga *et al.* (1982) and Mäki-Paakkanen *et al.* (1984). It was reported in an abstract (Hüttner & Schöneich, 1981) that a four-fold increase in total aberration frequency occurred in smokers (1.87%) as compared with nonsmokers (0.45%), with some evidence [data not given] that the aberration frequency correlated with the numbers of cigarettes smoked per day.

An extensive study was carried out by Obe *et al.* (1982, 1984) on peripheral blood lymphocytes from 170 cigarette smokers and 124 nonsmokers cultured in different media; a significant excess of exchange aberrations (1.42 *versus* 0.69 per cell) was observed in smokers' cells cultured in Ham's F-10 culture medium, but no significant difference was reported in samples from smaller numbers of probands cultured in other culture media. No significant relationship was found between aberration frequency and the numbers of cigarettes smoked per day. When account was taken of the type of cigarette smoked, however, a relationship was seen between the amount smoked and aberration frequency. The difference in aberration frequencies between cigarette smokers and nonsmokers was somewhat less than the six-fold difference noted by Obe and Herha earlier (1978); however, it should be noted that 12 of 20 smokers in the first study had a vascular disease, and no detailed analysis of confounding factors was undertaken.

(ii) *Sister chromatid exchanges in peripheral blood lymphocytes and bone-marrow cells*

Studies on the prevalence of sister chromatid exchanges (SCEs) in peripheral blood lymphocytes of smokers and nonsmokers have yielded some conflicting results: a majority of reports show a significant excess in smokers, and a minority indicate no significant difference between the groups. Moreover, in a number of studies, an increasing prevalence of SCEs with increasing numbers of cigarettes, or with increasing tar content of the tobacco smoked, has also been reported.

Data from individual studies that showed no significant difference in the prevalence of SCEs in peripheral blood lymphocytes between smokers and nonsmokers are summarized in Table 51. It should be noted, however, that in all but three of these reports, the SCE incidence in cigarette smokers was higher than that in nonsmokers; moreover, data from Fredga *et al.* (1982) demonstrate a 35% increase in the frequency of SCEs in smokers as compared with nonsmokers. In these studies, the number of cigarettes smoked ranged from 'a few' to more than ten per day. No difference in SCE frequencies in cord blood samples of neonates was observed between smoking and nonsmoking mothers (Seshadri *et al.*, 1982; Lundberg & Livingston, 1983).

Data from studies that showed a significant increase in the frequency of SCEs in blood cells of smokers are shown in Table 52. The frequencies in smokers were 10-88% higher than those in nonsmokers, an approximately 30% increase being most common. A certain dose-dependence of SCE yields has been reported with amount smoked (e.g., Lambert *et al.*, 1978; Murthy, 1979; Hopkin & Evans, 1980), and some reports indicate a dose-response relationship (e.g. Husum *et al.*, 1982; Wulf *et al.*, 1984) and a dependence of SCE frequency on the number of years of smoking (Murthy, 1979). Carrano (1982) reported increased frequencies of SCEs in smokers over those in nonsmokers of approximately 12% with use of 20 cigarettes/day, 20% with 40 cigarettes/day and 35% with 60 cigarettes/day; this dose-response is similar to that reported by Husum *et al.* (1982). An effect on SCE frequency related to years of exposure, measured as cumulative pack-years, was observed among smokers (Livingston & Fineman, 1983). Wulf *et al.* (1983) also reported increases in SCE frequency in cigar and pipe smokers.

Table 51. Studies of sister chromatid exchange (SCE) frequencies in peripheral lymphocytes of cigarette smokers and nonsmokers, in which no significant difference was observed between groups

SCEs per cell ^a		Reference
Smokers	Nonsmokers	
11.7 (69)	11.9 (6)	Hollander <i>et al.</i> (1978)
10.6 (35)	10.0 (85)	Crossen & Morgan (1980)
8.1 (10) ^b	8.1 (10) ^b	Ardito <i>et al.</i> (1980)
5.7 (10) ^c	5.9 (10) ^c	Ardito <i>et al.</i> (1980)
10.5 (6)	7.8 (6)	Fredga <i>et al.</i> (1982)
8.6 (6)	7.3 (6)	Fredga <i>et al.</i> (1982)
11.9 (23) ^b	11.4 (30) ^b	Seshadri <i>et al.</i> (1982)
9.0 (25) ^c	9.0 (30) ^c	Seshadri <i>et al.</i> (1982)
9.8 (21)	9.6 (27)	Högstedt <i>et al.</i> (1983)
7.2 (9) ^c	7.0 (6) ^c	Lundberg & Livingston (1983)

^aNumbers in parentheses are numbers of probands studied

^bSmoking and nonsmoking mothers

^cCord blood from neonates of smoking and nonsmoking mothers

The overall evidence strongly indicates that SCE frequencies are increased in cigarette smokers (but rarely by more than 50%) over those in nonsmokers and that the increase is largest in those who smoke most. However, there is much variation between individuals (Wulf *et al.*, 1984), which, together with the slight effects observed in light smokers, probably account for the absence of significant differences between smokers and nonsmokers in some studies.

Small differences in mean SCE frequency between individuals could reflect variations in background frequency, such as occur in different subsets of peripheral blood lymphocytes (Santesson *et al.*, 1979; Lambert *et al.*, 1982). The variation in distribution and mean frequencies of SCE within groups of nonsmoking individuals raises the question of whether the increase in SCE frequencies in smokers is a true reflection of smoke-induced DNA damage and/or a reflection of smoke-induced changes in the population structure of lymphocytes. In smokers, the presence of cells with exceptionally high numbers of SCE 'outliers' (Carrano, 1982) implies that smoking increases the real incidence of SCE and does not simply change the cell population structure. This conclusion is supported by the recent demonstration of significantly elevated SCE frequencies in bone-marrow cells of mice exposed *in vivo* to cigarette smoke (Benedict *et al.*, 1984; Putman *et al.*, 1985).

Table 52. Studies of sister chromatid exchange (SCE) frequency in peripheral lymphocytes of smokers and nonsmokers, in which significant differences were observed between groups

SCEs per cell ^a		Reference
Smokers	Nonsmokers	
15.2 (9) ^b	13.2 (37)	Lambert <i>et al.</i> (1978)
17.2 (15) ^c		
7.7 (20)	6.4 (12)	Murthy (1979)
6.4 (14) ^b		
10.1 (6) ^c		
8.4 (10)	7.4 (10)	Hopkin & Evans (1980)
7.8 (6) ^d		
9.3 (4) ^e		
9.6 (43)	8.1 (40)	Husgafvel-Pursiainen <i>et al.</i> 1980)
10.5 (45)	9.3 (86)	Husum <i>et al.</i> (1981)
15.2 (23)	12.5 (32)	Hüttner & Schöneich (1981)
10.9 (6)	7.6 (6)	Fredga <i>et al.</i> (1982)
9.9 (6)	7.4 (6)	
9.2 (89)	8.3 (60)	Husum <i>et al.</i> (1982)
8.6 (21) ^b		
9.1 (38) ^f		
9.7 (30) ^e		
16.3 (91)	13.5 (128)	Lambert <i>et al.</i> (1982)
8.3 (6)	4.4 (6)	Meiying <i>et al.</i> (1982)
9.0 (23) ^g	8.3 (60)	Wulf <i>et al.</i> (1983)
9.2 (42) ^h		
9.5 (64) ⁱ		
10.5 (30) ^j		
9.6 (30) ^k		
11.6 (3) ^e	7.6 (3)	Vijayalaxmi & Evans (1982)
10.8 (24)	8.5 (24)	Livingston & Fineman (1983)
11.4 (8)	9.0 (6)	Lundberg & Livingston (1983)
5.8 (24)	4.8 (20)	Obe <i>et al.</i> (1984)
8.8 (24) ^b	8.1 (58)	Wulf <i>et al.</i> (1984)
9.2 (44) ^f		
9.7 (39) ^e		
8.6 (26) ^l	7.8 (10) ^l	Husgafvel-Pursiainen <i>et al.</i> (1984)

^aNumbers in parentheses are numbers of probands studied

^b<10 cigarettes/day

^c>10 cigarettes/day

^d<20 cigarettes/day

^e>20 cigarettes/day

^f11-20 cigarettes/day

^gFiltered low-'tar' cigarettes (9-14 mg condensate)

^hUnfiltered high-'tar' cigarettes (21-30 mg condensate)

ⁱFiltered high-'tar' cigarettes (20-26 mg condensate)

^jCheroots

^kPipe

^lMeans of four consecutive blood samples per individual

(iii) *Micronuclei in peripheral blood lymphocytes and bone-marrow cells*

In a study of 28 individuals occupationally exposed to ethylene oxide and of 20 controls, Högstedt *et al.* (1983) reported a small increase in the frequency of chromosomal aberrations, but not of micronuclei, in peripheral blood lymphocytes of exposed individuals. However, in the total population there was a small but significantly increased frequency of micronuclei in lymphocytes of cigarette smokers as opposed to nonsmokers. A similar increase in the frequency of micronuclei was observed in erythroblasts of smokers as compared with nonsmokers, as well as in ethylene oxide-exposed as compared with nonexposed workers. [No detail of cigarette smoking habits was given, and no quantitative assessment of a relationship between micronucleus frequency and cigarette smoking is possible.] In a later study (Högstedt, 1984), on 38 individuals exposed to styrene and 20 controls, a small, but significant increase in micronuclear frequency was observed in the peripheral blood lymphocytes of cigarette smokers *versus* nonsmokers. Similar levels of difference were also attributable to low exposure to styrene, and, together with an age effect, these three factors accounted for less than 25% of the variation in micronuclear incidence in the population studied. In contrast with these findings, Obe *et al.* (1982, 1984) reported no significant increase in the frequencies of micronuclei in three-day cultures from 95 cigarette smokers compared with 39 nonsmokers, but a significant increase in the frequency of chromosomal aberrations and SCE in peripheral blood lymphocytes of smokers.

An elevated frequency of micronucleated buccal mucosal cells was observed in subjects who were cigarette smokers (>1 pack/day) and alcohol drinkers; neither smoking alone (≥ 60 cigarettes/day) nor alcohol drinking alone led to a detectable increase in micronucleated buccal mucosa cells (Stich & Rosin, 1983).

(iv) *Sperm morphology*

The possibility that an increased frequency of abnormally shaped sperm might reflect exposure to a mutagen (Wyrobeck, 1982) has led to a number of studies on sperm morphology, and various other facets of spermatogenesis, in cigarette smokers as compared with nonsmokers (Evans, H.J., 1982; Vogt *et al.*, 1984).

Viczián (1969) reported that in a population of 120 cigarette smokers who had smoked varying amounts for more than one year prior to the study, and 50 nonsmokers, the frequency of abnormally shaped spermatozoa was significantly higher in smokers (28%) than in nonsmokers (19%), with some evidence of a dose-response relationship; the highest levels of abnormality were found in the heaviest (>30 per day) smokers. In a more recent blind study of 43 smokers and 43 controls, matched for age and sperm count, which excluded individuals exposed to agents or with conditions that influence sperm morphology, Evans, H.J. *et al.* (1981) and Evans, H.J. (1982) reported a highly significant increase in the prevalence of abnormal forms in smokers. There was no clear relationship between numbers of cigarettes smoked and the percentage of morphologically abnormal sperm. A similar study, extending over eight years, by Godfrey (1981) on 75 smokers and 74 nonsmokers showed no significant increase in the number of abnormal sperm in smokers. An absence of comparable prevalence of abnormally shaped sperm between smokers and nonsmokers has also been reported by Nebe and Schirren (1980), Rodriguez-Rigau *et al.* (1982) and, most recently, by Vogt *et al.* (1984). Vogt *et al.* (1984) studied sperm parameters

in 98 smokers and 82 nonsmokers who were carefully selected so as not to include individuals in whom other known factors might have influenced sperm morphology and concluded that for this end-point there was no difference between the groups.

(v) *Constitutional genetic defects in offspring*

Although several reports have suggested a teratogenic effect from smoking (Choi & Klavonski, 1970; Andrews & McGarry, 1972; Himmelberger *et al.*, 1978; Evans, D.R. *et al.*, 1979), the evidence that smoking induces germ cell mutations is less substantial.

Kelsey *et al.* (1978) reported data on women who smoked 20 or more cigarettes per day that were consistent with a small increased risk for the presence of congenital malformations and constitutional chromosomal abnormalities in their offspring as compared with those of nonsmokers. In contrast, in a larger study of 67 609 pregnancies by Evans, D.R. *et al.* (1979), there was no indication of an increased number of abnormalities that would have been a reflection of single gene or chromosomal mutations.

Studies on perinatal mortality in a series of 5200 pregnancies revealed a significant increase in perinatal mortality when the father smoked more than 10 cigarettes/day. The frequency of perinatal mortality was independent of maternal smoking habits (Mau & Netter, 1974). An earlier study (Comstock & Lundin, 1967) reported higher perinatal mortality rate among children of nonsmoking mothers whose husbands were smokers than among children of nonsmoking parents. In an abstract, Shiota *et al.* (1976) reported a study consisting of nearly 30 000 induced abortions, in which 421 intact empty sacs (indicating early death of postimplantation embryos) were found. The prevalence of smoking was higher among cases (18.6%) than among controls (13.3%).

4. Summary

Carcinogenicity studies in animals

Considerable effort has been devoted to developing experimental animal systems to study the carcinogenicity of cigarette smoke. Useful models have been developed for testing both whole smoke, by inhalation, and smoke condensate, by topical application.

Studies involving inhalation of smoke are hampered by difficulties in reproducing the exposure of humans. Technical problems occur in the generation of smoke and its delivery to animals; moreover, the respiratory systems of animals and humans differ. Rodents are obligatory nose breathers, and the structure of their nasal turbinates is more complex than that of humans. Unlike humans, experimental animals smoke involuntarily, with shallow, hesitant breathing patterns. Other difficulties are caused by the toxicity of nicotine and carbon monoxide. Despite these problems, however, informative data have been obtained concerning the carcinogenicity of whole smoke and its gaseous phase.

In some experiments in mice, exposure to whole cigarette smoke resulted in the induction of lung tumours. In one study involving long-term exposure of rats to cigarette smoke, tumours of the respiratory tract were induced. In hamsters, various experiments demonstrated reproducibly the induction of laryngeal carcinomas. Studies in rabbits and

dogs of whole cigarette smoke were inadequate for evaluation. No treatment-related tumour other than in the respiratory tract has yet been produced by smoke inhalation in experimental animals.

Experiments on the carcinogenicity of the gaseous phase of cigarette smoke in hamsters and rats resulted in negative or inadequate findings; an increased incidence of lung tumours was observed in one study in mice.

Exposure of hamsters pretreated with 7,12-dimethylbenz[*a*]anthracene to whole smoke resulted in a significant increase in the incidence of tumours of the respiratory system. Such effects were less pronounced when hamsters or rats were pretreated with [benzo[*a*]pyrene. A cocarcinogenic effect between radon daughters and cigarette smoke was observed in the induction of lung tumours in rats.

In some experiments, animals exposed to cigarette smoke survived longer than controls; in other experiments, rats exposed to smoke had lower incidences of some tumours (e.g., mammary tumours) than did controls. These effects may have been a consequence of the reduced weight gain often seen in smoke-exposed animals.

An extensive number of studies on the carcinogenicity of cigarette-smoke condensate (CSC) on mouse skin have demonstrated consistently the induction of benign and malignant skin tumours. The carcinogenic effect would appear to result from the interaction of various CSC constituents, since CSC and its constituents have been shown to possess tumour-initiating, tumour-promoting and other cocarcinogenic activities. Cigar- and pipe-smoke tars are also carcinogenic to mouse skin. The mouse-skin assay may not, however, detect all of the carcinogenic activity of whole cigarette smoke, since CSC lacks most of the volatile and many of the semivolatile constituents of whole smoke. Skin tumours have also been observed in rabbits following application of CSC.

Direct injection of CSC in a lipid vehicle into the lungs of rats caused squamous-cell carcinomas of the lung. Topical application of CSC to the oral mucosa of mice resulted in the induction of lung tumours and, perhaps, lymphomas.

Cigarette smoke contains many chemicals known to be carcinogenic to experimental animals and/or humans, and these data are summarized.

Other relevant biological data from experimental studies

In chronically exposed animals, the rate of body-weight gain is generally slower than that in unexposed animals. Other cellular and chemical responses include: increased carboxyhaemoglobin levels in blood, increases in the levels of certain tissue-derived enzymes in pulmonary lavage fluid, and decreases in pulmonary function. Histopathological changes observed following short-term daily exposure to smoke include: increased numbers and types of pulmonary alveolar macrophages and polymorphonuclear cells and increased epithelial hyperplasia; fibrotic changes were observed in dogs.

Alterations to the structure and function of the reproductive system have been observed in both male and female animals.

T-cell and macrophage functions are impaired, and pulmonary macrophage numbers are increased. B-cell function is affected to a lesser extent.

Many of the functional and pathological changes described are reversible following cessation of exposure to smoke.

Exposure of animals to tobacco smoke causes increases in pulmonary tissue, glyco-protein synthesis, DNA synthesis, mitotic activity and levels of cyclic guanosine 5'-monophosphate and microsomal monooxygenases. The changes in levels of microsomal monooxygenases and their associated enzymes have been studied in detail; the results show that: (1) induction occurs in lungs of all rodents tested, except for guinea-pigs; (2) the inducing components are found in the particulate phase of tobacco smoke; (3) the changes are dependent on RNA and protein synthesis; (4) the induced enzymes alter the metabolism of many chemical carcinogens; and (5), as a result, levels of DNA-bound metabolites are changed.

The metabolism of prostaglandin E₂ and of arachidonic acid is decreased.

Other changes are due either directly to smoke or to the increased numbers and types of pulmonary alveolar macrophages and polymorphonuclear cells that result from exposure to smoke. These changes include altered glutathione metabolism, inactivation of α_1 -anti-proteases and increased levels of lysosomal hydrolases.

Tobacco smoke and extracts of particulate matter collected on filters in rooms containing cigarette smoke were mutagenic to *Salmonella typhimurium* in the presence of an exogenous metabolic system.

All tobacco smoke condensates tested were found to be mutagenic to *S. typhimurium*, and, with the exception of condensates obtained from nitrate-treated cigarettes, the activity was seen only in the presence of an exogenous metabolic system. Most of the mutagenic activity was present in basic fractions, with less in acidic fractions and almost none in neutral fractions. The mutagenic activity per unit weight of CSC from high-, medium- and low-'tar' cigarettes was equivalent, and various filters reduced mutagenicity only marginally. The specific mutagenic activity per unit weight of CSC diminished in the order cigar > cigarette > pipe. The fractions of CSC that are most mutagenic in bacteria are not the most effective in inducing skin tumours in rodents, due to the differential sensitivity and specificity of the two assay systems in detecting different classes of chemicals in CSCs.

Tobacco smoke has also been shown to inhibit DNA repair in mice, to induce mitotic recombination, gene conversion and mutation in yeast and sex-linked recessive lethal mutations in *Drosophila melanogaster*, and to increase the frequency of sister chromatid exchange in human lymphocytes *in vitro* and in rodent bone-marrow cells exposed *in vivo*.

The urine of rats and baboons exposed to cigarette smoke showed mutagenic activity in *S. typhimurium*.

CSCs induced mutation and gene conversion in fungi, sex-linked recessive lethal mutations in *D. melanogaster*, chromosomal aberrations in plants, mutations in cultured mammalian cells, sister chromatid exchanges in mammalian cells exposed *in vitro* and neoplastic transformation in mammalian cells in culture.

Observations in humans

Exposure to tobacco smoke can be determined by measuring biochemical or biological markers of tobacco smoke constituents or by measuring intake indirectly, e.g., from butts or puffing patterns.

A general dose-response relationship is observed between the number of cigarettes smoked and the levels of tobacco-specific intake markers, such as nicotine, its metabolite cotinine and carboxyhaemoglobin. Pipe and cigar smokers usually have lower carboxyhaemoglobin values than cigarette smokers, because they inhale less.

Several reports have demonstrated increased urinary mutagenicity in smokers.

Studies have shown that smoke from cigarettes with low 'tar' yields is inhaled to a relatively greater extent than smoke from cigarettes with high 'tar' yields (so-called 'compensatory smoking'); but, in general, the compensation is not complete.

The only currently available biochemical markers that can satisfactorily distinguish passively exposed nonsmokers from nonexposed ones are urinary and salivary nicotine measurements and cotinine measurements in urine, saliva and plasma. Average values of these tobacco-specific markers in passively exposed, urban nonsmokers are usually about 0.1-1% of those observed among cigarette smokers. Thiocyanate concentrations in body fluids and levels of carboxyhaemoglobin and carbon monoxide in end-expired air are not considered sufficiently specific measures to detect passive exposure to tobacco smoke.

Approximately 80% of the 'tar' inhaled from mainstream cigarette smoke is deposited in the respiratory tract — the majority in the tracheobronchial region. There is wide inter-subject variation in the amount of 'tar' deposited, depending on the pattern of smoke inhalation and exhalation. However, the pattern of inhalation is relatively constant in any one individual, so that the 'tar' retained from the smoking of different products is directly related to the yield obtained by that individual. The relative distribution of 'tar' in the lung is similar with the smoking of high- and low-'tar' cigarettes. Deposition of 'tar' from aged sidestream and exhaled smoke appears to be similar to that of inert particles of that size, suggesting that the bulk of 'tar' is deposited in the lung periphery.

Tobacco smoke impairs lung defence mechanisms and affects some systemic aspects of the immune system. The consequences of these changes on tobacco smoke pathogenesis are currently unknown.

Studies of genetic host factors that influence susceptibility to the biological effects of tobacco smoke have concentrated almost exclusively on the metabolism of foreign compounds. These show that: (1) metabolism of many foreign compounds is under specific genetic control; (2) patients with lung cancer who smoke are more frequently extensive metabolizers of the drug debrisoquine (measured *in vivo*) than are nonsmoking controls; and (3) high levels of aryl hydrocarbon hydroxylase (one of the microsomal monofunctional oxidases) are found more frequently in lung cancer patients who smoke than in smoking controls. There is no apparent connection between levels of *N*-acetyl transferase and the occurrence of bladder cancer in cigarette smokers.

It is uncertain whether genetically determined differences in the metabolism of some foreign substances underlie increased risks of lung and bladder cancer in cigarette smokers; the differences may be secondary to malignancy rather than predisposing to its development.

Tobacco smoking results in genetic damage to somatic cells: cigarette smokers have significantly raised levels of chromosomal damage (structural aberrations and micronuclei) in somatic cells. There is some evidence that the prevalence of chromosomal aberrations in blood cells of smokers is a function of the number and 'tar' yield of cigarettes smoked. More positive evidence for a dose-response relationship is provided by studies on the prevalence of sister chromatid exchanges in somatic cells of smokers.

Studies on germ cells and on the products of conception of smokers provide equivocal results as to whether or not cigarette smoking results in heritable mutations that are transmitted to progeny. The evidence concerning an increased prevalence of morphologically abnormal sperm in smokers is conflicting. More data are required before any firm conclusion can be drawn.

EPIDEMIOLOGICAL STUDIES OF CANCER IN HUMANS

1. Introduction

Knowledge on the relationship between tobacco usage and a variety of human cancers depends primarily on epidemiological evidence. An immense amount of such evidence has been obtained, and, of necessity, only a small proportion can be referred to here. Cancers that are clearly related to smoking, described later in this monograph (i.e., cancers of the lung, upper respiratory and digestive tracts, lower urinary tract and pancreas) occur at lower rates of incidence (and mortality) in religious groups that proscribe smoking (particularly Seventh Day Adventists and Mormons) than in the corresponding national populations. Although many aspects of lifestyle differ in such populations, it seems probable that differences in smoking contribute substantially to the differences seen in smoking-related disease rates (Lyon *et al.*, 1978, 1980; Phillips *et al.*, 1980).

Case-control (retrospective) and cohort (prospective) studies first published in the early 1950s — though using different methodologies — are in qualitative, and approximately quantitative, agreement as to the risk among tobacco users for several types of cancer, among which lung cancer predominates.

The most readily comprehensible evidence, although often not the first nor the most detailed (which has commonly come from case-control studies), has been obtained in several large cohort studies, and they are, in consequence, referred to repeatedly in the sections that follow. Many of the case-control studies are described later in different sections of the monograph. To save unnecessary repetition, the large cohort studies are described and commented upon here:

Cohort studies on smoking and cancer

The first cohort studies to compare the risk of cancer among smokers and nonsmokers were begun in 1951. In most instances, smoking habits were ascertained through self-administered questionnaires. The cohorts studied were subsequently followed up to discover cancer deaths, or in some studies, incident cases of cancer. The design of those studies is summarized below and in Table 53.

American Cancer Society Nine-State Study (Hammond & Horn, 1958a,b)

Over 22 000 volunteers to the American Cancer Society were trained to have questionnaires filled out by 10 white men 50-69 years old whom he or she knew well. During 1952, a total of 204 547 smoking histories were collected in nine states. Several thousands were excluded for a variety of reasons. Follow-up of 187 783 men was conducted from 1952

Table 53. Main characteristics of major cohort studies on the relationship between smoking and cancer

Study	Year of enrollment	Sample size: initial samples; in brackets, population for follow-up	Source of information on smoking (proportion of respondents)	Duration of follow-up and no. of deaths	Completeness of follow-up for mortality
American Cancer Society Nine-State Study	1952	204 547 men [187 783]	Self-administered questionnaire	44 months 11 870 deaths	98.9%
Canadian Study	1955-1956	207 397 subjects (aged 30+) [92 000]	Self-administered questionnaire (57% respondents)	6 years 9491 deaths in men; 1794 deaths in women	NA ^a
British Doctors Study	1951	34 440 men (aged 20+)	Self-administered questionnaire (69% respondents)	20 years 10 072 deaths	99.7%
		6194 women (aged 20+)	Self-administered questionnaire (60% respondents)	22 years 1094 deaths	99%
American Cancer Society 25-State Study	1959-1960	1 078 894 subjects First follow-up: 440 558 men, 562 671 women (aged 35-84); second follow-up: 358 422 men, 483 519 women	Self-administered questionnaire	4.5 + 5 years 26 448 deaths in men; 16 773 deaths in women	97.4% in women 97.9% in men in first follow-up
US Veterans Study	1954	293 958 men (aged 31-84) [248 046]	Self-administered questionnaire (85% respondents)	16 years 107 563 deaths	'Almost 100%' ascertainment of vital status; 97.6% of death certificates retrieved
Californian Study	1954-1957	68 153 men (aged 35-64)	Self-administered questionnaire	5-8 years 4706 deaths	NA
Swedish Study	1963	27 342 men, 27 732 women (aged 18-69)	Self-administered questionnaire (89% respondents)	10 years 5655 deaths (2968 autopsies)	NA
Japanese Study	1965	122 261 men, 142 857 women (aged 40+)	Interview (95% of population in area)	16 years 51 422 deaths	Total

^aNA, not available

through 1955 (average duration, 44 months), with losses of 1.1% and with 11 870 deaths (6.2%). Death certificates were collected for all deceased people, and, whenever cancer was mentioned, further information was collected from the physician, hospital or tumour registry. The distribution of smoking habits in the study population was in close agreement with that in a large survey on smoking habits in a sample of the US population (Haenszel *et al.*, 1956).

Canadian Study (Best *et al.*, 1961; Lossing *et al.*, 1966)

After a pilot study to validate questionnaires, in 1955-1956, 207 397 war veterans listed by the Canadian Pension Commission were mailed a questionnaire on smoking habits, principal occupations and residence history. Approximately 118 000 forms (57%) were returned; however, after removal of duplicates and unusable forms, only 92 000 (44%) remained. Follow-up was conducted from 1956 to 1962 through quarterly lists of deaths made available by the Department of Veterans Affairs. There were 9491 deaths among the male respondents and 1794 deaths among women; in most cases the cause of death was confirmed by autopsy.

British Doctors Study (Doll & Hill, 1964a,b; Doll & Peto, 1976; Doll *et al.*, 1980)

In 1951, a questionnaire on smoking habits was sent to all British doctors included in the Medical Register; 34 440 men and 6194 women responded (69% and 60%, respectively, of those who were alive). Further questionnaires about changes in smoking habits were sent in 1957, 1966 and 1972, with, on each occasion, about 97% of the survivors responding. Reports were published on cause-specific mortality from 1 November 1951 to 31 October 1971 (men) and to 31 October 1973 (women); 99.7% and 99% of the subjects were traced. Information on deaths was obtained principally from the Registrars General of the UK and from records of the General Medical Council and of the British Medical Association. There were 10 072 deaths among men and 1094 among women. Because the subjects in this study were themselves physicians, (i) they were a reasonably uniform socioeconomic group, and (ii) the causes of many of the deaths that occurred among them were certified more accurately than might have been the case among a sample of the general population. Whenever lung cancer was mentioned on the death certificate, details were reviewed centrally (by a chest physician who was unaware of the smoking history).

American Cancer Society 25-State Study (Hammond, 1966; Hammond & Seidman, 1980)

More than one million subjects were enrolled between October 1959 and February 1960 in 25 states. Enrollment was done through volunteers to the American Cancer Society and was by family; all family members over 30 years of age were requested to fill out detailed questionnaires. Each subject was traced annually and every two years had to fill in a brief questionnaire. Of the subjects originally enrolled, 1% could not be identified in the follow-up ascertainment, and for 2% the questionnaires were unusable. For the remaining 1 045 087 subjects, vital status was monitored by the volunteers up to September 1963, and was 97% complete. Death certificates were obtained from state or local authorities, and, when cancer was mentioned, further information was sought from physicians. For 483 519 white women

and 358 422 white men alive at the end of 1966, follow-up for mortality was extended to 31 December 1971. The proportion of these people who had been traced at the end of 1971 was about 99%. This is the largest of the cohort studies, and hence the one least subject to purely random error, even for quite rare causes of death. In particular, it gives the most reliable information that is currently available on lung cancer incidence rates among lifelong nonsmokers.

US Veterans Study (Kahn, 1966; Rogot & Murray, 1980)

Beginning in January 1954, 293 958 policy holders of US Government Life Insurance who had served in the armed forces at any time between 1917 and 1940 were sent a questionnaire on smoking habits; 198 834 (68%) responded, and 49 361 additional replies were obtained by a subsequent mailing in 1957 (total response rate, 85%). Policy holders were mainly white men of the middle and upper social classes. Follow-up of subjects occurred from 1954 through 1969. There were 107 563 deaths. Whenever a claim was filed for payment of a policy, a copy of the death certificate was sent routinely by the Veterans' Administration to the National Institutes of Health study office. 'Terminated' policies were also checked annually to ascertain if termination was due to death or to other reasons. Additional information was requested from a certifying physician or hospital for deceased people. The 16-year follow-up of cause and year of death was considered to be almost complete by Rogot and Murray (1980), with 97.6% of the death certificates having been obtained.

Californian Study (Weir & Dunn, 1970)

Self-administered questionnaires were collected in 1954-1957 from 68 153 labour union members (men aged 35-64) in California, USA; information on occupational exposures and smoking history was obtained. Follow-up for mortality was conducted up to December 1962 (average follow-up time, 7.1 years) through California death records; 4706 deaths occurred in the cohort. [The Working Group noted that the data available on smoking habits were less extensive than those in other studies.]

Swedish Study (Cederlöf *et al.*, 1975)

A sample drawn from the 1960 census of the Swedish population was stratified by sex, year of birth and urban-rural residence. A questionnaire was mailed in 1963, and, of 55 074 eligible subjects, 89% responded and some information was collected for another 5.3%. A 20% sub-sample were mailed a second questionnaire in 1969, with the aims of validating the accuracy of the replies and collecting information about changes in smoking patterns. Mortality in the cohort was ascertained through death certificates; an evaluation was made of the accuracy of registration and, for cancers at most sites, was found to be satisfactory. Between 1963 and 1972, 5655 deaths occurred in the cohort, and 2968 autopsies were performed; in addition, cancer incidence was ascertained from 1963 to 1970 through the Swedish Cancer Registry. Information is not available on the completeness of follow-up. This study is unusual in involving a population sample (stratified by place of residence), although the proportion of people with a *prolonged* history of smoking was low in Sweden in 1963, which will have affected some of the estimates of risk.

Japanese Study (Hirayama, 1967, 1975a,b, 1977a, 1978, 1982, 1985)

In 1965, 122 261 men and 142 857 women, aged 40 years and over (95% of the census population), were interviewed in 29 health centre districts in Japan. The main items studied were diet, smoking, drinking, occupation and marital status. A record linkage system was established for the annual follow-up. During 16 years of follow-up, 51 422 deaths occurred. This study is large and is unique in being of a non-Caucasian population and in being based on interviews rather than on self-completed questionnaires.

2. Cancer of the lung

The following section summarizes some of the epidemiological evidence on smoking-related factors that modify the incidence of lung cancer, assesses the proportion of lung cancer risk currently attributable to smoking in several different parts of the world, and shows how trends in the consumption of cigarette tobacco and changes from one type of cigarette to another relate to trends in the incidence of lung cancer in a few particular countries.

One factor that affects the estimate of relative risk in different studies is misdiagnosis of the disease. Although some patients with other disease may be misdiagnosed as having cancer of the lung (Heasman & Lipworth, 1966), these account for only a small proportion of cases nowadays. About 94% of deaths attributed to lung cancer were confirmed by hospital diagnosis in a study based on the Third National Cancer Survey in the USA (Percy *et al.*, 1981). Among nonsmokers, however, lung cancer is so rare that misdiagnoses may, in studies that are undertaken without careful histological evaluation, appreciably change the measured rates of lung cancer among nonsmokers, thereby biasing the relative (though not necessarily the absolute) excess risk of the disease among smokers. For this reason (and because the relative risks associated with smoking appear to be different for different histological categories of lung cancer, see below), histological characterization of the lung cancers that are studied is of substantial value.

(a) *Factors affecting risk*

(i) *Tobacco products smoked*

Evidence that the risk of lung cancer differs according to the tobacco product smoked was first obtained in case-control studies, such as those in the USA (Wynder & Graham, 1950) and in the UK (Doll & Hill, 1950). In these and other, similar studies, the estimated risk of lung cancer has usually been greatest among cigarette smokers (the largest and most recent study being that reported by Lubin *et al.*, 1984a), with the estimated risk in pipe and cigar smokers being intermediate between the risks in cigarette smokers and in nonsmokers. These findings have been fully corroborated in cohort studies, and the results are described in detail below. In contrast, adequate cohort studies are not yet available to assess whether changes in the composition of cigarettes (e.g., use of filters, 'tar' level reductions, etc.) have modified the risk of lung cancer conferred by *prolonged* use of such cigarettes. Therefore,

other types of evidence relating to this question are also described. The same is true for assessment of the health effects of *bidis*, which are the chief form in which tobacco is smoked in large parts of southern Asia.

(1) *Cigarettes, cigars and pipes*. In the American Cancer Society Nine-State study (Hammond & Horn, 1958a,b), there were 448 male deaths from lung cancer during the follow-up. The ratio of death rates (standardized for age), comparing people who smoked only cigarettes with lifelong nonsmokers, was 9.9 (Table 54); those who smoked only pipe and/or cigar tobacco had a relative risk of 2.3. A similar gradient was found between the death rates of nonsmokers, cigarette smokers and other smokers in each five-year age group. Thus, those who smoked cigarettes only had the highest lung cancer death rate, while pipe and cigar smokers experienced markedly lower excess risks of lung cancer death. Those smoking both cigarettes and some other type of tobacco had a risk intermediate between those people smoking 'cigarettes only' and 'cigars or pipe only' (Table 54).

In the Canadian Study (Lossing *et al.*, 1966), 343 lung cancer deaths occurred among current and ex-smokers, and seven in nonsmokers. The 325 current smokers of cigarettes only had a relative risk of 14.9 in relation to nonsmokers. The relative risks for cigar and pipe smokers were 2.9 and 4.4, respectively (Table 54).

In the American Cancer Society 25-State Study (Hammond, 1966), 1159 lung cancer deaths occurred among the 440 558 men in the cohort until 30 September 1963. The ratio of age-standardized death rates (or relative risks) for different smoking categories are given in Table 54. The rate for those who had smoked cigarettes only was 9.2 times the rate for those who had never smoked regularly, while those for men who smoked only cigars or only pipes were 1.8 and 2.2, respectively. The patterns in different age groups were roughly similar to that for the total group. Hammond and Seidman (1980) reported the results of follow-up of 358 422 white men and 483 519 white women in the same cohort during the five-year period 1967-1971. Those men who had smoked pipes or cigars only had an age-standardized mortality ratio (SMR) of 1.5 (nonsmokers, 1.0), while for those who had smoked cigarettes only the SMR was 8.5.

In the Swedish Study there were 116 lung cancer deaths in men and 28 in women (Cederlöf *et al.*, 1975). The relative risk for male cigarette smokers was 7.0; the highest relative risk, of 10.9, was found among those who smoked both cigarettes and a pipe (Table 54). An exceptionally high relative risk (9.2) was found for cigar smokers in this study. [The Working Group noted that this estimate was based on very small numbers.]

In the 20-year follow-up of the British Doctors Study (Doll & Peto, 1976), there were 441 male deaths that, after review, were attributed to lung cancer. The risks of lung cancer death in different smoking categories were expressed as death rates (indirectly standardized for age) per 100 000 person-years; these are shown as relative risks in Table 54. The relative risk for pipe and/or cigar smokers who had never previously smoked cigarettes was 5.8; that for pipe and/or cigar smokers who also smoked cigarettes, 8.2; and that for current cigarette smokers only, 14.0.

Table 54. Relative risks of lung cancer in some large cohort studies among men smoking cigarettes and other types of tobacco

Study	Smoking category	Relative risk	Death rate per 100 000	No. of cases
American Cancer Society Nine-State Study	Never smoked	1.0	^a 12.8	15
	Occasionally only	1.5	19.2	8
	Cigarettes only	9.9	127.2	249
	Cigars only	1.0	13.1	7
	Pipes only	3.0	38.5	18
	Cigarettes + other	7.6	97.7	148
	Cigars + pipes	0.6	7.3	3
Canadian Study	Nonsmokers	1.0		7
	Cigarettes only	14.9		325
	Cigars only	2.9		2
	Pipe only	4.4		18
	Ex-smokers	6.1		18
American Cancer Society 25-State Study	Never smoked	1.0	^a 12	49
	Cigarettes only	9.2	111	719
	Cigars only	1.9	22	23
	Pipes only	2.2	27	21
	Cigars + pipes	0.9	11	11
Swedish Study	Nonsmokers	1.0	^a	7
	Cigarettes only	7.0		28
	Cigarettes + pipe	10.9		27
	Pipe only	7.1		31
	Cigars only	9.2		6
	Ex-smokers	6.1		12
British Doctors Study	Nonsmokers	1.0	10	
	Current smokers	10.4	104	
	Cigarettes only	14.0	140	
	Pipes and/or cigars only	5.8	58	
	Ex-smokers	4.3	43	
US Veterans Study	Nonsmokers	1.0	^a	
	Cigarettes	11.3		2609
	Cigarettes only	12.1		1095
	Cigars only	1.7		41
	Ex-cigarette smokers	4.0		517
Norwegian Study	Nonsmokers	1.0	^a	7
	Cigarettes	9.7		88
	Cigarettes only	9.5		70
	Pipes or cigars only	2.6		12
	Ex-smokers	2.8		11

^aFigures given in original report

There were 11 979 men and 13 998 women in a Norwegian cohort, 35-69 years of age, studied by Lund and Zeiner-Henriksen (1981); 120 male and 26 female lung cancer cases were identified from the files of the Cancer Registry of Norway. Table 54 gives the risks relative to that of nonsmokers for lung cancer in men; male cigarette smokers had a distinctly higher risk of lung cancer than smokers of other types of tobacco.

(2) *Bidis*. The association between lung cancer and the smoking of *bidis*, small hand-rolled Indian cigarettes, was investigated in two matched-pair, case-control studies conducted in Bombay, India. Notani and Sanghvi (1974) collected data on 520 patients with lung cancer seen at the Tata Memorial Hospital, Bombay, from 1963-1970 and on hospital controls matched for sex, age and community. Data on smoking habits were collected routinely from new patients coming to the hospital, irrespective of their ultimate diagnosis; 327 were *bidi* smokers. A matched-pairs analysis gave a relative risk of 2.6 for *bidi* smokers; the risk was 1.6 for those smoking <10 *bidis* per day, 2.8 for those smoking 10-19 per day, 2.8 for 20-29 per day, and 5.3 for 30 or more per day.

Jussawalla and Jain (1979) reported on 792 (i.e., 43%) of the male lung cancer patients diagnosed between 1964 and 1973 in the Greater Bombay area. Controls, randomly selected from a list of registered voters, were subsequently matched with cases for age and community and were interviewed at home by medical social workers. Of the patients, 451 were *bidi* smokers. The relative risk was found to be 19.3 for *bidi* smokers (12.3 for those smoking <20 *bidis* per day and 56.7 for those smoking 20 or more *bidis* per day).

[The Working Group noted the substantially different estimates of relative risk derived from these two studies, even though they were based largely on the same cases of lung cancer; the control series were different (hospital *versus* community), the latter risking some confounding by socioeconomic status, as all cases may not have been on the lists of registered voters.]

(ii) *Duration of smoking*

One of the key features of the relationship between cigarette smoking and lung cancer is the relevance of duration of regular cigarette smoking to lung cancer onset rates. For example, using a statistical model fitted to data from the British male doctors study, Doll and Peto (1978) estimated that the excess annual incidence rates of lung cancer after about 45, 30 and 15 years of cigarette smoking were in the approximate ratio 100:20:1 to each other (Table 55).

Thus, according to the model fitted, a three-fold increase in the duration of regular tobacco use would increase the annual incidence of lung cancer by about a hundred-fold. This particular relationship, derived from one detailed epidemiological study, may apply elsewhere, even though the additional evidence from cohort studies is sparse (Table 56). However, in the entire adult male population of England and Wales in the 1970s, the proportions of smokers at various different ages were not very different (Lee, P.N., 1976), yet the lung cancer death rate at 80 years of age was about 100 times that at 40 years of age (Office of Population Censuses and Surveys, 1984b). [The Working Group considered that the most likely explanation is that the 80-year-old smokers had been smoking cigarettes for about three times as long as the 40-year-old smokers.]

Table 55. Approximate^a effects of various durations of cigarette smoking on annual excess incidence of lung cancer

Years of cigarette smoking	Annual excess incidence	
	Moderate smokers (%)	Heavy smokers (%)
15	0.005	0.01
30	0.1	0.2
45	0.5	1

^aEstimated by Peto and Doll (1984) from the model reported by Doll and Peto (1978) fitted to incidence data for male UK doctors

Table 56. Relationship between risk of lung cancer and duration of smoking in men, based on available information from cohort studies


Reference	Duration of smoking (years)	Standardized mortality ratio (no. of observed deaths)	Approximate annual excess death rate (%) ^a
Weir & Dunn (1970)	1-9	1.13	0.002 (0.001)
	10-19	6.45	0.09 (0.05)
	20+	8.66	0.12 (0.08)
	nonsmokers	1.0	0
Cederlöf <i>et al.</i> (1975)	1-29	1.8 (5)	0.01 (0.008)
	≥30	7.4 (23)	0.1 (0.06)
	nonsmokers	1.0 (7)	0

^aThe mortality rate among nonsmokers was assumed to be 15.6/100 000 per year, as in the American Cancer Society study (see p. 230). Figures in parentheses were computed by the Working Group applying the British doctors' mortality rate among nonsmokers (10.0/100 000 per year) (see p. 230).

(1) *Nature of the relationship with duration.* The annual lung cancer incidence among regular cigarette smokers can be separated arithmetically into the 'background' (nonsmoker) rate, which, like the onset rates of many other types of carcinoma, depends strongly on age (Garfinkel, 1981), plus an 'excess' rate, which depends strongly on the duration of regular exposure (Doll, 1971; Doll & Peto, 1978, 1981). Examples of background and excess rates for males are given in Figure 8, while those for females might be about two-thirds as great (Doll *et al.*, 1980).


One feature of the effects of the duration of smoking is illustrated in Figure 9, which shows how the annual excess risk of lung cancer at age 60 in the US Veterans Study depended on whether men started to smoke at 15 or at 25 years of age (i.e., on whether, by the age of 60, they had smoked for 45, or for only 35, years). Some of the cohort studies of smoking and lung cancer have not produced differences

Fig. 8. Background and excess risks: lung cancer death rates among nonsmokers in relation to age (lower line) and among regular cigarette smokers, in relation to approximate years of smoking (upper line)^a



^aFrom Doll (1971) and Peto and Doll (1984)

Fig. 9. Relationship between age of starting regular cigarette smoking in early adult life and lung cancer death rates at age 55-64 (mean, 60) for US men. Data presented separately for heavy and for moderate smokers^a



^aFrom Doll and Peto (1981)

as marked as these (Table 57); however, the ratios in the Swedish Study were based on small numbers of deaths. The long delay that is commonly seen between an increase in cigarette usage and emergence of its full effects on national lung cancer rates in old age (Doll & Peto, 1981) shows that it is *prolonged* cigarette smoking that produces large lung cancer risks.

Table 57. Relationship between risk of lung cancer and age at start of cigarette smoking in men, based on available information from cohort studies

Reference	Age at start of smoking (years)	Mortality ratio (no. of observed deaths)
American Cancer Society 25-State Study (Hammond, 1966)	25+	3.21 (20)
	20-24	9.72 (110)
	15-19	12.81 (315)
	<15	15.10 (101)
	nonsmoker	1.0 (49)
Japanese Study (Hirayama, 1975a)	25+	2.87
	20-24	3.85
	<20	4.44
	nonsmoker	1.0
		(NA)
Swedish Study (Cederlöf <i>et al.</i> , 1975)	≥19	6.5 (11)
	17-18	9.8 (10)
	≤16	6.4 (7)
	nonsmoker	1.0 (7)

Current patterns of mortality from lung cancer in late middle age or in old age therefore depend not only on current patterns of cigarette use, but also on the patterns of cigarette use among young adults perhaps half a century ago. Current trends, current urban-rural differences, and current international differences in lung cancer rates reflect, among other things, past trends, past urban-rural differences, and past international differences in cigarette usage by young adults.

For example, Doll and Peto (1981) pointed out that, in 1930, US cigarette consumption was increasing rapidly among young men, and national sales rose from <2 cigarettes per adult a day in 1920 to about 10 per adult a day in 1950 (Lee, P.N., 1975). However, the effects on the lung cancer incidence rate of those increases are only now becoming fully apparent, and, largely as a very long delayed result, US male lung cancer rates in late middle and old age are still rising steeply, despite the fact that cigarette sales per adult have remained at approximately 10-12 a day since 1950 (Doll & Peto, 1981).

Doll and Peto (1981) noted that when the national lung cancer rates for one generation are related to national cigarette consumption rates when that generation were young adults, a moderately close relationship emerges. They concluded that it is wrong to suggest that the poor international correlation between current smoking habits and current lung cancer rates indicates that smoking is not the chief determinant of worldwide lung cancer mortality.

(2) *Effects of age.* The effects of the duration of smoking are so strong, and so closely correlated with age, that it is virtually impossible to determine exactly whether ageing *per se* has any independent effect on excess lung cancer rates among people of different ages who have all smoked similarly for a similar number of years. If age has any independent effect, however, this would seem to be small compared with the cumulative effect of duration of smoking (Peto *et al.*, 1975, 1985; see also Likhachev *et al.*, 1985).

(3) *Time course of the effects of stopping smoking.* When smoking ceases, the annual excess risk of lung cancer appears to remain roughly (perhaps to within a factor of two) constant for many years thereafter (Doll & Peto, 1976). It is not consistently apparent that the annual absolute excess risk decreases substantially (Table 58). Two cohort studies have suggested that it decreases to zero after 10 years (Hammond, 1966; Cederlöf *et al.*, 1975), but others do not (Doll & Peto, 1976; Rogot & Murray, 1980). Hirayama (1975b) reported a rate ratio of 1.35 between people who had stopped smoking for 10 or more years and nonsmokers. Table 55 shows that the annual excess risk after 30 years of smoking is about 0.1% (1 per 1000). If a smoker stops after 30 years, for example, 15 years later the annual excess risk may still be about 0.1% instead of the 0.5% that it would have been had smoking continued. Therefore, about 80% of the excess risk that would have accrued with continuation of smoking has been avoided.

(4) *Time course of the effects of changes in smoking that fall short of complete cessation.* In the mid-1950s, the 'tar' level¹ per manufactured cigarette was high throughout the world, and in several developing countries (e.g., China, India, Indonesia, Pakistan, the Philippines and Zaire) and some developed ones (e.g., Denmark, eastern European countries, France, Italy and the USSR) it still is high (Lee, P.N., 1984; Jenkins, R.A. *et al.*, 1986; see pp. 60-65). In some developing countries (e.g., Chile, Kenya, Nicaragua and Papua New Guinea), 'tar' levels were greatly reduced by the end of the 1970s, and in several developed countries (e.g., Canada, Finland, the UK and the USA), 'tar' levels had already been greatly reduced by the end of the 1960s (Lee, P.N., 1976; US Department of Health and Human Services, 1981; Lee, P.N., 1984). In the latter countries, therefore, the 'tar' level per manufactured cigarette has been much lower than it was in the mid-1950s for the past 15 years.

[The Working Group considered that this period may, depending on the time course of any effects such changes may have on lung cancer rates, be long enough to evaluate whether lifelong exposure to such cigarettes is likely to be different from lifelong exposure to the types of cigarettes that were ubiquitous 30 years ago. One particular source of difficulty in answering this question epidemiologically, which affects both the usual cohort studies and the usual case-control studies of individuals, is that in many countries it is impossible to

¹[The Working Group noted that many changes have occurred in cigarette design and smoke composition, including the introduction of filters, porous paper and changes in types of tobacco. These changes affect the tar yield of smoke. For convenience, therefore, in the following pages the term 'tar' levels is used to describe all these changes in cigarette design.]

Table 58. Relationship between risk of lung cancer and number of years since stopping smoking, in men, based on available information from cohort studies

Reference	No. of years since stopping smoking	Mortality ratio (no. of observed deaths)
American Cancer Society 25-State Study (Hammond, 1966)	1-19 cigarettes/day	
	Current smokers	6.5 (80)
	<1	7.2 (3)
	1-4	4.6 (5)
	5-9	1.0 (1)
	10+	0.4 (1)
	Nonsmokers	1.0 (32)
	20+ cigarettes/day	
	Current smokers	13.7 (351)
	<1	29.1 (33)
	1-4	12.0 (33)
	5-9	7.2 (32)
	10+	1.1 (5)
	Nonsmokers	1.0 (32)
Swedish Study (Cederlöf <i>et al.</i> , 1975)	<10	6.1 (12)
	>10	1.1 (3)
	Nonsmokers	1.0 (7)
British Doctors Study (Doll & Peto, 1976)	Current smokers	15.8 (123)
	1-4	16.0 (15)
	5-9	5.9 (12)
	10-14	5.3 (9)
	15+	2.0 (7)
	Nonsmokers	1.0 (7)
Rogot & Murray (1980)	Current smokers	11.3 (2609)
	<5	18.8 (47)
	5-9	~ 7.5 (86)
	10-14	~ 5.0 (100)
	15-19	~ 5.0 (115)
	20+	2.1 (123)
	Nonsmokers	1.0 NA

NA, not available

compare prolonged smoking of high-tar cigarettes with prolonged smoking of low-tar cigarettes directly, simply because they have never coexisted: in the early 1950s there were no really low-tar cigarettes, while now in many countries there are no really high-tar ones. Moreover, the 'tar' level of the cigarettes smoked by many individuals may not remain consistently higher than average or consistently lower than average. Another source of difficulty, which affects not only studies of individuals but also studies of national trends, is

that it is not possible to predict reliably whether any effect of changing 'tar' levels would be rapid or slow to emerge. If such changes had analogous effects to those of cessation of smoking, then within 10-15 years of 'tar'-level decreases, changes in lung cancer might emerge. In view, however, of the great importance (see Fig. 9) of cigarette smoking in early adult life, it is possible that 'tar' levels in early adult life might be relevant to lung cancer risks many decades later, in which case the full effects of any changes in 'tar' levels might take many decades to emerge.]

Among UK men, decreases in lung cancer incidence are occurring at all ages, with the largest in the youngest age groups (Table 59). Although decreases in UK cigarette consumption have recently begun to be seen (particularly in men, but also in women: Royal College of Physicians, 1983), these did not start until 1975, and did not start to be rapid until after 1980 (average per-caput consumption by men of 10-11/day in 1940-1975; 9/day in 1980; 8/day in 1981; 7/day in 1982) (Wald, 1985). In men, including those under the age of 40, increases in cigarette usage were seen in the period 1950-1973 (Lee, P.N., 1976; and see Table 60). Changes in cigarette usage could account, therefore, for only a small part of the large decrease in lung cancer that was seen by 1978 and that has continued thereafter. Since no large improvement in the curability of the disease has taken place since the 1950s, it seems that for people in early middle age the lung cancer risk per cigarette is now substantially lower than it was more than 25 years ago. The interpretation of these trends is also discussed below (pp. 235-242). The percentage change in early middle age may provide the first clear indication of what can ultimately be expected throughout adult life, even though only a small minority of cancer deaths take place in early middle age.

Table 59. Trends in lung cancer death certification rates (per million) in middle-aged UK men (average of five years around each date)^a

Age range (years)	1953 ^b	1958 ^b	1963 ^b	1968 ^c	1973 ^c	1978 ^d	1983 ^{d,e}	Change over past 25 years (%)
30-34	37	36	33	25	24	17	14	-62
35-39	100	94	90	76	58	56	44	-53
40-44	250	253	225	218	177	139	122	-52
45-49	584	594	565	532	504	402	321	-46
50-54	1232	1254	1225	1162	1073	999	765	-39
55-59	2018	2326	2288	2203	2076	1897	1705	-27

^aCalculated by the Working Group from Office of Population Censuses and Surveys, 1975 (numerators, 1951-1970; denominators, 1951-1960), 1980a (numerators, 1971-1978), 1980b,c, 1982, 1983b, 1984a,b, 1984c (denominators, 1961-1981), 1984d (denominators, 1981-1983), 1985a (numerators, 1979-1984; denominators, 1984)

^bICD6 162-164

^cICD8 162, 163

^dICD9 162-165

^e1982-1984

Table 60. Cigarette consumption in the UK, 1943-1975^a

Parameter	1943	1953	1963	1973	1975
No. of cigarettes/adult male per year	3930	3690	3820	3980	3730
Mean tar level (mg/cigarette)	ND	ND	31.4 (1965)	18.7	17.9
Proportion of never smokers (%)	ND	ND	16.9	18.4	20.3
Proportion of ex-smokers (%)	ND	ND	15.1	16.0	18.2
Proportion of nonsmokers by age group (%)					
16-19	} ND	} ND	39	42	43
20-24			26	26	29
25-29			20	26	27
30-34			20	20	23
35-49			13	16	19
50-59			11	10	10
60+			11	9	12

^aFrom Lee, P.N. (1976)

ND, no data

(iii) *Intensity of smoking*

(1) *Effects on observed dose-response relationships.* In view of the importance of duration of smoking, the prospective studies undertaken in Sweden (Cederlöf *et al.*, 1975) and Japan (Hirayama, 1977a), in which cigarette smoking in early adult life was not widely prevalent among the smokers who were studied, greatly underestimate both the absolute and the relative risks that are to be expected from lifelong cigarette smoking in those countries. Similar problems exist in the USA, for the first generation of US men who had really heavy exposure to cigarettes in early adult life was that reaching adulthood just after the Second World War (i.e., those born after 1925) (Beese, 1972). Consequently, the relative risks observed among male cigarette smokers in the US cohort studies of the 1950s and 1960s may be substantially lower than those that may be observed in the 1980s, the 1990s and beyond, and this bias would be even greater for US women, although changes in 'tar' levels may complicate the picture.

Even in the UK, where cigarette smoking among men has been widespread for much longer than in most other parts of the world, similar problems affected the interpretation of the risks observed in both cohort (Doll & Peto, 1976) and case-control (Doll & Hill, 1950, 1952) studies. For British men born in the previous century, the relationships observed between lung cancer risks and daily cigarette dose-rates were probably underestimates, and this is even more true for British women. Indeed, in all countries, the widespread adoption of cigarette smoking by women is so recent that no adequate study of the full effects of lifelong smoking on female mortality is yet available.

(2) *Changes in relative risk with age.* A related difficulty is that (as reviewed by Doll, 1971; see also Fig. 8), even among people who have smoked cigarettes regularly since early adult life, the relative risk (i.e., the ratio of the annual lung cancer risk among regular smokers to that among lifelong nonsmokers) is not constant — indeed, it may be about three or four times as large in old age as in early middle age (Doll & Peto, 1978). [The Working Group considered, therefore, that no single (age-independent) relative risk can strictly or adequately characterize a particular smoking habit, and even the relative risks derived from epidemiological studies of lifelong cigarette smokers are hybrid mixtures of various different age-specific relative risks.]

(3) *Relationships observed in cohort studies with average daily amount of tobacco* (Table 61). In the American Cancer Society Nine-State Study (Hammond & Horn, 1958a,b), four categories of cigarette smokers were formed: <0.5 pack; 0.5-1 pack; 1-2 packs; and more than 2 packs per day. A consistent increase was found in the relative risk of lung cancer with increase in amount smoked per day (Table 61).

In the Canadian Study (Lossing *et al.*, 1966), the relative risk of lung cancer among men, compared with nonsmokers, was 10.0 for smokers of 1-9 cigarettes/day and 17.3 for smokers of ≥ 21 cigarettes/day (Table 61).

In the American Cancer Society 25-State Study reported by Hammond (1966), the relative risk of lung cancer (compared to nonsmokers) in men was 4.6 among smokers of 1-9 cigarettes per day and 16.6 among those smoking 40 or more cigarettes per day; a consistent dose-response relationship was seen (Table 61). Among women, the risk was 1.1 for those smoking 1-19 cigarettes per day and 4.8 for those smoking 20 or more cigarettes per day. [The Working Group considered that the findings for men and, especially, for women probably underestimate the relative risks that prolonged cigarette use will cause.]

In the Californian Study (Weir & Dunn, 1970), the category 'nonsmokers' included (in contrast with the practice in other studies) those cigar and pipe smokers who had never smoked cigarettes. The relative risk for lung cancer increased with increasing amount smoked daily (see Table 61).

In the Japanese Study (Hirayama, 1985), 1324 male lung cancer deaths were observed during a 16-year follow up (1966-1981). The relative risks for those who smoked different amounts of cigarettes are given in Table 61. Although, again, these relative risks may grossly underestimate what will eventually be seen with the prolonged use of cigarettes, a consistent correlation was found between the amount smoked and the relative risk of lung cancer.

A dose-response relationship in the relative risk of lung cancer was found in the Swedish Study (Cederlöf *et al.*, 1975) by the amount of cigarettes smoked daily and, also, by the amount of pipe tobacco used (Table 61).

In the British Doctors Study (Doll & Peto, 1976), the indirectly standardized death rate per 100 000 was calculated for three groups of male current smokers (any tobacco): 1-14, 15-24 and 25+ g tobacco/day. A consistent gradient in the death rate was found: 52, 106 and 224 per 100 000, respectively. The rate for nonsmokers was 10. A separate analysis was made for those current smokers who smoked cigarettes only: the death rates were somewhat higher than those among current smokers of any tobacco (see Table 61). On the basis of the

Table 61. Dose-response relationship between the amount smoked and risk of lung cancer in men in some cohort studies

Study	Smoking category	Relative risk	Death rate per 100 000	No. of cases
American Cancer Society Nine-State Study (Hammond & Horn, 1958b)	(No. of packs/day)		<i>a</i>	
	0	1.0	12.8	15
	<0.5	7.4	95.2	24
	0.5-1	8.4	107.8	84
	1-2	17.9	229.2	90
	> 2	20.6	264.2	27
Canadian Study (Lossing <i>et al.</i> , 1966)	(No. of cigarettes/day)	<i>a</i>		
	0	1.0		
	1-9	10.0		57
	10-20	16.4		204
	21+	17.3		63
American Cancer Society 25-State Study (Hammond, 1966)	(No. of cigarettes/day)	<i>a</i>	<i>a</i>	
	0	1.0	12	49
	1-9	4.6	56	26
	10-19	7.5	90	82
	20-39	13.1	159	381
	40+	16.6	201	82
Californian Study (Weir & Dunn, 1970)	(No. of packs/day)	<i>a</i>		
	0	1.0		
	about ½ or less	3.7		
	about 1	9.1		
	about 1½ or more	9.6		
Japanese Study 16-year follow-up (Hirayama, 1985)	(No. of cigarettes/day)	<i>a</i>		
	0	1.0	23.0	80
	1-9	2.3	49.6	74
	10-19	4.0	93.2	486
	20-29	5.9	137.0	464
	30-39	6.1	141.3	52
	40-49	7.2	170.0	28
50+	15.2	352.6	12	
Swedish Study (Cederlöf <i>et al.</i> , 1975)		<i>a</i>		
	Nonsmokers	1.0		7
	Cigarettes only			
	1-7/day	2.3		4
	8-15/day	8.8		11
	16+/day	13.9		13
	Pipe tobacco only			
<6 g/day	2.9		4	
>6 g/day	9.1		27	

Table 61 (contd)

Study	Smoking category	Relative risk	Death rate per 100 000	No. of cases
British Doctors Study (Doll & Peto, 1976)	(No. of cigarettes/day)		<i>a</i>	
	0	1.0	10	
	1-14	7.8	78	
	15-24	12.7	127	
	25+	25.1	251	
US Veterans Study (Rogot & Murray, 1980)	(No. of cigarettes/day)	<i>a</i>		
	0	1.0		
	1-9	3.9		
	10-20	9.6		
	21-39	16.7		
	40+	23.7		
Norwegian Study (Lund & Zeiner-Henriksen, 1981)	(No. of cigarettes/day)	<i>a</i>		
	0	1.0		7
	1-9	6.0		19
	10-19	9.9		31
	20+	18.2		20

^aFigures given in original report

data obtained in this study, Doll and Peto (1978) made a more detailed analysis of the relationship between the number of cigarettes smoked regularly and the risk of dying from lung cancer. They fitted a model indicating an upward curvature of the dose-response relationship in the range 0-40 cigarettes per day.

The results of the British Doctors Study for women were reported by Doll *et al.* (1980). There were only 27 lung cancer deaths during the entire 22-year follow-up period. The death rates were standardized for age to the age distribution of the person-years experienced by the male part of the cohort (Doll & Peto, 1976). The rate for nonsmokers was 7 (men, 10). Among current cigarette smokers, the groups smoking 1-14, 15-24 and 25 or more cigarettes per day had death rates of 9, 45 and 208, respectively (men: 78, 127 and 251, respectively). It was noted that the women who were light and moderate smokers had started later than men and also inhaled less. [The Working Group noted that, as with all studies of female smoking, the observed rates probably greatly underestimate the rates that will eventually be produced by prolonged tobacco use.]

The relative risks of those smoking different numbers of cigarettes per day in the US Veterans Study reported by Rogot and Murray (1980) are given in Table 61. Among men

who smoked <10 cigarettes per day, the relative risk was 3.9, while among men who smoked 40 or more cigarettes per day it was 23.7. A similar gradient, although less prominent, was found among ex-cigarette smokers: an increase in the risk from 1.2 to 7.8 as the number of cigarettes smoked before stopping increased from <10 to 40 or more per day.

In the Norwegian Study of Lund and Zeiner-Henriksen (1981), the relative risk of lung cancer also increased with increasing amount of cigarettes smoked per day (Table 61).

(4) *Comparison of effects of prolonged use of different types of cigarette (e.g., filter/nonfilter, high/medium/low 'tar', etc.)* (see footnote, p. 210). The most serious difficulties arise when comparing the effects of prolonged (i.e., lifelong) use of various different types of cigarette, for substantial changes in cigarette composition are so recent that prolonged use of the 'modern types' introduced in western countries in the late 1950s and early 1960s has not yet taken place. Therefore, epidemiological studies dating from the 1960s or early 1970s may underestimate the differences in risk that may exist between lifelong use of different types of cigarette. Lee, P.N. and Garfinkel (1981) noted the consistent reduction in mortality from lung cancer in early epidemiological studies with use of the more 'modern' cigarette. They also noted their limitations, imposed by the short duration of use of 'modern' cigarettes. [The Working Group noted that these studies related chiefly to comparisons between filter and nonfilter cigarettes; this distinction does not correspond fully to changes in tar delivery per cigarette.] Since then, a case-control study has been reported (Lubin *et al.*, 1984b) which is unusually large (involving the study of 23 000 people, one-third of whom were lung cancer cases and two-thirds controls) and involves longer exposure to the 'modern' types of cigarettes (because it took place in the late 1970s). Because of its large size and late date, the results from this study are perhaps more informative than those from the earlier and smaller studies.

Because the effects only of short-term use of 'modern' cigarettes could be assessed in the early studies, only two (in addition to that of Lubin *et al.*, 1984b) are reviewed here in detail (Hammond *et al.*, 1976; Wynder & Stellman, 1979). The results of the others are summarized in Table 62.

Hammond *et al.* (1976) reported the results obtained in the American Cancer Society 25-State Study with regard to the association between 'tar' content of cigarettes and risk of lung cancer. The subjects in this part of the study were those 40 years of age or older in July 1960 and who then said that they were currently smoking cigarettes regularly and had never smoked pipes or cigars regularly (first period — follow-up July 1960 to June 1966), or who in a later contact in 1965-1966 said that they were currently smoking cigarettes (second period — July 1966 to June 1972). Cigarettes containing 25.8-35.7 mg tar were classified into the 'high-tar' category, those with 17.6-25.7 mg into the 'medium-tar' category, and those with <17.6 mg into the 'low-tar' category. [Note that this terminology differs from that proposed on p. 61 of this monograph.] Those who reported use of the high-tar cigarettes experienced the highest risk of lung cancer death. The results were similar for men and women and for the two periods under study. Those who never had smoked cigarettes, pipes or cigars regularly had a distinctly lower risk of lung cancer than those who had smoked low-tar cigarettes (Table 63).

Table 62. Relative risk for lung cancer by type of cigarette smoked (filter vs. nonfilter), in men, based on cohort and case-control studies

Reference	Type of study	Relative risk
Hawthorne & Fry (1978)	Cohort	0.8
Rimington (1981)	Cohort	0.7
Bross & Gibson (1968)	Case-control	0.6
Wynder <i>et al.</i> (1970)	Case-control	0.6
Dean <i>et al.</i> (1977)	Case-control	0.5

Table 63. Age-standardized mortality ratio of lung cancer in two time periods, by tar content of cigarettes usually smoked, by sex^a

Sex	Period	Mortality ratio			
		Tar content (mg/cigarette)			Never smoked
		25.8 - 35.7	17.6 - 25.7	< 17.6	
Male	1 July 1960- 30 June 1966	1.0	0.96	0.83	0.07
	1 July 1966- 30 June 1972	1.0	0.94	0.79	0.07
Female	1 July 1960- 30 June 1966	1.0	0.86	0.57	0.25
	1 July 1966- 30 June 1972	1.0	0.73	0.62	0.14

^aFrom Hammond *et al.* (1976)

Wynder and Stellman (1979) calculated the risk of lung cancer among those who had been filter-cigarette smokers for more than ten years and compared it with the risk among nonfilter-cigarette smokers. The risk among filter-cigarette smokers, both men and women, was smaller in all categories defined by the amount smoked, except for women who smoked 31 or more cigarettes per day (Table 64).

Lubin *et al.* (1984b) reported on a comparison of 7804 lung cancer cases with 15 207 hospital-based controls in five European countries or territories (Austria, Federal Republic of Germany, France, Italy and Scotland). Results of a standard analysis of the data from the entire study suggest that lifelong use of filter, as opposed to nonfilter, cigarettes is associated

Table 64. Relative risk of lung cancer for current smokers who had used filter cigarettes for ≥ 10 years to that among current smokers whose present brand was nonfilter^a

No. of cigarettes smoked	Relative risk of lung cancer (filter for 10+ years: current nonfilter)	
	Men	Women
1 - 10	0.6	0.4
11 - 20	0.9	0.7
21 - 30	0.7	0.8
31 - 40	0.7	-
31+	-	1.0
41+	0.9	-

^aFrom Wynder and Stellman (1979)

with avoidance of 40-50% (Table 65) of lung cancer cases. Because of the large numbers involved, this finding is highly statistically significant ($p < 0.001$). Data are also provided on different risks according to 'tar levels' of different brands (Table 66).

One part of this study (on Austria) has been presented separately (Kunze & Vutuc, 1980) in a report that claims a very large (about 80%) protective effect of 'tar-level' reductions. [The Working Group noted that this analysis depends upon the inappropriate use of a cumulative tar exposure index that appears to confuse the number of cigarettes smoked, the number of years for which they have been smoked, and their tar content in such a way that none can be informatively assessed.]

An analysis of another subset of this study (in France) (Benhamou *et al.*, 1985) showed findings similar to those of Lubin *et al.* (1984b), although when adjusting for daily cigarette consumption and type of cigarette, the relative risk associated with the use of nonfilter compared to filter cigarettes was 1.3 (not statistically significant).

[The Working Group noted that, in the report of Lubin *et al.* (1984b), lifelong filter-cigarette smoking is considered, whereas many of the smokers could have been expected to have commenced smoking before filter cigarettes became available. In addition, the reported relative risks for different proportions of 'low-tar' and 'high-tar' brands smoked were not adjusted for other characteristics of cigarette design such as use of filters. The latter consideration makes it difficult to determine which of the changes in cigarette design (filter or lower tar yield) were responsible for the reduction in risk.]

Table 65. Relative risk of lung cancer by proportion of years of use of nonfilter cigarettes^a

Proportion of years nonfilter cigarettes smoked ^b	Relative risk ^c	
	Men	Women
0.0 (all filter)	1.0	1.0
0.01 - 0.49	1.5	1.8
0.50 - 0.69	1.4	1.7
0.70 - 0.83	1.7	1.9
0.84 - 0.99	1.7	2.1
1.0 (all nonfilter)	1.7	2.0

^aFrom Lubin *et al.* (1984b)

^bApart from 0 and 1, these groups represent quartiles of the reported duration of use of filters

^cAdjusted for years of cigarette use, number smoked/day and years since cessation. Test for linear trend: $p < 0.001$

Table 66. Relative risk of lung cancer by proportion of smoking history during which brands with different 'tar' levels were used^a

Brand	Relative risk ^b	
	Men	Women
Low-tar brands (100%)	1.0	1.0
Low-tar brands (> 75%)	1.2	-
Other mixed brands	1.5	5.9
High-tar brands (> 75%)	1.8	4.0
High-tar brands (100%)	1.7	7.7

^aFrom Lubin *et al.* (1984b)

^bAdjusted for years of cigarette use, number smoked/day and years since cessation

While the 'low-tar' cigarette appears to reduce the risk for lung cancer, a recent report by Kauffmann *et al.* (1983) indicated that it has no protective effect against myocardial infarction. [The Working Group considered that possible differences in the effect of cigarette smoke in the pathogenesis of lung cancer and myocardial infarction may explain these findings.]

(b) *Histological types and association with smoking*

The association between smoking and different histological types of lung cancer has been analysed in many different ways. The problems related to the interpretation of the results obtained in epidemiological studies in which the histology of lung cancer is considered include variation in the nomenclature and criteria of classification of the tumours, inadequacy of the specimens that have been made available for histological classification in patients who are not subjected to operation, and the small size of many of the patient series, resulting in unstable risk estimates, particularly in women. Kreyberg (1962) divided epithelial lung cancers into two groups on the basis of the histological appearance of the tumour. Group I, squamous-cell (epidermoid) carcinoma and small (oat)-cell carcinoma; Group II, the rest, i.e., adenocarcinoma, large-cell undifferentiated carcinoma, combined squamous-cell and adenocarcinoma, bronchiolo-alveolar carcinoma, carcinoid tumours and tumours of mucous glands. Quite often, these two broad categories, referred to as Kreyberg Groups I and II, have been applied without more detailed description. Moreover, in many areas, a substantial proportion of lung cancer cases are not verified histologically; cases diagnosed by other means (cytology, X-ray, etc.) do not constitute a random sample of the total material.

In the study of Doll *et al.* (1957), there were 878 male and 76 female lung cancer patients with histological verification of diagnosis, and 1357 male and 108 female 'matched-control' patients of the same age distribution with other diseases. A substantial part of the material was histologically reclassified into Kreyberg Groups I and II. The risks of developing different histological types of lung cancer relative to nonsmokers are given in Table 67. There was a consistent increase in the relative risk for Kreyberg Group I tumours in both men and women, and for Kreyberg Group II tumours only in women (based on only eight cases in smokers).

The relative risk of lung cancer among cigarette smokers compared to nonsmokers was 4.3 for adenocarcinoma and 31.0 for cancers other than adenocarcinoma in the study of Hammond and Horn (1958b). For those smoking other types of tobacco, the corresponding relative risks were 1.3 and 3.7, respectively. The dose-response relationship among cigarette smokers between the amount smoked and risk of adenocarcinoma or other types of lung cancer is given in Table 67. An increase in the relative risk with increasing amount of cigarettes smoked was seen for both groups, the slope being, however, much steeper for types other than adenocarcinoma.

Doll and Hill (1964a) analysed the death rate ascribed to different histological types of lung cancer in groups with different smoking habits within the cohort of male British doctors (Table 67). A consistent increase in the death rate by increasing amount smoked was found for epidermoid, oat-cell and anaplastic carcinomas but not for adenocarcinoma. However, in a later analysis of the cohort for the years 1951-1971, a statistically significant trend was observed with respect to the number of cigarettes smoked in the age-standardized incidence of all four major histological types, i.e., squamous-cell carcinoma, small-cell carcinoma, adenocarcinoma and undifferentiated carcinoma (Doll & Peto, 1978).

Table 67. Main results of studies dealing with the relationship between smoking and different histological types of lung cancer

Reference	Histological type	Results						Comments	
		Sex	No. of cases	Relative risk					No. observed
Doll <i>et al.</i> (1957)				Amount of tobacco smoked (g)					
				<5	5-14	15-24	25+		
Doll <i>et al.</i> (1957)	Kreyberg I	M	829	4.7	10.6	14.3	25.4	3	
		F	32	1.0	1.7	8.3	16		
	Kreyberg II	M	38	0.5	0.8	1.2	1.1	2	
		F	8	1.1	2.3	4.1	5		
	Hammond & Horn (1958b)	Relative risk						Nonsmokers, 1.0 Only regular smokers considered	
		No. of packs/day							
<½		½-1	1+						
Hammond & Horn (1958b)	Adenocarcinoma	2.0	2.5	7.0					
	Other types	16.3	25.5	88.0					
Doll & Hill (1964a)	Death rate/1000						Men only		
	Amount of tobacco smoked								
	Ex-smokers		1-14 g	15-24 g	25+ g				
	Squamous-cell carcinoma	0.09	0.22	0.33	0.45				
	Small-cell and anaplastic carcinoma	0.05	0.10	0.20	0.38				
Adenocarcinoma	0.03	0.03	0.12	0.07					

Table 67 (contd)

Reference	Histological type	Results					Comments						
		Never smoked	Ex-smokers	Occasional cigarette smokers	Regular cigarette smokers								
					<1 pack/day	>1 pack/day							
Haenszel & Taeuber (1964)	Adenocarcinoma	0.78	0.35	2.46	1.17	7.50	Women only; standardized mortality ratios; total group, 1.00						
	Squamous-cell and undifferentiated carcinoma	0.59	0.52	1.15	2.19	8.78							
Hanbury (1964)		No. of cases (%) 'Heavy' and 'medium' smokers			Nonsmokers and 'remainder'		Women only						
	Small-cell carcinoma	18 (47)			21 (34)								
	Undifferentiated carcinoma	9 (24)			14 (23)								
	Squamous-cell carcinoma	9 (24)			12 (19)								
	Adenocarcinoma	2 (5)			15 (24)								
Vincent, T.N. <i>et al.</i> (1965)		Total no. of cases	Number of cigarettes smoked/day								Women only		
	None		1-20		21-40		41+		Unknown				
			No.	%	No.	%	No.	%	No.	%	No.	%	
		Squamous-cell carcinoma	19	10	53	3	16	2	10	2	10	2	10
		Small-cell carcinoma	17	2	12	7	41	6	35	2	12	0	0
		Adenocarcinoma	64	51	80	6	9	4	6	0	0	3	5
		Undifferentiated	22	12	54	4	18	6	27	0	0	0	0
	Others	41	32	78	8	20	1	2	0	0	0	0	
	Total	163	107	66	28	17	19	12	4	2	5	3	

Table 67 (contd)

Reference	Histological type	Results			Comments		
		Pack-years	Number of tumours	Smokers			
Deaner & Trummer (1970)	Undifferentiated carcinoma	40	40	40 (100%)			
	Adenocarcinoma	12	19	13 (68%)			
	Epidermoid carcinoma	52	9	9 (100%)			
Wynder <i>et al.</i> (1970)	Kreyberg I	Sex	No. (%)		Heavy = 41+ cigarettes/day		
			Cigarette smokers	Heavy smokers			
	M	191 (91.0)	59 (29.9)				
	F	24 (80.0)	3 (12.0)				
	Kreyberg II	M	61 (82.4)	9 (14.1)			
		F	21 (58.3)	1 (4.8)			
	Controls	M	199 (47.4)	26 (9.8)			
		F	53 (40.2)	3 (5.4)			
	Weiss, W. <i>et al.</i> (1972)	Death rate per 1000 man-years of observation (adjusted for age and race)					
		No. of cigarettes/day					
		1 - 10	10 - 19	20+			
Squamous-cell carcinoma		-	0.8	2.1			
Well differentiated		-	0.4	1.0			
Poorly differentiated		0.7	0.4	1.0			
Small-cell carcinoma	-	0.3	0.7				
Adenocarcinoma	-	0.6	1.0				

Table 67 (contd)

Reference	Histological type	Results					Comments			
Vincent, R.G. <i>et al.</i> (1977)		No. of cigarettes smoked/day								
		0	1-20	21-40	41+	Other				
	Squamous-cell carcinoma	14	219	110	120	16				
	Adenocarcinoma	28	101	66	53	7				
	Small-cell carcinoma	4	103	62	56	6				
	Large-cell carcinoma	2	40	32	33	1				
	Bronchiolo-alveolar carcinoma	6	20	9	6	0				
Mixed	0	9	5	5	0					
Other	6	30	18	17	4					
Chan <i>et al.</i> (1979)		Smoking category (kg tobacco smoked during lifetime)						Women only		
		Non-smokers	<100	100-199	>200					
			Manufac- tured	All	Manufac- tured	All	Manufac- tured		All	
	Squamous-cell and small-cell carcinomas	1.0	3.6	3.4	3.7	4.2	2.6	4.1		
	Adenocarcinoma	1.0	1.9	1.4	1.4	1.8	1.6	1.7		
Joly, O.G. <i>et al.</i> (1983)		Relative risk by duration of smoking (years)								Nonsmokers, 1.0
		Men				Women				
		1-29	30-39	40-49	50+	1-29	30-39	40-49	50+	
	Squamous-cell carcinoma	15.0	15.9	39.5	42.2	4.4	9.4	31.4	51.9	
	Adenocarcinoma	2.0	3.2	5.3	5.7	2.1	2.7	4.7	4.0	
Undifferentiated carcinoma	26.0	26.4	40.7	50.0	3.9	15.6	20.6	28.3		
Poorly differentiated carcinoma	6.4	7.7	10.8	10.2	3.2	7.8	5.4	13.1		

Haenszel and Taeuber (1964) estimated the standardized mortality ratio of different types of lung cancer in groups defined by smoking habits among women in the USA. In each category, a sizeable smoking-class gradient was found (Table 67), and no clear difference between adenocarcinoma and other histological types was discernible.

One hundred consecutive female lung cancer cases diagnosed in a hospital in London were classified by smoking habit and cell type of the tumour in the study of Hanbury (1964). Five per cent of the tumours among heavy and medium smokers were adenocarcinomas (2/38) compared to 24% among nonsmokers and others (15/62) (Table 67).

Vincent, T.N. *et al.* (1965) classified 163 lung cancers in women by histological type and smoking habits. Of Kreyberg Group I tumours (squamous-cell and small-cell carcinomas), 65% (22/34) were among cigarette smokers; but only 19% (19/102) of Kreyberg Group II tumours (adenocarcinoma, carcinoma with mucus production, bronchiolo-alveolar carcinoma, carcinoid tumour and adenoid cystic carcinoma) were in smokers. Four cancers were diagnosed among heavy smokers (41 or more cigarettes a day); all had Kreyberg Group I tumours (Table 67).

In a series of female lung cancer cases from California, USA (Deaner & Trummer, 1970), all patients with epidermoid carcinoma (9) and those with undifferentiated carcinoma (40) were cigarette smokers. The average number of pack-years was 52 for epidermoid and 40 for undifferentiated carcinoma. Among patients with adenocarcinoma, 13/19 were cigarette smokers, the average number of pack-years being 12.

Wynder *et al.* (1970) interviewed a hospital series of 210 men and 30 women with Kreyberg Group I (squamous- and small-cell carcinomas) and 74 men and 36 women with Kreyberg Group II tumours ('glandular') of the lung. A control group from the same hospital, twice the size of the cancer group, was matched by age to the male Kreyberg Group I patients and to all female patients; these individuals had no tobacco-related disease. In male cases, there was a significantly higher percentage of cigarette smokers and of heavy cigarette smokers in both histological groups than in the controls, and the percentage was even higher in Kreyberg Group I than in Kreyberg Group II cases (Table 67). In women, the difference between lung cancer patients and controls was similar to that in men for Kreyberg Group I; but for Kreyberg Group II the difference was small and not significant.

In a study by Weiss, W. *et al.* (1972), a US male cohort of 2580 men who regularly smoked cigarettes and 830 nonsmokers was followed up for 10 years for risk of lung cancer of different histological types. No lung cancer developed among nonsmokers, but there were 67 among smokers. The death rates from well-differentiated squamous-cell carcinoma, small-cell carcinoma and adenocarcinoma showed a dose-response relationship to cigarette smoking, but poorly differentiated squamous-cell carcinoma did not (Table 67).

Smoking histories were obtained from the clinical records of 112 female lung cancer patients at the Sheffield Royal Infirmary in the UK diagnosed in 1955-1971 (Kennedy, 1973). The tumours were histologically reclassified. The proportion of nonsmokers was 25% among 87 patients with Kreyberg Group I tumour and 40% among 25 patients with Kreyberg Group II tumour. The difference was not statistically significant.

Beamis *et al.* (1975) reclassified histological specimens of 142 female lung cancer cases seen in one hospital in the USA in 1957-1972. Data on smoking habits were obtained from clinical records. Among those with Kreyberg Group I tumour (squamous-cell, small-cell, large-cell and undifferentiated carcinomas), 25/86 (29%) were nonsmokers compared to 35/56 (63%) among cases with Kreyberg Group II tumours (adenocarcinoma and bronchiolo-alveolar-cell carcinomas).

Vincent, R.G. *et al.* (1977) analysed the histology of lung cancer in a series of 1208 male and female lung cancer cases in different smoking categories in the Roswell Park Memorial Institute in the USA. The proportion of adenocarcinomas among nonsmoking patients was 46.7% compared to 19.8% among cigarette smokers (without much variation between different numbers of cigarettes smoked a day). The proportions of squamous-cell and small-cell carcinomas among nonsmokers were 23.3 and 6.7%, respectively, compared to 40.5 and 19.8% among cigarette smokers (again, without much variation between numbers of cigarettes smoked a day).

A case-control study was carried out in Hong Kong in 1976-1977 in order to analyse the relationship between smoking and lung cancer by histological type (Chan *et al.*, 1979). There were 208 male and 189 female patients and 204 male and 189 female controls; the controls were orthopaedic patients in the same hospitals as the lung cancer patients. Data on smoking habits were obtained through interviews of patients. Histological specimens were reclassified. The risk of lung cancer among smokers was greater than that in nonsmokers, both in men and women, but there was little evidence of a dose-response relationship. The risk was greater for squamous-cell and small-cell carcinomas (combined) than for adenocarcinoma. These findings were similar for manufactured cigarettes and for all forms of tobacco (Table 67).

In a case-control study carried out in Cuba in 1978-1980 (Joly, O.G., *et al.*, 1983), there were 607 male and 219 female patients, and 979 hospital and 539 neighbourhood controls. The histological specimens were reclassified (all patients had a histological and/or cytological verification of tumour). Cigarette smoking was associated with all major histological types of lung cancer, although the relative risk for adenocarcinoma was lower than that for the other types. The risk of lung cancer increased significantly with longer duration of cigarette smoking for all histological types (Table 67).

Shimizu *et al.* (1982) analysed a series of 14 946 lung cancer cases diagnosed in 1972-1976 in Los Angeles County, USA. A specific histological diagnosis was available for 76% of the cases; no reclassification was performed. Data (relative risks on the relationship between the amount smoked and risk of total lung cancer, adenocarcinoma and squamous-cell carcinoma) were obtained from a previous case-control study (Pike *et al.*, 1979). Using this information, the authors calculated 'residual' incidence rates of different histological types of lung cancer, i.e., rates as they would be if the total population were nonsmokers. The observed and 'residual' incidence rates per 100 000 for squamous-cell carcinoma were 117.3 and 12.2 in men, and 22.3 and 2.5 in women, whereas the corresponding figures for adenocarcinoma were 47.5 and 9.8 in men and 20.2 and 10.9 in women. In other words, the male:female ratio of the observed rates for squamous-cell carcinoma (5.3) was close to that of the 'residual' rates (5.0), while the ratio of the observed rates for adenocarcinoma (2.3)

disappeared (0.9 for the 'residual' rates). Smoking could explain 90% of the squamous-cell carcinoma cases in both men and women but only 79% of male and 46% of female cases with adenocarcinoma.

In a study from Hong Kong reported by Lam, W.K. *et al.* (1983), there were 267 male and 140 female lung cancer cases diagnosed in 1976-1980 with known smoking habits. The 204 male and 189 female controls were the same individuals as in the study of Chan *et al.* (1979). The relative risks in men of different types of lung cancer in relation to the risk among nonsmokers were 6.9 for squamous-cell carcinoma, 10.4 for small-cell carcinoma, 3.2 for large-cell carcinoma and 0.9 for adenocarcinoma. Among women, the relative risks were 6.5 for squamous-cell carcinoma, 8.3 for small-cell carcinoma, 1.1 for large-cell carcinoma and 1.8 for adenocarcinoma.

Auerbach *et al.* (1979) studied autopsy specimens from the bronchi of US men who died in 1955-1960 or 1970-1977. Changes in the bronchial epithelium, such as basal-cell hyperplasia, loss of cilia and occurrence of cells with atypical nuclei, were recorded for smokers and nonsmokers separately. In both periods studied, these histological changes occurred far less frequently in nonsmokers than in cigarette smokers and increased in frequency with amount of smoking, adjusted for age. The frequencies of epithelial changes in each of the smoking categories in 1970-1977 were much lower than those in 1955-1960. [The Working Group noted that, although the changes recorded are not necessarily direct indicators of cancer risk, they illustrate the dose-response effect between smoking and epithelial changes in the bronchi, possibly related to squamous-cell carcinoma, and reduction in the frequency of these changes with time, at least partly attributable to changes in the smoke content and design of the cigarettes consumed.]

In certain populations, the risk of adenocarcinoma is exceptionally high, even when exposure to tobacco smoke has been low and short in duration. These populations include Chinese women in some regions (Law *et al.*, 1976; MacLennan *et al.*, 1977; Gao, 1986). It is possible that in these populations the etiological factors involved are not related to smoking but to other cultural and environmental exposures, e.g., ways of cooking (MacLennan *et al.*, 1977).

There have been some reports that the proportion of adenocarcinoma may be increasing, particularly in Japan (Hanai *et al.*, 1982) and in the USA (Vincent, R.G. *et al.*, 1977). [The Working Group noted that trends in the relative frequency of histological type must be interpreted very cautiously, since, in addition to real increases in incidence, many other reasons, such as changes in the criteria for histological diagnosis, in the diagnostic facilities available and in the extent to which resections are performed, may have an effect on these trends.]

(c) *Proportion of risk currently attributable to smoking*

Very few attempts have been made to quantify the proportion of cases of lung cancer attributable to tobacco smoking in well-defined populations (Hammond & Seidman, 1980; Davies, J.M., 1981; Doll & Peto, 1981; US Department of Health and Human Services, 1982).

The number of cases attributable to tobacco smoking in a given population is the number that would have been avoided had the individuals of that population not smoked. The simplest way of counting them is to assume that the risk in smokers would have been that in nonsmokers if the former had never smoked, and to consider that the number of person-years of observation would not have been affected to any meaningful extent by such a change in population behaviour. On the basis of these hypotheses, the number of cases attributable to smoking (AC) can be calculated from:

$$AC = (N \times \lambda) - (N \times \lambda_0)$$

and the attributable proportion (AP) from:

$$AP = \frac{\lambda - \lambda_0}{\lambda}$$

where N , λ , λ_0 are, respectively, the number of person-years of observation, the actual observed rate in the total population and the rate in nonsmokers.

The attributable proportion can also be calculated from case-control studies (Miettinen, 1974; Whittemore, 1983).

In addition to tobacco, various occupational and other factors are known to affect lung cancer risks (Merletti *et al.*, 1984), and others may await discovery. Since little is known about the correlation between smoking and such other factors, some uncertainty will remain in the estimates of the exact risks attributable to tobacco smoking. The uncertainty is not, however, so large as to hinder reasonable estimations in many populations.

The best data for calculating the number of lung cancer cases attributable to smoking would be the nonsmoker rate in each category of confounding variable for a representative sample of the population (Table 68). At present, the most reliable such data are those of the American Cancer Society (ACS) for the nonsmoking population of the USA. Table 68 indicates that this rate applies to other populations. The rates are fairly stable over time (Garfinkel, 1981).

Stevens and Moolgavkar (1984) suggested that there may have been a small decrease in the rate of lung cancer for British nonsmoking men in recent years. This result was obtained by fitting a statistical model to population data, partitioning the observed rate between smokers and nonsmokers as described by their proportion and their consumption by birth cohort. [The Working Group noted that residual artefact of the procedure cannot be completely excluded.]

The mortality rates in nonsmokers by age group are shown in Table 69 and Figure 10. The good linearity of the data suggests that a smoothing of the rate could be used in estimating the attributable number of cases and attributable proportion. The results of a weighted linear regression for re-estimating age-group rates from the ACS study are shown in Table 70.

Since there is no indication of differences in rates in nonsmokers in the various countries for which it has been looked at, one can use the previously estimated rates to calculate the number of lung cancer deaths attributable to tobacco smoking in those countries, using vital statistics and the formulae given above. The results are shown in Table 71 for the last year for which deaths are available from the Global Epidemiological Surveillance and Health Situation Assessment data bank of the WHO. In Canada, the USA and England and Wales

Table 68. Lung cancer mortality in nonsmokers

Study	Reference	Start of study	Length of follow-up (years)	Age range (years)	Person-years in nonsmokers		No. of lung cancer death in nonsmokers		Rate/100 000/year ^a	
					Males	Females	Males	Females	Males	Females
ACS 25-state	Garfinkel (1980, 1981)	1959	12	30+	961 975	3 950 186	189 (195)	503 (564)	19.6 (15.6)	12.7 (13.3)
British Doctors	Doll & Hill (1966)	1951	M: 10	20+	54 660	32 075	3	1	<15.9 ^b	<17.5 ^b
	Doll & Peto (1976); Doll <i>et al.</i> (1980)		M: 20 F: 22	20+	NA	NA	7	NA	(10)	(7)
US Veterans	Kahn (1966)	1954	8.5 (up to 1962)	35-84	443 856	-	78	-	17.6 ^b	-
	Garfinkel (1981)		16	NA	-	168 ^c	-	NA	(17.1) ^b	-
Japanese study	Hirayama (1967)	1965	1.25	40+	29 188	148 920	3	9	<29 ^b	<11.4 ^b
	Hirayama (1975b)		8	NA	NA	NA	NA	NA	(14.8)	NA
	Hirayama (1982)		13	248 155	1 431 798	NA	NA	(20.7)	(15.8)	
Swedish study	Cederlöf <i>et al.</i> (1975)	1963	10	18-69	63 520	176 790	7	19	11.0 ^b	10.7 ^b
Canadian study	Lossing <i>et al.</i> (1966)	1955-1956	6	30+	398 328	-	7	-	16.6 ^b	

^aCrude or standardized (in parentheses) rates; since the latter are usually standardized internally, they do not allow strict comparison between countries. <, upper limit of two-sided 95% confidence interval

^bCalculated by the Working Group

^c78 included in 168

Table 69. Lung cancer mortality (rates per 100 000 per year) in nonsmokers, by age group^a


Reference	Population	Age group (years)				
		35-44	45-54	55-64	65-74	75+
Garfinkel (1980) ^b	ACS men	4 (1.0-9.7)	5 (3.1-7.8)	14 (9.9-19.3)	27 (29.3-37.7)	60 (36.1-94.4)
	ACS women	1 (0.4-2.1)	4 (3.0-5.2)	9 (7.3-10.9)	17 (13.7-20.8)	38 (28.6-49.9)
Kahn (1966)	American veterans ^c	0 (0-10.5)	0 (0-24.4)	10 (7.6-17.3)	30 (21.2-37.8)	46 (13.0-120.2)
Hirayama (1985)	Japanese men	-	3.5 ^d (0.4-12.4)	17.6 ^d (10.5-27.9)	43.8 ^d (10.5-27.9)	54.9 ^d (32.5-86.8)

^aIn parentheses, confidence intervals calculated by the Working Group from published rates and person-years

^bWay in which rates were standardized was not specified, and the numbers of cases by age group were not given.

^c16-year follow-up rates calculated by Rogot and Murray (1980), but data not given

^dCalculated by the Working Group

Fig. 10. Lung cancer mortality in nonsmokers, by age^a

^aAdapted by the Working Group from Garfinkel (1981)

Table 70. 'Best' estimate^a of lung cancer mortality rates per 100 000 population per year by age group in nonsmokers

	Age group (years)				
	35-44	45-54	55-64	65-74	75+
Men	2.48	6.23	13.20	25.10	43.50
Women	1.17	3.58	8.92	19.32	37.71

^aSmoothing the American Cancer Society rate (Garfinkel, 1981) by fitting a linear model on a double logarithmic scale, weighting each of five points according to the corresponding period \times years of observations

the results are very similar. In Sweden (Cederlöf *et al.*, 1975), where there is a moderate risk for lung cancer, it is worth comparing the estimate of the attributable proportion with the estimate obtainable directly from the cohort, using percentage of smokers and risk estimates. In men, 6352 out of 25 444 persons who answered the questionnaire were nonsmokers, and the relative risk for smokers was 7. From these figures, an attributable proportion equal to 82% can be calculated. In women, 17 679 out of 26 467 persons who answered were nonsmokers, and the risk for smokers was 4.5, giving an attributable

Table 71. Lung cancer deaths attributable to tobacco smoking in certain countries

Country	Year	No. of deaths ^a	Expected deaths in nonsmokers ^b	Crude rate in persons aged 35+		AC ^c	AP ^d
				Observed	In non-smokers		
Canada							
Men	1978	6 435	556	142.8	11.8	5 762	0.9
Women	1978	1 681	487	34.0	9.9	1 194	0.71
England & Wales							
Men	1981	26 297	1 576	228.5	13.3	24 720	0.94
Women	1981	8 430	1 663	63.3	12.4	6 767	0.80
Japan							
Men	1981	16 638	2 868	64.8	10.7	13 184	0.83
Women	1981	6 161	2 593	21.0	8.9	3 568	0.58
Sweden							
Men	1981	1 777	301	85.0	14.0	1 476	0.83
Women	1981	654	281	28.0	12.3	373	0.57
USA							
Men	1979	72 803	5 778	166.7	12.7	67 024	0.92
Women	1979	25 648	5 736	50.0	11.1	19 912	0.78

^aFrom Global Epidemiological Surveillance and Health Situation Assessment data bank of WHO

^bRate given in Table 70 extrapolated down to 20 and 30 years for calculating rate in age groups 0-24 and 25-34 years. This procedure slightly overestimates the number of expected deaths.

^cAC, number of cases attributable to smoking

^dAP, proportion of cases attributable to smoking

proportion equal to 54%. [These figures are remarkably close to that obtained from applying the smoothed ACS rate to the Swedish population, and it suggests that the method could also be used for many of the countries not listed in Table 71, but perhaps not for those with substantial Chinese populations; see pp. 234-235.]

In France, a large hospital-based case-control study conducted between 1976 and 1980 mainly in the Paris area assembled 1217 cases of histologically confirmed lung cancer cases of Kreyberg Groups I and II. Among 1098 cases of the first group, 24 were in nonsmokers, and the relative risk for smoking was 17.2. Of the 119 cases of the second histological type, nine were in nonsmokers and the relative risk was 3.6 for smoking (Benhamou *et al.*, 1985). [Attributable proportions of 96% and 66%, respectively, can be calculated, giving an attributable proportion of 89% for lung cancer of any type. Using the ACS rate, one can calculate that 14 019 male lung cancer deaths out of the 15 635 observed in the French population in 1981 were due to smoking, giving an attributable proportion of 90%, a figure

again in remarkable agreement with that obtained from the case-control study. The low figure of 17% obtained for women is a composite of very different rates for different age groups; e.g., 40% in 45-54-year-old women and 3% in 75+-year-old women. It would, however, be unwise to use this (ACS-based) method for some populations; for example, in some heavily occupationally exposed populations, the rate for nonsmokers may be higher than that in the ACS study.]

In Italy, a population-based case-control study was conducted in the Lombardy region, which is covered by a cancer registry (Berrino *et al.*, 1982). Among the 204 male cases reported in the analysis, 194 were in smokers; and the relative risk for smoking, adjusted for occupational exposure, was found to be 7.1. An attributable proportion of 81% was due to smoking (Pastorino *et al.*, 1984). [The ACS-based method for the whole male Italian population would give 89% for 1979. Although the difference between these two figures is not statistically significant, the existence of a real difference cannot be excluded.]

Attributable risks reported in one part of Japan by Hirayama (1982) were 69% and 13% for men and women, respectively, over the period 1965-1978. [The proportions calculated using the ACS-based method for the whole of Japan in 1981, i.e., about ten years later, are 83% in men and 58% in women.]

Data for estimating attributable proportions are available for only a few other countries. For example, in Havana, Cuba, a case-control study was conducted between 1978 and 1980 (Joly, O.G. *et al.*, 1983), including all incident cases, one hospital control and one neighbourhood control per case; 595 of the 607 men were smokers, and a relative risk of 12.4 was reported. [An attributable proportion of 90% can thus be calculated.] Among the 219 female cases, 167 were in smokers, and a relative risk of 5.1 was reported [giving an attributable proportion of 61%].

In Bombay, India, a hospital-based case-control study was conducted between 1963 and 1970 (Notani & Sanghvi, 1974). The study participants were matched for sex, community and age, but the results are reported for the two sexes combined. [It is thus impossible to calculate attributable proportions in men and women separately. Since 80% of the cases were in smokers and the relative risk was 2.5, however, the attributable proportion would be somewhat lower (about 50%) than those calculated in Table 71.] Jussawalla and Jain (1979) later reported a much higher relative risk (16.8) for male smokers in the same town. In the latter study, 43% of the male incident cases were compared to a random sample of Bombay residents taken from the voters' list. The proportions of smokers in cases and controls were 81% and 21%, respectively. [If the cases interviewed are a representative sample of cases arising in this population, in which 21% of individuals are smokers, the proportion of male cases attributable to smoking (either *bidis* or cigarettes) would be about 75%, a fairly high proportion in view of the low observed lung cancer rate found in Bombay (truncated rate of 22.6 in men; Waterhouse *et al.*, 1982).]

A hospital-based case-control study was conducted in Singapore between January 1972 and June 1973, including 147 male Chinese lung cancer cases, of whom 142 were smokers. A relative risk of 3.8 for smoking was reported. In women, 21/39 Cantonese lung cancer cases and 21/44 non-Cantonese lung cancer cases were in smokers; relative risks of 1.6 and 3.6, respectively, were calculated. Despite the small number of cases, it is clear that tobacco

smoking explains very little of the relatively high rate of lung cancer in Cantonese women. In this study, a relatively high proportion of adenocarcinomas was found (30% in 54 Cantonese female cases for whom histological typing was possible), and this tendency could explain the result (MacLennan *et al.*, 1977). A similar study was carried out in Hong Kong (Chan *et al.*, 1979). Two histological groups were examined separately: squamous-cell carcinoma + small-cell carcinoma and adenocarcinoma + large-cell carcinoma; relative risks of 3.9 and 1.6 were found for female current smokers, with proportions of 30% and 59%, respectively, of nonsmokers among female cases. In Los Angeles County, USA, Shimizu *et al.* (1982) found that only 46% of female adenocarcinomas were due to smoking; they also reported a high rate of adenocarcinomas in Chinese women in that county.

Hinds, M.W. *et al.* (1981) compared the smoking histories of 375 female lung cancer cases obtained from medical records between 1968 and 1978 in Hawaii with that of 2404 sex- and race-matched controls. After controlling for socioeconomic status, very different relative risks for smoking were found according to ethnic origin (10.5 for Hawaiians, 4.9 for Japanese, 1.8 for Chinese). This finding is largely explained by the proportion of adenocarcinomas in each group. Using the above relative risk estimate, the authors calculated attributable proportions of 79%, 44% and 11%, respectively, for the three ethnic groups. The incidence was greater, however, in Chinese than in Japanese women.

[Attributable proportions must be interpreted with caution. If an attributable proportion is 90%, it does not mean that, if smoking is given up tomorrow, 90% of lung cancer deaths will be eliminated immediately; this will happen only in the course of time. The calculated proportion applies to a population as a whole and cannot be extrapolated to smaller populations among which an occupational hazard exists. Low attributable proportions may be interpreted differently and should be examined in conjunction with incidence rates. Because of the combined effect of smoking and occupational exposure, a figure of 90% for tobacco smoking does not imply that the effect of an occupation is less than 10%; nor does it mean that an occupationally exposed smoker with lung cancer has a 90% probability that the cancer was caused by smoking.]

(d) *Trends in lung cancer incidence in relation to cigarette usage*

(i) *Introduction*

In the world as a whole, the overall pattern for lung cancer is one of rapid increase. About 600 000 new cases of the disease were estimated for 1975 (Parkin *et al.*, 1984), and this number will have increased since then. Three factors contribute to this continuing increase. First, especially in old people, increased access to diagnosis and progressive improvements in the accuracy of certification of cause of death mean that an increasing proportion of fatal lung cancers are recognized as such (Waterhouse *et al.*, 1976; Doll & Peto, 1981). Second, the absolute size of the world population of adults old enough to be at risk of developing the disease is increasing rapidly. Finally, and most importantly, large increases in the numbers of people smoking cigarettes have produced — and are producing — large, real increases in age-specific lung cancer rates (Doll & Peto, 1981).

Indeed, although lung cancer is believed to be the commonest fatal neoplastic disease in the world today (on the basis of knowledge of the worldwide trends of lung and stomach cancer and the data of Parkin *et al.*, 1984), most of the increase that has thus far materialized has been the delayed result of increases in cigarette smoking by young adults that took place in the first half of this century (US Department of Health and Human Services, 1982). Little has yet been seen of the increase in lung cancer rates that will be produced over the next few decades as a delayed result of the large increases in cigarette smoking by young adults that have been (and still are) taking place during the second half of the century, not only in the developed but also, now, in the developing world (Royal College of Physicians, 1983). [Reliable predictions are not yet available, but it is plausible that by the year 2000 the 1975 total of 600 000 lung cancer deaths a year worldwide will have increased to about two million, the large majority of which will be due to tobacco.]

Rather than present tabulations of past and present lung cancer rates in many countries, the Working Group chose to present (after a review of some general methodological considerations) the patterns of increase for six countries — five developed and one developing — selected to illustrate different types of evolution of the disease onset rates.

The first two (Finland and the UK) are countries where cigarette smoking by young men appears to have become widespread in the first quarter of the century and increased slowly up to 1975 (Lee, P.N., 1976). In the UK, extensive changes to cigarettes that lowered 'tar' yields were implemented in the third quarter (Lee, P.N., 1976; Wald *et al.*, 1981a). Consequently, any effects that these changes in cigarette composition may have on lung cancer can be assessed against a background rate of lung cancer that had, at least in early middle age, already approximately stabilized (at a very high level) (Doll & Peto, 1981; Teppo, 1984).

The third (the USA) is a country where cigarette smoking by men increased substantially in the second quarter of the century (Lee, P.N., 1975), and where 'tar'-level reductions were also implemented in the third quarter (US Department of Health and Human Services, 1982). Consequently, any effects of these reductions on lung cancer rates have to be assessed against a background of the rapid rises in lung cancer produced by the delayed effects of the earlier increase in cigarette usage (Doll & Peto, 1981).

An example of a country where smoking by women became common only in the third quarter of the century is France (Hill, C. & Flamant, 1986). The large increases in lung cancer that this will eventually produce have not yet really begun to materialize, as discussed on p. 213.

The fifth example, the USSR, differs not so much in timing but in 'tar' trends. The USSR is a country where cigarette smoking by young men appears to have become widespread during the first half of the century [Actual data were not available to the Working Group.], but where 'tar' levels still remain much higher than they currently are in the first three countries (see Table 10, p. 64), and where the absolute lung cancer rates in early middle age appear to be remaining as high as those in the UK before 'tar' levels were reduced (Napalkov *et al.*, 1983).

The final example presented in this section is a city (Shanghai, China) in a developing country, which is unusual among developing parts of the world in that cigarette consumption among men has been widespread for many decades (see Table 13, p. 69), and in which 'tar levels' remain high (see Table 10, p. 64). Once due allowance has been made for various methodological problems in assessing rates and trends in developing parts of the world (Waterhouse *et al.*, 1976), the high lung cancer rates in Shanghai (Shanghai Cancer Institute, Shanghai Sanitary Antiepidemic Centre, 1982) illustrate what can be expected elsewhere in China — and, indeed in other developing countries — when the delayed health effects materialize of the large changes in cigarette consumption that have already taken place in many such areas.

(ii) *Methodology*

(1) *Sources of data on history of cigarette usage.* In developed countries, where cigarette sales are monitored quite closely, data on actual cigarette sales per head (Lee, P.N., 1975) are usually reasonably reliable. Data from questionnaires on the proportion of smokers or on the total numbers of cigarettes smoked may be biased, as antismoking propaganda may have a larger effect on people's self-reported smoking than on their actual smoking, as seen by recent divergences between the trends in self-reported smoking and sales in the USA (Warner, 1978) and France (Hill, C. & Flamant, 1986).

(2) *Assessment of separate age-specific trends.* Throughout this section, 'age' is used to mean age in years, while 'time' is used to mean calendar year. 'Age' is conventionally divided into five-year age groups (10 for the USSR), but, because lung cancer is so rare in childhood and early adult life, the present analyses are of lung cancer trends only at ages 30-34 and upwards (to 80-84 and finally 85+ — a total of 12 different age groups). When, in one country, the trends in certain age groups are downwards but those in certain others are upwards, these are examined separately.

(3) *Miscertification of cause of death.* Due to errors in death certification procedures, lung cancer rates derived from death certificates may not reflect the true lung cancer death rate, particularly in old people, and progressive rectification can cause large, purely artefactual increases in the age-specific death certification rates in older age groups (Doll & Peto, 1981). Such artefactual errors were large in all people of all ages, even in developed countries, during the first half of the century and may still be so in many developing countries. Since 1950, however, such increases may have been important in most developed countries only for old people.

(4) *Misregistration of incident cases.* Related problems may also affect the use of lung cancer incidence rates to assess the real trends in disease onset rates: discrepancies between the two may exist, due generally to progressive improvement in disease registration techniques. Nevertheless, for certain areas, only incidence trends are usable, either because mortality trends are unavailable or because they are completely unreliable (Doll & Peto, 1981).

(iii) *Effects of nationwide adoption of cigarette usage*

Cigarettes cause a far greater risk of lung cancer than other forms of tobacco do. So, when a nation adopts widespread cigarette usage, large, real increases in lung cancer rates

will eventually follow, whether the switch is from no tobacco use to cigarettes or from use of other forms of tobacco to cigarettes. These large increases in lung cancer rates may, however, appear many decades after the large increases in cigarette usage, because it is those who start to smoke in early adult life who are at greatest risk in middle and old age (Doll & Peto, 1981). Thirty years separate the late teenage years from the age range 45-49, while 60 years separate the late teenage years from the age range 75-79. For 30 years after cigarette smoking among teenagers finally becomes maximal, lung cancer rates in people aged 45-49 may continue to rise. Thereafter, they will, other things being equal, become stable, while lung cancer rates in people of the age range 65-69 may continue to rise for another 20 years before they too stabilize. Hence, it will probably not be until about 20, 30, 40, 50 and 60 years after cigarette smoking in people in their late teens or early twenties approaches a maximum that lung cancer rates in people aged 35-39, 45-49, 55-59, 65-69 and 75-79 can be expected to do so.

This possibility is exemplified by UK male lung cancer death certification rates (Table 72). Those rates in italics are for men born in about 1900 and are approximately maximal. The general pattern in each age group is one of sharp increases preceding this maximum, followed by an approximate stability that is disturbed only by the recent decreases that have begun to take place in early middle age. These decreases were examined in more detail on pp. 210-212, where they were attributed to changes in 'tar' delivery per cigarette.

Similar decreases are beginning to emerge in Finland (Fig. 11), where 'tar' levels have probably decreased slightly more sharply than in the UK, due in part to progressive abandonment of the 'Russian-style' *papirossi* cigarettes that used to be favoured in Finland (Lee, P.N., 1975). Due to the use of a log scale, the decreases over the past 15 years (i.e., 1963-1978) at ages 45-49, 40-44 and 35-39 may not look important, yet they would, respectively, represent avoidance of about 31%, 41% and 53% of the lung cancer deaths at these ages in 1963. Except for a temporary decrease during the Second World War, cigarette consumption per Finnish adult has been fairly steady for more than 50 years, averaging about four/day and five/day, respectively, in the second and third quarters of the present century (Lee, P.N., 1975).

It is interesting to contrast these figures from countries where substantial changes in cigarette composition have occurred with the corresponding figures from a country such as the USSR, where they have not (Table 73). In the USSR, typical 'tar' deliveries per cigarette are still about 20-30 mg (see Table 10, p. 64), with a mean of about 25 mg. This is nearly as high as the 'tar' deliveries of UK and US cigarettes in the 1950s, before they were halved, together with other changes in cigarette design and smoke composition (Wald *et al.*, 1981a; US Department of Health and Human Services, 1982), and it may be noteworthy that the USSR lung cancer incidence rates in middle age (Table 73) appear to be converging towards the high UK lung cancer rates of the 1950s and not towards the lower rates that now obtain in both the UK (Table 72) and Finland (Fig. 11).

The increases between 1960 and 1970 of about 50% (Table 73), suggested by the incidence data, are larger than the corresponding increases suggested by the mortality data — indeed, the crude male lung cancer death certification rate rose by only about 25% between 1961 and 1970 in the USSR (Cooper, 1982). Recent mortality data are not available, but there was by 1970 a reasonable correspondence between the mortality and the incidence data (Napalkov *et al.*, 1983), so the recent incidence data (Table 73) may suffice.

Table 72. Annual number of death certifications from respiratory cancer (per 100 000) in UK men, 1943-1983 (average of five years around each date)^a

Age range (years)	1943 ^b	1953 ^c	1963 ^d	1973 ^e	1983 ^f
30-34	4	4	3	2	1
40-44	20 ^g	25	22	18	12
50-54	63	123	122	107	77
60-64	107	258	367	354	299
70-74	80	265	497	678	640
80-84	. ^h	144	342	602	834
No. of cigarettes/man per day in preceding year	10.7	9.9	10.6	10.6	7.1

^aCalculated by the Working Group from Office of Population Censuses (1975, 1980a,b,c, 1982, 1983b, 1984a,b,c,d, 1985a) (see footnote *a* to Table 59)

^bICD5 47b

^cICD6 162-164

^dICD7 162-164

^eICD8 162, 163


^fICD9 162-165

^gFigures in italics, rates for men born in about 1900

^hSubject to gross undercertification

If the hypothesis is true that 'tar' level decreases and other changes in cigarette design and smoke composition are largely responsible for the recent decreases in lung cancer mortality among people in early middle age in the UK and Finland (see Table 72 and Fig. 11), then it may be asked why corresponding decreases are not seen in other countries. They may, however, be occurring but being swamped by the large increases in lung cancer mortality due to the delayed effects of past changes in cigarette usage (Doll & Peto, 1981; Peto & Doll, 1984). Finland and the UK provide an opportunity to observe the effects of 'tar' level changes because they are probably the only two countries in the world (Lee, P.N., 1975) where cigarette smoking by young adults became established so long ago that the lung cancer rates in early middle age had stabilized by the late 1950s, i.e., before the large 'tar' level reductions began.

In the USA (Table 74), cigarette sales increased between the First and Second World Wars from two (in 1920) up to five (in 1939) cigarettes per adult per day; during the Second World War, the number doubled and has remained thereafter at 10-12 per adult per day (US Department of Agriculture, 1965; Lee, P.N., 1975). A delayed effect of this large increase in cigarette usage was the large increases in male lung cancer death rates that took place throughout the 1950s and 1960s, the maximal rate in any age group being seen among those

Fig. 11. Lung cancer incidence in Finnish men, 1956-1980^a

^aFrom Finnish Cancer Registry (1963-1983)

Table 73. Annual lung cancer incidence registration rates per 100 000 men in the USSR 1960-1980^a compared with corresponding rates in the UK, 1958^b and 1983^c

Age range (years)	USSR Incidence					England & Wales Mortality $\times 1.1^d$	
	1960	1965	1970	1975	1980	1958	1983
30-39	3	5	6	7	6	7	3
40-49	24	29	35	46	47	47	24
50-59	85	127	142	153	176	197	136

^aFrom Napalkov *et al.* (1980, 1982); incidence data for 1960 are published for people aged 60 years and over, without subdivision

^bFrom Doll and Peto (1981)

^cFrom Office of Population Censuses and Surveys (1984b)

^dBy 1958, UK mortality rates at ages 30-59 had reached their maxima and had stabilized. Rates for 10-year age groups are estimated as averages of the rates for the two corresponding five-year age groups. Multiplication by 1.1 provides an approximate estimate of the ratio of incidence to mortality (Waterhouse *et al.*, 1976, 1982).

who reached adulthood in the late 1940s. Thus, at ages 30-34, 35-39, 40-44 and 45-49, the maximal lung cancer rate has been reached (Doll & Peto, 1981); and at 50-54 it should recently have been reached (Table 74). Within each age group, the large increases before the maxima are clearly seen; in addition, however, there does appear to be a slight decrease after the maximum is attained (especially at ages 30-34).

Table 74. Annual number of deaths from respiratory cancer (per 100 000) among US men, 1940-1980^a

Age range (years)	1940	1950	1960	1970	1980 ^b
30-34	1.5	1.7	2.4 ^c	2.1	1.1
40-44	7	11	15	22	17
50-54	24	47	67	87	91
60-64	41	97	166	225	236
70-74	38	103	211	355	422
80-84	30	77	152	291	460
Actual period studied	1938-1942	1948-1952	1958-1962	1968-1972	1978-1981
No. of cigarette/ adult per day in preceding year ^d	5	9	10	10	11 ^e

^aFrom Doll and Peto (1981), except where otherwise stated

^bFrom Horm *et al.* (1984)

^cFigures in italics, rates for men born in about 1920

^dFrom Lee, P.N. (1975)

^eFrom Peto and Doll (1984)

Shanghai was, before the establishment of the People's Republic of China in 1949, one of the larger oriental markets for western cigarette manufacturers, and still about half the men in Shanghai smoke cigarettes, the 'tar' levels in many of which appear to be 'very high' (Gao, 1986; see Table 10, p. 64). Men in the municipal area of Shanghai had, in the early 1970s, lung cancer rates that were the highest of any municipal area or province in China (Li *et al.*, 1979); and, indeed, they exceed the absolute rates seen in many developed countries (Table 75).

Comparison of the earlier with the more recent figures (Table 75 and Shanghai Cancer Institute, Shanghai Sanitary Antiepidemic Centre, 1982) suggests the age dependence of the trends. Very few middle-aged or older women in Shanghai have smoked cigarettes regularly for any substantial length of time, and no clear trend in the age-specific lung cancer incidence rates among women aged 30-54 is seen. Among women aged 55-64, however, a moderate upward trend is apparent, while among older women a vast upward 'trend' is in progress. [In principle, real increases could be in progress only in old age, but the lack of any

Table 75. Trends in lung cancer incidence rates in Shanghai city, 1963-1965 to 1972-1979^a

Age (years)	Men			Women		
	1963-1965	1972-1979	Increase (%)	1963-1965	1972-1979	Increase (%)
30-	2	2	} 31	2	2	} 7
35-	4	5		2	4	
40-	11	14		7	7	
45-	24	32		13	12	
50-	51	75	45	26	27	4
55-	98	157	60	38	45	16
60-	157	272	73	62	82	31
65	177	391	121	61	125	105
70-	210	475	126	65	155	138
75-	213	436	104	74	153	107
80-	} 141	375	} ~150	} 38	138	} ~200
85+		334			108	

^aShanghai Cancer Registry (1970); Shanghai Cancer Institute, Shanghai Sanitary Antiepidemic Centre (1982)

trend in early middle age (and the lack of much tobacco use among Shanghai women) suggests that there may be no real trend at any age, and that apparent female trends are due to changes in diagnostic practices, especially in old people.] In contrast, there does seem to be a substantial trend in lung cancer onset rates in men in early middle age in Shanghai. [The Working Group considered that the lack of any such trend among women of comparable age makes it plausible that this trend among men in early middle age is mostly real. However, the trends among older women suggest that much of the upward trend in lung cancer in older men may also be artefactual.] The current rates in middle-aged men in Shanghai (Table 75) are already similar to those in the UK (Table 72), but the rates in old men are much lower in Shanghai. [The Working Group noted that this may reflect the slowness with which the effects of smoking (or whatever other causes underly the increase among men in early middle age) extend themselves into old age. In either case, the rates recorded in old age will probably continue to rise at least throughout this century.]

(e) Summary

Lung cancer is believed now to be the commonest fatal neoplastic disease in the world, and rapid increases in its incidence are still in progress in many developed and developing countries. Tobacco smoking causes most cases of lung cancer, and where prolonged cigarette smoking is widespread the habit generally accounts for more than 80% of the disease. In populations in which the effect of smoking has not yet reached its peak—including most female populations—the proportion may be lower.

The three principal types of lung cancer are squamous-cell, small-cell and adenocarcinoma. All of these types are caused by smoking, although the relative risk is least extreme for adenocarcinoma.

The observed incidence of lung cancer may depend on four factors:

(i) *The daily dose of tobacco*

It is consistently found that, among otherwise similar cigarette smokers, there is a direct relationship between the daily dose and the excess risk of lung cancer in both men and women. The observed relationship is, in many studies, one of approximate linear proportionality.

(ii) *The duration of regular smoking*

Because damage to the lung accumulates with continuous smoking, the incidence of lung cancer depends strongly on the duration of smoking. So,

(1) those who start to smoke in adolescence and continue to smoke are at the greatest risk of developing lung cancer in adult life;

(2) there is a delay of several decades between the widespread adoption of cigarette smoking by young adults and emergence of the full effects on national lung cancer rates;

(3) even among people who have been smoking for many years, those who have not already developed lung cancer (or some other disease) can, by ceasing to smoke, avoid most of their subsequent lifelong risk of tobacco-induced lung cancer.

(iii) *The form in which tobacco is smoked (cigarettes, cigars, pipes and bidis)*

It is generally found that, among otherwise similar smokers, those who have used only cigarettes have lung cancer risks much higher than those who have used only pipes and/or cigars, although the latter materials do cause some appreciable risk.

In large parts of Asia, the chief form in which tobacco is smoked is the *bidi*, and there is evidence that regular use of *bidis* also increases the risk for lung cancer.

(iv) *The type of cigarette*

Soon after the lung cancer risks from smoking, especially of cigarettes, were first established during the 1950s, substantial modifications of cigarette manufacture were introduced in some countries. At present, only about 20 years after their introduction, no direct comparison of the health effects of lifelong use of modified and unmodified cigarettes is possible, but:

(1) In one large cohort study, cigarettes delivering less than 17.6 mg 'tar' were associated with a lower lung cancer risk than were those delivering more than 25.7 mg 'tar'. In other epidemiological studies — mostly case-control — there was a fairly consistent tendency for lung cancer risks to be lower among users of filter than of nonfilter cigarettes. The reduction in the largest and most recent such study was about 40-50%, which was highly significant; in that study, 'tar' yields were also recorded and were positively associated with lung cancer risk.

(2) In a few countries where changes in cigarette design and composition began to be made in the late 1950s or early 1960s, cigarette smoking by young men had been established so many years previously that some of the lung cancer rates in men in early middle age had largely or wholly completed their rise by 1960, and might have been expected to remain

approximately constant thereafter if the risk per cigarette had remained constant. A few years after the changes in cigarettes (associated with reductions in 'tar' levels) became substantial, however, substantial decreases in lung cancer rates began to appear in these particular age groups, without a corresponding reduction in the number of cigarettes smoked.

3. Cancer of the urinary tract

(a) *Geographic and temporal correlation studies*

(i) *Lower urinary tract*

Lea (1966), on the assumption that death rates from cancer of the bladder are correlated with death rates from cancer of the lung if these two neoplasms are both related to cigarette smoking, compared such rates in 20 countries. The correlation coefficient (0.6) was highly statistically significant for males but not for females. Fraumeni (1968) compared variation in bladder cancer mortality between men and women in the USA with the per-caput cigarette sales, estimated from tax revenues; a correlation coefficient of 0.73 was found and persisted when adjusted for urbanization. Hoover and Cole (1971) examined trends in smoking habits and bladder cancer incidence or mortality for successive birth cohorts in the USA, Denmark, and England and Wales; an association, consistent in both sexes, was found between increase in smoking and increased occurrence of the disease. Similarly, Armstrong and Doll (1974) attributed an increase in bladder cancer mortality rates in UK male cohorts born since 1870 to an increase in cigarette smoking since 1890. A cohort analysis of bladder cancer mortality (1951-1970) in England and Wales in relation to cigarette consumption has been reported by Stevens and Moolgavkar (1979); the relative risk due to smoking of 20 cigarettes/day for 20 years was estimated to be around 3.0. The same estimate has been obtained from an extension of the analysis to 1941-1970 (Moolgavkar & Stevens, 1981).

(ii) *Kidney*

Fraumeni (1968) also reported a correlation coefficient of 0.49 between cigarette consumption and kidney cancer mortality in the USA, independent of level of urbanization.

(b) *Analytical studies*

(i) *Study designs*

Cohort studies on smokers have been reported from the UK (Doll & Hill, 1964a,b; Doll & Peto, 1976; Doll *et al.*, 1980), the USA (Hammond & Horn, 1958a,b; Hammond, 1966; Kahn, 1966; Weir & Dunn, 1970; Hammond & Seidman, 1980; Rogot & Murray, 1980), Canada (Lossing *et al.*, 1966), Japan (Hirayama, 1967, 1975a,b, 1977, 1985) and Sweden (Cederlöf *et al.*, 1975). The design of these studies is described on pp. 199-203.

The study designs of available case-control investigations are summarized in Table 76.

Table 76. Case-control studies on smoking and urinary-tract cancer: main characteristics of study design

Reference (place and years of study)	Numbers of cases and controls	Criteria of eligibility and comments
Lower urinary tract		
Lilienfeld <i>et al.</i> (1956) (USA, 1945-1955)	Men: 321 cases and 663 controls; women: 118 cases and 1205 controls	Hospital-based study; male controls: 287 prostate cancers, 39 benign bladder conditions and 337 healthy men; women: 776 breast cancers, 110 benign bladder conditions and 319 healthy women
Lockwood (1961) (Denmark, 1956-)	Men: 282 cases and 282 controls; women: 87 cases and 87 controls	Population-based study; living cases from the Danish Cancer Registry (1956-1957); controls selected from Population Registry
Schwartz <i>et al.</i> (1961) (France, 1954-)	Men: 214 cases and 214 controls	Hospital-based study; age-matched controls were subjects admitted to hospitals for accidents
Wynder <i>et al.</i> (1963a) (USA, 1960-1961)	Men: 300 cases and 300 controls; women: 70 cases and 70 controls	Hospital-based study; sex- and age-matched controls; papillomas excluded; controls: cancers of respiratory system, upper alimentary tract and myocardial infarction excluded
Cobb & Ansell (1965) (USA, 1951-1961)	Men and women: 136 cases and 342 controls	Hospital-based study; 120 colon cancer controls + 222 controls with 'pulmonary problems'; data on smoking available for 131
Staszewski (1966) (Poland, 1958-1964)	Men: 150 cases and 750 controls	Hospital-based study; age-matched controls with cancer or other diseases
Dunham <i>et al.</i> (1968) (USA, 1958-1964)	Men: 334 cases and 350 controls; women: 159 cases and 177 controls	402 incidence cases in New Orleans and 91 prevalent cases or cases not living in the city; hospital controls, including unspecified numbers of bronchitis, emphysema, myocardial infarction; 162 (29%) of eligible cases not interviewed
Anthony & Thomas (1970) (UK, 1958-1967)	Men: 381 cases and 275 controls	Hospital-based study; surgical controls (excluding chest, genitourinary and malignant disease) in 1955-1958
Cole <i>et al.</i> (1971) (USA, 1967-1968)	Men: 360 cases and 381 controls; women: 108 cases and 117 controls	Cases randomly selected among all (668) eligible incident cases occurring in 1967-1968 in 87 cities of the Boston area (20-89-years old); controls: random sample of 20-89-year-old residents, matched for sex and age; interviews of 140/470 cases and 78/500 controls obtained from spouse or next-of-kin

Table 76 (contd)

Reference (place and years of study)	Numbers of cases and controls	Criteria of eligibility and comments
Tyrrell <i>et al.</i> (1971) (Ireland, 1967-1968)	Men: 200 cases and 200 controls; women: 50 cases and 50 controls	Hospital-based study; age- and sex-matched urological controls
Makhyoun (1974) (Egypt, 1966-1971)	Men: 365 cases and 365 controls	Hospital-based study; age-matched non-cancer controls; 278 cases and 278 matched controls had previous urinary bilharziasis
Morgan & Jain (1974) (Canada)	Men: 158 cases and 158 controls; women: 74 cases and 74 controls	Hospital-based study; controls matched for sex and age; postal questionnaires: responses were 67% (cases) and 57% (controls) among men; 73% (cases) and 57% (controls) among women
Schmauz & Cole (1974) (USA)	Men: 18 cases renal pelvis and ureter cancer (1:8) and 376 controls	Population-based study of cancer of the renal pelvis and ureter (see Cole <i>et al.</i> , 1971, for design)
Wynder & Goldsmith (1977) (USA, 1969-1974)	Men: 574 cases and 574 controls; women: 158 cases and 158 controls	Hospital-based study on 40-80+-year-old cases and sex-, ethnic group-, hospital- and age-matched controls; controls had no 'tobacco-related condition'
Miller, C.T. <i>et al.</i> (1978) (Canada)	Men: 188 cases and 564 controls; women: 77 cases and 231 controls	Hospital-based study; two sex- and age-matched controls (only subjects over 40 years) for each case; self-completed questionnaires
Sadeghi <i>et al.</i> (1979) (Iran, 1969-1976)	Men: 88 cases and 88 controls	Hospital-based study; sex- and age-matched hospital controls excluding cancer, pulmonary and bladder disease (23/122 cases discarded due to poor information)
Howe <i>et al.</i> (1980) (Canada, 1974-1976)	Men: 480 cases and 480 controls; women: 152 cases and 152 controls	Population-based study; eligible cases: all patients with newly diagnosed bladder cancer in 3 Canadian provinces (77% interviewed); controls matched for sex, age and neighbourhood (refusals were 20%, 4% and none in the 3 provinces; refusing controls were substituted); male cases had higher education and income than controls
Tola <i>et al.</i> (1980) (Finland, 1975-1976)	Men: 134 cases and 134 controls; women: 46 cases and 46 controls	Originally eligible cases were all (274) those reported to the Finnish Cancer Registry for 5 Finnish provinces; postal questionnaires sent to 269 cases and 271 sex- and age-matched hospital controls or their relatives; responses were 80% (cases) and 81% (controls); source of information was a relative for 39% (cases) and 12% (controls)

Table 76 (contd)

Reference (place and years of study)	Numbers of cases and controls	Criteria of eligibility and comments
McCredie <i>et al.</i> (1982) (Australia, 1977-1980)	Men: 27 cases and 70 controls; women: 40 cases and 110 controls	Cancer registry and hospital-based study; renal pelvis cancer cases; friends or relatives of other patients (1st control group), plus additional controls attending a screening clinic (2nd control group); 37% of cases and 16% of controls interviewed at home; 24 cases and no controls interviewed by their doctors; higher socio-economic status among screening clinic controls
Najem <i>et al.</i> (1982) (USA, 1978)	Men: 65 cases and 123 controls; women: 10 cases and 19 controls	Hospital-based study; prevalent cases only; 2 controls per case matched for sex, age, ethnic group, place of birth and place of residence (cancer and tobacco-related heart disease excluded)
Cartwright <i>et al.</i> (1983) (UK, 1978-1981)	Men: 932 cases and 1402 controls; women: 327 cases and 579 controls	90% of incidence cases in West Yorkshire (1978-1981) and prevalent cases included; sex- and age-matched hospital controls (25% arterial disease; 60% accident, minor surgery; 10% chest conditions)
McCredie <i>et al.</i> (1983) (Australia, 1977-1982 [ureter], 1980-1982 [renal pelvis])	Men: 36 (ureter) and 29 (pelvis) cases; 307 controls	Population-based (cancer registry) study; cancers of the ureter and renal pelvis only; controls were a random sample of the general population; questionnaires mailed to cases and controls (no. of non-respondents not given); higher educational level among controls
McLaughlin <i>et al.</i> (1983) (USA, 1974-1979)	Men: 50 cases and 428 controls; women: 24 cases and 269 controls	Population-based study on cancer of the renal pelvis (71/74 were transitional-cell carcinomas); controls were (1) a random sample of the general population and (2) a group of deceased individuals matched to the deceased cases
Møller-Jensen <i>et al.</i> (1983) (Denmark, 1979-1981)	Men: 286 cases and 574 controls; women: 95 cases and 193 controls	Cases, 2/3 of all incident cases in Greater Copenhagen (under age 75); controls, a random sample of the general population (out of 1052 controls approached, 109 refused, 114 were not located and 39 were too ill)
Mommsen & Aagaard (1983) (Denmark, 1977-1979 [men], 1977-1980 [women])	Men: 165 cases and 165 controls; women: 47 cases and 94 controls	Population-based study; controls: random sample of general population; cases interviewed at hospital, controls by phone

Table 76 (contd)

Reference (place and years of study)	Numbers of cases and controls	Criteria of eligibility and comments
Morrison <i>et al.</i> (1984) (UK and Japan, 1976-1978; USA, 1976-1977)	Men: Greater Man- chester, 398 cases and 490 controls; Nagoya (Japan), 224 cases and 442 controls; Boston area, 427 cases and 391 controls Women: Greater Man- chester, 155 cases and 241 controls; Nagoya, 66 cases and 146 con- trols; Boston area, 165 cases and 142 con- trols	Population-based study in USA, Japan, UK; 96% (Manchester), 84% (Nagoya) and 81% (Boston) of all incident cases (aged 21-89) were interviewed; controls were randomly selected from electoral registers; in Nagoya most cases were interviewed in hospital, all other groups at home; 95% of tumours were of the bladder
Vineis <i>et al.</i> (1984) (Italy, 1978-1983)	Men: 512 cases and 596 controls	Hospital-based study; 210/512 prevalent cases and 225 age-matched pairs (with urological controls); 287 cases and 371 unmatched controls from surgical departments (87 hernias, 41 peripheral arteriopathies and other diagnoses)
Kidney		
Schwartz <i>et al.</i> (1961) (France, 1954-)	Men: 69 cases and 69 controls	See Schwartz <i>et al.</i> (1961) above
Bennington & Laubscher (1968) (USA, 1951-1966)	Men: 88 cases and 170 controls; women: 12 cases and 20 controls	Hospital-based study; information on smoking habits retrieved from clinical records; information lacking for 22/122 cases and 70/190 controls (the latter were replaced)
Wynder <i>et al.</i> (1974) (USA, 1965-1973)	Men: 129 cases and 256 controls; women: 73 cases and 138 controls	Hospital-based study; controls were patients admitted for conditions not related to smoking (75% of which were malignant neoplasms) and age-matched to the cases
Armstrong <i>et al.</i> (1976) (UK, 1972-1974)	Parenchyma: men: 74 cases and 74 controls; women: 32 cases and 32 controls Renal pelvis: men: 22 cases and 22 controls; women: 11 cases and 11 controls	Hospital-based study; age- and sex-matched hospital controls (tobacco-related diseases not excluded); 48% of eligible cases in Oxford area and 44% in London could not be interviewed (mostly because of death); 19 lost controls replaced
McLaughlin <i>et al.</i> (1984) (USA, 1974-1979)	Men: 313 cases and 428 controls; women 182 cases and 269 controls	Population-based study; all newly diagnosed cases in the Minneapolis-St Paul area; controls: age- and sex-stratified random sample of the population and 495 randomly selected deceased individuals matched (for age, sex and year of death) to deceased cases

(ii) *Cancer of the lower urinary tract: men*

The denomination 'lower urinary tract' comprises the renal pelvis, ureter, bladder and urethra. Cancers originating in the urothelium at these sites are mostly transitional-cell carcinomas. These cancers are discussed together, unless a distinction is expressly made in the studies that are considered.

(1) *Dose-response relationship and duration of cigarette smoking.* Table 77 gives the relative risks according to average daily number of cigarettes smoked. With the exception of the study by Anthony and Thomas (1970), in Leeds, UK, all the others show an association between cancer of the lower urinary tract and cigarette smoking in men. Another case-control study conducted in Leeds (Cartwright *et al.*, 1983) failed to show a clear-cut dose-response relationship in men, although a statistically significant overall relative risk of 1.6 was found. [The Working Group noted that the control group used in this study included patients with tobacco-related diseases, a choice that could have biased the result.] Considerable variations in the relationship between relative risks and average daily amount of cigarettes smoked are evident (Table 77). For male smokers of more than 20 cigarettes/day, the relative risk is around 5.0 in one study in the USA (Wynder *et al.*, 1963a), in two studies in Canada (Morgan & Jain, 1974; Howe *et al.*, 1980) and in one study in Denmark (Møller-Jensen *et al.*, 1983); but other studies in the USA (Dunham *et al.*, 1968; Cole *et al.*, 1971; Wynder & Goldsmith, 1977), France (Schwartz *et al.*, 1961) and Japan (Morrison *et al.*, 1984) report lower relative risks, between 2.0 and 3.0, for the same category of smokers. Intermediate values have been reported from Boston, USA, and Manchester, UK (Morrison *et al.*, 1984). Estimates of around 2.0 for all smokers have been published from Denmark (Mommensen & Aagaard, 1983), the USA (Najem *et al.*, 1982), Poland (Staszewski, 1966) and Finland (Tola *et al.*, 1980). Higher estimates have been reported in Denmark (Lockwood, 1961) and Italy (Vineis *et al.*, 1984), although, in the latter study, relative risks are around 2.0 when only blond (flue-cured tobacco) cigarettes are considered.

Several of the studies report a levelling-off of the dose-response curve (Dunham *et al.*, 1968; Cole *et al.*, 1971; Cartwright *et al.*, 1983; Møller-Jensen *et al.*, 1983). [The Working Group noted that the wide variations in the dose-response relationship could be explained by a number of factors, namely, different study designs, different ways of smoking, or different types of tobacco smoked. It was noted that the apparent levelling-off of the dose-response curve could reflect an artefact in data collection, due to underestimation of levels of consumption by the interviewees.] A clear-cut dose-response was observed in other studies (Lockwood, 1961; Schwartz *et al.*, 1961; Morgan & Jain, 1974; Howe *et al.*, 1980; Morrison *et al.*, 1984; Vineis *et al.*, 1984).

Duration of cigarette smoking shows a direct relationship with relative risks for bladder cancer in men in a few studies that have examined it. Tyrrell *et al.* (1971) reported relative risks of 3.6 (based on 21 exposed cases) for 1-19 years of smoking, 4.2 (32) for 20-29, 2.8 (31) for 30-39, 3.9 (38) for 40-49 and 4.4 (40) for 50-59 years [calculated by the Working Group]. Wynder and Goldsmith (1977) in the USA reported the following estimates: 0.9 (95% confidence limits, 0.4-2.1) for 1-10 years, 1.1 (0.6-2.1) for 11-20, 1.9 (1.3-2.9) for 21-30, 2.5 (1.8-3.5) for 31-40, and 2.8 (2.1-3.9) for 41 years and more. Howe *et al.* (1980) in Canada reported estimates of 1.8 (1.1-3.3) for 1-20 years, 3.9 (2.6-6.4) for 21-40 and 4.8 (3.3-7.7) for

Table 77. Cancer of the lower urinary tract and average daily number of cigarettes smoked

Reference	Subjects	Average consumption (cigarettes/day)	Relative risk ^a	Comments
Case-control studies				
Lilienfeld <i>et al.</i> (1956)	Men	Nonsmokers Smokers	1.0 (51) 2.1 (151)	Crude risks calculated by the Working Group; unadjusted
	Women	Nonsmokers Smokers	1.0 (108) 0.4 (10)	
Lockwood (1961)	Men	Nonsmokers (g tobacco/day)	1.0 (24)	Crude risks calculated by the Working Group
		1-10 g/day	1.3 (16)	
		11-20	3.3 (40)	
		21-30	9.5 (18)	
	31+	15.8 (10)		
	Women	Nonsmokers (g tobacco/day)	1.0 (49)	
1-10 g/day	0.9 (8)			
11-20	4.6 (4)			
21+	no cases or controls			
Schwartz <i>et al.</i> (1961)	Men	Nonsmokers	1.0 (24)	Crude risks calculated by the Working Group
		1-9	1.4 (31)	
		10-19	2.1 (69)	
		20-29	2.6 (63)	
		30+	3.8 (15)	
Wynder <i>et al.</i> (1963a)	Men	Nonsmokers	1.0 (21)	Crude risks calculated by the Working Group
		1-9	2.1 (12)	
		10-15	1.5 (15)	
		16-20	2.8 (86)	
		21-34	5.2 (63)	
	35+	5.7 (78)		
	Women	Nonsmokers	1.0 (43)	
		1-9	3.1 (9)	
		10-20	3.3 (14)	
		21+	4 cases, 0 controls	
Cobb & Ansell (1965)	Men and women	Nonsmokers	1.0 (6)	Age-adjusted relative risks computed by the Working Group; hospital controls with colon cancer only; heavy smokers smoked > 1 pack of cigarettes/day for 30+ years
		Light and medium smokers	3.0 (21)	
		Heavy smokers	10.3 (104)	

Table 77 (contd)

Reference	Subjects	Average consumption (cigarettes/day)	Relative risk ^a	Comments	
Staszewski (1966)	Men	Nonsmokers	1.0 (10)	Nonsmokers include smokers of <1 g tobacco per day for <1 year.	
		Smokers	2.7 (140)		
Dunham <i>et al.</i> (1968)	Men	White	Nonsmokers	1.0 (55)	Crude risks calculated by the Working Group
			<10	1.2 (19)	
			10-19	2.1 (76)	
			20+	1.1 (114)	
		Black	Nonsmokers	1.0 (14)	
			<10	0.9 (9)	
	Women	White	Nonsmokers	1.0 (77)	
			<10	0.7 (6)	
			10-19	1.0 (12)	
			20+	1.9 (17)	
		Black	Nonsmokers	1.0 (28)	
			<10	1.0 (8)	
Anthony & Thomas (1970)	Men (aged 40-69)	Nonsmokers	1.0 (18)	Age-adjusted relative risks computed by the Working Group; only surgical controls considered	
		<15 g/day	0.7 (81)		
		•15+	1.1 (104)		
Cole <i>et al.</i> (1971)	Men (aged 20-89)	Nonsmokers	1.0 (70)	Smoker defined as smoking at least 100 cigarettes in life; amount considered is maximum amount smoked per day during life	
		≤ ½ pack/day	1.0 (36)		
		½-1½ packs/day	2.0 (140)		
		1½-2½ packs/day	2.2 (85)		
		> 2 ½ packs/day	1.8 (25)		
	Women (aged 20-89)	Nonsmokers	1.0 (50)		
		≤ ½ pack/day	1.5 (13)		
		> 1½ packs/day	3.8 (12)		
Tyrrell <i>et al.</i> (1971)	Men	Nonsmokers	1.0 (7)	Crude relative risks computed by the Working Group	
		Smokers	3.7 (163)		
		Nonsmokers			
		Smokers			
	Women	Nonsmokers	1.0 (31)		
		Smokers	0.8 (19)		

Table 77 (contd)

Reference	Subjects	Average consumption (cigarettes/day)	Relative risk ^a	Comments		
Makhyoun (1974)	Men with urinary bilharziasis	Nonsmokers Moderate smokers Heavy smokers	1.0 (66) 1.5 (42) 1.4 (21)	Crude relative risks computed by the Working Group; moderate smokers: (average number of cigarettes per day × duration of smoking) = 300-600; heavy smokers: > 600		
	Men without urinary bilharziasis	Nonsmokers Moderate smokers Heavy smokers	.0 (15) 2.3 (41) 3.3 (28)			
Morgan & Jain (1974)	Men	Nonsmokers	1.0 (22)			
		1-14 15-24 25+	2.6 (57) 2.7 (42) 6.4 (37)			
	Women	Nonsmokers	1.0 (45)			
		1-14 15-24 25+	1.2 (16) 1.1 (9) 4.4 (4)			
Schmauz & Cole (1974)	Men (cancer of the renal pelvis and ureter)	Nonsmokers	1.0 (4)			
		≤½ pack/day	1.2 (2)			
		½-1½ pack/day	1.3 (5)			
		1½-2½ packs/day >2½ packs/day	1.1 (2) 10.0 (5)			
Wynder & Goldsmith (1977)	Men	Nonsmokers	1.0 (65)	} (338)		
		1-10 11-20 21-30 31-40 41+	1.4 (0.9-2.2) 2.4 (1.7-3.3) 2.7 (1.8-4.1) 2.3 (1.5-3.4) 3.3 (2.1-5.3)			
	Women	Nonsmokers	1.0 (67)			
		1-10 11-20 21+	1.7 (0.9-3.3) (28) 2.3 (1.3-4.2) (39) 2.4 (1.1-5.1) (20)			
		Miller, C.T. <i>et al.</i> (1978)	Men		Nonsmokers	1.0
					Ever smoked	1.6
	Women	Nonsmokers	1.0			
		Ever smoked	0.8			

Table 77 (contd)

Reference	Subjects	Average consumption (cigarettes/day)	Relative risk ^a	Comments					
Sadeghi <i>et al.</i> (1979)	Men	Nonsmokers	1.0 (17)						
		Smokers	2.0 (27)						
Howe <i>et al.</i> (1980)	Men	Nonsmokers	1.0						
		<10	2.6 (1.7-4.4)						
		10-20	3.8 (2.6-6.0)						
		>20	5.1 (3.5-8.6)						
	Women	Nonsmokers	1.0						
		>15	2.6 (1.4-6.9)						
Tola <i>et al.</i> (1980)	Men	Nonsmokers	1.0 (19)	Crude relative risks computed by the Working Group					
		Ever smoked	1.9 (114)						
	Women	Nonsmokers	1.0 (25)						
		Ever smoked	5.4 (17)						
McCredie <i>et al.</i> (1982)	Men (cancer of renal pelvis)	Nonsmokers	1.0	Relative risks adjusted for consumption of analgesics; first set of controls, 'contacts'; second set of controls, 'screening clinic'					
		Smokers	1.0 (0.2-4.3)						
	Women (cancer of renal pelvis)	Nonsmokers	1.0						
		Smokers	2.2 (0.8-5.9) 7.0 (2.5-19.7)						
Najem <i>et al.</i> (1982)	Men and women	Nonsmokers	1.0	Data not given separately					
		Smokers	2.0 (1.1-3.7) (36)						
Cartwright <i>et al.</i> (1983)	Men	Duration of cigarette smoking (years)						Reference category includes nonsmokers (<1000 cigarettes in life) and smokers up to 5 years; incident and prevalent cases considered together	
		<u>≤5 6-15 16-25 26-35 36-45 46+</u>							
		<10	1.0	0.85	1.3	1.6	1.3		1.9
		10-20	1.0	1.8	1.8	1.5	1.7		1.8
		21+	1.0	1.4	1.1	1.3	1.5		0.85
	Women	Duration of cigarette smoking (years)							
		<u>≤5 6-15 16-25 26-35 36-45 46+</u>							
		<10	1.0	2.4	1.2	1.4	1.4		1.6
		10-20	1.0	1.0	2.0	1.5	1.6		1.5
21+	not enough data								
McCredie <i>et al.</i> (1983)	Men (ureter cancer)	Nonsmokers	1.0	Relative risks adjusted for phenacetin consumption and age					
		1-249 kg tobacco in life	1.9						
		≥250 kg tobacco in life	4.6						

Table 77 (contd)

Reference	Subjects	Average consumption (cigarettes/day)	Relative risk ^a	Comments
McCredie <i>et al.</i> (contd)	Men (cancer of renal pelvis)	Nonsmokers	1.0	
		1-249 kg tobacco in life	1.3	
		≥250 kg tobacco in life	4.2	
McLaughlin <i>et al.</i> (1983)	Men (cancer of renal pelvis)	Nonsmokers	1.0 (3)	Light, ≤32 pack-years of cigarettes; moderate, 33-57; heavy, ≥58; relative risks adjusted for age and type of respondent (living case/control or next of kin)
		Light smokers	5.5 (1.4-25.5) (15)	
		Moderate smokers	9.6 (2.5-43.4) (17)	
		Heavy smokers	10.7 (2.7-48.9) (15)	
	Women (cancer of renal pelvis)	Nonsmokers	1.0 (8)	
		Light smokers	4.9 (1.2-20.2) (7)	
		Moderate smokers	7.6 (1.9-31.3) (6)	
Møller-Jensen <i>et al.</i> (1983)	Men	Nonsmokers	1.0 (9)	Crude relative risks computed by the Working Group
		1-14	4.2 (82)	
		15-24	4.9 (112)	
		25+	4.3 (54)	
	Women	Nonsmokers	1.0 (23)	
		1-14	2.0 (30)	
		15+	2.5 (42)	
Mommsen & Aagaard (1983); Mommsen <i>et al.</i> (1982, 1983)	Men	Nonsmokers	1.0	Figure 1 in Mommsen & Aagaard (1983) suggests that relative risks are around 6.5 for smokers of 201-300 and 9.5 for smokers of 301-400 (years × no. of cigarettes/day) during life
		Smokers	1.9 (crude) (1.2-3.0) (122)	
	Women	Nonsmokers	1.0	
		Smokers	1.9 (crude) (0.9-3.9) (22)	
Morrison <i>et al.</i> (1984)	Boston area men	Nonsmokers	1.0 (53)	
		Current smokers		
		< 1 pack/day	1.4 (25)	
		1 pack/day	3.2 (91)	
		≥2 packs/day	4.7 (67)	
		Ex- and current smokers	1.9 (1.3-2.8)	

Table 77 (contd)

Reference	Subjects	Average consumption (cigarettes/day)	Relative risk ^a	Comments
Morrison <i>et al.</i> (contd)	Women	Nonsmokers	1.0 (49)	
		Current smokers		
		<1 pack/day	4.3 (18)	
		≥1 pack/day	6.2 (48)	
		Ex- and current smokers	4.2 (2.5-7.1)	
	Manchester area Men	Nonsmokers	1.0 (28)	
		Current smokers		
		<1 pack/day	1.9 (85)	
		1 pack/day	3.2 (104)	
		≥2 packs/day	4.0 (31)	
		Ex- and current smokers	2.2 (1.4-3.5)	
	Women	Nonsmokers	1.0 (63)	
Current smokers				
<1 pack/day		2.1 (40)		
≥1 pack/day		2.2 (26)		
	Ex- and current smokers	1.3 (0.8-2.0)		
Nagoya area Men	Nonsmokers	1.0 (24)		
	Current smokers			
	<1 pack/day	1.6 (47)		
	1 pack/day	2.1 (92)		
	≤2 packs/day	2.8 (33)		
	Ex- and current smokers	1.7 (1.1-2.9)		
Women	Nonsmokers	1.0 (45)		
	Current smokers			
	<1 pack/day	4.4 (11)		
	≥1 pack/day	4.2 (7)		
	Ex- and current smokers	4.3 (2.0-9.2)		
Vineis <i>et al.</i> (1984)	Men	Nonsmokers	1.0 (19)	
		1-14	4.0 (2.4-6.8) (181)	
		15-29	5.7 (3.5-9.3) (261)	
		30+	10.1 (4.9-20.7) (47)	
Cohort studies				
Hammond & Horn (1958b)	187 783 men, aged 50-69	Nonsmokers	1.0 (38)	In parentheses, observed no. of deaths in each category Microscopically verified cancer of the genitourinary system Bladder only, microscopically verified
		<½ pack/day	2.0 (14)	
		½-1 pack/day	2.0 (42)	
		>1 pack/day	3.4 (41)	
		Smokers	2.2 (59)	

Table 77 (contd)

Reference	Subjects	Average consumption (cigarettes/day)	Relative risk ^a	Comments
Hammond (1966)	440 558 men and 562 671 women aged ≥ 30	Nonsmokers	1.0 (10)	Relative risks computed by the Working Group as ratios of age-adjusted annual death rates
		Smokers	1.8 (59)	
		Men (aged 45-64) Nonsmokers	1.0 (13)	
		Men (aged 65-79) Smokers	2.9 (56)	
Kahn (1966)	293 658 men aged 35-84 followed up 1954-1962	Nonsmokers	1.0 (52)	
		<10	1.0 (11)	
		10-20	2.3 (71)	
		21-39	3.1 (51)	
		40+	3.0 (9)	
Lossing <i>et al.</i> (1966)	78 000 men, aged ≥ 30	Nonsmokers	1.0	Genitourinary cancers
		<10/day	1.3 (29)	
		10-20/day	1.4 (57)	
		>20 day	1.4 (15)	
Weir & Dunn (1970)	68 153 men aged 35-64	Nonsmokers	1.0	Total observed deaths from bladder cancer, 27
		< 1/2 pack/day	1.5	
		1/2-1 pack/day	2.8	
		> 1 pack/day	5.4	
Cederlöf <i>et al.</i> (1975)	Men	Nonsmokers	1.1 (16)	
		1-7	1.5 (6)	
		8-15	1.6 (6)	
		≥ 16	2.7 (6)	
	Women	Nonsmokers	1.1 (24)	
		1-7	1.2 (2)	
		8-15	2.1 (4)	
		≥ 16	0.8 (1)	
Doll & Peto (1976)	34 440 male British doctors	Nonsmokers	1.0	Relative risks, calculated by the Working Group, are ratios of age-adjusted annual death rates; total observed deaths from bladder cancer, 80
		1-14	2.2	
		15-24	2.2	
		>25	1.4	
Hirayama (1977b, 1985)	122 261 men aged 40+	Nonsmokers Smokers	1.0 1.4 (59)	

Table 77 (contd)

Reference	Subjects	Average consumption (cigarettes/day)	Relative risk ^a	Comments
Doll <i>et al.</i> (1980)	6194 female British doctors	Nonsmokers Smokers	1 0.6	Total deaths from bladder cancer, 5
Rogot & Murray (1980)	293 958 men aged 31-84; same cohort as described by Kahn (1966), but followed up 1954-1969	Smokers	2.16 (326)	Standardized mortality ratio

^aIn parentheses, absolute number of cases or deaths or 95% confidence limits

more than 40 years. Cartwright *et al.* (1983) reported relative risks in relation to both average daily consumption of cigarettes and duration.

When cancers of the renal pelvis and of the ureter are considered separately (Schmauz & Cole, 1974; McCredie *et al.*, 1982; McLaughlin *et al.*, 1983), a dose-response relationship with daily or cumulative consumption of tobacco is found, and relative risks are generally higher than those reported for the bladder. In the population-based study by McLaughlin *et al.* (1983), the overall relative risk for men who had ever smoked was 7.6.

Cohort studies consistently show an excess of deaths from bladder cancer among male smokers, with relative risks of between 3.0 and 5.4 for smokers of 20 or more cigarettes/day in the US studies (Hammond & Horn, 1958b; Kahn, 1966; Weir & Dunn, 1970). The cohort study on British male doctors failed to show a dose-response relationship (Doll & Peto, 1976) (see Table 77).

(2) *Type of cigarette, effect of inhaling.* In only one study (Vineis *et al.*, 1984) are estimates reported of the relative risks for lower urinary tract cancers separately for smokers of black (air-cured) and blond (flue-cured) tobacco, although the assignment of brands to these classifications is reported by the authors to be tentative. Relative risks for smokers of black tobacco were more than twice those for smokers of blond tobacco, adjusted for age, occupation, average daily consumption of cigarettes, years since stopping and use of a filter tip.

The use of filter-tip cigarettes has been analysed in several studies, with conflicting results (Table 78). A weaker effect of filter cigarettes was reported by Howe *et al.* (1980) and Cartwright *et al.* (1983), whereas no difference between filter and nonfilter cigarettes was

found in the study by Wynder and Goldsmith (1977) or in the investigation by Morrison *et al.* (1984). In Italy (Vineis *et al.*, 1984), the relative risk for lifelong smokers of filter-tip cigarettes was 0.3 in comparison with the risk for smokers of less than 50% filter cigarettes smoked throughout life (adjusted for age, type of tobacco, number of cigarettes smoked, years since stopping and high-risk occupation).

A slight effect of inhaling has been reported by Cole *et al.* (1971), Howe *et al.* (1980) and Morrison *et al.* (1984), but not by Lockwood (1961) (Table 78).

(3) *Effect of stopping and of age at starting cigarette smoking.* A lowering of risk in men after stopping cigarette smoking (Table 79) is evident from studies conducted in the USA (Kahn, 1966; Wynder & Goldsmith, 1977; Rogot & Murray, 1980; Morrison *et al.*, 1984), in Canada (Howe *et al.*, 1980), in the UK (Doll & Peto, 1976; Cartwright *et al.*, 1983; Morrison *et al.*, 1984), in Japan (Morrison *et al.*, 1984) and in Italy (Vineis *et al.*, 1984). The risk for ex-smokers approximates that of nonsmokers more than 15 years after cessation (Wynder & Goldsmith, 1977). At least one study does not, however, show a clear-cut decreasing trend of risk (Tyrrell *et al.*, 1971).

The role played by age at starting to smoke was considered by Cole *et al.* (1971), who reported a lower mean age among cases than among controls (at a statistically significant *p* value). Tyrrell *et al.* (1971) reported relative risks of 4.7 (based on 11 exposed cases) for age at starting <10 years, 4.9 (51) for 10-14, 3.5 (60) for 15-19, 3.7 (28) for 20-24, 3.0 (7) for 25-29 and 1.2 (5) for 30+ [calculated by the Working Group]. Morrison *et al.* (1984) reported the following relative risks for age at start of 15-19 and 20+ years, respectively (reference category, less than 15 years; relative risks adjusted for intensity of smoking): 1.1 (based on 89 cases) and 1.0 (36) in Boston; 1.3 (92) and 0.9 (39) in Manchester; and 0.7 (109) for ≥ 20 years in Nagoya (*versus* <20 years). In the study reported by Vineis *et al.* (1984), relative risks were 7.9 (95% confidence limits, 2.4-25.2), 8.0 (3.5-18.5) and 7.3 (3.1-17.0) for cases under the age of 50 and 8.5 (2.7-26.8), 6.3 (2.6-15.3) and 8.2 (3.7-17.9) in the age group 50-59 for age at start of <13, 13-16 and ≥ 17 , respectively, in relation to nonsmokers.

(4) *Other types of smoking (cigar, pipe).* Conflicting evidence is available on the role of pipe smoking in the etiology of bladder cancer in men (Table 80). Relative risks of about 1.0 were reported by Hammond and Horn (1958b), Kahn (1966), Cole *et al.* (1971), Wynder and Goldsmith (1977) and Mommsen and Aagaard (1983). However, an association was found by Wynder *et al.* (1963a; based on six cases), by Dunham *et al.* (1968; only among black men; based on three cases), by Howe *et al.* (1980; with a statistically significant relative risk of 8.8 for men heavily inhaling pipe smoke, adjusted for cigarette smoking) and by Morrison *et al.* (1984; particularly in the Manchester area). In the Danish study, by Mommsen and Aagaard (1983), the relative risk for current pipe smokers was 6.2 (95% confidence limits, 1.1-36.6).

Risks in men associated with the smoking of cigars and cigarillos vary from about 1.0 (Wynder *et al.*, 1963a; Dunham *et al.*, 1968, in black men; Cole *et al.*, 1971; Wynder & Goldsmith, 1977) to 1.4 (Mommsen & Aagaard, 1983) or 1.6 (Dunham *et al.*, 1968, in white men). In Denmark, Møller-Jensen *et al.* (1983) detected a crude relative risk of 2.4 (based on 29 cases) for smokers of products other than cigarettes. A second Danish study (Mommsen & Aagaard, 1983) reported a relative risk of 2.3 for current cigar/cigarillo smokers (see Table 80).

Table 78. Cancer of the lower urinary tract and use of filter-tip cigarettes and effect of inhaling. Relative risks (RR) in relation to nonsmokers, unless otherwise specified

Reference	Subjects	Use of filter-tip cigarettes	Relative risk ^a	Inhalation pattern	Relative risk ^a	Comments
Lockwood (1961)	Men	-		Inhaling vs. noninhaling	0.7 (65)	Age-adjusted relative risks computed by the Working Group from Table 52 of the reference
Cole <i>et al.</i> (1971)	Men	-		'Somewhat inhaling'	1.0	
				'Deeply inhaling' (vs. not inhaling)	1.4	
	Women	-		'Somewhat inhaling'	1.8	
				'Deeply inhaling' (vs. not inhaling)	2.5	
Wynder & Goldsmith (1977)	Men	Filter > 10 years	3.0 (2.1-4.3)			
		Non-filter > 10 years	3.1 (2.1-4.7)			
Howe <i>et al.</i> (1980)	Men	Nonfilter	1.1	Inhale nonfilter moderately	0.7	Computed by the Working Group from regression coefficients; reference category, all other smokers of the same amount
		Filter	1.0	Inhale nonfilter heavily	1.1	
				Inhale filter moderately	1.2	
				Inhale filter heavily	1.1	

Table 78 (contd)

Reference	Subjects	Use of filter-tip cigarettes	Relative risk ^a	Inhalation pattern	Relative risk ^a	Comments
Howe <i>et al.</i> (1980) (contd)	Women	Nonfilter	1.1	Inhale nonfilter moderately	1.1	
		Filter	1.0	Inhale nonfilter heavily	0.8	
				Inhale filter moderately	1.1	
				Inhale filter heavily	2.4	
Cartwright <i>et al.</i> (1983)	Women and men	Nonfilter cigarettes only	1.4 (1.1-1.7)			Adjusted for age and sex
		Filter cigarettes only	1.05(0.7-1.5)			
		Both types	1.6 (1.3-2.0)			
Morrison <i>et al.</i> (1984)	Men					RRs are for deep inhalers vs. inhaling somewhat or not at all and adjusted for current intensity of smoking
	Boston area	Users vs. nonusers	1.3 (0.7-2.3)	Inhaling vs. noninhaling	1.4 (0.8-2.3)	
	Manchester area	Users vs. nonusers	1.2 (0.8-1.8)	Inhaling vs. noninhaling	1.3 (0.8-1.9)	
	Nagoya area	Users vs. nonusers	1.0 (0.5-1.9)	Inhaling vs. noninhaling	1.4 (1.0-2.1)	

Table 78 (contd)

Reference	Subjects	Use of filter-tip cigarettes	Relative risk ^a	Inhalation pattern	Relative risk ^a	Comments
Morrison <i>et al.</i> (contd)	Women					
	Boston area			Inhaling vs. noninhaling	2.4 (0.7-7.8)	
	Manchester area			Inhaling vs. noninhaling	0.7 (0.3-1.8)	
Vineis <i>et al.</i> (1984)	Men	50% filter-tip cigarettes	1.0			Relative risks adjusted for age, high-risk occupation, average daily amount, years since stopping and type of tobacco
		50-74%	1.1			
		75-99%	0.5			
		100%	0.3			

^aIn parentheses, no. of exposed cases or 95% confidence limits

Table 79. Cancer of the lower urinary tract and effect of stopping cigarette smoking. Relative risks (RR) in relation to nonsmokers

Reference	Subjects	Smoking status	Relative risk ^a	Comments		
Case-control studies						
Anthony & Thomas (1970)	Men	Current pure cigarette smokers	0.9 (185)	Age-adjusted relative risks computed by the Working Group		
		Ex-pure cigarette smokers	1.2 (43)			
Tyrrell <i>et al.</i> (1971)	Men	0 years since stopping	3.9 (129)	Crude relative risks computed by the Working Group		
		0.1-3.9	1.5 (3)			
		4.0-6.9	2.9 (5)			
		7.0-12.9	4.1 (6)			
		13.0-21.9	6.2 (9)			
		22.0+	2.7 (11)			
		Nonsmokers	1.0 (7)			
Wynder & Goldsmith (1977)	Men	1-3 years since stopping	2.6 (1.6-4.5)			
		4-6	2.9 (1.7-5.2)			
		7-9	1.5 (0.8-3.0)			
		10-12	1.6 (0.8-3.1)			
		13-15	1.2 (0.6-2.5)			
		16+	1.1 (0.7-1.8)			
	Women	1-6 years since stopping	2.5 (1.0-6.2)			
		7+	1.2 (0.5-2.9)			
	Howe <i>et al.</i> (1980)	Men	2-15 years since stopping		0.6 (0.4-0.9)	Relative risks computed by the Working Group from logistic regression coefficients; reference category, current smokers
			>15		0.5 (0.4-0.8)	
Women	Ex-smokers		0.2 (0.1-0.5)			

Table 79 (contd)

Reference	Subjects	Smoking status	Relative risk ^a	Comments	
Cartwright <i>et al.</i> (1983)	Men (current and ex-smokers)	Smoking for ≤ 5 years	1.7	Reference category, never smokers, and those with >35 years since stopping	
		6-15 years since stopping	1.0		
		16-25	1.1		
		26-35	0.9		
	Women (current and ex-smokers)	Smoking for ≤ 5 years	1.4		
		6-15 years since stopping	0.5		
McLaughlin <i>et al.</i> (1983)	Men	Current and ex-smokers	7.6 (47)	Renal pelvic cancer	
		≥ 10 years since stopping	4.3		
	Women	Current and ex-smokers	5.8 (16)		
		≥ 10 years since stopping	3.9		
Morrison <i>et al.</i> (1984)	Men, ex-smokers	Boston area vs. nonsmokers	1.5 (191)	Relative risks adjusted for intensity of smoking; those for ex-smokers calculated using nonsmokers and current smokers as reference category, respectively	
			0.5 (0.4-0.8)		
	Manchester area	vs. nonsmokers	1.8 (150)		
		vs. current smokers	0.7 (0.5-0.9)		
	Nagoya area	vs. nonsmokers	1.0 (28)		
		vs. current smokers	0.5 (0.3-0.8)		
	Women, ex-smokers	Boston area	vs. nonsmokers		3.4 (50)
			vs. nonsmokers		0.7 (26)
		Manchester area	vs. nonsmokers		0.7 (26)
			vs. nonsmokers		Not given (3)

Table 79 (contd)

Reference	Subjects	Smoking status	Relative risk ^a	Comments
Vineis <i>et al.</i> (1984)	Men aged < 60	0-2 years since stopping	10.2 (5.0-21.2)	
		3-9	3.3 (1.2-9.2)	
		10-14	1.6 (0.3-8.2)	
		15+	1.9 (0.5-7.9)	
	Men aged >60	0-2 years since stopping	3.8 (2.0-7.2)	
		3-9	2.8 (1.2-6.6)	
		10-14	2.4 (0.9-6.3)	
		15+	2.5 (1.0-5.8)	
Cohort studies				
Kahn (1966)	Men	Nonsmokers	1.0	Relative risks statistically significant ($p < 0.01$)
		Current smokers	2.2 (82)	
		Ex-smokers	1.6 (51)	
Doll & Peto (1976)	Men	Current smokers	2.1	Ratio of annual death rates $\times 10^6$ men; total number of deaths, 80; calculated by the Working Group
		Ex-smokers	1.2	
Rogot & Murray (1980)	Men	Current smokers	2.16 (326)	Standardized mortality ratio
		Ex-smokers	1.41 (126)	

^aIn parentheses, no. of exposed cases or 95% confidence limits

Table 80. Cancer of the lower urinary tract and smoking of products other than cigarettes: Relative risks in relation to nonsmokers

Reference	Subjects	Product smoked	Relative risk ^a	Comments
Case-control studies				
Lockwood (1961)	Men	Preferring cigars Preferring cigarillos Preferring pipe	1.7 (50) 1.2 (52) 1.4 (70)	Age-adjusted relative risks computed by the Working Group
	Women	Cigarillos only	1.5 (25)	
Schwartz <i>et al.</i> (1961)	Men	Pipe only	0.5 (2)	Crude relative risk computed by the Working Group
Wynder <i>et al.</i> (1963a)	Men	Pipe only	2.2 (6)	Crude relative risks computed by the Working Group
		Cigar only	0.8 (9)	
Dunham <i>et al.</i> (1968)	White men	Cigar only Pipe only	1.6 (8) 0.4 (1)	Crude relative risks computed by the Working Group
	Black men	Cigar only Pipe only	1.0 (2) 3.0 (3)	
Anthony & Thomas (1970)	Men	Pipe and cigar Pipe only	1.6 (18) 0.7 (39)	Age-adjusted relative risks computed by the Working Group
Cole <i>et al.</i> (1971)	Men	Pipe	1.1	Adjusted for cigarettes
		Cigar	1.2	
Tyrrell <i>et al.</i> (1971)	Men	Pipe only	3.9 (30)	Crude relative risk computed by the Working Group

Table 80 (contd)

Reference	Subjects	Product smoked	Relative risk ^a	Comments
Wynder & Goldsmith (1977)	Men	Pipe only	0.7 (7) (0.3-1.9)	
		Cigar only	0.9 (19) (0.5-1.7)	
Howe <i>et al.</i> (1980)	Men	Pipe		Adjusted for cigarettes
		<50 000 pipefuls	1.3 (0.7-2.1)	} Adjusted for amount of tobacco smoked
		>50 000 pipefuls	2.0 (1.2-3.5)	
		Inhale pipe moderately	1.1 (0.6-2.1)	
Inhale pipe heavily	8.8 (1.1-71.7)			
Mommsen & Aagaard (1983)	Men	Cigars/cigarillos only	1.4 (0.9-2.2)	RR for current cigar/cigarillo smokers, 2.3 (0.7-7.4)
		Pipe only	1.3 (0.9-2.1)	RR for current pipe smokers, 6.2 (1.1-36.6)
	Women	Cigar/cigarillos	3.3 (1.3-8.5)	
Møller-Jensen <i>et al.</i> (1983)	Men	Ever smoked other than cigarettes only	2.4 (29)	Crude relative risk computed by the Working Group
Morrison <i>et al.</i> (1984)	Men			Ever smoked pipe
		Boston area	Pipe only	1.7 (0.8-3.6)
		Manchester area	Pipe only	3.9 (1.3-11.8)
		Nagoya area	Pipe only (<i>kizami</i> type)	1.3 (0.5-3.5)
Cohort studies				
Hammond & Horn (1958b)	Men	Pipe only	1.2 (21)	Genitourinary system
		Cigar only	1.1 (19)	

Table 80 (contd)

Reference	Subjects	Product smoked	Relative risk ^a	Comments
Kahn (1966)	Men	Cigar only, current smokers	0.9 (10)	
		Pipe only, current smokers	1.2 (8)	
Lossing <i>et al.</i> (1966)	Men	Cigar only		Genitourinary system
		<3/day	1.1 (2)	
		3-10/day	1.7 (1)	
		Pipe only	0.6 (10)	
Cederlöf <i>et al.</i> (1975)	Men	Pipe, ≤5 g/day	0.6 (2)	No cigarette smoking after 1953 (pipe smoked at least 10 years)
		Pipe, ≥6 g/day	1.9 (15)	
Doll & Peto (1976)	Men	Pipe and/or cigar only	1.5	Ratio of annual death rates × 10 ⁻⁵ men; absolute numbers not given

^aIn parentheses, no. of exposed cases or 95% confidence limits

(iii) *Cancer of the lower urinary tract: women*

Most published studies (Table 77) report a positive association between cigarette smoking and cancer of the lower urinary tract in women. In one study, the relative risk was about 1.0 (Miller, C.T. *et al.*, 1978), and, in another, no clear-cut dose-response relationship was seen (Cartwright *et al.*, 1983). The relative risks for women are sometimes lower (Tyrrell *et al.*, 1971; Morgan & Jain, 1974; Howe *et al.*, 1980; Møller-Jensen *et al.*, 1983; Morrison *et al.*, 1984, in the Manchester area) and sometimes higher than those for men (Cole *et al.*, 1971 and Morrison *et al.*, 1984, both in the Boston and Nagoya areas; McCredie *et al.*, 1982, for cancer of the renal pelvis). [On the basis of the available data, it is not possible to establish whether such variations reflect different types of tobacco smoked by people of the two sexes in different countries, different susceptibilities of the two sexes, or random fluctuations due to small numbers.]

The reported relative risk in ex-smokers was lower in women (Wynder & Goldsmith, 1977; Howe *et al.*, 1980; Cartwright *et al.*, 1983), except in one study (Morrison *et al.*, 1984, in the Boston area) (see Table 79). Information on risks associated with tobacco products other than cigarettes is available only for men, with the exception of two studies in Denmark, reporting relative risks of 1.5 for use of cigarillos (Lockwood, 1961) and 3.3 for use of cigars/cigarillos in women (Mommsen & Aagaard, 1983) (see Table 80).

(iv) *Kidney (adenocarcinoma)*

(1) *Case-control studies.* A study described by Schwartz *et al.* (1961) reported that 69 cases and 69 matched controls smoked the same average number of cigarettes per day, suggesting the absence of an association between adenocarcinoma of the kidney and cigarette smoking. In a study by Bennington and Laubscher (1968), however, the age-adjusted relative risk for male smokers of more than 10 cigarettes/day was 5.1 (based on 60 cases); for pipe smokers, the corresponding figure was 10.3 (based on 8 cases); and for cigar smokers, 12.9 (55 cases). For ex-smokers and women the numbers were too small to calculate risks.

Wynder *et al.* (1974) reported the following relative risks for adenocarcinoma and cigarette smoking in men: 1-9 cigarettes/day, 1.5 (based on 12 cases); 10-20, 1.9 (45 cases); ≥ 21 , 2.2 (37 cases). Among women, the corresponding figures were 1.1 (9 cases), 1.5 (18 cases) and 2.2 (8 cases). Male cigar smokers had a relative risk of 1.3 (8 cases), and pipe smokers one of 1.5 (3 cases). When only men under 50 years old were considered, cigarette smokers had relative risks of 3.3 (1-20 cigarettes/day) and 8.0 (≥ 21 cigarettes/day).

Armstrong *et al.* (1976) reported from their hospital-based study relative risks for adenocarcinoma of 1.1 for current male cigarette smokers (95% confidence limits, 0.5-2.2) and 1.0 for women (0.3-3.4). The corresponding estimate for transitional-cell carcinoma of the renal pelvis was 1.8 (0.5-6.8) in men. There was no excess of cases compared with controls who smoked tobacco in forms other than cigarettes. [The Working Group noted that almost 50% of eligible cases could not be interviewed, whereas this proportion was much lower in the controls; in addition, people with 'tobacco-related diseases' were not expressly excluded from the hospital-control group.]

McLaughlin *et al.* (1984) reported from a large case-control study a statistically significant association between renal-cell carcinoma (adenocarcinoma) and cigarette smoking, both in men and women, with a dose-response relationship: relative risks in men were 1.2 for light smokers, 1.3 for moderate smokers and 2.3 for heavy smokers; the corresponding figures in women were 1.8, 1.9 and 2.1. All relative risks were adjusted for respondent type (i.e., living case/control or next-of-kin). These risks remained virtually the same after adjustment for potential confounders such as phenacetin abuse and body weight. The relative risk for male cigar smokers was 0.6 (95% confidence limits, 0.2-2.0) and for pipe smokers 2.2 (0.7-6.9). The relative risk was 1.1 for men who had stopped smoking >10 years prior to diagnosis, 1.7 for those who had stopped \leq 10 years before and 1.8 for continuing smokers (relative to nonsmokers). Among women, the corresponding figures were 1.6, 1.7 and 2.0.

(2) *Cohort studies* (see Table 77 for numbers of subjects). Hammond and Horn (1958b) reported a ratio of 1.6 between 35 deaths from histologically proved cancer of the kidney observed among regular cigarette smokers and the expected value based on nonsmokers (men only).

Kahn (1966) estimated a mortality ratio of 0.7 for current male smokers of <10 cigarettes/day (6 deaths), 1.6 for 10-20 cigarettes/day (39 deaths), 2.0 for 21-39 (28 deaths) and 2.7 for \geq 40 (7 deaths). For cigar smoking, the estimate was 0.8, and that for pipe smoking, 1.3 (both based on 6 deaths). Among ex-cigarette smokers, the relative risk was 1.7 (based on 40 deaths).

Hammond (1966) reported mortality ratios of 1.4 (ages 45-64, based on 54 deaths in smokers) and of 1.6 (ages 65-79, based on 28 deaths) for cigarette smoking in men.

Weir and Dunn (1970) reported a relative risk for 35-64-year-old men of 2.5; the risk was 0.9 for smokers of one-half a pack/day or less; 3.3 for smokers of about one pack; and 2.6 for one to one-and-a-half packs or more; a total of 27 deaths was observed.

In the study on male British doctors (Doll & Peto, 1976), although the absolute numbers of deaths from kidney cancer (46) was small for comparisons, the annual death rate ($\times 10^{-5}$ men, age-adjusted) was 8 among current smokers or ex-smokers (any tobacco), 9 among ex-smokers, and 3 among nonsmokers.

Hirayama (1977b), in a cohort study on 122 261 men followed up from 1966 to 1975, found 24 deaths from cancer of the kidney among smokers, corresponding to a standardized mortality ratio of 1.2.

In the study of US veterans (Rogot & Murray, 1980), a standardized mortality ratio for kidney cancer of 1.4 (based on 175 observed deaths) was reported for current cigarette smokers and of 1.2 (82 deaths) for ex-cigarette smokers.

[The Working Group did not consider studies based only on death certificates, since these cannot distinguish between adenocarcinoma of the kidney and carcinoma of the renal pelvis.]

(c) *Estimates of risk attributable to smoking*

The proportion of bladder cancers occurring in the general population due to cigarette smoking has been estimated in a few population-based studies from different countries. In men, the estimated proportions were 39% (Cole *et al.*, 1971) and 44% (Morrison *et al.*, 1984) in the Boston, USA, area; 61% in a Canadian population (Howe *et al.*, 1980); 32% in a rural population in Denmark (Mommsen & Aagaard, 1983); 46% in the Manchester, UK, area and 34% in Nagoya, Japan (Morrison *et al.*, 1984). Among women, the following estimates have been given: 29% (Cole *et al.*, 1971), 26% (Howe *et al.*, 1980), 22% (Mommsen & Aagaard, 1983), 56% (Boston), 14% (Manchester) and 24% (Nagoya) (Morrison *et al.*, 1984). Attributable risks of 31% for men and 15% for women have been estimated from the large cohort study conducted in Japan by Hirayama (1982). Moolgavkar and Stevens (1981) computed estimates of 73% among men and 14% among women in England and Wales (1941-1970).

A few estimates are available for cancers of the renal pelvis and ureter: 39% (Schmauz & Cole, 1974; Boston area) and 82% in men, and 61% in women (McLaughlin *et al.*, 1983; Minneapolis-St Paul area).

Only one estimate has been given for renal adenocarcinoma from a population-based study: 30% among men and 24% among women (McLaughlin *et al.*, 1984; Minneapolis-St Paul area).

(d) *Summary*

Cancers of the bladder and renal pelvis have been associated consistently with cigarette smoking in many cohort and case-control studies conducted in various parts of the world. These studies have generally shown a dose-response relationship, with risks for heaviest cigarette smokers being about five times those for nonsmokers. Relative risks in women are usually lower, although the risk estimates for women were often based on much smaller numbers and less prolonged smoking. No other factor (e.g., occupation) has been shown to confound this association. It can be concluded that cigarette smoking is an important cause of bladder cancer, and that 50% of male cases and 25% of female cases in some populations are attributable to smoking.

Several studies have shown an association between renal adenocarcinoma and cigarette smoking.

4. Cancers in other organs

(a) *Cancers of the upper respiratory and upper digestive tracts*

The sites considered here are the lip, oral cavity, pharynx, larynx and oesophagus, cancers that share a common feature — they are usually studied in relation to smoking and to some other factor, such as alcohol in western countries, chewing of betel quid in south-east Asia (IARC, 1985a) and other factors elsewhere. Thus, it is possible to assess the role of tobacco only on the basis of studies that address both tobacco and other factors suspected to be of importance.

The oral use of snuff has been implicated in the etiology of cancer of the oral cavity and, to a lesser extent, of the pharynx. While one case-control study has suggested that the oral use of snuff may be associated with certain types of cancer of the nasal sinus, in other case-control studies no association was evident between snuff and cancer of the oesophagus. Four case-control studies indicated that use of unspecified smokeless-tobacco products is moderately to strongly associated with the occurrence of oral cancer, although smoking habits were not controlled for in three of the studies; a dose-response relationship was found in one large case-control study. In one cohort study, there were two- to three-fold increased risks of death from oral, pharyngeal and oesophageal cancer in users of unspecified smokeless-tobacco products; in another study, an increased mortality from oesophageal cancer was seen (IARC, 1985a).

Cancers of the oral cavity and pharynx occur at relatively high frequency in countries of south-east Asia, where smoking is commonly associated with betel-quid chewing. The role of the latter was reviewed in detail in a monograph (IARC, 1985a) which described three case-control studies in which various combinations of the two habits were analysed. The relative risk among nonchewing male smokers was found to be 5.7 for oral cancer in Pakistan (Jafarey *et al.*, 1977), 2.1 for oral cancer and 28.5 for cancer of the oropharynx in India and Sri Lanka (Hirayama, 1966) and 1.2 for oral cancer in Calcutta, India (Chandra, 1962). There is *sufficient evidence* that the combined habits of smoking tobacco and chewing betel quid that does not contain tobacco cause oral and pharyngeal cancer, although the evidence considered did not allow an assessment of the possible contribution of betel quid without tobacco to this carcinogenic risk (IARC, 1985a).

Although most cohort studies showed an increased risk among smokers for cancers of the lip, oral cavity, pharynx, larynx and oesophagus, only one made a distinction between smokers who drink and those who do not. Hirayama (1978) found an excess of cancers at each site among daily cigarette smokers; the excesses of cancers of the mouth, pharynx and oesophagus, however, were lower among smokers 'only' as compared with 'drinking' smokers (Table 81).

In the US Veterans Study (Kahn, 1966), cited as an example of other cohort studies (Table 82), a dose-response relationship was seen for cancer at each site among cigarette smokers; the standardized mortality ratio was greater for cancers of the larynx and pharynx than for those at other sites. For cigar smokers, there was a contrast between the slightly elevated risk for lung cancer (see pp. 204-206) and the higher relative risks for cancers of the mouth, oesophagus and larynx.

Table 81. Mortality ratios for cancers at various sites in men in a Japanese cohort study^a

Site	Buccal cavity	Pharynx	Oesophagus	Larynx
No. of deaths	23	12	172	35
Daily smoking plus daily drinking ^b	5.26	3.01	2.26	4.51
Daily smoking only ^b	2.46	0.82	1.18	4.93

^aFrom Hirayama (1978)

^bIn relation to those who neither smoke nor drink

Table 82. Mortality ratios for cancers of the upper respiratory and digestive tracts in a US prospective study^a

Smoking category	No. of person-years of observation	Buccal cavity (ICD 140-144)		Pharynx (ICD 145-148)		Oesophagus (ICD 150)		Larynx (ICD 161)	
		No. of deaths	Mortality ratio	No. of deaths	Mortality ratio	No. of deaths	Mortality ratio	No. of deaths	Mortality ratio
Never smoked	443 856	11	1.00	4	1.00	11	1.00	3	1.00
Current cigarette smokers (all levels)	701 768	56	3.75	48	9.60	77	5.87	40	9.45
1 - 9/day	95 462	5	2.12	4	4.60	6	2.53	3	4.53
10 - 20/day	333 619	18	2.56	21	8.72	24	3.83	16	8.33
21-39/day	207 821	24	5.90	18	14.35	38	11.88	16	13.26
> 39/day	34 738	7	9.26	5	21.71	5	8.38	5	21.17
Current smokers of cigars only	82 912	9	4.11	-	-	12	5.33	6	10.33
Current smokers of pipe only	49 545	4	3.12	1	1.98	3	1.99	-	-

^aFrom Kahn (1966)

(i) *Cancer of the lip*

Lip cancer cases are included in many studies of oral cancer, but when findings for this subsite are reported separately the number of lip cancer cases is usually small. Three large case-control studies of lip cancer, however, do provide information on the relationship with tobacco smoking.

Keller (1970) studied 314 male cases, representing a 20% sample of patients discharged from all Veterans' Administration hospitals in the USA from 1958 through 1962. Two control groups were identified by sampling — one of patients with cancers of the mucous membrane of the mouth and pharynx, the other of patients discharged during the same period with no oral or pharyngeal cancer. The authors concluded that smoking of pipes, cigars and cigarettes, but not of pipes alone, was significantly associated with lip cancer, but the data do not include amount smoked or duration of smoking.

Spitzer *et al.* (1975) studied all male cases of squamous-cell carcinoma of the lip occurring in Newfoundland, Canada, over an 11-year period (1961-1971) (366 cases). Three control groups were used: 132 patients with oral cavity cancer, 81 patients with squamous-cell carcinoma of the skin of the head and neck, and 210 randomly selected population controls. In a comparison with the population controls, the relative risk for lip cancer associated with pipe smoking, adjusted for age, was 1.5 ($p < 0.05$), and that for lip cancer associated with all tobacco use was 1.1 (not significant). [The Working Group noted that the paper focused on risk of lip cancer related to the occupation of fishing and gave no other information on tobacco use.]

Lindqvist (1979) studied all cases (290) of lip cancer diagnosed in Finland in 1972-1973. Patients with squamous-cell cancer of the skin of the head and neck were used as controls. He concluded that, in men, tobacco smoking and outdoor work act together to cause lip cancer (relative risk, 15.4; $p < 0.001$) but that neither factor had a significant independent effect (relative risk for smoking only, 2.0; that for outdoor work only, 1.4). Cigarette smoking accounted for almost all of the tobacco use; only 8% of male cases (compared to 6% of male controls) smoked a pipe.

(ii) *Cancer of the oral cavity*

Among nondrinkers, the relative risk for oral cancer for cigarette smokers was found to be 3.0 (Wynder *et al.*, 1957b), 1.5 (Rothman & Keller, 1972) and 1.5 (Graham, S. *et al.*, 1977). The first two studies indicated a dose-response relationship. For three levels of increasing smoking, the values computed from the data of Wynder *et al.* (1957b) were 2.9, 1.8 and 8.4 (given by Rothman & Keller, 1972), and from those of Rothman and Keller (1972), 1.5, 1.4 and 2.4, respectively. The relative risk for oral cancer among pipe, cigar and mixed smokers in the study of Wynder *et al.* (1957b) was 4.9.

In an early hospital-based case-control study in India and Sri Lanka Hirayama (1966) found a significant association between current smoking and cancer of the buccal mucosa (relative risk, 3.3 in men who did not chew betel quid or tobacco). The relative risk for male *bidi* smokers in Sri Lanka was 2.6.

Jussawalla and Deshpande (1971) conducted a case-control study in Bombay of patients with cancers of the oral cavity, pharynx, larynx and oesophagus. Equal numbers of controls matched by age, sex and religion were selected from voters' lists. Risks relative to those for nonsmokers and nonchewers were determined for those who smoked, for chewers of betel quid with or without tobacco and for those with both habits. The relative risks for oral cancer were 2.8, 6.0 and 10.1, respectively. Examination of risks separately for cigarette smokers and for *bidi* smokers suggested that there was little or no effect of cigarette smoking on the incidence of oral cancer, but an important effect of *bidis* (relative risk, 2;

$p < 0.001$). Jayant *et al.* (1977), using data from the same study, calculated 'etiologic fractions' [attributable risks] of 65% for smoking and 90% for smoking plus chewing.

Reverse *chutta* smoking (in which the burning end is inserted in the mouth) has been associated with cancer of the hard palate (Ramalu & Reddy, 1972).

(iii) *Cancer of the larynx*

Wynder *et al.* (1976) in an analysis of laryngeal cancer in the USA found the following relative risks among male cigarette smokers who were non- and light drinkers: for smokers of 1-15 cigarette equivalents/day of tobacco, 3.0; for 16-34 cigarette equivalents/day, 6.0; and for smokers of >35 cigarette equivalents/day, 7.0. Similar risks were found for supraglottic and glottic tumours.

In a Canadian study (Burch *et al.*, 1981), the risks for laryngeal cancer among nondrinkers were estimated as follows: relative risk for smokers who had smoked $<150\ 000$ cigarettes (lifetime consumption), 2.0; for 150 000-299 000, 3.9; and for $\geq 300\ 000$, 7.6. In another study from Canada, Elwood *et al.* (1984) distinguished cancers of the extrinsic and intrinsic larynx; for smokers of 1-9, 10-19, 20-29 and ≥ 30 cigarettes/day, the relative risks were 2.1, 6.8, 5.4 and 4.1 for extrinsic larynx and 1.7, 2.1, 4.0 and 3.9 for intrinsic larynx, respectively.

In a hospital-based case-control study of cancer of the larynx in the USA, Wynder and Stellman (1979) examined the risk from nonfilter cigarette use relative to long-term (at least 10 years) use of filter cigarettes. After adjustment for duration of smoking, number of cigarettes used per day and alcohol consumption, the relative risks were 1.5 (95% confidence limits, 1.1-2.1) for men and 4.0 (2.0-7.7) for women.

Jussawala and Deshpande (1971) found relative risks of 7.7, 4.6 and 20.1 for smokers, chewers and smokers + chewers, respectively, for laryngeal cancer. Using the same data, Jayant *et al.* (1977) calculated an 'etiologic fraction' [attributable risk] of 87% for smoking and 95% for smoking + chewing for cancer of the larynx.

(iv) *Cancer of the pharynx*

Cancers of the pharynx have usually been considered in conjunction with cancers at other sites in case-control studies. Elwood *et al.* (1984) reported some increase in risk for cancer of the pharynx (grouping oro- and hypopharynx) with increasing smoking, but the relationship was weak and nonsignificant.

In a case-control study in India and Sri Lanka, a relative risk of 21.0 was found for oropharyngeal cancer among nonchewing tobacco smokers of both sexes (Hirayama, 1966). Jussawala and Deshpande (1971) found relative risks for oropharyngeal cancer of 11.8, 3.3 and 31.7, respectively, for smokers, for chewers of betel quid with or without tobacco and for people who both smoked and chewed. Cigarette smokers had a relative risk of 2, while *bidi* smokers had a risk of 14; smokers of both cigarettes and *bidis* had a risk of 6; all were statistically significant ($p < 0.001$). Using the same data, Jayant *et al.* (1977) calculated 'etiologic fractions' [attributable risks] of 92% for smoking and 97% for smoking and chewing in relation to oropharyngeal cancer.

With regard to hypopharyngeal cancer, Jussawalla and Deshpande (1971) reported relative risks of 3.6, 6.2 and 16.9 for smokers, chewers and those with both habits, respectively; and the 'etiologic fractions' [attributable risks] were 72% for smoking and 94% for smoking and chewing (Jayant *et al.*, 1977).

Three case-control studies have reported a positive association between nasopharyngeal tumours and cigarette smoking. Relative risks of about 3 in Taiwan (Lin, T.M. *et al.*, 1973) and of 1.8 in Kwantung province of China (Hu & Huang, 1972, cited by Henderson & Louie, 1978) were reported for smokers of >20 cigarettes/day, as compared to nonsmokers. Jussawalla and Deshpande (1971) found relative risks of 3.3, 1.8 and 4.8 for smokers, chewers and those with mixed habits, respectively, in relation to nasopharyngeal cancer. Two case-control studies conducted in California, USA (Henderson *et al.*, 1976) and Singapore (Shanmugaratnam *et al.*, 1978) demonstrated no such association. In a case-control study in Hong Kong (Geser *et al.*, 1978), the choice as controls of patients with cancers related to smoking precluded evaluation of the association.

(v) *Cancer of the oesophagus*

As for other sites in the upper digestive tract, the effect of smoking on the incidence of oesophageal cancer is often combined with that of other factors. In the western world, alcohol is the most common additional factor. In a study in New York, USA, Wynder and Bross (1961) reported an association between oesophageal cancer incidence and smoking among light drinkers, and mentioned that the risk was greater for cigar and/or pipe smokers than for cigarette smokers. In a region of France where the incidence of oesophageal cancer is high, the relative risks among light drinkers were 3.4 for males smoking 10-19 g tobacco/day and 5.1 for smokers of ≥ 20 g (Tuyns *et al.*, 1977). An analysis of the data by type of smoking (Tuyns & Estève, 1983) also indicated that the risk might be greater among pipe smokers and smokers of hand-rolled cigarettes than among smokers of commercial cigarettes.

From the data of Jussawalla (1971), Day *et al.* (1982) calculated relative risks for oesophageal cancer among non-chewing male smokers of *bidis* and of western cigarettes to be 8.0 and 2.8, respectively, and that for smokers of both types, 37.5. Using the data of Jussawalla and Deshpande (1971), Jayant *et al.* (1977) calculated 'etiologic fractions' [attributable risks] of 54% for smokers and 84% for smokers and chewers in relation to cancer of the oesophagus.

In Iran, another area where the incidence of oesophageal cancer is very high, Cook-Mozaffari *et al.* (1979) found a statistically significant relative risk of 1.5 among male cigarette smokers.

In South Africa, the relative risks for oesophageal cancer among male cigarette smokers, pipe smokers and combined smokers were reported by Day *et al.* (1982) to be 2.3, 3.7 and 5.0 in Johannesburg and 0.8, 2.3 and 8.5 in Durban. They noted a higher risk among users of pipe tobacco than among cigarette smokers.

(b) *Cancer of the stomach*

(i) *Cohort studies*

The major cohort studies on smoking have also addressed the risk of stomach cancer among smokers. Most studies have reported relative risks of the order of 1.4 to 1.5 for cigarette smoking, but no dose-response relationship (Hammond, 1966; Kahn, 1966; Doll & Peto, 1976). [The Working Group noted that if the association reported in the study by Hirayama (1982) is causal, the number of excess deaths from stomach cancer attributed to smoking in the Japanese cohort would be equivalent to those from lung cancer.]

(ii) *Case-control studies* (Table 83)

Wynder *et al.* (1963b) found no relationship between smoking and stomach cancer in their hospital-based, multicentre case-control study.

A negative association between smoking and stomach cancer was observed in a gastroscopy-clinic-based case-control study in Chile (Armijo *et al.*, 1981). [The Working Group noted that the smoking experience of the study subjects was presented as mean number of years smoked for cases and controls, and that control selection may not have been appropriate since they may have had diseases associated with smoking.]

A hospital-based case-control study carried out in Hiroshima and Miyagi, Japan, demonstrated a weak association between cigarette smoking and stomach cancer (Haenszel *et al.*, 1976).

A hospital-based case-control study carried out among Hawaiian Japanese (Haenszel *et al.*, 1972) and another in France (Hoey *et al.*, 1981) revealed increased risks for stomach cancer among cigarette smokers as compared to nonsmokers. In the study in Hawaiian Japanese, the risk was greater in Issei (first-generation migrants) than in all Hawaiian Japanese. [The Working Group considered that, in the study of Hoey *et al.* (1981), alcohol did not seem to confound the association with cigarette smoking; however, although the relative risks observed were high, the population studied was very small.]

One population-based case-control study carried out in three areas of Canada (Newfoundland, Manitoba and Toronto, Ontario) revealed only a slight elevation of relative risk for stomach cancer with cigarette smoking, after adjustment for various dietary factors (Risch *et al.*, 1985).

(c) *Cancer of the liver*

Cancer of the liver was positively associated with cigarette smoking in the Japanese Study (Hirayama, 1981a) and the American Cancer Society 25-State Study (Hammond, 1966). The latter reported relative risks of 2.8 for men aged 45-64 and of 1.3 for men aged 65-79. No information was available on alcohol consumption, but the finding of standardized mortality ratios for liver cirrhosis of 2.1 and 2.0 in the two age groups, respectively, is indicative of a major confounding effect. In the Japanese Study, the results were stratified by alcohol consumption (daily drinking *versus* less than daily): within each drinking category a significant increase in risk is seen with increasing level of smoking

Table 83. Case-control studies on stomach cancer and cigarette smoking

Reference (place and years of study)	No. of cases	No. of controls	Factors adjusted for	Relative risk (95% confidence limits)	Comments
Haenszel <i>et al.</i> (1972) (Hawaii, 1963-1969)	220 men and women	440 men and women	-	1.5 (Hawaiian Japanese) ^a ; 1.9 ^a (Issei)	Smokers <i>versus</i> nonsmokers; no dose- response
Haenszel <i>et al.</i> (1976) (Japan, 1962-1964: Hiroshima; 1962-1965: Miyagi)	367 men and women (Hiroshima); 416 men and women (Miyagi)	734 men and women (Hiroshima); 832 men and women (Miyagi)	-	1.1 (Hiroshima) 1.3 (Miyagi)	Smokers <i>versus</i> nonsmokers
Hoey <i>et al.</i> (1981) (France, 1978-1980)	40	168	Eating lettuce, age	4.8 (1.6-14.8) 9.3 (4.9-19.0)	Smokers <i>versus</i> nonsmokers Smokers and drinkers <i>versus</i> nonsmokers
Risch <i>et al.</i> (1985) (Canada, 1979-1982)	246	246	Alcohol, diet	1.3 (1.0-1.6) ($p = 0.036$)	Smokers of > 20 cigarettes <i>versus</i> nonsmokers

^aSignificant at $p < 0.05$

(Table 84). [The Working Group noted that both studies are based on examination of death certificates, on which secondary liver cancers may have been included in the category 'liver cancer', and that many smoking-related cancers metastasize to the liver.]

Table 84. Age-standardized^a mortality ratios for liver cancer according to cigarette consumption and alcohol use^b

Life-long no. of cigarettes smoked	Alcohol use	
	Occasional, rare or none	Daily
None	26.5	24.0
1-190 000	38.8	49.4
200 000-390 000	39.9	45.8
400 000	45.2	66.9

^aStandardized to the age distribution of the entire study population

^bFrom Hirayama (1981a)

Hardell *et al.* (1984) examined a variety of exposures for 83 cases of hepatocellular carcinoma (HCC), 15 cases of cholangiocellular carcinoma and 200 controls in Sweden. A small positive association between HCC and smoking disappeared after controlling for alcohol consumption. A strong association was found between cholangiocellular carcinoma and smoking.

A case-control study of incident HCC among 11 black and 81 white non-Asians in Los Angeles, USA, in 1975-1979 (Yu *et al.*, 1983) reported an excess risk associated with cigarette smoking. The risks relative to that for nonsmokers and ex-smokers combined were 2.6 (95% confidence limits, 1.0-6.7) for smokers of >1 pack/day, and 1.2 (0.6-2.5) for smokers of ≤1 pack/day. Results were stratified by alcohol consumption (≥80 g ethanol/day versus 0-79 g ethanol/day). [The Working Group considered that because only four controls drank ≥80 g/day ethanol, there were insufficient data to study the effect of smoking among heavy drinkers. Among lighter drinkers, the effect does not reach significance, is lower in magnitude than the unstratified effect, and may be influenced by residual confounding.]

In two studies (Trichopoulos *et al.*, 1980; Lam, K.C. *et al.*, 1982), increased risks for HCC were associated with smoking among individuals whose sera gave negative results for the presence of hepatitis B surface antigen (HBsAg).

The study from Athens (Trichopoulos *et al.*, 1980) was based on 79 patients with HCC, 23 patients suspected of having HCC but in whom the diagnosis had not been confirmed, and 204 matched controls. The controls were diagnosed as having diseases other than cancer or liver disease. The sera of 40 of the HCC cases were HBsAg-negative, and a strong relationship with smoking of >20 cigarettes/day was seen in this group (relative risk, 5.5); the effect persisted after adjusting for alcohol consumption.

The study in Hong Kong (Lam, K.C. *et al.*, 1982) was based on an incident series of cases of HCC diagnosed over a 32-month period, and sex- and age-matched controls chosen from the orthopaedic ward of the same hospital. The series consisted of 149 cases, of which 107 were included in the study; but only 19 were HBsAg-negative. The cigarette consumption of these 19 cases was compared with that of the 107 controls; the relative risk for smokers of >20 cigarettes/day was 3.3 (95% confidence limits, 1.0-13.4). Only one of the HCC patients who was a heavy smoker was also a heavy drinker, and, overall, there was no significant association between alcohol consumption and risk for HCC. In this study, peanuts were not considered to be an important source of aflatoxin.

[The Working Group noted that in three of the studies no data were given on possible exposure to aflatoxins.]

(d) *Cancer of the pancreas*

(i) *Correlation studies*

Pancreatic cancer incidence and mortality rates have been rising in western countries and in Japan for many decades, with a possible decrease or levelling off from around 1970 (Gordis, 1980). This may be due in part to improving ability to diagnose the disease. The high rates in blacks in the USA suggest, however, that this is not solely a diagnosis of those with access to advanced medical care (Levin, D.L. *et al.*, 1981).

Stocks (1970) compared the average cigarette consumption per adult for the years 1951-1954 in 20 industrialized countries with the sex-specific, age-standardized pancreatic cancer mortality rates from those same countries in 1964-1965. Comparing mortality rates in countries with average adult cigarette consumption above the median to those with below median consumption, he found nonsignificant excesses for both men and women in countries where there was higher use. Using a somewhat more sensitive analysis (Pearson product-moment correlation coefficient; Kendall & Stuart, 1958), but very similar data, Binstock *et al.* (1983) found small, nonsignificant, positive correlations between pancreatic cancer mortality in 1971-1974 in 17 countries and the corresponding annual number of cigarettes and total tobacco consumption in adults in 1957-1965.

Breslow and Enstrom (1974) found that cigarette consumption, as estimated from US tax revenue data, showed a nonsignificant positive correlation with mortality from pancreatic cancer in both men and women. Kono and Ikeda (1979), using Japanese tax and mortality figures, found a similar lack of association. [The Working Group noted that, in both studies, the pattern of purchase of cigarettes, as reflected in tax figures, may not reflect actual geographic patterns of consumption.]

Two studies employed specific survey data within countries, as opposed to national trade or tax data, to estimate exposure to tobacco. In Hawaii, Hinds, M.W. *et al.* (1980) used cigarette consumption data from personal interviews to estimate male and female intakes for each of five ethnic groups, from which they estimated that 20 pack-years of cigarette use resulted in approximately a 50% increase in pancreatic cancer rate. Using exposure data derived from survey and trade statistics compiled by the Tobacco Research Council, Moolgavkar and Stevens (1981) found that all gender effects and a substantial

portion of cohort effects in pancreatic cancer mortality in England and Wales from 1941 to 1975 could be explained by taking into account age-, sex- and calendar time-specific estimates of lifetime cumulative smoking histories, with a relative risk of 1.6 for 20 pack-years of smoking.

Three studies have indicated an association between lung and pancreatic cancer (Winkelstein *et al.*, 1977; Blot *et al.*, 1978; Howe *et al.*, 1984).

(ii) *Cohort studies* (Table 85)

In the cohort study of male British Doctors (Doll & Peto, 1976), 92 cases of pancreatic cancer had accumulated by 1971. The comparison of pancreatic cancer mortality between nonsmokers and all others (current and ex-smokers of different forms of tobacco) was nonsignificant, but the trend in risk among smokers was statistically significant. The experience of women who responded in the same survey has been reported through 1973 (Doll *et al.*, 1980). Only 14 deaths from pancreatic cancer had occurred, and no pattern relating to tobacco use is evident.

In the cohort of US Veterans (Kahn, 1966), 415 deaths from or associated with pancreatic cancer were identified from July 1954 to December 1962, with a monotonic increase in risk over categories of intensity of current smoking. Current smokers of pipes and cigars only had no excess risk (cigars only, 1.5; pipe only, 0.7; pipe and/or cigars, 1.1; pipe plus cigars, 0.9), and ex-smokers had a modest gradient according to intensity of former smoking. A follow-up of this cohort to the end of 1969 (Rogot & Murray, 1980) continued to indicate elevated risks for both current and ex-smokers. In a follow-up of Canadian veterans (Lossing *et al.*, 1966), results very similar to those of Kahn (1966) were obtained.

The American Cancer Society cohort studies (Hammond & Horn, 1958a,b; Hammond, 1966; Hammond & Seidman, 1980) indicated approximate doubling of risk for pancreatic cancer in male and female smokers of all ages. Male pipe and cigar smokers had risks only slightly lower than those of cigarette smokers. Risks for nonsmoking men and women were very similar.

Follow-up of the mortality experience of the Swedish cohort over 10 years also yielded a picture of a graded effect of smoking on risk for pancreatic cancer for both men and women (Cederlöf *et al.*, 1975).

In the Californian cohort study, Weir and Dunn (1970) found a ratio of directly age-standardized death rates in smokers to nonsmokers of 2.4, based on 71 observed deaths, with a striking gradient of *decreasing* relative risk for pancreatic cancer with increasing quantity typically smoked. Strong positive risk gradients were seen for both lung and bladder cancer; the paradoxical pattern for pancreatic cancer remains unexplained.

In the Japanese cohort (Hirayama, 1981a), the relative risk for pancreatic cancer in male smokers after 13 years of follow-up was of the order of 1.6, an effect which persisted after adjustment for social class and consumption of meat and of green, leafy vegetables.

Heuch *et al.* (1983) assembled three subgroups of Norwegians for whom smoking data were available from 1960. When analysis was confined to the 22 histologically verified cases, a marginally significant relative risk for pancreatic cancer of 2.0 was identified.

Table 85. Cohort studies on pancreatic cancer and tobacco smoking

Reference	Cases	Rate/Ratio estimates ^a							Comments			
Doll & Peto (1976)	78 men	G/D	0	1-	15-	25+	Ex		Trend $p < 0.1$ among current smokers			
		Rate	14	14	18	27	12					
Doll <i>et al.</i> (1980)	14 women	Rate	9	4	24	16	11					
Kahn (1966)	415 men	C/D	0	Oc	1-	10-	21-	40+	Ex	P+C		
		Ratio	1.0	1.1	1.4	1.8	2.2	2.7	1.3	0.9		
Lossing <i>et al.</i> (1966)	- ^b	Ratio	1.0		1.4	2.0	2.4					
		Never regular										
Hammond & Horn (1958b)	117 men	Ratio	1.0	1.5								
Hammond (1966)		Rates	Age	Never	Ever							
	274 men		45-64	7	19							
			65-79	31	66							
	108 women		45-64	6	11							
Cederlöf <i>et al.</i> (1975)		C/D	0	1-	8-	16+	Ex	Pipe	G/D	1-	6+	C+P
	46 men	Ratio	1.0	1.6	3.4	5.9	4.8 ^c			2.2	6.2 ^c	3.8 ^c
		Rate	0.8									
	37 women	Ratio	1.0	2.4	2.5	3.0	5.5					
		Rate	1.6									
Weir & Dunn (1970)	71 men	C/D	0	10	20	30+						
		Ratio	1.0	2.9	2.5	1.4						
			'Smokers', current and ex-smokers; 'non-smokers', also pipe and cigar									
Hirayama (1981a)	251 men	C/D	0	Oc	1-	10-	20+	Ex				
		Rate	13.3	12.8	14.7	19.8	20.3	15.4				
			Ratio ever vs never, 1.6 ^c									
Heuch <i>et al.</i> (1983)	22 men and women	C/D	0	10+								
		Ratio	1.0	2.0								
			Histologically confirmed									

^aRates per 100 000 person-years at risk. Abbreviations: C/D, no. of cigarettes/day; ex, former cigarette use; oc, occasional cigarette use; P+C, pipe and cigar use; G/D, grams of tobacco/day; C+P, cigarette and pipe use

^bNo. of cases in nonsmoking men not given; 28 cases in male cigarette smokers

^c $p < 0.05$

(iii) *Case-control studies* (Table 86)

The most common study design has included incident cases diagnosed in hospitals and compared to hospitalized controls, excluding patients admitted for tobacco-related diseases. The oldest data of this type stem from a study carried out by Stocks in 1952-1954 but reported only recently (Kinlen & McPherson, 1984). In both men and women, there was a modest, positive association between smoking and relative risk. Wynder *et al.* (1973) reported a smooth increase in relative risk with typical (current or former) cigarette consumption in men. A subsequent, larger study from a hospital-surveillance scheme (Wynder *et al.*, 1983) yielded similarly increased risks. In a study in which the control group further excluded patients with diabetes and any biliary or pancreatic disease, MacMahon *et al.* (1981) found modestly increased relative risks for male and female daily smokers.

Whittemore *et al.* (1983) reported an analysis of data on pancreatic cancer mortality drawn from a follow-up system covering 50 000 men who were students at Harvard University from 1916-1950 or at the University of Pennsylvania from 1931-1940. In a case-control analysis of 126 pancreatic cancer decedents and 504 men sampled from the cohort at risk, they examined data obtained during university health examinations and later surveys in relation to subsequent risk for pancreatic cancer. They found relative risks of approximately 2.5 for men who had smoked ≥ 10 cigarettes/day at college as compared to nonsmokers at college. Similar risk elevations were identified on the basis of cumulative adult cigarette exposure.

In two case-control studies with controls taken from the general population, results of the same order of magnitude as those of the hospital-based studies were found. Durbec *et al.* (1983) obtained 199 controls for 69 cases in a door-to-door neighbourhood search. They estimated a nonsignificant relative risk of 1.3 for each 10 g/day increase in tobacco consumption after controlling for age, sex and alcohol consumption (which was a strong predictor of pancreatic cancer). Using more refined control sampling techniques as part of a regional case-control study of cancer and water-borne asbestos, Polissar *et al.* (1984) found a statistically significant overall relative risk of 1.7 for women who had ever smoked.

[The Working Group noted that the only case-control study in which a positive association between smoking and pancreatic cancer was not found (Lin, R.S. & Kessler, 1981) included persons with smoking-related diseases in the control group, an approach that can produce a negative bias in estimates of relative risk.]

(e) *Cancer of the cervix*

Data from 15 studies in which the association between cigarette smoking and risk of cervical cancer was explicitly considered are displayed in Table 87. The studies vary widely in size, in methods and in the type of case included. Some are confined to invasive cancers, or even to death from invasive cancers; others concentrate on precancerous conditions; some include both invasive and preinvasive lesions.

Table 86. Case-control studies of pancreatic cancer and tobacco smoking

Reference (place and years of study)	Numbers and sources of		Covariates adjusted for	Rate ratio estimates ^a						Comments	
	Cases	Controls		C/W	0	10-49	50-149	150+	Pipe		
Kinlen & McPherson (1984) (UK, 1952-1954)	109 men	218 men	Age, sex	C/W	0	10-49	50-149	150+	Pipe		
	107 women	214 women		Men	1.0	1.3	1.6	1.1	1.2		
	Not specified	Cancers unrelated to smoking		Women	1.0	1.1	1.6				
Wynder <i>et al.</i> (1973) (USA, 1950-1964)	100 men	200 men	Controls matched for age, sex, race	C/D	0	1-10	11-20	21-40	≥41		
	42 women	107 women		Men	1.0	2.0	2.2	3.6	5.0	p<0.25 } Calculated by the p<0.5 } Working Group	
	9 hospitals	hospitalized, without tobacco- related disease		Women	1.0	0.7	5.3	1.6	0		
Wynder <i>et al.</i> (1983) (USA, 1981)	153 men	7994 men and	Age	C/D	0	1-10	11-20	21-30	>31	ex	P/C
	122 women	women hospi- talized without		Men	1.0	0.9	2.1 ^b	2.3 ^b	3.0 ^b	1.7 ^b	2.0 ^b
	15 hospitals	tobacco-disease		Women	1.0	1.8	1.5	2.0 ^b		1.4	
MacMahon <i>et al.</i> (1981) (USA, 1974-1979)	218 men	306 men	Age, sex	C/D	0	1-19	≥20	ex			Trend:
	149 women	337 women		Men	1.0	1.1	1.4	1.4			p>0.05
	11 hospitals	hospitalized without tobacco- or alcohol- related disease		Women	1.0	1.5	1.6	1.3			p<0.05

Table 86 (contd)

Reference (place and years of study)	Numbers and sources of		Covariates adjusted for	Rate ratio estimates ^a					Comments
	Cases	Controls		Pack-years	0	1-9	10-19	20-29	
Whittemore <i>et al.</i> (1983) (USA, 1962-1966)	122 men University of Harvard and University of Pennsylvania	481 men Random classmates	Age, school year						Overall $p < 0.05$ Data obtained by mail survey prior to diagnosis
Durbec <i>et al.</i> (1983) (France, 1979- 1980)	37 men 32 women 3 hospitals	100 men 99 women Neighbourhood search	Age, sex, neighbourhood, alcohol	1.3 per 10 g/day current intake					
Polissar <i>et al.</i> (1984) (USA, 1977- 1980)	13 men 10 women Population- based tumour registry	213 men 249 women Census tract	Age, alcohol, education, asbestos	Men	Never	Ever			
				Women	1.0	0	5.4 ^b		

^aAbbreviations: C/W, no. of cigarettes/week; C/D, no. of cigarettes/day; ex, former smokers; P/C, pipe and/or cigar smoker

^b $p < 0.05$ for the value given

Table 87. Summary of studies with data on the association between cervical cancer and smoking

Reference (place and years of study)	No. of cases	Type of case ^a	Relative risk	Dose-response	Variables adjusted for and effect of adjustment	Other comments or relevant findings
Tokuhata (1967) (Southern USA, 1950-1966)	283	Deaths from carcinoma of cervix (266), vagina and vulva (17)	1.2	Similar in white and black women		Use of snuff more strongly associated (overall relative risk, 1.5) not affected by adjustment for a number of social variables
Thomas, D.B. (1973) (USA, 1963-1969)	209	CIS and dysplasia	CIS, 1.7 Dysplasia, 1.2		Variety of social factors After adjustment, CIS, 1.5 Dysplasia, 1.1	'Cases and controls did not differ significantly by the proportion that had ever smoked regularly, the proportion that smoked when interviewed, amount smoked, or age at which smoking started' (statement by authors)
Cederlöf <i>et al.</i> (1975) (Sweden, 1963- 1973)	178	Not explicitly stated but must contain many CIS cases Prospective study	Age-adjusted, 3.0	By amount smoked/day 1-7 2.8 8-15 3.0 ≥16 3.4 Ex-smoker 1.4	Place of residence and income Little confounding	

Table 87 (contd)

Reference (place and years of study)	No. of cases	Type of case ^a	Relative risk	Dose-response	Variables adjusted for and effect of adjustment	Other comments or relevant findings
Hirayama (1975b) (Japan, 1965- 1973)	288	Deaths from cervical cancer Prospective study	SMR for smoking, 1.72	Cigs /day 0 1.0 <20 1.8 20-29 3.5		
Williams, R.R. & Horm (1977) (USA, 1969- 1971)	266	Invasive		Packs- years ≤20 1.2 21-39 1.6 ≥40 1.8	After adjustment for race, no. of children and socioeconomic indicators, a 'mild' positive association remained	Relative risk higher for snuff taking (3.1, 2.3 for different consumption levels), which increases after adjustment for smoking (4.7, 3.6) and remains after adjustment for education level
Wright <i>et al.</i> (1978) (UK, 1968-1974)	65	6 invasive 33 CIS 26 dysplasia Prospective study		Cigs/ day 1-14 1.5 15+ 2.9	Significance unaltered by adjustment for contraceptive method	'In our view, it is unlikely that use of tobacco could have any direct effect on the cervix.' (statement by authors)

Table 87 (contd)

Reference (place and years of study)	No. of cases	Type of case ^a	Relative risk	Dose-response	Variables adjusted for and effect of adjustment	Other comments or relevant findings																																			
Garfinkel (1980) (USA, 1960- 1972)	308	Deaths from cervical cancer Prospective study	Non-smokers/ all of cohort, SMR, 0.87																																						
Harris, R.W.C. <i>et al.</i> (1980) (UK, 1974-1979)	237	Dysplasia and CIS	<table border="1"> <tr> <td>Cigs/ day</td> <td>Mild dys- plasia</td> <td>Severe dys- plasia</td> <td>CIS</td> </tr> <tr> <td>0</td> <td>1.0</td> <td>1.0</td> <td>1.0</td> </tr> <tr> <td><15</td> <td>3.1</td> <td>2.7</td> <td>1.9</td> </tr> <tr> <td>15-19</td> <td>1.7</td> <td>3.5</td> <td>3.3</td> </tr> <tr> <td>20-24</td> <td>5.0</td> <td>3.1</td> <td>4.3</td> </tr> <tr> <td>≥25</td> <td>1.7</td> <td>5.1</td> <td>2.8</td> </tr> </table>	Cigs/ day	Mild dys- plasia	Severe dys- plasia	CIS	0	1.0	1.0	1.0	<15	3.1	2.7	1.9	15-19	1.7	3.5	3.3	20-24	5.0	3.1	4.3	≥25	1.7	5.1	2.8		<table border="1"> <tr> <td colspan="2">Cigs/ day</td> </tr> <tr> <td>None</td> <td>1.0</td> </tr> <tr> <td><15</td> <td>2.2</td> </tr> <tr> <td>15-19</td> <td>2.4</td> </tr> <tr> <td>≥20</td> <td>2.1</td> </tr> </table>	Cigs/ day		None	1.0	<15	2.2	15-19	2.4	≥20	2.1	No. of sexual partners; pregnancy outside marriage; use of oral contraceptives:	Weak effect of alcohol consumption, made weaker by adjustment for number of sexual partners
Cigs/ day	Mild dys- plasia	Severe dys- plasia	CIS																																						
0	1.0	1.0	1.0																																						
<15	3.1	2.7	1.9																																						
15-19	1.7	3.5	3.3																																						
20-24	5.0	3.1	4.3																																						
≥25	1.7	5.1	2.8																																						
Cigs/ day																																									
None	1.0																																								
<15	2.2																																								
15-19	2.4																																								
≥20	2.1																																								
Stellman <i>et al.</i> (1980) (USA, 1974- 1977)	332	Invasive	Risk ratios for >10 cigarettes/day range from 1.4-1.6 before adjustment and from 1.2-1.3 after adjustment for age and socioeconomic status, the value depending on the amount smoked. Smokers of <10/day have a relative risk of <1			Socioeconomic status has little confounding effect; the reduction of the relative risks after adjustment is due mainly to age																																			

Table 87 (contd)

Reference (place and years of study)	No. of cases	Type of case ^a	Relative risk	Dose-response	Variables adjusted for and effect of adjustment	Other comments or relevant findings
Wigle <i>et al.</i> (1980) (Canada, 1971-1973)	676	168 invasive 508 CIS	Invasive: current, 2.0 former, 1.0 CIS: current, 3.8 former, 1.3	<u>Pack-years</u> <10 11-20 21-30 ≥31 No adjustment made for social or sexual variables	<u>Invasive</u> 1.2 1.7 2.1 2.7 <u>CIS</u> 2.8 4.0 3.9 3.7	
Buckley <i>et al.</i> (1981) (UK, 1974-1979)	31 cases all reporting only 1 sexual partner	17 preinvasive 14 invasive	Matched Current smokers, 7.0 Ex-smokers, 2.8	No. of sexual partners of husband Current, 7.8 Ex-smokers, 3.7	Smoking of husbands of cases <u>Before</u> <u>After</u> <u>adjustment</u> <u>adjustment</u> Current 3.2 2.2 Ex- 2.7 2.0 smokers	Relative risk, 35, among a small series of multiple-partner women with husbands who smoke <i>versus</i> those with non- or ex-smoking husbands

Table 87 (contd)

Reference (place and years of study)	No. of cases	Type of case ^a	Relative risk	Dose-response	Variables adjusted for and effect of adjustment	Other comments or relevant findings																				
Clarke <i>et al.</i> (1982) (Canada, 1973-1976)	178	Invasive squamous-cell cancer	Current smokers, 2.3 Ex-smokers, 1.7	<10/day, 2.2 >20/day, 2.9	'Sexual stability'; age at first intercourse; grade of education. Current smoker, 2.2	'Sexual stability' and age at first intercourse equally related to smoking and cervical cancer risk, 2 and 2.1																				
Berggren & Sjostedt (1983) (Sweden, 1974- 1978)	609	Preinvasive	2.7 (crude)	None given in terms of relative risk	Urban/rural difference	Relative risk changes sharply with age: <table border="1" style="margin-left: 20px;"> <thead> <tr> <th>Relative risk</th> <th>Age (years)</th> </tr> </thead> <tbody> <tr><td>9.5</td><td>15-24</td></tr> <tr><td>4.4</td><td>25-29</td></tr> <tr><td>3.1</td><td>30-34</td></tr> <tr><td>2.5</td><td>35-39</td></tr> <tr><td>2.8</td><td>40-44</td></tr> <tr><td>1.6</td><td>45-49</td></tr> <tr><td>1.3</td><td>50-54</td></tr> <tr><td>1.5</td><td>55-59</td></tr> <tr><td>5.1</td><td>60+</td></tr> </tbody> </table>	Relative risk	Age (years)	9.5	15-24	4.4	25-29	3.1	30-34	2.5	35-39	2.8	40-44	1.6	45-49	1.3	50-54	1.5	55-59	5.1	60+
Relative risk	Age (years)																									
9.5	15-24																									
4.4	25-29																									
3.1	30-34																									
2.5	35-39																									
2.8	40-44																									
1.6	45-49																									
1.3	50-54																									
1.5	55-59																									
5.1	60+																									

Table 87 (contd)

Reference (place and years of study)	No. of cases	Type of case ^a	Relative risk	Dose-response	Variables adjusted for and effect of adjustment	Other comments or relevant findings
Marshall, J.R. <i>et al.</i> (1983) (USA, 1957-1965)	513	Cervical cancer (presumably invasive)	Current smokers, 1.6 Ex-smokers, 0.8	Cigs/day Never 1.0 Occa- sionally <10 1.7 19-19 1.7 20-40 1.0 >40 0.4	No. of marriages; age at marriage; dietary factors Unmarried women smokers, [1.1] ^b Married women smokers, [0.5] ^b	'Smoking and number of marriages are interchangeable suggesting that both are surrogates of some third factor' (paraphrase of authors' comments)
Martin & Hill (1984) (South Africa, 1950-1969 [survey] 1970-1974 [follow- up])	257	Cervical cancer	Use of tobacco in any form, 1.5		Use of alcohol 1.3; $\chi^2=2.32$	Relative risk associated with indigenous alcohol, 3.2, which is the strongest association in the study

^aCIS, carcinoma *in situ*

^bCalculated by the Working Group
SMR, standardized mortality ratio

The studies of Tokuata (1967), Hirayama (1975b), Williams, R.R. and Horm (1977), Garfinkel (1980), Stellman *et al.* (1980), Wigle *et al.* (1980), Clarke *et al.* (1982), Marshall, J.R. *et al.* (1983) and Martin and Hill (1984) gave results separately for invasive disease. Leaving aside the study by Garfinkel (1980), since the comparison group used consisted entirely of women, not smokers, the values for the unadjusted (except for age) relative risks by amount smoked are well within the range explicable by moderate confounding effects, except for heavy smokers in the two Canadian studies (Wigle *et al.*, 1980; Clarke *et al.*, 1982) and the Japanese study (Hirayama, 1975b) (Table 88). In the studies by Tokuata (1967), Hirayama (1975b) and Wigle *et al.* (1980), no adjustment for social or sexual variables was performed. In the study of Clarke *et al.* (1982), adjustment for 'sexual stability' and age at first intercourse had little effect, but neither variable is strongly associated with disease; they are both moderately related to smoking. [The Working Group considered that the effect of smoking is confounded by sexual variables, but that the data were not adequate to remove the confounding effect.] In the studies by Stellman *et al.* (1980), Marshall, J.R. *et al.* (1983) and Martin and Hill (1984), the crude odds ratios were reduced by adjusting for a range of variables. [The Working Group considered that a reasonable conclusion to draw from the studies of invasive disease is that the results, although all indicating a positive effect of smoking, are compatible with the residual confounding effects of variables that play a more basic role in the epidemiology of the disease.]

Table 88. Relative risks for invasive cancer of the cervix

Reference	Nonsmokers	No. of cigarettes/day				
		<10	10-19	20-29	30-39	≥40
Tokuata (1967)	1.0	← 1.2 →				
Hirayama (1975b)	1.0	← 1.8 → 3.5				
Williams, R.R. & Horm (1977) ^a	1.0	← 1.2 → <1.6 — 1.8 →				
Stellman <i>et al.</i> (1980)	1.0	0.7	1.4	1.5	← 1.4 →	→
Wigle <i>et al.</i> (1980)	1.0	1.2	1.7	2.1	← 2.7 →	→
Clarke <i>et al.</i> (1982)	1.0	2.2	-	← 2.9 →		
Marshall, J.R. <i>et al.</i> (1983)	1.0	1.7	1.7	← 1.0 →	→ 0.4	→
Martin & Hill (1984)	1.0	← 1.5 →				

^aConsumption expressed as pack-years

In the study by Buckley *et al.* (1981), husband's smoking was strongly related to his sexual activities and to his wife's cervical cancer risk, although the association was weakened by adjustment for the husband's sexual experience.

In a review by Winkelstein *et al.* (1984), data are presented showing a strong association between level of herpes simplex virus-2 antibodies and smoking. Low levels of antibodies gave relative risks of 3 and 8 in smokers and nonsmokers, respectively; and high antibody levels gave values of 12 and 8 for smokers and nonsmokers.

[The Working Group considered that the results of these two studies add weight to the contention that smoking is associated with determinants of a sexually-transmitted disease.]

The studies of preinvasive lesions, or in which a majority of cases were preinvasive (Thomas, D.B., 1973; Cederlöf *et al.*, 1975; Harris, R.W.C. *et al.*, 1980; Wigle *et al.*, 1980; Buckley *et al.*, 1981; Berggren & Sjöstedt, 1983) give, on average, higher relative risks for smoking than do the studies of invasive disease.

[A large number of studies have reported an increased risk for cervical cancer or its preinvasive precursors among women who smoke. The data refer almost entirely to cigarette smoking. In general, the increase in risk reported is about two fold, although higher values have been reported. Little information seems to be available on whether smokers are more or less frequent attenders at screening clinics, but it is conceivable that smoking and non-attendance are positively correlated: the incidence of invasive cancer is often five to ten times higher among non-attenders than among regular attenders; for preinvasive lesions, the prevalence at first attendance is typically five times greater or more than at the third or later attendance, so that both for invasive and preinvasive disease a woman's screening history is a strong potential confounder.

[For cervical cancer, it is reasonable to suppose that there is a specific causal agent — most probably an infective agent transmitted sexually. Since this agent has not been unequivocally identified, and, in particular, was not included in the studies under review, surrogate measures have been used to reflect degree of sexual activity. Smoking is positively related to sexual activity. Any observed crude association between smoking and risk of cervical cancer may be confounded. Since the specific factor by which the analysis should be adjusted is not known, the confounding effect can be removed only partially.]

(f) *Cancer of the endometrium*

In four studies, a decreased risk for the development of endometrial cancer among smokers compared to nonsmokers is reported. A population-based case-control study in Washington State, USA, in 1975-1976 (Weiss, N.S. *et al.*, 1980), in which 322 incident cases aged 50-74 years were compared with a random control sample of 289 women aged 50-74 years from the general population, showed a deficit of endometrial cancer among smokers, with a relative risk of 0.4 (95% confidence limits, 0.2-0.7) among nonusers of exogenous oestrogens. The results were obtained using logistic regression in a model which included parity, hypertension, smoking, weight, age (three strata), duration, mode and dose of

oestrogen use, and time since stopping use of oestrogens. This negative association did not vary with daily number of cigarettes smoked.

In a second case-control study, with 167 incident cases and 903 hospital controls (Kelsey *et al.*, 1982; Baron, 1984), a risk of 0.8 was reported for women who had ever smoked regularly relative to nonsmokers. The analysis was adjusted for age, parity, weight, menopausal status, education and use of oral contraceptives and oestrogens.

The US Third National Cancer Survey (Williams, R.R. & Horm, 1977), which comprised 358 cases and 3188 hospital controls, resulted in a risk of 0.7 for women with 20-40 pack-years of cigarette smoking relative to nonsmokers. The analysis controlled for age and race.

The Swedish cohort study (data derived by Baron, 1984, from Cederlöf *et al.*, 1975), with 80 incident cases (33 deaths), reported a risk of 0.7 for current smokers relative to nonsmokers, after adjusting for age. This study and an American Cancer Society cohort study (Garfinkel, 1980) reported standardized mortality ratios for cigarette-associated risk of death from endometrial cancer of 1.9 (based on 33 deaths) and approximately 1, respectively.

[The Working Group noted that there are a number of methodological problems in the interpretation of mortality studies of endometrial cancer, relating in particular to the accuracy of death certification. For these reasons, results based on mortality should be given less weight than those based on incidence.]

There is consistent evidence that age at menopause is reduced by one to two years among cigarette smokers (Baron, 1984). [This effect indicates that smoking affects hormonal status, which is known to be related to endometrial cancer.]

(g) *Cancer of the breast*

A large number of studies have addressed the association between breast cancer and cigarette smoking, including 18 case-control and cohort studies (summarized in Tables 89 and 90) investigating the health effects of oral contraceptives and the major prospective studies of smoking. There is some suggestion of a decreased risk, but the reported relative risks are distributed on both sides of unity, ranging from 0.7 (Doll *et al.*, 1980) to 1.4 (Hirayama, 1975a).

[The Working Group considered that the effect of smoking on age at menopause could be expected to reduce breast cancer risk, but by an amount scarcely detectable by epidemiological studies, i.e., about 5%. The epidemiological results are consistent with such a decrease, but cannot be said to demonstrate it.]

(h) *Summary*

For cancers of the upper respiratory and upper digestive tracts, all the studies that examined the role of smoking in the absence of alcohol drinking showed an effect of tobacco smoking and a dose-response relationship (see following section for combined effects). The relative risks observed for cancer of the oesophagus, however, were lower than those for oral

Table 89. Case-control studies on breast cancer and smoking

Reference (place and years of study)	Subjects	Confounding variables considered	Contrast	Relative risk
MacMahon & Feinleib (1959) (USA, 1957-1959)	340 cases; 340 hospital controls	Age, race, religion, nativity, marital status, parity, hospital, hospital service	Current smoker vs nonsmoker	1.0 ^a
Valaoras <i>et al.</i> (1969) (Greece, 1965-1967)	799 cases; 2470 hospital controls	Age, hospital	Ever smoker vs never smoker	1.0 ^a
Lin, T.M. <i>et al.</i> (1971) (Taiwan, 1954-1963)	213 cases; 648 hospital controls	Age, hospital	Ever smoker vs never smoker	0.9 ^a
Mirra <i>et al.</i> (1969) (Brazil, 1966-1968)	536 cases; 1550 hospital controls	Age, hospital	Smoker vs nonsmoker	Approximately 1
Williams, R.R. & Horm (1977); Cutler <i>et al.</i> 1974 (USA, 1969-1971)	1167 cases, 3188 hospital controls	Age, race	20-40 pack-years vs nonsmoker	0.9
Paffenbarger <i>et al.</i> (1979) (USA, 1973- 1977)	1432 cases, 2560 hospital controls	Age, race	Ever smoker vs never smoker	0.8 ^{a,b}

Table 89 (contd)

Reference (place and years of study)	Subjects	Confounding variables considered	Contrast	Relative risk
Kelsey <i>et al.</i> (1981) (USA, 1977-1979)	332 cases; 1353 hospital controls	Age, age at first birth, age at menarche, age at menopause, history of benign breast disease, family history of breast cancer, menopausal status, oral contracep- tive/oestrogen use, and others	Ever regular smoker vs never smoker	0.8 ^c
Vessey <i>et al.</i> (1982, 1983) (UK, 1968-1980)	1176 cases, 1176 hospital controls	Age, marital status, parity, age at first term birth, social class, menopausal status, family history of breast cancer, history of benign breast disease, oral contraceptive/ oestrogen use	1-14 cigarettes daily vs never smoker	0.8 ^{c,d}
Centers for Disease Control (1983) (USA, 1980-1981)	1473 cases; 1839 community controls	Age, region of residence	Ever smoker vs never smoker	1.0 ^c
Janerich <i>et al.</i> (1983) (USA, 1974-1976)	278 cases; 520 community controls	Age, county of residence, age of first term birth	Ever smoker vs never smoker	1.2 ^a

^aDerived by Baron (1984) from data given in the reference

^bObserved number of smoking cases significantly less than expected, at $p < 0.05$

^cReported by Baron (1984)

^dStatistically different from 1, at $p < 0.05$

Table 90. Cohort studies on breast cancer and tobacco smoking^a

Reference (place and years of study)	No. of incident cases or deaths	Source of subjects	Confounding variables considered	Contrast	Event followed	Rate ratio
Royal College of General Practitioners (1974) ^b (UK, 1968-1976)	133 cases ^c	Patient volunteers	Age, parity, social class	Current smoker vs nonsmoker	Incidence	0.81 ^c
Cederlöf <i>et al.</i> (1975) (Sweden, 1963-1973)	214 cases ^a 136 deaths ^a	Population sample	Age	Current smoker vs nonsmoker	Incidence Death	0.92 ^c 0.69 ^c
Hirayama (1975a) (Japan, 1965-1973)	108 deaths	Population sample	Age, social class	Daily smoker vs nonsmoker	Death	1.39
Vessey <i>et al.</i> (1976) (UK, 1968-1974)	92 cases ^c	Family planning clinic volunteers	Age, social class, age at first term birth	Current smoker vs nonsmoker	Incidence	0.71 ^c
Doll <i>et al.</i> (1980) (UK, 1951-1973)	84 deaths	British physicians	Age	1-14 cigarettes daily vs never smokers	Death	0.65 ^a

Table 90 (contd)

Reference (place and years of study)	No. of incident cases or deaths	Source of subjects	Confounding variables considered	Contrast	Event followed	Rate ratio
Garfinkel (1980) (USA, 1959-1972)	3096 deaths ^d	Volunteers	Age	Ever smoker vs entire cohort	Death	Approximately 1 ^e
Ramcharan <i>et al.</i> (1981) (USA, 1969-1977)	94 cases	Health screenings	Age, parity, education, oestrogen use	≥1 pack/day vs never smoker	Incidence	0.85 ^{a,f} 1.13 ^{a,g}
Hiatt <i>et al.</i> (1982) (USA, 1960-1977)	714 cases	Health screenings	Age, parity, race, Quetelet's index, menopausal status, age at menarche, alcohol con- sumption, education, serum cholesterol	Ever smoker vs never smoker	Incidence	1.10

^aDerived by Baron (1984) from data given in the reference

^bInterim report

^cReported by Baron (1984)

^dAmong never regular smokers only

^eRate ratio of 1.0 for never regular smokers *versus* the entire study cohort

^fNever users of oral contraceptives

^gEver users of oral contraceptives

and laryngeal cancer. The available data did not allow a firm conclusion to be reached about the relation of pharyngeal cancer to smoking.

Pipe and/or cigar smokers have excess risks for oral and oesophageal cancer that are about as high as those for cigarette smokers.

For stomach cancer, in general, the relative risks due to tobacco smoking are of the order of 1.5. There is, however, no consistent dose-response relationship. In some of the reported studies, the possible confounding effect of other variables, such as some dietary factors, were considered. However, at present it is not possible to conclude that the observed association is causal.

Moderate excesses of hepatocellular carcinoma have been observed in some of the major cohort studies, but mention of liver cancer on death certificates may be unreliable, and the possible role of confounding factors make interpretation of these findings difficult. Two studies of populations with relatively high rates of liver cancer found associations with cigarette smoking among hepatitis B surface antigen-negative individuals, but, in the absence of information on other risk factors, e.g., aflatoxin, generalization of these results to other populations is at present unjustified.

For pancreatic cancer, correlation, case-control and cohort studies are consistent in pointing to a role of tobacco smoking as an important cause. No factor that could explain this relationship by confounding has been identified.

A large number of studies have reported an increased incidence of invasive cervical cancer or its precursors (carcinoma *in situ* or dysplasia) among women who smoke. However, in none of the studies has there been adequate control for the possible major cause — associated with sexual activity. Accordingly, the causal nature of the association of carcinoma of the cervix with smoking remains uncertain.

For cancer of the endometrium, with the exception of one prospective study, studies have consistently shown lower relative risks for women who smoke cigarettes. Since smoking has been shown to reduce the age at which menopause occurs, a protective effect of smoking against endometrial cancer through an endocrine mechanism is plausible, but the possibility of confounding has not been excluded.

In contrast, a number of studies have shown no consistent effect of smoking on the risk for breast cancer.

5. Interactions with other causative factors

Many factors could potentially modify the effects of smoking in causing lung or other cancers. The Working Group has, however, restricted its attention to the possible modifying effects of alcohol, asbestos exposure and some exposures to ionizing radiation, as these are well-documented environmental factors that give rise to greatly increased risks of tobacco-related cancers.

(a) *Alcohol*(i) *Cohort studies*

Only the Japanese prospective study (Hirayama, 1978) covered risks in male cigarette smokers who do not drink and in those who do. Their respective standardized mortality ratios with respect to nondrinking nonsmokers were 2.5 and 5.3 for cancer of the buccal cavity, 0.8 and 3.0 for pharyngeal cancer, and 1.2 and 2.3 for oesophageal cancer. No such difference was seen either for laryngeal (4.9 and 4.5) or lung cancer (4.8 and 4.6).

(ii) *Case-control studies*

Early quantitative assessments of the relation between use of alcohol and tobacco and the risk of cancers of the oral cavity, oropharynx and hypopharynx suggested that the risk associated with smoking was multiplied in the presence of alcohol. In a hospital-based case-control study, Schwartz *et al.* (1957) observed that the risk relative to low consumers of alcohol for all three cancers combined increased with increasing levels of alcohol consumption in every category of smoking. The multiplicative effect of smoking on cancer risk observed in the lowest category of alcohol consumption applied essentially unchanged to the higher risk, high consumption categories.

With regard to *oral* cancers alone, Rothman and Keller (1972) reviewed the effect of joint exposure to tobacco and alcohol, using data published earlier by Keller and Terris (1965). The relative risks observed are shown in Table 91. The authors concluded that a simple multiplicative function of the relative risks associated with alcohol and tobacco separately provided an adequate summary of their joint effect.

Table 91. Relative risks of oral cancer according to level of exposure to smoking and alcohol^a

Alcohol (g/day)	Smoking (cigarette equivalents/day)			
	0	<20	20-39	≥40
0	1.0	1.5	1.4	2.4
<11.3	1.4	1.7	3.2	3.3
11.3-42.5	1.6	4.4	4.5	8.2
≥45.4	2.3	4.1	9.6	15.5

^aFrom Keller and Terris (1965), adapted by Rothman and Keller (1972)

In an extensive study of etiological factors in cancer of the *oesophagus*, Wynder and Bross (1961) considered the effects of tobacco and alcohol separately and together. Consumption of three, compared to less than three, alcoholic drinks per day increased the risk by about five fold; consumption of less than one or one or more packs of cigarettes increased the risks by about two and three fold, respectively, over that for nonsmokers, and the combined effect again appeared to be multiplicative. The risk for heavier drinkers

among pipe and cigar smokers was increased by about 50% above that that would have been anticipated from a simple multiplication of the individual effects. [The Working Group noted that precise quantitative estimates are not available from this publication, since key results are presented only in graphical form.]

In a study of oesophageal cancer in Brittany, France, Tuyns *et al.* (1977) found a similar pattern of joint effect (Table 92). Further analyses of the same material, adjusting for alcohol consumption, showed that the effect of heavy smoking predominates in causation of cancer in the upper third of the oesophagus as compared with the middle third (Keil *et al.*, 1980). A more detailed statistical analysis indicated that the relative risks of joint exposure could be expressed as a multiplicative function of the individual exposures (Breslow & Day, 1980).

Table 92. Relative risks for oesophageal cancer according to daily amounts of tobacco and alcohol consumed^a

Alcohol consumption (g/day)	Tobacco consumption (g/day)			
	0 - 9	10 - 19	20 - 29	≥ 30
0-40	1.0	3.4	3.2	7.8
41-80	7.3	8.4	8.8	35.0
81-120	11.8	13.6	12.6	83.0
≥121	49.6	65.9	137.6	155.6

^aFrom Tuyns *et al.* (1977), adapted by Day and Muñoz (1982)

In their study on environmental factors in cancer of the *larynx*, Wynder *et al.* (1976) showed a combined effect of tobacco and alcohol (Table 93). Cigarette smoke appears to act on laryngeal epithelium even in the absence of alcohol. In the presence of smoking, however, heavy drinking increases the risk, especially for cancer of the supraglottic portion of the larynx. Similar findings were obtained by Burch *et al.* (1981).

When cancers of the oral cavity, pharynx and larynx in British Columbia, Canada, were considered together (Elwood *et al.*, 1984), additive and multiplicative effects of alcohol and tobacco consumption could not be distinguished clearly. [The Working Group noted that the risk ratios observed by Elwood *et al.* were lower than those reported in Tables 91-93, making specification of the mathematical model difficult.]

(b) *Asbestos*

A large cohort, consisting of 17 800 insulation workers in the USA and Canada, exposed to chrysotile and amosite (Selikoff *et al.*, 1973) was followed for a 10-year period, and the mortality rates for lung cancer in smoking and nonsmoking insulation workers were compared to those in 73 763 unexposed male subjects in the American Cancer Society

Table 93. Relative risks for laryngeal cancer in males according to daily amounts of tobacco and alcohol consumed^a

No. of alcoholic drinks/day	Cigarette equivalents/day							
	0		1-15		16-34		≥35	
	No. of cases	Relative risk	No. of cases	Relative risk	No. of cases	Relative risk	No. of cases	Relative risk
None/occasional	5	1.0	12	3.0	38	6.0	31	7.0
1-6	0	-	5	4.0	18	6.7	25	10.3
≥7	0	-	5	3.3	39	13.8	46	22.1

^aFrom Wynder *et al.* (1976)

(ACS) 25-State Study (Hammond, 1966), with adjustment for age (Hammond *et al.*) (Table 94). The relative risk for lung cancer associated with smoking in the asbestos insulation workers was 10.3 and in the ACS volunteers, 10.9. [These results indicate that the joint effects of asbestos exposure and smoking are multiplicative.]

Table 94. Age-standardized death rates^a from lung cancer in cigarette smokers and nonsmokers with or without occupational exposure to asbestos dust^b

Smoking status	Asbestos exposure	Death rate	Mortality ratio
Nonsmoker	No	11.3	1.00
	Yes	58.4	5.17
Smoker	No	122.6	10.85
	Yes	601.6	53.24

^aRate per 100 000 man-years standardized for age on the distribution of the man-years of all the asbestos workers. Number of lung cancer deaths based on information from death certificates

^bFrom Hammond *et al.* (1979)

Several investigations have been reported on other classes of workers, often with mixed exposure (chrysotile and amphiboles; Lindell, 1973) to asbestos. For example, in men and women at one factory in the UK followed from 1971-1980 (Berry *et al.*, 1985), the relative risks for lung cancer associated with factory employment were, for both sexes combined, 2.4 (calculated by the Working Group: observed deaths, 75; expected deaths, 31.2) in smokers and 7.3 (standardized for sex and category, and duration of exposure; observed deaths, 4; expected deaths, 0.4) in nonsmokers. Factory workers exposed to amosite at one US plant

and followed from 1961 to 1977 (Selikoff *et al.*, 1980) had a relative risk of 4.7 (observed deaths, 45; expected deaths, 9.6) in smokers and 25.0 (observed deaths, 5; expected deaths, 0.2) in nonsmokers. In a case-control study including 223 cases and 715 controls who had died from lung cancer between 1951 and 1975 in a defined population of chrysotile-asbestos miners and millers in Quebec, Canada, relative risks associated with asbestos exposure of 1.7 in smokers (714 subjects) and 3.0 in nonsmokers (224 subjects) were observed (Berry *et al.*, 1985). [The Working Group noted that, although accurate dust exposures for relevant job categories are difficult to obtain, those that are available suggest lower exposures for asbestos miners and millers and some factory workers than for insulation workers.]

[The pattern that emerges from these studies is of an interaction between occupational exposure to the different varieties of asbestos and tobacco smoking. In insulators, the joint effect is multiplicative. The pattern of a higher relative risk for lung cancer from asbestos exposure in nonsmokers than in smokers, which has been found regularly in other groups (in particular miners and millers) suggests a weaker joint effect, perhaps related to lower levels of dust exposure.]

(c) *Radiation*

The relationship between cancer mortality and cigarette smoking and exposure to ionizing radiation among atomic-bomb survivors in Hiroshima and Nagasaki has been studied with regard to all nonhaematological cancer, stomach cancer and other digestive-tract cancers and to lung cancer. For lung cancer, the patterns of relative risk were consistent equally with a multiplicative or an additive relationship. For the other cancers studied, the joint effect was less than multiplicative and possibly even additive, especially for those cases who were young at the time of exposure to radiation (Prentice *et al.*, 1983).

Uranium miners exposed to radioactive alpha emissions in underground mines in Colorado, Arizona, New Mexico and Utah, USA, have formed the object of several studies. Using the data base of the US Public Health Service, Whittemore and McMillan (1983) selected 194 lung cancer deaths and four times as many controls and, through a proportional hazard model analysis, derived an estimate of relative risk of 19.2 for workers exposed to more than 1800 working-level months as compared to those exposed to 1-21 working-level months in smokers of more than 30 pack-years and an estimate of 18.2 in smokers of 0-10 pack-years, i.e., indicating a multiplicative effect.

Studies have been reported from other underground mining operations involving exposure to radon daughters at levels considerably lower than those analysed by Whittemore and McMillan (1983). All of the studies indicated that the joint effect of smoking and lower level of radon daughter exposures was less than the multiplicative relationship observed by Whittemore and McMillan in uranium miners (Axelson & Sundell, 1978; Dahlgren, 1979; Damber & Larsson, 1982; Edling, 1982; Edling & Axelson, 1983; Radford & St Clair Renard, 1984).

(d) *Summary*

Studies of tobacco smokers who were exposed jointly to certain other agents show that there are segments of the population for whom tobacco smoking poses risks of cancer

substantially greater than that for the general population. Most prominent among these groups are heavy alcohol drinkers, heavily-exposed asbestos-insulation workers and persons heavily exposed to ionizing radiation in uranium mines. For each of these agents, exposures have been shown to interact approximately multiplicatively with smoking to increase the risk of cancer.

The available studies show that the enhancement of risk by alcohol is dose-dependent. The risk relative to nonsmoking nondrinkers for each level of smoking increases approximately multiplicatively with increasing level of alcohol consumption. The evidence that occupational exposures to asbestos and radiation other than in insulation work and uranium mining enhance multiplicatively the risk of lung cancer induced by smoking is equivocal.

6. Cancers related to passive exposure to tobacco smoke

(a) *Cancer of the lung*

(i) *Cohort studies*

The mortality of 91 540 nonsmoking women was examined in relation to their husbands' smoking habit in a cohort study in Japan (Hirayama, 1981b, 1983, 1984a,b). A total of 429 deaths from lung cancer was recorded in women during the 16 years of follow-up from 1966 to 1981. Of these, 303 were nonsmokers and 200 were married women whose husbands' smoking habits were known. The exposure index in this study was based on smoking habits of husbands. The standardized mortality ratios of lung cancer in nonsmoking women were 1.0, 1.4, 1.4, 1.6 and 1.9 when the husbands were nonsmokers, ex-smokers, daily smokers of 1-14, 15-19 and ≥ 20 cigarettes/day, respectively (p for trend = 0.002). A similar dose-response relationship was observed in each subcategory, defined by age and by occupation of husband, by age of wife, and in each time period of observation. No other characteristic of husbands or wives themselves was found to elevate the risk of lung cancer in their nonsmoking partners. Nonsmoking husbands of women smokers also showed an elevated risk of lung cancer, with standardized mortality ratios of 1.0, 2.1 and 2.3 for nonsmoking husbands with nonsmoking wives, for wives smoking 1-19, and for wives smoking ≥ 20 cigarettes daily, respectively ($p = 0.02$). [The Working Group noted that some nonsmoking women could have been ex- or current smokers, but such a possibility is likely to be quite small.]

In an American Cancer Society cohort study of 375 000 nonsmoking women (Garfinkel, 1981), the husband's smoking habits were known for 176 739 (47%). The follow-up rate was 92.8%. Of the 153 nonsmoking women with lung cancer, 88 were married to smokers. The lung cancer mortality ratios were 1.0, 1.3 and 1.1 for women married to men who never smoked, to men who currently smoked < 20 cigarettes/day, and to men who currently smoked ≥ 20 cigarettes/day, respectively. When matched on the basis of the wife's five-year age group, husband's occupational exposure, highest educational level of husband or wife, race, urban-rural residence and absence of serious disease at the start of the study, the mortality ratios became 1.0, 1.4 and 1.0, respectively. Neither analysis showed a statistically significant increase in risk.

(ii) *Case-control studies*

A case-control study was conducted on nonsmoking female residents of Athens, Greece, from September 1978 to 1982 (Trichopoulos *et al.*, 1981, 1983). For a total of 77 lung cancer cases, interviewed in a cancer hospital, and 225 nonsmoking female controls, interviewed in an orthopaedic hospital, the relative risk of lung cancer for never-married women or for those with husbands who were nonsmokers or ex-smokers who had not smoked for 5-20 years was 1.0; that for wives of ex-smokers who had not smoked for less than five years was 1.9; that for wives of men currently smoking 1-20 cigarettes daily was 2.4; and that for wives of men currently smoking 21 or more cigarettes daily was 3.4. The dose-response relationship was highly statistically significant.

A case-control study that investigated the smoking habits of parents, as well as spouses, included 30 ever-married nonsmoking lung cancer patients and 313 such controls in Louisiana, USA (Correa *et al.*, 1983). Passive exposure to smoke was calculated as total lifetime number of cigarettes smoked by the spouses at the time of interview. Nonsmokers married to heavy smokers had an increased risk of lung cancer, the relative risks being 1.0, 1.5 and 3.1 when spouses had smoked none, 1-300 000, and $\geq 300\ 000$ cigarettes/lifetime, respectively, in the past. The trends with regard to passive smoking exposure remained when adenocarcinomas were excluded. With regard to risk from smoking by parents, an association between lung cancer risk and maternal smoking in male smokers persisted after controlling for variables indicative of active smoking. No such association was obtained for paternal smoking. [The Working Group considered that the association with maternal smoking might have been due to residual associations between the smoking habits of cases and those of their parents.]

In a case-control study conducted in New York, USA, between 1971 and 1980 (Kabat & Wynder, 1984), 134 cases of lung cancer in nonsmokers were compared with an equal number of age-, sex-, race- and hospital-matched nonsmoking controls. Data on exposure to passive inhalation of tobacco smoke were available for a subset of 25 male and 53 female pairs of cases and controls. There was no difference in exposure of spouses, except for more frequent exposure to sidestream tobacco smoke at work among 18/25 male cases and 11/25 controls; the relative risk was 3.3 ($p < 0.045$).

In a case-control study conducted in Hong Kong (Chan & Fung, 1982), 84/189 female lung cancer patients were nonsmoking married women, 40.5% of whom lived with husbands who smoked. Of the 84, 15 had squamous-cell or epidermoid cancer, 38 had adenocarcinomas, 16 other types and 15 had no histological verification. Of the 139 control patients, 47.5% had husbands who smoked. Thus, no excess of lung cancer was demonstrated in the women passively exposed to smoke at home.

A further case-control study was conducted in Hong Kong (Koo *et al.*, 1984) on 200 female lung cancer patients and 200 healthy district controls who were interviewed to identify and quantify the various sources of passive smoking among Chinese women in Hong Kong. For the 'ever' smokers, passive exposure from external sources did not appear to add to their risk. For the 'never' smokers, various assessments of passive smoking showed no significant difference between patients and controls. Moreover, higher relative risks were not associated with higher levels of passive smoking for the 'ever' or 'never' smokers.

[The Working Group noted that in all of the case-control studies described above, under-reporting of active smoking by 'nonsmokers' could have resulted in an over-estimation of risk, on the assumption that the smoking habits of spouses are correlated. By contrast, any random misclassification of spouse's smoking habits could have resulted in an underestimation of risk.]

(b) *Cancers in organs other than the lung*

Positive associations have been reported between passive exposure to tobacco smoke and cancers at all sites (Hirayama, 1984b; Sandler *et al.*, 1985a,b), for nasal sinus cancer and brain tumours (Hirayama, 1984b), and for cancers at many individual sites other than the lung (Sandler *et al.*, 1985a,b). The Working Group noted that these findings were at present difficult to interpret, as many related to sites that have not been strongly associated with active smoking.]

(c) *Childhood cancers and parental cigarette smoking (Table 95)*

A limited number of studies have considered the association of risk of cancer in childhood with exposure to parental smoking, including mother's smoking in pregnancy.

A case-control study on leukaemia in children (aged 0-14) was conducted by Manning and Carroll (1957). No difference between the cases and different control groups was noticed in the proportion of mothers who smoked. In the study of Stewart *et al.* (1958), a statistically significant risk for leukaemia of 1.1 was found for children of mothers who had ever smoked.

Two prospective studies were conducted in 10 hospitals in the province of Ontario, Canada, and in England and Wales (Neutel & Buck, 1971). Detailed prenatal histories were collected for 72 952 births in Ontario (all births occurring in the 10 hospitals in 1959, 1960 and 1961) and for 16 350 in England and Wales (all those occurring between 3-9 March 1958). A follow-up was conducted from January 1959 to December 1968 in Ontario (corresponding to a minimum follow-up period of seven and a maximum of 10 years) and up to the age of seven years in England and Wales. Death certificates mentioning cancer were obtained, and visits were made to all the Ontario cancer clinics to obtain information on children who had been treated for cancer. [The ways in which cancer diagnoses were ascertained in the UK children are not described.] The number of observed cases of cancer was 97 (65 deaths and 32 survivors); expected numbers of deaths were computed from the age-specific cancer mortality rates in Ontario, to verify the completeness of ascertainment. A similar verification was done for surviving cases. A relative risk of 1.3 (95% confidence limits, 0.8-2.2) was found when comparing children of mothers who had smoked during pregnancy with those of nonsmoking mothers. No dose-response relationship was seen, nor was the association more evident in particular age groups of children. [The Working Group noted that data are not given separately for different sites.]

In an exploratory case-control study in Baltimore, MD, USA (Gold *et al.*, 1979), 84 children with brain tumours were compared with children in two age- and sex-matched control groups (one with other cancers and one healthy). Although a relative risk of 5.0 was found for continuous maternal smoking during pregnancy, this finding was not statistically significant ($p = 0.22$) and originated from a large number of multiple comparisons.

Table 95. Childhood cancers and exposure to parental smoking

Reference	Country	Type of study	Sample	Source of information on exposure	Duration (from birth) and completeness of follow-up	Results
Manning & Carroll (1957)	USA	Case-control (hospital-based)	188 cases of leukaemia, 42 lymphomas, 93 others, 50 hospital controls	Interview	3 yrs diagnosis of children 0-14 yrs old	Proportions of mothers smoking ≥ 10 cigarettes/day (at the moment of the interview): leukaemia, 39%; lymphoma, 31%; other cancers, 37%; controls, 38%
Stewart <i>et al.</i> (1958)	UK	Case-control (population-based)	677 deceased cases of leukaemia; 739 children deceased from other cancers; 1416 living matched controls	Home interview	3 yrs diagnosis of children < 10 yrs old	Relative risk, 1.1 ($p = 0.04$) for mother's smoking (ever)
Neutel & Buck (1971)	Canada & UK	Cohort	72 952 births in Ontario; 16 350 births in England & Wales	Interview	7-10 yrs in Ontario; 7 yrs in England & Wales Completeness not available	Relative risk, 1.3 (95% confidence limits, 0.8-2.2) for all cancers (mother's smoking in pregnancy)
Gold <i>et al.</i> (1979)	USA	Case-control (population-based)	84 incident cases of brain tumour; 73 matched controls from the general population and 78 matched cancer controls	Home interview	10 yrs diagnosis of children < 20 yrs old	Relative risk, 5.0 (based on 5 cases) from continued maternal smoking during the index pregnancy

Table 95 (contd)

Reference	Country	Type of study	Sample	Source of information on exposure	Duration (from birth) and completeness of follow-up	Results
Grufferman <i>et al.</i> (1982)	USA	Case-control (population-based)	33 incident cases of rhabdomyosarcoma; 99 randomly-selected population controls	Home interview	9 yrs diagnosis of children 0-14 yrs old	Relative risk, 1.0 (95% confidence limits, 0.4-2.4) for mother's smoking during pregnancy; 3.9 (1.5-9.6) for father's cigarette smoking (ever); 2.8 ($p = 0.07$) when adjusted for social class
Preston-Martin <i>et al.</i> (1982)	USA	Case-control (population-based)	209 incident cases of brain tumour (out of 317 eligible) and 209 matched controls (selected from among friends or neighbours of cases)	Telephone interview	5 yrs diagnosis of children <25 yrs old	Relative risk, 1.1 for mother's smoking in pregnancy; 1.5 (one-sided p value, 0.03) for father's smoking
van Steensel-Moll <i>et al.</i> (1983)	Netherlands	Case-control (population-based)	519 cases of acute lymphocytic leukaemia; 507 matched controls	Mailed questionnaire	7 yrs diagnosis of children \leq 14 yrs old	Relative risk, 1.0 (95% confidence limits, 0.8-1.3) for mother's smoking in year before pregnancy; 0.9 (0.7-1.3) for father's smoking in the same period

A population-based case-control study on rhabdomyosarcoma in childhood was conducted in North Carolina, USA (Grufferman *et al.*, 1982). All incident cases in 1967-1976 in the age group 0-14 years were collected using diagnostic indices, tumour registries and pathological records from hospitals. For each of the 33 cases, three controls of the same age (\pm two months), sex and race were selected randomly from birth certificates in North Carolina. The parents of all 33 cases were interviewed. Nine control parents refused, and 20 were not traced; these 29 lost controls were replaced in two subsequent rounds. Comparisons for a number of social characteristics among original participating controls, nonparticipating controls and replacement controls showed that among the replacement controls a considerably lower proportion of fathers had professional or managerial occupations. The relative risk for rhabdomyosarcoma of children with mothers who had smoked during pregnancy was 1.0 (95% confidence limits, 0.4-2.4), and a relative risk of 3.9 (1.5-9.6) was found for children whose fathers had ever smoked cigarettes. When the latter estimate was adjusted for social class, it became 2.8 ($p = 0.07$). [The Working Group noted that the association with father's smoking was one of a large number of comparisons, and that a highly negative association between rhabdomyosarcoma and social class was found, indicating a possible bias in the selection of controls.]

Preston-Martin *et al.* (1982) conducted a case-control study of brain tumours in childhood. All residents of Los Angeles County, USA, under 25 years of age with a brain tumour diagnosed in 1972-1977 were eligible. Of 317 eligible patients, 226 could be included in the study, and their mothers were interviewed. Controls were selected from among friends and neighbours of the cases and were matched by sex, race, year of birth and socioeconomic status. In all, 209 mothers of matched controls were interviewed. The relative risks for brain tumour were 1.1 for children whose mothers smoked during pregnancy, and 1.5 for children whose mothers lived with a smoker during pregnancy.

A case-control study was conducted in the Netherlands of childhood lymphocytic leukaemia (van Steensel-Moll *et al.*, 1983). The 519 cases were drawn from a nationwide register; 507 age-, sex- and residence-matched controls were selected from the general population. No association was found with smoking by either parent.

(d) Summary

Several epidemiological studies have reported an increased risk of lung cancer in nonsmoking spouses of smokers, although some others have not. In some studies, the risk of lung cancer in nonsmokers increased in relation to the extent of spouses' smoking. Each of the studies had to contend with substantial difficulties in determination of passive exposure to tobacco smoke and to other possible risk factors for the various cancers studied. The resulting errors could arguably have artefactually depressed or raised estimated risks, and, as a consequence, each is compatible either with an increase or with an absence of risk. As the estimated relative risks are low, the acquisition of further evidence bearing on the issue may require large-scale observational studies involving reliable measures of exposure both in childhood and in adult life.

The studies on childhood cancer do not provide clear evidence as to whether or not there is a clear association with parental smoking.

CONCLUSIONS AND EVALUATIONS

1. Conclusions

(a) Usage and trends

Smoking of tobacco is practised worldwide by hundreds of millions of people. In 1982, 6.7 million tonnes of tobacco were produced; annual per-caput consumption in the USA ranged up to more than 3500 cigarettes. In developing countries, cigarette smoking is increasing, and many cigarettes and other products, including *bidis*, have very high tar (up to 55 mg per cigarette) and nicotine yields. In many developed countries, sizeable decreases in total consumption, sales and smoking rates have occurred. Generally, between one-third and one-half of men smoke, with some countries having notably higher rates. In most developed and some developing countries, about one-third of women smoke, although in some countries fewer do.

Sales-weighted average tar and nicotine contents (as measured by standard laboratory methods) have declined significantly since the 1950s in some parts of the world. The chemical composition of smoke depends on (a) the type of tobacco; (b) cigarette design, including filtration, blend selection (e.g., reconstituted sheet, expanded tobacco), ventilation, paper and additives; and (c) the smoking pattern.

Tobacco is smoked principally in cigarettes, with pipes, cigars, *bidis* and other forms being used either to a minor extent or only in certain regions. Combustion of tobacco products delivers mainstream and sidestream smoke which differ in physicochemical nature. In addition, sidestream smoke contains greater amounts of identified carcinogens than mainstream smoke. Passive smoking is a universal phenomenon where smoking is common. The uptake of smoke constituents by smokers and by passive smokers has been studied in only a few countries, although extensive analysis of smoke shows cigarette smoking to be a major source of exposure to tobacco-specific nitroso compounds, polynuclear aromatic compounds, aromatic amines and some other carcinogens.

(b) Carcinogenicity in animals

Cigarette smoke has been tested for carcinogenicity in experimental animals by inhalation and by topical application of condensate and in other ways. Exposure of hamsters and rats to whole smoke results in the induction of malignant respiratory-tract tumours. Cigarette smoke condensate induces skin cancers in mice and rabbits after application to the skin, and lung cancers in rats after intrapulmonary injection. Cigarette smoke contains many chemicals known to produce cancer in animals and/or humans.

More tumours occur in animals exposed to both cigarette smoke and 7,12-dimethylbenz[*a*]anthracene than to either one alone; the same is true for concomitant exposure to benzo[*a*]pyrene or radon daughters.

No study was available that was designed specifically to investigate the carcinogenicity of passive smoking to experimental animals.

(c) *Genetic activity and short-term test results*

Tobacco smoke and smoke condensate are mutagenic and cause chromosomal damage in various test systems with multiple genetic endpoints. Exposure to these complex mixtures results in mutagenic urine in smokers and in increased chromosomal damage in the somatic cells of smokers compared to nonsmokers. Cigarette-smoke condensate induces neoplastic transformation in mammalian cells *in vitro*.

Overall assessment of data from short-term tests^a on cigarette smoke

	Genetic activity			Cell transformation
	DNA damage	Mutation	Chromosomal effects	
Prokaryotes		+		
Fungi/ Green plants		+	+ ^b	
Insects		+		
Mammalian cells (<i>in vitro</i>)			+ ^b	
Mammals (<i>in vivo</i>)			+	
Humans (<i>in vivo</i>)			+	
Degree of evidence in short-term tests for genetic activity: <i>Sufficient</i>				Cell transformation: No data

^aThe groups into which the table is divided and the symbols are defined on pp. 21-22 of the Preamble; the degrees of evidence are defined on pp. 22-23.

^bGas phase of smoke only

Overall assessment of data from short-term tests^a on cigarette smoke condensate (CSC)

	Genetic activity			Cell transformation
	DNA damage	Mutation	Chromosomal effects	
Prokaryotes		+		
Fungi/ Green plants		+	+	
Insects		+		
Mammalian cells (<i>in vitro</i>)		+	+	+
Mammals (<i>in vivo</i>)			+	
Humans (<i>in vivo</i>)				
Degree of evidence in short-term tests for genetic activity: <i>Sufficient</i>				Cell transformation: Positive

^aThe groups into which the table is divided and the symbols are defined on pp. 21-22 of the Preamble; the degrees of evidence are defined on pp. 22-23.

(d) *Human exposure*

Smokers of cigarettes with low 'tar' yields tend to inhale to a greater extent than do smokers of cigarettes with high 'tar' yields, but, in general, their intake of smoke components is reduced.

Certain biochemical markers of smoke intake, e.g., cotinine in plasma, urine or saliva, are sufficiently sensitive and specific to identify passive smokers. Passive smokers who have been examined in western Europe and North America generally have levels between about 0.1% to 1% of these markers as compared to active smokers. The precise quantitative relationship between the measured levels of these markers and the intake of carcinogenic compounds in tobacco smoke is not known.

Approximately 80% of inhaled particles from cigarette mainstream smoke is deposited in the respiratory tract, the majority in the tracheobronchial region. Wide variation is found, however, among individuals. The distribution of particulate matter in the lung is similar in smokers of 'high-' and 'low-tar' cigarettes. The pattern of deposition of sidestream smoke is very different: the proportion deposited is smaller and is likely to occur mainly in the periphery of the lung.

(e) *Genetic host factors*

Genetic polymorphism in microsomal monooxygenases exists in humans. Lung cancer patients with a history of smoking are more often extensive metabolizers of the drug debrisoquine or have high induced levels of aryl hydrocarbon hydroxylase than smokers without lung cancer. It remains to be established whether this association implies that individuals with such genotypes are at increased risk of tobacco smoke-associated cancer.

(f) *Cancer in humans*

Lung cancer is believed to be the most important cause of death from cancer in the world, with estimated total deaths in excess of one million annually. The major cause of the disease is tobacco smoking, primarily of cigarettes. Risk of lung cancer is particularly dependent on duration of smoking; therefore, the earlier the age at initiation of smoking, the greater the individual risk. Further, the longer the time period during which a major proportion of adults in a population have smoked, the greater the incidence and mortality from the disease in that population. Risk of lung cancer is also proportional to the numbers of cigarettes smoked, increasing with increasing cigarette usage. In populations with a long duration and heavy intensity of cigarette usage, the proportion of lung cancer attributable to smoking is of the order of 90%. This attributable proportion applies to men in most western populations; in populations in which women are increasingly using cigarettes, the attributable proportion in women is also approaching this level.

In smokers who have smoked for any length of time, the annual lung cancer risk incurred persists at approximately the same level after cessation of smoking, so that the increasing risk that would have been incurred by continuation of smoking is prevented.

Although cigarettes are the predominant cause of lung cancer, some increased risk also results from pipe and/or cigar smoking.

Smokers of other types of tobacco, particularly in Asia (e.g., of *bidis* in India), also appear to be at an increased risk of lung cancer. At present it is not possible to determine whether prolonged *bidi* smoking increases the risk of lung cancer to the same extent as does prolonged smoking of cigarettes.

Cigarettes appear to increase the risk of squamous-cell (epidermoid) and small-cell carcinomas of the lung to a greater extent than that of adenocarcinomas. However, each of these three main histological types of lung cancer is caused by tobacco smoking.

The risk of lung cancer associated with cigarette smoking is substantially increased in conjunction with high-dose exposures to radon daughters or asbestos.

Tobacco smoking (particularly of cigarettes) is an important cause of bladder cancer and cancer of the renal pelvis. The proportion of these diseases attributable to smoking in most countries with a history of prolonged cigarette usage is of the order of 50% in men and 25% in women. The relationships of risk with duration and intensity of smoking are similar to those for lung cancer, although the risks are lower. Pipe and/or cigar smoking probably also increases the risk of bladder cancer, but at lower levels than the risk caused by cigarette-smoking.

Tobacco smoking is an important cause of oral, oropharyngeal, hypopharyngeal, laryngeal and oesophageal cancers. Pipe and/or cigar smoking appears to increase the risk of these cancers to approximately the same extent as cigarette smoking. The risks of these cancers associated with cigarette smoking are substantially increased in conjunction with high-dose exposure to alcohol. Tobacco smokers also appear to have increased risks for cancer of the lip.

Cigarette smoking is an important cause of pancreatic cancer and perhaps of renal adenocarcinoma. The proportion of these diseases that is attributable to smoking is not possible to quantify with the same accuracy as for lung cancer. The data now available on tobacco smoking and stomach and liver cancers do not permit a conclusion that the associations noted in some studies are causal.

Although the risk of cancer of the cervix is increased in tobacco smokers, it is not possible to conclude that the association is causal. Further, although in some studies a reduction in risk of endometrial cancer has been found in smokers as compared to non-smokers it cannot be concluded that smoking protects against cancer at this site.

The cigarettes that are currently sold differ, in many countries, from those that were sold prior to the general recognition of the hazards associated with their use. When the newer cigarettes are smoked under standard laboratory conditions, the yield of some components — particularly of tar and nicotine — is, in consequence, reduced. It is difficult, however, to deduce from this how hazardous such cigarettes are likely to be as they tend to be smoked differently, and the differences observed with laboratory testing may not be reproduced when they are smoked by people. It is difficult, too, to detect their effect on a national scale, as the harmful effects of smoking accumulate over many years and the risk of developing cancer attributable to smoking depends on both recent and past exposure.

Nevertheless, the Group noted that:

(1) Although smokers of 'low tar'-level cigarettes tend to compensate for lower yields of nicotine and perhaps other smoke components, chiefly by changing the manner of smoking, they do not in general compensate fully for lower tar yields.

(2) Case-control and cohort studies suggest that prolonged use of nonfilter and 'high-tar' cigarettes is associated with greater lung cancer risks than prolonged use of filter and 'low-tar' cigarettes.

(3) In a few countries, in which smoking had been established for many years, a substantial reduction in mortality from lung cancer has been observed in young and middle-aged men, which is greatest in the youngest age groups. This has occurred at a time when the number of cigarettes smoked by young men in these countries has remained approximately constant. No substantial cause (or cofactor) has so far been identified that offers a plausible explanation for the observed magnitude of the reduction of risk for lung cancer, other than changes in cigarette design which include reduction in tar content.

It was concluded that the risk of lung cancer associated with the types of cigarettes commonly smoked before the middle 1950s is greater than that for modified cigarettes with 'low tar' levels now generally available in some countries.¹

The health benefits from the cessation of smoking, however, greatly exceed those to be expected from changes in cigarette composition.

Tobacco smoke affects not only people who smoke but also people who are exposed to the combustion products of other people's tobacco. The effects produced are not necessarily the same, as the constituents of smoke vary according to its source. Three main sources exist: (i) mainstream smoke, (ii) sidestream smoke, and (iii) smoke exhaled to the general atmosphere by smokers. Smokers are exposed to all three to a greater extent than are nonsmokers. It follows that it is unlikely that any effects will be produced in passive smokers that are not produced to a greater extent in smokers and that types of effects that are not seen in smokers will not be seen in passive smokers. Examination of smoke from the different sources shows that all three types contain chemicals that are both carcinogenic and mutagenic. The amounts absorbed by passive smokers are, however, small, and effects are unlikely to be detectable unless exposure is substantial and very large numbers of people are observed. The observations on nonsmokers that have been made so far are compatible with either an increased risk from 'passive' smoking or an absence of risk. Knowledge of the nature of sidestream and mainstream smoke, of the materials absorbed during 'passive' smoking, and of the quantitative relationships between dose and effect that are commonly observed from exposure to carcinogens, however, leads to the conclusion that passive smoking gives rise to some risk of cancer.

2. Evaluations

There is *sufficient evidence* that inhalation of tobacco smoke as well as topical application of tobacco smoke condensate cause cancer in experimental animals.

There is *sufficient evidence* that tobacco smoke is carcinogenic to humans.

The occurrence of malignant tumours of the respiratory tract and of the upper digestive tract is causally related to the smoking of different forms of tobacco (cigarettes, cigars, pipes, *bidis*). The occurrence of malignant tumours of the bladder, renal pelvis and pancreas is causally related to the smoking of cigarettes.

¹See General Introduction: Smoking and the Public Health', pp. 37-45, for a discussion of effects on other tobacco-related diseases.

REFERENCES

- Abramson, R.K. & Hutton, J.J. (1975) Effects of cigarette smoking on aryl hydrocarbon hydroxylase activity in lungs and tissues of inbred mice. *Cancer Res.*, 35, 23-29
- Ada, G.L. (1982) *Host factors important in immune surveillance against tumours*. In: Bartsch, H. & Armstrong, B., eds, *Host Factors in Human Carcinogenesis (IARC Scientific Publications No. 39)*, Lyon, International Agency for Research on Cancer, pp. 223-239
- Adams, J.D., Brunnemann, K.D. & Hoffmann, D. (1978) *Determination of nitric oxide in unaged smoke by GSC-TEA*. In: *Proceedings of the 32nd Tobacco Chemists' Research Conference, Montreal, 1978*, Abstract 36, p. 19
- Adams, J.D., Lee, S.J., Vinchkoski, N., Castonguay, A. & Hoffmann, D. (1983) On the formation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone during smoking. *Cancer Lett.*, 17, 339-346
- Adams, J.D., Lee, S.J. & Hoffmann, D. (1984) Carcinogenic agents in cigarette smoke and the influence of nitrate on their formation. *Carcinogenesis*, 5, 221-223
- Aeschbacher, H.U. & Chappuis, C. (1981) Non-mutagenicity of urine from coffee drinkers compared with that from cigarette smokers. *Mutat. Res.*, 89, 161-177
- Afelius, B.A. (1976) A human syndrome caused by immotile cilia. *Science*, 193, 317-319
- Ahmad, M. (1983) Tobacco in Afghanistan. *Tob. Rep.*, 116, 46-50
- Akehurst, B.C. (1981) *Tobacco*, 2nd ed., London, Longman, p. 764
- Akin, F.J. & Benner, J.F. (1976) Induction of aryl hydrocarbon hydroxylase in rodent lung by cigarette smoke: A potential short-term bioassay. *Toxicol. appl. Pharmacol.*, 36, 331-337
- Albert, R.E., Lippmann, M. & Briscoe, W. (1969) The characteristics of bronchial clearance in humans and the effects of cigarette smoking. *Arch. environ. Health*, 18, 738-755
- Alfheim, I. & Ramdahl, T. (1984) Contribution of wood combustion to indoor air pollution as measured by mutagenicity in *Salmonella* and polycyclic aromatic hydrocarbon concentration. *Environ. Mutagenesis*, 6, 121-120
- Andrews, J. & McGarry, J.M. (1972) A community study of smoking in pregnancy. *J. Obstet. Gynaecol. Br. Commonw.*, 79, 1057-1073
- Anon. (1890) Cancer and smoking. *Br. med. J.*, i, 748
- Anon. (1980) German men not smoking as they used to, but women's numbers rise. *Tobacco int.*, 182, 28, 46
- Anon. (1983a) Smoking in Southern Asia. *World Smoking Health*, 8, 24-27
- Anon. (1983b) Tobacco habits in Sweden, 1982. Some results from the study on smoking habits carried out by the NTS (Swed.) (Abstract). *Tobaken Vi*, 28, 16-20

- Anthony, H.M. & Thomas, G.M. (1970) Bladder tumours and smoking. *Int. J. Cancer*, 5, 266-272
- Ardito, G., Lamberti, L., Ansaldi, E. & Ponzetto, P. (1980) Sister chromatid exchanges in cigarette-smoking human females and their newborns. *Mutat. Res.*, 78, 209-212
- Aringer, L., Hogstedt, C., Svensson, E., Lidums, V. & Wrangle, R. (1983) *Evaluation of some factors affecting determination of thioethers in urine* (Abstract). In: *International Seminar on Methods of Monitoring Human Exposure to Carcinogenic and Mutagenic Agents, 12-15 December 1983, Espoo, Finland*, Helsinki, Institute of Occupational Health, p. 37
- Armijo, R., Orellana, M., Medina, E., Coulson, A.H., Sayre, J.W. & Detels, R. (1981) Epidemiology of gastric cancer in Chile. I. Case-control study. *Int. J. Epidemiol.*, 10, 53-56
- Armitage, A.K. & Turner, D.M. (1970) Absorption of nicotine in cigarette and cigar smoke through the oral mucosa. *Nature*, 226, 1231-1232
- Armitage, A.K., Dollery, C.T., George, C.F., Houseman, T.H., Lewis, P.J. & Turner, D.M. (1975) Absorption and metabolism of nicotine from cigarettes. *Br. med. J.*, iv, 313-316
- Armstrong, B. & Doll, R. (1974) Bladder cancer mortality in England and Wales in relation to cigarette smoking and saccharin consumption. *Br. J. prev. soc. Med.*, 28, 233-240
- Armstrong, B., Garrod, A. & Doll, R. (1976) A retrospective study of renal cancer with special reference to coffee and animal protein consumption. *Br. J. Cancer*, 33, 127-136
- Arnold, W.P., Aldred, R. & Murad, F. (1977) Cigarette smoke activates guanylate cyclase and increases guanosine 3',5'-monophosphate in tissues. *Science*, 198, 934-936
- Arrendale, R.F., Severson, R.F. & Snook, M.E. (1980) Quantitative determination of naphthalenes in tobacco smoke by gas chromatography. *Beitr. Tabakforsch.*, 10, 100-105
- Arrendale, R.F., Severson, R.F. & Chortyk, O.T. (1984) The application of capillary gas chromatography to the analyses of acidic constituents of tobacco leaf and smoke. *Beitr. Tabakforsch.*, 12, 186-197
- Ashton, H., Watson, D.W., Marsh, R. & Sadler, J. (1970) Puffing frequency and nicotine intake in cigarette smokers. *Br. med. J.*, iii, 679-681
- Ashton, H., Stepney, R. & Thompson, J.W. (1979) Self titration by cigarette smokers. *Br. med. J.*, ii, 357-360
- Atlas, S.A., Vesell, E.S. & Nebert, D.W. (1976) Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes. *Cancer Res.*, 36, 4619-4630
- Auerbach, O., Hammond, E.C., Kirman, D. & Garfinkel, L. (1970) Effects of cigarette smoking on dogs. II. Pulmonary neoplasms. *Arch. environ. Health*, 21, 754-768
- Auerbach, O., Hammond, E.C. & Garfinkel, L. (1979) Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977. *New Engl. J. Med.*, 300, 381-386
- Autrup, H., Harris, C.C., Trump, B.F. & Jeffrey, A.M. (1978) Metabolism of benzo[a]pyrene and identification of the major benzo[a]pyrene-DNA adducts in cultured human colon. *Cancer Res.*, 38, 3689-3696
- Aviado, D.M. & Watanabe, T. (1974) Functional and biochemical effects on the lung following inhalation of cigarette smoke and constituents. I. High- and low-nicotine cigarettes in mice. *Toxicol. appl. Pharmacol.*, 30, 185-200
- Axelson, O. & Sundell, L. (1978) Mining, lung cancer and smoking. *Scand. J. Work Environ. Health*, 4, 46-52

- Ayesh, R., Idle, J.R., Ritchie, J.C., Crothers, M.J. & Hetzel, M.R. (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. *Nature*, *312*, 169-170
- Ayres, C.I. & Thornton, R.E. (1965) Determination of benzo(a)pyrene and related compounds in cigarette smoke. *Beitr. Tabakforsch.*, *3*, 285-290
- Bache, C.A., Lisk, D.J., Doss, G.J., Hoffmann, D. & Adams, J.D. (1986) Cadmium and nickel in mainstream particulates of cigarettes containing tobacco grown on a low-cadmium soil-sludge mixture. *J. Toxicol. environ. Health* (in press)
- Badger, G.M. (1962) Mode of formation of carcinogens in human environment. *Natl Cancer Inst. Monogr.*, *9*, 1-16
- Baehner, R.L., Boxer, L.A. & Ingraham, L.M. (1982) *Reduced oxygen by-products and white blood cells*. In: Pryor, W., ed., *Free Radicals in Biology*, Vol. 5, New York, Academic Press, pp. 91-113
- Bahna, S.L., Heiner, D.C. & Myhre, B.A. (1983) Changes in serum IgD in cigarette smokers. *Clin. exp. Immunol.*, *51*, 624-630
- Baker, R.R. (1980) Mechanisms of smoke formation and delivery. *Recent Adv. Tob. Sci.*, *6*, 184-224
- Baker, R.R. (1981) Product formation mechanisms inside a burning cigarette. *Progr. Energy Combustion Sci.*, *7*, 135-153
- Baker, R.R. (1982) Variation of sidestream gas formation during the smoking cycle. *Beitr. Tabakforsch.*, *11*, 181-193
- Baker, R.R. (1984) The effect of ventilation of cigarette combustion mechanisms. *Recent Adv. Tob. Sci.*, *10*, 88-150
- Baron, J.A. (1984) Smoking and estrogen-related disease. *Am. J. Epidemiol.*, *119*, 9-22
- Bartsch, H., Ohshima, H., Muñoz, N., Crespi, M., Cassale, V., Ramazotti, V., Lambert, R., Minaire, Y., Forichon, J. & Walters, C.L. (1984) *In-vivo nitrosation, precancerous lesions and cancers of the gastrointestinal tract. On-going studies and preliminary results*. In: O'Neill, I.K., von Borstel, R.C., Miller, C.T., Long, J. & Bartsch, H., eds, *N-Nitroso Compounds: Occurrence, Biological Effects and Relevance to Human Cancer (IARC Scientific Publications No. 57)*, Lyon, International Agency for Research on Cancer, pp. 957-964
- Basler, A. (1982) SCEs in lymphocytes of rats after exposure in vivo to cigarette smoke or to cyclophosphamide. *Mutat. Res.*, *102*, 137-143
- Basrur, P.K., McClure, S. & Zilkey, B. (1978) *A comparison of short term bioassay results with carcinogenicity of experimental cigarettes*. In: Nieburgs, H.E., ed., *Prevention and Detection of Cancer*, Part 1, Vol. 2, New York, Marcel Dekker, pp. 2041-2048
- Bassi, J.A., Rosso, P., Moessinger, A.C., Blanc, W.A. & James, L. (1984) Fetal growth retardation due to maternal tobacco smoke exposure in the rat. *Pediatr. Res.*, *18*, 127-130
- Battista, S.P. (1976) *Ciliotoxic components of cigarette smoke*. In: Wynder, E.L., Hoffmann, D. & Gori, G.B., eds, *Smoking and Health. I. Modifying the Risk for the Smoker (DHEW Publ. No. (NIH) 76-1221)*, Washington DC, US Department of Health, Education, and Welfare, pp. 517-534
- Baumberger, J.P. (1923) The amount of smoke produced from tobacco and its absorption in smoking as determined by electrical precipitation. *J. Pharmacol. exp. Ther.*, *21*, 47-57
- Beamis, J.F., Jr, Stein, A. & Andrews, J.L., Jr (1975) Changing epidemiology of lung cancer. Increasing incidence in women. *Med. Clin. North Am.*, *59*, 315-325

- Beese, D.H., ed. (1972) *Tobacco Consumption in Various Countries (Research Paper 6)*, 3rd ed., London, Tobacco Research Council
- Bell, J.H. (1980) Determination of glycyrrhizic acid in licorice extracts and chewing tobacco. *Tob. Sci.*, *24*, 126-129
- Bell, J.H., Sanders, A.O. & Spears, A.W. (1966) The contribution of tobacco constituents to phenol yield of cigarettes. *Tob. Sci.*, *10*, 138-142
- Bell, J.H., Ireland, S. & Spears, A.W. (1969) Identification of aromatic ketones in cigarette smoke condensate. *Anal. Chem.*, *41*, 310-313
- Benedict, W.F., Rucker, N., Faust, J. & Kouri, R.E. (1975) Malignant transformation of mouse cells by cigarette smoke condensate. *Cancer Res.*, *35*, 857-860
- Benedict, W.F., Banerjee, A., Kangalingam, K.K., Dansie, D.R., Kouri, R.E. & Henry, C.J. (1984) Increased sister-chromatid exchange in bone-marrow cells of mice exposed to whole cigarette smoke. *Mutat. Res.*, *136*, 73-80
- Benhamou, S., Benhamou, E., Tirmarche, M. & Flamant, R. (1985) Lung cancer and use of cigarettes: A French case-control study. *J. natl Cancer Inst.*, *74*, 1169-1175
- Bennington, J.L. & Laubscher, F.A. (1968) Epidemiologic studies of carcinoma of the kidney. I. Association of renal adenocarcinoma with smoking. *Cancer*, *21*, 1069-1071
- Benowitz, N.L. (1983) *The Use of Biological Fluid Samples in Assessing Tobacco Smoke Consumption (National Institute on Drug Abuse, Research Monograph No. 48; DHHS Publ. No. (ADM) 83-1285)*, Rockville, MD, Department of Health and Human Services, pp. 6-26
- Benowitz, N.L. & Jacob, P., III (1984) Nicotine and carbon monoxide intake from high and low-yield cigarettes. *Clin. pharmacol. Ther.*, *36*, 265-270
- Benowitz, N.L., Jacob, P., III, Jones, R.T. & Rosenberg, J. (1982) Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. *J. Pharmacol. exp. Ther.*, *221*, 368-372
- Benowitz, N.L., Hall, S.M., Herning, R.I., Jacob, P., III, Jones, R.T. & Osman, A.-L. (1983) Smokers of low-yield cigarettes do not consume less nicotine. *New Engl. J. Med.*, *309*, 139-142
- Ben-Sira, Z. (1983) *Smoking Among Adults and Youths: Trends, Predictions and Justifications for Smoking and Its Cessation*, Jerusalem, The Israel Institute for Applied Social Research
- Berggren, G. & Sjöstedt, S. (1983) Preinvasive carcinoma of the cervix uteri and smoking. *Acta obstet. gynecol. scand.*, *62*, 593-598
- Bergman, H., Edling, C. & Axelson, O. (1984) *Indoor radon daughter concentrations and passive smoking*. In: Berglund, B., Lindvall, T. & Sundell, J., eds, *Proceedings of the 3rd International Conference on Indoor Air Quality and Climate, Stockholm, August 20-24*, Vol. 2, *Radon, Passive Smoking, Particulates and Housing Epidemiology*, Stockholm, Swedish Council for Building Research, pp. 79-84
- Bernfeld, P. (1975) Acute toxicity of smoke from different brands of cigarettes, measured in mice. *Toxicol. appl. Pharmacol.*, *31*, 413-420
- Bernfeld, P. & Homburger, F. (1976) Mouse skin assay of condensate from smoking products other than tobacco. *J. natl Cancer Inst.*, *56*, 741-747
- Bernfeld, P. & Homburger, F. (1983) Skin painting studies in Syrian hamsters. *Prog. exp. Tumor Res.*, *26*, 128-153
- Bernfeld, P., Homburger, F. & Russfield, A.B. (1974) Strain differences in the response of inbred Syrian hamsters to cigarette smoke inhalation. *J. natl Cancer Inst.*, *53*, 1141-1157

- Bernfeld, P., Homburger, F., Soto, E. & Pai, K.J. (1979) Cigarette smoke inhalation studies in inbred Syrian golden hamsters. *J. natl Cancer Inst.*, *63*, 675-689
- Bernfeld, P., Homburger, F. & Soto, E. (1983) Subchronic cigarette smoke inhalation studies in inbred Syrian golden hamsters that develop laryngeal carcinoma upon chronic exposure. *J. natl Cancer Inst.*, *71*, 619-623
- Berrino, F., Crosignani, P., Riboli, E. & Vigano, C. (1982) *Cancer incidence in the Varese Province, Italy*. In: Waterhouse, J., Muir, C., Shanmugaratnam, K. & Powell, J., eds, *Cancer Incidence in Five Continents, Vol. IV (IARC Scientific Publications No. 42)*, Lyon, International Agency for Research on Cancer, pp. 490-493
- Berry, G., Newhouse, M.L. & Antonis, P. (1985) Combined effect of asbestos and smoking on mortality from lung cancer and mesothelioma in factory workers. *Br. J. ind. Med.*, *42*, 12-18
- Bertolini, A., Bernardi, M. & Genedani, S. (1982) Effects of prenatal exposure to cigarette smoke and nicotine on pregnancy, offspring development and avoidance behavior in rats. *Neurobehav. Toxicol. Teratol.*, *4*, 545-548
- Best, E.W.R., Josie, G.H. & Walker, C.B. (1961) A Canadian study of mortality in relation to smoking habits. A preliminary report. *Can. J. publ. Health*, *52*, 99-106
- Bilimoria, M.H. & Ecobichon, D.J. (1980) Responses of rodent hepatic, renal and pulmonary aryl hydrocarbon hydroxylase following exposure to cigarette smoke. *Toxicology*, *15*, 83-89
- Bilimoria, M.H., Johnson, J., Hogg, J.C. & Witschi, H.P. (1977) Pulmonary aryl hydrocarbon hydroxylase: Tobacco smoke-exposed guinea pigs. *Toxicol. appl. Pharmacol.*, *41*, 433-440
- Binstock, M., Krakow, D., Stamler, J., Reiff, J., Persky, V., Liu, K. & Moss, P. (1983) Coffee and pancreatic cancer: An analysis of international mortality data. *Am. J. Epidemiol.*, *118*, 630-640
- Black, A. & Pritchard, J.N. (1984) A comparison of the regional deposition and short-term clearance of tar particulate material from cigarette smoke, with that of 2.5 μm polystyrene microspheres. *J. Aerosol Sci.*, *15*, 224-227
- Blacklock, J.W.S. (1961) An experimental study of the pathological effects of cigarette condensate in the lungs with special reference to carcinogenesis. *Br. J. Cancer*, *15*, 745-762
- Blot, W.J., Fraumeni, J.F., Jr & Stone, B.J. (1978) Geographic correlates of pancreas cancer in the United States. *Cancer*, *42*, 373-380
- Bock, F.G., Swain, A.P. & Stedman, R.L. (1969) Bioassay of major fractions of cigarette smoke condensate by an accelerated technic. *Cancer Res.*, *29*, 584-587
- Bock, F.G., Swain, A.P. & Stedman, R.L. (1971) Composition studies on tobacco. XLIV. Tumor-promoting activity of subfractions of the weak acid-fraction of cigarette smoke condensate. *J. natl Cancer Inst.*, *47*, 429-436
- Bodgen, J.D., Kemp, F.W., Buse, M., Thind, I.S., Louria, D.B., Forgacs, J., Lianos, G. & Terrones, I.M. (1981) Composition of tobaccos from countries with high and low incidences of lung cancer. I. Selenium, polonium-210, *Alternaria*, tar, and nicotine. *J. natl Cancer Inst.*, *66*, 27-31
- Bohning, D.E., Albert, R.E., Lippmann, M. & Foster, W.M. (1975) Tracheobronchial particle deposition and clearance. *Arch. environ. Health*, *30*, 457-462
- Bonnet, J. & Neukomm, S. (1956) On the chemical composition of tobacco. I. Analysis of the neutral fraction (Fr.). *Helv. chim. Acta*, *39*, 1724-1733
- Boobis, A.R. & Davies, D.S. (1984) Human cytochrome P-450. *Xenobiotica*, *14*, 151-185

- Boren, H.G. (1970) *Pulmonary cell kinetics after exposure to cigarette smoke*. In: Hanna, M.G., Jr, Nettesheim, P. & Gilbert, J.R., eds, *Inhalation Carcinogenesis (US Atomic Energy Commission Symposium Series No. 18)*, Oak Ridge, TN, US Atomic Energy Commission, pp. 229-241
- Borgers, D. & Junge, B. (1979) Thiocyanate as an indicator of tobacco smoking. *Prev. Med.*, 8, 351-357
- Børresen, A.L., Berg, K. & Magnus, P. (1981) A twin study of aryl hydrocarbon hydroxylase (AHH) inducibility in cultured lymphocytes. *Clin. Genet.*, 19, 281-289
- Bos, R.P., Theuvs, J.L.G. & Henderson, P.T. (1983) Excretion of mutagens in human urine after passive smoking. *Cancer Lett.*, 19, 85-90
- Boucher, R.C., Johnson, J., Inoue, S., Hulbert, W. & Hogg, J.C. (1980) The effect of cigarette smoke on the permeability of guinea pig airways. *Lab. Invest.*, 43, 94-100
- Bourlas, M.C., Magin, D.F., Kornfeld, R.A. & Laszlo, T.S. (1980) The generation of water in the tobacco oven volatile test. *Beitr. Tabakforsch.*, 10, 149-154
- Boutwell, R.K. & Bosch, D.K. (1959) The tumor-promoting action of phenol and related compounds for mouse skin. *Cancer Res.*, 19, 413-424
- Boyland, E., Nice, E. & Williams, K. (1971) The catalysis of nitrosation by thiocyanate from saliva. *Food Cosmet. Toxicol.*, 9, 639-643
- Breslow, N.E. & Day, N.E. (1980) *Statistical Methods in Cancer Research, Vol. 1, The Analysis of Case-Control Studies (IARC Scientific Publications No. 32)*, Lyon, International Agency for Research on Cancer
- Breslow, N.E. & Enstrom, J.E. (1974) Geographic correlations between cancer mortality rates and alcohol-tobacco consumption in the United States. *J. natl Cancer Inst.*, 53, 631-639
- Brinkmann, H. (1914) *Statistische Übersicht über 108 Fälle von Primären Bronchial und Lungenkarzinom, nebst einem Fall von Bronchus-karzinom mit Tödlicher Arrosion der Arteria Pulmonalis* [Statistical Overview of 108 Cases of Primary Bronchial and Lung Carcinoma together with One Case of Carcinoma of the Bronchus with Fatal Erosion of the Pulmonary Artery], Leipzig, Verlag Emil Lehmann
- Brody, A.R. & Craighead, J.E. (1975) Cytoplasmic inclusions in pulmonary macrophages of cigarette smokers. *Lab. Invest.*, 32, 125-132
- Bross, I.D.J. & Gibson, R. (1968) Risk of lung cancer in smokers who switch to filter cigarettes. *Am. J. publ. Health*, 58, 1396-1403
- Brott, K. (1981) Tobacco smoking in Papua New Guinea. *Papua New Guinea med. J.*, 24, 229-236
- Browne, C.L., Keith, C.H. & Allen, R.E. (1980) The effect of filter ventilation on the yield and composition of mainstream and sidestream smokes. *Beitr. Tabakforsch.*, 10, 81-90
- Browne, C.L., Glock, E. & Severson, R.F., eds (1984) Design of low tar cigarettes. *Recent Adv. Tob. Sci.*, 10, 1-160
- Brunnemann, K.D. & Hoffmann, D. (1974a) The pH of tobacco smoke. *Food Cosmet. Toxicol.*, 12, 115-124
- Brunnemann, K.D. & Hoffmann, D. (1974b) Chemical studies on tobacco smoke. XXIV. A quantitative method for carbon monoxide and carbon dioxide in cigarette and cigar smoke. *J. chromatogr. Sci.*, 12, 70-75

- Brunnemann, K.D. & Hoffmann, D. (1975) Chemical studies on tobacco smoke. XXXIV. Gas chromatographic determination of ammonia in cigarette and cigar smoke. *J. chromatogr. Sci.*, *13*, 159-163
- Brunnemann, K.D. & Hoffmann, D. (1978) *Chemical studies on tobacco smoke. LIX. Analysis of volatile nitrosamines in tobacco smoke and polluted indoor environments.* In: Walker, E.A., Castegnaro, M., Gričič, L. & Lyle, R.E., eds, *Environmental Aspects of N-Nitroso Compounds (IARC Scientific Publications No. 19)*, Lyon, International Agency for Research on Cancer, pp. 343-356
- Brunnemann, K.D. & Hoffmann, D. (1981) Assessment of the carcinogenic *N*-nitrosodiethanolamine in tobacco products and tobacco smoke. *Carcinogenesis*, *2*, 1123-1127
- Brunnemann, K.D. & Hoffmann, D. (1982) Pyrolytic origins of major gas phase constituents of cigarette smoke. *Recent Adv. Tob. Sci.*, *8*, 103-140
- Brunnemann, K.D., Hoffmann, D., Wynder, E.L. & Gori, G.B. (1976a) *Chemical studies on tobacco smoke. XXXVII. Determination of tar, nicotine and carbon monoxide in cigarette smoke. A comparison of international smoking conditions.* In: Wynder, E.L., Hoffmann, D. & Gori, G.B., eds, *Proceedings of the Third World Conference on Smoking and Health, New York, June 2-5, 1975*, Vol. 1, *Modifying the Risk of the Smoker (DHEW Publ. No. (NIH) 76-1221)*, Washington DC, US Department of Health, Education, and Welfare, National Institutes of Health, National Cancer Institute, pp. 441-449
- Brunnemann, K.D., Lee, H.-C. & Hoffmann, D. (1976b) Chemical studies on tobacco smoke. XLVII. On the quantitative analysis of catechols and their reduction. *Anal. Lett.*, *9*, 939-955
- Brunnemann, K.D., Yu, L. & Hoffmann, D. (1977a) Chemical studies on tobacco smoke. XLIX. Gas chromatographic determination of hydrogen cyanide and cyanogen in tobacco smoke. *J. anal. Toxicol.*, *1*, 38-42
- Brunnemann, K.D., Yu, L. & Hoffmann, D. (1977b) Assessment of carcinogenic volatile *N*-nitrosamines in tobacco and in mainstream and sidestream smoke from cigarettes. *Cancer Res.*, *37*, 3218-3222
- Brunnemann, K.D., Stahnke, G. & Hoffmann, D. (1978) Chemical studies on tobacco smoke. LXI. Volatile pyridines: Quantitative analysis in mainstream and sidestream smoke of cigarettes and cigars. *Anal. Lett.*, *A11*, 545-560
- Brunnemann, K.D., Fink, W. & Moser, F. (1980) Analysis of volatile *N*-nitrosamines in mainstream and sidestream smoke from cigarettes by GLC-TEA. *Oncology*, *37*, 217-222
- Brunnemann, K.D., Scott, J.C. & Hoffmann, D. (1983) *N*-Nitrosoproline, an indicator for *N*-nitrosation of amines in processed tobacco. *J. agric. Food Chem.*, *31*, 905-909
- Buckley, J.D., Doll, R., Harris, R.W.C., Vessey, M.P. & Williams, P.T. (1981) Case-control study of the husbands of women with dysplasia or carcinoma of the cervix uteri. *Lancet*, *ii*, 1010-1015
- Burch, J.D., Howe, G.R., Miller, A.B. & Semenciw, R. (1981) Tobacco, alcohol, asbestos, and nickel in the etiology of cancer of the larynx: A case-control study. *J. natl Cancer Inst.*, *67*, 1219-1224
- Burton, H.R. & Childs, G., Jr (1975) The thermal degradation of tobacco. VI. Influence of extraction on the formation of some major gas phase constituents. *Beitr. Tabakforsch.*, *8*, 174-180
- Butts, W.C., Kuehneman, M. & Widdowson, G.M. (1974) Automated method for determining serum thiocyanate to distinguish smokers from nonsmokers. *Clin. Chem.*, *20*, 1344-1348

- Camner, P. & Philipson, K. (1972) Tracheobronchial clearance in smoking-discordant twins. *Arch. environ. Health*, 25, 60-63
- Camner, P., Philipson, K. & Friberg, I. (1972) Tracheobronchial clearance in twins. *Arch. environ. Health*, 24, 82-87
- Camner, P., Philipson, K. & Arvidsson, T. (1973) Withdrawal of cigarette smoking. *Arch. environ. Health*, 26, 90-92
- Campbell, J.M. & Lindsey, A.J. (1957) Polycyclic hydrocarbons in cigar smoke. *Br. J. Cancer*, 11, 192-195
- Cano, J.-P., Catalin, J., Badré, R., Dumas, C., Viala, A. & Guillerme, R. (1970) Analysis of nicotine by gas chromatography. II. Applications (Fr.). *Ann. pharm. fr.*, 28, 633-640
- Carmella, S.G., Hecht, S.S., Tso, T.C. & Hoffmann, D. (1984) Roles of tobacco cellulose, sugars, and chlorogenic acid as precursors to catechol in cigarette smoke. *J. agric. Food Chem.*, 32, 267-273
- Carp, H. & Janoff, A. (1978) Possible mechanisms of emphysema in smokers. *In vitro* suppression of serum elastase-inhibitory capacity by fresh cigarette smoke and its prevention by antioxidants. *Am. Rev. resp. Dis.*, 118, 617-621
- Carr, K., Oates, J.A., Nies, A.S. & Woosley, R.L. (1978) Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: A rapid method for determination of acetylator phenotype. *Br. J. clin. Pharmacol.*, 6, 421-429
- Carrano, A.V. (1982) *Sister chromatid exchange as an indicator of human exposure*. In: Bridges, B.A., Butterworth, B.E. & Weinstein, I.B., eds, *Indicators of Genotoxic Exposure (Banbury Report 13)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 307-318
- Carter, W.L. & Hasegawa, I. (1975) Fixation of tobacco smoke aerosols for size distribution studies. *J. Colloid Interface Sci.*, 53, 134-141
- Cartwright, R.A., Glashan, R.W., Rogers, H.J., Ahmad, R.A., Barham-Hall, D., Higgins, E. & Kahn, M.A. (1982) Role of *N*-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. *Lancet*, ii, 842-845
- Cartwright, R.A., Adib, R., Appleyard, I., Glashan, R.W., Gray, B., Hamilton-Stewart, P.A., Robinson, M. & Barham-Hall, D. (1983) Cigarette smoking and bladder cancer: An epidemiological inquiry in West Yorkshire. *J. Epidemiol. commun. Health*, 37, 256-263
- Cartwright, R.A., Philip, P.A., Rogers, H.J. & Glashan, R.W. (1984) Genetically determined debrisoquine oxidation capacity in bladder cancer. *Carcinogenesis*, 5, 1191-1192
- Castleden, C.M. & Cole, P.V. (1973) Inhalation of tobacco smoke by pipe and cigar smokers. *Lancet*, ii, 21-22
- Castonguay, A., Stoner, G.D., Schut, H.A.J. & Hecht, S.S. (1983) Metabolism of tobacco-specific *N*-nitrosamines by cultured human tissues. *Proc. natl Acad. Sci. USA*, 80, 6694-6697
- Cederlöf, R., Friberg, L., Hrubec, Z. & Lorch, U. (1975) *The Relationship of Smoking and Some Social Covariables to Mortality and Cancer Morbidity. A Ten Year Follow-Up in a Probability Sample of 55,000 Swedish Subjects, Age 18-69*, Part 1 and Part 2, Stockholm, Department of Environmental Hygiene, The Karolinska Institute
- Centers for Disease Control (1983) Long-term oral contraceptive use and the risk of breast cancer. *J. Am. med. Assoc.*, 249, 1591-1595

- Central Statistical Office of Finland (1980) *Tupakkatuotteiden Kulutus* [Consumption of tobacco products] (*Tutkimuksia No. 55*), Helsinki, pp. 12, 19
- Central Statistical Office of Finland (1984) *Tupakkatilasto 1983* [Tobacco statistics 1983], Helsinki, pp. 18, 21
- Chameaud, J., Perraud, R., Chrétien, J., Masse, R. & Lafuma, J. (1982) Lung carcinogenesis during in vivo cigarette smoking and radon daughter exposure in rats. *Rec. Res. Cancer Res.*, 82, 11-20
- Chan, W.C. & Fung, S.C. (1982) *Lung cancer in non-smokers in Hong Kong*. In: Grundmann, E., ed., *Cancer Campaign*, Vol. 6, *Cancer Epidemiology*, Stuttgart, Gustav Fischer, pp. 199-202
- Chan, W.C., Colbourne, M.J., Fung, S.C. & Ho, H.C. (1979) Bronchial cancer in Hong Kong 1976-1977. *Br. J. Cancer*, 39, 182-192
- Chandra, S. (1962) Different habits and their relation with cancer cheek. *Chittaranjan Cancer Hosp. Calcutta natl Cancer Res. Centre Bull.*, 33-36
- Chang, W.-C., Fukuda, S. & Tai, H.-H. (1983) Cigarette smoking stimulates lipoxygenase but not cyclooxygenase pathway in platelets. *Biochem. biophys. Res. Commun.*, 115, 499-505
- Chantler, E.N., Elder, J.B. & Elstein, M., eds (1982) Mucus in health and disease. II. *Adv. exp. Med. Biol.*, 144, 335-443
- Choi, N.W. & Klaponski, F.A. (1970) On neural-tube defects: An epidemiological elicitation of etiological factors. *Neurology*, 20, 399-400
- Chopra, N.M. & Domanski, J.J. (1972) Systematic studies on the breakdown of p,p'-DDT in tobacco smoke. III. Isolation and identification of the non-volatile degradation products of p,p'-DDT in p,p'-DDT-treated tobacco smokes. *Beitr. Tabakforsch.*, 6, 139-143
- Chopra, N.M., Campbell, B.S. & Hurley, J.C. (1978) Systematic studies on the breakdown of endosulfan in tobacco smokes: Isolation and identification of the degradation products from the pyrolysis of endosulfan I in a nitrogen atmosphere. *J. agric. Food Chem.*, 26, 255-258
- Chopra, N.M., Verma, M.M. & Zuniga, T.H. (1982) On the fate of maleic hydrazide in tobacco smokes. *J. agric. Food Chem.*, 30, 672-676
- Chow, C.K., Chen, L.H., Thacker, R.R. & Griffith, R.B. (1984) Dietary vitamin E and pulmonary biochemical responses of rats to cigarette smoking. *Environ. Res.*, 34, 8-17
- Church, D.F. & Pryor, W.A. (1986) The free radical chemistry of cigarette smoke and its toxicological implications. *Environ. Health Perspect.* (in press)
- Clarke, E.A., Morgan, R.W. & Newman, A.M. (1982) Smoking as a risk factor in cancer of the cervix: additional evidence from a case-control study. *Am. J. Epidemiol.*, 115, 59-66
- Clemmesen, J. (1965) *Statistical Studies in the Aetiology of Malignant Neoplasms. I. Review and Results*, Copenhagen, Munksgaard
- Clive, D., Johnson, K.O., Spector, J.F.S., Batson, A.G. & Brown, M.M.M. (1979) Validation and characterization of the L51178Y/TK^{+/-} mouse lymphoma mutagen assay system. *Mutat. Res.*, 59, 61-108
- Cobb, B.G. & Ansell, J.S. (1965) Cigarette smoking and cancer of the bladder. *J. Am. med. Assoc.*, 193, 79-82
- Coggins, C.R.E. (1980) *Changes in the respiratory physiology of rats exposed to different phases of cigarette smoke*. In: Sanders, C.L., Cross, F.T., Dagle, J.E. & Mahaffey, J.A., eds, *Pulmonary Toxicology of Respirable Particles*, Washington DC, US Department of Energy, Technical Information Center, pp. 420-430

- Coggins, C.R.E., Fouillet, X.L.M., Lam, R. & Morgan, K.T. (1980) Cigarette smoke induced pathology of the rat respiratory tract: A comparison of the effects of the particulate and vapour phases. *Toxicology*, 16, 83-101
- Coggins, C.R.E., Musy, C. & Ventrone, R. (1982) Changes in the minute ventilation of rats exposed to different concentrations of cigarette smoke. *Toxicol. Lett.*, 11, 181-185
- Cohen, B.S. & Harley, N.H. (1982) Radioactivity in cigarette smoke. *New Engl. J. Med.*, 307, 310-311
- Cohen, B.S., Eisenbud, M. & Harley, N.H. (1979) Alpha radioactivity in cigarette smoke. *Radiat. Res.*, 83, 190-196
- Cohen, B.S., Eisenbud, M. & Harley, N.H. (1980) Measurement of the α -radioactivity on the mucosal surface of the human bronchial tree. *Health Phys.*, 39, 619-632
- Cohen, D., Arai, S.F. & Brain, J.D. (1979) Smoking impairs long-term dust clearance from the lung. *Science*, 204, 514-517
- Cohen, G.M., Uotila, P., Hartiala, J., Suolinna, E.-M., Simberg, N. & Pelkonen, O. (1977) Metabolism and covalent binding of [^3H]benzo[*a*]pyrene by isolated perfused lungs and short-term tracheal organ culture of cigarette smoke-exposed rats. *Cancer Res.*, 37, 2147-2155
- Cohen, G.M., Mehta, R. & Meredith-Brown, M. (1979) Large interindividual variations in metabolism of benzo[α]pyrene by peripheral lung tissue from lung cancer patients. *Int. J. Cancer*, 24, 129-133
- Cohen, J.I. (1982) Radioactivity in cigarette smoke. *New Engl. J. Med.*, 307, 310
- Cohen, S.I., Perkins, N.M., Ury, H.K. & Goldsmith, J.R. (1971) Carbon monoxide uptake in cigarette smoking. *Arch. environ. Health*, 22, 55-60
- Cole, P., Monson, R.R., Haning, H. & Friedell, G.H. (1971) Smoking and cancer of the lower urinary tract. *New Engl. J. Med.*, 284, 129-134
- Collishaw, N.E. (1984) Recent trends in the consumption of tobacco in Canada and in other countries (Fr.). *Mal. chron. Canada*, 4, 58-60
- Comer, A.K. & Creighton, D.E. (1978) *The effect of experimental conditions on smoking behaviour*. In: Thornton, R.E., ed. *Smoking Behaviour. Physiological and Psychological Influences*, Edinburgh, Churchill Livingstone, pp. 76-86
- Commins, B.T. & Lindsey, A.J. (1956) Some phenolic constituents of cigarette smoke. *Br. J. Cancer*, 10, 504-506
- Comstock, G.W. & Lundin, F.E., Jr (1967) Parental smoking and perinatal mortality. *Am. J. Obstet. Gynaecol.*, 98, 708-718
- Connor, T.H., Ramanujam, V.M.S., Ward, J.B., Jr & Legator, M.S. (1983) The identification and characterization of a urinary mutagen resulting from cigarette smoke. *Mutat. Res.*, 113, 161-172
- Cook-Mozaffari, P.J., Azordegan, F., Day, N.E., Ressicaud, A., Sabai, C. & Aramesh, B. (1979) Oesophageal cancer studies in the Caspian littoral of Iran: Results of a case-control study. *Br. J. Cancer*, 39, 293-309
- Cooper, R. (1982) Smoking in the Soviet Union. *Br. med. J.*, 285, 549-551
- Cornell, A., Cartwright, W.F. & Bertinuson, T.A. (1979) Influence of microorganisms (fermentation) on the chemistry of tobacco. *Recent Adv. Tob. Sci.*, 5, 27-62
- Correa, P., Pickle, L.W., Fontham, E., Lin, Y. & Haenszel, W. (1983) Passive smoking and lung cancer. *Lancet*, ii, 595-597

- Creighton, D.E. & Lewis, P.H. (1978) *The effect of smoking pattern on smoke deliveries*. In: Thornton, R.E., ed., *Smoking Behaviour. Physiological and Psychological Influences*, Edinburgh, Churchill Livingstone, pp. 301-314
- Creighton, D.E., Noble, M.J. & Whewell, R.T. (1978) *Instruments to measure, record and duplicate human smoking patterns*. In: Thornton, R.E., ed., *Smoking Behaviour. Physiological and Psychological Influences*, Edinburgh, Churchill Livingstone, pp. 277-288
- Croninger, A.B., Graham, E.A. & Wynder, E.L. (1958) Experimental production of carcinoma with tobacco products. V. Carcinoma induction in mice with cigar, pipe and all-tobacco cigarette tar. *Cancer Res.*, 18, 1263-1271
- Cross, F.T., Palmer, R.F., Filipy, R.E., Dagle, G.E. & Stuart, B.O. (1982) Carcinogenic effects of radon daughters, uranium ore dust and cigarette smoke in beagle dogs. *Health Phys.*, 42, 33-52
- Crossen, P.E. & Morgan, W.F. (1980) Sister chromatid exchange in cigarette smokers. *Human Genet.*, 53, 425-426
- Cuddeback, J.E., Donovan, J.R. & Burg, W.R. (1976) Occupational aspects of passive smoking. *Am. ind. Hyg. Assoc. J.*, 37, 263-267
- Curren, R.D., David, R.M., Henry, C.J. & Stone, C.J. (1984) Cytological and biochemical evaluation of pulmonary lavage fluid from rats exposed to cigarette smoke. *Toxicologist*, 4, Abstract 246
- Cutler, S.J., Scotto, J., Devesa, S.S. & Connelly, R.R. (1974) Third National Cancer Survey - An overview of available information. *J. natl Cancer Inst.*, 53, 1565-1575
- Dagle, G.E., McDonald, K.E., Smith, L.G. & Stevens, D.L., Jr (1978) Pulmonary carcinogenesis in rats given implants of cigarette smoke condensate in beeswax pellets. *J. natl Cancer Inst.*, 61, 905-910
- Dahlgren, E. (1979) Lung cancer, cardiovascular disease and smoking in a group of mineworkers (Sw.) *Läkartidningen*, 76, 4811-4814
- Dalbey, W.E., Nettesheim, P., Griesemer, R., Caton, J.E. & Guerin, M.R. (1980) Chronic inhalation of cigarette smoke by F344 rats. *J. natl Cancer Inst.*, 64, 383-390
- Dalhamn, T., Edfors, M.-L. & Rylander, R. (1968a) Mouth absorption of various compounds in cigarette smoke. *Arch. environ. Health*, 16, 831-835
- Dalhamn, T., Edfors, M.-L. & Rylander, R. (1968b) Retention of cigarette smoke components in human lungs. *Arch. environ. Health*, 17, 746-748
- Damber, L. & Larsson, L.-G. (1982) Combined effects of mining and smoking in the causation of lung carcinoma: A case-control study in northern Sweden. *Acta radiol. oncol.*, 21, 305-313
- Daniele, R.P., Dauber, J.H., Altose, M.D., Rowlands, D.T., Jr & Gorenberg, D.J. (1977) Lymphocyte studies in asymptomatic cigarette smokers. *Am. Rev. resp. Dis.*, 116, 997-1005
- Davies, J.M. (1981) Estimation of relative risk from vital data: Smoking and cancers of the lung and bladder. *J. natl Cancer Inst.*, 66, 611-612
- Davies, R.F. & Day, T.D. (1969) A study of the comparative carcinogenicity of cigarette and cigar smoke condensate on mouse skin. *Br. J. Cancer*, 23, 363-368
- Davis, B.R., Whitehead, J.K., Gill, M.E., Lee, P.N., Butterworth, A.D. & Roe, F.J.C. (1975a) Response of rat lung to inhaled tobacco smoke with or without prior exposure to 3,4-benzpyrene (BP) given by intratracheal instillation. *Br. J. Cancer*, 31, 469-484

- Davis, B.R., Whitehead, J.K., Gill, M.E., Lee, P.N., Butterworth, A.D. & Roe, F.J.C. (1975b) Response of rat lung to inhaled vapour phase constituents (VP) of tobacco smoke alone or in conjunction with smoke condensate or fractions of smoke condensate given by intratracheal instillation. *Br. J. Cancer*, 31, 462-468
- Davis, B.R., Whitehead, J.K., Gill, M.E., Lee, P.N., Butterworth, A.D. & Roe, F.J.C. (1975c) Response of rat lung to tobacco smoke condensate or fractions derived from it administered repeatedly by intratracheal instillation. *Br. J. Cancer*, 31, 453-461
- Davis, D.L., Vaught, A., Tso, T.C. & Bush, L.P. (1984) *Analysis of a new lower yield research cigarette*. In: *Abstracts of CORESTA 84, 8th International Tobacco Scientific Congress, Vienna, October 7-12, 1984*, Paris, Centre de Coopération pour les Recherches Scientifiques Relatives au Tabac, Abstract No. PP03
- Day, N.E. & Muñoz, N. (1982) *Esophagus*. In: Schottenfeld, D. & Fraumeni, J.F., Jr, eds, *Cancer Epidemiology and Prevention*, Philadelphia, PA, W.B. Saunders Co., pp. 596-623
- Day, N.E., Muñoz, N. & Ghadirian, P. (1982) *Epidemiology of esophageal cancer: A review*. In: Correa, P. & Haenszel, W., eds, *Epidemiology of Cancer of the Digestive Tract*, The Hague, Martinus Nijhoff, pp. 21-57
- Dean, G., Lee, P.N., Todd, G.F. & Wicken, A.J. (1977) *Report on a Second Retrospective Study in North-east England. Part I. Factors Related to Mortality from Lung Cancer, Bronchitis, Heart Disease and Stroke in Cleveland County, with Particular Emphasis on the Relative Risks Associated with Smoking Filter and Plain Cigarettes (Research Paper 14)*, London, Tobacco Research Council
- Deaner, R.M. & Trummer, M.J. (1970) Carcinoma of the lung in women. *J. thorac. cardiovasc. Surg.*, 59, 551-554
- De Flora, S., Bennicelli, C., Zanacchi, P., Camoirano, A., Petruzzelli, S. & Giuntini, C. (1984) Metabolic activation and deactivation of mutagens by preparations of human lung parenchyma and bronchial tree. *Mutat. Res.*, 139, 9-14
- DeMarini, D.M. (1981a) Mutagenicity of fractions of cigarette smoke condensate in *Neurospora crassa* and *Salmonella typhimurium*. *Mutat. Res.*, 88, 363-374
- DeMarini, D.M. (1981b) Mutagenicity of cigarette smoke condensate in *Neurospora crassa*. *Mutat. Res.*, 88, 375-388
- DeMarini, D.M. (1983) Genotoxicity of tobacco smoke and tobacco smoke condensate. *Mutat. Res.*, 114, 59-89
- Department of Health and Social Security (1979) *Developments in Tobacco Products and the Possibility of 'Lower-risk' Cigarettes (Second Report of the Independent Scientific Committee on Smoking and Health)*, London, Her Majesty's Stationery Office
- De Raat, W.K. (1979) Comparison of the induction by cigarette smoke condensates of sister-chromatid exchanges in Chinese hamster cells and of mutations in *Salmonella typhimurium*. *Mutat. Res.*, 66, 253-259
- Dickens, F. & Jones, H.E.H. (1963) Further studies on the carcinogenic and growth-inhibitory activity of lactones and related substances. *Br. J. Cancer*, 17, 100-108
- Dickens, F. & Jones, H.E.H. (1965) Further studies on the carcinogenic action of certain lactones and related substances in the rat and mouse. *Br. J. Cancer*, 19, 392-403
- Di Franza, J.R. & Winters, T.H. (1982) Radioactivity in cigarette smoke. *New Engl. J. Med.*, 307, 312-313

- DiPaolo, J.A. & Levin, M.L. (1965) Tumor incidence in mice after oral painting with cigarette smoke condensate. *J. natl Cancer Inst.*, *34*, 595-600
- DiVicenzo, G.D. & Kaplan, C.J. (1981) Uptake, metabolism and elimination of methylene chloride vapor by humans. *Toxicol. appl. Pharmacol.*, *59*, 130-140
- Doihara, T., Kobashi, U., Sugawara, S. & Kaburaki, Y. (1965) Studies on flavoring effect. V. The simple analysis of polyols in cigarettes by gas chromatographic method (Jpn). *Sci. Papers Central Res. Inst. Jpn Tob. Salt Corp.*, *107*, 141-145
- Dolara, P., Mazzoli, S., Rosi, D., Buiatti, E., Baccetti, S., Turchi, A. & Vannucci, V. (1981) Exposure to carcinogenic chemicals and smoking increases urinary excretion of mutagens in humans. *J. Toxicol. environ. Health*, *8*, 95-103
- Doll, R. (1971) The age distribution of cancer: Implications for models of carcinogenesis. *J. R. stat. Soc. A*, *134*, 133-155
- Doll, R. & Hill, A.B. (1950) Smoking and carcinoma of the lung. Preliminary report. *Br. med. J.*, *ii*, 739-748
- Doll, R. & Hill, A.B. (1952) A study of the aetiology of carcinoma of the lung. *Br. med. J.*, *ii*, 1271-1286
- Doll, R. & Hill, A.B. (1954) The mortality of doctors in relation to their smoking habits. A preliminary report. *Br. med. J.*, *i*, 1451-1455
- Doll, R. & Hill, A.B. (1964a) Mortality in relation to smoking: Ten years' observations of British doctors. *Br. med. J.*, *i*, 1399-1410
- Doll, R. & Hill, A.B. (1964b) Mortality in relation to smoking: Ten years' observations of British doctors. *Br. med. J.*, *i*, 1460-1467
- Doll, R. & Hill, A.B. (1966) Mortality of British doctors in relation to smoking: Observations on coronary thrombosis. *Natl Cancer Inst. Monogr.*, *19*, 205-268
- Doll, R. & Peto, R. (1976) Mortality in relation to smoking: 20 years' observations on male British doctors. *Br. med. J.*, *ii*, 1525-1536
- Doll, R. & Peto, R. (1978) Cigarette smoking and bronchial carcinoma: Dose and time relationships among regular smokers and lifelong non-smokers. *J. Epidemiol. commun. Health*, *32*, 303-313
- Doll, R. & Peto, R. (1981) The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. *J. natl Cancer Inst.*, *66*, 1191-1308
- Doll, R., Hill, A.B. & Kreyberg, L. (1957) The significance of cell type in relation to the aetiology of lung cancer. *Br. J. Cancer*, *11*, 43-48
- Doll, R., Gray, R., Hafner, B. & Peto, R. (1980) Mortality in relation to smoking: 22 years' observations on female British doctors. *Br. med. J.*, *i*, 967-971
- Dong, M., Schmeltz, I., Jacobs, E. & Hoffmann, D. (1978) Aza-arenes in tobacco smoke. *J. anal. Toxicol.*, *2*, 21-25
- Dontenwill, W.P. (1974) *Tumorigenic effect of chronic cigarette smoke inhalation on Syrian golden hamsters*. In: Karbe, E. & Park, J.F., eds, *Experimental Lung Cancer. Carcinogenesis and Bioassays*, New York, Springer, pp. 331-359
- Dontenwill, W., Chevalier, H.-J., Harke, H.-P., Klimisch, H.-J., Lafrenz, O. & Reckzeh, G. (1972) Experimental studies on tumorigenic activity of cigarette smoke condensate on mouse skin. IV. Comparative studies of condensates from different reconstituted tobacco sheets, the effect of NaNO₃ as additive to tobacco or reconstituted tobacco sheets, the effect of volatile constituents of smoke, the effect of initial treatment with dimethylbenzanthracene (Ger.). *Z. Krebsforsch.*, *78*, 236-264

- Dontenwill, W., Chevalier, H.J., Harke, H.P., Lafrenz, U., Reckzeh, G. & Schneider, B. (1973) Investigations on the effects of chronic cigarette smoke inhalation in Syrian golden hamsters. *J. natl Cancer Inst.*, 51, 1781-1832
- Dontenwill, W., Chevalier, H.-J., Harke, H.-P., Klimisch, H.-J., Kuhnigle, C., Reckzeh, G. & Schneider, B. (1977a) Studies on the effect of chronic cigarette smoke inhalation in Syrian golden hamsters and the importance of vitamin A on morphological alterations after smoke exposure (Ger.). *Z. Krebsforsch.*, 89, 153-180
- Dontenwill, W., Chevalier, H.-J., Harke, H.-P., Klimisch, H.-J., Reckzeh, G., Fleischmann, B. & Keller, W. (1977b) Experimental investigations on the tumorigenic activity of cigarette smoke condensate on mouse skin. VII. Comparative studies of condensates from different modified cigarettes (Ger.). *Z. Krebsforsch.*, 89, 145-151
- van Doorn, R., Bos, R.P., Leijdekkers, Ch.-M., Wagenaas-Zegers, M.A.P., Theuws, J.L.G. & Henderson, P.Th. (1979) Thioether concentration and mutagenicity of urine from cigarette smokers. *Int. Arch. occup. environ. Health*, 43, 159-166
- van Doorn, R., Leijdekkers, Ch.-M., Bos, R.P., Brouns, R.M.E. & Henderson, P.Th. (1981) Detection of human exposure to electrophilic compounds by assay of thioether detoxication products in urine. *Ann. occup. Hyg.*, 24, 77-92
- Drath, D.B., Harper, A., Gharibian, J., Karnovsky, M.L. & Huber, G.L. (1978) The effect of tobacco smoke on the metabolism and function of rat alveolar macrophages. *J. cell. Physiol.*, 95, 105-114
- Drayer, D.E. & Reidenberg, M.M. (1977) Clinical consequences of polymorphic acetylation of basic drugs. *Clin. Pharmacol. Ther.*, 22, 251-258
- Dube, M.F. & Green, C.R. (1982) Methods of collection of smoke for analytical purposes. *Recent Adv. Tob. Sci.*, 8, 42-102
- Dunham, L.J., Rabson, A.S., Stewart, H.L., Frank, A.S. & Young, J.L. (1968) Rates, interview, and pathology study of cancer of the urinary bladder in New Orleans, Louisiana. *J. natl Cancer Inst.*, 41, 683-709
- Durbec, J.P., Chevillotte, G., Bidart, J.M., Berthezene, P. & Sarles, H. (1983) Diet, alcohol, tobacco and risk of cancer of the pancreas: A case-control study. *Br. J. Cancer*, 47, 463-470
- Durocher, D.F. (1984) The choice of paper components for low tar cigarettes. *Recent Adv. Tob. Sci.*, 10, 52-71
- Ebert, R.V., McNabb, McK.E., McCusker, K.T. & Snow, S.L. (1983) Amount of nicotine and carbon monoxide inhaled by smokers of low-tar, low-nicotine cigarettes. *J. Am. med. Assoc.*, 250, 2840-2842
- Edling, C. (1982) Lung cancer and smoking in a group of iron ore miners. *Am. J. ind. Med.*, 3, 191-199
- Edling, C. & Axelson, O. (1983) Quantitative aspects of radon daughter exposure and lung cancer in underground miners. *Br. J. ind. Med.*, 40, 182-187
- Eichelbaum, M. (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. *Clin. Pharmacokinet.*, 7, 1-22
- Eichelbaum, M. (1984) Polymorphic drug oxidation in humans. *Fed. Proc.*, 43, 2298-2302
- Eichelbaum, M., Bertilsson, L. & Säwe, J. (1983) Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine. *Br. J. clin. Pharmacol.*, 15, 317-321

- El-Bayoumy, K., O'Donnell, M., Hecht, S.S. & Hoffmann, D. (1985) On the analysis of 1-nitro-naphthalene, 1-nitropyrene and 6-nitrochrysene in cigaret smoke. *Carcinogenesis*, 6, 505-507
- Eling, T.E. & Ally, A.I. (1984) Pulmonary biosynthesis and metabolism of prostaglandins and related substances. *Environ. Health Perspect.*, 55, 159-168
- Ellington, J.J., Schlotzhauer, P.F. & Schepartz, A.I. (1978) Quantitation of hexane-extractable lipids in serial samples of flue-cured tobaccos. *J. Food agric. Chem.*, 26, 270-273
- Elliot, L.P. & Rowe, D.R. (1975) Air quality during public gatherings. *J. Air Pollut. Control Assoc.*, 25, 635-363
- Elmenhorst, H. (1972) Acids and phenols in the 'semivolatile' fraction of smoke of blended, Virginia, Burley, and oriental cigarettes (Ger.). *Beitr. Tabakforsch.*, 6, 182-188
- Elmenhorst, H. & Schultz, C. (1968) Volatile constituents of tobacco smoke. Chemical components of the gas-vapour phase (Ger.). *Beitr. Tabakforsch.*, 4, 90-123
- Elson, L.A., Betts, T.E. & Passey, R.D. (1972) The sugar content and the pH of the smoke of cigarette, cigar and pipe tobaccos in relation to lung cancer. *Int. J. Cancer*, 9, 666-675
- Elwood, J.M., Pearson, J.C.G., Skippen, D.H. & Jackson, S.M. (1984) Alcohol, smoking, social and occupational factors in the aetiology of cancer of the oral cavity, pharynx and larynx. *Int. J. Cancer*, 34, 603-612
- Encyclopaedia Britannica, Inc. (1966) *Encyclopaedia Britannica*, Chicago, William Benton, Vol. 5, pp. 766-769; Vol. 17, pp. 1106-1107; Vol. 20, pp. 937-938; Vol. 22, pp. 263-267
- Entwistle, I.D. & Johnstone, R.A.W. (1965) Alkenes in cigarette smoke condensate. *Chem. Ind. London*, February, 269
- Enzell, C.R. & Wahlberg, I. (1980) Leaf composition in relation to smoking quality and aroma. *Recent Adv. Tob. Sci.*, 6, 67-122
- Enzell, C.R., Wahlberg, I. & Aasen, A.J. (1977) *Isoprenoids and alkaloids of tobacco*. In: Herz, W., Grisebach, H. & Kirby, G.W., eds, *Progress in the Chemistry of Organic Natural Products*, Vol. 34, Vienna, Springer, pp. 1-79
- Esber, H.J., Menninger, F.F., Jr, Bogden, A.E. & Mason, M.M. (1973) Immunological deficiency associated with cigarette smoke inhalation by mice. *Arch. environ. Health*, 27, 99-104
- Evans, D.A.P. & White, T.A. (1964) Human acetylation polymorphism. *J. Lab. clin. Med.*, 63, 394-403
- Evans, D.R., Newcombe, R.G. & Campbell, H. (1979) Maternal smoking habits and congenital malformations: A population study. *Br. med. J.*, ii, 171-173
- Evans, H.J. (1982) *Sperm morphology in cigarette smokers*. In: Bridges, B.A., Butterworth, B.E. & Weinstein, I.B., eds, *Indicators of Genotoxic Exposure (Banbury Report 13)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 543-554
- Evans, H.J., Fletcher, J., Torrance, M. & Hargreave, T.B. (1981) Sperm abnormalities and cigarette smoking. *Lancet*, i, 627-629
- Fagerström, K.-O. (1982) Effects of a nicotine-enriched cigarette on nicotine titration, daily cigarette consumption, and levels of carbon monoxide, cotinine and nicotine. *Psychopharmacology*, 77, 164-167
- Falck, K. (1982) *Urinary mutagenicity caused by smoking*. In: Sorsa, M. & Vainio, H., eds, *Mutagens in Our Environment*, New York, Alan R. Liss, pp. 387-400

- Federal Republic of Germany (1977) *Verordnung über Tabakerzeugnisse (Tabakverordnung)* [Regulation on tobacco products (Tobacco order)], (*Bundesgesetzblatt No. 89*), Bonn, pp. 2831-2837
- Ferri, E.S. & Baratta, E.J. (1966) Polonium-210 in tobacco products and human tissues. *Radiol. Health Data Rep.*, 7, 485-488
- Ferson, M., Edwards, A., Lind, A., Milton, G.W. & Hersey, P. (1979) Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. *Int. J. Cancer*, 23, 603-609
- Feyerabend, C., Higenbottam, T. & Russell, M.A.H. (1982) Nicotine concentrations in urine and saliva of smokers and non-smokers. *Br. med. J.*, 284, 1002-1004
- Feyerabend, C., Ings, R.M.J. & Russell, M.A.H. (1985) Nicotine pharmacokinetics and its application to intake from smoking. *Br. J. clin. Pharmacol.*, 19, 239-248
- Finnish Cancer Registry (1963-1983) *Cancer in Finland 1956-1980 [Annual Reports]*, Helsinki
- Fogelmark, B., Rylander, R., Sjöstrand, M. & Reininghaus, W. (1980) Free lung cell phagocytosis and the effect of cigarette smoke exposure. *Exp. Lung Res.*, 1, 131-138
- Foliart, D., Benowitz, N.L. & Becker, C.E. (1983) Passive absorption of nicotine in airline flight attendants. *New Engl. J. Med.*, 308, 1105
- Forbes, W.F., Robinson, J.C., Hanley, J.A. & Colburn, H.N. (1976) Studies on the nicotine exposure of individuals smokers. I. Changes in mouth-level exposure to nicotine on switching to lower nicotine cigarettes. *Int. J. Addict.*, 11, 933-950
- Fortmann, S.P., Rogers, T., Vranizan, K., Haskell, W.L., Solomon, D.S. & Farquhar, J.W. (1984) Indirect measures of cigarette use: Expired-air carbon monoxide versus plasma thiocyanate. *Prev. Med.*, 13, 127-135
- Frasca, J.M., Auerbach, O., Carter, H.W. & Parks, V.R. (1983) Morphologic alterations induced by short term cigarette smoking. *Am. J. Pathol.*, 111, 11-20
- Fraumeni, J.F., Jr (1968) Cigarette smoking and cancers of the urinary tract: Geographic variation in the United States. *J. natl Cancer Inst.*, 41, 1205-1211
- Fredga, K., Dävring, L., Sunner, M., Bengtsson, B.O., Elinder, C.-G., Sigtryggsson, P. & Berlin, M. (1982) Chromosome changes in workers (smokers and non-smokers) exposed to automobile fuels and exhaust gases. *Scand. J. Work Environ. Health*, 8, 209-221
- Freedman, S. & Fletcher, C.M. (1976) Changes of smoking habits and cough in men smoking cigarettes with 30% NSM tobacco substitute. *Br. med. J.*, i, 1427-1430
- Freeman, A.E., Kelloff, G.J., Gilden, R.V., Lane, W.T., Swain, A.P. & Huebner, R.J. (1971) Activation and isolation of hamster-specific C-type RNA viruses from tumors induced by cell cultures transformed by chemical carcinogens. *Proc. natl Acad. Sci. USA*, 68, 2386-2390
- Friberg, L., Piscator, M., Nordberg, G.F. & Kjellström, T. (1974) *Cadmium in the Environment*, 2nd ed., Cleveland, OH, CRC Press, pp. 14-15
- Frith, C.D. (1971) The effect of varying the nicotine content of cigarettes on human smoking behaviour. *Psychopharmacologia*, 19, 188-192
- Furst, A. & Haro, R.T. (1969) A survey of metal carcinogenesis. *Progr. exp. Tumor Res.*, 12, 102-133
- Gadek, J.E., Fells, G.A. & Crystal, R.G. (1979) Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. *Science*, 206, 1315-1316

- Gairola, C. (1982) Genetic effects of fresh cigarette smoke in *Saccharomyces cerevisiae*. *Mutat. Res.*, 102, 123-136
- Galanakis, D.K., Laurent, P., Janoff, A. & Chung, S.I. (1982) Cigarette smoke contains anti-coagulants against fibrin aggregation and factor XIIIa in plasma. *Science*, 217, 642-645
- Galuškinová, V. (1964) 3,4-Benzpyrene determination in the smoky atmosphere of social meeting rooms and restaurants. A contribution to the problem of the noxiousness of so-called passive smoking. *Neoplasia*, 11, 465-468
- Gao, T.-T. (1986) *Smoking and lung cancer in Shanghai*. In: Zaridze, D. & Peto, R., eds, *Tobacco: A Major International Health Hazard (IARC Scientific Publications No. 74)*, Lyon, International Agency for Research on Cancer (in press)
- Garfinkel, L. (1980) Cancer mortality in nonsmokers: Prospective study by the American Cancer Society. *J. natl Cancer Inst.*, 65, 1169-1173
- Garfinkel, L. (1981) Time trends in lung cancer mortality among nonsmokers and a note on passive smoking. *J. natl Cancer Inst.*, 66, 1061-1066
- Garner, W.W. (1951) *The Production of Tobacco*, 1st rev. ed., New York, Blakiston Co.
- Gaudin, D., Gregg, R.S. & Yielding, K.L. (1972) Inhibition of DNA repair by cocarcinogens. *Biochem. biophys. Res. Comm.*, 48, 945-949
- Gerrard, J.W., Heiner, D.C., Ko, C.G., Mink, J., Meyers, A. & Dosman, J.A. (1980) Immunoglobulin levels in smokers and non-smokers. *Ann. Allergy*, 44, 261-262
- Geser, A., Charnay, N., Day, N.E. & de-Thé, G. (1978) *Environmental factors in the etiology of nasopharyngeal carcinoma: Report on a case-control study in Hong Kong*. In: de-Thé, G. & Ito, Y., eds, *Nasopharyngeal Carcinoma: Etiology and Control (IARC Scientific Publications No. 20)*, Lyon, International Agency for Research on Cancer, pp. 213-229
- Giins, L.C., Goldenheim, P.D., Miller, L.G., Burton, R.C., Gillick, L., Colvin, R.B., Goldstein, G., Kung, P.C., Hurwitz, C. & Kazemi, H. (1982) T-lymphocyte subsets in smoking and lung cancer. *Am. Rev. resp. Dis.*, 126, 265-269
- Glatt, H. & Oesch, F. (1984) *Variations in epoxide hydrolase activities in human liver and blood*. In: Omenn, G.S. & Gelboin, H.V., eds, *Genetic Variability in Responses to Chemical Exposure (Banbury Report 16)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 189-203
- Glowinski, I.B. & Weber, W.W. (1982) Genetic regulation of aromatic amine *N*-acetylation in inbred mice. *J. biol. Chem.*, 257, 1424-1430
- Godfrey, B. (1981) Sperm morphology in smokers. *Lancet*, i, 948
- Goffman, T.E., Hassinger, D.D. & Mulvihill, J.J. (1982) Familial respiratory tract cancer. Opportunities for research and prevention. *J. Am. med. Assoc.*, 247, 1020-1023
- Gold, E., Gordis, L., Tonascia, J. & Szklo, M. (1979) Risk factors for brain tumors in children. *Am. J. Epidemiol.*, 109, 303-319
- Goodman, R.M., Yergin, B.M., Landa, J.F., Golinvaux, M.H. & Sackner, M.A. (1978) Relationship of smoking history and pulmonary function tests to tracheal mucous velocity in nonsmokers, young smokers, ex-smokers, and patients with chronic bronchitis. *Am. Rev. resp. Dis.*, 177, 205-214
- Gordis, L. (1980) *Epidemiology of pancreatic cancer*. In: Lilienfeld, A., ed., *Reviews of Cancer Epidemiology*, Amsterdam, Elsevier/North-Holland Biomedical Press, pp. 84-117

- Gori, G.B., ed. (1976a) *Report No. 1. Toward Less Hazardous Cigarettes. The First Set of Experimental Cigarettes (DHEW Publ. No. (NIH) 76-905)*, Washington DC, US Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute
- Gori, G.B., ed. (1976b) *Report No. 2. Toward Less Hazardous Cigarettes. The Second Set of Experimental Cigarettes (DHEW Publ. No. (NIH) 76-1111)*, Washington DC, US Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute
- Gori, G.B., ed. (1977) *Report No. 3. Toward Less Hazardous Cigarettes. The Third Set of Experimental Cigarettes (DHEW Publ. No. (NIH) 77-1280)*, Washington DC, US Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute
- Gori, G.B., ed. (1980) *Report No. 4. Toward Less Hazardous Cigarettes. The Fourth Set of Experimental Cigarettes*, Washington DC, US Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute
- Goubran, E.Z., Mikhail, M.M., Malaty, H.A. & Mahfouz, M. (1978) A study of some histochemical changes in the lung, heart and aorta and some blood enzymes under the influence of experimental exposure to cigarette smoke in the rat. *Cell. mol. Biol.*, 23, 119-131
- Government Information Services (1982) *Anti-Smoking Fact Sheet*, Hong Kong, Government Printer
- Graham, E.A., Croninger, A.B. & Wynder, E.L. (1957) Experimental production of carcinoma with cigarette tar. IV. Successful experiments with rabbits. *Cancer Res.*, 17, 1058-1066
- Graham, S., Dayal, H., Rohrer, T., Swanson, M., Sultz, H., Shedd, D. & Fischman, S. (1977) Dentition, diet, tobacco, and alcohol in the epidemiology of oral cancer. *J. natl Cancer Inst.*, 59, 1611-1618
- Green, C.R. (1977) Neutral oxygenated compounds in cigarette smoke and their possible precursors. *Recent Adv. Tob. Sci.*, 3, 94-120
- Green, G.M. & Carolin, D. (1967) The depressant effect of cigarette smoke on the in vitro antibacterial activity of alveolar macrophages. *New Engl. J. Med.*, 276, 421-427
- Greenberg, L.A., Lester, D. & Haggard, H.W. (1952) The absorption of nicotine in tobacco smoking. *J. Pharmacol. Ther.*, 109, 162-167
- Greenberg, R.A., Haley, N.J., Etzel, R.A. & Loda, F.A. (1984) Measuring the exposure of infants to tobacco smoke. Nicotine and cotinine in urine and saliva. *New Engl. J. Med.*, 310, 1075-1078
- Griest, W.H., Guerin, M.R., Quincy, R.B., Jenkins, R.A. & Kubota, H. (1980) *Chemical characterization of experimental cigarettes and cigarette smoke condensates in the fourth cigarette experiment*. In: Gori, G.B., ed., *Report No. 4. Toward Less Hazardous Cigarettes. The Fourth Set of Experimental Cigarettes*, Washington DC, US Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute, pp. 65-97
- Grimmer, G., Böhnke, H. & Harke, H.-P. (1977a) Passive smoking: Measuring of concentrations of polycyclic aromatic hydrocarbons in rooms after machine smoking of cigarettes (Ger.). *Int. Arch. occup. environ. Health*, 40, 83-92

- Grimmer, G., Böhnke, H. & Harke, H.-P. (1977b) Passive smoking: Intake of polycyclic aromatic hydrocarbons by breathing of cigarette smoke-containing air (Ger.). *Int. Arch. occup. environ. Health*, 40, 93-99
- Grise, V.H. (1984) Market growth of reduced tar cigarettes. *Recent Adv. Tob. Sci.*, 10, 4-14
- Grob, K. (1962) Gas chromatography of cigarette smoke. 2. Improved resolution with capillary columns (Ger.). *Beitr. Tabakforsch.*, 1, 315-323
- Grob, K. & Voellmin, J.A. (1970) GC-MS analysis of the 'semi-volatiles' of cigarette smoke. *J. chromatogr. Sci.*, 8, 218-220
- Grufferman, S., Wang, H.H., DeLong, E.R., Kimm, S.Y.S., Delzell, E.S. & Falletta, J.M. (1982) Environmental factors in the etiology of rhabdomyosarcoma in childhood. *J. natl Cancer Inst.*, 68, 107-113
- Guerin, M.R. (1980) *Chemical composition of cigarette smoke*. In: Gori, G.B. & Bock, F.G., eds, *A Safe Cigarette? (Banbury Report 3)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 191-204
- Guerin, M.R. & Olerich, G. (1976) Direct gas chromatographic determination of catechol in cigarette smoke. *Tob. Sci.*, 20, 17-18
- Guerrero, R.R., Rounds, D.E. & Hall, T.C. (1979) Bioassay procedure for the detection of mutagenic metabolites in human urine with the use of sister chromatid exchange analysis. *J. natl Cancer Inst.*, 62, 805-809
- Gurtoo, H.L., Williams, C.J., Gottlieb, K., Mulhern, A.I., Caballes, L., Vaught, J.B., Marinello, A.J. & Bansal, S.J. (1983) Population distribution of placental benzo[a]pyrene metabolism in smokers. *Int. J. Cancer*, 31, 29-37
- Guthrie, F.E. (1968) The nature and significance of pesticide residues on tobacco and in tobacco smoke. *Beitr. Tabakforsch.*, 4, 229-246
- Guthrie, F.E. & Bowery, T.G. (1967) Pesticide residues on tobacco. *Residue Rev.*, 19, 31-56
- Haenszel, W. & Taeuber, K.E. (1964) Lung-cancer mortality as related to residence and smoking histories. II. White females. *J. natl Cancer Inst.*, 32, 803-838
- Haenszel, W., Marcus, S.C. & Zimmerer, E.G. (1956) *Cancer Morbidity in Urban and Rural Iowa (Public Health Monograph No. 37; Public Health Series Publication No. 426)*, Washington DC, US Government Printing Office
- Haenszel, W., Kurihara, M., Segi, M. & Lee, R.K.C. (1972) Stomach cancer among Japanese in Hawaii. *J. natl Cancer Inst.*, 49, 969-988
- Haenszel, W., Kurihara, M., Locke, F.B., Shimuzu, K. & Segi, M. (1976) Stomach cancer in Japan. *J. natl Cancer Inst.*, 56, 265-278
- Hagopian, M. & Rosenkrantz, H. (1969) Respiratory tract retention of blue tetrazolium reducing substances from tobacco smoke. *Proc. Soc. exp. Biol. Med. USA*, 130, 1234-1237
- Haley, N.J. & Hoffmann, D. (1985) Analysis for nicotine and cotinine in hair to determine cigarette smoker status. *Clin. Chem.*, 31, 1598-1600
- Haley, N.J., Axelrad, C.M. & Tilton, K.A. (1983) Validation of self-reported smoking behavior: Biochemical analyses of cotinine and thiocyanate. *Am. J. publ. Health*, 73, 1204-1207
- Hammond, E.C. (1966) Smoking in relation to the death rates of one million men and women. *Natl Cancer Inst. Monogr.*, 19, 127-204

- Hammond, E.C. & Horn, D. (1954) The relationship between human smoking habits and death rates: A follow-up study of 187,766 men. *J. Am. med. Assoc.*, 155, 1316-1328
- Hammond, E.C. & Horn, D. (1958a) Smoking and death rates — Report on forty-four months of follow-up of 187,783 men. I. Total mortality. *J. Am. med. Assoc.*, 166, 1159-1172
- Hammond, E.C. & Horn, D. (1958b) Smoking and death rates — Report on forty-four months of follow-up of 187,783 men. II. Death rates by cause. *J. Am. med. Assoc.*, 166, 1294-1308
- Hammond, E.C. & Seidman, H. (1980) Smoking and cancer in the United States. *Prev. Med.*, 9, 169-173
- Hammond, E.C., Auerbach, O., Kirman, D. & Garfinkel, L. (1970) Effects of cigarette smoking on dogs. I. Design of experiment, mortality, and findings in lung parenchyma. *Arch. environ. Health*, 21, 740-753
- Hammond, E.C., Garfinkel, L., Seidman, H. & Lew, E.A. (1976) 'Tar' and nicotine content of cigarette smoke in relation to death rates. *Environ. Res.*, 12, 263-274
- Hammond, E.C., Selikoff, I.J. & Seidman, H. (1979) Asbestos exposure, cigarette smoking and death rates. *Ann. N.Y. Acad. Sci.*, 330, 473-490
- Hamosh, M., Schechter, Y. & Hamosh, P. (1979) Effect of tobacco smoke on the metabolism of rat lung. *Arch. environ. Health*, 34, 17-23
- Hanai, A., Hiyama, T., Nakai, K., Matsuo, S., Susuki, T., Fujimoto, I. & Tateishi, R. (1982) Trends of histological types of lung cancer in Osaka (Jpn.). *Jpn. J. Cancer Clin.*, 28, 1589-1596
- Hanbury, W.J. (1964) Bronchogenic carcinoma in women. *Thorax*, 19, 338-342
- Hannan, M.A., Estes, R.S. & Hurley, L.H. (1980) Induction and potentiation of lethal and genetic effects of ultraviolet light by tobacco smoke condensates in yeast. *Environ. Res.*, 21, 97-107
- Hannan, M.A., Recio, L., Deluca, P.P. & Enoch, H. (1981) Co-mutagenic effects of 2-aminoanthracene and cigarette smoke condensate or smoker's urine in the Ames *Salmonella* assay system. *Cancer Lett.*, 13, 203-212
- Hardell, L., Bengtsson, N.O., Jonsson, U., Eriksson, S. & Larsson, L.G. (1984) Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria — An epidemiological investigation. *Br. J. Cancer*, 50, 389-397
- Harley, N.H., Cohen, B.S. & Tso, T.C. (1980) *Polonium-210: A questionable risk factor in smoking-related carcinogenesis*. In: Gori, G.B. & Bock, F.G., eds, *A Safe Cigarette? (Banbury Report 3)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 93-104
- Harris, C.C., Autrup, H., Connor, R., Barrett, L.A., McDowell, E.M. & Trump, B.F. (1976) Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi. *Science*, 194, 1067-1069
- Harris, C.C., Autrup, H., Stoner, G.D., Trump, B.F., Hillman, E., Schafer, P.W. & Jeffrey, A.M. (1979) Metabolism of benzo(a)pyrene, *N*-nitrosodimethylamine and *N*-nitrosopyrrolidine and identification of the major carcinogen-DNA adducts formed in cultured human esophagus. *Cancer Res.*, 39, 4401-4406
- Harris, H.W., Knight, R.A. & Selin, M.J. (1958) Comparison of isoniazid concentrations in the blood of people of Japanese and European descent — Therapeutic and genetic implications. *Ann. Rev. Tuberc. pulm. Dis.*, 78, 944-948
- Harris, J.O. & Gonzalez-Rothi, J. (1984) Abnormal phagolysosome fusion in pulmonary alveolar macrophages of rats exposed chronically to cigarette smoke. *Am. Rev. resp. Dis.*, 130, 467-471

- Harris, R.J.C. & Negroni, G. (1967) Production of lung carcinomas in C57Bl mice exposed to a cigarette smoke and air mixture. *Br. med. J.*, *iv*, 637-641
- Harris, R.J.C., Negroni, G., Ludgate, S., Pick, C.R., Chesterman, F.C. & Maidment, B.J. (1974) The incidence of lung tumours in C57BL mice exposed to cigarette smoke:air mixtures for prolonged periods. *Int. J. Cancer*, *14*, 130-136
- Harris, R.W.C., Brinton, L.A., Cowdell, R.H., Skegg, D.C.G., Smith, P.G., Vessey, M.P. & Doll, R. (1980) Characteristics of women with dysplasia or carcinoma *in situ* of the cervix uteri. *Br. J. Cancer*, *42*, 359-369
- Hartiala, J., Uotila, P. & Nienstedt, W. (1978) The effects of cigarette smoke exposure on testosterone metabolism in the isolated perfused rat lung. *J. Steroid Biochem.*, *9*, 365-368
- Hartman, T.G. & Rosen, J.D. (1983) Inhibition of metabolic cooperation by cigarette smoke condensate and its fractions in V-79 Chinese hamster lung fibroblasts. *Proc. natl Acad. Sci. USA*, *80*, 5305-5309
- Hawthorne, V.M. & Fry, J.S. (1978) Smoking and health: The association between smoking behaviour, total mortality and cardiorespiratory disease in West Central Scotland. *J. Epidemiol. commun. Health*, *32*, 260-266
- Hay, D.R. (1984) Intercensal trends in cigarette smoking in New Zealand. I. Age, sex and ethnic status. *N. Z. med. J.*, *97*, 283-285
- Health Departments of the United Kingdom (1984) *Tar, Carbon Monoxide and Nicotine Yields of Cigarettes (HMSO-D88264-21)*, London, Her Majesty's Stationery Office
- Health Education Bureau (1980) *Tobacco Consumption in Ireland: Fact Sheet 15, Smoking*, Dublin
- Heasman, M.A. & Lipworth, L. (1966) *Accuracy of Certification of Causes of Death (General Register Office Studies on Medical and Population Subjects No. 20)*, London, Her Majesty's Stationery Office
- Hecht, S.S., Bondinell, W.E. & Hoffmann, D. (1974) Chrysene and methylchrysenes: Presence in tobacco smoke and carcinogenicity. *J. natl Cancer Inst.*, *53*, 1121-1133
- Hecht, S.S., Carmella, S. & Hoffmann, D. (1981a) Quantitative analysis of alkyl-2-hydroxy-2-cyclopenten-1-ones in tobacco smoke. *J. agric. Food Chem.*, *29*, 401-404
- Hecht, S.S., Carmella, S., Mori, H. & Hoffmann, D. (1981b) A study of tobacco carcinogenesis. XX. Role of catechol as a major cocarcinogen in the weakly acidic fraction of smoke condensate. *J. natl Cancer Inst.*, *66*, 163-169
- Hecht, S.S., Adams, J.D., Numoto, S. & Hoffmann, D. (1983) Induction of respiratory tract tumors in Syrian golden hamsters by a single dose of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and the effect of smoke inhalation. *Carcinogenesis*, *4*, 1287-1290
- Heckman, R.A. & Best, F.W. (1981) An investigation of the lipophilic bases of cigarette smoke condensate. *Tob. Sci.*, *25*, 33-39
- Hedner, K., Högstedt, B., Kolnig, A.-M., Mark-Vendel, E., Strombeck, B. & Mitelman, F. (1983) Sister chromatid exchanges and structural chromosome aberrations in relation to smoking in 91 individuals. *Hereditas*, *98*, 77-81
- Heinonen, T., Kytöniemi, V., Sorsa, M. & Vainio, H. (1983) Urinary excretion of thioethers among low-tar and medium-tar cigarette smokers. *Int. Arch. occup. environ. Health*, *52*, 11-16

- Henderson, B.E. & Louie, E. (1978) *Discussion of risk factors for nasopharyngeal carcinoma*. In: de-Thé, G. & Ito, Y., eds, *Nasopharyngeal Carcinoma: Etiology and Control (IARC Scientific Publications No. 20)*, Lyon, International Agency for Research on Cancer, pp. 251-260
- Henderson, B.E., Louie, E., Jing, J.S.H., Buell, P. & Gardner, M.B. (1976) Risk factors associated with nasopharyngeal carcinoma. *New Engl. J. Med.*, 295, 1101-1106
- Hengen, N. & Hengen, M. (1978) Gas liquid chromatographic determination of nicotine and cotinine in plasma. *Clin. Chem.*, 24, 50-53
- Hengy, H. & Thirion, J. (1970) The determination of malathion residues in tobacco and tobacco smoke condensate. *Beitr. Tabakforsch.*, 5, 175-178
- Henry, C.J., Hwang, K.K., Kanagalingam, K.K. & Kouri, R.E. (1983) *Recent developments in inhalation toxicology: Evaluation of selected short-term endpoints following 'nose-only' exposure of rodents*. In: Homburger, F., ed., *Safety Evaluation and Regulation of Chemicals*, Basel, Karger, pp. 233-242
- Henry, C.J., Hall, W.C., David, R.M. & Stone, C.J. (1984) Methodology for toxicological evaluation of cigarette smoke after nose-only inhalation in mice and rats. *Toxicologist*, 4, Abstract 271
- Herning, R.I., Jones, R.T., Bachman, J. & Mines, A.H. (1981) Puff volume increases when low-nicotine cigarettes are smoked. *Br. med. J.*, 283, 187-189
- Herning, R.I., Johanna, S.H. & Jones, R.T. (1983a) The importance of inhalation volume when measuring smoking behavior. *Behav. Res. Meth. Instrumentation*, 15, 561-568
- Herning, R.I., Jones, R.T., Benowitz, N.L. & Mines, A.H. (1983b) How a cigarette is smoked determines blood nicotine levels. *Clin. Pharmacol. Ther.*, 33, 84-90
- Heuch, I., Kvåle, G., Jacobsen, B.K. & Bjelke, E. (1983) Use of alcohol, tobacco and coffee, and risk of pancreatic cancer. *Br. J. Cancer*, 48, 637-643
- Hewer, T., Rose, E., Ghadirian, P., Castegnaro, M., Bartsch, H., Malaveille, C. & Day, N. (1978) Ingested mutagens from opium and tobacco pyrolysis products and cancer of the oesophagus. *Lancet*, ii, 494-496
- Hiatt, R.A., Friedman, G.D., Bawol, R.D. & Ury, H.K. (1982) Breast cancer and serum cholesterol. *J. natl Cancer Inst.*, 68, 885-889
- Higenbottam, T., Shipley, M.J. & Rose, G. (1982) Cigarettes, lung cancer and coronary heart disease: The effects of inhalation and tar yield. *J. Epidemiol. commun. Health*, 36, 113-117
- Hilding, A.C. (1957) Ciliary streaming in the bronchial tree and the time element in carcinogenesis. *New Engl. J. Med.*, 256, 634-640
- Hill, C. & Flamant, R. (1986) Cause of a major epidemic: Increase in tobacco consumption in France (Fr.). *Rev. Epidemiol. Santé publ.* (in press)
- Hill, C.R. (1982) Radioactivity in cigarette smoke. *New Engl. J. Med.*, 307, 311
- Hill, D. & Gray, N. (1984) Australian patterns of tobacco smoking and related health beliefs in 1983. *Commun. Health Stud.*, 8, 307-316
- Hill, P. & Marquardt, H. (1980) Plasma and urine changes after smoking different brands of cigarettes. *Clin. Pharmacol. Ther.*, 27, 652-658
- Hiller, F.C., McCusker, K.T., Mazumder, M.K., Wilson, J.D. & Bone, R.C. (1982) Deposition of sidestream cigarette smoke in the human respiratory tract. *Am. Rev. resp. Dis.*, 125, 406-408
- Himmelberger, D.U., Brown, B.W., Jr & Cohen, E.N. (1978) Cigarette smoking during pregnancy and the occurrence of spontaneous abortion and congenital abnormality. *Am. J. Epidemiol.*, 108, 470-479

- Hinds, M.W., Kolonel, L.N., Lee, J. & Hirohata, T. (1980) Associations between cancer incidence and alcohol/cigarette consumption among five ethnic groups in Hawaii. *Br. J. Cancer*, 41, 929-940
- Hinds, M.W., Stemmermann, G.N., Yang, H.-Y., Kolonel, L.N., Lee, J. & Wegner, E. (1981) Differences in lung cancer risk from smoking among Japanese, Chinese and Hawaiian women in Hawaii. *Int. J. Cancer*, 27, 297-302
- Hinds, W.C. (1978) Size characteristics of cigarette smoke. *Am. ind. Hyg. Assoc. J.*, 39, 48-54
- Hinds, W.C. & First, M.W. (1975) Concentrations of nicotine and tobacco smoke in public places. *New Engl. J. Med.*, 292, 844-845
- Hinds, W., First, M.W., Huber, G.L. & Shea, J.W. (1983) A method for measuring respiratory deposition of cigarette smoke during smoking. *Am. ind. Hyg. Assoc. J.*, 44, 113-118
- Hirayama, T. (1966) An epidemiological study of oral and pharyngeal cancer in Central and South-east Asia. *Bull. World Health Organ.*, 34, 41-69
- Hirayama, T. (1967) *Smoking in Relation to the Death Rates of 265,118 Men and Women in Japan*, Tokyo, National Cancer Center, Research Institute
- Hirayama, T. (1975a) *Smoking and cancer: A prospective study on cancer epidemiology based on a census population in Japan*. In: Steinfeld, J., Griffiths, W., Ball, K. et al., eds, *Proceeding of the 3rd World Conference on Smoking and Health, Vol. II*, Washington DC, US Department of Health, Education, and Welfare, pp. 65-72
- Hirayama, T. (1975b) *Prospective studies on cancer epidemiology based on census population in Japan*. In: Bucalossi, P., Veronesi, U. & Cascinelli, N., eds, *Proceedings of the XIth International Cancer Congress, Florence, 1974, Vol. 3, Cancer Epidemiology, Environmental Factors*, Amsterdam, Excerpta Medica, pp. 26-35
- Hirayama, T. (1977a) *Epidemiology of lung cancer based on population studies*. In: National Cancer Center Library, ed., *Collected Papers from the National Cancer Center Research Institute*, Vol. 12, Tokyo, National Cancer Center, pp. 452-461
- Hirayama, T. (1977b) *Changing patterns of cancer in Japan with special reference to the decrease in stomach cancer mortality*. In: Hiatt, H.H., Watson, J.D. & Winsten, J.A., eds, *Origins of Human Cancer, Book A, Incidence of Cancer in Humans*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 55-75
- Hirayama, T. (1978) *Prospective studies on cancer epidemiology based on census population in Japan*. In: Nieburgs, H.E., ed., *Prevention and Detection of Cancer, Vol. 1, Etiology*, New York, Marcel Dekker, pp. 1139-1147
- Hirayama, T. (1981a) *A large-scale cohort study on the relationship between diet and selected cancers of digestive organs*. In: Bruce, W.R., Correa, P., Lipkin, M., Tannenbaum, S.R. & Wilkins, T.D., eds, *Gastrointestinal Cancer: Endogenous Factors (Banbury Report 7)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 409-426
- Hirayama, T. (1981b) Non-smoking wives of heavy smokers have a higher risk of lung cancer; A study from Japan. *Br. med. J.*, 282, 183-185
- Hirayama, T. (1982) *Smoking and cancer in Japan. A prospective study on cancer epidemiology based on census population in Japan. Results of 13 years follow up*. In: Tominaga, S. & Aoki, K., eds, *The UICC Smoking Control Workshop, Nagoya, Japan, August 24-25, 1981*, Nagoya, The University of Nagoya Press, pp. 2-8
- Hirayama, T. (1983) Passive smoking and lung cancer; consistency of association. *Lancet*, ii, 1425-1426

- Hirayama, T. (1984a) *Lung cancer in Japan: Effects of nutrition and passive smoking*. In: Mizell, M. & Correa, P., eds, *Lung Cancer: Causes and Prevention*, New York, Verlag Chemie International, pp. 175-195
- Hirayama, T. (1984b) Cancer mortality in nonsmoking women with smoking husbands based on a large-scale cohort study in Japan. *Prev. Med.*, *13*, 680-690
- Hirayama, T. (1985) *A cohort study on cancer in Japan*. In: Blot, W.J., Hirayama, T. & Hoel, D.G., eds, *Statistical Methods in Cancer Epidemiology*, Hiroshima, Radiation Effects Research Foundation, pp. 73-91
- Hocking, W.G. & Golde, D.W. (1979) The pulmonary-alveolar macrophage. *New Engl. J. Med.*, *301*, 580-587, 639-645
- Hoey, J., Montvernay, C. & Lambert, R. (1981) Wine and tobacco: Risk factors for gastric cancer in France. *Am. J. Epidemiol.*, *113*, 668-674
- Hoffmann, D. & Brunnemann, K.D. (1983) Endogenous formation of *N*-nitrosoproline in cigarette smokers. *Cancer Res.*, *43*, 5570-5574
- Hoffmann, D. & Mazzola, V. (1970) Chemical studies on tobacco smoke. XI. Dibenzofurans in cigarette smoke. *Beitr. Tabakforsch.*, *5*, 183-188
- Hoffmann, D. & Rathkamp, G. (1968) Chemical studies in tobacco smoke. III. Primary and secondary nitroalkanes in cigarette smoke. *Beitr. Tabakforsch.*, *4*, 124-134
- Hoffmann, D. & Woziwodzki, H. (1968) Chemical studies on tobacco smoke. IV. The quantitative determination of free nonvolatile fatty acids in tobacco and tobacco smoke. *Beitr. Tabakforsch.*, *4*, 167-175
- Hoffmann, D. & Wynder, E.L. (1960) On the isolation and identification of polycyclic aromatic hydrocarbons. *Cancer*, *13*, 1062-1073
- Hoffmann, D. & Wynder, E.L. (1971) A study of tobacco carcinogenesis. XI. Tumor initiators, tumor accelerators, and tumor promoting activity of condensate fractions. *Cancer*, *27*, 848-864
- Hoffmann, D. & Wynder, E.L. (1972a) Smoke of cigarettes and little cigars: An analytical comparison. *Science*, *178*, 1197-1199
- Hoffmann, D. & Wynder, E.L. (1972b) *Chemical composition and tumorigenicity of tobacco smoke*. In: Schmeltz, I., ed., *The Chemistry of Tobacco and Tobacco Smoke*, New York, Plenum Press, pp. 123-147
- Hoffmann, D., Rathkamp, G. & Wynder, E.L. (1963) Comparison of the yields of several selected components in the smoke from different tobacco products. *J. natl Cancer Inst.*, *31*, 627-637
- Hoffmann, D., Rathkamp, G. & Woziwodzki, H. (1968) Chemical studies on tobacco smoke. VI. The determination of carbazoles in cigarette smoke. *Beitr. Tabakforsch.*, *4*, 253-263
- Hoffmann, D., Rathkamp, G. & Wynder, E.L. (1969) Chemical studies on tobacco smoke. IX. Quantitative analysis of chlorinated hydrocarbon insecticides. *Beitr. Tabakforsch.*, *5*, 140-148
- Hoffmann, D., Rathkamp, G., Nesnow, S. & Wynder, E.L. (1972) Fluoranthenes: Quantitative determination in cigarette smoke, formation by pyrolysis, and tumor-initiating activity. *J. natl Cancer Inst.*, *49*, 1165-1175
- Hoffmann, D., Rathkamp, G., Brunnemann, K.D. & Wynder, E.L. (1973) Chemical studies on tobacco smoke. XXII. On the profile analysis of tobacco smoke. *Sci. total Environ.*, *2*, 157-171
- Hoffmann, D., Sanghvi, L.D. & Wynder, E.L. (1974) Comparative chemical analysis of Indian bidi and American cigarette smoke. *Int. J. Cancer*, *14*, 49-53

- Hoffmann, D., Brunnemann, K.D., Gori, G.B. & Wynder, E.L. (1975) *On the carcinogenicity of marijuana smoke*. In: Runeckles, V.C., ed., *Recent Advances in Phytochemistry*, Vol. 9, New York, Plenum Press, pp. 63-81
- Hoffmann, D., Patrianakos, C. & Brunnemann, K.D. (1976) Chromatographic determination of vinyl chloride in tobacco smoke. *Anal. Chem.*, 48, 47-50
- Hoffmann, D., Rivenson, A., Hecht, S.S., Hilfrich, J., Kobayashi, N. & Wynder, E.L. (1979) Model studies in tobacco carcinogenesis with the Syrian golden hamster. *Prog. exp. Tumor Res.*, 24, 370-390
- Hoffmann, D., Adams, J.D., Piade, J.J. & Hecht, S.S. (1980) *Chemical studies on tobacco smoke. LXVIII. Analysis of volatile and tobacco-specific nitrosamines in tobacco products*. In: Walker, E.A., Castegnaro, M., Griciute, L. & Börzsönyi, M., eds, *N-Nitroso Compounds: Analysis, Formation and Occurrence (IARC Scientific Publications No. 31)*, Lyon, International Agency for Research on Cancer, pp. 507-516
- Hoffmann, D., Adams, J.D. & Haley, N.J. (1983a) Reported cigarette smoke values: A closer look. *Am. J. publ. Health*, 73, 1050-1053
- Hoffmann, D., Haley, N.J., Brunnemann, K.D., Adams, J.D. & Wynder, E.L. (1983b) *Cigarette sidestream smoke: Formation, analysis and model studies on the uptake by nonsmokers*. Presented at the *US-Japan Meeting on 'New Etiology of Lung Cancer'*. Honolulu, Hawaii, March 21-23
- Hoffmann, D., Brunnemann, K.D., Adams, J.D. & Hecht, S.S. (1984a) *Formation and analysis of N-nitrosamines in tobacco products and their endogenous formation in tobacco consumers*. In: O'Neill, I.K., von Borstel, R.C., Miller, C.T., Long, J. & Bartsch, H., eds, *N-Nitroso Compounds: Occurrence, Biological Effects and Relevance to Human Cancer (IARC Scientific Publications No. 57)*, Lyon, International Agency for Research on Cancer, pp. 743-762
- Hoffmann, D., Brunnemann, K.D., Adams, J.D. & Haley, N.J. (1984b) *Indoor air pollution by tobacco smoke: Model studies on the uptake by nonsmokers*. In: Berglund, B., Lindvall, T. & Sundell, J., eds, *Indoor Air*, Vol. 2, *Radon, Passive Smoking, Particulates and Housing Epidemiology*, Stockholm, Swedish Council for Building Research, pp. 313-318
- Hoffmann, D., Haley, N.J., Brunnemann, K.D., Adams, J.D. & Wynder, E.L. (1984c) Cigarette sidestream smoke: Uptake by nonsmokers. *Prev. Med.*, 13, 608-617
- Högstedt, B. (1984) Micronuclei in lymphocytes with preserved cytoplasm. A method for assessment of cytogenetic damage in man. *Mutat. Res.*, 130, 63-72
- Högstedt, B., Gullberg, B., Hedner, K., Kolnig, A.-M., Mitelman, F., Skerfving, S. & Widegren, B. (1983) Chromosome aberrations and micronuclei in bone marrow cells and peripheral blood lymphocytes in humans exposed to ethylene oxide. *Hereditas*, 98, 105-113
- Hoidal, J.R. & Niewoehner, D.E. (1982) Lung phagocyte recruitment and metabolic alterations induced by cigarette smoke in humans and in hamsters. *Am. Rev. resp. Dis.*, 128, 548-582
- Holland, R.H., Wilson, R.H., Morris, D., McCall, M.S. & Lanz, H. (1958) The effect of cigarette smoke on the respiratory system of the rabbit. A preliminary report. *Cancer*, 11, 709-712
- Holland, R.H., Kozlowski, E.J. & Booker, L. (1963) The effect of cigarette smoke on the respiratory system of the rabbit. A final report. *Cancer*, 16, 612-615
- Hollander, D.H., Tockman, M.S., Liang, Y.W., Borgaonkar, D.S. & Frost, J.K. (1978) Sister chromatid exchanges in the peripheral blood of cigarette smokers and in lung cancer patients; and the effect of chemotherapy. *Human Genet.*, 44, 165-171

- Holmes, J.C., Hardcastle, J.E. & Mitchell, R.I. (1959) The determination of particle size and electric charge distribution in cigarette smoke. *Tob. Sci.*, 3, 148-153
- Holt, P.G. & Keast, D. (1977) Environmentally induced changes in immunological function: Acute and chronic effects of inhalation of tobacco smoke and other atmospheric contaminants in man and experimental animals. *Bacteriol. Rev.*, 41, 205-216
- Holt, P.G., Finlay-Jones, D., Lynette, M., Keast, D. & Papadimitriou, J.M. (1976) Immunological function in mice chronically exposed to nitrogen oxides. *Environ. Res.*, 19, 154-162
- Holt, P.G., Keast, D. & MacKensie, J.S. (1978) Animal model of human disease: Immunosuppression associated with cigarette smoking. *Am. J. Pathol.*, 90, 281-284
- Holt, P.G., Finlay-Jones, L.M., Keast, D. & Papadimitrou, J.M. (1979) Immunological function in mice chronically exposed to nitrogen oxides (NO_x). *Environ. Res.*, 19, 154-162
- Hoover, R. & Cole, P. (1971) Population trends in cigarette smoking and bladder cancer. *Am. J. Epidemiol.*, 94, 409-418
- Hopkin, J.M. & Evans, H.J. (1979) Cigarette smoke condensates damage DNA in human lymphocytes. *Nature*, 279, 241-242
- Hopkin, J.M. & Evans, H.J. (1980) Cigarette smoke-induced DNA damage and lung cancer risks. *Nature*, 283, 388-390
- Hopkin, J.M. & Perry, P.E. (1980) Benzo(a)pyrene does not contribute to the SCEs induced by cigarette smoke condensate. *Mutat. Res.*, 77, 377-381
- Horm, J.W., Asire, A.J., Young, J.L., Jr & Pollack, E.S., eds (1984) *SEER Program: Cancer Incidence and Mortality in the United States 1973-81 (NIH Publication No. 85-1837)*, Bethesda, MD, National Cancer Institute, p. 206
- Houqing, S. (1984) Water-pipe tobacco holds its following in China. *World Tob.*, 84, 111, 113
- Howe, G.R., Burch, J.D., Miller, A.B., Cook, G.M., Esteve, J., Morrison, B., Gordon, P., Chambers, L.W., Fodor, G. & Winsor, G.M. (1980) Tobacco use, occupation, coffee, various nutrients, and bladder cancer. *J. natl Cancer Inst.*, 64, 701-713
- Howe, G.R., Sherman, G.J. & Malhotra, A. (1984) Correlations between cancer incidence rates from the Canadian National Cancer Incidence Reporting System, 1969-78. *J. natl Cancer Inst.*, 72, 585-591
- Ho-Yen, D.O., Spence, V.A., Moody, J.P. & Walker, W.F. (1982) Why smoke fewer cigarettes? *Br. med. J.*, 284, 1905-1907
- Hudson, L.G., Shaikh, T., Toscano, W.A., Jr & Greenlee, W.F. (1983) Induction of 7-ethoxycoumarin C-deethylase activity in cultured human epithelial cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): evidence for TCDD receptor. *Biochem. biophys. Res. Commun.*, 115, 611-617
- Hugod, C., Hawkins, L.H. & Astrup, P. (1978) Exposure of passive smokers to tobacco smoke constituents. *Int. Arch. occup. environ. Health*, 42, 21-29
- Hulbert, W.C., Walker, D.C., Jackson, A. & Hogg, J.C. (1981) Airway permeability to horseradish peroxidase in guinea pigs: The repair phase after injury by cigarette smoke. *Am. Rev. resp. Dis.*, 123, 320-326
- Hunninghake, G.W., Gadek, J.E., Kawanami, O., Ferrans, V.J. & Crystal, R.G. (1979) Inflammatory and immune processes in the human lung in health and disease: Evaluation by bronchoalveolar lavage. *Am. J. Pathol.*, 97, 149-206

- Husgafvel-Pursiainen, K., Mäki-Paakkanen, J., Norppa, H. & Sorsa, M. (1980) Smoking and sister chromatid exchange. *Hereditas*, 92, 247-250
- Husgafvel-Pursiainen, K., Sorsa, M., Järventaus, H. & Norppa, H. (1984) Sister-chromatid exchanges in lymphocytes of smokers in an experimental study. *Mutat. Res.*, 138, 197-203
- Husum, B., Wulf, H.C. & Niebuhr, E. (1981) Sister-chromatid exchanges in lymphocytes in women with cancer of the breast. *Mutat. Res.*, 85, 357-362
- Husum, B., Wulf, H.C. & Niebuhr, E. (1982) Increased sister chromatid exchange frequency in lymphocytes in healthy cigarette smokers. *Hereditas*, 96, 85-88
- Hüttner, E. & Schöneich, J. (1981) Effects of smoking on the frequencies of chromosomal aberrations and SCE in man (Abstract). *Mutat. Res.*, 81, 255
- Hutton, J.J. & Hackney, C. (1975) Metabolism of cigarette smoke condensates by human and rat homogenates to form mutagens detectable by *Salmonella typhimurium* TA1538. *Cancer Res.*, 35, 2461-2468
- IARC (1974a) *IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man*, Vol. 4, *Some Aromatic Amines, Hydrazine and Related Substances, N-Nitroso Compounds and Miscellaneous Alkylating Agents*, Lyon, pp. 127-136
- IARC (1974b) *IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man*, Vol. 4, *Some Aromatic Amines, Hydrazine and Related Substances, N-Nitroso Compounds and Miscellaneous Alkylating Agents*, Lyon, pp. 173-179
- IARC (1974c) *IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man*, Vol. 5, *Some Organochlorine Pesticides*, Lyon
- IARC (1976a) *IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man*, Vol. 11, *Cadmium, Nickel, Some Epoxides, Miscellaneous Industrial Chemicals and General Considerations on Volatile Anaesthetics*, Lyon, pp. 231-240
- IARC (1976b) *IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man*, Vol. 10, *Some Naturally Occurring Substances*, Lyon, pp. 113-119
- IARC (1976c) *IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man*, Vol. 12, *Some Carbamates, Thiocarbamates and Carbazides*, Lyon, pp. 37-53
- IARC (1977) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man*, Vol. 15, *Some Fumigants, the Herbicides 2,4-D and 2,4,5-T, Chlorinated Dibenzodioxins and Miscellaneous Industrial Chemicals*, Lyon, pp. 265-271
- IARC (1978) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 17, *Some N-Nitroso Compounds*, Lyon
- IARC (1982a) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 29, *Some Industrial Chemicals and Dyestuffs*, Lyon, pp. 345-389
- IARC (1982b) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Suppl. 4, *Chemicals, Industrial Processes and Industries Associated with Cancer in Humans*, *IARC Monographs, Volumes 1 to 29*, Lyon, pp. 14-16, 25-27
- IARC (1982c) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 29, *Some Industrial Chemicals and Dyestuffs*, Lyon, pp. 331-343
- IARC (1983a) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 32, *Polynuclear Aromatic Compounds, Part 1, Chemical, Environmental and Experimental Data*, Lyon, pp. 37-38, 122-134, 277-288, 315-320

- IARC (1983b) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 30, *Miscellaneous Pesticides*, Lyon, pp. 103-129, 367
- IARC (1984) *Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity*, No. 11, Lyon
- IARC (1985a) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 37, *Tobacco Habits Other Than Smoking; Betel-Quid and Areca-Nut Chewing; and Some Related Nitrosamines*, Lyon
- IARC (1985b) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 36, *Allyl Compounds, Aldehydes, Epoxides and Peroxides*, Lyon, pp. 101-132
- IARC (1985c) *IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Vol. 36, *Allyl Compounds, Aldehydes, Epoxides and Peroxides*, Lyon, pp. 133-162
- Ibrahim, A.S. (1982) *Smoking in Egypt*. In: Tominaga, S. & Aoki, K., eds, *The UICC Smoking Control Workshop, Nagoya, August 24-25, 1981*, Nagoya, University of Nagoya Press, pp. 36-39
- Idle, J.R., Mahgoub, A., Sloan, T.P., Smith, R.L., Mbanefo, C.O. & Bababunmi, E.A. (1981) Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer. *Cancer Lett.*, 11, 331-338
- International Committee for Cigar Smoke Study (1974) Machine smoking of cigars. *CORESTA Inform. Bull.*, 1, 31-34
- Inui, N. & Takayama, S. (1971a) Effect of cigarette tar upon tissue culture cells. Neoplastic transformation of hamster lung cells by tobacco tar in tissue culture. *Br. J. Cancer*, 25, 574-583
- Inui, N. & Takayama, S. (1971b) Acceleration of proliferation and tumor production rate of L-strain cells by treatment with cigarette tar. *Gann*, 62, 315-320
- Ishiguro, S., Sakuma, H., Kusama, M., Yano, S., Shimojima, N. & Sugawara, S. (1976) Glass capillary column gas chromatographic analysis of tobacco and cellulose cigarette smoke. I. Acidic fractions (Jpn.). *Sci. Papers central Res. Inst. Jpn Tob. Salt Corp.*, 118, 207-211
- Ishiguro, S., Watanabe, Y. & Okada, T. (1984) *Formation of volatile nitrosamines in sidestream smoke from cellulose cigarettes impregnated with various N-containing compounds*. In: *38th Tobacco Chemists' Research Conference, Atlanta, GA, 5-8 November* (Abstract No. 37)
- Izard, C., Moustacchi, E. & Fayeulle, J.P. (1976) Genetic effects of the gas phase of cigarette smoke on *Saccharomyces cerevisiae* (Fr.). *C.R. Acad. Sci. Paris*, 282, 1141-1143
- Izard, C., Valadaud-Barriieu, D., Fayeulle, J.P. & Testa, A. (1980) Influence of smoking parameters on the genotoxic activity of the gas phase of cigarette smoke, measured in human lymphocytes and yeast (Fr.). *Mutat. Res.*, 77, 341-344
- Jacob, C.V., Stelzer, G.T. & Wallace, J.H. (1980) The influence of cigarette tobacco smoke products on the immune response. The cellular basis of immunosuppression by a water-soluble condensate of tobacco-smoke. *Immunology*, 40, 621-627
- Jafarey, N.A., Mahmood, Z. & Zaidi, S.H.M. (1977) Habits and dietary pattern of cases of carcinoma of the oral cavity and oropharynx. *J. Pakistan med. Assoc.*, 27, 340-343
- Jaffe, R.L., Nicholson, W.J. & Garro, A.J. (1983) Urinary mutagen levels in smokers. *Cancer Lett.*, 20, 37-42
- Jaiswal, A.K., Gonzalez, F.J. & Nebert, D.W. (1985) Human dioxin-inducible cytochrome P₁-450: Complementary DNA and amino acid sequence. *Science*, 228, 80-83

- James (1604) *A Counterblaste to Tobacco* (Published anonymously; republished, 1954), London, The Rodale Press
- Janerich, D.T., Polednak, A.P., Glebatis, D.M. & Lawrence, C.E. (1983) Breast cancer and oral contraceptive use: A case-control study. *J. chron. Dis.*, *36*, 639-646
- Janoff, A., Carp, H., Lee, D.K. & Drew, R.T. (1979) Cigarette smoke inhalation decreases α_1 -antitrypsin activity in rat lung. *Science*, *206*, 1313-1314
- Janzon, L., Lindell, S.-E., Trelle, E. & Larne, P. (1981) Smoking habits and carboxyhaemoglobin. A cross-sectional study of an urban population of middle-aged men. *J. Epidemiol. commun. Health*, *35*, 271-273
- Jarvis, M.J., Russell, M.A.H. & Saloojee, Y. (1980) Expired air carbon monoxide: a simple breath test of tobacco smoke intake. *Br. med. J.*, *281*, 484-485
- Jarvis, M.J., Russell, M.A.H. & Feyerabend, C. (1983) Absorption of nicotine and carbon monoxide from passive smoking under natural conditions of exposure. *Thorax*, *38*, 829-833
- Jarvis, M., Tunstall-Pedoe, H., Feyerabend, C., Vesey, C. & Saloojee, Y. (1984) Biochemical markers of smoke absorption and self-reported exposure to passive smoking. *J. Epidemiol. commun. Health*, *38*, 335-339
- Jayant, K., Balakrishnan, V., Sanghvi, L.D. & Jussawalla, D.J. (1977) Quantification of the role of smoking and chewing tobacco in oral, pharyngeal, and oesophageal cancers. *Br. J. Cancer*, *35*, 232-235
- Jenkins, R.A. (1985) *Occurrence of selected metals in cigarette tobaccos and smoke*. In: O'Neill, I.K., Schuller, P. & Fishbein, L., eds, *Environmental Carcinogens. Selected Methods of Analysis*, Vol. 8, *Some Metals: As, Be, Cd, Cr, Ni, Pb, Se, Zn* (IARC Scientific Publications No. 71), Lyon, International Agency for Research on Cancer (in press)
- Jenkins, R.A., White, S.K., Griest, W.H. & Guerin, M.R. (1983) *Chemical Characterization of the Smokes of Selected US Commercial Cigarettes: Tar, Nicotine, Carbon Monoxide, Oxides of Nitrogen, Hydrogen Cyanide, and Acrolein (ORNL/TM-8749)*, Oak Ridge, TN, Oak Ridge National Laboratory
- Jenkins, R.A., Holladay, S.K., Griest, W.H. & Guerin, M.R. (1986) *Tar, nicotine, and carbon monoxide deliveries of commercial cigarettes from selected nations*. In: *Fifth World Conference on Smoking and Health, Winnipeg, Canada, 10-15 July 1983*, Ottawa, Canadian Council on Smoking and Health (in press)
- Jenkins, R.W., Jr, Newman, R.H., Lester, G.L., Frisch, A.F. & Williamson, T.G. (1982) Neutron activation analysis in tobacco and cigarette smoke studies: The halogens. *Beitr. Tabakforsch.*, *11*, 195-202
- Jermini, C., Weber, A. & Grandjean, E. (1976) Quantitative analysis of various gas-phase components of sidestream smoke of cigarettes in ambient air as a contribution to the problem of passive smoking (Ger.). *Int. Arch. occup. Health*, *36*, 169-181
- Jett, J.R., Moses, H.L., Branum, E.L., Taylor, W.F. & Fontana, R.S. (1978) Benzo[a]pyrene metabolism and blast transformation in peripheral blood mononuclear cells from smoking and nonsmoking populations and lung cancer patients. *Cancer*, *41*, 192-200
- Johnson, W.R. & Kang, J.C. (1971) Mechanisms of hydrogen cyanide formation from the pyrolysis of amino acids and related compounds. *J. org. Chem.*, *36*, 189-192
- Johnson, W.R., Hale, R.W., Clough, S.C. & Chen, P.H. (1973a) Chemistry of the conversion of nitrate nitrogen to smoke products. *Nature*, *243*, 223-225

- Johnson, W.R., Hale, R.W., Nedlock, J.W., Grubbs, H.J. & Powell, D.H. (1973b) The distribution of products between mainstream and sidestream smoke. *Tob. Sci.*, 17, 141-144
- Johnson, W.R., Hale, R.W. & Nedlock, J.H. (1973c) Aliphatic amides in cigarette smoke. *Tob. Sci.*, 17, 73
- Johnston, C. (1981) Cigarette smoking and the outcome of human pregnancies: A status report on the consequences. *Clin. Toxicol.*, 18, 189-209
- Joly, D.J. (1975) Cigarette smoking in Latin America — A survey of eight cities. *Pan Am. Health Organ. Bull.*, 9, 329-344
- Joly, O.G., Lubin, J.H. & Caraballoso, M. (1983) Dark tobacco and lung cancer in Cuba. *J. natl Cancer Inst.*, 70, 1033-1039
- Jones, J.G., Lawler, P., Crawley, J.C.W., Minty, B.D., Hulands, G. & Veall, N. (1980) Increased alveolar epithelial permeability in cigarette smokers. *Lancet*, i, 66-68
- Jones, J.G., Royston, D. & Minty, B.D. (1983) Changes in alveolar capillary barrier function in animals and humans. *Am. Rev. resp. Dis.*, 127, S51-S59
- Jones, R., Bolduc, P. & Reid, L. (1973) Goblet cell glycoprotein and tracheal gland hypertrophy in rat airways: The effect of tobacco smoke with or without the anti-inflammatory agent phenylmethyl oxadiazole. *Br. J. exp. Pathol.*, 54, 229-239
- Jones, R., Phil, M. & Reid, L. (1978) Secretory cell hyperplasia and modification of intracellular glycoprotein in rat airways induced by short periods of exposure to tobacco smoke, and the effect of the antiinflammatory agent phenylmethyloxadiazole. *Lab. Invest.*, 39, 41-48
- Joumard, R., Chiron, M., Vidon, R., Maurin, M., Rouzioux, J.-M. (1981) Mathematical models of the uptake of carbon monoxide on hemoglobin at low carbon monoxide levels. *Environ. Health Perspect.*, 41, 277-289
- Josse, D. (1985) *Smoking Behaviour in Canadians, 1983* (Cat. no. #39-66/1985E), Ottawa, Supply and Services Canada
- Jussawalla, D.J. (1971) *Epidemiological assessment of aetiology of oesophageal cancer in Greater Bombay*. In: Jussawalla, D.J. & Doll, R., eds, *International Seminar on the Epidemiology of Oesophageal Cancer, Bangalore, 4 November 1971*, Bombay, Indian Cancer Society, pp. 20-30
- Jussawalla, D.J. (1982) *Different types of smoking and chewing habits in India*. In: Tominaga, S. & Aoki, K., eds, *The UICC Smoking Control Workshop, Nagoya, August 24-25, 1981*, Nagoya, University of Nagoya Press, pp. 40-47
- Jussawalla, D.J. & Deshpande, V.A. (1971) Evaluation of cancer risk in tobacco chewers and smokers: an epidemiologic assessment. *Cancer*, 28, 244-252
- Jussawalla, D.J. & Jain, D.K. (1979) Lung cancer in Greater Bombay: Correlations with religion and smoking habits. *Br. J. Cancer*, 40, 437-448
- Just, J., Borkowska, M. & Maziarka, S. (1972) Tobacco smoke in the air of Warsaw coffee rooms (Pol.). *Rocz. Państw. Zakł. Hig.*, 23, 129-135
- Kabat, G.C. & Wynder, E.L. (1984) Lung cancer in nonsmokers. *Cancer*, 53, 1214-1221
- Kado, N.Y., Manson, C., Eisenstadt, E. & Hsieh, D.P. (1985) The kinetics of mutagen excretion in the urine of cigarette smokers. *Mutat. Res.*, 157, 227-233
- Kahn, H.A. (1966) The Dorn study of smoking and mortality among US veterans. Report on eight and one-half years of observation. *Natl Cancer Inst. Monogr.*, 19, 1-125

- Kale, P.G. & Baum, J.W. (1982) Mutagenicity of cigarette smoke in *Drosophila melanogaster*. *Mutat. Res.*, 105, 149-156
- Kanzler, M., Jaffe, J.H. & Nee, J. (1983) Low nicotine cigarettes: Cigarette consumption and breath carbon monoxide after one year. *Clin. Pharmacol. Ther.*, 34, 408-415
- Kassman, A.J. (1984) Design of the filter system. *Recent Adv. Tob. Sci.*, 10, 72-87
- Kauffmann, F., Tessier, J.-F. & Oriol, P. (1983) Adult passive smoking in the home environment: A risk factor for chronic airflow limitation. *Am. J. Epidemiol.*, 117, 269-280
- Keast, D. & Ayre, D. (1980) Effects of chronic tobacco smoke exposure from high-tar or low-tar cigarettes on the systemic clearance mechanisms of mice. *Environ. Res.*, 23, 429-443
- Keast, D. & Taylor, K. (1983) The effects of chronic tobacco smoke exposure from high-tar cigarettes on the phagocytic and killing capacity of polymorphonuclear cells of mice. *Environ. Res.*, 31, 66-75
- Keast, D., Ayre, D.J. & Papadimitriou, J.M. (1981) A survey of pathological changes associated with long-term high tar tobacco smoke exposure in a murine model. *J. Pathol.*, 135, 249-257
- Keil, S., Tuyns, A. & Lowenfels, A.B. (1980) Esophageal cancer: A study of risk factors by subsite. *N.Y. med. Q.*, 2, 38-40
- Keith, C.H. & Derrick, J.C. (1960) Measurement of the particle size distribution and concentration of cigarette smoke by the 'Conifuge'. *J. Colloid Sci.*, 15, 340-356
- Keith, C.H. & Tesh, P.G. (1965) Measurement of the total smoke issuing from a burning cigarette. *Tob. Sci.*, 9, 61-64
- Keller, A.Z. (1970) Cellular types, survival, race, nativity, occupations, habits and associated diseases in the pathogenesis of lip cancers. *Am. J. Epidemiol.*, 91, 486-499
- Keller, A.Z. & Terris, M. (1965) The association of alcohol and tobacco with cancer of the mouth and pharynx. *Am. J. publ. Health*, 55, 1578-1585
- Kellermann, G., Shaw, C.R. & Luyten-Kellermann, M. (1973) Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. *New Engl. J. Med.*, 934-937
- Kelsey, J.L., Dwyer, T., Holford, T.R. & Bracken, M.B. (1978) Maternal smoking and congenital malformations: An epidemiological study. *J. Epidemiol. commun. Health*, 32, 102-107
- Kelsey, J.L., Fischer, D.B., Holford, T.R., LiVolsi, V.A., Mostow, E.D., Goldenberg, I.S. & White, C. (1981) Exogenous estrogens and other factors in the epidemiology of breast cancer. *J. natl Cancer Inst.*, 67, 327-333
- Kelsey, J.L., LiVolsi, V.A., Holford, T.R., Fischer, D.B., Mostow, E.D., Schwartz, P.E., O'Connor, T. & White, C. (1982) A case-control study of cancer of the endometrium. *Am. J. Epidemiol.*, 116, 333-342
- Kendall, M.G. & Stuart, A. (1958) *The Advanced Theory of Statistics*, Vol. 1, *Distribution Theory*, 6th ed., Newent, UK, Griffin
- Kendrick, J., Nettesheim, P., Guerin, M., Caton, J., Dalbey, W., Griesemer, R., Rubin, I. & Maddox, W. (1976) Tobacco inhalation studies in rats. *Toxicol. appl. Pharmacol.*, 37, 557-569
- Kennedy, A. (1973) Relationship between cigarette smoking and histological type of lung cancer in women. *Thorax*, 28, 204-208
- Ketkar, M.B., Haas, H. & Althoff, J. (1979) Implantation of cigarette smoke condensate in the lungs of Syrian golden hamsters. *J. Cancer Res. clin. Oncol.*, 94, 111-114

- Kier, L.D., Yamasaki, E. & Ames, B.N. (1974) Detection of mutagenic activity in cigarette smoke condensates. *Proc. natl Acad. Sci. USA*, 71, 4159-4163
- Kim, C.S., Lewars, G.A., Ford, D. & Sackner, M.A. (1982) Acute effect of smoking a single cigarette on aerosol deposition in the lung (Abstract). *Am. Rev. resp. Dis.*, 125, 158
- Kinlen, L.J. & McPherson, K. (1984) Pancreas cancer and coffee and tea consumption: A case-control study. *Br. J. Cancer.*, 49, 93-96
- Kiryu, S. & Kuratsune, M. (1966) Polycyclic aromatic hydrocarbons in cigarette tar produced by human smoking. *Gann*, 57, 317-322
- Klimisch, H.-J. & Dontenwill, W. (1977) Investigations of cigarette smoke dosages in inhalation experiments with Syrian hamsters. II. Uptake of cigarette smoke by the animals; comparisons of the influence of the gas phase and the whole smoke of different cigarettes. *J. natl Cancer Inst.*, 58, 935-939
- Klus, H. & Kuhn, H. (1982) Distribution of different tobacco smoke constituents in mainstream and sidestream smoke (A review) (Ger.). *Beitr. Tabakforsch.*, 11, 229-265
- Knowles, G.K., Taylor, P. & Turner-Warwick, M. (1981) A comparison of antibody responses to admune inactivated influenza vaccine in serum and respiratory secretions of healthy non-smokers, healthy cigarette-smokers and patients with chronic bronchitis. *Br. J. Dis. Chest*, 75, 283-290
- Kobayashi, H. & Hayatsu, H. (1984) A time-course study on the mutagenicity of smoker's urine. *Gann*, 75, 489-493
- Kobayashi, N., Hoffmann, D. & Wynder, E.L. (1974) A study of tobacco carcinogenesis. XII. Epithelial changes induced in the upper respiratory tracts of Syrian golden hamsters by cigarette smoke. *J. natl Cancer Inst.*, 53, 1085-1089
- Kono, S. & Ikeda, M. (1979) Correlation between cancer mortality and alcoholic beverage in Japan. *Br. J. Cancer*, 40, 449-455
- Koo, L.C., Ho, J.H.-C. & Saw, D. (1984) Is passive smoking an added risk factor for lung cancer in Chinese women? *J. exp. clin. Cancer Res.*, 3, 277-283
- Korte, A., Wagner, H.M. & Obe, G. (1981) Simultaneous exposure of Chinese hamsters to ethanol and cigarette smoke: Cytogenetic aspects. *Toxicology*, 20, 237-246
- Kotin, P. & Falk, H.L. (1960) The role and action of environmental agents in the pathogenesis of lung cancer. II. Cigarette smoke. *Cancer*, 13, 250-262
- Kouri, R.E., Rude, T.H., Curren, R.D., Brandt, K.R., Sosnowski, R.G., Schechtman, L.M., Benedict, W.F. & Henry, C.J. (1979a) Biological activity of tobacco smoke and tobacco smoke-related chemicals. *Environ. Health Perspect.*, 29, 63-69
- Kouri, R.E., Imblum, R.L., Sosnowski, R.G., Slomiany, D.J. & McKinney, C.E. (1979b) Parameters influencing quantitation of 3-methylcholanthrene-induced aryl hydrocarbon hydroxylase activity in cultured human lymphocytes. *J. environ. Pathol. Toxicol.*, 2, 1079-1098
- Kouri, R.E., Schechtman, L.M. & Nebert, D.W. (1980) *Metabolism of chemical carcinogens*. In: Kouri, R.E., ed., *Genetic Differences in Chemical Carcinogenesis*, Boca Raton, FL, CRC Press, pp. 21-66
- Kouri, R.E., Oberdorf, J., Slomiany, D.J. & McKinney, C.E. (1981) A method for detecting aryl hydrocarbon hydroxylase activities in cryopreserved human lymphocytes. *Cancer Lett.*, 14, 29-40

- Kouri, R.E., McKinney, C.E., Slomiany, D.J., Snodgrass, D.R., Wray, N.P. & McLemore, T.L. (1982) Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. *Cancer Res.*, *42*, 5030-5037
- Kouri, R.E., Lubet, R.A., McKinney, C.E., Connolly, G.M., Nebert, D.W. & McLemore, T.L. (1983) *Aryl hydrocarbon hydroxylase activity 'of mice and humans'*. In: Milman, H.A. & Sell, S., eds, *Applications of Biological Markers to Carcinogen Testing*, New York, Plenum, pp. 179-197
- Kouri, R.E., Levine, A.S., Edwards, B.K., McLemore, T.L., Vesell, E.S. & Nebert, D.W. (1984) *Source of interindividual variations in aryl hydrocarbon hydroxylase in mitogen-activated human lymphocytes*. In: Omenn, G.S. & Gelboin, H.V., eds, *Genetic Variability in Responses to Chemical Exposure (Banbury Report 16)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 131-144
- Kousaka, Y., Okuyama, K. & Wang, C.-S. (1982) Response of cigarette smoke particles to change in humidity. *J. chem. Eng. Jpn*, *15*, 75-76
- Kozlowski, L.T., Frecker, R.C., Khouw, V. & Pope, M.A. (1980) The misuse of 'less hazardous' cigarettes and its detection: Hole-blocking of ventilated filters. *Am. J. publ. Health*, *70*, 1202-1203
- Kreyberg, L. (1962) Histological lung cancer types. A morphological and biological correlation. *Acta pathol. microbiol. scand.*, *Suppl. 157*
- Kriebel, D., Commoner, B., Bollinger, D., Bronsdon, A., Gold, J. & Henry, J. (1983) Detection of occupational exposure to genotoxic agents with a urinary mutagen assay. *Mutat. Res.*, *108*, 67-79
- Kuntzman, R., Pantuck, E.J., Kaplan, S.A. & Conney, A.H. (1977) Phenacetin metabolism: Effect of hydrocarbons and cigarette smoking. *Clin. Pharmacol. Ther.*, *22*, 757-764
- Kunze, M. & Vutuc, C. (1980) *Threshold of tar exposure: Analysis of smoking history of male lung cancer cases and controls*. In: Gori, G.B. & Bock, F.G., eds, *A Safe Cigarette? (Banbury Report 3)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 29-36
- Laboratory of the Government Chemist (1982) *Report of the Government Chemist 1981*, London, Her Majesty's Stationery Office, p. 109
- Laboratory of the Government Chemist (1984) *Tar, Carbon Monoxide and Nicotine Yields of Cigarettes*, London, Her Majesty's Stationery Office
- Ladd, K.F., Newmark, H.L. & Archer, M.C. (1984) *N-Nitrosation of proline in smokers and nonsmokers*. *J. natl Cancer Inst.*, *73*, 83-87
- Lam, K.C., Yu, M.C., Leung, J.W.C. & Henderson, B.E. (1982) Hepatitis B virus and cigarette smoking: Risk factors for hepatocellular carcinoma in Hong Kong. *Cancer Res.*, *42*, 5246-5248
- Lam, R. (1980) Transient epithelial loss in rat larynx after acute exposure to tobacco smoke. *Toxicol. Lett.*, *6*, 327-335
- Lam, W.K., So, S.Y. & Yu, D.Y.C. (1983) Clinical features of bronchogenic carcinoma in Hong Kong. Review of 480 patients. *Cancer*, *52*, 369-376
- Lambert, B., Lindblad, A., Nordenskjöld, M. & Werelius, B. (1978) Increased frequency of sister chromatid exchanges in cigarette smokers. *Hereditas*, *88*, 147-149
- Lambert, B., Lindblad, A., Holmberg, K. & Francesconi, D. (1982) *The use of sister chromatid exchange to monitor human populations for exposure to toxicologically harmful agents*. In: Wolff, S., ed., *Sister Chromatid Exchange*, New York, John Wiley & Sons, pp. 149-182

- Landesman-Dwyer, S. & Emanuel, I. (1979) Smoking during pregnancy. *Teratology*, *19*, 119-126
- Langone, J.J., Gjika, H.B. & Van Vunakis, H. (1973) Nicotine and its metabolites. Radio-immunoassays for nicotine and cotinine. *Biochemistry*, *12*, 5025-5030
- Lasnitzki, I. (1958) Observations on the effects of condensates from cigarette smoke on human foetal lung *in vitro*. *Br. J. Cancer*, *12*, 547-552
- Lasnitzki, I. (1968) The effect of a hydrocarbon-enriched fraction of cigarette smoke condensate on human fetal lung grown *in vitro*. *Cancer Res.*, *28*, 510-516
- Laurene, A.H., Cundiff, R.H. & Green, G.H. (1965) Determination of glycerol and propylene glycol in cigarette smoke. *Tob. Sci.*, *9*, 1-4
- LaVoie, E.J., Hecht, S.S., Hoffmann, D. & Wynder, E.L. (1980) *The less harmful cigarette and tobacco smoke flavors*. In: Gori, G.B. & Bock, F.G., eds, *A Safe Cigarette? (Banbury Report 3)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 251-260
- Law, C.H., Day, N.E. & Shanmugaratnam, K. (1976) Incidence rates of specific histological types of lung cancer in Singapore Chinese dialect groups, and their aetiological significance. *Int. J. Cancer*, *17*, 304-309
- Lawley, P.D. (1984) *Carcinogenesis by alkylating agents*. In: Searle, C.E., ed., *Chemical Carcinogens (ACS Monograph 182)*, Vol. 1, Washington DC, American Chemical Society, p. 395
- Lazar, Ph., Chouroulinkov, I., Izard, C., Moree-Testa, P. & Hemon, D. (1974) Bioassays of carcinogenicity after fractionation of cigarette smoke condensate. *Biomedicine*, *20*, 214-222
- Lea, A.J. (1966) Cigarette smoking and cancer of the lungs and of the bladder. *Lancet*, *i*, 590-591
- Ledez, P. (1978) *Tobacco economy. Production, manufacture, distribution, consumption. The SEITA faced with the tobacco-health problem (Fr.)*. In: *De la Difficulté du Passage de la Connaissance à la Décision: Le Cas Exemplaire du Tabac* [The Difficulty of Moving from Knowledge to Decision: The Example of Tobacco], Paris, Atelier Santé, pp. 39-63
- Lee, H.P. (1980) Smoking and blood pressure among adults in Singapore. *Ann. Acad. Med.*, *9*, 416-420
- Lee, M.L., Novotny, M.V. & Bartle, K.D. (1976) Gas chromatography/mass spectrometric and nuclear magnetic resonance spectrometric studies of carcinogenic polynuclear aromatic hydrocarbons in tobacco and marijuana smoke condensates. *Anal. Chem.*, *48*, 405-418
- Lee, P.N., ed. (1975) *Tobacco Consumption in Various Countries (Research Paper 6)*, 4th ed., London, Tobacco Research Council
- Lee, P.N. (1976) *Statistics of Smoking in the United Kingdom (Research Paper 1)*, 7th ed., London, Tobacco Research Council
- Lee, P.N. (1984) *Lung cancer incidence and type of cigarette smoked*. In: Mizell, M. & Correa, P., eds, *Lung Cancer: Causes and Prevention*, New York, Verlag Chemie International, pp. 273-284
- Lee, P.N. & Garfinkel, L. (1981) Mortality and type of cigarette smoked. *J. Epidemiol. commun. Health*, *35*, 16-22
- Lee, P.N., Rothwell, K. & Whitehead, J.K. (1977) Fractionation of mouse skin carcinogens in cigarette smoke condensate. *Br. J. Cancer*, *35*, 730-742
- Leuchtenberger, C. & Leuchtenberger, R. (1970) *Effects of chronic inhalation of whole fresh cigarette smoke and of its gas phase on pulmonary tumorigenesis in Snell's mice*. In: Nettesheim, P., Hanna, M.G., Jr & Deatherage, J.W., Jr, eds, *Morphology of Experimental Respiratory Carcinogenesis*, Oak Ridge, TN, US Atomic Energy Commission, Division of Technical Information, pp. 329-346

- Levin, D.L., Connelly, R.R. & Devesa, S.S. (1981) Demographic characteristics of cancer of the pancreas: Mortality, incidence, and survival. *Cancer*, 47, 1456-1468
- Levin, M.L., Goldstein, H. & Gerhardt, P.R. (1950) Cancer and tobacco smoking. *J. Am. med. Assoc.*, 143, 336-338
- Levine, A.S., McKinney, C.E., Echelberger, C.K., Kouri, R.E., Edwards, B.K. & Nebert, D.W. (1984) Aryl hydrocarbon hydroxylase inducibility among primary relatives of children with leukemia or solid tumors. *Cancer Res*, 44, 358-362
- Lewis, D.J. (1981) Factors affecting the distribution of tobacco smoke-induced lesions in the rodent larynx. *Toxicol. Lett.*, 9, 189-194
- Lewis, D.J., Braybrook, K.J. & Prentice, D.E. (1979) The measurement of ultrastructural changes induced by tobacco smoke in rat alveolar macrophages. A comparison of high and low tar cigarettes. *Toxicol. Lett.*, 4, 175-181
- Lewis, G.P., Jusko, W., Coughlin, L. & Hartz, S. (1972) Contribution of cigarette smoking to cadmium accumulation in man. *Lancet*, i, 291-292
- Li, J. et al., eds (1979) *Atlas of Cancer Mortality in the People's Republic of China*, Shanghai, China Map Press
- Lieberman, J. (1974) Alpha₁-antitrypsin deficiency. *Med. Clin. North Am.*, 57, 691-706
- Likhachev, A., Anisimov, V. & Montesano, R., eds (1985) *Age-related Factors in Carcinogenesis (IARC Scientific Publications No. 58)*, Lyon, International Agency for Research on Cancer
- Lilienfeld, A.M., Levin, M.L. & Moore, G.E. (1956) The association of smoking with cancer of the urinary bladder in humans. *Arch. int. Med.*, 98, 129-135
- Lin, R.S. & Kessler, I.I. (1981) A multifactorial model for pancreatic cancer in man. Epidemiological evidence. *J. Am. med. Assoc.*, 245, 147-152
- Lin, T.M., Chen, K.P. & MacMahon, B. (1971) Epidemiologic characteristics of cancer of the breast in Taiwan. *Cancer*, 27, 1497-1504
- Lin, T.M., Chen, K.P., Lin, C.C., Hsu, M.M., Tu, S.M., Chiang, T.C., Jung, P.F. & Hirayama, T. (1973) Retrospective study on nasopharyngeal carcinoma. *J. natl Cancer Inst.*, 51, 1403-1408
- Lindell, K.V. (1973) *Industrial uses of asbestos*. In: Bogovski, P., Gilson, J.C., Timbrell, V. & Wagner, J.C., eds, *Biological Effects of Asbestos (IARC Scientific Publications No. 8)*, Lyon, International Agency for Research on Cancer, pp. 323-328
- Lindqvist, C. (1979) Risk factors in lip cancer: A questionnaire survey. *Am. J. Epidemiol.*, 109, 521-530
- Lippmann, M., Yeates, D.B. & Albert, R.E. (1980) Deposition, retention and clearance of inhaled particles. *Br. J. ind. Med.*, 37, 337-362
- Liu, Y.-Y. & Hoffmann, D. (1973) Quantitative chromatographic determination of maleic hydrazide in cigarette smoke. *Anal. Chem.*, 45, 2270-2273
- Liu, Y.Y., Schmeltz, I. & Hoffmann, D. (1974) Chemical studies on tobacco smoke. Quantitative analysis of hydrazine in tobacco and cigarette smoke. *Anal. Chem.*, 46, 885-889
- Livingston, G.K. & Fineman, R.M. (1983) Correlation of human lymphocyte SCE frequency with smoking history. *Mutat. Res.*, 119, 59-64

- Löchsen, P.M., Bjartveit, K., Hauknes, A. & Aaro, L.E. (1982) *Trends in Tobacco Consumption and Smoking Habits in Norway*, Oslo, Norwegian National Council on Smoking and Health
- Lockwood, K. (1961) On the etiology of bladder tumors in Kobenhavn-Frederiksberg. An inquiry of 369 patients and 369 controls. *Acta pathol. microbiol. scand.*, 51 (Suppl. 145)
- Loeb, L.A., Ernster, V.L., Warner, K.E., Abbotts, J. & Laszlo, J. (1984) Smoking and lung cancer: An overview. *Cancer Res.*, 44, 5940-5958
- Löfroth, G., Nilsson, L. & Alfeim, I. (1983) *Passive smoking and urban air pollution: Salmonella/microsome mutagenicity assay of simultaneously collected indoor and outdoor particulate matter*. In: Waters, M.D., Sandhu, S.S., Lewtas, J., Claxton, L., Chernoff, N. & Nesnow, S., eds, *Short-term Bioassays in the Analysis of Complex Environmental Mixtures*, Vol. III, New York, Plenum, pp. 515-525
- Lossing, E.H., Best, E.W.R., McGregor, J.T., Josie, G.H., Walker, C.B., Delaquis, F.M., Baker, P.M. & McKenzie, A.C. (1966) *A Canadian Study of Smoking and Health*, Ottawa, Department of National Health & Welfare
- Lower, G.M., Jr (1982) Concepts in causality: Chemically-induced human urinary bladder cancer. *Cancer*, 49, 1056-1066
- Lower, G.M., Jr (1983) Molecular epidemiology of arylamine-induced urinary bladder cancer: Some theoretical considerations. *Fed. Proc.*, 42, 3094-3097
- Lower, G.M., Jr & Bryan, G.T. (1973) Enzymatic *N*-acetylation of carcinogenic aromatic amines by liver cytosol of species displaying different organ susceptibilities. *Biochem. Pharmacol.*, 22, 1581-1588
- Lower, G.M., Jr, Nilsson, T., Nelson, C.E., Wolf, H., Gamsky, T.E. & Bryan, G.T. (1979) *N*-Acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. *Environ. Health Perspect.*, 29, 71-79
- Lubawy, W.C. & Isaac, R.S. (1980) Acute tobacco smoke exposure alters the profile of metabolites produced from benzo[*a*]pyrene by the isolated perfused rabbit lung. *Toxicology*, 18, 37-47
- Lubawy, W.C., Valentovic, M.A., Atkinson, J.E. & Gairola, G.C. (1983) Chronic cigarette smoke exposure adversely alters ¹⁴C-arachidonic acid metabolism in rat lungs, aortas and platelets. *Life Sci.*, 33, 577-584
- Lubin, J.H., Richter, B.S. & Blot, W.J. (1984a) Lung cancer risk with cigar and pipe use. *J. natl Cancer Inst.*, 73, 377-381
- Lubin, J.H., Blot, W.J., Berrino, F., Flamant, R., Gillis, C.R., Kunze, M., Schmahl, D. & Visco, G. (1984b) Patterns of lung cancer risk according to type of cigarette smoked. *Int. J. Cancer*, 33, 569-576
- Lund, E. & Zeiner-Henriksen, T. (1981) Smoking as a risk factor for cancer among 26 000 Norwegian males and females (Norw.). *Tidsskr. nor. Loegeforen.*, 101, 1937-1940
- Lundberg, M.S. & Livingston, G.K. (1983) Sister-chromatid exchange frequency in lymphocytes of smoking and nonsmoking mothers and their newborn infants. *Mutat. Res.*, 121, 241-246
- Lynch, H.T., Lynch, P.M. & Guirgis, H.A. (1980) *Host-environmental interaction and carcinogenesis in man*. In: Kouri, R.E., ed., *Genetic Differences in Chemical Carcinogenesis*, Boca Raton, FL, CRC Press, pp. 185-209
- Lyon, J.L., Wetzler, H.P., Gardner, J.W., Klauber, M.R. & Williams, R.R. (1978) Cardiovascular mortality in Mormons and non-Mormons in Utah, 1969-1971. *Am. J. Epidemiol.*, 108, 357-366
- Lyon, J.L., Gardner, J.W. & West, D.W. (1980) Cancer incidence in Mormons and non-Mormons in Utah during 1967-75. *J. natl Cancer Inst.*, 65, 1055-1061

- MacLennan, R., Da Costa, J., Day, N.E., Law, C.H., Ng, Y.K. & Shanmugaratnam, K. (1977) Risk factors for lung cancer in Singapore Chinese, a population with high female incidence rates. *Int. J. Cancer*, 20, 854-860
- MacMahon, B. & Feinleib, M. (1960) Breast cancer in relation to nursing and menopausal history. *J. natl Cancer Inst.*, 24, 733-753
- MacMahon, B., Yen, S., Trichopoulos, D., Warren, K. & Nardi, G. (1981) Coffee and cancer of the pancreas. *New Engl. J. Med.*, 304, 630-633
- Madle, S., Korte, A. & Obe, G. (1981) Cytogenetic effects of cigarette smoke condensates in vitro and in vivo. *Human Genet.*, 59, 349-352
- Maeda, K., Kondo, F., Tokida, A. & Noguchi, K. (1978) Effect of the degree of perforation of cigarette paper and tipping paper on the performance of filter cigarettes. IV. On the reduction of the main vapor phase components in cigarette smoke. *Sci. Paper central Res. Inst. Jpn Tob. Salt Corp.*, 120, 51-60
- Makhyoun, N.A. (1974) Smoking and bladder cancer in Egypt. *Br. J. Cancer*, 30, 577-581
- Mäki-Paakkanen, J., Sorsa, M. & Vainio, H. (1984) Sister-chromatid exchanges and chromosome aberrations in rubber workers. *Teratog. Carcinog. Mutagenesis*, 4, 189-200
- Mann, J.I., Doll, R., Thorogood, M., Vessey, M.P. & Waters, W.E. (1976) Risk factors for myocardial infarction in young women. *Br. J. prev. soc. Med.*, 30, 94-100
- Manning, M.D. & Carroll, B.E. (1957) Some epidemiological aspects of leukemia in children. *J. natl Cancer Inst.*, 19, 1087-1094
- Maron, M.B., Crowe, T.D. & Braughler, J.M. (1984) Cigarette smoke causes acute fluctuations in the cyclic GMP content of the isolated intact lung. *Respiration*, 45, 39-44
- Marshall, J.R., Graham, S., Byers, T., Swanson, M. & Brasure, J. (1983) Diet and smoking in the epidemiology of cancer of the cervix. *J. natl Cancer Inst.*, 70, 847-851
- Marshall, M.V., Noyola, A.J. & Rogers, W.R. (1983) Analysis of urinary mutagens produced by cigarette-smoking baboons. *Mutat. Res.*, 118, 241-256
- Martell, E.A. (1974) Radioactivity of tobacco trichomes and insoluble cigarette smoke particles. *Nature*, 249, 215-217
- Martell, E.A. (1982) Radioactivity in cigarette smoke. *New Engl. J. Med.*, 307, 309-310
- Martin, P.M.D. & Hill, G.B. (1984) Cervical cancer in relation to tobacco and alcohol consumption in Lesotho, southern Africa. *Cancer Detect. Prev.*, 7, 109-115
- Masironi, R. & Rothwell, K. (1985) *Smoking in Developing Countries III (WHO/SMO/85.1)*, Geneva, World Health Organization
- Masuda, Y. & Hoffmann, D. (1969) Quantitative determination of 1-naphthylamine and 2-naphthylamine in cigarette smoke. *Anal. Chem.*, 41, 650-652
- Masuda, Y. & Kuratsune, M. (1972) Comparison of the yield of polycyclic aromatic hydrocarbons in smoke from Japanese tobacco. *Jpn. J. Hyg.*, 27, 339-341
- Matintalo, M. & Uotila, P. (1983) The effect of low-, medium- and high-tar cigarette smoke on the fate of arachidonic acid in isolated hamster lungs. *Acta pharmacol. toxicol.*, 53, 280-287
- Matintalo, M., Kuusisto, T., Männistö, J. & Uotila, P. (1983) The metabolism of prostaglandin E₂ is decreased by high- and medium-tar but not by low-tar cigarette smoke in isolated rat lungs. *Acta pharmacol. toxicol.*, 52, 230-233

- Matsukura, S., Taminato, T., Kitano, N., Seino, Y., Hamada, H., Uchihashi, M., Nakajima, H. & Hirata, Y. (1984) Effect of environmental tobacco smoke on urinary cotinine excretion in nonsmokers. Evidence for passive smoking. *New Engl. J. Med.*, *311*, 828-832
- Matsumoto, T., Yoshida, D., Mizusaki, S. & Okamoto, H. (1977) Mutagenic activity of amino acid pyrolyzates in *Salmonella typhimurium* TA98. *Mutat. Res.*, *48*, 279-286
- Matsumoto, T., Yoshida, D. & Tomita, H. (1981) Determination of mutagens, amino- α -carbolines in grilled foods and cigarette smoke condensate. *Cancer Lett.*, *12*, 105-110
- Matsushima, S., Ishiguro, S. & Sugawara, S. (1979) Composition studies on some varieties of tobacco and their smoke. I. Major components in smoke condensate. *Beitr. Tabakforsch.*, *10*, 31-38
- Mattison, D.R. (1982) The effects of smoking on fertility from gametogenesis to implantation. *Environ. Res.*, *28*, 410-433
- Matulionis, D.H. & Traurig, H.H. (1977) In situ response of lung macrophages and hydrolase activities to cigarette smoke. *Lab. Invest.*, *37*, 314-326
- Mau, G. & Netter, P. (1974) The effect of the cigarette consumption of the father on perinatal mortality and malformation frequency (Ger.). *Dtsch. med. Wochenschr.*, *99*, 1113-1118
- Maxwell, J.C. (1976-1984) How the brands ranked - Maxwell international estimates. *World Tob.*, *57*, *61*, *62*, 71-83, 85
- McCredie, M., Ford, J.M., Taylor, J.S. & Stewart, J.H. (1982) Analgesics and cancer of the renal pelvis in New South Wales. *Cancer*, *49*, 2617-2625
- McCredie, M., Stewart, J.H. & Ford, J.M. (1983) Analgesics and tobacco as risk factors for cancer of the ureter and renal pelvis. *J. Urol.*, *130*, 28-30
- McGregor, J.F. (1976) Tumor-promoting activity of cigarette tar in rat skin exposed to irradiation. *J. natl Cancer Inst.*, *56*, 429-430
- McGregor, J.F. & Myers, D.K. (1982) Enhancement of skin tumorigenesis by cigarette smoke condensate following β -irradiation in rats. *J. natl Cancer Inst.*, *68*, 605-611
- McLaughlin, J.K., Blot, W.J., Mandel, J.S., Schuman, L.M., Mehl, E.S. & Fraumeni, J.F., Jr (1983) Etiology of cancer of the renal pelvis. *J. natl Cancer Inst.*, *71*, 287-291
- McLaughlin, J.K., Mandel, J.S., Blot, W.J., Schuman, L.M., Mehl, E.S. & Fraumeni, J.F., Jr (1984) A population-based case-control study of renal cell carcinoma. *J. natl Cancer Inst.*, *72*, 275-284
- Meiying, C., Jiujin, X. & Xianting, Z. (1982) Comparative studies on spontaneous and mitomycin C-induced sister-chromatid exchanges in smokers and non-smokers. *Mutat. Res.*, *105*, 195-200
- Menon, M.M. & Bhide, S.V. (1984) Mutagenicity of urine of bidi and cigarette smokers and tobacco chewers. *Carcinogenesis*, *5*, 1523-1524
- Merletti, F., Heseltine, E., Saracci, R., Simonato, L., Vainio, H. & Wilbourn, J. (1984) Target organs for carcinogenicity of chemicals and industrial exposures in humans: A review of results in the IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. *Cancer Res.*, *44*, 2244-2250
- Miettinen, O.S. (1974) Proportion of disease caused or prevented by a given exposure, trait or intervention. *Am. J. Epidemiol.*, *99*, 325-332
- Miller, C.T., Neutel, C.I., Nair, R.C., Marrett, L.D., Last, J.M. & Collins, W.E. (1978) Relative importance of risk factors in bladder carcinogenesis. *J. chron. Dis.*, *31*, 51-56

- Miller, J.A. & Miller, E.C. (1977) *Ultimate chemical carcinogens as reactive mutagenic electrophiles*. In: Hiatt, H.H., Watson, J.D. & Winsten, J.A., eds, *Origins of Human Cancer, Book B, Mechanisms of Carcinogenesis*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 605-627
- Miller, J.E. (1964) *Determination of the components of pipe tobacco and cigar smoke by means of a new smoking machine*. In: *Proceedings of the 3rd World Tobacco Scientific Congress, Salisbury, Southern Rhodesia, 1963*, Salisbury, Salisbury Printers, Ltd, pp. 584-585
- Miller, L.G., Goldstein, G., Murphy, M. & Ginns, L.C. (1982) Reversible alterations in immunoregulatory T cells in smoking. Analysis by monoclonal antibodies and flow cytometry. *Chest*, **82**, 526-529
- Mills, C.A. & Porter, M.M. (1950) Tobacco-smoking habits and cancer of the mouth and respiratory system. *Cancer Res.*, **10**, 539-542
- Mirra, A.P., Cole, P. & MacMahon, B. (1971) Breast cancer in an area of high parity: São Paulo, Brazil. *Cancer Res.*, **31**, 77-83
- Mitchell, A.D., Evans, E.L., Jotz, M.M., Riccio, E.S., Mortelmans, K.E. & Simmon, V.F. (1981) Mutagenic and carcinogenic potency of extracts of diesel and related environmental emissions: *In vitro* mutagenesis and DNA damage. *Environ. int.*, **5**, 393-401
- Mitchell, R.I. (1962) Controlled measurement of smoke-particle retention in the respiratory tract. *Am. Rev. resp. Dis.*, **85**, 526-533
- Mizusaki, S., Okamoto, H., Akiyama, A. & Fukuhara, Y. (1977a) Relation between chemical constituents of tobacco and mutagenic activity of cigarette smoke condensate. *Mutat. Res.*, **48**, 319-326
- Mizusaki, S., Takashima, T. & Tomaru, K. (1977b) Factors affecting mutagenic activity of cigarette smoke condensate in *Salmonella typhimurium* TA1538. *Mutat. Res.*, **48**, 29-36
- Mohtashampur, E., Norpoth, K. & Heger, M. (1984) Urinary excretion of frameshift mutagens in rats caused by passive smoking. *J. Cancer Res. clin. Oncol.*, **108**, 296-301
- Mohtashampur, E., Norpoth, K. & Lieder, F. (1985) Isolation of frameshift mutagens from smokers' urine: Experiences with three concentration methods. *Carcinogenesis*, **6**, 783-788
- Møller, M. & Dybing, E. (1980) Mutagenicity studies with urine concentrates from coke plant workers. *Scand. J. Work Environ. Health*, **6**, 216-220
- Møller-Jensen, O., Knudsen, J.B., Sørensen, B.L. & Clemmesen, J. (1983) Artificial sweeteners and absence of bladder cancer risk in Copenhagen. *Int. J. Cancer*, **32**, 577-582
- Mommsen, S. & Aagaard, J. (1983) Tobacco as a risk factor in bladder cancer. *Carcinogenesis*, **4**, 335-338
- Mommsen, S., Aagaard, J. & Sell, A. (1982) An epidemiological case-control study of bladder cancer in males from a predominantly rural district. *Eur. J. Cancer clin. Oncol.*, **18**, 1205-1210
- Mommsen, S., Aagaard, J. & Sell, A. (1983) A case-control study of female bladder cancer. *Eur. J. Cancer clin. Oncol.*, **19**, 725-729
- Moolgavkar, S.H. & Stevens, R.G. (1981) Smoking and cancers of bladder and pancreas: Risks and temporal trends. *J. natl Cancer Inst.*, **67**, 15-23
- Morgan, R.W. & Jain, M.G. (1974) Bladder cancer: Smoking, beverages and artificial sweeteners. *Can. med. Assoc. J.*, **111**, 1067-1070

- Morie, G.P. (1972) Method for the rapid determination of acetic acid and higher acids in cigarette smoke. *Beitr. Tabakforsch.*, 6, 173-177
- Morie, G.P. & Baggett, M.S. (1977) Observations on the distribution of certain tobacco smoke components with respect to particle size. *Beitr. Tabakforsch.*, 9, 72-78
- Morrison, A.S., Buring, J.E., Verhoek, W.G., Aoki, K., Leck, I., Ohno, Y. & Obata, K. (1984) An international study of smoking and bladder cancer. *J. Urol.*, 131, 650-654
- Müller, F.H. (1939) Tobacco abuse and lung carcinoma (Ger.). *Z. Krebsforsch.*, 49, 57-85
- Müller, K.H., Neurath, G. & Horstmann, H. (1964) Influence of air permeability of cigarette paper on the yield of smoke and on its composition (Ger.). *Beitr. Tabakforsch.*, 2, 271-281
- Müller, R., Moldenhauer, W. & Schlemmer, P. (1967) Experiences with the quantitative determination of polycyclic hydrocarbons in tobacco smoke (Ger.). *Ber. Inst. Tabakforsch. Dresden*, 14, 159-173
- Murthy, P.B.K. (1979) Frequency of sister chromatid exchange in cigarette smokers. *Hum. Genet.*, 52, 343-345
- Nagano, K., Miyakawa, Y., Takahashi, M., Furukawa, F., Kokubo, T. & Hayashi, Y. (1982) Comparative studies on anatomical and histological structures of nasal cavity in rodents. *Natl publ. Health Inst. Jpn*, 100, 101-109
- Najem, R.G., Louria, D.B., Seebode, J.J., Thind, I.S., Prusakowski, J.M., Ambrose, R.B. & Fernicola, A.R. (1982) Life time occupation, smoking, caffeine, saccharine, hair dyes and bladder carcinogenesis. *Int. J. Epidemiol.*, 11, 212-217
- Nakagawa, A., Chiba, K., Ishizaki, T. & Nakamura, K. (1983) Influence of cigarette smoke on antipyrine metabolite formation in rats. *Res. Commun. chem. Pathol. Pharmacol.*, 41, 473-491
- Napalkov, N.P., Tserkovny, G.F. & Merabishvili, V.M. (1980) *Malignant Neoplasms in the USSR*, Leningrad, N.N. Petrov Research Institute of Oncology
- Napalkov, N.P., Merabishvili, V.M., Tserkovny, G.F. & Preobrajenskaya, M.N. (1982) Malignant neoplasms in the USSR in the period 1970 to 1980 (Russ.). *Vopr. Onkol.*, 28, 26-71
- Napalkov, N.P., Tserkovny, G.F., Merabishvili, V.M., Parkin, D.M., Smans, M. & Muir, C.S., eds (1983) *Cancer Incidence in the USSR*, 2nd revised ed. (IARC Scientific Publications No. 48), Lyon, International Agency for Research on Cancer
- National Cancer Institute (1980) *Towards Less Hazardous Cigarettes (Report No. 5)*, Bethesda, MD, Smoking and Health Program
- National Institute for Occupational Safety and Health (1971) *Health Aspects of Smoking in Transport Aircraft*, Washington DC, US Department of Health, Education, and Welfare
- National Research Council (1975) *Nickel*, Washington DC, National Academy Press, p. 182
- National Research Council (1981) *Indoor Pollutants*, Washington DC, National Academy Press, pp. 155-168
- National Research Council (1982) *Reduced Tar and Nicotine Cigarettes: Smoking Behavior and Health*, Washington DC, National Academy Press
- Nebe, K.H. & Schirren, C. (1980) Statistical studies among andrologic patients. III. Nicotine and ejaculation parameter (Ger.). *Andrologia*, 12, 493-502
- Nebert, D.W., Winkler, J. & Gelboin, H.V. (1969) Aryl hydrocarbon hydroxylase activity in human placenta from cigarette smoking and non-smoking women. *Cancer Res.*, 29, 1763-1769

- Nebert, D.W., Atlas, S.A., Guenther, T.M. & Kouri, R.E. (1978) *The Ah locus: Genetic regulation of the enzymes which metabolize polycyclic hydrocarbons and the risk for cancer*. In: Gelboin, H.V. & T'so, P.O.P., eds, *Polycyclic Hydrocarbons and Cancer*, Vol. 2, *Molecular and Cell Biology*, New York, Academic Press, pp. 345-390
- Neel, J.V. (1984) A revised estimate of the amount of genetic variation in human proteins: Implications for the distribution of DNA polymorphisms. *Am. J. human Genet.*, *36*, 1135-1148
- Neher, G.H. (1974) Nicotine-induced depression of lymphocyte growth. *Toxicol. appl. Pharmacol.*, *27*, 253-258
- Neurath, G.B. (1972) *Nitrosamine formation from precursors in tobacco smoke*. In: Bogovski, P., Preussmann, R. & Walker, E.A., eds, *N-Nitroso Compounds. Analysis and Formation (IARC Scientific Publications No. 3)*, Lyon, International Agency for Research on Cancer, pp. 134-136
- Neurath, G. & Ehmke, H. (1964a) Apparatus to study sidestream smoke (Ger.). *Beitr. Tabakforsch.*, *2*, 117-121
- Neurath, G. & Ehmke, H. (1964b) Study of nitrate content of tobacco (Ger.). *Beitr. Tabakforsch.*, *2*, 333-344
- Neurath, G., Gewe, J. & Wichern, H. (1968) Occurrence of benzofurans in tobacco smoke (Ger.). *Beitr. Tabakforsch.*, *4*, 247-249
- Neutel, C.I. & Buck, C. (1971) Effect of smoking during pregnancy on the risk of cancer in children. *J. natl Cancer Inst.*, *47*, 59-63
- Newell, M.P., Heckman, R.A., Moates, R.F., Green, C.R., Best, F.W. & Schumacher, J.N. (1978) Isolation and identification of new components in the ether-soluble portion of cigarette smoke condensate. *Tob. Sci.*, *22*, 6-11
- Newsome, J.R. & Keith, C.H. (1965) Variation of the gas phase composition within a burning cigarette. *Tob. Sci.*, *9*, 65-69
- Nordenson, I., Beckman, G., Beckman, L. & Nordström, S. (1978) Occupational and environmental risks in and around a smelter in northern Sweden. II. Chromosomal aberrations in workers exposed to arsenic. *Hereditas*, *88*, 47-50
- Norman, V. (1977) An overview of the vapor phase, semivolatile and nonvolatile components of cigarette smoke. *Rec. Adv. Tob. Sci.*, *3*, 28-58
- Norman, V. (1982) Changes in smoke chemistry of modern day cigarettes. *Recent Adv. Tob. Sci.*, *8*, 141-177
- Norman, V., Ihrig, A.M., Larson, T.M. & Moss, B.L. (1983) The effect of some nitrogenous blend components on NO/NO_x and HCN levels in mainstream and sidestream smoke. *Beitr. Tabakforsch.*, *12*, 55-62
- Notani, P. & Sanghvi, L.D. (1974) A retrospective study of lung cancer in Bombay. *Br. J. Cancer*, *29*, 477-482
- Obe, G., ed. (1984) *Mutations in Man*, Berlin, Springer
- Obe, G. & Herha, J. (1978) Chromosomal aberrations in heavy smokers. *Human Genet.*, *41*, 259-263
- Obe, G., Vogt, H.-J., Madle, S., Fahning, A. & Heller, W.D. (1982) Double blind study on the effect of cigarette smoking on the chromosomes of human peripheral blood lymphocytes in vivo. *Mutat. Res.*, *92*, 309-319

- Obe, G., Heller, W.D. & Vogt, H.J. (1984) *Mutagenic activity of cigarette smoke*. In: Obe, G., ed, *Mutations in Man*, Berlin, Springer, pp. 223-246
- Oesch, F., Tegtmeier, F., Kohl, F.-V., Rüdiger, H. & Glatt, H.R. (1980) Interindividual comparison of epoxide hydratase and glutathione *S*-transferase activities in cultured human fibroblasts. *Carcinogenesis*, 1, 305-309
- Office of Population Censuses and Surveys (1975) *Cancer Mortality, England and Wales, 1911-1970 (Studies on Medical and Population Subjects No. 29)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1980a) *Cancer Mortality in England and Wales, 1971-1978 (OPCS Monitor DH1 80/3)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1980b) *Mortality Statistics: Cause, 1979 (Series DH2, No. 5)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1980c) *Mortality Statistics: Cause, 1980 (Series DH2, No. 6)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1982) *Mortality Statistics: Cause, 1981 (Series DH2, No. 7)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1983a) *General Household Survey: Cigarette Smoking 1972 to 1982 (OPCS Monitor GHS 83/3)*, London, Information Branch
- Office of Population Censuses and Surveys (1983b) *Mortality Statistics: Cause, 1982 (Series DH2, No. 8)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1984a) *Mortality Statistics: Cause, 1983 (Series DH2, No. 9)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1984b) *Mortality Statistics: Cause, 1983, England and Wales (Series DH2, No. 10)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1984c) *Final Mid-1981 and Revised Mid-1961 to Mid-1980 Population Estimates for England and Wales (OPCS Monitor PPI 84/1)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1984d) *Mid-1983, Final Mid-1981 and Mid-1982 Population Estimates for England and Wales (OPCS Monitor PPI 84/3)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1985a) *Mortality Statistics: Cause, 1984 (Series DH2, No. 11)*, London, Her Majesty's Stationery Office
- Office of Population Censuses and Surveys (1985b) *Mid-1984 Population Estimates for England and Wales (OPCS Monitor PPI 84/3)*, London, Her Majesty's Stationery Office
- Ohmori, T., Mori, H. & Rivenson, A. (1981) A study of tobacco carcinogenesis. XX. Mastocytoma induction in mice by cigarette smoke particulates ('cigarette tar'). *Am. J. Pathol.*, 102, 381-387
- Ohshima, H. & Bartsch, H. (1981) Quantitative estimation of endogenous nitrosation in humans by monitoring *N*-nitrosoproline excreted in urine. *Cancer Res.*, 41, 3658-3662
- Ohshima, H., Nair, J., Bourgade, M.-C., Friesen, M., Garren, L. & Bartsch, H. (1985) Identification and occurrence of two new *N*-nitrosamino acids in tobacco products: 3-(*N*-Nitroso-*N*-methylamino)propionic acid and 4-(*N*-nitroso-*N*-methylamino)butyric acid. *Cancer Lett.*, 26, 153-162
- Okada, T. & Matsunuma, K. (1974) Determination of particle-size distribution and concentration of cigarette smoke by a light scattering method. *J. Colloid Interface Sci.*, 48, 461-469

- Okey, A.B., Bondy, G.P., Mason, M.E., Kahl, G.F., Eisen, H.J., Guenther, T.M. & Nebert, D.W. (1979) Regulatory gene product of the *Ah* locus. Characterization of the cytosolic inducer receptor complex and evidence for its nuclear translocation. *J. biol. Chem.*, *254*, 11636-11648
- Okuda, T., Vesell, E.S., Plotkin, E., Tarone, R., Bast, R.C. & Gelboin, H.V. (1977) Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. *Cancer Res.*, *37*, 3904-3911
- Oles, P. (1983) The extent of tobacco use in Poland. *World Smoking Health*, *8*, 38-44
- Omar, S., Hussein, M., Ebeid, N., Basset El Aaser, A., Galal, A., El Merzabani, M. & Sayed, G.M. (1982) *Prevention of the Smoking Epidemic in a Developing Country — Egypt. A Review Paper*, Cairo, The National Cancer Institute, Cairo University
- Omenn, G.S. & Gelboin, H.V., eds (1984) *Genetic Variability in Response to Chemical Exposure (Banbury Report 16)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory
- Ong, T.M., Stewart, J. & Whong, W.Z. (1984) A simple in situ mutagenicity test system for detection of mutagenic air pollutants. *Mutat. Res.*, *139*, 177-181
- Ontario Council of Health (1982) *Smoking and Health in Ontario: A Need for Balance*, Toronto, pp. 66, 77
- Osman, S., Schmeltz, I., Higman, H.C. & Stedman, R.L. (1963) Volatile phenols of cigar smoke. *Tob. Sci.*, *7*, 141-143
- Otto, H. & Elmenhorst, H. (1967) Experimental studies on tumour induction with the gas phase of cigarette smoke (Ger.). *Z. Krebsforsch.*, *70*, 45-47
- Paffenbarger, R.S., Jr, Kampert, J.B. & Chang, H.-G. (1979) Oral contraceptives and breast cancer risk. *Inst. natl. Santé Rech. méd.*, *83*, 93-114
- Paigen, B., Ward, E., Steenland, K., Houten, L., Gurtoo, H.L. & Minowada, J. (1978) Aryl hydrocarbon hydroxylase in cultured lymphocytes of twins. *Am. J. human Genet.*, *30*, 561-571
- Paigen, B., Ward, E., Reilly, A., Houten, L., Gurtoo, H.L., Minowada, J., Steenland, K., Havens, M.B. & Sartori, P. (1981) Seasonal variations of aryl hydrocarbon hydroxylase activity in human lymphocytes. *Cancer Res.*, *41*, 2757-2761
- Pandey, K.N., Benner, J.F. & Sabharwal, P.S. (1978) Cytogenetic effects of the gaseous phase of cigarette smoke on root-tip cells of *Allium sativum* L. *Environ. exp. Bot.*, *18*, 67-75
- Park, B.K. (1982) Assessment of the drug metabolism capacity of the liver. *Br. J. clin. Pharmacol.*, *14*, 631-651
- Park, K.-H. & Shin, Y.-K. (1980) Simple correlation of ammonia in smoke to the constituents of leaf tobacco (Kor.). *J. Korean Soc. Tob. Sci.*, *2*, 78-82
- Park, S.S., Kikkawa, Y., Goldring, I.P., Daly, M.M., Zelefsky, M., Shim, C., Spierer, M. & Morita, T. (1977) An animal model of cigarette smoking in beagle dogs. Correlative evaluation of effects on pulmonary function, defense and morphology. *Am. Rev. resp. Dis.*, *115*, 971-979
- Parker, J.A. & Montgomery, R.T. (1979) Design criteria for ventilated filters. *Beitr. Tabakforsch.*, *10*, 1-6
- Parker, R.L., Gong, Y.-L., Shan, L.-G., Huang, D.-Y. & Hinman, A.R. (1982) The sample household health interview survey. *Am. J. publ. Health*, *72*, 65-70
- Parkin, M., Stjernswärd, J. & Muir, C. (1984) Estimates of the worldwide frequency of twelve major cancers. *Bull. World Health Organ.*, *62*, 163-182

- Pastorino, U., Berrino, F., Gervasio, A., Pesenti, V., Riboli, E. & Crosignani, P. (1984) Proportion of lung cancers due to occupational exposure. *Int. J. Cancer*, *33*, 231-237
- Patrianakos, C. & Hoffmann, D. (1979) Chemical studies on tobacco smoke. LXIV. On the analysis of aromatic amines in cigarette smoke. *J. anal. Toxicol.*, *3*, 150-154
- Peirce, T.H., York, G.K., Franti, C.E. & Cross, C.E. (1976) Biochemical effect of ozone exposure in rats exposed to cigarette smoke. *Arch. environ. Health*, *31*, 290-292
- Pelkonen, O. & Nebert, D.W. (1982) Metabolism of polycyclic aromatic hydrocarbons: Etiologic role in carcinogenesis. *Pharmacol. Rev.*, *34*, 189-225
- Pelkonen, O., Kaltiala, E.H., Larmi, T.K.I. & Kärki, N.T. (1974) Cytochrome P-450-linked monooxygenase system and drug-induced spectral interactions in human liver microsomes. *Chem.-biol. Interact.*, *9*, 205-216
- Percy, C., Stanek, E., III & Gloeckler, L. (1981) Accuracy of cancer death certificates and its effect on cancer mortality statistics. *Am. J. publ. Health*, *71*, 242-250
- Perinelli, M.A. & Carugno, N. (1978) Determination of trace metals in cigarette smoke by flameless atomic absorption spectrometry. *Beitr. Tabakforsch.*, *9*, 214-217
- Perry, J. (1973) Fasten your seat belts: No smoking. *Br. Columbia med. J.*, *15*, 304-305
- Pescitelli, A.R. (1979) Mutagenicity of cigarette smoke condensate and cigarette smoke in *Drosophila melanogaster*. *Environ. Mutagenesis*, *1*, 118
- Petersen, B.H., Steimel, L.F. & Callaghan, J.T. (1983) Suppression of mitogen-induced lymphocyte transformation in cigarette smokers. *Clin. Immunol. Immunopathol.*, *27*, 135-140
- Peto, R. & Doll, R. (1984) *Keynote address: The control of lung cancer*. In: Mizell, M. & Correa, P., eds, *Lung Cancer: Causes and Prevention*, New York, Verlag Chemie International, pp. 1-19
- Peto, R., Roe, F.J.C., Lee, P.N., Levy, L. & Clack, J. (1975) Cancer and ageing in mice and men. *Br. J. Cancer*, *32*, 411-426
- Peto, R., Parish, S.E. & Gray, R.G. (1985) *There is no such thing as ageing, and cancer is not related to it*. In: Likhachev, A., Anisimov, V. & Montesano, R., eds, *Age-related Factors in Carcinogenesis (IARC Scientific Publications No. 58)*, Lyon, International Agency for Research on Cancer, pp. 43-53
- Pettigrew, A.R. & Fell, G.S. (1972) Simplified colorimetric determination of thiocyanate in biological fluids, and its application to investigation of the toxic amblyopias. *Clin. Chem.*, *18*, 996-1000
- Philippe, R.J. & Hackney, E.J. (1959) The presence of nitrous oxide and methyl nitrite in cigarette smoke and tobacco pyrolysis gases. *Tob. Sci.*, *3*, 139-143
- Philippe, R.J. & Honeycutt, R.G. (1965) Methyl isocyanate in cigarette smoke and its retention by an adsorption-type filter. *Tob. Sci.*, *9*, 33-37
- Phillips, R.L., Garfinkel, L., Kuzma, J.W., Beeson, W.L., Lotz, T. & Brin, B. (1980) Mortality among California Seventh-Day Adventists for selected cancer sites. *J. natl Cancer Inst.*, *65*, 1097-1107
- Pike, M.C., Jing, J.S., Rosario, I.P., Henderson, B.E. & Menck, H.R. (1979) *Occupation: 'Explanation' of an apparent air pollution-related localized excess of lung cancer in Los Angeles County*. In: Breslow, N.E. & Whittemore, A.S., eds, *Energy and Health*, Philadelphia, SIAM Institute Mathematics Society, pp. 3-16
- Pillsbury, H.C., Bright, C.C., O'Connor, K.J. & Irish, F.W. (1969) Tar and nicotine in cigarette smoke. *J. Assoc. off. anal. Chem.*, *52*, 458-462

- Pindborg, J.J., Mehta, F.S., Gupta, P.C., Daftary, D.K. & Smith, C.J. (1971) Reverse smoking in Andhra Pradesh, India: A study of palatal lesions among 10,169 villagers. *Br. J. Cancer*, *25*, 10-20
- Poindexter, E.H., Jr & Carpenter, R.D. (1962) The isolation of harman and norharman from tobacco and cigarette smoke. *Phytochemistry*, *1*, 215-221
- Pojer, R., Whitfield, J.B., Poulos, V., Eckhard, I.F., Richmond, R. & Hensley, W.J. (1984) Carboxyhemoglobin, cotinine and thiocyanate assay compared for distinguishing smokers from non-smokers. *Clin. Chem.*, *30*, 1377-1380
- Poland, A., Glover, E. & Kende, A.S. (1976) Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin by hepatic cytosol: Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. *J. biol. Chem.*, *251*, 4936-4946
- Polissar, L., Severson, R.K. & Boatman, E.S. (1984) A case-control study of asbestos in drinking water and cancer risk. *Am. J. Epidemiol.*, *119*, 456-471
- Polydorová, M. (1961) *An attempt to determine the retention of tobacco smoke by means of membrane filters*. In: Davies, C.N., ed., *Inhaled Particles and Vapours*, Oxford, Pergamon Press, pp. 142-147
- Prentice, R.L., Yoshimoto, Y. & Mason, M.W. (1983) Relationship of cigarette smoking and radiation exposure to cancer mortality in Hiroshima and Nagasaki. *J. natl Cancer Inst.*, *70*, 611-622
- Preston-Martin, S., Yu, M.C., Benton, B. & Henderson, B.E. (1982) *N*-Nitroso compounds and childhood brain tumors; A case-control study. *Cancer Res.*, *42*, 5240-5245
- Pritchard, J.N. & Black, A. (1984) *An estimation of the tar particulate material depositing in the respiratory tracts of healthy male middle- and low-tar cigarette smokers*. In: Liu, B.Y.H., Pui, D.Y.H. & Fissan, H.J., eds, *Aerosols. Science, Technology and Industrial Applications of Airborne Particles*, New York, Elsevier Science Publishing, pp. 989-992
- Pritchard, J.N., Black, A., Foord, N. & Walsh, M. (1980) *A comparison of the regional deposition of monodisperse polystyrene aerosols in the respiratory tracts of healthy male smokers and non-smokers*. In: Stober, W. & Hochrainer, D., eds, *Aerosols in Science, Medicine and Technology — Physical and Chemical Properties of Aerosols*, Schmallenberg, Gesellschaft für Aerosolforschung, pp. 245-250
- Proctor, D.F. & Chang, J.C.F. (1983) *Comparative anatomy and physiology of the nasal cavity*. In: Reznik, G. & Stinson, S.F., eds, *Nasal Tumors in Animals and Man*, Vol. 1, *Anatomy, Physiology and Epidemiology*, Boca Raton, FL, CRC Press, pp. 1-33
- Pujic', Z. & Knežević, Z. (1963) Po-210 amount in tobacco. Determination of polonium in the environment (Slov.). *Bull. Soc. chem. Technol. (Sarajevo)*, *12*, 75-79
- Putman, D.L., David, R.M., Melhorn, J.M., Dansie, D.R., Stone, C.J. & Henry, C.J. (1985) Dose-responsive increase in sister-chromatid exchanges in bone-marrow cells of mice exposed nose-only to whole cigarette smoke. *Mutat. Res.*, *156*, 181-186
- Putzrath, R.M., Langley, D. & Eisenstadt, E. (1981) Analysis of mutagenic activity in cigarette smokers' urine by high performance liquid chromatography. *Mutat. Res.*, *85*, 97-108
- Pyriki, C. (1963) Polycyclic and aliphatic hydrocarbons in tobacco smoke (Ger.). *Nahrung*, *7*, 439-448

- Racoveanu, C., Teculescu, D., Manicatide, M. & Nicolaescu, V. (1975) Smoking habits in Romania. *Int. J. Epidemiol.*, *4*, 25-29
- Radford, E.P., Jr & Hunt, V.R. (1964) Polonium-210: A volatile radioelement in cigarettes. *Science*, *143*, 247-249
- Radford, E.P. & St Clair Renard, K.G. (1984) Lung cancer in Swedish iron miners exposed to low doses of radon daughters. *New Engl. J. Med.*, *310*, 1485-1494
- Ramalu, C. & Reddy, C.R.R.M. (1972) Carcinoma of the hard palate and its relationship to reverse smoking. *Int. Surg.*, *57*, 636-641
- Ramcharan, S., Pellegrin, F.A., Ray, R. & Hsu, J.-P. (1981) *The Walnut Creek Contraceptive Drug Study, A Prospective Study of the Side Effects of Oral Contraceptives*, Vol. III, *An Interim Report: A Comparison of Disease Occurrence Leading to Hospitalization or Death in Users and Nonusers of Oral Contraceptives* (NIH Publ. No. 81-564), Washington DC, Department of Health and Human Services
- Rasmussen, R.E., Boyd, C.H., Dansie, D.R., Kouri, R.E. & Henry, C.J. (1981) DNA replication and unscheduled DNA synthesis in lungs of mice exposed to cigarette smoke. *Cancer Res.*, *41*, 2583-2588
- Rathkamp, G., Tso, T.C. & Hoffmann, D. (1973) Chemical studies on tobacco smoke. XX. Smoke analysis of cigarettes made from bright tobaccos differing in variety and stalk position. *Beitr. Tabakforsch.*, *7*, 179-189
- Ravenholt, R.T. (1982) Radioactivity in cigarette smoke. *New Engl. J. Med.*, *307*, 312
- Rawbone, R.G. (1984) Switching to low tar cigarettes: Are the tar league tables relevant? *Thorax*, *39*, 657-662
- Recio, L., Enoch, H. & Hannan, M.A. (1982) Parameters affecting the mutagenic activity of cigarette smokers' urine. *J. appl. Toxicol.*, *2*, 241-246
- Reckzeh, G., Rücker, K., Harke, P. & Dontenwill, W. (1969) Studies to determine the acute and chronic toxicity of cigarette smoke in experimental animals after passive smoking (Ger.). *Arzneimittelforschung*, *19*, 237-241
- Reynolds, M.L. (1978) Influence of filter additives on smoke composition. *Recent Adv. Tob. Sci.*, *4*, 47-67
- Reznik, G. (1983) *Comparative anatomy and histomorphology of the nasal and paranasal cavities in rodents*. In: Reznik, G. & Stinson, S.F., eds, *Nasal Tumors in Animals and Man*, Vol. I, *Anatomy, Physiology and Epidemiology*, Boca Raton, FL, CRC Press, pp. 35-44
- Reznik, G. & Borgmeyer, L. (1980) Deposition and clearance of labelled cigarette smoke particles in rat respiratory and digestive tract. *J. Toxicol. environ. Health*, *6*, 433-444
- Reznik-Schuller, H.M. (1980) Acute effects of cigarette smoke inhalation on the Syrian hamster lungs. *J. environ. Pathol. Toxicol.*, *4*, 285-291
- Rhim, J.S. & Huebner, R.J. (1973) *In vitro* transformation assay of major fractions of cigarette smoke condensate (CSC) in mammalian cell lines (37162). *Proc. Soc. exp. biol. Med.*, *142*, 1003-1007
- Richter, M. & Erfurth, I. (1979) Gas chromatographic determination of acrolein in its original state in the mainstream smoke of cigarettes (Ger.). *Int. Tabakforsch.*, *26*, 36-45
- Rickert, W.S. & Robinson, J.C. (1981) Estimating the hazards of less hazardous cigarettes. II. Study of cigarette yields of nicotine, carbon monoxide and hydrogen cyanide in relation to levels of cotinine, carboxyhaemoglobin and thiocyanate in smokers. *J. Toxicol. environ. Health*, *7*, 391-403

- Rimington, J. (1981) The effect of filters on the incidence of lung cancer in cigarette smokers. *Environ. Res.*, 24, 162-166
- Rimpelä, M. (1978) *Adult Use of Tobacco in Finland in the 1950s to 1970s (Kansanterveystieteen Julkaisuja M 40/78)*, Tampere, University of Tampere, pp. 29-30
- Risch, H.A., Jain, M., Choi, N.W., Fodor, J.G., Pfeiffer, C.J., Howe, G.R., Harrison, L.W., Craib, K.J.P. & Miller, A.B. (1985) Dietary factors and the incidence of cancer of the stomach. *Am. J. Epidemiol.*, 122, 947-959
- Rivedal, E. & Sanner, T. (1980) Potentiating effect of cigarette smoke extract on morphological transformation of hamster embryo cells by benzo(a)pyrene. *Cancer Lett.*, 10, 193-198
- Rivedal, E., Hemstad, J. & Sanner, T. (1980) *Synergistic effects of cigarette smoke extracts, benz(a)pyrene and nickel sulphate on morphological transformation of hamster embryo cells*. In: Holmstedt, B., Lauwerys, R., Mercier, M. & Roberfroid, M., eds, *Mechanism of Toxicity and Hazard Evaluation*, Amsterdam, Elsevier/North-Holland Biomedical Press, pp. 259-263
- Robinson, J.C., Young, J.C. & Rickert, W.S. (1982) A comparative study of the amount of smoke absorbed from low yield ('less hazardous') cigarettes. Part 1: Non-invasive measures. *Br. J. Addict.*, 77, 383-397
- Robinson, J.C., Young, J.C., Rickert, W.S., Fey, G. & Kozlowski, L.T. (1983) A comparative study of the amount of smoke absorbed from low yield ('less hazardous') cigarettes. Part 2: Invasive measures. *Br. J. Addict.*, 78, 79-87
- Rodgman, A., Cook, L.C. & Latimer, P.H., Jr (1959) The composition of cigarette smoke. II. Solanesyl and phytosteryl esters. *Tob. Sci.*, 3, 125-128
- Rodgman, A., Cook, L.C. & Chapell, C.K. (1961) The composition of cigarette smoke. VI. Comparison of different tobacco types. *Tob. Sci.*, 5, 1-5
- Rodgman, A., Cook, L.C., Bellin, S.A., Mims, S.S. & Young, G.W. (1962) The composition of cigarette smoke. IX. An aliphatic ester fraction from tobacco and tobacco smoke. *Tob. Sci.*, 6, 42-49
- Rodriguez-Rigau, L.J., Smith, K.D. & Steinberger, E. (1982) Cigarette smoking and semen quality. *Fertil. Steril.*, 38, 115-116
- Rogot, E. & Murray, J.L. (1980) Smoking and causes of death among US veterans: 16 years of observation. *Publ. Health Rep.*, 95, 213-222
- Roszman, T.L., Elliott, L.H. & Rogers, A.S. (1975) Suppression of lymphocyte function by products derived from cigarette smoke. *Am. Rev. resp. Dis.*, 111, 453-457
- Rothman, K. & Keller, A. (1972) The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx. *J. chron. Dis.*, 25, 711-716
- Rottman, H. (1898) *Über primäre Lungencarcinoma* [On primary lung carcinoma] (Inaugural dissertation), Universität Würzburg
- Rowland, R.L. & Roberts, D.L. (1963) Macrocyclic diterpenes isolated from tobacco. α - and β -3,8,13-duvatriene-1,5-diols. *J. org. Chem.*, 28, 1165-1169
- Royal College of General Practitioners (1974) *Oral Contraceptives and Health*, London, Pitman Medical
- Royal College of Physicians (1983) *Health or Smoking? Follow-Up Report of the Royal College of Physicians*, London, Pitman, pp. 21-35

- Rühl, C., Adams, J.D. & Hoffmann, D. (1980) Chemical studies on tobacco smoke. LXVI. Comparative assessment of volatile and tobacco-specific *N*-nitrosamines in the smoke of selected cigarettes from the USA, West Germany and France. *J. anal. Toxicol.*, 4, 255-259
- Runeckles, V.C. (1961) Natural radioactivity in tobacco and tobacco smoke. *Nature*, 191, 322-325
- Russell, M.A.H. (1979) *Tobacco dependence: Is nicotine rewarding or aversive?* In: Krasnegor, N.A., ed., *Cigarette Smoking as a Dependence Process*, Bethesda, MD, Department of Health, Education and Welfare
- Russell, M.A.H. (1980) *The case for medium-nicotine, low-tar, low-carbon monoxide cigarettes.* In: Gori, G. & Bock, F., eds, *A Safe Cigarette? (Banbury Report 3)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 297-310
- Russell, M.A.H. & Feyerabend, C. (1975) Blood and urinary nicotine in non-smokers. *Lancet*, i, 179-181
- Russell, M.A.H., Wilson, C., Patel, U.A., Cole, P.V. & Feyerabend, C. (1973a) Comparison of effect on tobacco consumption and carbon monoxide absorption of changing to high and low nicotine cigarettes. *Br. med. J.*, iv, 512-516
- Russell, M.A.H., Cole, P.V. & Brown, E. (1973b) Absorption by non-smokers of carbon monoxide from room air polluted by tobacco smoke. *Lancet*, i, 576-579
- Russell, M.A.H., Wilson, C., Patel, U.A., Feyerabend, C. & Cole, P.V. (1975) Plasma nicotine levels after smoking cigarettes with high, medium and low nicotine yields. *Br. med. J.*, ii, 414-416
- Russell, M.A.H., Jarvis, M., Iyer, R. & Feyerabend, C. (1980) Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. *Br. med. J.*, 280, 972-976
- Russell, M.A.H., Sutton, S.R., Iyer, R., Feyerabend, C. & Vesey, C.J. (1982) Long term switching to low-tar low-nicotine cigarettes. *Br. J. Addict.*, 77, 145-158
- Russell, M.A.H., West, R.J. & Jarvis, M.J. (1985) Intravenous nicotine simulation of passive smoking to estimate dosage to exposed non-smokers. *Br. J. Addict.*, 80, 201-206
- Rylander, R. (1973) Toxicity of cigarette smoke components: free lung cell response in acute exposures. *Am. Rev. resp. Dis.*, 108, 1279-1282
- Sabadie, N., Malaveille, C., Camus, A.-M. & Bartsch, H. (1980) Comparison of the hydroxylation of benzo(a)pyrene with the metabolism of vinyl chloride, *N*-nitrosomorpholine and *N*-nitroso-*N'*-methylpiperazine to mutagens by human and rat liver microsomal fractions. *Cancer Res.*, 40, 119-126
- Sabadie, N., Richter-Reichhelm, H.B., Saracci, R., Mohr, U. & Bartsch, H. (1981) Inter-individual differences in oxidative benzo(a)pyrene metabolism by normal and tumourous surgical lung specimens from 105 lung cancer patients. *Int. J. Cancer*, 27, 417-425
- Sabharwal, P.S., Gulati, D.K. & Bhalla, P.R. (1975) Cytological studies on onion root-tip cells treated with water-soluble extract of tobacco smoke condensate from commercial cigarettes. *Mutat. Res.*, 31, 217-224
- Sabharwal, P.S., Garrett, N.E., Lidgerding, B. & Chortyk, O.T. (1977) Induction of transformation by tobacco smoke condensate using host-mediated system. *In Vitro*, 13, 183
- Sadeghi, A., Behmard, S. & Vesselinovich, S.D. (1979) Opium: A potential urinary bladder carcinogen in man. *Cancer*, 43, 2315-2321
- Sakuma, H., Kusama, M., Shimojima, N. & Sugawara, S. (1978) Gas chromatographic analysis of the *p*-nitrophenylhydrazones of low boiling carbonyl compounds in cigarette smoke. *Tob. Sci.*, 22, 158-160

- Sakuma, H., Kusama, M., Munakata, S., Ohsami, T. & Sugawara, S. (1983) The distribution of cigarette smoke components between mainstream and sidestream smoke. I. Acidic components. *Beitr. Tabakforsch.*, 12, 63-71
- Sakuma, H., Kusama, M., Yamaguchi, K., Matsuki, T. & Sugawara, S. (1984a) The distribution of cigarette smoke components between mainstream and sidestream smoke. II. Bases. *Beitr. Tabakforsch.*, 12, 199-209
- Sakuma, H., Kusama, M., Yamaguchi, K. & Sugawara, S. (1984b) The distribution of cigarette smoke components between mainstream and sidestream smoke. III. Middle and higher boiling components. *Beitr. Tabakforsch. int.*, 12, 251-258
- Salomaa, S., Sorsa, M., Alfheim, I. & Leppänen, A. (1985) Genotoxic emissions of smoke emissions in mammalian cells. *Environ. Int.*, 11, 311-316
- Saloojee, Y., Vesey, C.J., Cole, P.V. & Russell, M.A.H. (1982) Carboxyhaemoglobin and plasma thiocyanate: Complementary indicators of smoking behaviour? *Thorax*, 37, 521-525
- Sandler, D.P., Everson, R.B. & Wilcox, A.J. (1985a) Passive smoking in adulthood and cancer risk. *Am. J. Epidemiol.*, 121, 37-48
- Sandler, D.P., Wilcox, A.J. & Everson, R.B. (1985b) Cumulative effects of lifetime passive smoking on cancer risk. *Lancet*, i, 312-314
- Sanghvi, L.D., Jayant, K. & Pakhale, S.S. (1980) Tobacco use and cancer in India. *World Smoking Health*, 5, 4-10
- Santesson, B., Lindahl-Kiessling, K. & Mattsson, A. (1979) SCE in B and T lymphocytes. Possible implications for Bloom's syndrome. *Clin. Genet.*, 16, 133-135
- Sardar, Z. (1982) Sheesha cancer. *New Sci.*, 93, 459-460
- Sasson, I.M., Haley, N.J., Hoffmann, D., Wynder, E.L., Hellberg, D. & Nilsson, S. (1985a) Cigarette smoking and neoplasia of the uterine cervix: Smoke constituents in cervical mucus. *New Engl. J. Med.*, 312, 315-316
- Sasson, I.M., Coleman, D.T., LaVoie, E.J., Hoffmann, D. & Wynder, E.L. (1985b) Mutagens in human urine: Effects of cigarette smoking and diet. *Mutat. Res.*, 158, 149-157
- Sato, S., Seino, Y., Ohka, T., Yahagi, T., Nagao, M., Matsushima, T. & Sugimura, T. (1977) Mutagenicity of smoke condensates from cigarettes, cigars and pipe tobacco. *Cancer Lett.*, 3, 1-8
- Sato, S., Ohka, T., Nagao, M., Tsuji, K. & Kosuge, T. (1979) Reduction in mutagenicity of cigarette smoke condensate by added sugars. *Mutat. Res.*, 60, 155-161
- Schairer, E. & Schöniger, E. (1943) Lung cancer and tobacco consumption (Ger.). *Z. Krebsforsch.*, 54, 261-269
- Schell, S. & Griffith, R.B. (1972) A procedure for determining the relative toxicity to mice of inhaled smoke from various experimental cigarettes. In: *Proceedings of the University of Kentucky Tobacco and Health Institute*, pp. 295-302
- Schlesinger, R.B. & Lippmann, M. (1978) Selective particle deposition and bronchogenic carcinoma. *Environ. Res.*, 15, 424-431
- Schlotzhauer, W.S. & Schmeltz, I. (1967) Non-alkaloidal bases from pyrolysis of tobacco leaf pigment at the approximate burn temperature of a cigarette. *Tob. Sci.*, 11, 89-90
- Schlotzhauer, W.S., Severson, R.F., Chortyk, O.T., Arrendale, R.F. & Higman, H.C. (1976) Pyrolytic formation of polynuclear aromatic hydrocarbons from petroleum ether extractable constituents of flue-cured tobacco leaf. *J. agric. Food Chem.*, 24, 992-997

- Schlotzhauer, W.S., Martin, R.M., Snook, M.E. & Williamson, R.E. (1982) Pyrolytic studies on the contribution of tobacco leaf constituents to the formation of smoke catechols. *J. agric. Food Chem.*, 30, 372-374
- Schmauz, R. & Cole, P. (1974) Epidemiology of cancer of the renal pelvis and ureter. *J. natl Cancer Inst.*, 52, 1431-1434
- Schmeltz, I. & Hoffmann, D. (1977) Nitrogen-containing compounds in tobacco and tobacco smoke. *Chem. Rev.*, 77, 295-311
- Schmeltz, I. & Schlotzhauer, W.S. (1962) Nonvolatile acids of cigar smoke. *Tob. Sci.*, 6, 90-91
- Schmeltz, I., de Paolis, A. & Hoffmann, D. (1975) Phytosterols in tobacco: Quantitative analysis and fate in tobacco combustion. *Beitr. Tabakforsch.*, 8, 211-218
- Schmeltz, I., Brunnemann, K.D., Hoffmann, D. & Cornell, A. (1976a) On the chemistry of cigar smoke: Comparisons between experimental little and large cigars. *Beitr. Tabakforsch.*, 8, 367-377
- Schmeltz, I., Tosk, J. & Hoffmann, D. (1976b) Formation and determination of naphthalenes in cigarette smoke. *Anal. Chem.*, 48, 645-650
- Schmeltz, I., Tosk, J., Jacobs, G. & Hoffmann, D. (1977) Redox potential and quinone content of cigarette smoke. *Anal. Chem.*, 49, 1924-1929
- Schmeltz, I., Chiong, K.G. & Hoffmann, D. (1978) Formation and determination of ethyl carbamate in tobacco and tobacco smoke. *J. anal. Toxicol.*, 2, 265-268
- Schmeltz, I., Wenger, A., Hoffmann, D. & Tso, T.C. (1979) Chemical studies on tobacco smoke. 63. On the fate of nicotine during and in a burning cigarette. *J. agric. Food Chem.*, 27, 602-608
- Schrek, R., Baker, L.A., Ballard, G.P. & Dolgoff, S. (1950) Tobacco smoking as an etiologic factor in disease. I. Cancer. *Cancer Res.*, 10, 49-58
- Schüler, G., Stransky, M., Schwarzenbach, F.H., Epstein, F.H. & Schär, M. (1980) Smoking habits in two rural communities in the canton of Zurich, Switzerland (Ger.). *Schweiz. Rundschau. Med. (Praxis)*, 69, 1661-1670
- Schumacher, J.N., Green, C.R., Best, F.W. & Newell, M.P. (1977) Smoke composition. An extensive investigation of the water-soluble portion of cigarette smoke. *J. agric. Food Chem.*, 25, 310-320
- Schwartz, D., Denoix, P.-F. & Anquerra, G. (1957) Search for sites of cancer associated with tobacco and alcohol factors in humans (Fr.). *Bull. Assoc. fr. Etude Cancer*, 44, 336-361
- Schwartz, D., Flamant, R., Lellouch, J. & Denoix, P.F. (1961) Results of a French survey on the role of tobacco, particularly inhalation, in different cancer sites. *J. natl Cancer Inst.*, 26, 1085-1108
- Sehgal, C.B. & Hutton, J.J. (1977a) Metabolism of carcinogens and tobacco smoke fraction by adult and fetal rat liver homogenates to form mutagens detectable by *Salmonella* test system. *J. cytol. Genet.*, 12, 1-9
- Sehgal, C.B. & Hutton, J.J. (1977b) Homogenates of pregnant rat and fetal tissues metabolize carcinogens to mutagens detected by *Salmonella typhimurium* TA98 and TA100. *Mutat. Res.*, 46, 325-344
- Selikoff, I.J., Hammond, E.C. & Seidman, H. (1973) *Cancer risk of insulation workers in the United States*. In: Bogovski, P., Gilson, J.C., Timbrell, V. & Wagner, J.C., eds, *Biological Effects of Asbestos (IARC Scientific Publications No. 8)*, Lyon, International Agency for Research on Cancer, pp. 209-216
- Selikoff, I.J., Seidman, H. & Hammond, E.C. (1980) Mortality effects of cigarette smoking among amosite asbestos factory workers. *J. natl Cancer Inst.*, 65, 507-513
- Selke, W.A. (1980) *Reconstituted tobacco sheet*. In: Gori, G.B. & Bock, F.G., eds, *A Safe Cigarette? (Banbury Report 3)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 205-213

- Seshadri, R., Baker, E. & Sutherland, G.R. (1982) Sister chromatid exchange (SCE) analysis in mothers exposed to DNA-damaging agents and their newborn infants. *Mutat. Res.*, *37*, 139-146
- Severson, R.F., Schlotzhauer, W.S., Arrendale, R.F., Snook, M.E. & Higman, H.C. (1977) Correlation of polynuclear aromatic hydrocarbon formation between pyrolysis and smoking. *Beitr. Tabakforsch.*, *9*, 23-37
- Severson, R.F., Arrendale, R.F., Chortyk, O.T. & Snook, M.E. (1978) A method for determining the transfer of lipids from tobacco to smoke. *Tob. Sci.*, *22*, 130-133
- Severson, R.F., Arrendale, R.F., Chaplin, J.F. & Williamson, R.E. (1979) Use of pale-yellow tobacco to reduce smoke polynuclear aromatic hydrocarbons. *J. agric. Food Chem.*, *27*, 896-900
- Shanghai Cancer Institute, Shanghai Sanitary Antiepidemic Centre (1982) Analysis of cancer incidence, survival and mortality rates in Shanghai urban area, 1972-1979. *Shanghai Tumour*, *2*, 1-6
- Shanghai Cancer Registry (1970) *Official Report on Cancer Incidence and Mortality Rates in Shanghai Urban Area for the Period 1963-65* (Chin.), Shanghai
- Shanmugaratnam, K., Tye, C.Y., Goh, E.H. & Chia, K.B. (1978) *Etiological factors in nasopharyngeal carcinoma: A hospital-based, retrospective, case-control, questionnaire study*. In: de-Thé, G. & Ito, Y., eds, *Nasopharyngeal Carcinoma: Etiology and Control (IARC Scientific Publications No. 20)*, Lyon, International Agency for Research on Cancer, pp. 199-212
- Sheets, T.J. & Leidy, R.B. (1979) Influence of insecticides and nematicides on the chemistry of tobacco. *Recent Adv. Tob. Sci.*, *5*, 83-131
- Shien, T. (1982) Modernization continues as JTS faces reform. *Tob. int.*, *184*, 5, 6, 8, 9, 10, 12, 14, 16
- Shimizu, H., Preston-Martin, S., Casagrande, J.T., Ross, R.K., Henderson, B.E. & Pike, M.C. (1982) Epidemiological characteristics of adenocarcinoma of the lung in Los Angeles County. *Natl Cancer Inst. Monogr.*, *62*, 161-164
- Shiota, K., Chou, M.J. & Nishimura, H. (1976) Factors associated with the occurrence of early resorption of human embryos. *Mutat. Res.*, *38*, 347-348
- Silverman, N.A., Potvin, C., Alexander, J.C., Jr & Chretien, P.B. (1975) *In vitro* lymphocyte reactivity and T-cell levels in chronic cigarette smokers. *Clin. exp. Immunol.*, *22*, 285-292
- Simberg, N. & Uotila, P. (1978) Stimulatory effect of cigarette smoke on the metabolism and covalent binding of benzo[*a*]pyrene in the trachea of the rat. *Int. J. Cancer*, *22*, 28-31
- Sloan, C.H. (1980) Coulometric determination of hydrogen cyanide in cigarette smoke. *Beitr. Tabakforsch.*, *10*, 106-110
- Smith, G., Wilton, L.V. & Binns, R. (1978) Sequential changes in the structure of the rat respiratory system during and after exposure to cigarette smoke. *Toxicol. appl. Pharmacol.*, *46*, 579-591
- Snook, M.E. & Chortyk, O.T. (1984) The rapid determination of harman and norharman in cigarette smoke. *Tob. Sci.*, *28*, 36-40
- Snook, M.E., Severson, R.F., Arrendale, R.F., Higman, H.C. & Chortyk, O.T. (1977) The identification of high molecular weight polynuclear aromatic hydrocarbons in a biologically active fraction of cigarette smoke condensate. *Beitr. Tabakforsch.*, *9*, 79-101
- Snook, M.E., Severson, R.F., Arrendale, R.F., Higman, C.H. & Chortyk, O.T. (1978) Multi-alkylated polynuclear aromatic hydrocarbons of tobacco smoke: Separation and identification. *Beitr. Tabakforsch.*, *9*, 222-247

- Snook, M.E., Fortson, P.J. & Chortyk, O.T. (1980) Application of gel chromatography to characterize more completely the phenols of cigarette smoke. *Tob. Sci.*, 24, 30-36
- Snook, M.E., Fortson, P.J. & Chortyk, O.T. (1981) Isolation and identification of aza-arenes of tobacco smoke. *Beitr. Tabakforsch.*, 11, 67-78
- Snook, M.E., Chortyk, O.T. & Arrendale, R.F. (1984) Isolation and identification of *N*-acylalkaloids of cigarette smoke. *Beitr. Tabakforsch.*, 12, 227-243
- Sömmering, S.T. (1795) *De morbis vasorum absorbentium corporis humani*, Frankfurt, Varrentrapp & Wenner
- Sorsa, M., Norppa, H., Leppänen, A. & Rimpelä, M. (1982) Induction of sister-chromatid exchange in human lymphocytes by smoke condensates from different brands of cigarette. *Mutat. Res.*, 103, 149-153
- Sorsa, M., Falck, K., Heinonen, T., Vainio, H., Norppa, H. & Rimpelä, M. (1984) Detection of exposure to mutagenic compounds in low-tar and medium-tar cigarette smokers. *Environ. Res.*, 33, 312-321
- Sorsa, M., Einistö, P., Husgafvel-Pursiainen, K., Järventaus, H., Kivistö, H., Peltonen, Y., Tuomi, T., Valkonen, S. & Pelkonen, O. (1985) Passive and active exposure to cigarette smoke in a smoking experiment. *J. Toxicol. environ. Health*, 16, 523-534
- Spears, A.W. (1963) Quantitative determination of phenol in cigarette smoke. *Anal. Chem.*, 35, 320-322
- Spears, A.W., Lassiter, C.W. & Bell, J.H. (1963) Quantitative determination of alkanes in cigarette smoke. *J. Gas Chromatogr.*, 1, 34-37
- Spielberg, S.P. (1984) In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans. *Fed. Proc.*, 43, 2308-2313
- Spielberg, S.P., Kramer, L.I., Goodman, S.I., Butler, J., Tietze, F., Quinn, P. & Schulman, J.D. (1977) 5-Oxoprolinuria: Biochemical observations and case report. *J. Pediatr.*, 91, 237-241
- Spitzer, W.O., Hill, G.B., Chambers, L.W., Helliwell, B.E. & Murphy, H.B. (1975) The occupation of fishing as a risk factor in cancer of the lip. *New Engl. J. Med.*, 293, 419-424
- Stanton, M.F., Miller, E., Wrench, C. & Blackwell, R. (1972) Experimental induction of epidermoid carcinoma in the lungs of rats by cigarette smoke condensate. *J. natl Cancer Inst.*, 49, 867-877
- Staszewski, J. (1966) Smoking and cancer of the urinary bladder in males in Poland. *Br. J. Cancer*, 20, 32-35
- Stedman, R.L. (1968) The chemical composition of tobacco and tobacco smoke. *Chem. Rev.*, 68, 153-207
- Stedman, R.L., Burdick, D. & Schmeltz, I. (1963) Composition studies on tobacco. XVII. Steam-volatile acidic fraction of cigarette smoke. *Tob. Sci.*, 7, 166-169
- van Steensel-Moll, H.A., Valkenburg, H.A., Vandenbroucke, J.P. & van Zanen, G.E. (1983) *Risk factors in childhood leukaemia: A case-control study of prenatal factors*. In: van Steensel-Moll, H.A., ed., *Childhood Leukaemia in the Netherlands. A Register Based Epidemiologic Study*, pp. 98-116
- Stehlik, G., Richter, O. & Altmann, H. (1982) Concentration of dimethylnitrosamine in the air of smoke-filled rooms. *Ecotoxicol. environ. Saf.*, 6, 495-500
- Stellman, S.D., Austin, H. & Wynder, E.L. (1980) Cervix cancer and cigarette smoking: A case-control study. *Am. J. Epidemiol.*, 111, 383-388

- Stepney, R. (1981) Would a medium-nicotine, low-tar cigarette be less hazardous to health? *Br. med. J.*, 283, 1292-1296
- Stepney, R. (1982) Exposure to carbon monoxide in smokers of middle and low-tar cigarettes. *Br. J. Dis. Chest.*, 76, 390-396
- Stevens, R.G. & Moolgavkar, S.H. (1979) Estimation of relative risk from vital data: Smoking and cancers of the lung and bladder. *J. natl Cancer Inst.*, 63, 1351-1357
- Stevens, R.G. & Moolgavkar, S.H. (1984) A cohort analysis of lung cancer and smoking in British males. *Am. J. Epidemiol.*, 119, 624-641
- Stewart, A., Webb, J. & Hewitt, D. (1958) A survey of childhood malignancies. *Br. med. J.*, i, 1495-1508
- Stich, H.F. & Rosin, M.P. (1983) Quantitating the synergistic effect of smoking and alcohol consumption with the micronucleus test on human buccal mucosa cells. *Int. J. Cancer*, 31, 305-308
- Stocks, P. (1970) Cancer mortality in relation to national consumption of cigarettes, solid fuel, tea and coffee. *Br. J. Cancer*, 24, 215-225
- Stone, P.J., Calore, J.D., McGowan, S.E., Bernardo, J., Snider, G.L. & Franzblau, C. (1983) Functional α_1 -protease inhibitor in the lower respiratory tract of cigarette smokers is not decreased. *Science*, 221, 1187-1189
- Sugimura, T., Nagao, M., Kawachi, T., Honda, M., Yahagi, T., Seino, Y., Sato, S., Matsukura, N., Matsushima, T., Shirai, A., Sawamura, M. & Matsumoto, H. (1977) *Mutagen-carcinogens in food, with special reference to highly mutagenic pyrolytic products in broiled foods*. In: Hiatt, H.H., Watson, J.D. & Winsten, J.A., eds, *Origins of Human Cancer, Book C, Human Risk Assessment*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 1561-1577
- Suolinna, E.-M., Vanttinen, E. & Aitio, A. (1982) Induction of aryl hydrocarbon hydroxylase activity in cultured human lymphocytes. *Toxicology*, 24, 73-84
- Sutton, S.R., Russell, M.A.H., Iyer, R., Feyerabend, C. & Saloojee, Y. (1983) Relationship between cigarette yields, puffing patterns, and smoke intake: Evidence for tar compensation? *World Smoking Health*, 8, 4-12
- Swedish Tobacco Company (1982) *Svenska Tobaks AB, 1982*, Stockholm
- Takayama, S., Katoh, Y., Hirakawa, T. & Tanaka, M. (1978) *In vitro* morphological transformation of cryopreserved hamster embryo cells with tobacco tar. *Gann*, 69, 85-90
- Tamburini, M., Malvezzi, I. & Ravasi, G. (1981) *The Italian Smokers' Ways of Living*, Milan, Istituto Nazionale per lo Studio e la Cura dei Tumori
- Teppo, L. (1984) *Lung cancer in Scandinavia: Time trends and smoking habits*. In: Mizell, M. & Correa, P., eds, *Lung Cancer: Causes and Prevention*, New York, Verlag Chemie International, pp. 21-31
- Thomas, D.B. (1973) An epidemiologic study of carcinoma in situ and squamous dysplasia of the uterine cervix. *Am. J. Epidemiol.*, 98, 10-28
- Thomas, W.R., Holt, P.G. & Keast, D. (1974) Development of alterations in the primary immune response of mice by exposure to fresh cigarette smoke. *Int. Arch. Allergy*, 46, 481-486
- Thomas, W.R., Holt, P.G. & Keast, D. (1975) Humoral immune response of mice with long-term exposure to cigarette smoke. *Arch. environ. Health*, 30, 78-80

- Thorstenson, J.H. & Dorough, H.W. (1976) Chlorinated insecticide residues in the University of Kentucky reference and alkaloid series cigarettes. *Tob. Sci.*, 20, 22-25
- Tobin, M.J. & Sackner, M.A. (1982) Monitoring smoking patterns of low and high tar cigarettes with inductive plethysmography. *Am. Rev. resp. Dis.*, 126, 258-264
- Tobin, M.J., Jenouri, G. & Sackner, M.A. (1982) Subjective and objective measurement of cigarette smoke inhalation. *Chest*, 82, 696-700
- Todd, G.F. (1978) Cigarette consumption per adult of each sex in various countries. *J. Epidemiol. commun. Health*, 22, 289-293
- Tokuhata, G.K. (1967) IV, Tobacco and cancer of the genitalia among married women. *Am. J. publ. Health*, 57, 830-839
- Tokuhata, G.K. & Lilienfeld, A.M. (1963a) Familial aggregation of lung cancer in humans. *J. natl Cancer Inst.*, 30, 289-312
- Tokuhata, G.K. & Lilienfeld, A.M. (1963b) Familial aggregation of lung cancer among hospital patients. *Publ. Health Rep.*, 78, 277-283
- Tola, S., Tenho, M., Korkala, M.-L. & Järvinen, E. (1980) Cancer of the urinary bladder in Finland. Association with occupation. *Int. Arch. occup. environ. Health*, 46, 43-51
- Tominaga, S. (1982) *Smoking in Japan*. In: Tominaga, S. & Aoki, K., eds, *The UICC Smoking Control Workshop, Nagoya, 1981*, Nagoya, University of Nagoya Press, pp. 27-35
- Trichopoulos, D., MacMahon, B., Sparros, L. & Merikas, G. (1980) Smoking and hepatitis B-negative primary hepatocellular carcinoma. *J. natl Cancer Inst.*, 65, 111-114
- Trichopoulos, D., Kalandidi, A., Sparros, L. & McMahon, B. (1981) Lung cancer and passive smoking. *Int. J. Cancer*, 27, 1-4
- Trichopoulos, D., Kalandidi, A. & Sparros, L. (1983) Lung cancer and passive smoking; conclusion of Greek study. *Lancet*, ii, 677-678
- Tso, T.C. (1966) Micro- and secondary elements in tobacco. *Acad. Sin. Inst. Bot. Bull.*, 7, 28-63
- Tso, T.C. (1972) *Physiology and Biochemistry of Tobacco Plants*, Stroudsburg, PA, Dowden, Hutchinson & Ross, pp. 6, 162, 172-174, 305-311, 343-350
- Tso, T.C. (1980) *Modification through agricultural techniques for developing a safer tobacco*. In: Gori, G. & Bock, F., eds, *A Safe Cigarette? (Banbury Report 3)*, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, pp. 181-190
- Tso, T.C. (1986) *Tobacco plants*. In: Adlkofer, F. & Scherer, G., eds, *Handbook of Tobacco and Tobacco Products*, Hamburg, Beitrage zur Tabakforschung International, Ch. 1 (in press)
- Tso, T.C. & Chaplin, J.F. (1977) *Simple Correlation and Multiple Regression Among Leaf Characteristics, Smoke Components and Biological Responses of Bright Tobaccos (Technical Bull. No. 1551)*, Washington DC, US Department of Agriculture, Agricultural Research Service
- Tso, T.C., Harley, N. & Alexander, L.T. (1966) Source of lead-210 and polonium-210 in tobacco. *Science*, 153, 880-882
- Turner, J.A.Mc.M., Sillett, R.W. & Ball, K.P. (1974) Some effects of changing to low-tar and low-nicotine cigarettes. *Lancet*, ii, 737-739
- Tuyns, A.J. & Estève, J. (1983) Pipe, commercial and hand-rolled cigarette smoking in oesophageal cancer. *Int. J. Epidemiol.*, 12, 110-113

- Tuyns, A.J., Péquignot, G. & Jensen, O.M. (1977) Oesophageal cancer in Ille et Vilaine in relation to alcohol and tobacco consumption. Multiplicative risks (Fr.). *Bull. Cancer*, *64*, 45-60
- Tyrrell, A.B., MacAirt, J.G. & McCaughey, W.T.E. (1971) Occupational and non-occupational factors associated with vesical neoplasms in Ireland. *J. Irish med. Assoc.*, *64*, 213-217
- Umezawa, K., Takayama, S., Fujie, S., Matsushima, T. & Sugimura, T. (1978) In vitro transformation of hamster embryo cells by betel tobacco extracts. *Toxicol. Lett.*, *2*, 243-246
- Uotila, P. (1977) Effects of single and repeated smoke-exposures on the activities of aryl hydrocarbon hydroxylase, epoxide hydratase and UDP-glucuronosyltransferase in rat lung, kidney and small intestinal mucosa. *Res. Commun. chem. Pathol. Pharmacol.*, *17*, 101-114
- Uotila, P. & Marniemi, J. (1976) Variable effects of cigarette smoking on aryl hydrocarbon hydroxylase, epoxide hydratase and UDP-glucuronosyltransferase activities in rat lung, kidney, and small intestinal mucosa. *Biochem. Pharmacol.*, *25*, 2323-2328
- Uotila, P., Pelkonen, O. & Cohen, G.M. (1977a) The effects of cigarette smoke on the metabolism of [³H]benzo[*a*]pyrene by rat lung microsomes. *Cancer Res.*, *37*, 2156-2161
- Uotila, P., Hartiala, J. & Aitio, A. (1977b) Cigarette smoke: Inducer of glucuronide synthesis in the isolated perfused rat lung. *Toxicol. appl. Pharmacol.*, *41*, 445-448
- US Department of Agriculture (1965) *Tobacco Situation, March*, Washington DC, Economic Research Service, p. 10
- US Department of Agriculture (1983) *Agricultural Statistics*, Washington DC, US Government Printing Office, pp. 97-111
- US Department of Agriculture (1984) *Tobacco Situation, October 3*, Washington DC, Commodity Economics Division, Economic Research Service
- US Department of Health and Human Services (1979) *Smoking and Health, Report of the Surgeon General (DHEW Publ. No. (PHS) 79-50066)*, Washington DC, US Public Health Service, pp. 1-42
- US Department of Health and Human Services (1981) *The Health Consequences of Smoking: The Changing Cigarette. A Report of the Surgeon General*, Washington DC, US Public Health Service
- US Department of Health and Human Services (1982) *The Health Consequences of Smoking: Cancer. A Report of the Surgeon General*, Washington DC, US Public Health Service, pp. 13-169, 193-194
- US Department of Health and Human Services (1983) *The Health Consequences of Smoking. Cardiovascular Disease. A Report of the Surgeon General*, Rockville, MD, Office on Smoking and Health, p. 369
- US Federal Trade Commission (1985) *Tar, Nicotine and Carbon Monoxide of the Smoke of 207 Varieties of Domestic Cigarettes*, Washington DC
- Valadaud-Barrieu, D. & Izard, C. (1979) Action of the gas phase of cigarette smoke on the level of sister chromatid exchanges in human lymphocytes *in vitro* (Fr.). *C.R. Acad. Sci. Paris*, *288*, 899-901
- Valaoras, V.G., MacMahon, B., Trichopoulos, D. & Polychronopoulou, A. (1969) Lactation and reproductive histories of breast cancer patients in Greater Athens, 1965-67. *Int. J. Cancer*, *4*, 350-363
- Van Cantfort, J. & Gielen, J. (1975) Organ specificity of aryl hydrocarbon hydroxylase induction by cigarette smoke in rats and mice. *Biochem. Pharmacol.*, *24*, 1253-1256

- Van Cantfort, J. & Gielen, J. (1977) Induction by cigarette smoke of aryl hydrocarbon hydroxylase activity in the rat kidney and lung. *Int. J. Cancer*, *19*, 538-545
- Van Duuren, B.L. (1958a) The polynuclear aromatic hydrocarbons in cigarette-smoke condensate. II. *J. natl Cancer Inst.*, *21*, 623-630
- Van Duuren, B.L. (1958b) Identification of smoke polynuclear aromatic hydrocarbons in cigarette-smoke condensate. *J. natl Cancer Inst.*, *21*, 1-16
- Van Duuren, B.L. & Goldschmidt, B.M. (1976) Cocarcinogenic and tumor-promoting agents in tobacco carcinogenesis. *J. natl Cancer Inst.*, *56*, 1237-1242
- Van Duuren, B.L., Bilbao, J.A. & Joseph, C.A. (1960) The carcinogenic nitrogen heterocyclics in cigarette-smoke condensate. *J. natl Cancer Inst.*, *25*, 53-61
- Venema, G. (1959) The influence of substances extracted from cigarette-smoke on mitotic processes in *Allium cepa*. *Chromosoma*, *10*, 679-685
- Vesey, C.J., Saloojee, Y., Cole, P.V. & Russell, M.A.H. (1982) Blood carboxyhaemoglobin, plasma thiocyanate, and cigarette consumption: Implications for epidemiological studies in smokers. *Br. med. J.*, *284*, 1516-1518
- Vessey, M., Doll, R., Peto, R., Johnson, B. & Wiggins, P. (1976) A long-term follow-up study of women using different methods of contraception. An interim report. *J. biosoc. Sci.*, *8*, 373-427
- Vessey, M.P., McPherson, K., Yeates, D. & Doll, R. (1982) Oral contraceptive use and abortion before first term pregnancy in relation to breast cancer risk. *Br. J. Cancer*, *45*, 327-331
- Vessey, M., Baron, J., Doll, R., McPherson, K. & Yeates, D. (1983) Oral contraceptives and breast cancer. Final report of an epidemiological study. *Br. J. Cancer*, *47*, 455-462
- Vickroy, D.G. (1976) The characterization of cigarette smoke from Cytrel® smoking products and its comparison to smoke from flue-cured tobacco. I. Vapor phase analysis. *Beitr. Tabakforsch.*, *8*, 415-421
- Viczián, M. (1969) Results of sperm studies in cigarette smokers (Ger.). *Z. Heut.-Geschlechtskr.*, *44*, 183-187
- Vijayalaxmi & Evans, H.J. (1982) In vivo and in vitro effects of cigarette smoke on chromosomal damage and sister-chromatid exchange in human peripheral blood lymphocytes. *Mutat. Res.*, *92*, 321-332
- Vilcins, G. & Lephardt, J.O. (1975) Ageing processes of cigarette smoke: formation of methyl nitrite. *Chem. Ind.*, November, 974-975
- Vincent, R.G., Pickren, J.W., Lane, W.W., Bross, I., Takita, H., Houten, L., Gutierrez, A.C. & Rzepka, T. (1977) The changing histopathology of lung cancer. A review of 1682 cases. *Cancer*, *39*, 1647-1655
- Vincent, T.N., Satterfield, J.V. & Ackerman, L.V. (1965) Carcinoma of the lung in women. *Cancer*, *18*, 559-570
- Vineis, P., Estève, J. & Terracini, B. (1984) Bladder cancer and smoking in males: Types of cigarettes, age at start, effect of stopping and interaction with occupation. *Int. J. Cancer*, *34*, 165-170
- Voges, E. (1984) *Tobacco Encyclopedia*, Mainz, Tobacco Journal International
- Vogt, H.J., Heller, W.D. & Obe, G. (1984) *Spermatogenesis in smokers and non-smokers: An andrological and genetic study*. In: Obe, G., ed., *Mutations in Man*, Berlin, Springer, pp. 247-291
- Wagner, W.L. (1982) Radioactivity in cigarette smoke. *New Engl. J. Med.*, *307*, 311
- Wahlberg, I. & Enzell, C.R. (1984) Tobacco cembranoids. *Beitr. Tabakforsch.*, *12*, 93-104

- Wakile, L.A., Sloan, T.P., Idle, J.R. & Smith, R.L. (1979) Genetic evidence for the involvement of different oxidative mechanisms in drug oxidation. *J. Pharm. Pharmacol.*, *31*, 350-352
- Wald, N.J. (1985) *Smoking*. In: Vessey, M.P. & Gray, M., eds, *Cancer Risks and Prevention*, Oxford, Oxford University Press, pp. 44-67
- Wald, N.J., Howard, S. & Evans, J. (1976) Smoking tables for carbon monoxide? *Br. med. J.*, *i*, 434-435
- Wald, N., Idle, M., Smith, P.G. & Bailey, A. (1977) Carboxyhaemoglobin levels in smokers of filter and plain cigarettes. *Lancet*, *i*, 110-112
- Wald, N.J., Idle, M. & Bailey, A. (1978) Carboxyhaemoglobin levels and inhaling habits in cigarette smokers. *Thorax*, *33*, 201-206
- Wald, N.J., Idle, M., Boreham, J. & Bailey, A. (1980) Inhaling habits among smokers of different types of cigarette. *Thorax*, *35*, 925-928
- Wald, N., Doll, R. & Copeland, G. (1981a) Trends in tar, nicotine, and carbon monoxide yields of UK cigarettes manufactured since 1934. *Br. med. J.*, *282*, 763-765
- Wald, N.J., Idle, M., Boreham, J. & Bailey, A. (1981b) Carbon monoxide in breath in relation to smoking and carboxyhaemoglobin levels. *Thorax*, *36*, 366-369
- Wald, N.J., Idle, M., Boreham, J., Bailey, A. & Van Vunakis, H. (1982) Nicotine, carbon monoxide and heart disease. *Lancet*, *i*, 40-41
- Wald, N.J., Idle, M., Boreham, J. & Bailey, A. (1983) Inhaling and lung cancer: An anomaly explained. *Br. med. J.*, *287*, 1273-1275
- Wald, N.J., Boreham, J., Bailey, A., Ritchie, C., Haddow, J.E. & Knight, G. (1984a) Urinary cotinine as marker of breathing other people's tobacco smoke. *Lancet*, *i*, 230-231
- Wald, N.J., Boreham, J. & Bailey, A. (1984b) Relative intakes of tar, nicotine and carbon monoxide from cigarettes of different yields. *Thorax*, *39*, 361-364
- Walker, D., Wilton, L.V. & Binns, R. (1978a) Inhalation toxicity studies on cigarette smoke. VI. 6-Week comparative experiments using modified flue-cured cigarettes: Histopathology of the lung. *Toxicology*, *10*, 229-240
- Walker, D., Wilton, L.V. & Binns, R. (1978b) Inhalation toxicity studies on cigarette smoke. VII. 6-Week comparative experiments using modified flue-cured cigarettes: Histopathology of the conducting airways. *Toxicology*, *10*, 241-259
- Waltz, P., Häusermann, M. & Krull, A. (1965) Methods for quantitative determination of catechol in cigarette smoke (Ger.). *Beitr. Tabakforsch.*, *3*, 263-277
- Wanner, A. (1977) Clinical aspects of mucociliary transport. *Am. Rev. resp. Dis.*, *116*, 73-125
- Warner, K.E. (1978) Possible increases in the underreporting of cigarette consumption. *J. Am. stat. Soc.*, *73*, 314-318
- Warren, C.P.W., Holford-Strevens, V., Wong, C. & Manfreda, J. (1982) The relationship between smoking and total immunoglobulin E levels. *J. Allergy clin. Immunol.*, *69*, 370-375
- Wassink, W.F. (1948) Distribution of lung cancer by occupation (Dutch). *Ned. Tijdschr. Geneesk.*, *92*, 3732-3747
- Waterhouse, J., Muir, C., Correa, P. & Powell, J., eds (1976) *Cancer Incidence in Five Continents, Vol. III (IARC Scientific Publications No. 15)*, Lyon, International Agency for Research on Cancer

- Waterhouse, J., Muir, C., Shanmugaratnam, K. & Powell, J., eds (1982) *Cancer Incidence in Five Continents, Vol. IV (IARC Scientific Publications No. 42)*, Lyon, International Agency for Research on Cancer
- Weber, A. (1984) *Environmental tobacco smoke exposure: Acute effects — acceptance levels — Protective measures*. In: Berglund, B., Lindvall, T. & Sundell, J., eds, *Indoor Air, Vol. 2, Radon, Passive Smoking, Particulates and Housing Epidemiology*, Stockholm, Swedish Council for Building Research, pp. 297-301
- Weber, A. & Fischer, T. (1980) Passive smoking at work. *Int. Arch. occup. environ. Health*, **47**, 209-221
- Weber, K.H. (1976) *Recent changes in tobacco products and acceptance by the consumer*. In: *Proceedings of the 6th International Tobacco Science Congress, Tokyo, 14-20 November, 1976*, Tokyo, Japan Tobacco and Salt Public Corporation, pp. 47-63
- Weber-Tschopp, A., Fischer, T. & Grandjean, E. (1976) Physiological and psychological effects of passive smoking (Ger.). *Int. Arch. occup. environ. Health*, **37**, 277-288
- Wehner, A.P., Busch, R.H. & Olson, R.J. (1974) *Effect of chronic exposure to cigarette smoke on tumor incidence in the Syrian golden hamster*. In: Karbe, E. & Park, J.F., eds, *Experimental Lung Cancer. Carcinogenesis and Bioassays*, New York, Springer, pp. 360-368
- Wehner, A.P., Busch, R.H., Olson, R.J. & Craig, D.K. (1975a) Chronic inhalation of nickel oxide and cigarette smoke by hamsters. *Am. ind. Hyg. Assoc. J.*, **36**, 801-810
- Wehner, A.P., Busch, R.H., Olson, R.J. & Craig, D.K. (1975b) Chronic inhalation of asbestos and cigarette smoke by hamsters. *Environ. Res.*, **10**, 368-383
- Wehner, A.P., Olson, R.J. & Busch, R.H. (1976) Increased life span and decreased weight in hamsters exposed to cigarette smoke. *Arch. environ. Health*, **31**, 146-153
- Wehner, A.P., Dagle, G.E., Milliman, E.M., Phelps, D.W., Carr, D.B., Decker, J.R. & Filipy, R.E. (1981) Inhalation bioassay of cigarette smoke in rats. *Toxicol. appl. Pharmacol.*, **61**, 1-17
- Wehner, F.C., Van Rensburg, S.J. & Thiel, P.G. (1980) Mutagenicity of marijuana and Transkei tobacco smoke condensates in the *Salmonella*/microsome assay. *Mutat. Res.*, **77**, 135-142
- Weir, J.M. & Dunn, J.E., Jr (1970) Smoking and mortality: A prospective study. *Cancer*, **25**, 105-112
- Weiss, N.S., Farewell, V.T., Szekely, D.R., English, D.R. & Kiviat, N. (1980) Oestrogens and endometrial cancer: Effect of other risk factors on the association. *Maturitas*, **2**, 185-190
- Weiss, W., Boucot, K.R., Seidman, H. & Carnahan, W.J. (1972) Risk of lung cancer according to histologic type and cigarette dosage. *J. Am. med. Assoc.*, **222**, 799-801
- Welch, R.M., Loh, A. & Conney, A.H. (1971) Cigarette smoke: Stimulatory effect on metabolism of 3,4-benzopyrene by enzymes in rat lung. *Life Sci.*, **10**, 215-221
- White, R., White, J. & Janoff, A. (1979) Effects of cigarette smoke on elastase secretion by murine macrophages. *J. Lab. clin. Med.*, **94**, 489-499
- Whittemore, A.S. (1983) Estimating attributable risks from case-control studies. *Am. J. Epidemiol.*, **117**, 76-85
- Whittemore, A.S. & McMillan, A. (1983) Lung cancer mortality among US uranium miners: A reappraisal. *J. natl Cancer Inst.*, **71**, 489-499
- Whittemore, A.S., Paffenbarger, R.S., Jr, Anderson, K. & Halpern, J. (1983) Early precursors of pancreatic cancer in college men. *J. chron. Dis.*, **36**, 251-256

- WHO (1979) *Controlling the Smoking Epidemic (Tech. Rep. Ser. No. 636)*, Geneva
- WHO (1983) *Smoking Control Strategies in Developing Countries (Tech. Rep. Ser. No. 695)*, Geneva, p. 13
- Wigle, D.T., Mao, T. & Grace, M. (1980) Letter to the Editor. Re: Smoking and cancer of the uterine cervix: Hypothesis. *Am. J. Epidemiol.*, *111*, 125-127
- Wilkey, D.D., Lee, P.S., Hass, F.J., Gerrity, T.R., Yeates, D.B. & Lourenco, R.V. (1980) Mucociliary clearance of deposited particles from the human lung: Intra- and inter-subject reproductivity, total and regional lung clearance, and model comparisons. *Arch. environ. Health*, *35*, 294-302
- Williams, R.R. & Horm, J.W. (1977) Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: Interview study from the Third National Cancer Survey. *J. natl Cancer Inst.*, *58*, 525-547
- Williams, T.B. (1980) The determination of nitric oxide in gas phase cigarette smoke by non-disperse infrared analysis. *Beitr. Tabakforsch.*, *10*, 91-99
- Windholz, M. (1983) *Merck Index*, 10th ed., Rahway, NJ, Merck & Co., pp. 786, 1098
- Winkelstein, W., Jr, Sacks, S.T., Ernster, V.L. & Selvin, S. (1977) Correlations of incidence rates for selected cancers in the nine areas of the Third National Cancer Survey. *Am. J. Epidemiol.*, *105*, 407-419
- Winkelstein, W., Jr, Shillitoe, E.J., Brand, R. & Johnson, K.K. (1984) Further comments on cancer of the uterine cervix, smoking, and herpesvirus infection. *Am. J. Epidemiol.*, *119*, 1-8
- Wright, N.H., Vessey, M.P., Kenward, B., McPherson, K. & Doll, R. (1978) Neoplasia and dysplasia of the cervix uteri and contraception: A possible protective effect of the diaphragm. *Br. J. Cancer*, *38*, 273-279
- Wulf, H.C., Husum, B. & Niebuhr, E. (1983) Sister chromatid exchanges in smokers of high-tar cigarettes, low-tar cigarettes, cheroots and pipe tobacco. *Hereditas*, *98*, 225-228
- Wulf, H.C., Husum, B., Plesner, A.M. & Niebuhr, E. (1984) Distribution of SCEs in lymphocytes in persons with normal, slightly increased, and heavily increased SCEs. *Mutat. Res.*, *125*, 263-268
- Wynder, E.L. & Bross, I.J. (1961) A study of etiological factors in cancer of the oesophagus. *Cancer*, *14*, 389-413
- Wynder, E.L. & Goldsmith, R. (1977) The epidemiology of bladder cancer. A second look. *Cancer*, *40*, 1246-1268
- Wynder, E.L. & Graham, E.A. (1950) Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma. A study of six hundred and eighty-four proved cases. *J. Am. med. Assoc.*, *143*, 329-336
- Wynder, E.L. & Hoffmann, D. (1959) The carcinogenicity of benzofluoranthenes. *Cancer*, *12*, 1194-1199
- Wynder, E.L. & Hoffmann, D. (1960) Some practical aspects of the smoking-cancer problem. *New Engl. J. Med.*, *262*, 540-545
- Wynder, E.L. & Hoffmann, D. (1961a) Present status of laboratory studies on tobacco carcinogenesis. *Acta pathol. microbiol. scand.*, *52*, 119-132
- Wynder, E.L. & Hoffmann, D. (1961b) A study of tobacco carcinogenesis. VIII. The role of the acidic fractions as promoters. *Cancer*, *14*, 1306-1315

- Wynder, E.L. & Hoffmann, D. (1963) Experimental contribution to tobacco smoke carcinogenicity (Ger.). *Dtsch. med. Wochenschr.*, 88, 623-628
- Wynder, E.L. & Hoffmann, D. (1967) *Tobacco and Tobacco Smoke. Studies in Experimental Carcinogenesis*, New York, Academic Press
- Wynder, E.L. & Hoffmann, D. (1968) Experimental tobacco carcinogenesis. *Science*, 162, 862-871
- Wynder, E.L. & Hoffmann, D. (1969) A study of tobacco carcinogenesis. X. Tumor promoting activity. *Cancer*, 24, 289-301
- Wynder, E.L. & Hoffmann, D. (1979) Tobacco and health, a societal challenge. *New Engl. J. Med.*, 300, 894-903
- Wynder, E.L. & Hoffmann, D. (1982) *Tobacco*. In: Schottenfeld, D. & Fraumeni, J.F., Jr, eds, *Cancer Epidemiology and Prevention*, Philadelphia, W.B. Saunders, pp. 277-292
- Wynder, E.L. & Stellman, S.D. (1979) The impact of long-term filter cigarette usage on lung and larynx cancer risk: A case-control study. *J. natl Cancer Inst.*, 62, 471-477
- Wynder, E.L. & Wright, G. (1957) A study of tobacco carcinogenesis. I. The primary fractions. *Cancer*, 10, 255-271
- Wynder, E.L., Graham, E.A. & Croninger, A.B. (1953) Experimental production of carcinoma with cigarette tar. *Cancer Res.*, 13, 855-864
- Wynder, E.L., Gottlieb, S. & Wright, G. (1957a) A study of tobacco carcinogenesis. IV. Different tobacco types. *Cancer*, 10, 1206-1209
- Wynder, E.L., Bross, I.J. & Feldman, R.M. (1957b) A study of the etiological factors in cancer of the mouth. *Cancer*, 10, 1300-1323
- Wynder, E.L., Onderdonk, J. & Mantel, N. (1963a) An epidemiological investigation of cancer of the bladder. *Cancer*, 16, 1388-1407
- Wynder, E.L., Kmet, J., Dungal, N. & Segi, M. (1963b) An epidemiological investigation of gastric cancer. *Cancer*, 16, 1461-1496
- Wynder, E.L., Taguchi, K.T., Baden, V. & Hoffmann, D. (1968) Tobacco carcinogenesis. IX. Effect of cigarette smoke on respiratory tract of mice after passive inhalation. *Cancer*, 21, 134-153
- Wynder, E.L., Mabuchi, K. & Beattie, E.J., Jr (1970) The epidemiology of lung cancer. Recent trends. *J. Am. med. Assoc.*, 213, 2221-2228
- Wynder, E.L., Mabuchi, K., Maruchi, N. & Fortner, J.G. (1973) Epidemiology of cancer in the pancreas. *J. natl Cancer Inst.*, 50, 645-667
- Wynder, E.L., Mabuchi, K. & Whitmore, W.F., Jr (1974) Epidemiology of adenocarcinoma of the kidney. *J. natl Cancer Inst.*, 53, 1619-1634
- Wynder, E.L., Covey, L.S., Mabuchi, K. & Mushinski, M. (1976) Environmental factors in cancer of the larynx. A second look. *Cancer*, 38, 1591-1601
- Wynder, E.L., Hall, N.E.L. & Polansky, M. (1983) Epidemiology of coffee and pancreatic cancer. *Cancer Res.*, 43, 3900-3906
- Wyrobeck, A.J. (1982) *Sperm assays as indicators of chemically induced germ-cell damage in man*. In: Heddle, J.A., ed., *Mutagenicity: New Horizons in Genetic Toxicology*, New York, Academic Press, pp. 337-350
- Wyss, A., Virca, G.D. & Schnebli, H.P. (1984) Cigarette smoke components are not very effective in directly inactivating α_1 -proteinase inhibitor. *Hoppe-Seyler's Z. Physiol. Chem.*, 365, 511-516

- Yamasaki, E. & Ames, B.N. (1977) Concentration of mutagens from urine by adsorption with the nonpolar resin XAD-2: Cigarette smokers have mutagenic urine. *Proc. natl Acad. Sci. USA*, **74**, 3555-3559
- Yamasaki, H., Huberman, E. & Sachs, L. (1977) Metabolism of the carcinogenic hydrocarbon benzo(a)pyrene in human fibroblast and epithelial cells. II. Differences in metabolism to water-soluble products and aryl hydrocarbon hydroxylase activity. *Int. J. Cancer*, **19**, 378-382
- Yamasaki, Y. & Tomaru, K. (1976) Analytical method for captan residues in tobacco leaves and smoke condensate (Jpn.). *Sci. Papers central Res. Inst. Jpn Tob. Salt Corp.*, **118**, 17-24
- York, G.K., Peirce, T.H., Schwartz, L.W. & Cross, C.E. (1976) Stimulation by cigarette smoke of glutathione peroxidase system enzyme activities in rat lung. *Arch. environ. Health*, **31**, 286-290
- Yoshida, D. & Matsumoto, T. (1978) Changes in mutagenicity of protein pyrolyzates by reaction with nitrite. *Mutat. Res.*, **58**, 35-40
- Yoshida, D. & Matsumoto, T. (1980) Amino- α -carbolines as mutagenic agents in cigarette smoke condensate. *Cancer Lett.*, **10**, 141-149
- Yoshida, D., Matsumoto, T., Yoshimura, R. & Matsuzaki, T. (1978) Mutagenicity of amino- α -carbolines in pyrolysis products of soybean globulin. *Biochem. biophys. Res. Comm.*, **83**, 915-920
- Yu, M.C., Mack, T., Hanisch, R., Peters, R.L., Henderson, B.E. & Pike, M.C. (1983) Hepatitis, alcohol consumption, cigarette smoking, and hepatocellular carcinoma in Los Angeles. *Cancer Res.*, **43**, 6077-6079

APPENDICES

**Appendix 1. International tobacco sales
(millions of pieces), 1966-1983**

APPENDIX 1. INTERNATIONAL TOBACCO SALES

381

1974	1975	1976	1977	1978	1979	1980	1981	1982	1983
		8400	11 900	12 500					
33 450	38 200	37 000	36 900	36 900	38 200	38 300	35 200	32 400	35 000
29 800	31 300	30 900	32 000	32 800	32 800	34 100	34 300	34 200	33 400
14 400	14 000	14 400	14 700	15 100	15 700	15 500	15 700	15 500	
				13 545	14 796	15 115			
25 700	20 600	20 200	19 900	18 000	19 300	19 500	19 800		
9973	11 128		1333	1304	1257	1265	1155	600	
100 300	109 400	115 000	124 700	136 000	136 000	142 700	134 900	132 300	129 200
14 467	13 680		16 340	14 500	13 908	13 262	13 659		
57 100	57 000	60 700	61 800	62 600	63 900	64 500	66 500	66 300	62 800
							100		
9200									
	18 904	18 300	25 000	25 000	30	31	31	32	
2000	2200	2200	2300	2400	2400	2400	2100	2200	2200
			830	850	867	881	917	969	1082
22 200									
				56 700					
6700	7100	7500	7400	7300	7400	7200	7100	7800	7300
2830	3010	3190	3000	3220	3290	3410	3420	3400	3500
3570	3780	3653	3974	3946	4000	3700	4000	4600	
17 500	20 000	22 300	24 500	25 900	29 700			35 000	
2208	1980	2000	2513	2617	2606		2300	2300	2100
1500	1700	2000							
	469	513	536	535	561	551		550	530
7900	8100	6400	6600	6600	6900	7100	6600	6900	
80 492	82 100	81 200	83 800	82 500	87 900	84 500	85 400	86 400	
126 500	123 900	128 000	115 900	121 700	123 600	127 000	129 800	108 500	113 700
18 200	18 900	20 000	20 900	21 900	21 900	21 900	23 500		
				493					
2400	2300	2600	2700	2600	2500	2700	2200	2200	
	7648	7740	7933	7089	8315	9299	9514	8260	9300
22 900	24 500	24 600	24 900	25 600	25 600	26 400	26 100	26 100	26 500
	334						445	416	437

APPENDIX I. INTERNATIONAL TOBACCO SALES

383

1974	1975	1976	1977	1978	1979	1980	1981	1982	1983
60 800	66 100	66 000	69 000	74 100	79 900	77 300	87 700		
24 681	25 536	22 000(?)	21 300(?)	26 638	29 516	29 506	27 000	26 000	
	402	833							
29 022	29 261								
15 300	17 700	21 200	23 300		16 600				
	7000	7450							
	5200	5500	5500	5800	5700	5600	6000	6200	
87 500	88 700	89 700	90 300	88 800	96 800	98 700	100 900	101 600	102 000
	1490	1540	1480						
278 090	290 202	291 772	299 000	301 800	313 800	306 800	307 200	313 800	311 900
	1540	1850	2100	2200	2400				
	2400	2600	2700						
	3605	3800	3400						
	2945	4219	4199	3915	4027	4328			
							270		
	10 900	10 800	11 500	12 600	13 100	13 600	16 000	16 600	14 500
424	454	528	511	594	614	638	660	652	643
43 700	45 300	45 000	47 900	48 900	51 600	53 300	53 100	53 000	49 100
	7200	8200	9143	10 558	11 600				
		7761	1663	1332	1076	1105			
23 400	23 900	22 500	26 900	23 600	26 600	22 000	21 100	21 300	22 000
	5700	5900	6200	6200	6300				
			1838	1800	1500				1900
8455	13 000	14 800	16 000						
				7600	7700	7500	7200	6700	
1750	1685	1720	1957	1850	2000	2200	2000	1800	1800
29 200	25 521	29 000	29 170	31 000	32 000	32 000	35 800	35 500	
	1054	1080	957	1054	1049	1061	1038	993	1065
	9824								
					3600	3900	4000	4000	
44 700	45 000	49 600	51 000			58 800	59 900	60 200	60 100
80 483	85 025	88 052	90 677	91 442	92 966	94 245	89 021	91 376	83 741
11 052	12 043	11 834	12 504	12 537	12 300	12 300	13 200	13 500	13 700
			3800	3700	3600	3600	3600	3600	3500

APPENDIX 1. INTERNATIONAL TOBACCO SALES

1974	1975	1976	1977	1978	1979	1980	1981	1982	1983
51 318				64 071	66 480	69 759		74 000	74 700
2700	3900	5200	6700						
3300	3200	3200	3000	3400	3500	2800	3900	4100	4200
59 214	58 100	63 100	66 800	63 400	70 600	70 400	64 200	68 700	75 400
1393	1615	1727	1871	2271	2338				
11 100	11 700	12 000	9800	10 050	11 900	11 900	11 500	12 100	
17 600	15 500	15 300	15 900	15 400	15 000			16 000	16 300
	20 700	21 813		24 084	25 584	25 532			
20 500	22 700	24 400	23 400	24 100	27 500				
4080									
				56 884	67 905	62 000	74 000	78 000	
			1850	1900	715	611			
137 000	132 600	130 600	125 300	125 200	123 300	120 800	110 300	102 000	101 600
					3600	4163	3223		
								4000	3900
591 840	599 410	603 530	603 800	605 000	612 000	618 570	627 150	624 010	596 190
16 000	16 700	18 500	20 100	20 600	21 100	20 600	20 600	20 100	20 800
	4595	3348	6000	3600		2700	3000	3100	
								255	

^aFrom Maxwell (1976-1984)

^bOutput

^cConsumption

^dIncludes Luxembourg

^eFigure unverified

^fForeign brands

^gDomestic product (separate figures not given after 1976)

^hImported products

ⁱKretek

^jProduction

^kFigures prior to 1971 are from east and west Pakistan; figures for Bangladesh are given only from 1971

Appendix 2. Chemical compounds identified in tobacco smoke that have been evaluated for carcinogenicity in the *IARC Monographs* series

Many individual components of tobacco smoke appear to be carcinogenic in bioassays with laboratory animals. Compounds found in cigarette smoke that show *sufficient evidence* of carcinogenicity in experimental animals according to the IARC criteria include one monocyclic aromatic hydrocarbon, 12 polycyclic aromatic hydrocarbons, two aldehydes (acetaldehyde and formaldehyde), 10 *N*-nitroso compounds, four polycyclic aza-arenes, nine miscellaneous nitrogen compounds, one halogen compound, three inorganic elements and the agricultural chemical, DDT. Some of these compounds are also carcinogenic or suspected to be carcinogenic in humans.

Appendix 2. Chemical compounds identified in tobacco smoke that have been evaluated for carcinogenicity in the IARC Monographs series

Compound ^a	Degree of evidence in animals (and humans)	Reference ^b
<i>1. Aliphatic hydrocarbons</i>		
ethylene* (200-400) (4)	No data on carcinogenicity	Vol. 19, pp. 157-186
propylene* (50-100) (4)	No data on carcinogenicity	Vol. 19, pp. 213-230
<i>2. Aromatic hydrocarbons</i>		
<i>Monocyclic aromatic hydrocarbons</i>		
benzene* (12-48) (3)	Sufficient evidence in animals with new data from US National Toxicology Program (sufficient evidence in humans)	Vol. 7, pp. 203-221; Suppl. 1, p. 25; Vol. 29, pp. 93-148, 391-397; Suppl. 4, p. 56
styrene (10)	Limited evidence animals (inadequate evidence in humans)	Vol. 19, pp. 231-274; Suppl. 4, pp. 229-233
<i>Di- and polycyclic aromatic hydrocarbons</i>		
anthanthrene* (0.002-0.02) (3)	Limited evidence	Vol. 32, pp. 95-104
anthracene (0.023-0.23) (3)	No evidence	Vol. 32, pp. 105-121
benz[<i>a</i>]anthracene (0.04-0.07)	Sufficient evidence	Vol. 3, pp. 45-48; Vol. 32, pp. 135-145
benzo[<i>b</i>]fluoranthene* (0.03) (1)	Sufficient evidence	Vol. 3, pp. 69-81; Vol. 32, pp. 147-153
benzo[<i>j</i>]fluoranthene* (0.06) (1)	Sufficient evidence, initiating activity	Vol. 3, pp. 82-90; Vol. 32, pp. 155-161
benzo[<i>k</i>]fluoranthene (0.006-0.012) (3)	Sufficient evidence, initiating activity	Vol. 32, pp. 163-170
benzo[<i>ghi</i>]fluoranthene (0.001-0.004) (3)	Inadequate evidence	Vol. 32, pp. 171-175
benzo[<i>a</i>]fluorene (0.049-0.18) (3)	Inadequate evidence	Vol. 32, pp. 177-182
benzo[<i>b</i>]fluorene (0.02) (3)	Inadequate evidence	Vol. 32, pp. 183-187
benzo[<i>c</i>]fluorene (3)	Inadequate evidence	Vol. 32, pp. 189-193
benzo[<i>ghi</i>]perylene* (0.06) (1)	Inadequate evidence, cocarcinogenic activity	Vol. 32, pp. 195-204
benzo[<i>c</i>]phenanthrene (3)	Inadequate evidence, initiating activity	Vol. 32, pp. 205-209

Appendix 2. (contd)

Compound ^a	Degree of evidence in animals (and humans)	Reference ^b
<i>Di-, and polycyclic aromatic hydrocarbons (contd)</i>		
benzo[<i>a</i>]pyrene* (0.01-0.05) (1)	Sufficient evidence, initiating activity	Vol. 3, pp. 91-136; Vol. 32, pp. 211-224; Suppl. 4, pp. 227-228
benzo[<i>e</i>]pyrene* (0.002-0.03) (3)	Inadequate evidence, initiator(?), promoting activity	Vol. 3, pp. 137-158; Vol. 32, pp. 225-237
chrysene* (0.04-0.06) (1)	Limited evidence, initiating activity, enhancing activity when administered simultaneously with <i>n</i> -dodecane	Vol. 3, pp. 159-177; Vol. 32, pp. 247-261
coronene (0.001) (3)	Inadequate evidence, initiating activity	Vol. 32, pp. 263-268
dibenz[<i>a,c</i>]anthracene* (3)	Limited evidence, initiating activity	Vol. 32, pp. 289-297
dibenz[<i>a,h</i>]anthracene* (1)	Sufficient evidence	Vol. 3, pp. 178-196; Vol. 32, pp. 299-308
dibenz[<i>a,f</i>]anthracene* (0.01) (3)	Limited evidence	Vol. 32, pp. 309-313
dibenzo[<i>a,e</i>]fluoranthene (5)	Limited evidence, initiating activity	Vol. 32, pp. 321-325
dibenzo[<i>a,e</i>]pyrene (3)	Sufficient evidence	Vol. 3, pp. 201-206; Vol. 32, pp. 327-330
dibenzo[<i>a,h</i>]pyrene (3)	Sufficient evidence	Vol. 3, pp. 207-214; Vol. 32, pp. 331-335
dibenzo[<i>a,i</i>]pyrene (0.002-0.003) (3)	Sufficient evidence	Vol. 3, pp. 215-223; Vol. 32, pp. 337-342
dibenzo[<i>a,l</i>]pyrene (3)	Sufficient evidence	Vol. 3, pp. 224-228; Vol. 32, pp. 343-347
1,4-dimethylphenanthrene (3)	Inadequate evidence, initiating activity	Vol. 32, pp. 349-353
fluoranthene* (0.1-0.26) (1)	No evidence, cocarcinogenic activity	Vol. 32, pp. 355-364
fluorene* (3)	Inadequate evidence	Vol. 32, pp. 365-371
indeno[1,2,3- <i>cd</i>]pyrene (0.004-0.02) (3)	Sufficient evidence	Vol. 3, pp. 229-237; Vol. 32, pp. 373-379
1-methylchrysene (0.003) (3)	Inadequate evidence, initiating activity	Vol. 32, pp. 379-397
2-methylchrysene (0.001) (3)	Limited evidence, initiating activity	Vol. 32, pp. 379-397
3-methylchrysene (0.006) (3)	Limited evidence, initiating activity	Vol. 32, pp. 379-397
4-methylchrysene (3)	Limited evidence, initiating activity	Vol. 32, pp. 379-397
5-methylchrysene* (0.0006) (1)	Sufficient evidence, initiating activity	Vol. 32, pp. 379-397
6-methylchrysene (0.007) (3)	Limited evidence, initiating activity	Vol. 32, pp. 379-397
2-methylfluoranthene (3)	Limited evidence, initiating activity	Vol. 32, pp. 399-404
3-methylfluoranthene (3)	Inadequate evidence	Vol. 32, pp. 399-404

Appendix 2. (contd)

Compound ^a	Degree of evidence in animals (and humans)	Reference ^b
<i>Di- and polycyclic aromatic hydrocarbons (contd)</i>		
1-methylphenanthrene (0.03) (3)	Inadequate evidence	Vol. 32, pp. 405-409
perylene* (0.003-0.005) (3)	Inadequate evidence	Vol. 32, pp. 411-418
phenanthrene (0.09- 0.6) (3)	Inadequate evidence	Vol. 32, pp. 419-430
pyrene* (0.05-0.2) (1)	No evidence, cocarcinogenic activity	Vol. 32, pp. 431-445
triphenylene* (3)	Inadequate evidence	Vol. 32, pp. 447-451
<i>3. Phenols and phenol ethers</i>		
catechol (40-350) (1)	Inadequate evidence, cocarcinogenic activity	Vol. 15, pp. 155-175
eugenol (2-4) (3)	Limited evidence	Vol. 36, pp. 75-97
hydroquinone* (88-155) (3)	Inadequate evidence	Vol. 15, pp. 155-175
resorcinol* (8-80) (3)	Inadequate evidence	Vol. 15, pp. 155-175
cholesterol (22) (3)	No evaluation in animals (limited evidence in humans)	Vol. 10, pp. 99-111; vol. 31, pp. 95-132
<i>4. Aldehydes</i>		
acetaldehyde* (18-1400) (2)	Sufficient evidence, cocarcinogenic activity	Vol. 36, pp. 101-132
acrolein* (25-140) (2)	Inadequate evidence	Vol. 19, pp. 479-494; Vol. 36, pp. 133-161
formaldehyde* (20-88) (1)	Sufficient evidence	Vol. 29, pp. 345-389; Suppl. 4, pp. 131-132
<i>5. Lactones</i>		
coumarin* (4)	Limited evidence	Vol. 10, pp. 113-119
γ -butyrolactone* (10) (3)	No evidence	Vol. 11, pp. 231-240
<i>6. Nitrogen compounds</i>		
<i>N-Nitroso compounds</i>		
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (0.08-0.7) (3)	Sufficient evidence	Vol. 37, pp. 209-223
N'-nitrosoanabasine (0-0.2) (3)	Limited evidence	Vol. 37, pp. 225-231
N'-nitrosoanatabine (0-3.7) (1)	Inadequate evidence	Vol. 37, pp. 233-240

Appendix 2 (contd)

Compound ^a	Degree of evidence in animals (and humans)	Reference ^b
<i>N-nitroso compounds (contd)</i>		
<i>N</i> -nitrosodimethylamine* (0.001-0.2) (1)	Sufficient evidence	Vol. 1, pp. 95-106; Vol. 17, pp. 125-175
<i>N</i> -nitrosodiethylamine* (0-0.01) (1)	Sufficient evidence	Vol. 1, pp. 107-124; Vol. 17, pp. 83-124
<i>N</i> -Nitroso- <i>N</i> -methylethylamine (0.0001-0.01) (1)	Sufficient evidence	Vol. 17, pp. 221-226
<i>N</i> -nitrosornicotine (0.13-0.25) (1)	Sufficient evidence	Vol. 17, pp. 281-286; Vol. 37, pp. 241-261
<i>N</i> -nitrosodiethanolamine (0-0.09) (3)	Sufficient evidence	Vol. 17, pp. 77-82
<i>N</i> -nitrosopyrrolidine* (0.002-0.042) (1)	Sufficient evidence	Vol. 17, pp. 313-326
<i>N</i> -nitrosopiperidine (0-0.009) (1)	Sufficient evidence	Vol. 17, pp. 287-301
<i>N</i> -nitrosodi- <i>n</i> -butylamine* (0-0.003) (1)	Sufficient evidence	Vol. 4, pp. 197-210; Vol. 17, pp. 51-75
<i>N</i> -nitrosodi- <i>n</i> -propylamine* (0-0.001) (3)	Sufficient evidence	Vol. 17, pp. 177-189
<i>Polycyclic aza-arenes</i>		
carbazole* (1) (3)	Limited evidence	Vol. 32, pp. 239-245
dibenz[<i>a,h</i>]acridine (0.0001) (3)	Sufficient evidence	Vol. 3, pp. 247-253; Vol. 32, pp. 277-281
dibenz[<i>a,j</i>]acridine (0.003-0.010) (3)	Sufficient evidence	Vol. 3, pp. 254-259; Vol. 32, pp. 283-288
7 <i>H</i> -dibenzo[<i>c,g</i>]carbazole (0.0007) (3)	Sufficient evidence	Vol. 3, pp. 260-268; Vol. 32, pp. 315-319
benz[<i>a</i>]acridine (3)	Inadequate evidence	Vol. 32, pp. 123-127
benz[<i>c</i>]acridine (3)	Limited evidence	Vol. 3, pp. 241-246; Vol. 32, pp. 129-134
<i>Miscellaneous nitrogen compounds</i>		
acetamide* (38-56) (3)	Limited evidence	Vol. 7, pp. 197-202
acrylonitrile* (3.2-15) (1)	Sufficient evidence (limited evidence in humans)	Vol. 19, pp. 73-113; Suppl. 4, pp. 25-27
4-aminobiphenyl* (0.002-0.005) (3)	Sufficient evidence (sufficient evidence in humans)	Vol. 1, pp. 74-79; Suppl. 4, pp. 37-38
aniline* (0.1-0.4) (3)	Limited evidence	Vol. 4, pp. 27-39; Vol. 27, pp. 39-61

Appendix 2 (contd)

Compound ^a	Degree of evidence in animals (and humans)	Reference ^b
<i>Miscellaneous nitrogen compounds</i> (contd)		
<i>ortho</i> -anisidine hydrazine* (0.024-0.043) (1)	Sufficient evidence Sufficient evidence (inadequate evidence in humans)	Vol. 27, pp. 63-80 Vol. 4, pp. 127-136; Suppl. 4, pp. 136-138
1,1-dimethylhydrazine* 1-naphthylamine (0.003-0.004) (1)	Sufficient evidence Inadequate evidence (inadequate evidence in humans)	Vol. 4, pp. 137-143 Vol. 4, pp. 87-96; Suppl. 4, pp. 164-165
2-naphthylamine (0.001-0.022) (1)	Sufficient evidence in animals (sufficient evidence in humans)	Vol. 4, pp. 97-111; Suppl. 4, pp. 166-167
2-nitropropane (0.73-1.21) (1)	Sufficient evidence	Vol. 29, pp. 331-343
<i>ortho</i> -toluidine* (0.03-0.2) (3)	Sufficient evidence (inadequate evidence in humans)	Vol. 16, pp. 349-366; Vol. 27, pp. 155-175; Suppl. 4, pp. 245-246
urethane* (0.020-0.038) (1)	Sufficient evidence, initiating and cocarcinogenic activity	Vol. 7, pp. 111-140
<i>N</i> -phenyl-2-naphthylamine* (3)	Inadequate evidence (inadequate evidence in humans)	Vol. 16, pp. 325-341; Suppl. 4, pp. 213-215
<i>7. Agricultural chemicals and derivatives</i>		
captan* (0.4-34) (3)	Limited evidence	Vol. 30, pp. 295-318
DDT* (0.7-1.2) (3)	Sufficient evidence, cocarcinogenic activity	Vol. 5, pp. 83-124; Suppl. 4, pp. 105-108
endrin (3)	Inadequate evidence	Vol. 5, pp. 157-166
malathion (3)	No evidence	Vol. 30, pp. 103-129
maleic hydrazide (0.1-2.1) (3)	Inadequate evidence	Vol. 4, pp. 173-179
succinic anhydride* (3)	Limited evidence	Vol. 15, pp. 265-271
<i>8. Halogen compounds</i>		
vinyl chloride* (0.001-0.016) (1)	Sufficient evidence (sufficient evidence in humans)	Vol. 7, pp. 291-318; Vol. 19, pp. 377-438; Suppl. 4, pp. 260-262

Appendix 2. (contd)

Compound ^a	Degree of evidence in animals (and humans)	Reference ^b
9. Inorganic elements		
arsenic* (1-25) (2)	Inadequate evidence (sufficient evidence in humans)	Vol. 1, p. 41; Vol. 2, pp. 48-73; Vol. 23, pp. 39-141; Suppl. 4, pp. 50-51
cadmium* (0.009-0.07) (1)	Sufficient evidence (limited evidence in humans)	Vol. 2, pp. 74-99; Vol. 11, pp. 39-74; Suppl. 4, pp. 71-73
chromium VI* (0.004-0.07) (3)	Sufficient evidence (sufficient evidence in humans)	Vol. 2, pp. 100-125; Vol. 23, pp. 205-323; Suppl. 4, pp. 91-93
nickel* (0-0.6) (1)	Sufficient evidence (limited evidence in humans)	Vol. 2, pp. 126-149; Vol. 11, pp. 75-112; Suppl. 4, pp. 167-170
lead (3)	Sufficient (inadequate evidence in humans)	Vol. 1, pp. 40-50; vol. 2, p. 52; vol. 23, pp. 40, 209, 325-415; Suppl. 4, pp. 149-150
selenium	Inadequate evidence	Vol. 9, pp. 245-260
10. Miscellaneous		
methyl acrylate (3)	Inadequate evidence	Vol. 19, p. 52; Vol. 39 (in press)

^aIn parentheses: concentration expressed as μg in the mainstream smoke of one cigarette; exceptionally, as $\mu\text{g/g}$ tobacco smoked. Second parentheses refer to the following references:

- (1) Wynder & Hoffmann (1982)
- (2) Wynder & Hoffmann (1979)
- (3) See *Monographs* volume(s) referenced
- (4) Wynder & Hoffmann (1967)
- (5) IARC (1983a)

^b*IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans*, Volumes 1-39 and Supplement 4

*Animal studies in progress or recently completed (*Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity*, No. 11, Lyon, IARC)

SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-37

Corrigenda covering volumes 1-6 appeared in Volume 7; others appeared in Volumes 8, 10-13 and 15-37.

Volume 36

- | | | |
|--------|---------------------------------|--|
| p. 24 | 4th para,
line 4 | <i>replace 00 and 00 by 15-16 and 19</i> |
| p. 283 | 1st para,
lines 10
and 11 | <i>should read [the inci]dences of squamous-cell carcinomas of the forestomach were 2/50 in the low-dose group and 19/50 in the high-dose group; one animal in the high-dose group had an adenocarcinoma of</i> |

**CUMULATIVE INDEX TO IARC MONOGRAPHS
ON THE EVALUATION OF THE CARCINOGENIC RISK
OF CHEMICALS TO HUMANS**

Numbers in italics indicate volume, and other numbers indicate page. References to corrigenda are given in parentheses. Compounds marked with an asterisk(*) were considered by the working groups in the year indicated, but monographs were not prepared because adequate data on carcinogenicity were not available.

A

Acetaldehyde	36, 101
Acetaldehyde formylmethylhydrazone	31, 163
Acetamide	7, 197
Acetylsalicylic acid (1976)*	
Acridine orange	16, 145
Acriflavinium chloride	13, 31
Acrolein	19, 479
	36, 133
Acrylic acid	19, 47
Acrylic fibres	19, 86
Acrylonitrile	19, 73
	<i>Suppl. 4, 25</i>
Acrylonitrile-butadiene-styrene copolymers	19, 9
Actinomycins	10, 29 (corr. 29, 399; 34, 197)
Adipic acid (1978)*	
Adriamycin	10, 43
	<i>Suppl. 4, 29</i>
AF-2	31, 47
Aflatoxins	1, 145 (corr. 7, 319; 8, 349)
	10, 51
	<i>Suppl. 4, 31</i>
Agaritrine	31, 63

Aldrin	5, 25 <i>Suppl. 4, 35</i>
Allyl chloride	36, 39
Allyl isothiocyanate	36, 55
Allyl isovalerate	36, 69
Aluminium production	34, 37
Amaranth	8, 41
5-Aminoacenaphthene	16, 243
2-Aminoanthraquinone	27, 191
<i>para</i> -Aminoazobenzene	8, 53
<i>ortho</i> -Aminoazotoluene	8, 61 (corr. 11, 295)
<i>para</i> -Aminobenzoic acid	16, 249
4-Aminobiphenyl	1, 74 (corr. 10, 343) <i>Suppl. 4, 37</i>
3-Amino-1,4-dimethyl-5 <i>H</i> -pyrido-[4,3- <i>b</i>]indole and its acetate	31, 247
1-Amino-2-methylanthraquinone	27, 199
3-Amino-1-methyl-5 <i>H</i> -pyrido[4,3- <i>b</i>]indole and its acetate	31, 255
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole	7, 143
4-Amino-2-nitrophenol	16, 43
2-Amino-4-nitrophenol (1977)*	
2-Amino-5-nitrophenol (1977)*	
2-Amino-5-nitrothiazole	31, 71
6-Aminopenicillanic acid (1975)*	
Amitrole	7, 31 <i>Suppl. 4, 38</i>
Amobarbital sodium (1976)*	
Anaesthetics, volatile	11, 285 <i>Suppl. 4, 41</i>
Aniline	4, 27 (corr. 7, 320) 27, 39 <i>Suppl. 4, 49</i>
Aniline hydrochloride	27, 40
<i>ortho</i> -Anisidine and its hydrochloride	27, 63
<i>para</i> -Anisidine and its hydrochloride	27, 65
Anthanthrene	32, 95
Anthracene	32, 105
Anthranilic acid	16, 265
Apholate	9, 31
Aramite®	5, 39

- Arsenic and arsenic compounds 1, 41
 Arsanilic acid 2, 48
 Arsenic pentoxide 23, 39
 Arsenic sulphide *Suppl.* 4, 50
 Arsenic trioxide
 Arsine
 Calcium arsenate
 Dimethylarsinic acid
 Lead arsenate
 Methanearsonic acid, disodium salt
 Methanearsonic acid, monosodium salt
 Potassium arsenate
 Potassium arsenite
 Sodium arsenate
 Sodium arsenite
 Sodium cacodylate
- Asbestos 2, 17 (corr. 7, 319)
 Actinolite 14 (corr. 15, 341; 17, 351)
 Amosite *Suppl.* 4, 52
 Anthophyllite
 Chrysotile
 Crocidolite
 Tremolite
- Asiaticoside (1975)*
Auramine 1, 69 (corr. 7, 319)
 Suppl. 4, 53 (corr. 33, 223)
- Aurothioglucose 13, 39
5-Azacytidine 26, 37
Azaserine 10, 73 (corr. 12, 271)
Azathioprine 26, 47
 Suppl. 4, 55
- Aziridine 9, 37
2-(1-Aziridinyl)ethanol 9, 47
Aziridyl benzoquinone 9, 51
Azobenzene 8, 75
- B**
- Benz[*a*]acridine 32, 123
Benz[*c*]acridine 3, 241
 32, 129
Benzal chloride 29, 65
 Suppl. 4, 84
Benz[*a*]anthracene 3, 45
 32, 135

Benzene	7, 203 (corr. 11, 295) 29, 93, 391 <i>Suppl. 4</i> , 56 (corr. 35, 249)
Benzidine and its salts	1, 80 29, 149, 391 <i>Suppl. 4</i> , 57
Benzo[<i>b</i>]fluoranthene	3, 69 32, 147
Benzo[<i>j</i>]fluoranthene	3, 82 32, 155
Benzo[<i>k</i>]fluoranthene	32, 163
Benzo[<i>ghi</i>]fluoranthene	32, 171
Benzo[<i>a</i>]fluorene	32, 177
Benzo[<i>b</i>]fluorene	32, 183
Benzo[<i>c</i>]fluorene	32, 189
Benzo[<i>ghi</i>]perylene	32, 195
Benzo[<i>c</i>]phenanthrene	32, 205
Benzo[<i>a</i>]pyrene	3, 91 <i>Suppl. 4</i> , 227 32, 211
Benzo[<i>e</i>]pyrene	3, 137 32, 225
<i>para</i> -Benzoquinone dioxime	29, 185
Benzotrichloride	29, 73 <i>Suppl. 4</i> , 84
Benzoyl peroxide	36, 267
Benzoyl chloride	29, 83 <i>Suppl. 4</i> , 84
Benzyl chloride	11, 217 (corr. 13, 243) 29, 49 (corr. 30, 407) <i>Suppl. 4</i> , 84
Benzyl violet 4B	16, 153
Beryllium and beryllium compounds	1, 17
Bertrandite	23, 143 (corr. 25, 392)
Beryllium acetate	<i>Suppl. 4</i> , 60
Beryllium acetate, basic	
Beryllium-aluminium alloy	
Beryllium carbonate	
Beryllium chloride	
Beryllium-copper alloy	
Beryllium-copper-cobalt alloy	
Beryllium fluoride	
Beryllium hydroxide	
Beryllium-nickel alloy	
Beryllium oxide	
Beryllium phosphate	
Beryllium silicate	
Beryllium sulphate and its tetrahydrate	
Beryl ore	
Zinc beryllium sulphate	

- Betel-quid and areca-nut chewing 37, 141
 Bis(1-aziridinyl)morpholinophosphine sulphide 9, 55
 Bis(2-chloroethyl)ether 9, 117
N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine) 4, 119 (corr. 30, 407)
 Suppl. 4, 62
 Bischloroethyl nitrosourea (BCNU) 26, 79
 Suppl. 4, 63
 Bis-(2-chloroisopropyl)ether (1976)*
 1,2-Bis(chloromethoxy)ethane 15, 31
 1,4-Bis(chloromethoxymethyl)benzene 15, 37
 Bis(chloromethyl)ether 4, 231 (corr. 13, 243)
 Suppl. 4, 64
 Bitumens 35, 39
 Bleomycins 26, 97
 Suppl. 4, 66
 Blue VRS 16, 163
 Boot and shoe manufacture and repair 25, 249
 Suppl. 4, 138
 Brilliant blue FCF diammonium and disodium salts 16, 171 (corr. 30, 407)
 1,4-Butanediol dimethanesulphonate (Myleran) 4, 247
 Suppl. 4, 68
 Butyl benzyl phthalate 29, 194 (corr. 32, 455)
 Butyl-*cis*-9,10-epoxystearate (1976)*
 β -Butyrolactone 11, 225
 γ -Butyrolactone 11, 231
- C
- Cadmium and cadmium compounds 2, 74
 Cadmium acetate 11, 39 (corr. 27, 320)
 Cadmium chloride *Suppl.* 4, 71
 Cadmium oxide
 Cadmium sulphate
 Cadmium sulphide
 Calcium cyclamate 22, 58 (corr. 25, 391)
 Suppl. 4, 97
 Calcium saccharin 22, 120 (corr. 25, 391)
 Suppl. 4, 225
 Cantharidin 10, 79
 Caprolactam 19, 115 (corr. 31, 293)
 Captan 30, 295
 Carbaryl 12, 37
 Carbazole 32, 239

Carbon blacks	3, 22 33, 35
Carbon tetrachloride	1, 53 20, 371 <i>Suppl. 4, 74</i>
Carmoisine	8, 83
Carpentry and joinery	25, 139 <i>Suppl. 4, 139</i>
Carrageenan	10, 181 (corr. 11, 295) 31, 79
Catechol	15, 155
Chloramben (1982)*	
Chlorambucil	9, 125 26, 115 <i>Suppl. 4, 77</i>
Chloramphenicol	10, 85 <i>Suppl. 4, 79</i>
Chlordane	20, 45 (corr. 25, 391) <i>Suppl. 4, 80</i>
Chlordecone (Kepone)	20, 67
Chlordimeform	30, 61
Chlorinated dibenzodioxins	15, 41 <i>Suppl. 4, 211, 238</i>
Chlormadinone acetate	6, 149 21, 365 <i>Suppl. 4, 192</i>
Chlorobenzilate	5, 75 30, 73
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)	26, 173 (corr. 35, 249) <i>Suppl. 4, 83</i>
Chloroform	1, 61 20, 401 <i>Suppl. 4, 87</i>
Chloromethyl methyl ether	4, 239 <i>Suppl. 4, 64</i>
4-Chloro- <i>ortho</i> -phenylenediamine	27, 81
4-Chloro- <i>meta</i> -phenylenediamine	27, 82
Chloroprene	19, 131 <i>Suppl. 4, 89</i>
Chloropropham	12, 55
Chloroquine	13, 47
Chlorothalonil	30, 319
<i>para</i> -Chloro- <i>ortho</i> -toluidine and its hydrochloride	16, 277 30, 61

5-Chloro- <i>ortho</i> -toluidine (1977)*	
Chlorotrianisene	21, 139
Chlorpromazine (1976)*	
Cholesterol	10, 99
	31, 95
Chromium and chromium compounds	2, 100
Barium chromate	23, 205
Basic chromic sulphate	<i>Suppl. 4, 91</i>
Calcium chromate	
Chromic acetate	
Chromic chloride	
Chromic oxide	
Chromic phosphate	
Chromite ore	
Chromium carbonyl	
Chromium potassium sulphate	
Chromium sulphate	
Chromium trioxide	
Cobalt-chromium alloy	
Ferrochromium	
Lead chromate	
Lead chromate oxide	
Potassium chromate	
Potassium dichromate	
Sodium chromate	
Sodium dichromate	
Strontium chromate	
Zinc chromate	
Zinc chromate hydroxide	
Zinc potassium chromate	
Zinc yellow	
Chrysene	3, 159
	32, 247
Chrysoidine	8, 91
C.I. Disperse Yellow 3	8, 97
Cinnamyl anthranilate	16, 287
	31, 133
Cisplatin	26, 151
	<i>Suppl. 4, 93</i>
Citrus Red No. 2	8, 101 (corr. 19, 495)
Clofibrate	24, 39
	<i>Suppl. 4, 95</i>

Clomiphene and its citrate	21, 551 <i>Suppl. 4, 96</i>
Coal gasification	34, 65
Coal-tars and derived products	35, 83
Coke production	34, 101
Conjugated oestrogens	21, 147 <i>Suppl. 4, 179</i>
Copper 8-hydroxyquinoline	15, 103
Coronene	32, 263
Coumarin	10, 113
<i>meta</i> -Cresidine	27, 91
<i>para</i> -Cresidine	27, 92
Cycasin	1, 157 (corr. 7, 319) 10, 121
Cyclamic acid	22, 55 (corr. 25, 391)
Cyclochlorotine	10, 139
Cyclohexylamine	22, 59 (corr. 25, 391) <i>Suppl. 4, 97</i>
Cyclopenta[<i>cd</i>]pyrene	32, 269
Cyclophosphamide	9, 135 26, 165 <i>Suppl. 4, 99</i>
D	
2,4-D and esters	15, 111 <i>Suppl. 4, 101, 211</i>
Dacarbazine	26, 203 <i>Suppl. 4, 103</i>
D and C Red No. 9	8, 107
Dapsone	24, 59 <i>Suppl. 4, 104</i>
Daunomycin	10, 145
DDT and associated substances	5, 83 (corr. 7, 320)
DDD (TDE)	<i>Suppl. 4, 105</i>
DDE	
Diacetylaminoazotoluene	8, 113
<i>N,N'</i> -Diacetylbenzidine	16, 293
Diallate	12, 69 30, 235
2,4-Diaminoanisole and its sulphate	16, 51 27, 103
2,5-Diaminoanisole (1977)*	

4,4'-Diaminodiphenyl ether	16, 301 29, 203
1,2-Diamino-4-nitrobenzene	16, 63
1,4-Diamino-2-nitrobenzene	16, 73
2,4-Diaminotoluene	16, 83
2,5-Diaminotoluene and its sulphate	16, 97
Diazepam	13, 57
Diazomethane	7, 223
Dibenz[<i>a,h</i>]acridine	3, 247 32, 277
Dibenz[<i>a,j</i>]acridine	3, 254 32, 283
Dibenz[<i>a,c</i>]anthracene	32, 289 (corr. 34, 197)
Dibenz[<i>a,h</i>]anthracene	3, 178 32, 299
Dibenz[<i>a,j</i>]anthracene	32, 309
7 <i>H</i> -Dibenzo[<i>c,g</i>]carbazole	3, 260 32, 315
Dibenzo[<i>a,e</i>]fluoranthene	32, 321
Dibenzo[<i>h,rst</i>]pentaphene	3, 197
Dibenzo[<i>a,e</i>]pyrene	3, 201 32, 327
Dibenzo[<i>a,h</i>]pyrene	3, 207 32, 331
Dibenzo[<i>a,i</i>]pyrene	3, 215 32, 337
Dibenzo[<i>a,l</i>]pyrene	3, 224 32, 343
1,2-Dibromo-3-chloropropane	15, 139 20, 83
<i>ortho</i> -Dichlorobenzene	7, 231 29, 213 <i>Suppl.</i> 4, 108
<i>para</i> -Dichlorobenzene	7, 231 29, 215 <i>Suppl.</i> 4, 108
3,3'-Dichlorobenzidine and its dihydrochloride	4, 49 29, 239 <i>Suppl.</i> 4, 110
<i>trans</i> -1,4-Dichlorobutene	15, 149
3,3'-Dichloro-4,4'-diaminodiphenyl ether	16, 309
1,2-Dichloroethane	20, 429

Dichloromethane	20, 449 <i>Suppl. 4</i> , 111
Dichlorvos	20, 97
Dicofol	30, 87
Dicyclohexylamine	22, 60 (corr. 25, 391)
Dieldrin	5, 125 <i>Suppl. 4</i> , 112
Dienoestrol	21, 161 <i>Suppl. 4</i> , 183
Diepoxybutane	11, 115 (corr. 12, 271)
Di-(2-ethylhexyl)adipate	29, 257
Di-(2-ethylhexyl)phthalate	29, 269 (corr. 32, 455)
1,2-Diethylhydrazine	4, 153
Diethylstilboestrol	6, 55 21, 172 (corr. 23, 417) <i>Suppl. 4</i> , 184
Diethylstilboestrol dipropionate	21, 175
Diethyl sulphate	4, 277 <i>Suppl. 4</i> , 115
Diglycidyl resorcinol ether	11, 125 36, 181
Dihydrosafrole	1, 170 10, 233
Dihydroxybenzenes	15, 155
Dihydroxymethylfuratrizine	24, 77
Dimethisterone	6, 167 21, 377 <i>Suppl. 4</i> , 193
Dimethoate (1977)*	
Dimethoxane	15, 177
3,3'-Dimethoxybenzidine (<i>ortho</i> -Dianisidine)	4, 41 <i>Suppl. 4</i> , 116
<i>para</i> -Dimethylaminoazobenzene	8, 125 (corr. 31, 293)
<i>para</i> -Dimethylaminobenzenediazo sodium sulphionate	8, 147
<i>trans</i> -2[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole	7, 147 (corr. 30, 407)
3,3'-Dimethylbenzidine (<i>ortho</i> -Tolidine)	1, 87
Dimethylcarbamoyl chloride	12, 77 <i>Suppl. 4</i> , 118
1,1-Dimethylhydrazine	4, 137

- 1,2-Dimethylhydrazine 4, 145 (corr. 7, 320)
1,4-Dimethylphenanthrene 32, 349
Dimethyl sulphate 4, 271
Suppl. 4, 119
- Dimethylterephthalate (1978)*
1,8-Dinitropyrene 33, 171
Dinitrosopentamethylenetetramine 11, 241
1,4-Dioxane 11, 247
Suppl. 4, 121
- 2,4'-Diphenyldiamine 16, 313
Diphenylthiohydantoin (1976)*
Direct Black 38 29, 295 (corr. 32, 455)
Suppl. 4, 59
- Direct Blue 6 29, 311
Suppl. 4, 59
- Direct Brown 95 29, 321
Suppl. 4, 59
- Disulfiram 12, 85
Dithranol 13, 75
Dulcin 12, 97
- E
- Endrin 5, 157
Enflurane (1976)*
Eosin and its disodium salt 15, 183
Epichlorohydrin 11, 131 (corr. 18, 125; 26, 387)
Suppl. 4, 122 (corr. 33, 223)
- 1-Epoxyethyl-3,4-epoxycyclohexane 11, 141
3,4-Epoxy-6-methylcyclohexylmethyl-3,4-
epoxy-6-methylcyclohexane carboxylate 11, 147
- cis*-9,10-Epoxy stearic acid 11, 153
Ethinylloestradiol 6, 77
21, 233
Suppl. 4, 186
- Ethionamide 13, 83
Ethyl acrylate 19, 57
Ethylene 19, 157
Ethylene dibromide 15, 195
Suppl. 4, 124
- Ethylene oxide 11, 157
Suppl. 4, 126
36, 189

Ethylene sulphide	11, 257
Ethylenethiourea	7, 45 <i>Suppl. 4, 128</i>
Ethyl methanesulphonate	7, 245
Ethyl selenac	12, 107
Ethyl tellurac	12, 115
Ethynodiol diacetate	6, 173 21, 387 <i>Suppl. 4, 194</i>
Eugenol	36, 75
Evans blue	8, 151
F	
Fast green FCF	16, 187
Ferbam	12, 121 (corr. 13, 243)
Fluometuron	30, 245
Fluoranthene	32, 355
Fluorene	32, 365
Fluorescein and its disodium salt (1977)*	
Fluorides (inorganic used in drinking-water and dental preparations)	27, 237
Fluorspar	
Fluosilicic acid	
Sodium fluoride	
Sodium monofluorophosphate	
Sodium silicofluoride	
Stannous fluoride	
5-Fluorouracil	26, 217 <i>Suppl. 4, 130</i>
Formaldehyde	29, 345 <i>Suppl. 4, 131</i>
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole	7, 151 (corr. 11, 295)
Furazolidone	31, 141
The furniture and cabinet-making industry	25, 99 <i>Suppl. 4, 140</i>
2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide	31, 47
Fusarenon-X	11, 169 31, 153

G

L-Glutamic acid-5-[2-(4-hydroxymethyl)-phenylhydrazide]	31, 63
Glycidaldehyde	11, 175
Glycidyl oleate	11, 183
Glycidyl stearate	11, 187
Griseofulvin	10, 153
Guinea green B	16, 199
Gyromitrin	31, 163

H

Haematite	1, 29 <i>Suppl. 4, 254</i>
Haematoxylin (1977)*	
Hair dyes, epidemiology of	16, 29 27, 307
Halothane (1976)*	
Heptachlor and its epoxide	5, 173 20, 129 <i>Suppl. 4, 80</i>
Hexachlorobenzene	20, 155
Hexachlorobutadiene	20, 179
Hexachlorocyclohexane (α -, β -, δ -, ϵ -, technical HCH and lindane)	5, 47 20, 195 (corr. 32, 455) <i>Suppl. 4, 133</i>
Hexachloroethane	20, 467
Hexachlorophene	20, 241
Hexamethylenediamine (1978)*	
Hexamethylphosphoramide	15, 211
Hycanthone and its mesylate	13, 91
Hydralazine and its hydrochloride	24, 85 <i>Suppl. 4, 135</i>
Hydrazine	4, 127 <i>Suppl. 4, 136</i>
Hydrogen peroxide	36, 285
Hydroquinone	15, 155
4-Hydroxyazobenzene	8, 157
17 α -Hydroxyprogesterone caproate	21, 399 (corr. 31, 293) <i>Suppl. 4, 195</i>
8-Hydroxyquinoline	13, 101
Hydroxysenkirkine	10, 265

I

Indeno[1,2,3- <i>cd</i>]pyrene	3, 229 32, 373
Iron and steel founding	34, 133
Iron-dextran complex	2, 161 <i>Suppl. 4</i> , 145
Iron-dextrin complex	2, 161 (corr. 7, 319)
Iron oxide	1, 29
Iron sorbitol-citric acid complex	2, 161
Isatidine	10, 269
Isoflurane (1976)*	
Isonicotinic acid hydrazide	4, 159 <i>Suppl. 4</i> , 146
Isophosphamide	26, 237
Isoprene (1978)*	
Isopropyl alcohol	15, 223 <i>Suppl. 4</i> , 151
Isopropyl oils	15, 223 <i>Suppl. 4</i> , 151
Isosafrole	1, 169 10, 232

J

Jacobine	10, 275
----------	---------

K

Kaempferol	31, 171
------------	---------

L

Lasiocarpine	10, 281
Lauroyl peroxide	36, 315
Lead and lead compounds	1, 40 (corr. 7, 319)
Lead acetate and its trihydrate	2, 52 (corr. 8, 349)
Lead carbonate	2, 150
Lead chloride	23, 39, 205, 325
Lead naphthenate	<i>Suppl. 4</i> , 149
Lead nitrate	
Lead oxide	
Lead phosphate	
Lead subacetate	
Lead tetroxide	
Tetraethyllead	
Tetramethyllead	
The leather goods manufacturing industry (other than boot and shoe manufacture and tanning)	25, 279 <i>Suppl. 4</i> , 149

- The leather tanning and processing industries 25, 201
Suppl. 4, 142
- Ledate 12, 131
- Light green SF 16, 209
- Lindane 5, 47
20, 196
Suppl. 4, 133
- The lumber and sawmill industries (including logging) 25, 49
Suppl. 4, 143
- Luteoskyrin 10, 163
- Lynoestrenol 21, 407
Suppl. 4, 195
- Lysergide (1976)*
- M
- Magenta 4, 57 (corr. 7, 320)
Suppl. 4, 152
- Malathion 30, 103
- Maleic hydrazide 4, 173 (corr. 18, 125)
- Malonaldehyde 36, 163
- Maneb 12, 137
- Mannomustine and its dihydrochloride 9, 157
- MCPA *Suppl. 4*, 211
30, 255
- Medphalan 9, 168
- Medroxyprogesterone acetate 6, 157
21, 417 (corr. 25, 391)
Suppl. 4, 196
- Megestrol acetate 21, 431
Suppl. 4, 198
- Melphalan 9, 167
Suppl. 4, 154
- 6-Mercaptopurine 26, 249
Suppl. 4, 155
- Merphalan 9, 169
- Mestranol 6, 87
21, 257 (corr. 25, 391)
Suppl. 4, 188
- Methacrylic acid (1978)*
- Methallenoestril (1978)*
- Methotrexate 26, 267
Suppl. 4, 157

Methoxsalen	24, 101 <i>Suppl. 4</i> , 158
Methoxychlor	5, 193 20, 259
Methoxyflurane (1976)*	
Methyl acrylate	19, 52
2-Methylaziridine	9, 61
Methylazoxymethanol	10, 121
Methylazoxymethanol acetate	1, 164 10, 131
Methyl bromide (1978)*	
Methyl carbamate	12, 151
1-, 2-, 3-, 4-, 5- and 6-Methylchrysenes	32, 379
<i>N</i> -Methyl- <i>N</i> ,4-dinitrosoaniline	1, 141
4,4'-Methylene bis(2-chloroaniline)	4, 65 (corr. 7, 320)
4,4'-Methylene bis(<i>N,N</i> -dimethyl)benzenamine	27, 119
4,4'-Methylene bis(2-methylaniline)	4, 73
4,4'-Methylenedianiline	4, 79 (corr. 7, 320)
4,4'-Methylenediphenyl diisocyanate	19, 314
2- and 3-Methylfluoranthenes	32, 399
Methyl iodide	15, 245
Methyl methacrylate	19, 187
Methyl methanesulphonate	7, 253
2-Methyl-1-nitroanthraquinone	27, 205
<i>N</i> -Methyl- <i>N'</i> -nitro- <i>N</i> -nitrosoguanidine	4, 183
3-Methylnitrosaminopropionaldehyde	37, 263
3-Methylnitrosaminopropionitrile	37, 263
4-(Methylnitrosamino)-4-(3-pyridyl)butanal (NNA)	37, 205
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)	37, 209
Methyl parathion	30, 131
1-Methylphenanthrene	32, 405
Methyl protoanemonin (1975)*	
Methyl red	8, 161
Methyl selenac	12, 161
Methylthiouracil	7, 53
Metronidazole	13, 113 <i>Suppl. 4</i> , 160
Mineral oils	3, 30 <i>Suppl. 4</i> , 227 33, 87 (corr. 37, 269)
Mirex	5, 203 20, 283 (corr. 30, 407)

- Miristicin (1982)*
Mitomycin C 10, 171
Modacrylic fibres 19, 86
Monocrotaline 10, 291
Monuron 12, 167
5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)-
amino]-2-oxazolidinone 7, 161
Mustard gas 9, 181 (corr. 13, 243)
Suppl. 4, 163
- N
- Nafenopin 24, 125
1,5-Naphthalenediamine 27, 127
1,5-Naphthalene diisocyanate 19, 311
1-Naphthylamine 4, 87 (corr. 8, 349; 22, 187)
Suppl. 4, 164
2-Naphthylamine 4, 97
Suppl. 4, 166
1-Naphthylthiourea (ANTU) 30, 347
Nickel and nickel compounds 2, 126 (corr. 7, 319)
 Nickel acetate and its tetrahydrate 11, 75
 Nickel ammonium sulphate *Suppl. 4*, 167
 Nickel carbonate
 Nickel carbonyl
 Nickel chloride
 Nickel-gallium alloy
 Nickel hydroxide
 Nickelocene
 Nickel oxide
 Nickel subsulphide
 Nickel sulphate
Nihydrazone (1982)*
Niridazole 13, 123
Nithiazide 31, 179
5-Nitroacenaphthene 16, 319
5-Nitro-*ortho*-anisidine 27, 133
9-Nitroanthracene 33, 179
6-Nitrobenzo[*a*]pyrene 33, 187
4-Nitrobiphenyl 4, 113
6-Nitrochrysene 33, 195
Nitrofen 30, 271
3-Nitrofluoranthene 33, 201
5-Nitro-2-furaldehyde semicarbazone 7, 171

1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone	7, 181
<i>N</i> -[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide	1, 181
	7, 185
Nitrogen mustard and its hydrochloride	9, 193
	<i>Suppl.</i> 4, 170
Nitrogen mustard <i>N</i> -oxide and its hydrochloride	9, 209
2-Nitropropane	29, 331
1-Nitropyrene	33, 209
<i>N</i> -Nitrosatable drugs	24, 297 (corr. 30, 307)
<i>N</i> -Nitrosatable pesticides	30, 359
<i>N'</i> -Nitrosoanabasine	37, 225
<i>N'</i> -Nitrosoanatabine	37, 233
<i>N</i> -Nitrosodi- <i>n</i> -butylamine	4, 197
	17, 51
<i>N</i> -Nitrosodiethanolamine	17, 77
<i>N</i> -Nitrosodiethylamine	1, 107 (corr. 11, 295)
	17, 83 (corr. 23, 417)
<i>N</i> -Nitrosodimethylamine	1, 95
	17, 125 (corr. 25, 391)
<i>N</i> -Nitrosodiphenylamine	27, 213
<i>para</i> -Nitrosodiphenylamine	27, 227 (corr. 31, 293)
<i>N</i> -Nitrosodi- <i>n</i> -propylamine	17, 177
<i>N</i> -Nitroso- <i>N</i> -ethylurea	1, 135
	17, 191
<i>N</i> -Nitrosofolic acid	17, 217
<i>N</i> -Nitrosoguvacine	37, 263
<i>N</i> -Nitrosoguvacoline	37, 263
<i>N</i> -Nitrosohydroxyproline	17, 304
<i>N</i> -Nitrosomethylethylamine	17, 221
<i>N</i> -Nitroso- <i>N</i> -methylurea	1, 125
	17, 227
<i>N</i> -Nitroso- <i>N</i> -methylurethane	4, 211
<i>N</i> -Nitrosomethylvinylamine	17, 257
<i>N</i> -Nitrosomorpholine	17, 263
<i>N'</i> -Nitrosornicotine	17, 281
	37, 241
<i>N</i> -Nitrosopiperidine	17, 287
<i>N</i> -Nitrosoproline	17, 303
<i>N</i> -Nitrosopyrrolidine	17, 313
<i>N</i> -Nitrososarcosine	17, 327
<i>N</i> -Nitrososarcosine ethyl ester (1977)*	
Nitrovin	31, 185
Nitroxoline (1976)*	

- Nivalenol (1976)*
Noresthisterone and its acetate 6, 179
21, 441
Suppl. 4, 199
- Norethynodrel 6, 191
21, 461 (corr. 25, 391)
Suppl. 4, 201
- Norgestrel 6, 201
21, 479
Suppl. 4, 202
- Nylon 6 19, 120
Nylon 6/6 (1978)*
- O
- Ochratoxin A 10, 191
31, 191 (corr. 34, 197)
- Oestradiol-17 β 6, 99
21, 279
Suppl. 4, 190
- Oestradiol 3-benzoate 21, 281
Oestradiol dipropionate 21, 283
Oestradiol mustard 9, 217
Oestradiol-17 β -valerate 21, 284
Oestriol 6, 117
21, 327
- Oestrone 6, 123
21, 343 (corr. 25, 391)
Suppl. 4, 191
- Oestrone benzoate 21, 345
Suppl. 4, 191
- Oil Orange SS 8, 165
Orange I 8, 173
Orange G 8, 181
Oxazepam 13, 58
Oxymetholone 13, 131
Suppl. 4, 203
- Oxyphenbutazone 13, 185
- P
- Panfuran S (Dihydroxymethylfuratrizine) 24, 77
Parasorbic acid 10, 199 (corr. 12, 271)
Parathion 30, 153
Patulin 10, 205
Penicillic acid 10, 211
Pentachlorophenol 20, 203
Suppl. 4, 88, 205

Pentobarbital sodium (1976)*	
Perylene	32, 411
Petasitenine	31, 207
Phenacetin	13, 141 24, 135 <i>Suppl. 4</i> , 47
Phenanthrene	32, 419
Phenazopyridine [2,6-Diamino-3-(phenylazo)- pyridine] and its hydrochloride	8, 117 24, 163 (corr. 29, 399) <i>Suppl. 4</i> , 207
Phenelzine and its sulphate	24, 175 <i>Suppl. 4</i> , 207
Phenicarbazide	12, 177
Phenobarbital and its sodium salt	13, 157 <i>Suppl. 4</i> , 208
Phenoxybenzamine and its hydrochloride	9, 223 24, 185
Phenylbutazone	13, 183 <i>Suppl. 4</i> , 212
<i>ortho</i> -Phenylenediamine (1977)*	
<i>meta</i> -Phenylenediamine and its hydrochloride	16, 111
<i>para</i> -Phenylenediamine and its hydrochloride	16, 125
<i>N</i> -Phenyl-2-naphthylamine	16, 325 (corr. 25, 391) <i>Suppl. 4</i> , 213
<i>ortho</i> -Phenylphenol and its sodium salt	30, 329
<i>N</i> -Phenyl- <i>para</i> -phenylenediamine (1977)*	
Phenytoin and its sodium salt	13, 201 <i>Suppl. 4</i> , 215
Piperazine oestrone sulphate	21, 148
Piperonyl butoxide	30, 183
Polyacrylic acid	19, 62
Polybrominated biphenyls	18, 107
Polychlorinated biphenyls	7, 261 18, 43 <i>Suppl. 4</i> , 217
Polychloroprene	19, 141
Polyethylene (low-density and high-density)	19, 164
Polyethylene terephthalate (1978)*	
Polyisoprene (1978)*	
Polymethylene polyphenyl isocyanate	19, 314
Polymethyl methacrylate	19, 195
Polyoestradiol phosphate	21, 286
Polypropylene	19, 218
Polystyrene	19, 245
Polytetrafluoroethylene	19, 288
Polyurethane foams (flexible and rigid)	19, 320
Polyvinyl acetate	19, 346
Polyvinyl alcohol	19, 351

- Polyvinyl chloride 7, 306
19, 402
- Polyvinylidene fluoride (1978)*
- Polyvinyl pyrrolidone 19, 463
- Ponceau MX 8, 189
- Ponceau 3R 8, 199
- Ponceau SX 8, 207
- Potassium bis(2-hydroxyethyl)dithiocarbamate 12, 183
- Prednisone 26, 293
Suppl. 4, 219
- Procarbazine hydrochloride 26, 311
Suppl. 4, 220
- Proflavine and its salts 24, 195
- Progesterone 6, 135
21, 491 (corr. 25, 391)
Suppl. 4, 202
- Pronetalol hydrochloride 13, 227 (corr. 16, 387)
- 1,3-Propane sultone 4, 253 (corr. 13, 243; 20, 591)
- Propham 12, 189
- β -Propiolactone 4, 259 (corr. 15, 341)
- n*-Propyl carbamate 12, 201
- Propylene 19, 213
- Propylene oxide 11, 191
36, 227 (corr. 38, 395)
- Propylthiouracil 7, 67
Suppl. 4, 222
- The pulp and paper industry 25, 157
Suppl. 4, 144
- Pyrazinamide (1976)*
- Pyrene 32, 431
- Pyrimethamine 13, 233
- Pyrrolizidine alkaloids 10, 333
- Q
- Quercetin 31, 213
- Quinoestradol (1978)*
- Quinoestrol (1978)*
- para*-Quinone 15, 255
- Quintozene (Pentachloronitrobenzene) 5, 211
- R
- Reserpine 10, 217
24, 211 (corr. 26, 387; 30, 407)
Suppl. 4, 222
- Resorcinol 15, 155
- Retrorsine 10, 303
- Rhodamine B 16, 221

Rhodamine 6G	16, 233
Riddelliine	10, 313
Rifampicin	24, 243
Rotenone (1982)*	
The rubber industry	28 (corr. 30, 407)
	<i>Suppl. 4, 144</i>
Rugulosin (1975)*	
S	
Saccharated iron oxide	2, 161
Saccharin	22, 111 (corr. 25, 391)
	<i>Suppl. 4, 224</i>
Safrole	1, 169
	10, 231
Scarlet red	8, 217
Selenium and selenium compounds	9, 245 (corr. 12, 271; 30, 407)
Semicarbazide hydrochloride	12, 209 (corr. 16, 387)
Seneciophylline	10, 319
Senkirkine	10, 327
	31, 231
Shale-oils	35, 161
Simazine (1982)*	
Sodium cyclamate	22, 56 (corr. 25, 391)
	<i>Suppl. 4, 97</i>
Sodium diethyldithiocarbamate	12, 217
Sodium equilin sulphate	21, 148
Sodium oestrone sulphate	21, 147
Sodium saccharin	22, 113 (corr. 25, 391)
	<i>Suppl. 4, 224</i>
Soots and tars	3, 22
	<i>Suppl. 4, 227</i>
Soots	35, 219
Spirolactone	24, 259
	<i>Suppl. 4, 229</i>
Sterigmatocystin	1, 175
	10, 245
Streptozotocin	4, 221
	17, 337
Styrene	19, 231
	<i>Suppl. 4, 229</i>
Styrene-acrylonitrile copolymers	19, 97
Styrene-butadiene copolymers	19, 252
Styrene oxide	11, 201
	19, 275
	<i>Suppl. 4, 229</i>
	36, 245
Succinic anhydride	15, 265
Sudan I	8, 225

Sudan II	8, 233
Sudan III	8, 241
Sudan brown RR	8, 249
Sudan red 7B	8, 253
Sulfafurazole (Sulphisoxazole)	24, 275 <i>Suppl. 4, 233</i>
Sulfallate	30, 283
Sulfamethoxazole	24, 285 <i>Suppl. 4, 234</i>
Sulphamethazine (1982)*	
Sunset yellow FCF	8, 257
Symphytine	31, 239
T	
2,4,5-T and esters	15, 273 <i>Suppl. 4, 211, 235</i>
Tannic acid	10, 253 (corr. 16, 387)
Tannins	10, 254
Terephthalic acid (1978)*	
Terpene polychlorinates (Strobane®)	5, 219
Testosterone	6, 209 21, 519
Testosterone oenanthate	21, 521
Testosterone propionate	21, 522
2,2',5,5'-Tetrachlorobenzidine	27, 141
Tetrachlorodibenzo- <i>para</i> -dioxin (TCDD)	15, 41 <i>Suppl. 4, 211, 238</i>
1,1,2,2-Tetrachloroethane	20, 477
Tetrachloroethylene	20, 491 <i>Suppl. 4, 243</i>
Tetrachlorvinphos	30, 197
Tetrafluoroethylene	19, 285
Thioacetamide	7, 77
4,4'-Thiodianiline	16, 343 27, 147
Thiouracil	7, 85
Thiourea	7, 95
Thiram	12, 225
Tobacco habits other than smoking	37, 37
Tobacco smoking	38
2,4-Toluene diisocyanate	19, 303
2,6-Toluene diisocyanate	19, 303
<i>ortho</i> -Toluenesulphonamide	22, 121 <i>Suppl. 4, 224</i>
<i>ortho</i> -Toluidine and its hydrochloride	16, 349 27, 155 <i>Suppl. 4, 245</i>

Toxaphene (Polychlorinated camphenes)	20, 327
Treosulphan	26, 341 <i>Suppl. 4, 246</i>
1,1,1-Trichloroethane	20, 515
1,1,2-Trichloroethane	20, 533
Trichloroethylene	11, 263 20, 545 <i>Suppl. 4, 247</i>
2,4,5- and 2,4,6-Trichlorophenols	20, 349 <i>Suppl. 4, 88, 249</i>
Trichlorotriethylamine hydrochloride	9, 229
Trichlorphon	30, 207
T ₂ -Trichothecene	31, 265
Triethylene glycol diglycidyl ether	11, 209
Trifluralin (1982)*	
2,4,5-Trimethylaniline and its hydrochloride	27, 177
2,4,6-Trimethylaniline and its hydrochloride	27, 178
Triphenylene	32, 447
Tris(aziridinyl)- <i>para</i> -benzoquinone (Triaziquone)	9, 67 <i>Suppl. 4, 251</i>
Tris(1-aziridinyl)phosphine oxide	9, 75
Tris(1-aziridinyl)phosphine sulphide (Thiotepa)	9, 85 <i>Suppl. 4, 252</i>
2,4,6-Tris(1-aziridinyl)- <i>s</i> -triazine	9, 95
1,2,3-Tris(chloromethoxy)propane	15, 301
Tris(2,3-dibromopropyl)phosphate	20, 575
Tris(2-methyl-1-aziridinyl)phosphine oxide	9, 107
Trp-P-1 and its acetate	31, 247
Trp-P-2 and its acetate	31, 255
Trypan blue	8, 267
U	
Uracil mustard	9, 235 <i>Suppl. 4, 256</i>
Urethane	7, 111
V	
Vinblastine sulphate	26, 349 (corr. 34, 197) <i>Suppl. 4, 257</i>
Vincristine sulphate	26, 365 <i>Suppl. 4, 259</i>
Vinyl acetate	19, 341
Vinyl bromide	19, 367
Vinyl chloride	7, 291 19, 377 <i>Suppl. 4, 260</i>

Vinyl chloride-vinyl acetate copolymers	7, 311 19, 412
4-Vinylcyclohexene	11, 277
Vinylidene chloride	19, 439 <i>Suppl. 4</i> , 262 (corr. 31, 293)
Vinylidene chloride-vinyl chloride copolymers	19, 448
Vinylidene fluoride (1978)*	
N-Vinyl-2-pyrrolidone	19, 461
X	
2,4-Xylidine and its hydrochloride	16, 367
2,5-Xylidine and its hydrochloride	16, 377
2,6-Xylidine (1977)*	
Y	
Yellow AB	8, 279
Yellow OB	8, 287
Z	
Zearalenone	31, 279
Zectran	12, 237
Zineb	12, 245
Ziram	12, 259

**PUBLICATIONS OF THE INTERNATIONAL
AGENCY FOR RESEARCH ON CANCER**

SCIENTIFIC PUBLICATIONS SERIES

(Available from Oxford University Press)

- No. 1 LIVER CANCER (1971)
176 pages
- No. 2 ONCOGENESIS AND HERPES
VIRUSES (1972)
Edited by P.M. Biggs, G. de Thé &
L.N. Payne
515 pages
- No. 3 *N*-NITROSO COMPOUNDS -
ANALYSIS AND FORMATION (1972)
Edited by P. Bogovski, R. Preussmann
& E.A. Walker
140 pages
- No. 4 TRANSPLACENTAL
CARCINOGENESIS (1973)
Edited by L. Tomatis & U. Mohr,
181 pages
- No. 5 PATHOLOGY OF TUMOURS IN
LABORATORY ANIMALS. VOLUME 1.
TUMOURS OF THE RAT. PART 1 (1973)
Editor-in-Chief V.S. Turusov
214 pages
- No. 6 PATHOLOGY OF TUMOURS IN
LABORATORY ANIMALS. VOLUME 1.
TUMOURS OF THE RAT. PART 2 (1976)
Editor-in-Chief V.S. Turusov
319 pages
- No. 7 HOST ENVIRONMENT INTER-
ACTIONS IN THE ETIOLOGY OF
CANCER IN MAN (1973)
Edited by R. Doll & I. Vodopija,
464 pages
- No. 8 BIOLOGICAL EFFECTS OF
ASBESTOS (1973)
Edited by P. Bogovski, J.C. Gilson,
V. Timbrell & J.C. Wagner,
346 pages
- No. 9 *N*-NITROSO COMPOUNDS IN
THE ENVIRONMENT (1974)
Edited by P. Bogovski & E.A. Walker
243 pages
- No. 10 CHEMICAL CARCINOGENESIS
ESSAYS (1974)
Edited by R. Montesano & L. Tomatis,
230 pages
- No. 11 ONCOGENESIS AND HERPES-
VIRUSES II (1975)
Edited by G. de-Thé, M.A. Epstein
& H. zur Hausen
Part 1, 511 pages
Part 2, 403 pages
- No. 12 SCREENING TESTS IN
CHEMICAL CARCINOGENESIS (1976)
Edited by R. Montesano, H. Bartsch &
L. Tomatis
666 pages
- No. 13 ENVIRONMENTAL POLLUTION
AND CARCINOGENIC RISKS (1976)
Edited by C. Rosenfeld & W. Davis
454 pages
- No. 14 ENVIRONMENTAL *N*-NITROSO
COMPOUNDS — ANALYSIS AND
FORMATION (1976)
Edited by E.A. Walker, P. Bogovski &
L. Gričiute
512 pages
- No. 15 CANCER INCIDENCE IN FIVE
CONTINENTS. VOL. III (1976)
Edited by J. Waterhouse, C.S. Muir,
P. Correa & J. Powell
584 pages
- No. 16 AIR POLLUTION AND CANCER
IN MAN (1977)
Edited by U. Mohr, D. Schmahl &
L. Tomatis
331 pages
- No. 17 DIRECTORY OF ON-GOING
RESEARCH IN CANCER EPI-
DEMIOLOGY 1977 (1977)
Edited by C.S. Muir & G. Wagner,
599 pages; out of print
- No. 18 ENVIRONMENTAL CARCINO-
GENS - SELECTED METHODS OF
ANALYSIS
Editor-in-Chief H. Egan
Vol. 1 - ANALYSIS OF VOLATILE
NITROSAMINES IN FOOD (1978)
Edited by R. Preussmann,
M. Castegnaro, E.A. Walker
& A.E. Wassermann
212 pages

SCIENTIFIC PUBLICATIONS SERIES

No. 19 ENVIRONMENTAL ASPECTS OF *N*-NITROSO COMPOUNDS (1978)

Edited by E.A. Walker, M. Castegnaro, L. Gričiute & R.E. Lyle
566 pages

No. 20 NASOPHARYNGEAL CARCINOMA: ETIOLOGY AND CONTROL (1978)

Edited by G. de-Thé & Y. Ito,
610 pages

No. 21 CANCER REGISTRATION AND ITS TECHNIQUES (1978)

Edited by R. MacLennan, C.S. Muir, R. Steinitz & A. Winkler
235 pages

No. 22 ENVIRONMENTAL CARCINOGENS - SELECTED METHODS OF ANALYSIS

Editor-in-Chief H. Egan
Vol. 2 - METHODS FOR THE MEASUREMENT OF VINYL CHLORIDE IN POLY(VINYL CHLORIDE), AIR, WATER AND FOODSTUFFS (1978)
Edited by D.C.M. Squirrell & W. Thain,
142 pages

No. 23 PATHOLOGY OF TUMOURS IN LABORATORY ANIMALS. VOLUME II. TUMOURS OF THE MOUSE (1979)

Editor-in-Chief V.S. Turusov
669 pages

No. 24 ONCOGENESIS AND HERPES-VIRUSES III (1978)

Edited by G. de-Thé, W. Henle & F. Rapp
Part 1, 580 pages
Part 2, 522 pages

No. 25 CARCINOGENIC RISKS - STRATEGIES FOR INTERVENTION (1979)

Edited by W. Davis & C. Rosenfeld,
283 pages

No. 26 DIRECTORY OF ON-GOING RESEARCH IN CANCER EPIDEMIOLOGY 1978 (1978)

Edited by C.S. Muir & G. Wagner,
550 pages; out of print

No. 27 MOLECULAR AND CELLULAR ASPECTS OF CARCINOGEN SCREENING TESTS (1980)

Edited by R. Montesano, H. Bartsch & L. Tomatis
371 pages

No. 28 DIRECTORY OF ON-GOING RESEARCH IN CANCER EPIDEMIOLOGY 1979 (1979)

Edited by C.S. Muir & G. Wagner,
672 pages; out of print

No. 29 ENVIRONMENTAL CARCINOGENS - SELECTED METHODS OF ANALYSIS

Editor-in-Chief H. Egan
Vol. 3 - ANALYSIS OF POLYCYCLIC AROMATIC HYDROCARBONS IN ENVIRONMENTAL SAMPLES (1979)
Edited by M. Castegnaro, P. Bogovski, H. Kunte & E.A. Walker
240 pages

No. 30 BIOLOGICAL EFFECTS OF MINERAL FIBRES (1980)

Editor-in-Chief J.C. Wagner
Volume 1, 494 pages
Volume 2, 513 pages

No. 31 *N*-NITROSO COMPOUNDS: ANALYSIS, FORMATION AND OCCURRENCE (1980)

Edited by E.A. Walker, M. Castegnaro, L. Gričiute & M. Börzsönyi
841 pages

No. 32 STATISTICAL METHODS IN CANCER RESEARCH

Vol. 1. THE ANALYSIS OF CASE-CONTROL STUDIES (1980)
By N.E. Breslow & N.E. Day
338 pages

No. 33 HANDLING CHEMICAL CARCINOGENS IN THE LABORATORY - PROBLEMS OF SAFETY (1979)

Edited by R. Montesano, H. Bartsch, E. Boyland, G. Della Porta, L. Fishbein, R.A. Griesemer, A.B. Swan & L. Tomatis,
32 pages

No. 34 PATHOLOGY OF TUMOURS IN LABORATORY ANIMALS. VOLUME III. TUMOURS OF THE HAMSTER (1982)

Editor-in-Chief V.S. Turusov,
461 pages

No. 35 DIRECTORY OF ON-GOING RESEARCH IN CANCER EPIDEMIOLOGY 1980 (1980)

Edited by C.S. Muir & G. Wagner,
660 pages; out of print

SCIENTIFIC PUBLICATIONS SERIES

- No. 36 **CANCER MORTALITY BY OCCUPATION AND SOCIAL CLASS 1851-1971 (1982)**
By W.P.D. Logan
253 pages
- No. 37 **LABORATORY DECONTAMINATION AND DESTRUCTION OF AFLATOXINS B₁, B₂, G₁, G₂ IN LABORATORY WASTES (1980)**
Edited by M. Castegnaro, D.C. Hunt, E.B. Sansone, P.L. Schuller, M.G. Siriwardana, G.M. Telling, H.P. Van Egmond & E.A. Walker,
59 pages
- No. 38 **DIRECTORY OF ON-GOING RESEARCH IN CANCER EPIDEMIOLOGY 1981 (1981)**
Edited by C.S. Muir & G. Wagner,
696 pages; out of print
- No. 39 **HOST FACTORS IN HUMAN CARCINOGENESIS (1982)**
Edited by H. Bartsch & B. Armstrong
583 pages
- No. 40 **ENVIRONMENTAL CARCINOGENS. SELECTED METHODS OF ANALYSIS**
Editor-in-Chief H. Egan
Vol. 4. **SOME AROMATIC AMINES AND AZO DYES IN THE GENERAL AND INDUSTRIAL ENVIRONMENT (1981)**
Edited by L. Fishbein, M. Castegnaro, I.K. O'Neill & H. Bartsch
347 pages
- No. 41 **N-NITROSO COMPOUNDS: OCCURRENCE AND BIOLOGICAL EFFECTS (1982)**
Edited by H. Bartsch, I.K. O'Neill, M. Castegnaro & M. Okada,
755 pages
- No. 42 **CANCER INCIDENCE IN FIVE CONTINENTS. VOLUME IV (1982)**
Edited by J. Waterhouse, C. Muir, K. Shanmugaratnam & J. Powell,
811 pages
- No. 43 **LABORATORY DECONTAMINATION AND DESTRUCTION OF CARCINOGENS IN LABORATORY WASTES: SOME N-NITROSAMINES (1982)** Edited by M. Castegnaro, G. Eisenbrand, G. Ellen, L. Keefer, D. Klein, E.B. Sansone, D. Spincer, G. Telling & K. Webb
73 pages
- No. 44 **ENVIRONMENTAL CARCINOGENS. SELECTED METHODS OF ANALYSIS**
Editor-in-Chief H. Egan
Vol. 5. **SOME MYCOTOXINS (1983)**
Edited by L. Stoloff, M. Castegnaro, P. Scott, I.K. O'Neill & H. Bartsch,
455 pages
- No. 45 **ENVIRONMENTAL CARCINOGENS. SELECTED METHODS OF ANALYSIS**
Editor-in-Chief H. Egan
Vol. 6: **N-NITROSO COMPOUNDS (1983)**
Edited by R. Preussmann, I.K. O'Neill, G. Eisenbrand, B. Spiegelhalder & H. Bartsch
508 pages
- No. 46 **DIRECTORY OF ON-GOING RESEARCH IN CANCER EPIDEMIOLOGY 1982 (1982)**
Edited by C.S. Muir & G. Wagner,
722 pages; out of print
- No. 47 **CANCER INCIDENCE IN SINGAPORE (1982)**
Edited by K. Shanmugaratnam, H.P. Lee & N.E. Day
174 pages
- No. 48 **CANCER INCIDENCE IN THE USSR Second Revised Edition (1983)**
Edited by N.P. Napalkov, G.F. Tserkovny, V.M. Merabishvili, D.M. Parkin, M. Smans & C.S. Muir,
75 pages
- No. 49 **LABORATORY DECONTAMINATION AND DESTRUCTION OF CARCINOGENS IN LABORATORY WASTES: SOME POLYCYCLIC AROMATIC HYDROCARBONS (1983)**
Edited by M. Castegnaro, G. Grimmer, O. Hutzinger, W. Karcher, H. Kunte, M. Lafontaine, E.B. Sansone, G. Telling & S.P. Tucker
81 pages
- No. 50 **DIRECTORY OF ON-GOING RESEARCH IN CANCER EPIDEMIOLOGY 1983 (1983)**
Edited by C.S. Muir & G. Wagner,
740 pages; out of print

SCIENTIFIC PUBLICATIONS SERIES

No. 51 MODULATORS OF
EXPERIMENTAL CARCINO-
GENESIS (1983)

Edited by V. Turusov & R. Montesano
307 pages

No. 52 SECOND CANCER IN
RELATION TO RADIATION
TREATMENT FOR CERVICAL
CANCER: RESULTS OF A CANCER
REGISTRY COLLABORATION (1984)

Edited by N.E. Day & J.C. Boice, Jr,
207 pages

No. 53 NICKEL IN THE HUMAN
ENVIRONMENT (1984)

Editor-in-Chief, F.W. Sunderman, Jr,
529 pages

No. 54 LABORATORY
DECONTAMINATION AND
DESTRUCTION OF CARCINO-
GENS IN LABORATORY WASTES:
SOME HYDRAZINES (1983)

Edited by M. Castegnaro, G. Ellen,
M. Lafontaine, H.C. van der Plas,
E.B. Sansone & S.P. Tucker,
87 pages

No. 55 LABORATORY
DECONTAMINATION AND
DESTRUCTION OF CARCINOGENS
IN LABORATORY WASTES: SOME
N-NITROSAMIDES (1984)

Edited by M. Castegnaro,
M. Benard, L.W. van Broekhoven,
D. Fine, R. Massey, E.B. Sansone,
P.L.R. Smith, B. Spiegelhalter,
A. Stacchini, G. Telling & J.J. Vallon,
65 pages

No. 56 MODELS, MECHANISMS AND
ETIOLOGY OF TUMOUR PROMOTION
(1984)

Edited by M. Börszönyi, N.E. Day,
K. Lapis & H. Yamasaki
532 pages

No. 57 *N*-NITROSO COMPOUNDS:
OCCURRENCE, BIOLOGICAL EFFECTS
AND RELEVANCE TO HUMAN
CANCER (1984)

Edited by I.K. O'Neill, R.C. von Borstel,
C.T. Miller, J. Long & H. Bartsch,
1013 pages

No. 58 AGE-RELATED FACTORS
IN CARCINOGENESIS (1985)

Edited by A. Likhachev, V. Anisimov
& R. Montesano
288 pages

No. 59 MONITORING HUMAN
EXPOSURE TO CARCINOGENIC AND
MUTAGENIC AGENTS (1984)

Edited by A. Berlin, M. Draper,
K. Hemminki & H. Vainio
457 pages

No. 60 BURKITT'S LYMPHOMA: A
HUMAN CANCER MODEL (1985)

Edited by G. Lenoir, G. O'Connor
& C.L.M. Olweny
484 pages

No. 61 LABORATORY DECONTAMI-
NATION AND DESTRUCTION OF
CARCINOGENS IN LABORATORY
WASTES: SOME HALOETHERS (1984)

Edited by M. Castegnaro,
M. Alvarez, M. Iovu, E.B. Sansone,
G.M. Telling & D.T. Williams
55 pages

No. 62 DIRECTORY OF ON-GOING
RESEARCH IN CANCER EPI-
DEMIOLOGY 1984 (1984)

Edited by C.S. Muir & G. Wagner 728 pages

No. 63 VIRUS-ASSOCIATED CANCERS
IN AFRICA (1984)

Edited by A.O. Williams, G.T. O'Connor,
G.B. de-Thé & C.A. Johnson,
773 pages

No. 64 LABORATORY DECONTAMI-
NATION AND DESTRUCTION OF
CARCINOGENS IN LABORATORY
WASTES: SOME AROMATIC AMINES
AND 4-NITROBIPHENYL (1985)

Edited by M. Castegnaro, J. Barek,
J. Dennis, G. Ellen, M. Klibanov,
M. Lafontaine, R. Mitchum,
P. Van Roosmalen, E.B. Sansone,
L.A. Sternson & M. Vahl
85 pages

No. 65 INTERPRETATION OF
NEGATIVE EPIDEMIOLOGICAL
EVIDENCE FOR CARCINOGENICITY

Edited by N.J. Wald & R. Doll
232 pages

No. 66 THE ROLE OF THE REGISTRY
IN CANCER CONTROL

Edited by D.M. Parkin, G. Wagner
& C.S. Muir
155 pages

No. 67 TRANSFORMATION ASSAY OF
ESTABLISHED CELL LINES:
MECHANISMS AND APPLICATIONS

Edited by T. Kakunaga & H. Yamasaki
225 pages

SCIENTIFIC PUBLICATIONS SERIES

No. 68 ENVIRONMENTAL
CARCINOGENS — SELECTED
METHODS OF ANALYSIS.
VOL. 7: SOME VOLATILE HALOGENATED
ALKANES AND
ALKENES

Edited by L. Fishbein & I.K. O'Neill
479 pages

No. 69 DIRECTORY OF ON-GOING
RESEARCH IN CANCER
EPIDEMIOLOGY 1985 (1985)

Edited by C.S. Muir & G. Wagner
756 pages

No. 70 THE ROLE OF CYCLIC NUCLEIC
ACID ADDUCTS IN CARCINOGENESIS AND
MUTAGENESIS

Edited by B. Singer & H. Bartsch
(in press)

No. 71 ENVIRONMENTAL CARCINOGENS.
SELECTED METHODS OF ANALYSIS

VOL. 8: SOME METALS: As, Be, Cd,
Cr, Ni, Pb, Se, Zn

Edited by I.K. O'Neill, P. Schuller
& L. Fishbein (in press)

No. 72 ATLAS OF CANCER IN
SCOTLAND 1975-1980: INCIDENCE AND
EPIDEMIOLOGICAL PERSPECTIVE (1985)

Edited by I. Kemp, P. Boyle, M. Smans
& C. Muir
282 pages

No. 73 LABORATORY DECONTAMI-
NATION AND DESTRUCTION OF
CARCINOGENS IN LABORATORY
WASTES: SOME ANTINEOPLASTIC
AGENTS

Edited by M. Castegnaro, J. Adams,
M. Armour, J. Barek, J. Benvenuto,
C. Confalonieri, U. Goff, S. Ludeman,
D. Reed, E.B. Sansone & G. Telling
(1985) (in press)

No. 74 TOBACCO: A MAJOR INTER-
NATIONAL HEALTH HAZARD
Edited by D. Zaridze and R. Peto
(1986) (in press)

No. 75 CANCER OCCURRENCE IN
DEVELOPING COUNTRIES
Edited by D.M. Parkin
(1986) (in press)

No. 76 SCREENING FOR CANCER OF THE
UTERINE CERVIX

Edited by M. Hakama, A.B. Miller and
N.E. Day
(1986) (in press)

No. 77 HEXACHLOROBENZENE.
PROCEEDINGS OF AN INTERNATIONAL
SYMPOSIUM

Edited by C.R. Morris and J.R.P. Cabral
(1986) (in press)

NON SERIAL PUBLICATIONS

(Available from IARC)

ALCOOL ET CANCER (1978)

By A.J. Tuyns (in French only)
42 pages

CANCER MORBIDITY AND CAUSES OF
DEATH AMONG DANISH BREWERY
WORKERS (1980)

By O.M. Jensen
145 pages

**IARC MONOGRAPHS ON THE EVALUATION OF THE
CARCINOGENIC RISK OF CHEMICALS TO HUMANS**
(English editions only)

(Available from WHO Sales Agents)

- Volume 1**
Some inorganic substances, chlorinated hydrocarbons, aromatic amines, N-nitroso compounds, and natural products (1972)
184 pp.; out of print
- Volume 2**
Some inorganic and organometallic compounds (1973)
181 pp.; out of print
- Volume 3**
Certain polycyclic aromatic hydrocarbons and heterocyclic compounds (1973)
271 pp.; out of print
- Volume 4**
Some aromatic amines, hydrazine and related substances, N-nitroso compounds and miscellaneous alkylating agents (1974)
286 pp.
- Volume 5**
Some organochlorine pesticides (1974)
241 pp.; out of print
- Volume 6**
Sex hormones (1974)
243 pp.; US\$7.20; Sw.fr. 18.-
- Volume 7**
Some anti-thyroid and related substances, nitrofurans and industrial chemicals (1974)
326 pp.
- Volume 8**
Some aromatic azo compounds (1975)
357 pp.
- Volume 9**
Some aziridines, N-, S- and O-mustards and selenium (1975)
268 pp.
- Volume 10**
Some naturally occurring substances (1976)
353 pp.
- Volume 11**
Cadmium, nickel, some epoxides, miscellaneous industrial chemicals and general considerations on volatile anaesthetics (1976)
306 pp.
- Volume 12**
Some carbamates, thiocarbamates and carbazides (1976)
282 pp.
- Volume 13**
Some miscellaneous pharmaceutical substances (1977)
255 pp.
- Volume 14**
Asbestos (1977)
106 pp.
- Volume 15**
Some fumigants, the herbicides 2,4-D and 2,4,5-T, chlorinated dibenzodioxins and miscellaneous industrial chemicals (1977)
354 pp.
- Volume 16**
Some aromatic amines and related nitro compounds - hair dyes, colouring agents and miscellaneous industrial chemicals (1978)
400 pp.
- Volume 17**
Some N-nitroso compounds (1978)
365 pp.
- Volume 18**
Polychlorinated biphenyls and polybrominated biphenyls (1978)
140 pp.
- Volume 19**
Some monomers, plastics and synthetic elastomers, and acrolein (1979)
513 pp.
- Volume 20**
Some halogenated hydrocarbons (1979)
609 pp.
- Volume 21**
Sex hormones (II) (1979)
583 pp.
- Volume 22**
Some non-nutritive sweetening agents (1980)
208 pp.

IARC MONOGRAPHS SERIES

- Volume 23
Some metals and metallic compounds (1980)
438 pp.
- Volume 24
Some pharmaceutical drugs (1980)
337 pp.
- Volume 25
Wood, leather and some associated industries (1981)
412 pp.
- Volume 26
Some antineoplastic and immunosuppressive agents (1981)
411 pp.
- Volume 27
Some aromatic amines, anthraquinones and nitroso compounds, and inorganic fluorides used in drinking-water and dental preparations (1982)
341 pp.
- Volume 28
The rubber industry (1982)
486 pp.
- Volume 29
Some industrial chemicals and dyestuffs (1982)
416 pp.
- Volume 30
Miscellaneous pesticides (1983)
424 pp.
- Volume 31
Some food additives, feed additives and naturally occurring substances (1983)
314 pp.
- Volume 32
Polynuclear aromatic compounds, Part 1, Environmental and experimental data (1984)
477 pp.
- Volume 33
Polynuclear aromatic compounds, Part 2, Carbon blacks, mineral oils and some nitroarene compounds (1984)
245 pp.
- Volume 34
Polynuclear aromatic compounds, Part 3, Industrial exposures in aluminium production, coal gasification, coke production, and iron and steel founding (1984)
219 pp.
- Volume 35
Polynuclear aromatic compounds, Part 4, Bitumens, coal-tar and derived products, shale-oils and soots (1985)
271 pp.
- Volume 36
Allyl Compounds, aldehydes, epoxides and peroxides (1985)
369 pp.
- Volume 37
Tobacco habits other than smoking; betel-quid and areca-nut chewing; and some related nitrosamines (1985)
291 pp.
- Volume 38
Tobacco smoking (1986)
421 pp.
- Supplement No. 1
Chemicals and industrial processes associated with cancer in humans (IARC Monographs, Volumes 1 to 20) (1979)
71 pp.; out of print
- Supplement No. 2
Long-term and short-term screening assays for carcinogens: a critical appraisal (1980)
426 pp.
- Supplement No. 3
Cross index of synonyms and trade names in Volumes 1 to 26 (1982)
199 pp.
- Supplement No. 4
Chemicals, industrial processes and industries associated with cancer in humans (IARC Monographs, Volumes 1 to 29) (1982)
292 pp.
- Supplement No. 5
Cross index of synonyms and trade names in Volumes 1 to 36 (1985)
259 pp.

**INFORMATION BULLETINS ON THE
SURVEY OF CHEMICALS BEING
TESTED FOR CARCINOGENICITY**

(Available from IARC)

No. 8 (1979)

Edited by M.-J. Ghes, H. Bartsch
& L. Tomatis
604 pp.

No. 9 (1981)

Edited by M.-J. Ghes, J.D. Wilbourn,
H. Bartsch & L. Tomatis
294 pp.

No. 10 (1982)

Edited by M.-J. Ghes, J.D. Wilbourn
H. Bartsch
326 pp.

No. 11 (1984)

Edited by M.-J. Ghes, J.D. Wilbourn,
H. Vainio & H. Bartsch
336 pp.